-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: [email protected]
Originator-Key-Asymmetric:
MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
Q5k0DG9ib8cOtkmv3PpzkXA2AWutWd7e3wCRReVGqvOwmj2C/33h8qLzya0D2ZOW
z08geFkkiPAzjXntAjq6ag==
<SEC-DOCUMENT>0000897101-06-001326.txt : 20060628
<SEC-HEADER>0000897101-06-001326.hdr.sgml : 20060628
<ACCEPTANCE-DATETIME>20060628164258
ACCESSION NUMBER: 0000897101-06-001326
CONFORMED SUBMISSION TYPE: 10-K
PUBLIC DOCUMENT COUNT: 31
CONFORMED PERIOD OF REPORT: 20060428
FILED AS OF DATE: 20060628
DATE AS OF CHANGE: 20060628
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: MEDTRONIC INC
CENTRAL INDEX KEY: 0000064670
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 410793183
STATE OF INCORPORATION: MN
FISCAL YEAR END: 0430
FILING VALUES:
FORM TYPE: 10-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-07707
FILM NUMBER: 06930467
BUSINESS ADDRESS:
STREET 1: 710 MEDTRONIC PKWY
STREET 2: MS LC300
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55432
BUSINESS PHONE: 7635144000
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>medtronic062430s1_10k.htm
<DESCRIPTION>ANNUAL REPORT FOR FISCAL PERIOD ENDED 04-28-2006
<TEXT>
<HTML>
<HEAD>
<TITLE>Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR><BR>
<HR noshade color="black" size="3">
<HR noshade color="black" size="3">
<P style="font-weight:bold;text-align:center;font-size:14pt">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</P>
<P style="font-weight:bold;text-align:center;font-size:10pt;margin-top:-12pt">Washington, D.C. 20549</P>
<HR noshade color="black" width="20%">
<P style="font-weight:bold;text-align:center;font-size:24pt">FORM 10-K</P>
<DIV style="margin-top:10pt" ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER="0" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:12pt;font-weight:bold" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE="2" FACE="wingdings">x</FONT></TD>
<TD WIDTH="96%">Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934.<BR>For the fiscal
year ended April 28, 2006.</TD>
</TR>
<TR style="font-size:12pt;font-weight:bold" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE="2" FACE="wingdings">o</FONT></TD>
<TD WIDTH="96%">Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.<BR>For the transition
period from __________ to __________</TD>
</TR>
</TABLE>
</DIV>
<P style="font-size:10pt;font-weight:bold;text-align:center">Commission File No. 1-7707</P>
<HR noshade color="black" width="20%">
<DIV align="center">
<img src="med_blue.gif"></DIV>
<P style="text-align:center;font-size:24pt;font-weight:bold">Medtronic, Inc.</P>
<P style="text-align:center;font-size:10pt;margin-top:-12pt">(Exact name of registrant as specified in charter)</P>
<DIV align="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="bottom" style="font-size:10pt;padding-top:6pt">
<TD width="48%"><B>Minnesota</B></TD>
<TD width="2%"> </TD>
<TD align="right" width="48%"><B>41-0793183</B></TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD><B>(State of incorporation)</B></TD>
<TD> </TD>
<TD align="right"><B>(I.R.S. Employer Identification No.)</B></TD>
</TR>
</TABLE>
</DIV>
<P style="font-size:10pt;text-align:center"><B>710 Medtronic Parkway</B>
<BR><B>Minneapolis, Minnesota 55432</B>
<BR><B>(Address of principal executive offices)</B></P>
<P style="font-size:10pt;text-align:center"><B>Telephone Number: (763) 514-4000</B></P>
<P style="font-size:10pt;text-align:center;margin-top:3pt">
<B>Securities registered pursuant to section 12(b) of the Act:</B></P>
<DIV align="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM" style="font-size:8pt">
<TH align="left">Title of each class</TH>
<TH> </TH> <TH align="left">Name of each exchange on which registered</TH>
</TR>
<TR VALIGN="TOP" style="font-size:10pt">
<TD><B>Common stock, par value $0.10 per share</B></TD>
<TD width="2%"> </TD>
<TD><B>New York Stock Exchange, Inc.</B></TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt">
<TD><B>Preferred stock purchase rights</B></TD>
<TD> </TD>
<TD><B>New York Stock Exchange, Inc.</B></TD>
</TR>
</TABLE>
</DIV>
<P style="font-size:10pt;text-align:center">
<B>Securities registered pursuant to section 12(g) of the Act:<BR>None</B>
</P>
<HR noshade color="black" width="20%">
<P style="font-size:9pt">
<B>Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes
<FONT FACE="wingdings">x</FONT> No <FONT FACE="wingdings">o</FONT></B>
</P>
<P style="font-size:9pt">
<B>Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange
Act. Yes <FONT FACE="wingdings">o</FONT> No <FONT FACE="wingdings">x</FONT></B>
</P>
<P style="font-size:9pt">
<B>Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes
<FONT FACE="wingdings">x</FONT> No <FONT FACE="wingdings">o</FONT></B>
</P>
<P style="font-size:9pt">
<B>Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein,
and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated
by reference in Part III of this Form 10-K or any amendment to this Form 10-K. <FONT FACE="wingdings">o</FONT></B>
</P>
<P style="font-size:9pt">
<B>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.
See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act.<BR>Large
accelerated filer <FONT FACE="wingdings">x</FONT> Accelerated filer <FONT FACE="wingdings">o</FONT> Non-accelerated
filer <FONT FACE="wingdings">o</FONT></B>
</P>
<P style="font-size:9pt">
<B>Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).<BR>Yes <FONT
FACE="wingdings">o</FONT> No <FONT FACE="wingdings">x</FONT></B>
</P>
<P style="font-size:9pt">
<B>Aggregate market value of voting stock of Medtronic, Inc. held by nonaffiliates of the registrant as of October 28,
2005, based on the closing price of $56.79, as reported on the New York Stock Exchange: approximately $68.6 billion.
Shares of Common Stock outstanding on June 23, 2006: 1,154,790,616</B>
</P>
<P style="font-size:10pt;text-align:center;margin-top:3pt">
<B>DOCUMENTS INCORPORATED BY REFERENCE</B>
</P>
<P style="font-size:9pt">
<B>Portions of the Registrant’s 2006 Annual Report filed as Exhibit 13 hereto are incorporated by reference into Parts
I and II hereto and portions of Registrant’s Proxy Statement for its 2006 Annual Meeting are incorporated by reference
into Part III.</B>
</P>
<BR>
<HR noshade color="black" size="3">
<HR noshade color="black" size="3">
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt"><A href="#toc">Table of Contents</A></P>
<P style="font-size:10pt"><B>Trademarks and Other Rights</B></P>
<P style="font-size:10pt"> This Report contains trademarks, service marks, and
registered marks of Medtronic, Inc. and its subsidiaries, (“Medtronic” or the “Company”) and other
companies, as indicated.</P>
<P style="font-size:10pt"> The following are registered and unregistered trademarks
of Medtronic, Inc. and its affiliated companies:</P>
<P style="font-size:10pt"> AAAdvantage™, Access®, Activa®, Adapta™,
ADVANTAGE Supra®, AneuRx®, AneuRx AAAdvantage™, ATP During Charging™, Attain®, Attain Select®, Aurora™,
Bolus Wizard®, Bravo®, BRYAN®, CAPSTONE®, Cardioblate®, CardioSight®, Catalyst®, CD HORIZON®,
CD HORIZON LEGACY™, CD HORIZON® SEXTANT®, CG Future®, CGMS®, Chronicle®, Clo-Sur P.A.D.™, Crosslink®,
CrossPoint®, Cypher®, Driver®, ECLIPSE®, Endeavor®, EnPulse®, EnRhythm®, Enterra®, EnTrust®,
EVS®, Equestra®, Freestyle®, Gatekeeper®, GEM III®, GFX™, Guardian®, GuardWire Plus®, Hancock®,
HOURGLASS®, INFUSE®, InSync®, InSync Marquis™, InSync Maximo®, InSync Sentry®, InSync II Marquis™,
Intercept™, Interceptor®, INTER FIX™, InterStim®, Intrinsic®, Kappa®, Kinetra®, LandmarX®,
LandmarX Evolution®, Legend®, Legend EHS®, LIFENET®, LIFEPAK®, LIFEPAK CR®, LT-CAGE®, Magellan®,
Marquis®, MAVERICK™, Maximo®, MAST™, Medtronic CareLink®, Medtronic Hall®, MeroGel®, METRx®,
Micro-Driver™, Mosaic®, Mosaic Ultra™, MVP™, Multi-Exchange™, Mystique®, NexFrame®, NIM®,
NIM-Neuro®, NIM-Response®, NIM-Spine®, Octopus®, OptiVol®, Paradigm®, Paradigm Link®, Performer™,
Pioneer™, PRESTIGE®, PROSTIVA™, Racer®, Reliant™, Restore®, RestorePRIME™, Sensia™. SEXTANT®,
SiLo™, Sprint Fidelis®, Sprint Quattro®, Sprinter®, SPYDER®, Starfish®, StealthStation®, StimPilot™,
Stormer®, Strata®, SynchroMed®, Synergy®, SynergyCompact+™, SynergyPlus+™, Talent™, TransAccess®,
Transcend®, TUNA®, U-Clip™, Urchin®, Valiant™, Versa™, Vertex®, VERTE-STACK®, Vitatron®,
Xcelerant® and XPS®.</P>
<P style="font-size:10pt"> InductOs™ is a trademark of Wyeth.</P>
<P style="font-size:10pt">
<B>Annual Meeting and Record Dates</B>
</P>
<P style="font-size:10pt"> Medtronic’s Annual Meeting of Shareholders will
be held on Thursday, August 24, 2006 at 10:30 a.m., Central Daylight Time at the Company’s World Headquarters,
710 Medtronic Parkway, Minneapolis (Fridley), Minnesota. The record date for the Annual Meeting is June 26, 2006 and all
shareholders of record at the close of business on that day will be entitled to vote at the Annual Meeting.</P>
<P style="font-size:10pt">
<B>Medtronic Website</B>
</P>
<P style="font-size:10pt"> Our Annual Reports on Form 10-K, Quarterly Reports
on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a)
or 15(d) of the Securities Exchange Act of 1934 are available through our website (<U>www.medtronic.com</U> under the “Investor
Relations” caption) free of charge as soon as reasonably practicable after we electronically file such material with,
or furnish it to, the Securities and Exchange Commission (SEC).</P>
<P style="font-size:10pt"> Information relating to corporate governance at Medtronic,
including our Principles of Corporate Governance, Code of Conduct (including our Code of Ethics for Senior Financial Officers),
Code of Business Conduct and Ethics for Board Members and information concerning our executive officers, directors and Board
committees (including committee charters), and transactions in Medtronic securities by directors and executive officers,
is available on or through our website at <U>www.medtronic.com</U> under the “Corporate Governance” and “Investor
Relations” captions.</P>
<P style="font-size:10pt"> We are not including the information on our website
as a part of, or incorporating it by reference into, our Form 10-K.</P>
<P> </P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt;font-weight:bold;text-align:center">
<A name="toc"></A>TABLE OF CONTENTS</P>
<DIV align="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM" style="font-size:8pt">
<TH align="left">Item</TH>
<TH> </TH>
<TH>Description</TH>
<TH> </TH>
<TH>Page</TH>
</TR>
<TR>
<TD>
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD>
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD>
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt">
<TD></TD>
<TD width="4%"> </TD>
<TD align="center"><B> <A href="#toc1">PART I</A></B></TD>
<TD width="4%"> </TD>
<TD width=4%></TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>1.</TD>
<TD> </TD>
<TD><A href="#toc2">Business</A></TD>
<TD> </TD>
<TD align=right>1</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>1A.</TD>
<TD> </TD>
<TD><A href="#toc3">Risk Factors</A></TD>
<TD> </TD>
<TD align=right>26</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>1B.</TD>
<TD> </TD>
<TD><A href="#toc4">Unresolved Staff Comments</A></TD>
<TD> </TD>
<TD align=right>31</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>2.</TD>
<TD> </TD>
<TD><A href="#toc5">Properties</A></TD>
<TD> </TD>
<TD align=right>31</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>3.</TD>
<TD> </TD>
<TD><A href="#toc6">Legal Proceedings</A></TD>
<TD> </TD>
<TD align=right>32</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>4.</TD>
<TD> </TD>
<TD><A href="#toc7">Submission of Matters to a Vote of Security Holders</A></TD>
<TD> </TD>
<TD align=right>36</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD></TD>
<TD> </TD>
<TD align="center"><B> <A href="#toc8">PART II</A></B></TD>
<TD> </TD>
<TD align=right>36</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>5.</TD>
<TD> </TD>
<TD style="padding-left:5pt;text-indent:-5pt"><A href="#toc9">Market for Medtronic’s Common Equity, Related Shareholder Matters,
and Issuer Purchases of Equity Securities</A></TD>
<TD> </TD>
<TD align=right>36</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>6.</TD>
<TD> </TD>
<TD><A href="#toc10">Selected Financial Data</A></TD>
<TD> </TD>
<TD align=right>36</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>7.</TD>
<TD> </TD>
<TD style="padding-left:5pt;text-indent:-5pt"><A href="#toc11">Management’s Discussion and Analysis of Financial Condition
and Results of Operations</A></TD>
<TD> </TD>
<TD align=right>36</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>7A.</TD>
<TD> </TD>
<TD><A href="#toc12">Quantitative and Qualitative Disclosures About Market Risk</A></TD>
<TD> </TD>
<TD align=right>36</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>8.</TD>
<TD> </TD>
<TD><A href="#toc13">Financial Statements and Supplementary Data</A></TD>
<TD> </TD>
<TD align=right>37</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>9.</TD>
<TD> </TD>
<TD style="padding-left:5pt;text-indent:-5pt"><A href="#toc14">Changes in and Disagreements with Accountants on Accounting and Financial
Disclosure</A></TD>
<TD> </TD>
<TD align=right>37</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>9A.</TD>
<TD> </TD>
<TD><A href="#toc15">Controls and Procedures</A></TD>
<TD> </TD>
<TD align=right>37</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>9B.</TD>
<TD> </TD>
<TD><A href="#toc16">Other Information</A></TD>
<TD> </TD>
<TD align=right>37</TD>
<TD></TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD></TD>
<TD> </TD>
<TD align="center"><B> <A href="#toc17">PART III</A></B></TD>
<TD> </TD>
<TD align=right>37</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>10.</TD>
<TD> </TD>
<TD><A href="#toc18">Directors and Executive Officers of the Registrant</A></TD>
<TD> </TD>
<TD align=right>38</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>11.</TD>
<TD> </TD>
<TD><A href="#toc19">Executive Compensation</A></TD>
<TD> </TD>
<TD align=right>38</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>12.</TD>
<TD> </TD>
<TD style="padding-left:5pt;text-indent:-5pt"><A href="#toc20">Security Ownership of Certain Beneficial Owners and Management and
Related Shareholder Matters</A></TD>
<TD> </TD>
<TD align=right>38</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>13.</TD>
<TD> </TD>
<TD><A href="#toc21">Certain Relationships and Related Transactions</A></TD>
<TD> </TD>
<TD align=right>38</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>14.</TD>
<TD> </TD>
<TD><A href="#toc22">Principal Accounting Fees and Services</A></TD>
<TD> </TD>
<TD align=right>38</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD></TD>
<TD> </TD>
<TD align="center"><B> <A href="#toc23">PART IV</A></B></TD>
<TD> </TD>
<TD align=right> </TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD>15.</TD>
<TD> </TD>
<TD><A href="#toc24">Exhibits, Financial Statement Schedules</A></TD>
<TD> </TD>
<TD align=right>38</TD>
</TR>
</TABLE>
</DIV>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:12pt;font-weight:bold;text-align:center"><A name="toc1"></A>PART I</P>
<P style="font-size:12pt;font-weight:bold"><A name="toc2"></A>Item 1. Business</P>
<P style="font-size:10pt;font-weight:bold">Overview</P>
<P style="font-size:10pt"> Medtronic is the global leader in medical technology,
alleviating pain, restoring health and extending life for millions of people around the world. We are committed to offering
market-leading therapies worldwide to restore patients to fuller, healthier lives. With beginnings in the treatment of heart
disease, we have expanded well beyond our historical core business and today provide a wide range of products and therapies
that help solve many challenging, life-limiting medical conditions. We hold market-leading positions in almost all of the major
markets in which we compete.</P>
<P style="font-size:10pt"> We currently function in seven operating segments
that manufacture and sell device-based medical therapies. Our operating segments are:</P>
<div style="position:relative;float:left;width:52%">
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">•</TD>
<TD nowrap WIDTH="92%">Cardiac Rhythm Disease Management (CRDM)</TD></TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Spinal and Navigation</TD></TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Neurological</TD></TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Vascular</TD></TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Diabetes</TD></TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Cardiac Surgery</TD></TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Ear, Nose and Throat (ENT)</TD></TR>
</TABLE>
</DIV>
<div style="position:relative;float:right;width:48%">
<P align="center"><img src="a62430fy06pi.jpg"></P>
</DIV>
<BR clear=all>
<BR>
<P style="font-size:10pt"> The chart above shows the net sales and percentage
of total net sales contributed by each of our operating segments for the fiscal year ended April 28, 2006 (fiscal year
2006).</P>
<P style="font-size:10pt"> With innovation and market leadership, we have pioneered
advances in medical technology in all of our businesses and enjoyed steady growth. Over the last five years, our net sales
have more than doubled, from $5.552 billion in fiscal year 2001 to $11.292 billion in fiscal year 2006. We attribute
this growth to our commitment to develop or acquire new products to treat an expanding array of medical conditions.</P>
<P style="font-size:10pt"> Medtronic was founded in 1949, incorporated as a Minnesota
corporation in 1957, and today serves physicians, clinicians and patients in more than 120 countries worldwide. Beginning with
the development of the heart pacemaker in the 1950s, we have assembled a broad and diverse portfolio of progressive technology
expertise both through internal development of core technologies as well as acquisitions. We remain committed to a mission
written by our founder more than 40 years ago that directs us “to contribute to human welfare by application of biomedical
engineering in the research, design, manufacture and sale of products that alleviate pain, restore health and extend life.”</P>
<P style="font-size:10pt"> With approximately 36,000 dedicated employees worldwide
personally invested in supporting our Mission, our success in leading global advances in medical technology is the result of
several key strengths:</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">•</TD>
<TD WIDTH="92%">Broad and deep technological knowledge of microelectronics, implantable devices and techniques, power sources,
coatings, materials, programmable devices and related areas, as well as a tradition of technological pioneering and breakthrough
products that not only yield better medical outcomes, but more cost-effective therapies.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Strong intellectual property portfolio that underlies our key products.</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">1</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD width="4%"> </TD>
<TD width="4%">•</TD>
<TD width="92%">High product quality standards, backed with stringent systems to help ensure consistent performance that meet
or surpass customers’ expectations.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Strong professional collaboration with customers, extensive medical educational programs and thorough clinical research.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Full commitment to superior patient and customer service.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Extensive experience with the regulatory process and sound working relationships with regulators and reimbursement agencies,
including leadership roles in helping shape regulatory policy.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>A proven financial record of sustained growth.
</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>
Continual introduction of new products.</TD>
</TR>
</TABLE>
<P style="font-size:10pt"> Our strategic objective is to provide patients and
the medical community with comprehensive, life-long solutions for the management of chronic disease. Our key strengths parallel
the following basic, but well-implemented, strategies that guide our growth and success:</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">•</TD>
<TD WIDTH="92%">Increase market share in core product lines.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Meet unmet medical needs by leveraging our technologies.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Broaden our global presence in developed and developing markets.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Ensure that people who could benefit from our device therapies increasingly have access to them.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Acquire or invest in breakthrough technologies to treat an increasing number of chronic diseases.</TD>
</TR>
</TABLE>
<P style="font-size:10pt"> In this decade, we anticipate that technology advancements,
the Internet and increasing patient participation in treatment decisions will transform the nature of healthcare services and
will result in better care that is more cost effective to the healthcare system and greater quality of life and convenience
to the patient.</P>
<P style="font-size:10pt"> Our primary customers include hospitals, clinics,
third party healthcare providers and other institutions, including governmental healthcare programs and group purchasing organizations.</P>
<P style="font-size:10pt;font-weight:bold">Cardiac Rhythm Disease Management</P>
<P style="font-size:10pt"> In order to more clearly reflect the scope of our
products and the focus of our strategy, this year we changed the name of Cardiac Rhythm Management to Cardiac Rhythm Disease
Management (CRDM). CRDM is the world’s leading supplier of medical devices for cardiac rhythm disease management. We pioneered
the modern medical device industry by developing the first wearable external cardiac pacemaker in 1957, and manufactured the
first reliable long-term implantable pacing system in 1960. Since then, we have been the world’s leading producer of cardiac
rhythm technology, and from these beginnings, a $9 billion industry has emerged. Today, our products and technologies
treat and monitor a wide variety of heart rhythm diseases and conditions.</P>
<P style="font-size:10pt"> <B><I>Conditions Treated</I></B>
</P>
<P style="font-size:10pt"> Natural electrical impulses stimulate atria and ventricles,
the heart’s chambers, to rhythmically contract and relax with each heartbeat. Irregularities in the heart’s normal
electrical signals can result in debilitating and life-threatening conditions, including heart failure and sudden cardiac arrest,
one of the leading causes of death in the United States (U.S.). Physicians rely on our CRDM products to correct these irregularities
and restore the heart to its normal rhythm. Our CRDM products are designed to treat and monitor a broad range of heart conditions,
including those described below.</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">•</TD>
<TD WIDTH="92%">Bradycardia — abnormally slow or unsteady heart rhythms usually less than 60 beats per minute or unsteady
heart rhythms that cause symptoms such as dizziness, fainting, fatigue, and shortness of breath</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">2</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD width="4%"> </TD>
<TD width="4%">•</TD>
<TD width="92%">Tachyarrhythmia — heart rates that are dangerously fast or irregular, including ventricular tachycardia
and fibrillation, which occur in the lower chambers of the heart, the ventricles, and can lead to sudden cardiac arrest, as
well as atrial arrhythmias, or rapid and inconsistent beating of the upper chambers of the heart, the atria, which can affect
blood flow to the body and increase the risk of stroke</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Heart Failure — impaired heart function resulting in the inability to pump enough blood to meet the body’s
needs, characterized by difficulty breathing, chronic fatigue and fluid retention </TD>
</TR>
</TABLE>
<P style="font-size:10pt"> The charts below set forth net sales of our CRDM products
as a percentage of our total net sales for each of the last three fiscal years:</P>
<DIV align="center">
<img src="a62430crdm.jpg"></DIV>
<P style="font-size:10pt"> We offer the broadest array of products in the industry
for the diagnosis and treatment of heart rhythm disorders and heart failure. Because many patients exhibit multiple heart rhythm
problems, we have developed implantable devices that specifically address complex combinations of arrhythmias. In addition
to implantable devices, we also provide external defibrillators, leads, ablation products, electrophysiology catheters, navigation
systems and information systems for the management of patients with our devices. Our CRDM devices are currently implanted in
approximately 3 million patients worldwide.</P>
<P style="font-size:10pt"> <B><I>Implantable Cardiac Rhythm Devices.</I></B>
Bradycardia is a common condition, with hundreds of thousands of patients diagnosed each year, and millions
of people worldwide suffering from its effects. The only known treatment for this condition is a cardiac pacemaker, a battery-powered
device implanted in the chest that delivers electrical impulses to stimulate the heart to beat at an appropriate rate. In May
2005, we announced U.S. Food and Drug Administration (FDA) approval of EnRhythm, our newest dual-chamber pacemaker, which offers
a pacing mode called Managed Ventricular Pacing (MVP), which enables the device to be programmed to minimize pacing
pulses to the right ventricle. Clinical studies have shown that unnecessary pacing in the right ventricle can increase the
risk for heart failure and atrial fibrillation. EnRhythm joins our pacing product family which includes the EnPulse pacemaker,
a completely automatic pacemaker. The EnPulse system incorporates an array of unique features to help physicians optimize pacing
therapy and simplify patient care including a feature called Atrial Capture Management, which enables the pacemaker to automatically
adjust the electrical impulses delivered to the heart’s upper right chamber. In June 2005, we announced the clinical evaluation
of our Adapta family of pacemakers. The new Adapta pacemaker family, including the Adapta, Versa, and Sensia pacemakers, is
a portfolio of fully automatic pacemakers designed to provide physiologic pacing adapted to the needs of individual patients.
U.S. FDA approval of the Adapta family of pacemakers is expected in the summer of calendar year 2006.</P>
<P style="font-size:10pt"> Approximately 7 million people worldwide have tachyarrhythmia.
Tachyarrhythmia is a potentially fatal condition that can lead to sudden cardiac arrest, the sudden and complete cessation
of heart activity. Sudden cardiac arrest is one of the leading causes of death in the U.S., responsible for more than 300,000
deaths annually, with most due to ventricular fibrillation. Implantable cardioverter defibrillators (ICDs) are stopwatch-sized
devices that continually monitor the heart and deliver appropriate therapy when an abnormal heart rhythm is detected. Several
large clinical trials have shown implantable defibrillators significantly improve survival as compared to commonly prescribed
antiarrhythmic drugs.
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">3</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
In 2005, the results of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), sponsored by the National Institutes of
Health (NIH), with funding provided by Medtronic, were published in the <I>New England Journal of Medicine.</I> This 2,521
patient trial, the largest ICD trial ever conducted, showed ICDs reduced death by 23 percent in people with moderate heart
failure compared to those who did not receive ICDs. Also in 2005, the Centers for Medicare and Medicaid Services (CMS) expanded
coverage of ICDs for Medicare beneficiaries who meet SCD-HeFT indications. Despite the mounting evidence demonstrated in clinical
trials such as SCD-HeFT, only about 25 percent of all patients in the U.S. who are indicated for an ICD actually receive
one and significantly less than that outside the U.S., leaving hundreds of thousands of people at an increased risk for sudden
cardiac death. In June 2005, we announced the FDA approval of our EnTrust dual and single-chamber ICDs. EnTrust offers ATP
During Charging, a feature that automatically uses pacing pulses to painlessly stop fast, dangerous heartbeats, while concurrently
preparing to deliver a shock if needed, with no delay. EnTrust also has our new pacing mode MVP, which has been shown to reduce
the amount of right ventricular pacing to less than 5 percent, compared to 50 percent or more from ICDs with typical dual-chamber
pacing. In a clinical study of this new mode, 78 percent of patients experienced ventricular pacing less than 1 percent of
the time. For patients with little or no pacing needs, this clinical difference can be dramatic over a lifetime.</P>
<P style="font-size:10pt"> Heart failure is a large and growing health problem,
afflicting nearly 5 million Americans and 22 million people worldwide. Up to 550,000 new cases are diagnosed each year,
making it the most costly cardiovascular illness in the U.S., with an estimated $30 billion spent on managing heart failure
each year. For patients suffering from heart failure, we offer devices that provide cardiac resynchronization therapy (CRT),
which improves the efficiency of the heart by synchronizing the contractions of multiple heart chambers. Our InSync CRT system
is the world’s first tri-chamber heart device. The InSync III, our third generation cardiac resynchronization device,
has advanced programming functions to help physicians better manage heart failure patients and is available in both Europe
and the U.S. In March 2005, the results of the Cardiac Resynchronization in Heart Failure (CARE-HF) trial were reported at
the American College of Cardiology conference and concurrently published in the <I>New England Journal of Medicine.</I> This
813 patient study showed that patients who received Medtronic’s CRT showed a 37 percent reduction in combined all-cause
mortality or unplanned cardiovascular hospitalization. CRT patients in the study also showed a reduction in heart failure-related
hospitalizations and improved heart failure symptoms.</P>
<P style="font-size:10pt"> Medtronic continues to offer the industry’s broadest
selection of devices and features for the growing number of patients with heart failure who are also considered at high risk
of sudden cardiac arrest. Our InSync Sentry is a cardiac resynchronization device with defibrillator back-up (CRT-D) that offers
our exclusive OptiVol feature. OptiVol provides automatic fluid status monitoring in the thoracic cavity, the chest area encompassing
the lungs and heart. We believe that this feature will provide an advantage in managing heart failure, since thoracic fluid
accumulation is a primary indicator of worsening heart failure and often results in patient hospitalizations. Our InSync Maximo
is a CRT-D device that incorporates CRT to treat heart failure and the capacity to deliver high-output defibrillation energy
to stop a lethally fast heart rhythm. The InSync Maximo provides 35 joules of delivered energy and the industry leading charge
times in treating sudden cardiac arrest. Both the InSync Maximo and the InSync Sentry offer sequential biventricular pacing
or “V-to-V” (ventricle to ventricle) timing, a feature that allows physicians to separately adjust the timing of
electrical therapy delivered to the heart failure patient’s two ventricles, which can optimize the beating of the heart
and enhance the flow of blood throughout the body. Our CRT-D systems also offer unique ICD therapies, including anti-tachycardia
pacing (ATP) options for the pain-free termination of life-threatening tachyarrhythmias. These CRT-D devices represent an important
clinical advance since sudden cardiac arrest occurs in heart failure patients at six to nine times the rate observed in the
general population.</P>
<P style="font-size:10pt"> In March 2005, we announced the introduction of the
Attain Select 6238 TEL Guide Catheter, which aids in the safe implantation of device leads in the veins that serve the left
side of the heart for the treatment of heart failure. This catheter is part of a family of catheters that are highly specialized
and innovatively designed to give physicians a broad range of choices as they work from outside the body to safely and effectively
maneuver in tortuous veins between the lower chambers of the heart. In August 2005, we announced FDA approval to distribute
the SelectSecure Lead System (Model 3830). SelectSecure
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">4</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
is the world’s thinnest bipolar pacing lead. Its unique lumenless design allows for flexibility and a smaller body size
without sacrificing insulation thickness. SelectSecure is also the industry’s first lead designed to enable physicians
to reach selective sites of the right side of the heart.</P>
<P style="font-size:10pt"> In March 2006, we received Conformité Européenne
approval, or CE Mark approval, for the Virtuoso ICD and the Concerto CRT-D and received FDA approval in the first quarter of
fiscal year 2007. Market release of these devices commenced in the first quarter of fiscal year 2007. In the U.S., the system
will utilize the Medtronic CareLink Network mentioned below to transmit data from patients’ devices to their physicians
remotely. The Concerto/Virtuoso family represents our next step in the delivery of premium implantable devices, which, in addition
to MVP and ATP During Charging, will include for the first time OptiVol Fluid Status Monitoring
and Conexus Wireless Telemetry.</P>
<P style="font-size:10pt"> <B><I>Patient Management Tools.</I></B> We
have two types of patient management tools. In May 2005, we announced FDA approval to distribute a wireless-enabled, in-clinic
programmer, the Medtronic CareLink programmer (Model 2090). The new programmer version will enable wireless communication with
implanted devices using high-speed data connectivity. This approval sets the foundation for efficient and flexible clinician
access to important information retrieved from Medtronic devices that can help guide the care of chronic disease. The Medtronic
CareLink Network, currently available in the U.S., was developed to allow physicians to evaluate patient information remotely
via the Internet, offering the potential for more efficient chronic disease management and better patient outcomes. The Medtronic
CareLink Network connects cardiac device patients and physicians for “virtual office visits,” allowing patients with
our heart devices to receive medical care from the comfort of their home or even while traveling. Patients using the Medtronic
CareLink Network can send data about their heart and ICD activity to their physician from anywhere in the 50 states by holding
a small “antenna” over their implanted device. The system monitor automatically downloads the data from the “antenna”
and sends it through a standard telephone connection directly to the secure Medtronic CareLink Network. Clinicians access their
patients’ data by logging onto the clinician website from any Internet-connected computer, eliminating the need for an
office visit. A physician can use the diagnostic and therapeutic data collected by a CRDM device and then tailor various device
parameters to meet the individual needs of the patient. Patients also can view information about their device and condition
on their own personalized website, and family members or other caregivers can view this information if granted access by the
patient. The Medtronic CareLink Network is currently available to pacemaker patients with the Kappa family, EnPulse, and EnRhythm
pacemakers. ICDs or CRT-Ds
devices compatible with the Medtronic CareLink Network include the Medtronic GEM III family, Marquis family, Maximo
and EnTrust ICDs as well as our InSync Marquis, InSync II Marquis, InSync Maximo and InSync Sentry CRT-Ds. Today, the Medtronic
CareLink Network is being utilized in more than 900 electrophysiology clinics/practices and more than 70,000 patients are being
monitored with the Medtronic CareLink Network. In the future, tens of thousands of people with our other implantable cardiac
devices potentially could benefit from this innovative system, as it is designed to support all of our implanted cardiac rhythm
devices.</P>
<P style="font-size:10pt"> In August 2005, we announced FDA approval of our CardioSight
Service, an in-clinic data access tool now available to physicians treating heart failure patients who have one of several
Medtronic CRT-D or ICD devices. CardioSight provides clinically valuable, device-derived information to help specialty physicians
discern the status of the heart failure patient’s symptoms.</P>
<P style="font-size:10pt"> <B><I>External Defibrillators.</I></B> Many
victims of sudden cardiac arrest could be saved if they had quicker access to automated external defibrillators (AEDs). Nationally,
the survival rate for victims of sudden cardiac arrest is only about 5% because the average response time to an emergency call
for help is six to twelve minutes. Chances of survival are reduced significantly if the victim is not treated within five minutes.
In August 2004, results from the largest-ever clinical trial studying the outcomes of public access to defibrillation
were published in the <I>New England Journal of Medicine.</I> The data indicated that the use of portable AEDs by trained volunteers
can significantly improve the probability of saving lives that otherwise might have been lost to sudden cardiac arrest. Our
LIFEPAK series of external defibrillators offers a broad range of life-saving tools for multiple user needs and have been incorporated
in environments ranging from hospitals to emergency medical units to public places such as airports, sports arenas, schools
and workplaces. Today there are more than 500,000 LIFEPAK devices distributed
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">5</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
worldwide. We collaborate with Walgreens Co. and Costco Wholesale Corporation to offer AEDs by prescription on their respective
electronic commerce websites, <U>www.walgreens.com</U> and <U>www.costco.com</U>. These partnerships are designed to help
small businesses and consumers more easily access the life saving therapy of AEDs to protect their customers and their families.
In April 2005, we announced the Keep the Beat campaign, a nationwide outreach and education program designed to raise awareness
of sudden cardiac arrest and the benefits of early defibrillation. The initial phase of the Keep the Beat campaign raised
funds to support Neighborhood Heart Watch, a non-profit organization that helps implement AED programs in schools
across the country. AED placement in schools is important since up to 20 percent of the combined child and adult U.S. population
can be found in schools on any given school day.</P>
<P style="font-size:10pt"> <B><I>Customers and Competitors</I></B>
</P>
<P style="font-size:10pt"> The primary medical specialists who use our implanted
cardiac rhythm devices include electrophysiologists, implanting cardiologists, heart failure specialists, and cardiovascular
surgeons. We hold the leading market position among implantable cardiac rhythm device manufacturers. The primary customers
for our AED products are hospitals, schools, governments, businesses, and any other public facility. Our primary competitors
in the CRDM business are Boston Scientific Corporation, as a result of its recent acquisition of Guidant Corporation, and St.
Jude Medical, Inc. Our primary competitors in the AED business are Cardiac Science, Inc., Zoll Medical Corporation and
Royal Philips Electronics.</P>
<P style="font-size:10pt;font-weight:bold">Spinal and Navigation</P>
<P style="font-size:10pt"> Our Spinal and Navigation business provides spinal
products and image guided surgery systems that facilitate surgical planning and are used by surgeons during precision cranial
and orthopedic surgeries. Today we offer a wide range of products and therapies to treat a variety of conditions of the cranium
and spine that often dramatically impair the quality of life.</P>
<P style="font-size:10pt"> <B><I>Conditions Treated</I></B>
</P>
<P style="font-size:10pt"> Our Spinal business offers products for treatment
of the conditions described below.</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">•</TD>
<TD WIDTH="92%">Herniated Disc — A disc herniation occurs when the inner core of the intervertebral disc bulges out through
the outer layer of ligaments that surround the disc. This tear in the outer layer of ligaments causes pain in the back at the
point of herniation. If the protruding disc presses on a spinal nerve, the pain may spread to the area of the body that is
served by that nerve. The terms “ruptured,” “slipped,” and “bulging” are also commonly used to
describe this condition.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Degenerated Disc — As part of the natural aging process, intervertebral discs lose their flexibility and shock absorbing
characteristics. The ligaments that surround the discs become brittle and easier to tear. At the same time, the inner core
of the disc starts to dry out and shrink. Over time, these changes can cause the discs to lose their normal structure and/or
function.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Spinal Deformity — When viewed from behind, the human spine appears straight and symmetrical. When viewed from the
side, however, the spine is curved. Some curvature in the neck, upper trunk, i.e., forward bend, and lower trunk, i.e., backward
bend is normal. These curves help the upper body maintain proper balance and alignment over the pelvis. The term deformity
is used to describe any variation in this natural shape. One form of spinal deformity, scoliosis, involves a lateral, i.e.,
side-to-side, curvature of the spine. The vertebrae rotate along with the spine as a consequence of a scoliotic curve. Depending
on the severity of the curve, a scoliotic spine may create asymmetries in the shoulders, thoracic spine, and pelvis, leading
to an imbalance of the trunk and significant disfigurement.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Spinal Tumors — Tumors or cancers of the spine and spinal cord are relatively rare. Three types of tumors affect the
spine and spinal cord: primary benign tumors, primary malignant tumors, and metastatic tumors. The term primary is used to
designate a tumor originating from actual spine cells. Secondary spinal tumors, or cancers, which are more commonly called
metastases, spread from other organs in the body.</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">6</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD width="4%"> </TD>
<TD width="4%">•</TD>
<TD width="92%">Trauma/Fracture — Trauma to the spine refers to injury that has occurred to bony elements, soft tissues
and/or neurological structures. Stability to the spinal column can be compromised when bony elements are injured or there is
disruption to soft tissues such as ligaments. Instability causes the back to become unable to successfully carry normal loads,
which can lead to permanent deformity, severe pain, and, in some cases, catastrophic neurological injuries. Most often the
instability comes from a fracture in one of the bony parts of the vertebra. Osteoporosis, a condition characterized by loss
of bone mass and structural deterioration of bone tissue, can lead to bone fragility and an increased susceptibility to fracture.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Stenosis — A condition caused by a gradual narrowing of the spinal canal, stenosis results from degeneration of both
the facet joints and the intervertebral discs. Bone spurs, called osteophytes, which develop because of the excessive load
on the intervertebral disc, grow into the spinal canal. The facet joints also enlarge as they become arthritic, which contributes
to a decrease in the space available for the nerve roots.</TD>
</TR>
</TABLE>
<P style="font-size:10pt"> The charts below set forth net sales of our Spinal
and Navigation products as a percentage of our total net sales for each of the last three fiscal years:</P>
<DIV align="center">
<img src="a62430spinal.jpg"></DIV>
<P style="font-size:10pt"> Our Spinal and Navigation products, used in surgical
procedures of the cranium and spine, include thoracolumbar, cervical and interbody devices, bone growth substitutes and surgical
navigation tools.</P>
<P style="font-size:10pt"> <B><I>Spinal.</I></B> Each year
approximately 25 million Americans experience back pain that is severe enough to visit a healthcare professional. Of the
approximately 25 million Americans, 13 million endure a significant impairment of activity. We are committed to providing
spinal surgeons with the most advanced options for treating low back pain and other spinal conditions.</P>
<P style="font-size:10pt"> Today we offer one of the industry’s broadest
lines of devices, instruments, computerized image guidance products and biomaterials used in the treatment of spinal conditions,
including a wide range of sophisticated internal spinal stabilization devices. Our spinal products are used in spinal fusion
of both the thoracolumbar, the mid to lower vertebrae, and cervical, the upper spine and neck, regions of the spine. Spinal
fusions, which are currently one of the most common types of spine surgery, join the vertebrae to eliminate pain caused by
movement of the unstable vertebrae. Products used to treat spinal conditions include rods, pedicle screws, hooks, plates, and
interbody devices, such as cages, as well as biologics, which include bone growth substitutes, dowels and wedges. INFUSE Bone
Graft contains a recombinant human bone morphogenetic protein, or rhBMP-2, that induces the body to grow its own bone, eliminating
the need for a painful second surgery to harvest bone from elsewhere in the body. In early fiscal year 2005, we announced that
the FDA approved the use of INFUSE Bone Graft in the treatment of certain types of acute, open fractures of the tibial shaft,
a long bone in the lower leg. The approval broadens the indications of the use of our INFUSE Bone Graft technology. Since late
fiscal year 2005, we have had the right to market Wyeth’s InductOs Bone Graft, the European equivalent of the INFUSE
Bone Graft, for use in spinal fusion in European markets.</P>
<P style="font-size:10pt"> We have developed a series of Minimal Access Spinal
Technologies (MAST) that allow safe, reproducible access to the spine with minimal disruption of vital muscles and complementary
structures. These techniques involve the use of advanced navigation and instrumentation to allow surgeons to
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">7</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
operate with smaller incisions and less tissue damage than traditional surgeries, thus reducing pain, blood loss and improving
recovery periods. MAST techniques have been described as having the same impact on spinal fusion surgery that arthroscopy had
on knee surgery. Our expanding portfolio of minimally invasive spinal technologies includes the CD HORIZON SEXTANT II System,
which was launched in September 2005. Also launched in fiscal 2006
were a next-generation METRx System, to treat herniated discs and allow minimally invasive access for fusion, the
MAST QUADRANT Retractor System, a retractor that allows access to complex degenerative pathology, and the CD HORIZON ECLIPSE
Spinal System, to correct curvature of the spine in scoliosis patients. Fiscal 2006 also saw the launch of the TSRH SiLo system,
a thoracolumbar fixation system used to treat degenerative pathologies as well as spinal deformities and trauma, and the Mystique
Cervical Plate, the market’s first resorbable spinal plate.</P>
<P style="font-size:10pt"> In December 2005, we announced the completion of enrollment
in the PRESTIGE LP Cervical Disc clinical trial, our fourth major artificial disc trial. In addition to the PRESTIGE LP Cervical
Disc clinical trial, we have three other disc replacement programs currently under investigation in the U.S.: the
BRYAN Cervical Disc, obtained through the acquisition of Spinal Dynamics Corporation in October 2002; the MAVERICK Artificial
Disc for the lumbar spine; and the PRESTIGE ST Cervical Disc, an internally developed cervical disc. Fiscal year 2006 also
marked the filing of two U.S. Investigational Device Exemptions, which serve as a precursor to U.S. approval, for the DIAM
posterior dynamic stabilization device. These trials are both expected to begin patient enrollment in fiscal year 2007. In
addition to these studies in the dynamic stabilization realm, Medtronic also announced the filing of two pre-market approvals
for INFUSE Bone Graft– one for a posterolateral spinal indication, and the other for approval for use in oral/maxillofacial
indications.</P>
<P style="font-size:10pt"> <B><I>Navigation.</I></B> We are
one of the leaders in the field of computer-assisted surgery (CAS) and have installed approximately 2,000 StealthStation Treatment
Guidance Systems in hospitals worldwide. In recent years, the pace of innovation in CAS has quickened considerably. In response,
we have developed and delivered new and updated hardware and software solutions to assist with varied surgeries including total
joint replacements, minimally invasive spinal surgery, cranial tumor resection, biopsies, functional neurosurgery and functional
endoscopic sinus surgery. In September 2005, Medtronic and Breakaway Imaging, LLC, a privately held developer of medical imaging
systems for surgery, announced an agreement that grants exclusive worldwide distribution and marketing of Breakaway Imaging’s
O-arm Imaging System, an intraoperative crossover technology enabling two-dimensional, or fluoroscopy, multi-plane two-dimensional,
and three-dimensional volumetric imaging system, to Medtronic.</P>
<P style="font-size:10pt;font-weight:bold"></P>
<P style="font-size:10pt"> <B><I>Customers and Competitors</I></B>
</P>
<P style="font-size:10pt"> The primary medical specialists who use our Spinal
and Navigation products are spinal surgeons, orthopedic surgeons and neurosurgeons. Our primary competitors in the Spinal business
are Zimmer, Inc., Johnson & Johnson, Stryker Corporation, and Synthes-Stratec, Inc. The primary competitors
in our Navigation business are BrainLAB, Inc. and Stryker Corporation.</P>
<P style="font-size:10pt;font-weight:bold">Neurological</P>
<P style="font-size:10pt"> Our Neurological business develops, manufactures,
and markets devices for neurological disorders, gastroenterological disorders and urological disorders. We are a pioneer in
the field of restorative neuroscience, using site-specific neurostimulation and drug delivery to modulate and restore nervous
system function. Through close partnerships with our customers we have developed a unique portfolio of therapeutic technologies
for the treatment of debilitating chronic diseases that represent large, unmet medical needs.</P>
<P style="font-size:10pt"> In the fourth quarter of fiscal year 2006, we created
a dedicated organization within the Neurological operating segment called Emerging Therapies. This new organization will focus
on assessing new therapy opportunities and overseeing initial clinical study, market development activities and other business
development activities. The initial focus of the Emerging Therapies organization will be for the treatments of epilepsy, obesity,
and psychiatric disorders including obsessive-compulsive disorder, as well
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">8</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
as depression. The initial focus in these three areas will be to leverage neurological stimulation technology to develop therapies
to help meet these large unmet patient populations.</P>
<P style="font-size:10pt"> <B><I>Conditions Treated</I></B>
</P>
<P style="font-size:10pt"> Our Neurological business offers products for the
treatment of the conditions described below.</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">•</TD>
<TD WIDTH="92%">Neurological disorders — including Parkinson’s disease, essential tremor, chronic pain, spasticity
and dystonia</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Urological and digestive disorders — including gastroparesis, incontinence and enlarged prostate or benign prostatic
hyperplasia</TD>
</TR>
</TABLE>
<P style="font-size:10pt"> The charts below set forth net sales of our Neurological
products as a percentage of our total net sales for each of the last three fiscal years:</P>
<DIV align="center">
<img src="a62430neuro.jpg"></DIV>
<P style="font-size:10pt"> Our Neurological products consist of therapeutic and
diagnostic devices, including implantable neurostimulation systems, external and implantable drug administration devices, urology
products, gastroenterology products, functional diagnostic and sensing equipment.</P>
<P style="font-size:10pt"> <B><I>Neurological.</I></B> We produce
implantable systems that deliver drugs or electrical stimulation to the spinal cord, brain, and other parts of the nervous
system to treat chronic pain and movement disorders, as well as incontinence and gastroparesis. In April 2005, we announced
the launch of the RESTORE System, a rechargeable neurostimulator with the most powerful and longest lasting rechargeable battery
available. The introduction of the RestorePRIME System follows the recent launch of the Medtronic Restore neurostimulator,
and is a 16-electrode, non-rechargeable neurostimulator. In fiscal year 2006, we offered our new patient-activated pain control
device which is now available in the U.S. for people with difficult-to-treat chronic pain. The device, called the Patient
Therapy Manager enables patients with SynchroMed II drug pumps to respond to episodes of increased pain by delivering supplemental
doses of pain medication pre-prescribed by a physician. Previously, pump patients received a constant dose of pain medication
that had been pre-set by a physician using a programmer.</P>
<P style="font-size:10pt"> Additionally, in fiscal year 2006 we continued to
make progress in clinical trials designed to extend the application of our neurostimulation technologies to new neurological
disorders from which patients suffer. We continued to make progress in the Stimulation of the Anterior Nucleus of the
Thalamus for Epilepsy (SANTE) study for the Intercept Epilepsy Control System, our deep brain stimulation therapy
for patients with epilepsy. Epilepsy is a condition that affects more than 2.7 million Americans, and about one-third
of these people do not respond to current treatment options and continue to experience seizures. As pioneers in the area of
deep brain stimulation, we continue to explore innovative new ways to use deep brain stimulation for psychiatric disorders.
We are also evaluating our technologies in patients suffering from treatment-resistant depression and are targeting
the receipt of a Humanitarian Device Exemption (HDE) from the FDA in order to offer Activa Deep Brain Stimulation Therapy for
the treatment of chronic, treatment-resistant obsessive-compulsive disorder.</P>
<P style="font-size:10pt"> <B><I>Gastroenterology and Urology.</I></B> Our
diagnostic and therapeutic products for gastroenterology and urology include the EnterraTherapy for gastroparesis and the Bravo
pH Monitoring System for the
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">9</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
evaluation of gastroesophageal reflux disease, or GERD. They also include our InterStim Therapy for overactive bladder and urinary
retention, our recently approved PROSTIVA, our next generation device for treating enlarged prostate, and our functional diagnostic
equipment.</P>
<P style="font-size:10pt"> InterStim therapy for the treatment of overactive
bladder and urinary retention remains our largest product line in the area of gastroenterology and urology. Thanks to market
development efforts, InterStim therapy is increasingly accepted by physicians as an effective treatment option for bladder
control problems. Likewise, our Bravo pH diagnostic, a minimally invasive technology that encapsulates a small radio transmitter
for use in assessing pH levels and monitoring gastric reflux, is becoming more widely recognized by physicians and patients
for allowing subjects to enjoy their regular diet and activities without the embarrassment and discomfort associated with traditional
pH testing.</P>
<P style="font-size:10pt"> <B><I>Customers and Competitors</I></B>
</P>
<P style="font-size:10pt"> The primary medical specialists who use our neurological
products are neurosurgeons, neurologists, pain management specialists, and orthopedic spine surgeons. The primary medical specialists
who use our gastroenterology and urology products are urologists, urogynecologists and gastroenterologists. Our primary competitors
for neurological products are Johnson & Johnson, Boston Scientific Corporation, St. Jude Medical, Inc. and Stryker
Corporation. Our primary competitors for gastroenterology and urology products are Boston Scientific Corporation, Urologix, Inc.
and American Medical Systems.</P>
<P style="font-size:10pt;font-weight:bold">Vascular</P>
<P style="font-size:10pt"> Our Vascular business offers a full line of minimally
invasive products and therapies to treat coronary artery disease, aortic and thoracic aneurysms and peripheral vascular disease.</P>
<P style="font-size:10pt"> <B><I>Conditions Treated</I></B>
</P>
<P style="font-size:10pt"> Our Vascular business offers minimally invasive products
for the treatment of the conditions described below.</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">•</TD>
<TD WIDTH="92%">Coronary artery disease — deposits of cholesterol and other fatty materials (plaque) on the walls
of the heart’s arteries, causing narrowing or blockage of the vessel and reducing the blood supply to the heart</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Peripheral vascular disease — narrowing or blockage of arteries or veins outside the heart, impeding blood supply
to vital organs</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Abdominal/Thoracic aortic aneurysm (AAA/TAA) — weakening, and ballooning of the abdominal aorta and weakening
or dissection of the thoracic aorta</TD>
</TR>
</TABLE>
<P style="font-size:10pt"> The charts below set forth net sales of our Vascular
business as a percentage of our total net sales for each of the last three fiscal years:</P>
<DIV align="center">
<img src="a62430vascular.jpg"></DIV>
<P style="font-size:10pt"> Our Vascular products include coronary, endovascular,
and peripheral stents and related delivery systems, stent graft systems, distal embolic protection systems and a broad line
of balloon angioplasty catheters, guide catheters, guidewires, diagnostic catheters and accessories.</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">10</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
<B><I>Coronary Stents.</I></B> If a blockage in a coronary artery prevents the heart from receiving sufficient
oxygen, the heart cannot function properly and a heart attack or stroke may result. Coronary artery disease is commonly treated
with balloon angioplasty, a procedure in which a special balloon is threaded through the coronary artery system to the site
of the arterial blockage, where it is inflated, pressing the obstructive plaque against the wall of the vessel to improve blood
flow.</P>
<P style="font-size:10pt"> Following balloon angioplasty, physicians often place
coronary stents at the blockage site to prop open diseased arteries to maintain blood flow to the heart. Stents are cylindrical,
wire-mesh devices small enough to insert into coronary arteries. Our new-generation coronary stent system, the Driver, is the
first modular stent to be composed of an advanced cobalt-based alloy, which surpasses the limitations of stainless steel by
creating very strong, ultra-thin struts that offer excellent flexibility and vessel support. The Driver stent launched in Japan
in August 2004 and is now available in all major markets worldwide. The Micro-Driver coronary stent system received FDA approval
in April 2006. The Micro-Driver is a bare metal system designed specifically to perform in small vessels and tortuous anatomies.
This cobalt-alloy stent is the first bare metal stent for small vessels with an indication for new or untreated vessels (a
de novo indication), addressing an important need in the treatment of coronary artery disease.</P>
<P style="font-size:10pt"> <B><I>Drug Eluting Stents</I></B> Drug
eluting stents are designed to inhibit the re-narrowing or re-clogging of arteries, known as restenosis, after placement of
a stent. Our Endeavor Drug-Eluting Coronary Stent combines an innovative delivery system leveraging our discrete technology,
our advanced Driver cobalt-alloy stent, an effective drug — Zotarolimus (ABT-578 a sirolimus analogue), and a biomimetic
polymer coating that controls the release of the drug into the vessel wall. In May 2002, we entered into a ten year agreement
with Abbott Laboratories (Abbott) granting us co-exclusive use of Abbott’s proprietary immunosuppressant drug ABT-578,
as well as the phosphoryl choline coating Abbott has licensed from Biocompatibles International PLC for use in conjunction
with ABT-578. Clinical and preclinical studies have shown that this proprietary biocompatible polymer, which mimics the outer
membrane of a red blood cell is safe and thromboresistant.</P>
<P style="font-size:10pt"> Our Endeavor Drug-Eluting Coronary Stent program achieved
a number of significant regulatory and clinical milestones during fiscal year 2006. In July 2005, we received CE Mark approval
for the commercial sale of the Endeavor Drug-Eluting Coronary Stent with the Rapid Exchange Delivery System in European Union
member countries, making Endeavor the first cobalt alloy platform on the drug-eluting stent market. Endeavor has now been approved
in more than 85 countries outside the U.S.</P>
<P style="font-size:10pt"> In September 2005, 24-month and 12-month results
from the ENDEAVOR I and the ENDEAVOR II clinical trials, respectively, were presented at the European Society of Cardiology
medical conference in Stockholm, Sweden. The results from both of these trials demonstrated that the efficacy and safety of
the Endeavor stent is durable over longer follow-up periods, with no observations of late stent thrombosis. In May 2006, 36-month
and 24-month results from the ENDEAVOR I and the ENDEAVOR II clinical trials, respectively, were presented at the Paris Course
on Revascularization. The 36-month and 24-month results showed that Endeavor Drug-Eluting Coronary Stent continued to provide
significant and sustained efficacy and safety performance over time, with low rates of repeat procedures and no observation
of late stent thrombosis. The ENDEAVOR II trial included 1,197 patients comparing the Endeavor Drug-Eluting Coronary Stent
to Medtronic’s Driver cobalt-alloy stent. In October 2005, results of the ENDEAVOR III clinical trial were presented at
the Transcatheter Cardiovascular Therapeutics scientific symposium in Washington, D.C. The ENDEAVOR III trial, a confirmatory
study supporting U.S. approval, demonstrated that the Endeavor drug-eluting coronary stent provides clinical and angiographic
outcomes that are consistent with the ENDEAVOR I and ENDEAVOR II trials. ENDEAVOR III is a 436-patient equivalency study comparing
our Endeavor Drug-Eluting Coronary Stent to the Johnson & Johnson Cypher Sirolimus-eluting stent. Despite narrowly
missing the angiographic primary endpoint, there were no statistical differences in clinical outcomes between Endeavor and
Cypher. Enrollment continues in ENDEAVOR IV, the fourth and final phase of our U.S. clinical program for the Endeavor Drug-Eluting
Stent. ENDEAVOR IV will include 1,548 patients randomized one-to-one against the Taxus Paclitaxel-Eluting Coronary Stent System
from Boston Scientific Corporation. We expect to complete patient enrollment in Endeavor IV in the first quarter of fiscal
year 2007. We continue to progress toward the U.S. launch of our Endeavor Drug-Eluting Stent, which will be the first drug-eluting
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">11</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
stent on the U.S. market utilizing the advanced technology of a cobalt-alloy stent. In October 2005, we announced the submission
of the first module of the pre-market approval application to the FDA for the Endeavor Drug-Eluting Coronary Stent system.
This action represented the first step towards U.S. approval, which is expected during calendar 2007.</P>
<P style="font-size:10pt"> <B><I>Endovascular Stent Grafts, Peripheral Stents
and Embolic Protection Systems.</I></B> Our Vascular product line includes a range of endovascular stent
grafts and other peripheral vascular products. These include the market-leading AneuRx and Talent Stent Grafts for minimally
invasive AAA and TAA repair. Our AneuRx Stent Graft system is available in the U.S. and Europe, while the Talent AAA and Thoracic
Stent Graft systems are available in Europe and the rest of the world, excluding Japan. In July 2005, we announced the commercial
release of the Valiant Thoracic Stent Graft with the Xcelerant Delivery System, a next-generation stent graft. The Xcelerant
Delivery System is designed to provide physicians with a smooth, controlled and more trackable delivery platform. The Xcelerant
Delivery System is also available for use with the Talent Stent Graft in markets outside the U.S. In March 2006, we announced
that it has received FDA approval of the AneuRx AAAdvantage AAA stent graft with the Xcelerant Delivery System. Enhancements
to the new AAAdvantage system include contoured stents, broader proximal and distal sealing, and improved radiopaque markers.
These enhancements will provide greater patient applicability, help reduce the complexity of the procedure and upgrade the
durability of the stent graft. In June 2005, we announced FDA 510(k) clearance and market availability for the Reliant Stent
Graft Balloon Catheter, a multipurpose catheter used for temporary occlusion of large vessels and the expansion of vascular
prostheses.</P>
<P style="font-size:10pt"> In peripheral vascular, we offer balloon expandable
and self-expanding biliary stents that are designed to maintain bile flow in liver ducts restricted or blocked by malignant
tumors. In March 2006, we received CE mark for our Exponent RX Self-Expanding Carotid Stent used to treat patients afflicted
by carotid artery disease. The Exponent is used in conjunction with our next generation filter-based embolic protection device,
the Interceptor Plus, which also received CE mark in March 2006 for carotid and vein graft indications, and which is
undergoing clinical trials in the US. Embolic protection systems are designed to capture debris dislodged from the wall of
the vessel, during balloon angioplasty or placement of a stent, that might otherwise flow downstream toward the heart and result
in complications such as a heart attack or stroke. Our GuardWire Plus System is indicated for use in vein graft interventions
for certain individuals who have previously undergone coronary artery bypass graft (CABG) surgery.</P>
<P style="font-size:10pt"> <B><I>Customers and Competitors</I></B>
</P>
<P style="font-size:10pt"> The primary medical specialists who use our products
for treating coronary artery disease are interventional cardiologists, while products treating peripheral vascular disease
may be used by interventional radiologists, vascular surgeons and interventional cardiologists. Our primary competitors in
the Vascular business are Boston Scientific Corporation, Johnson & Johnson and Abbott Laboratories, Inc. as a result
of its purchase of Guidant’s vascular intervention business.</P>
<P style="font-size:10pt;font-weight:bold">Diabetes</P>
<P style="font-size:10pt"> Our Diabetes business develops, manufactures, and
markets devices for the treatment of diabetes. We are a world leader in advanced, device-based medical systems for the treatment
of diabetes, and we are committed to providing improved tools and technologies to help people with diabetes live longer, healthier
lives.</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">12</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt"> <B><I>Conditions Treated</I></B>
</P>
<P style="font-size:10pt"> Our Diabetes business offers products for the treatment
of diabetes, which is the inability to control blood glucose levels resulting from a failure of the pancreas to produce sufficient
insulin or the body’s inability to properly use insulin.</P>
<P style="font-size:10pt"> The charts below set forth net sales of our Diabetes
business as a percentage of our total net sales for each of the last three fiscal years:</P>
<DIV align="center">
<img src="a62430diabetes.jpg"></DIV>
<P style="font-size:10pt"> Our diabetes products are used to help diabetes patients
maintain near-normal glucose control. Diabetes afflicts roughly 200 million people worldwide, and more than 20 million
people in the U.S. Currently, our insulin pump products serve the insulin-dependent population, which includes approximately
five million people in the U.S. The key to managing diabetes is to maintain tight control of glucose levels. If not well-managed,
diabetes can lead to blindness, kidney failure, amputation, impotence and heart failure. More than $132 billion is spent
annually on diabetes and its complications, including $92 billion in direct medical costs.</P>
<P style="font-size:10pt"> Our products include external insulin pumps and related
disposables, continuous glucose monitoring systems, a subcutaneous glucose sensor and an implantable insulin pump. Our external
insulin pumps are primarily used by patients with type 1 diabetes, which occurs when the pancreas is unable to produce
insulin. In order to survive, people with type 1 diabetes must administer insulin using injections or an insulin pump.
Our therapies are also helpful in managing type 2 diabetes, which results from the body’s inability to produce enough
insulin or properly use the insulin.</P>
<P style="font-size:10pt"> Our family of MiniMed Paradigm insulin pumps is currently
the leading choice in insulin pump therapy. Worn on a belt like a pager, the MiniMed Paradigm insulin pump offers a simplified
and intuitive menu system to program insulin delivery, making it easier for people with diabetes to manage their disease without
daily insulin injections. Because pump therapy delivers insulin precisely to the body, it helps diabetes patients keep their
glucose levels within a near-normal range, offering both short-term and long-term health benefits.</P>
<P style="font-size:10pt"> In fiscal year 2006, we announced the launch outside
the U.S. of Guardian RT continuous glucose monitoring system, a device that displays real-time glucose readings around the
clock and alerts patients to high and low glucose levels. In July 2005, we received FDA approval of our Guardian RT continuous
glucose monitoring system and commercialized the product through a controlled market release in seven U.S. cities.</P>
<P style="font-size:10pt"> In April 2006, we received FDA approval of our MiniMed
Paradigm REAL-Time Insulin Pump and Continuous Glucose Monitoring System. For the first time ever, diabetes patients have
a dashboard of information on an insulin pump – from REAL-Time glucose readings – to trend graphs – to arrows
that indicate how fast and in which direction glucose is heading, adding a new layer of safety and control. This allows patients
to more effectively manage diabetes. This system was introduced in Canada, Europe, and the Middle East in 2005, and continues
to be introduced in countries around the world. We also made the Medtronic CareLink Therapy Management for Diabetes available
for use with the MiniMed Paradigm 522 and 722 insulin pumps. The Medtronic CareLink Therapy Managed System for Diabetes provides
a patient management system for use by patients and physicians, aiding the efficacy of overall disease management.</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">13</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt"> In order to drive broad acceptance of this new technology,
we are conducting the Sensor-augmented Therapy for A1C Reduction trials, or STAR trials, which will evaluate sensor-augmented
therapy versus traditional insulin pumps and multiple daily injection therapy. The strategic objective of the STAR trials is
to drive acceptance and improved reimbursement for insulin pump therapy and real-time continuous glucose monitoring using the
results anticipated from the data. Enrollment is complete in the first two phases of the trial and enrollment in the third
phase (STAR 3) is expected to commence in the first half of fiscal year 2007.</P>
<P style="font-size:10pt"> <B><I>Customers and Competitors</I></B>
</P>
<P style="font-size:10pt"> The primary medical specialists who use our diabetes
products are endocrinologists and internists. Our most significant competitors for diabetes products are Johnson & Johnson,
Roche Ltd., Smiths Group PLC and DexCom, Inc.</P>
<P style="font-size:10pt;font-weight:bold">Cardiac Surgery</P>
<P style="font-size:10pt"> We are a worldwide market leader with products in
revascularization, heart valve repair and replacement, blood management and surgical ablation.</P>
<P style="font-size:10pt"> <B><I>Conditions Treated</I></B>
</P>
<P style="font-size:10pt"> Our cardiac surgery products are used in the treatment
of the conditions described below.</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">•</TD>
<TD WIDTH="92%">Coronary artery disease — blockage in a coronary artery can prevent the heart from receiving sufficient
oxygen, which prevents the heart from functioning properly, potentially resulting in a heart attack</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Heart valve disorders — diseased or damaged heart valves can restrict blood flow or leak, which limits the heart’s
ability to pump blood, causing the heart to work harder to meet the needs of the circulatory system</TD>
</TR>
</TABLE>
<P style="font-size:10pt"> The charts below set forth net sales of our Cardiac
Surgery business as a percentage of our total net sales for each of the last three fiscal years:</P>
<DIV align="center">
<img src="a62430cs.jpg"></DIV>
<P style="font-size:10pt"> Our Cardiac Surgery products consist of perfusion
systems which oxygenate and circulate a patient’s blood during arrested heart surgery, positioning and stabilization systems
for beating heart surgery, products for the repair and replacement of heart valves, surgical accessories and surgical ablation
products.</P>
<P style="font-size:10pt"> <B><I>Coronary Artery Bypass Surgery.</I></B> When
physicians determine that they cannot effectively treat a blockage in a coronary artery using balloon angioplasty or a stent,
they typically turn to cardiac surgery to address the problem. The most common surgical procedure used to treat blockage in
a coronary artery is a CABG. In a CABG procedure, surgeons re-route the blood flow around the blockage by attaching
a graft, usually from an artery or vein from another part of the patient’s body, as an alternative pathway to the heart.
There are two primary techniques, arrested heart surgery and beating heart surgery.</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">14</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
<B><I>Arrested Heart Surgery.</I></B> In a conventional coronary artery bypass procedure, the patient’s
heart is temporarily stopped, or arrested. The patient is placed on a circulatory support system that temporarily replaces
the patient’s heart and lungs and provides blood flow to the body. We offer a complete line of blood-handling products
that form this circulatory support system and maintain and monitor blood circulation and coagulation status, oxygen supply
and body temperature during open heart surgery. In April 2006, we received FDA clearance for the Medtronic Performer Cardiopulmonary
Bypass System, an integrated, compact console capable of providing total support of the circulatory system during a variety
of cardiac surgical procedures, but occupying only a 20-inch by 22-inch space, just a third of the footprint of the time-honored
“heart-lung” consoles. As beating heart surgery has become more popular, the market for arrested heart surgery products
has been declining.</P>
<P style="font-size:10pt"> <B><I>Beating Heart Surgery.</I></B> As
an alternative to conventional bypass surgery, physicians are performing coronary artery bypass surgery on the beating heart
to avoid the complexity and potential risks of arresting the heart. To assist physicians performing beating heart surgery,
we offer positioning and stabilization technologies. These technologies include our Starfish 2 and Urchin heart positioners,
which use suction technology to gently lift and position the beating heart to expose arteries on any of its surfaces. These
heart positioners are designed to work in concert with our Octopus tissue stabilizer, which holds a small area of the cardiac
surface tissue nearly stationary while the surgeon is suturing the bypass grafts to the arteries. It is currently estimated
that beating heart surgeries make up about 20% of the estimated 270,000 coronary artery bypass surgeries that are performed
in the U.S. each year.</P>
<P style="font-size:10pt"> <B><I>Surgical Ablation.</I></B> For
patients undergoing cardiac surgery, who also suffer from atrial arrhythmias, our Cardioblate Ablation System is designed to
allow surgeons to efficiently restore a normal heart rhythm by creating lines of ablation that guide electrical conduction
within the atria. In October 2005, we announced the U.S. introduction of the new, low-profile Cardioblate LP Surgical Ablation
System, the latest addition to our Cardioblate surgical ablation systems, which offers cardiac surgeons new ease and flexibility
in creating ablation lines during open heart procedures.</P>
<P style="font-size:10pt"> <B><I>Heart Valves.</I></B> We offer
a complete line of valve replacement and repair products for damaged or diseased heart valves. Our replacement products include
both tissue and mechanical valves. The valve market continues to shift from mechanical to tissue valves, which is beneficial
to us due to our broad selection of tissue valve products. Our Mosaic bioprosthetic heart valve is a reduced-profile valve
engineered from porcine tissue incorporating a proven flexible stent. The low profile and flexibility of the stent make it
easier for the surgeon to implant the valve. In calendar year 2005 we released our newest tissue valve, the Mosaic Ultra. The
Mosaic Ultra valve includes a reduced sewing ring profile that facilitates the use of a larger valve. Other tissue product
offerings include the Freestyle stentless and Hancock II stented valves. Our mechanical heart valve offerings include the Medtronic
Hall, the ADVANTAGE and the ADVANTAGE Supra bileaflet valves. The ADVANTAGE Supra valve was released in Europe in November
2003 and is designed to allow the implantation of a larger valve thereby optimizing blood flow. Currently, the standard ADVANTAGE
aortic bileaflet valve is under evaluation by the FDA in the U.S. Our valve repair products include the Duran Flexible and
CG Future Band Annuloplasty Systems.</P>
<P style="font-size:10pt"> <B><I>Customers and Competitors</I></B>
</P>
<P style="font-size:10pt"> The principal medical specialists who use our cardiac
surgery products are cardiac surgeons. Our primary competitors in the Cardiac Surgery business are Edwards LifeSciences Corporation,
Boston Scientific Corporation, Johnson & Johnson, and St. Jude Medical, Inc.</P>
<P style="font-size:10pt;font-weight:bold">ENT</P>
<P style="font-size:10pt"> We develop, manufacture and market products and therapies
to treat diseases and conditions of the ear, nose and throat, as well as neurological diseases. As a market leader in ENT and
neurosurgery, we are changing the way ENT surgery is performed with innovative, minimally invasive products and techniques
that benefit both patients and surgeons.</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">15</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt"> <B><I>Conditions Treated</I></B>
</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">•</TD>
<TD WIDTH="92%">ENT diseases and disorders, such as chronic sinusitis, chronic otitis media, hearing loss, Ménière’s
disease, thyroid diseases and tumors of the head and neck.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>Neurological diseases and disorders, including both pediatric and normal pressure hydrocephalus, traumatic brain injury.</TD>
</TR>
</TABLE>
<P style="font-size:10pt"> The charts below set forth net sales of our ENT business
as a percentage of our total net sales for each of the last three fiscal years:</P>
<DIV align="center">
<img src="a62430ent.jpg"></DIV>
<P style="font-size:10pt"> Our primary ENT products include powered tissue-removal
systems and other surgical instruments, implantable devices, nerve monitoring systems, disposable fluid-control products, image-guided
surgery systems, and a Ménière’s disease therapy device. For neurological diseases, our main products include
high-speed powered surgical drill systems to facilitate surgical access in the spine and cranium, shunts for pediatric and
normal pressure hydrocephalus, drainage systems for the treatment of traumatic brain injury, neuroendoscopes, and a full line
of cranial fixation devices that include both titanium and resorbable plates and screws and a dura substitute.</P>
<P style="font-size:10pt"> <B><I>Chronic rhinosinusitis (sinus infections).</I></B>
For the surgical treatment of chronic sinus infections, we offer powered and manual instruments with a variety
of blade tips for removing diseased tissue and bone. Our bioresorbable nasal packing and dressings, such as MeroGel Dressing,
aid in wound-healing and help reduce postoperative complications following these procedures. We also offer image-guided surgery
systems to improve safety and efficacy when surgeons operate near critical structures such as the brain and eyes. The LandmarX
Evolution Plus provides a robust, expandable system that may be used for virtually any ENT image guidance procedure. The LandmarX
Element is a simple and convenient system ideal for FESS (functional endoscopic sinus surgery) and novice IGS users.</P>
<P style="font-size:10pt"> <B><I>Chronic otitis media (ear infections).</I></B>
For the treatment of chronic otitis media, we provide a wide range of middle ear ventilation tubes to facilitate
drainage and prevent fluid accumulation. We also offer powered instruments and drills, such as the XPS 3000 Powered ENT System,
to remove enlarged adenoid tissue, enable surgical access and remove diseased bone. Untreated chronic otitis media is the most
common cause of hearing loss in children, which can impair learning and speech development. It can also spread to other areas
of the head and neck and lead to serious complications.</P>
<P style="font-size:10pt"> <B><I>Hearing loss.</I></B> To correct
conductive hearing loss, we offer various types of implantable middle ear prostheses that replace missing bone(s) in the ear
necessary to conduct sound. These products are malleable/trimmable and may be shaped by the surgeon to fit each particular
patient’s anatomy.</P>
<P style="font-size:10pt"> <B><I>Thyroid disease.</I></B> For
surgery related to thyroid disease, we offer the NIM-Response 2.0 Nerve Integrity Monitor, NIM-Neuro 2.0 Nerve Integrity Monitor
and NIM EMG Tubes. These products assist surgeons in identifying and continuously monitoring the recurrent laryngeal or vagus
nerves during complicated, high-risk thyroid surgery. Since the actual versus perceived incidence of nerve damage during surgery
is much higher, using our nerve monitoring products in these procedures is a benefit to both the patient and the surgeon, reducing
the risk of patient injury and enabling more precise, complete dissection.</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">16</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
<B><I>Ménière’s disease.</I></B> To alleviate debilitating vertigo associated with the
inner ear condition known as Ménière’s disease, we offer the portable, minimally invasive Meniett Low-Pressure
Pulse Generator. Severe vertigo, which can cause nausea and vomiting, is considered by patients to be the most problematic
and debilitating symptom of Ménière’s disease, often causing them to become unable to work or participate
in daily activities. Using Meniett therapy, patients can self-administer their treatment at home or work for a few minutes
each day by delivering low-pressure air pulses through a tube connected to an earpiece placed in the outer ear.</P>
<P style="font-size:10pt"> <B><I>Surgical Access and Cranial Fixation.</I></B>
To facilitate surgical access in cranial, spinal and orthopedic procedures, we offer the Legend electric
and pneumatic high-speed powered surgical drill systems. The Stylus system, the most recent addition to the high-speed drill
line, provides significant power in a small, ergonomic design. We also offer titanium and resorbable polymer plates and screw
systems designed to provide for rigid fixation of the skull. In addition to plates and screws, our Durepair dura substitute
is indicated for use as both an on-lay and suturable graft for repair of the dura skin layer.</P>
<P style="font-size:10pt"> <B><I>Hydrocephalus.</I></B> The
Strata valve is an adjustable shunt system for the treatment of hydrocephalus, a condition characterized by an abnormal accumulation
of cerebral spinal fluid (CSF) in the brain. There are two primary forms of hydrocephalus, congenital or pediatric hydrocephalus,
and normal pressure hydrocephalus, which afflicts the elderly. The Strata valve allows surgeons to non-invasively adjust the
valve’s performance level settings with an external magnetic adjustment device. This enables the surgeon to change the
valve’s performance characteristics over time without subjecting the patient to additional surgery. The shunt line also
includes a wide assortment of nonadjustable valves.</P>
<P style="font-size:10pt"> <B><I>Brain Injury.</I></B> We also
provide a large selection of external drainage and monitoring systems such as the Becker and Exacta systems as well as catheters
that are used for the treatment of traumatic brain injury. These systems are designed to remove fluid from the brain in a controlled
fashion to alleviate the build-up of intracranial pressure, which can be life threatening.</P>
<P style="font-size:10pt"> <B><I>Customers and Competitors</I></B>
</P>
<P style="font-size:10pt"> Our primary customers for products relating to our
ENT diseases and disorders are ENT surgeons and the hospitals and clinics where they perform surgery. The most significant
competitors in this part of our ENT business are Gyrus Group PLC and Stryker Corporation.</P>
<P style="font-size:10pt"> The primary customers for our ENT neurosurgical products
are neurosurgeons, and spinal surgeons and the hospitals and clinics where they perform surgery. Significant competitors are
Johnson & Johnson, Stryker Corporation, Integra Life Sciences Holding Corporation and Anspach Effort, Inc.</P>
<P style="font-size:10pt;font-weight:bold">Research and Development</P>
<P style="font-size:10pt"> The markets in which we participate are subject to
rapid technological advances. Constant improvement of products and introduction of new products is necessary to maintain market
leadership. Our research and development efforts are directed toward maintaining or achieving technological leadership in each
of the markets we serve in order to assure that patients using our devices and therapies receive the most advanced and effective
treatment possible. We are committed to developing technological enhancements and new indications for existing products, as
well as less invasive and new technologies to address unmet patient needs and to help reduce patient care costs and length
of hospital stays. We have not engaged in significant customer or government-sponsored research.</P>
<P style="font-size:10pt"> Our research and development staff regularly works
with clinicians at medical and academic institutions in the development of new technologies and the evaluation and testing
of our products. These relationships are valuable in generating data necessary for regulatory compliance. During fiscal years
2006, 2005 and 2004, we spent $1,112.9 million (9.9% of net sales), $951.3 million (9.5% of net sales) and $851.5 million
(9.4% of net sales), on research and development, respectively. Our research and development activities include improving existing
products and therapies, expanding their indications and applications for use and developing new products. While we continue
to make substantial investments for the expansion of our existing product lines and for the search of new innovative products,
we have also focused heavily on carefully planned clinical trials, which lead to market expansion and enable further penetration
of our life changing devices.</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">17</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt;font-weight:bold">Acquisitions and Investments</P>
<P style="font-size:10pt"> Our strategy to provide a broad range of therapies
to restore patients to fuller, healthier lives requires a wide variety of technologies, products and capabilities. The rapid
pace of technological development in the medical industry and the specialized expertise required in different areas of medicine
make it difficult for one company alone to develop a broad portfolio of technological solutions. In addition to internally
generated growth through our research and development efforts, historically we have relied, and expect to continue to rely,
upon acquisitions, investments, and alliances to provide access to new technologies both in areas served by our existing businesses
as well as in new areas.</P>
<P style="font-size:10pt"> We expect to make future investments or acquisitions
where we believe that we can stimulate the development of, or acquire, new technologies and products to further our strategic
objectives and strengthen our existing businesses. Mergers and acquisitions of medical technology companies are inherently
risky and no assurance can be given that any of our previous or future acquisitions will be successful or will not materially
adversely affect our consolidated results of operations, financial condition, or cash flows.</P>
<P style="font-size:10pt"> On August 26, 2005, we acquired all the outstanding
stock of Image-Guided Neurologics, Inc. (IGN), a privately held company. Prior to the acquisition, we had an equity investment
in IGN, which was accounted for under the cost method of accounting. IGN specialized in precision navigation and delivery technologies
for brain surgery. The IGN product line includes the NexFrame disposable, “frameless” stereotactic head frame, which
is used in conjunction with image-guided surgery systems during deep brain stimulation. This acquisition complements our position
in deep brain stimulation by offering instruments that simplify the procedure for surgeons and improve patient comfort during
surgery. The total consideration for IGN was approximately $65.1 million, which includes $57.9 million in net cash
paid.</P>
<P style="font-size:10pt"> On July 1, 2005, we acquired all of the outstanding
stock of Transneuronix, Inc. (TNI), a privately held company. Prior to the acquisition, we had an equity investment in TNI,
which was accounted for under the cost method of accounting. TNI focused on the treatment of obesity by stimulation of the
stomach with an Implantable Gastric Stimulator, known as the Transcend device. The consideration for TNI was approximately
$268.7 million, which includes $227.3 million in net cash paid. The purchase price is subject to increases which
would be triggered by the achievement of certain milestones. During the third quarter of fiscal year 2006, we announced that
we missed the primary clinical endpoint in the Screen Health Assessment and Pacer Evaluation (SHAPE) trial, a
trial designed to study the efficacy and safety of gastric stimulation to treat obesity. Medtronic will continue following
patients enrolled in the SHAPE trial through 24-months of follow-up. The announcement has no impact on our obesity feasibility
study, Appetite Suppression Induced by Stimulation Trial (ASSIST), which evaluates implantable gastric stimulation therapy
in obese patients with type 2 diabetes. We continue to refine and evaluate the technology, although no definitive determination
has been made about its commercialization.</P>
<P style="font-size:10pt"> On May 18, 2005, we also acquired substantially
all of the spine-related intellectual property and related contracts, rights, and tangible materials owned by Gary Michelson,
M.D. and Karlin Technology, Inc. (Michelson) and settled all outstanding litigation and disputes between Michelson and the
Company. The acquired patents pertain to novel spinal technology and techniques that have both current application and the
potential for future patentable commercial products. The agreement required total consideration of $1,350.0 million for the
purchase of a portfolio of more than 100 issued U.S. patents, over 110 pending U.S. patent applications and numerous foreign
counterparts to these patents and patent applications, and the settlement of all ongoing litigation. A value of $550.0 million
was assigned to the settlement of past damages between the parties and was recorded as an expense in the fourth quarter of
fiscal year 2005. The remaining consideration, including direct acquisition costs, was allocated between $627.5 million of
acquired technology based intangible assets that have a useful life of 17 years and $175.1 million of IPR&D that was expensed
on the date of acquisition. During the first quarter of fiscal year 2006, we paid $1,320.0 million and committed to three future
installments of $10.0 million to be paid in May 2006, 2007, and 2008. The first installment of $10.0 million was paid in May
2006.</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">18</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt;font-weight:bold">Patents and Licenses</P>
<P style="font-size:10pt"> We rely on a combination of patents, trademarks, copyrights,
trade secrets, and nondisclosure and non-competition agreements to establish and protect our proprietary technology. We have
filed and obtained numerous patents in the U.S. and abroad, and regularly file patent applications worldwide in our continuing
effort to establish and protect our proprietary technology. In addition, we have entered into exclusive and non-exclusive licenses
relating to a wide array of third-party technologies. We have also obtained certain trademarks and trade names for our products
to distinguish our genuine products from our competitors’ products, and we maintain certain details about our processes,
products and strategies as trade secrets. Our efforts to protect our intellectual property and avoid disputes over proprietary
rights have included ongoing review of third-party patents and patent applications. See “Item 1A. Risk Factors” and
“Item 3. Legal Proceedings” for additional information.</P>
<P style="font-size:10pt;font-weight:bold">Markets and Distribution Methods</P>
<P style="font-size:10pt"> We sell most of our medical devices through direct
sales representatives in the U.S. and a combination of direct sales representatives and independent distributors in international
markets. The main target markets for our medical devices are the U.S., Western Europe and Japan. Our primary customers include
physicians, hospitals, other medical institutions and group purchasing organizations.</P>
<P style="font-size:10pt"> Our marketing and sales strategy is focused on rapid,
cost-effective delivery of high-quality products to a diverse group of customers worldwide. To achieve this objective, we organize
our marketing and sales teams around physician specialties. This focus enables us to develop highly knowledgeable and dedicated
sales representatives who are able to foster close professional relationships with physicians and other customers, and enhance
our ability to cross-sell complementary products. We believe that we maintain excellent working relationships with physicians
and others in the medical industry that enable us to gain a detailed understanding of therapeutic and diagnostic developments,
trends and emerging opportunities, and respond quickly to the changing needs of physicians and patients. We attempt to enhance
our presence in the medical community through active participation in medical meetings and by conducting comprehensive training
and educational activities. We believe that these activities contribute to physician expertise and loyalty to our products.</P>
<P style="font-size:10pt"> In keeping with the increased emphasis on cost-effectiveness
in healthcare delivery, the current trend among hospitals and other customers of medical device manufacturers is to consolidate
into larger purchasing groups to enhance purchasing power. As a result, transactions with customers have become increasingly
significant, more complex and tend to involve more long-term contracts than in the past. This enhanced purchasing power may
also lead to pressure on pricing and increased use of preferred vendors. We are not dependent on any single customer for more
than 10% of our total net sales.</P>
<P style="font-size:10pt;font-weight:bold">Competition and Industry</P>
<P style="font-size:10pt"> We compete in both the therapeutic and diagnostic
medical markets in more than 120 countries throughout the world. These markets are characterized by rapid change resulting
from technological advances and scientific discoveries. In the product lines in which we compete, we face a mixture of competitors
ranging from large manufacturers with multiple business lines to small manufacturers that offer a limited selection of products.
In addition, we face competition from providers of alternative medical therapies such as pharmaceutical companies. Competitive
factors include:</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">•</TD>
<TD WIDTH="92%">product reliability</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>product performance</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>product technology</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>product quality</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>breadth of product lines</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>product services</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>customer support</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">19</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD width="4%"> </TD>
<TD width="4%">•</TD>
<TD width="92%">price</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>reimbursement approval from healthcare insurance providers</TD>
</TR>
</TABLE>
<P style="font-size:10pt"> Major shifts in industry market share have occurred
in connection with product problems, physician advisories and safety alerts, reflecting the importance of product quality in
the medical device industry. In the current environment of managed care, economically motivated buyers, consolidation among
healthcare providers, increased competition and declining reimbursement rates, we have been increasingly required to compete
on the basis of price. In order to continue to compete effectively, we must continue to create or acquire advanced technology,
incorporate this technology into proprietary products, obtain regulatory approvals in a timely manner and manufacture and successfully
market these products.</P>
<P style="font-size:10pt;font-weight:bold">Worldwide Operations</P>
<P style="font-size:10pt"> For financial reporting purposes, net sales and long-lived
assets attributable to significant geographic areas are presented in Note 15 to the consolidated financial statements
and is set forth in Exhibit 13 hereto and which will be included in our fiscal year 2006 Annual Report to Shareholders
(the “2006 Annual Report”).</P>
<DIV align="center">
<img src="a62430us.jpg"></DIV>
<P style="font-size:10pt;font-weight:bold">Impact of Business Outside of the U.S.</P>
<P style="font-size:10pt"> Our operations in countries outside the U.S. are accompanied
by certain financial and other risks. Relationships with customers and effective terms of sale frequently vary by country,
often with longer-term receivables than are typical in the U.S. Inventory management is an important business concern due to
the potential for obsolescence, long lead times from sole source providers and currency exposure. Currency exchange rate fluctuations
can affect net sales from, and profitability of, operations outside the U.S. We attempt to hedge these exposures to reduce
the effects of foreign currency fluctuations on net earnings. See the “Market Risk” section of Management’s
Discussion and Analysis of Financial Condition and Results of Operations and Note 3 to the consolidated financial statements,
set forth in Exhibit 13 hereto. Certain countries also limit or regulate the repatriation of earnings to the U.S.
In general, operations outside the U.S. present complex tax and cash management issues requiring sophisticated planning and
analysis to meet our financial objectives.</P>
<P style="font-size:10pt;font-weight:bold">Production and Availability of Raw Materials</P>
<P style="font-size:10pt"> We manufacture most of our products at 22 manufacturing
facilities located in various countries throughout the world. The largest of these manufacturing facilities are located in
Arizona, California, Florida, Indiana, Ireland, Massachusetts, Mexico, Minnesota, Puerto Rico, Switzerland, Texas and Washington.
We purchase many of the components and raw materials used in manufacturing these products from numerous suppliers in various
countries. For reasons of quality assurance, sole source availability, or cost effectiveness, certain components and raw materials
are available only from a sole supplier. We work closely with our suppliers to assure continuity of supply while maintaining
high quality and reliability. Due to the FDA’s requirements regarding manufacture of our products, we may not be able
to quickly establish additional or replacement sources for certain components or materials. Generally, we
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">20</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
have been able to obtain adequate supplies of such raw materials and components. However, the reduction or interruption in supply,
and an inability to develop alternative sources for such supply, could adversely affect our operations.</P>
<P style="font-size:10pt;font-weight:bold">Employees</P>
<P style="font-size:10pt"> On April 28, 2006, we employed approximately
36,000 employees. Our employees are vital to our success. We believe we have been successful in attracting and retaining qualified
personnel in a highly competitive labor market due to our competitive compensation and benefits, and our rewarding work environment.
We believe our employee relations are excellent.</P>
<P style="font-size:10pt;font-weight:bold">Seasonality</P>
<P style="font-size:10pt"> Worldwide sales do not reflect any significant degree
of seasonality.</P>
<P style="font-size:10pt;font-weight:bold">Government Regulation and Other Considerations</P>
<P style="font-size:10pt"> Our medical devices are subject to regulation by numerous
government agencies, including the FDA and comparable foreign agencies. To varying degrees, each of these agencies requires
us to comply with laws and regulations governing the development, testing, manufacturing, labeling, marketing and distribution
of our medical devices.</P>
<P style="font-size:10pt"> Authorization to commercially distribute a new medical
device in the U.S. is generally received in one of two ways. The first, known as the 510(k) process, requires us to demonstrate
that our new medical device is substantially equivalent to a legally marketed medical device. In this process, we must submit
data that supports our equivalence claim. If human clinical data is required, it must be gathered in compliance with FDA investigational
device exemption regulations. We must receive an order from the FDA finding substantial equivalence to another legally marketed
medical device before we can commercially distribute the new medical device. Modifications to cleared medical devices can be
made without using the 510(k) process if the changes do not significantly affect safety or effectiveness. A very small number
of our devices are exempt from 510(k) clearance requirements.</P>
<P style="font-size:10pt"> The second, more rigorous process, known as pre-market
approval (PMA), requires us to independently demonstrate that the new medical device is safe and effective. We do this by collecting
data, including human clinical data for the medical device. The FDA will authorize commercial release if it determines there
is reasonable assurance that the medical device is safe and effective. This process is generally much more time-consuming and
expensive than the 510(k) process.</P>
<P style="font-size:10pt"> Both before and after a product is commercially released,
we have ongoing responsibilities under FDA regulations. The FDA reviews design and manufacturing practices, labeling and record
keeping, and manufacturers’ required reports of adverse experience and other information to identify potential problems
with marketed medical devices. We may be subject to periodic inspection by the FDA for compliance with the FDA’s good
manufacturing practice regulations among other FDA requirements, such as restrictions on advertising and promotion. These regulations,
also known as the Quality System Regulations, govern the methods used in, and the facilities and controls used for, the design,
manufacture, packaging and servicing of all finished medical devices intended for human use. If the FDA were to conclude that
we are not in compliance with applicable laws or regulations, or that any of our medical devices are ineffective or pose an
unreasonable health risk, the FDA could ban such medical devices, detain or seize adulterated or misbranded medical devices,
order a recall, repair, replacement, or refund of such devices, and require us to notify health professionals and others that
the devices present unreasonable risks of substantial harm to the public health. The FDA may also impose operating restrictions,
enjoin and restrain certain violations of applicable law pertaining to medical devices, and assess civil or criminal penalties
against our officers, employees, or us. The FDA may also recommend prosecution to the Department of Justice.</P>
<P style="font-size:10pt"> The FDA, in cooperation with U.S. Customs and Border
Protection (CBP), administers controls over the import of medical devices into the U.S. The CBP imposes its own regulatory
requirements on the import of our products, including inspection and possible sanctions for noncompliance. The FDA also administers
certain controls over the export of medical devices from the U.S. International sales of our
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">21</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
medical devices that have not received FDA approval are subject to FDA export requirements. Each foreign country to which we
export medical devices also subjects such medical devices to their own regulatory requirements. Frequently, we obtain regulatory
approval for medical devices in foreign countries first because their regulatory approval is faster or simpler than that of
the FDA. However, as a general matter, foreign regulatory requirements are becoming increasingly stringent. In the European
Union, a single regulatory approval process has been created, and approval is represented by the CE Mark. To obtain a CE Mark
in the European Union, defined products must meet minimum standards of safety and quality (i.e., the essential requirements)
and then comply with one or more of a selection of conformity routes. A Notified Body assesses the quality management systems
of the manufacturer and the product conformity to the essential and other requirements within the Medical Device Directive.
Medtronic is subject to inspection by Notified Bodies for compliance.</P>
<P style="font-size:10pt"> To be sold in Japan, medical devices must undergo
thorough safety examinations and demonstrate medical efficacy before they are granted approval, or “shonin.”
The Japanese government, through the Ministry of Health, Labour, and Welfare (MHLW), regulates medical devices under recently
enacted revisions to the Pharmaceutical Affairs Law (PAL). Implementation of PAL and enforcement practices thereunder are evolving,
and compliance guidance from MHLW is still in development. Consequently, companies continue to work on establishing improved
systems for compliance with PAL. Penalties for a company’s noncompliance with PAL could be severe, including revocation
or suspension of a company’s business license and criminal sanctions.</P>
<P style="font-size:10pt"> The process of obtaining approval to distribute medical
products is costly and time-consuming in virtually all of the major markets where we sell medical devices. We cannot assure
that any new medical devices we develop will be approved in a timely or cost-effective manner.</P>
<P style="font-size:10pt"> Federal and state laws protect the confidentiality
of certain patient health information, including patient medical records, and restrict the use and disclosure of patient health
information by healthcare providers. In particular, in April 2003, the U.S. Department of Health and Human Services (HHS) published
patient privacy rules under the Health Insurance Portability and Accountability Act of 1996 (HIPAA privacy rule). The HIPAA
privacy rule governs the use and disclosure of protected health information by “Covered Entities,” which are healthcare
providers that submit electronic claims, health plans and healthcare clearinghouses. Other than our Diabetes operating segment
and our health insurance plans, each of which is a Covered Entity, and the role representatives play in patient care, the HIPAA
privacy rule affects us only indirectly. The patient data that we receive and analyze may include protected health information.
We are committed to maintaining patients’ privacy and working with our customers and business partners in their HIPAA
compliance efforts. The ongoing costs and impacts of assuring compliance with the HIPAA privacy rules are not material to our
business.</P>
<P style="font-size:10pt"> Government and private sector initiatives to limit
the growth of healthcare costs, including price regulation, competitive pricing, coverage and payment policies, and managed-care
arrangements, are continuing in many countries where we do business, including the U.S. These changes are causing the marketplace
to put increased emphasis on the delivery of more cost-effective medical devices. Government programs, including Medicare and
Medicaid, private healthcare insurance and managed-care plans have attempted to control costs by limiting the amount of reimbursement
they will pay for particular procedures or treatments, and other mechanisms designed to constrain utilization and contain cost,
including, for example, gain sharing, where a supplier of medical goods or services is required to share any realized cost
savings with either the medical provider or payor as a condition of doing business with an entity. This has created an increasing
level of price sensitivity among customers for our products. Some third-party payors must also approve coverage for new or
innovative devices or therapies before they will reimburse healthcare providers who use the medical devices or therapies. Even
though a new medical device may have been cleared for commercial distribution, we may find limited demand for the device until
reimbursement approval has been obtained from governmental and private third-party payors. As a result of our manufacturing
efficiencies and cost controls, we believe we are well-positioned to respond to changes resulting from the worldwide trend
toward cost-containment; however, uncertainty remains as to the nature of any future legislation, making it difficult for us
to predict the potential impact of cost-containment trends on future operating results.</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">22</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt"> The delivery of our devices is subject to regulation
by HHS and comparable state and foreign agencies responsible for reimbursement and regulation of healthcare items and services.
U.S. laws and regulations are imposed primarily in connection with the Medicare and Medicaid programs, as well as the government’s
interest in regulating the quality and cost of healthcare. Foreign governments also impose regulations in connection with their
healthcare reimbursement programs and the delivery of healthcare items and services.</P>
<P style="font-size:10pt"> Federal healthcare laws apply when we submit a claim
on behalf of a Federal healthcare program beneficiary, or when a customer submits a claim for an item or service that is reimbursed
under Medicare, Medicaid or other federally-funded healthcare programs. The principal federal laws include: (1) the False Claims
Act which prohibits the submission of false or otherwise improper claims for payment to a federally-funded health care program;
(2) the Anti-Kickback Statute which prohibits offers to pay or receive remuneration of any kind for the purpose of inducing
or rewarding referrals of items or services reimbursable by a Federal healthcare program; and (3) the Stark law which prohibits
physicians from referring Medicare or Medicaid patients to an entity for the provision of certain designated health services
if the physician (or a member of the physician’s immediate family) has a financial relationship with that entity.</P>
<P style="font-size:10pt"> The laws applicable to us are subject to evolving
interpretations. If a governmental authority were to conclude that we are not in compliance with applicable laws and regulations,
Medtronic, its officers and employees, could be subject to severe criminal and civil penalties including, for example, exclusion
from participation as a supplier of product to beneficiaries covered by Medicare or Medicaid.</P>
<P style="font-size:10pt"> We operate in an industry characterized by extensive
patent litigation. Patent litigation can result in significant damage awards and injunctions that could prevent the manufacture
and sale of affected products or result in significant royalty payments in order to continue selling the products. At any given
time, we are generally involved as both a plaintiff and a defendant in a number of patent infringement actions. While it is
not possible to predict the outcome of patent litigation incident to our business, we believe the costs associated with this
litigation could generally have a material adverse impact on our consolidated results of operations, financial position
or cash flows. See “Legal Proceedings” for additional information.</P>
<P style="font-size:10pt"> We operate in an industry susceptible to significant
product liability claims. These claims may be brought by individuals seeking relief or by groups seeking to represent a class.
In addition, product liability claims may be asserted against us in the future based on events we are not aware of at the present
time.</P>
<P style="font-size:10pt"> We are also subject to various environmental laws
and regulations both within and outside the U.S. Like other medical device companies, our operations involve the use of substances
regulated under environmental laws, primarily manufacturing and sterilization processes. We do not expect that compliance with
environmental protection laws will have a material impact on our consolidated results of operations, financial position or
cash flows.</P>
<P style="font-size:10pt"> We have elected to self-insure most of our insurable
risks. This decision was made based on conditions in the insurance marketplace that have led to increasingly higher levels
of self-insurance retentions, increasing number of coverage limitations and dramatically higher insurance premium rates. We
continue to monitor the insurance marketplace to evaluate the value to us of obtaining insurance coverage in the future. Based
on historical loss trends, we believe that our self-insurance program accruals will be adequate to cover future losses. Historical
trends, however, may not be indicative of future losses. These losses could have a material adverse impact on our consolidated
results of operations, financial position or cash flows.</P>
<P style="font-size:10pt;font-weight:bold">Cautionary Factors That May Affect Future Results</P>
<P style="font-size:10pt"> This Annual Report on Form 10-K, including the
information incorporated by reference herein and the exhibits hereto, may include “forward-looking” statements. Forward-looking
statements broadly involve our current expectations or forecasts of future results. Our forward-looking statements generally
relate to our growth strategies, financial results, product development, regulatory approvals, competitive
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">23</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
strengths, intellectual property rights, litigation, mergers and acquisitions, market acceptance of our products, accounting
estimates, financing activities, ongoing contractual obligations, and sales efforts. Such statements can be identified by the
use of terminology such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“forecast,” “intend,” “may,” “plan,” “possible,” “project,” “should,”
“will” and similar words or expressions. One must carefully consider forward-looking statements and understand that
such statements may be affected by inaccurate assumptions and may involve a variety of risks and uncertainties, known and unknown,
including, among others, those discussed in the section entitled “Risk Factors” in this Annual Report on Form
10-K. Consequently, no forward-looking statement can be guaranteed and actual results may vary materially. We intend to take
advantage of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding our forward-looking
statements, and are including this sentence for the express purpose of enabling us to use the protections of the safe harbor
with respect to all forward-looking statements.</P>
<P style="font-size:10pt"> We undertake no obligation to update any statement
we make, but investors are advised to consult any further disclosures by us in our filings with the Securities and Exchange
Commission, especially on Forms 10-K, 10-Q, and 8-K, in which we may discuss in more detail various important factors
that could cause actual results to differ from expected or historical results. In addition, actual results may differ materially
from those anticipated due to a number of factors, including, among others, those discussed in the section entitled “Risk
Factors” in this Annual Report on Form 10-K. It is not possible to foresee or identify all such factors. As such, investors
should not consider any list of such factors to be an exhaustive statement of all risks, uncertainties or potentially inaccurate
assumptions.</P>
<P style="font-size:10pt;font-weight:bold">Executive Officers of Medtronic</P>
<P style="font-size:10pt"> Set forth below are the names and ages of current
executive officers of Medtronic, Inc., as well as information regarding their positions with Medtronic, Inc., their
periods of service in these capacities, and their business experiences. There are no family relationships among any of the
officers named, nor is there any arrangement or understanding pursuant to which any person was selected as an officer.</P>
<P style="font-size:10pt"> <B><I>Arthur D. Collins, Jr.,</I></B> age 58, has
been Chairman of the Board and Chief Executive Officer of Medtronic since April 2002; President and Chief Executive Officer
from May 2001 to April 2002; President and Chief Operating Officer from August 1996 to April 2001; Chief
Operating Officer from January 1994 to August 1996; and Executive Vice President of Medtronic and President of Medtronic
International from June 1992 to January 1994. He has been a director since August 1994. He was Corporate Vice
President of Abbott Laboratories from October 1989 to May 1992 and Divisional Vice President of that company from
May 1984 to October 1989. He is also a director of U.S. Bancorp and Cargill, Inc., a member of the Board of
Overseers of The Wharton School at the University of Pennsylvania and a member of the board of The Institute of Health Technology
Studies.</P>
<P style="font-size:10pt"> <B><I>Susan Alpert, Ph.D., M.D.,</I></B> age 60,
has been Senior Vice President, Chief Quality and Regulatory Officer since November 2005. Prior to that she
was Vice President, Chief Quality and Regulatory Officer from May 2004 to November 2005, and Vice President, Regulatory Affairs
and Compliance from July 2003 to May 2004. Prior to that, she was Vice President of Regulatory Sciences at C.R. Bard, Inc.
from October 2000 to July 2003. She held a variety of positions at the Food & Drug Administration from June 1987 to August
2000.</P>
<P style="font-size:10pt"> <B><I>Jean-Luc Butel,</I></B> age 49, has been Senior
Vice President and President, Asia Pacific, since September 2003. Prior to that, he was President of Independence Technology,
a Johnson & Johnson company, from 1999 to 2003. From 1991 to 1999, he worked for Becton Dickinson, initially as General
Manager of its Microbiology business in Japan and then as President of Nippon Becton Dickinson. His last assignment at Becton
Dickinson was President, Worldwide Consumer Healthcare. From 1984 to 1991, Mr. Butel was with Johnson & Johnson
and served multiple roles including General Manager of Fiji, China Project Manager and Marketing Director of the Johnson &
Johnson ophthalmic business in Southeast Asia.</P>
<P style="font-size:10pt"> <B><I>Terrance L. Carlson,</I></B> age 53, has been
Senior Vice President, General Counsel and Corporate Secretary since October 2004. Prior to that, he was Senior Vice
President, Business Development, General Counsel and Secretary at PerkinElmer, Inc. from June 1999 to September 2004; Deputy
General
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">24</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
Counsel of AlliedSignal (Honeywell International) and General Counsel of AlliedSignal Aerospace from April 1994 to June 1999;
and an associate and partner of Gibson Dunn & Crutcher from November 1978 to April 1994.</P>
<P style="font-size:10pt"> <B><I>H. James Dallas,</I></B> age 47, has been Senior
Vice President and Chief Information Officer since April 2006. Prior to that, he was Vice President and Chief Information Officer
of Georgia Pacific from December 2002 to December 2005; General Manager of the Transportation Division and President
of the Lumber Division from October 2001 to December 2002; and Vice President, Building Products Distribution
Sales and Logistics, Georgia Pacific Corporation from October 2000 to October 2001.</P>
<P style="font-size:10pt"> <B><I>Michael F. DeMane,</I></B> age 50, has been
Senior Vice President and President, Europe, Canada, Latin America and Emerging Markets since August 2005. He served as Senior
Vice President and President, Spinal, ENT and Navigation, since February 2002 and President, Spinal, since January 2000.
Prior to that, he was President, Interbody Technologies, a division of Sofamor Danek, from June 1998 to December 1999.
Prior to joining the Company in 1998, Mr. DeMane served as Managing Director, Australia and New Zealand, for Smith &
Nephew, Pty. Ltd from April 1996 to June 1998, after a series of research and development and general management
positions with Smith & Nephew Inc.</P>
<P style="font-size:10pt"> <B><I>Gary L. Ellis,</I></B> age 49, has been Senior
Vice President and Chief Financial Officer since May 2005. Prior to that, he was Vice President, Corporate Controller and Treasurer
since October 1999 and Vice President Corporate Controller from August 1994. Mr. Ellis joined Medtronic in 1989 as Assistant
Corporate Controller and was promoted to Vice President of Finance for Medtronic Europe in 1992, until being named as Corporate
Controller in 1994.</P>
<P style="font-size:10pt"> <B><I>Janet S. Fiola,</I></B> age 64, has been Senior
Vice President, Human Resources, since March 1994. She was Vice President, Human Resources, from February 1993 to
March 1994, and was Vice President, Corporate Human Resources, from February 1988 to February 1993.</P>
<P style="font-size:10pt"> <B><I>Robert M. Guezuraga,</I></B> age 57, has been
Senior Vice President and President, Diabetes since November 2004. He was Senior Vice President and President Cardiac Surgery,
from August 1999 to November 2004. He served as Vice President and General Manager of Medtronic Physio-Control International,
Inc., from September 1998 to August 1999. Mr. Guezuraga joined the Company after its acquisition of Physio-Control International,
Inc. in September 1998, where he had served as President and Chief Operating Officer since August 1994. Prior to that, Mr. Guezuraga
served as President and CEO of Positron Corporation from 1987 to 1994 and held various management positions within General
Electric Corporation, including GE’s Medical Systems division.</P>
<P style="font-size:10pt"> <B><I>William A. Hawkins,</I></B> age 52, has been
President and Chief Operating Officer since May 2004. He served as Senior Vice President and President, Medtronic Vascular,
from January 2002 to May 2004. He served as President and Chief Executive Officer of Novoste Corporation from 1998
to 2002, and was Corporate Vice President of American Home Products Corporation and President of its Sherwood Davis &
Geck Division from April 1997 to May 1998. He held executive positions with American Home Products, Johnson &
Johnson, Guidant Corporation, Eli Lilly & Co. and Carolina Medical Electronics, having begun his medical technology
career in 1977. Mr. Hawkins serves on the board of Deluxe Corporation, the board of trustees for the University of Virginia
Darden School of Business and the board of visitors for the Duke University School of Engineering.</P>
<P style="font-size:10pt"> <B><I>Richard Kuntz, M.D.,</I></B> age 48, has been
Senior Vice President and President, Neurological Gastroenterology and Urology, and Obesity Management since October 2005.
Prior to that, he was an interventional cardiologist and Chief of the Division of Clinical Biometrics at Brigham and Women’s
Hospital, Associate Professor of Medicine and Chief Scientific Office of the Harvard Clinical Research Institute.</P>
<P style="font-size:10pt"> <B><I>Stephen H. Mahle,</I></B> age 60, has been Executive
Vice President and President, Cardiac Rhythm Disease Management, since May 2004, and prior to that was Senior Vice President
and President, Cardiac Rhythm Management, since January 1998. Prior to that, he was President, Brady Pacing,
from 1995 to 1997 and Vice President and General Manager, Brady Pacing, from 1990 to 1995. Mr. Mahle has been with the
Company for 34 years and served in various general management positions prior to 1990. Mr. Mahle serves on the Board
of Directors of ATMI, Inc.</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">25</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt"> <B><I>Stephen N. Oesterle, M.D.,</I></B> age 55, has
been Senior Vice President, Medicine and Technology, since January 2002. Prior to that, he was Associate Professor of
Medicine at Harvard Medical School and Director of Invasive Cardiology Services at Massachusetts General Hospital from 1998
to 2002, and was Associate Professor of Medicine at Stanford University and Director of Cardiac Catheterization and Coronary
Intervention Laboratories at the Stanford University Medical Center from 1992 to 1998. Prior to that he held other academic
positions and directed interventional cardiology programs at Georgetown University and in Los Angeles.</P>
<P style="font-size:10pt"> <B><I>Oern R. Stuge, M.D.,</I></B> age 52, has been
Senior Vice President and President of Cardiac Surgery since March 1, 2005 and Vice President of Cardiac Rhythm
Management, Western Europe since May, 2002. Prior to that he was Vice President of Neurological, Spinal and
Diabetes for Western Europe from May 2000 to May 2002 and Vice President of Neurological for Europe, Middle East & Africa
from May 1998 to May 2000. Prior to joining the Company in 1998, Mr. Stuge worked at Abbott Laboratories where he held
regional director and general manager positions for the various Nordic countries and the Netherlands.</P>
<P style="font-size:10pt"> <B><I>Scott R. Ward,</I></B> age 46, has been Senior
Vice President and President, Vascular since May 2004. He served as Senior Vice President and President, Neurological
and Diabetes Business, from February 2002 to May 2004, and was President, Neurological, from January 2000 to
January 2002. He was Vice President and General Manager of Medtronic’s Drug Delivery Business from 1995 to 2000.
Prior to that, Mr. Ward led the Company’s Neurological Ventures in the successful development of new therapies. Mr. Ward
also held various research, regulatory and business development positions since joining Medtronic in 1981.</P>
<P style="font-size:10pt"> <B><I>Peter L. Wehrly,</I></B> age 47,
has been Senior Vice President and President, Spinal and Navigation since November 2005. Prior to that he was
President and General Manager of Medtronic Sofamor Danek, Inc. from August 2004 to November 2005, President of Biologies and
U.S. Sales from April 2003 to August 2004, and Division President of Interbody and Orthopedic Technologies from
2000 to April 2003. From 1983 to 2000 he was employed by Johnson and Johnson, most recently as Division
President at DePuy.</P>
<P style="font-size:10pt"> <B><I>Barry W. Wilson,</I></B> age 62, has been Senior
Vice President, International Affairs and President, Greater China since August 2005. He served as Senior Vice President
and President, Europe, Middle East, Canada and Emerging Markets since May 2004. Prior to that, Mr. Wilson was Senior Vice
President and President, International, from April 2001 to April 2004, and Senior Vice President, International, since
September 1997. He was President, Europe, Middle East and Africa, from April 1995 to March 2001. Prior to that,
Mr. Wilson was President, International, of the Lederle Division of American Cyanamid/American Home Products from 1993
to 1995 and President, Europe, of Bristol-Myers Squibb from 1991 to 1993, where he also served internationally in various general
management positions from 1980 to 1991. Mr. Wilson serves on the board of Bausch & Lomb Incorporated.</P>
<P style="font-size:12pt;font-weight:bold">
<A name="toc3"></A>Item 1A. Risk Factors</P>
<P style="font-size:10pt"> Investing in Medtronic involves a variety of risks
and uncertainties, known and unknown, including, among others, those discussed below.</P>
<P style="font-size:10pt"> <B><I>The medical device industry is highly competitive
and we may be unable to compete effectively.</I></B>
</P>
<P style="font-size:10pt"> We compete in both the therapeutic and diagnostic
medical markets in more than 120 countries throughout the world. These markets are characterized by rapid change resulting
from technological advances and scientific discoveries. In the product lines in which we compete, we face a mixture of competitors
ranging from large manufacturers with multiple business lines to small manufacturers that offer a limited selection of products.
Development by other companies of new or improved products, processes or technologies may make our products or proposed products
less competitive. In addition, we face competition from providers of alternative medical therapies such as pharmaceutical companies.
Competitive factors include:</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">•</TD>
<TD WIDTH="92%">product reliability,</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>product performance,</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>product technology,</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">26</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD width="4%"> </TD>
<TD width="4%">•</TD>
<TD width="92%">product quality,</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>breadth of product lines,</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>product services,</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>customer support,</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>price, and</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>reimbursement approval from healthcare insurance providers.</TD>
</TR>
</TABLE>
<P style="font-size:10pt"> Major shifts in industry market share have occurred
in connection with product problems, physician advisories and safety alerts, reflecting the importance of product quality in
the medical device industry. In the current environment of managed care, consolidation among healthcare providers, increased
competition and declining reimbursement rates, we have been increasingly required to compete on the basis of price. In order
to continue to compete effectively, we must continue to create, invest in or acquire advanced technology, incorporate this
technology into our proprietary products, obtain regulatory approvals in a timely manner and manufacture and successfully market
our products. Given these factors, we cannot guarantee that we will be able to continue our level of success in the industry.</P>
<P style="font-size:10pt"> <B><I>Reduction or interruption in supply and an inability
to develop alternative sources for supply may adversely affect our manufacturing operations and related product sales.</I></B>
</P>
<P style="font-size:10pt"> We manufacture most of our products at 22 manufacturing
facilities located throughout the world. We purchase many of the components and raw materials used in manufacturing these products
from numerous suppliers in various countries. Generally we have been able to obtain adequate supplies of such raw materials
and components. However, for reasons of quality assurance, cost effectiveness or availability, we procure certain components
and raw materials only from a sole supplier. While we work closely with our suppliers to try to ensure continuity of supply
while maintaining high quality and reliability, we cannot guarantee that these efforts will be successful. In addition, due
to the stringent regulations and requirements of the U.S. FDA regarding the manufacture of our products, we may not be able
to quickly establish additional or replacement sources for certain components or materials. A reduction or interruption in
supply, and an inability to develop alternative sources for such supply, could adversely affect our ability to manufacture
our products in a timely or cost effective manner and to make our related product sales.</P>
<P style="font-size:10pt"> <B><I>We are subject to many laws and governmental
regulations and any adverse regulatory action may materially adversely affect our financial condition and business operations.</I></B>
</P>
<P style="font-size:10pt"> Our medical devices are subject to regulation by numerous
government agencies, including the FDA and comparable foreign agencies. To varying degrees, each of these agencies requires
us to comply with laws and regulations governing the development, testing, manufacturing, labeling, marketing and distribution
of our medical devices. We cannot guarantee that we will be able to obtain marketing clearance from the FDA for our new products,
or enhancements or modifications to existing products, and if we do, such approval may:</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">•</TD>
<TD WIDTH="92%">take a significant amount of time,</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>require the expenditure of substantial resources,</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>involve stringent clinical and pre-clinical testing,</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>involve modifications, repairs or replacements of our products, and</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>result in limitations on the proposed uses of our products.</TD>
</TR>
</TABLE>
<P style="font-size:10pt"> Both before and after a product is commercially released,
we have ongoing responsibilities under FDA regulations. If the FDA were to conclude that we are not in compliance with applicable
laws or regulations, or that any of our medical devices are ineffective or pose an unreasonable health risk, the FDA could
ban such medical devices, detain or seize adulterated or misbranded medical devices, order a recall, repair, replacement, or
refund of such devices and require us to notify health professionals and
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">27</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
others that the devices present unreasonable risks of substantial harm to the public health. The FDA may also impose operating
restrictions, enjoin and restrain certain violations of applicable law pertaining to medical devices and assess civil or criminal
penalties against our officers, employees, or us. The FDA may also recommend prosecution to the Department of Justice. Any
adverse regulatory action, depending on its magnitude, may restrict us from effectively marketing and selling our products.</P>
<P style="font-size:10pt"> Foreign governmental regulations have become increasingly
stringent, and we may become subject to more rigorous regulation by foreign governmental authorities in the future. Penalties
for a company’s noncompliance with foreign governmental regulation could be severe, including revocation or suspension
of a company’s business license and criminal sanctions. Any domestic or foreign governmental law or regulation imposed
in the future may have a material adverse effect on us.</P>
<P style="font-size:10pt"> We are also subject to various environmental laws
and regulations both within and outside the U.S. Our operations involve the use of substances regulated under environmental
laws, primarily those used in manufacturing and sterilization processes. We cannot guarantee that compliance with environmental
protection laws and regulations will not have a material impact on our consolidated earnings, financial condition, or cash
flows.</P>
<P style="font-size:10pt"> <B><I>Our failure to comply with strictures relating
to reimbursement and regulation of healthcare goods and services may subject us to penalties and adversely impact our reputation
and business operations.</I></B>
</P>
<P style="font-size:10pt"> Our devices are subject to regulation regarding quality
and cost by the United States Department of HHS, including the CMS, as well as comparable state and foreign
agencies responsible for reimbursement and regulation of healthcare goods and services. Foreign governments also impose regulations
in connection with their healthcare reimbursement programs and the delivery of healthcare goods and services. U.S. federal
government healthcare laws apply when we submit a claim on behalf of a U.S. federal healthcare program beneficiary, or when
a customer submits a claim for an item or service that is reimbursed under a U.S. federal government funded healthcare program,
such as Medicare or Medicaid. The principal U.S. federal laws implicated include those that prohibit the filing of false or
improper claims for federal payment, those that prohibit unlawful inducements for the referral of business reimbursable under
federally-funded healthcare programs, known as the anti-kickback laws, and those that prohibit healthcare service providers
seeking reimbursement for providing certain services to a patient who was referred by a physician that has certain types of
direct or indirect financial relationships with the service provider, known as the Stark law.</P>
<P style="font-size:10pt"> The laws applicable to us are subject to evolving
interpretations. If a governmental authority were to conclude that we are not in compliance with applicable laws and regulations,
we and our officers and employees could be subject to severe criminal and civil penalties, including, for example, exclusion
from participation as a supplier of product to beneficiaries covered by CMS. If we are excluded from participation based on
such an interpretation it could adversely affect our reputation and business operations.</P>
<P style="font-size:10pt"> <B><I>Quality problems with our processes, goods and
services could harm our reputation for producing high quality products and erode our competitive advantage.</I></B>
</P>
<P style="font-size:10pt"> Quality is extremely important to us and our customers
due to the serious and costly consequences of product failure. Our quality certifications are critical to the marketing success
of our goods and services. If we fail to meet these standards our reputation could be damaged, we could lose customers and
our revenue could decline. Aside from specific customer standards, our success depends generally on our ability to manufacture
to exact tolerances precision engineered components, subassemblies and finished devices from multiple materials. If our components
fail to meet these standards or fail to adapt to evolving standards, our reputation as a manufacturer of high quality components
will be harmed, our competitive advantage could be damaged, and we could lose customers and market share.</P>
<P style="font-size:10pt"> <B><I>We are substantially dependent on patent and
other proprietary rights and failing to be successful in patent or other litigation may result in our payment of significant
money damages and/or royalty payments, negatively impact our ability to sell current or future products or prohibit us from
enforcing our patent and proprietary rights against others.</I></B>
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">28</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt"> We operate in an industry characterized by extensive
patent litigation. Patent litigation can result in significant damage awards and injunctions that could prevent our manufacture
and sale of affected products or require us to pay significant royalties in order to continue to manufacture or sell affected
products. At any given time, we are generally involved as both a plaintiff and a defendant in a number of patent infringement
actions, the outcomes of which may not be known for prolonged periods of time. While it is not possible to predict the outcome
of patent litigation incident to our business, we believe the results associated with any litigation could result in our payment
of significant money damages and/or royalty payments, negatively impact our ability to sell current or future products or prohibit
us from enforcing our patent and proprietary rights against others, which would generally have a material adverse impact on
our consolidated earnings, financial condition, or cash flows.</P>
<P style="font-size:10pt"> We rely on a combination of patents, trade secrets
and nondisclosure and non-competition agreements to protect our proprietary intellectual property, and will continue to do
so. While we intend to defend against any threats to our intellectual property, there can be no assurance that these patents,
trade secrets or other agreements will adequately protect our intellectual property. There can also be no assurance that pending
patent applications owned by us will result in patents issuing to us, that patents issued to or licensed by us in the past
or in the future will not be challenged or circumvented by competitors or that such patents will be found to be valid or sufficiently
broad to protect our technology or to provide us with any competitive advantage. Third parties could also obtain patents that
may require us to negotiate licenses to conduct our business, and there can be no assurance that the required licenses would
be available on reasonable terms or at all. We also rely on nondisclosure and non-competition agreements with certain employees,
consultants and other parties to protect, in part, trade secrets and other proprietary rights. There can be no assurance that
these agreements will not be breached, that we will have adequate remedies for any breach, that others will not independently
develop substantially equivalent proprietary information or that third parties will not otherwise gain access to our trade
secrets or proprietary knowledge.</P>
<P style="font-size:10pt"> <B><I>Product liability claims could adversely impact
our financial condition and our earnings and impair our reputation.</I></B>
</P>
<P style="font-size:10pt"> Our business exposes us to potential product liability
risks which are inherent in the design, manufacture and marketing of medical devices. In addition, many of the medical devices
we manufacture and sell are designed to be implanted in the human body for long periods of time. Component failures, manufacturing
flaws, design defects or inadequate disclosure of product-related risks or product-related information with respect to these
or other products we manufacture or sell could result in an unsafe condition or injury to, or death of, a patient. The occurrence
of such a problem could result in product liability claims or a recall of, or safety alert relating to, one or more of our
products which could ultimately result, in certain cases, in the removal from the body of such products and claims regarding
costs associated therewith. We have elected to self-insure with respect to product liability risks. Product liability claims
or product recalls in the future, regardless of their ultimate outcome, could have a material adverse effect on our business
and reputation and on our ability to attract and retain customers for our products.</P>
<P style="font-size:10pt"> <B><I>Our self-insurance program may not be adequate
to cover future losses.</I></B>
</P>
<P style="font-size:10pt"> We have elected to self-insure most of our insurable
risks. We made this decision based on conditions in the insurance marketplace that have led to increasingly higher levels of
self-insurance retentions, increasing numbers of coverage limitations and dramatically higher insurance premium rates. We continue
to monitor the insurance marketplace to evaluate the value to us of obtaining insurance coverage in the future. While based
on historical loss trends we believe that our self-insurance program accruals will be adequate to cover future losses, we cannot
guarantee that this will remain true. Historical trends may not be indicative of future losses. These losses could have a material
adverse impact on our consolidated earnings, financial condition or cash flows.</P>
<P style="font-size:10pt"> <B><I>If we experience decreasing prices for our goods
and services and we are unable to reduce our expenses, our results of operations will suffer.</I></B>
</P>
<P style="font-size:10pt"> We may experience decreasing prices for the goods
and services we offer due to pricing pressure experienced by our customers from managed care organizations and other third-party
payors; increased
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">29</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
market power of our customers as the medical device industry consolidates; and increased competition among medical engineering
and manufacturing services providers. If the prices for our goods and services decrease and we are unable to reduce our expenses,
our results of operations will be adversely affected.</P>
<P style="font-size:10pt"> <B><I>Our international operations are subject to
a variety of risks that could adversely affect those operations and thus our profitability and operating results.</I></B>
</P>
<P style="font-size:10pt"> Our operations in countries outside the U.S., which
accounted for 32% of our net sales for the year ended April 28, 2006, are accompanied by certain financial and other risks.
We intend to continue to pursue growth opportunities in sales internationally, which could expose us to greater risks associated
with international sales and operations. Our international operations are, and will continue to be, subject to a number of
risks and potential costs, including:</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">•</TD>
<TD WIDTH="92%">changes in foreign medical reimbursement programs and policies,</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>changes in foreign regulatory requirements,</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>local product preferences and product requirements,</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>longer-term receivables than are typical in the U.S.,</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>fluctuations in foreign currency exchange rates,</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>less protection of intellectual property in some countries outside of the U.S.,</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>trade protection measures and import and export licensing requirements,</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>work force instability,</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>political and economic instability, and</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>•</TD>
<TD>complex tax and cash management issues.</TD>
</TR>
</TABLE>
<P style="font-size:10pt"> <B><I>Consolidation in the healthcare industry could
have an adverse effect on our revenues and results of operations.</I></B>
</P>
<P style="font-size:10pt"> Many healthcare industry companies, including medical
device companies, are consolidating to create new companies with greater market power. As the healthcare industry consolidates,
competition to provide goods and services to industry participants will become more intense. These industry participants may
try to use their market power to negotiate price concessions or reductions for medical devices that incorporate components
produced by us. If we are forced to reduce our prices because of consolidation in the healthcare industry, our revenues would
decrease and our consolidated earnings, financial condition or cash flows would suffer.</P>
<P style="font-size:10pt"> <B><I>Healthcare policy changes may have a material
adverse effect on us.</I></B>
</P>
<P style="font-size:10pt"> Healthcare costs have risen significantly over the
past decade. There have been and may continue to be proposals by legislators, regulators and third-party payors to keep these
costs down. Certain proposals, if passed, could impose limitations on the prices we will be able to charge for our products,
or the amounts of reimbursement available for our products from governmental agencies or third-party payors. These limitations
could have a material adverse effect on our financial position and results of operations.</P>
<P style="font-size:10pt"> <B><I>Our business is indirectly subject to healthcare
industry cost containment measures that could result in reduced sales of medical devices containing our components.</I></B>
</P>
<P style="font-size:10pt"> Most of our customers, and the healthcare providers
to whom our customers supply medical devices, rely on third-party payors, including government programs and private health
insurance plans, to reimburse some or all of the cost of the procedures in which medical devices that incorporate components
we manufacture or assemble are used. The continuing efforts of government, insurance companies and other payors of healthcare
costs to contain or reduce these costs could lead to patients being unable to obtain approval for payment from these third-party
payors. If that were to occur, sales of finished
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">30</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
medical devices that include our components may decline significantly and our customers may reduce or eliminate purchases of
our components. The cost containment measures that healthcare providers are instituting, both in the U.S. and internationally,
could harm our ability to operate profitably. For example, managed care organizations have successfully negotiated volume discounts
for pharmaceuticals. While this type of discount pricing does not currently exist for medical devices, if managed care or other
organizations were able to affect discount pricing for devices, it may result in lower prices to our customers from their customers
and, in turn, reduce the amounts we can charge our customers for our medical devices.</P>
<P style="font-size:10pt"> <B><I>Our research and development efforts rely upon
investments and alliances, and we cannot guarantee that any previous or future investments or alliances will be successful.</I></B>
</P>
<P style="font-size:10pt"> Our strategy to provide a broad range of therapies
to restore patients to fuller, healthier lives requires a wide variety of technologies, products and capabilities. The rapid
pace of technological development in the medical industry and the specialized expertise required in different areas of medicine
make it difficult for one company alone to develop a broad portfolio of technological solutions. In addition to internally
generated growth through our research and development efforts, historically we have relied, and expect to continue to rely,
upon investments and alliances to provide us access to new technologies both in areas served by our existing businesses as
well as in new areas.</P>
<P style="font-size:10pt"> We expect to make future investments where we believe
that we can stimulate the development of, or acquire, new technologies and products to further our strategic objectives and
strengthen our existing businesses. Investments and alliances in and with medical technology companies are inherently risky,
and we cannot guarantee that any of our previous or future investments or alliances will be successful or will not materially
adversely affect our consolidated earnings, financial condition or cash flows.</P>
<P style="font-size:10pt"> <B><I>The success of many of our products depends
upon strong relationships with physicians.</I></B>
</P>
<P style="font-size:10pt"> If we fail to maintain our working relationships with
physicians, many of our products may not be developed and marketed in line with the needs and expectations of the professionals
who use and support our products, which could cause a decline in earnings and profitability. The research, development, marketing
and sales of many of our new and improved products is dependent upon our maintaining working relationships with physicians.
We rely on these professionals to provide us with considerable knowledge and experience regarding our products and the marketing
of our products. Physicians assist us as researchers, marketing consultants, product consultants, inventors and as public speakers.
If we are unable to maintain our strong relationships with these professionals and continue to receive their advice and input,
the development and marketing of our products could suffer, which could have a material effect on our consolidated earnings,
financial condition or cash flows.</P>
<P style="font-size:12pt;font-weight:bold">
<A name="toc4"></A>
Item 1B. Unresolved Staff Comments
</P>
<P style="font-size:10pt"> None.
</P>
<P style="font-size:12pt;font-weight:bold">
<A name="toc5"></A>Item 2. Properties</P>
<P style="font-size:10pt"> Our principal offices are owned by us and located
in the Minneapolis, Minnesota metropolitan area. Manufacturing or research facilities are located in Arizona, California, Colorado,
Connecticut, Florida, Indiana, Massachusetts, Michigan, Minnesota, Tennessee, Texas, Washington, Puerto Rico, China, France,
Ireland, Mexico, The Netherlands and Switzerland. Our total manufacturing and research space is approximately 3.0 million
square feet, of which approximately 75% is owned by us and the balance is leased.</P>
<P style="font-size:10pt"> We also maintain sales and administrative offices
in the U.S. at approximately 90 locations in 40 states or jurisdictions and outside the U.S. at approximately 100 locations
in 36 countries. Most of these locations are leased. We are using substantially all of our currently available productive space
to develop, manufacture and market our products. Our facilities are in good operating condition, suitable for their respective
uses and adequate for current needs.</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">31</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:12pt;font-weight:bold">
<A name="toc6"></A>Item 3. Legal Proceedings</P>
<P style="font-size:10pt"> A discussion of the Company’s policies with respect
to legal proceedings is discussed in the management’s discussion and analysis of financial condition and results of operations
set forth in Exhibit 13 incorporated herein by reference, and other loss contingencies are described in Note 13 of the consolidated
financial statements.</P>
<P style="font-size:10pt"> The Company is involved in a number of legal actions.
The outcomes of these legal actions are not within the Company’s complete control and may not be known for prolonged periods
of time. In some actions, the claimants seek damages, as well as other relief, including injunctions barring the sale of products
that are the subject of the lawsuit, which, if granted, could require significant expenditures or result in lost revenues.
In accordance with SFAS No. 5, “Accounting for Contingencies” (SFAS No. 5), the Company records a liability in the
consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably
estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate,
the minimum amount of the range is accrued. If a loss is reasonably likely but not known or probable, and can be reasonably
estimated, the estimated loss or range of loss is disclosed. If a loss is not probable or cannot be reasonably estimated,
a liability is not recorded in the consolidated financial statements. In most cases, significant judgment is required to estimate
the amount and timing of a loss to be recorded. While it is not possible to predict the outcome for most of the actions discussed
below and the Company believes that it has meritorious defenses against these matters, it is possible that costs associated
with them could have a material adverse impact on the Company’s consolidated earnings, financial condition or cash flows.</P>
<P style="font-size:10pt"> On October 6, 1997, Cordis Corporation (Cordis),
a subsidiary of Johnson & Johnson (J&J), filed suit in U.S. District Court for the District of Delaware against Arterial
Vascular Engineering, Inc., which Medtronic acquired in January 1999 and which is now known as Medtronic Vascular, Inc. (Medtronic
Vascular). The suit alleged that Medtronic Vascular’s modular stents infringe certain patents owned by Cordis. Boston
Scientific Corporation is also a defendant in this suit. On December 22, 2000, a jury rendered a verdict that Medtronic
Vascular’s previously marketed MicroStent and GFX stents infringed valid claims of two Cordis patents and awarded
damages to Cordis totaling approximately $270.0 million. On March 28, 2002, the District Court entered an order in favor
of Medtronic Vascular, deciding as a matter of law that Medtronic Vascular’s MicroStent and GFX stents did not infringe
the patents. Cordis appealed, and on August 12, 2003, the U.S. Court of Appeals for the Federal Circuit reversed the District
Court’s decision and remanded the case to the District Court for further proceedings. The District Court thereafter issued
a new patent claim construction and a new trial was held in March 2005. On March 14, 2005, the jury found that the previously
marketed MicroStent and GFX stent products infringed valid claims of Cordis’ patents. On March 27, 2006, the District
Court denied post-trial motions filed by the parties, including Cordis’ motion to reinstate the previous damages award.
On April 26, 2006, Medtronic filed its Notice of Appeal of the judgment of infringement. The District Court has deferred
any hearing on damages issues until after the U.S. Court of Appeals for the Federal Circuit resolves the appeal on the finding
of liability. Medtronic has not recorded an expense related to damages in this matter because any potential loss is
not currently probable or reasonably estimable under SFAS No. 5.</P>
<P style="font-size:10pt"> On December 24, 1997, Advanced Cardiovascular
Systems, Inc. (ACS), a subsidiary of Guidant Corporation (Guidant), sued Medtronic Vascular in U.S. District Court for the
Northern District of California alleging that certain models of Medtronic Vascular’s stents infringe the Lau stent patents
held by ACS, and seeking injunctive relief and monetary damages. Medtronic Vascular denied infringement and in February 1998,
Medtronic Vascular sued ACS in U.S. District Court for the District of Delaware alleging infringement of Medtronic Vascular’s
Boneau stent patents. On January 5, 2005, the District Court found as a matter of law that the ACS products in question
did not infringe any of Medtronic Vascular’s Boneau stent patents. Medtronic Vascular appealed this finding by
the District Court, and on May 25, 2006 the U.S. Court of Appeals for the Federal Circuit affirmed the trial court’s
ruling that the ACS products do not infringe Medtronic’s Boneau patents. In February 2005, following trial, a jury determined
that the ACS Lau stent patents were valid and that Medtronic’s Driver, GFX, MicroStent, S540, S660, S670, Bestent2 and
S7 stents infringe those patents. Medtronic Vascular has made numerous
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">32</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
post-trial motions challenging the jury’s verdict of infringement and validity and the District Court has not yet ruled
on those motions. On June 7 and 8, 2005, the District Court held an evidentiary hearing on Medtronic Vascular’s claim
that the ACS Lau stent patents are unenforceable due to inequitable conduct of ACS in obtaining the Lau patents. The District
Court has not yet issued a decision on Medtronic Vascular’s claim of inequitable conduct. Issues of damages have been
bifurcated from the liability phase of the proceedings. On August 9, 2005, the Court issued an order continuing a stay
of any further proceedings on the questions of damages or willfulness. These issues likely will not be addressed by a jury
or the Court until the U.S. Court of Appeals for the Federal Circuit has reviewed the underlying liability issues concerning
alleged infringement. In January 2006, Medtronic filed a Request for Reexamination at the United States Patent and Trademark
Office (USPTO) related to each of the four Lau patents asserted by ACS in the above matter. On February 14, 2006, the
USPTO granted Medtronic’s Request for Reexamination for each of the four Lau patents, finding that “substantial questions
exist” regarding the validity of the Lau patent claims in view of prior art submitted by Medtronic with the Request for
Reexamination. The USPTO will now reconsider whether the Lau patents should have been granted in the first instance, though
the timing of such reexamination is not known. Until this reexamination is concluded, its potential impact upon the claims
relating to the Lau patents in the above proceeding remains unknown. The Company has not recorded an expense related to damages
in this matter because any potential loss is not currently probable or reasonably estimable under SFAS No. 5.</P>
<P style="font-size:10pt"> On September 12, 2000, Cordis filed an additional
suit against Medtronic Vascular in U.S. District Court for the District of Delaware alleging that Medtronic Vascular’s
S670, S660 and S540 stents infringe the patents asserted in the October 1997 Cordis case above. Cordis subsequently added claims
that Medtronic Vascular’s S7 and Driver stents infringe the asserted patents. The court thereafter granted Medtronic Vascular’s
motion to stay the trial proceedings pending arbitration of Medtronic Vascular’s defense that its products are licensed
under a 1997 Agreement between Medtronic Vascular and Cordis. The arbitration commenced November 14, 2005 before a panel
of three neutral arbitrators. The scope of the arbitration was limited to the question of whether the products that are the
subject of the lawsuit are covered by the 1997 Agreement, and also whether a separate covenant by J&J not to sue Medtronic
and its affiliates contained within a 1998 amendment to the 1997 Agreement precludes the lawsuit. On February 20, 2006,
the Arbitration Panel issued its award concluding that the accused Medtronic products are licensed and that the covenant not
to sue contained within the 1998 amendment bars J&J’s and Cordis’ claims that Medtronic Vascular has infringed
the Cordis patents asserted in the 2000 lawsuit. On April 24 and 26, 2006, J&J served the Company demands for arbitration
for royalty payments on the products that have been determined to be licensed and covered by the covenant not to sue. The parties
have not yet selected arbitrators, and no dates have been set for the arbitration proceedings. The Company has not recorded
an expense related to damages in this matter because any potential loss is not currently probable or reasonably estimable under
SFAS No. 5.</P>
<P style="font-size:10pt"> On January 26, 2001, DePuy/AcroMed, a subsidiary
of J&J, filed suit in U.S. District Court for the District of Massachusetts alleging that MSD was infringing a patent relating
to a design for a thoracolumbar multiaxial screw (MAS). In March 2002, DePuy/AcroMed supplemented its allegations to claim
that MSD’s M10, M8 and Vertex screws infringe the patent. On April 17, 2003 and February 26, 2004, the District
Court ruled that those screws do not infringe. On October 1, 2004, a jury found that the MAS screw, which MSD no longer
sells in the U.S., infringes under the doctrine of equivalents. The jury awarded damages of $21.0 million and on February 9,
2005, the Court entered judgment against MSD, including prejudgment interest, in the aggregate amount of $24.3 million. In
the third quarter of fiscal year 2005, the Company recorded an expense equal to the $24.3 million judgment in the matter. DePuy/AcroMed
has appealed the Court’s decisions that the M10, M8 and Vertex screws do not infringe, and MSD has appealed the jury’s
verdict that the MAS screw infringes valid claims of the patent. On June 5, 2006, the U.S. Court of Appeals for the Federal
Circuit heard oral argument on the parties’ respective appeals, and has taken the appeals under advisement.</P>
<P style="font-size:10pt"> On May 2, 2003, Cross Medical Products, Inc.
(Cross) sued MSD in the U.S. District Court for the Central District of California. The suit alleges that MSD’s CD HORIZON,
Vertex and Crosslink products infringe certain patents owned by Cross. MSD has countered that Cross’ cervical plate products
infringe certain patents of MSD, and Cross has filed a reply alleging that certain MSD cervical plate
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">33</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
products infringe certain patents of Cross. On May 19, 2004, the Court found that the MAS, Vertex, M8, M10, CD HORIZON
SEXTANT and CD HORIZON LEGACY screw products infringe one Cross patent. A hearing on the validity of that patent was held on
July 12, 2004, after which the District Court ruled that the patents were valid. Cross made a motion for permanent injunction
on the multiaxial screw products, which the District Court granted on September 20, 2004, but stayed the effect of the
injunction until January 3, 2005. MSD requested an expedited appeal of the ruling and the U.S. Court of Appeals for the
Federal Circuit granted the request. The Federal Circuit heard the appeal on March 11, 2005. On September 30, 2005,
the Federal Circuit vacated the injunction, modified the trial court’s claim construction rulings, and remanded the matter
for trial in the District Court. The Federal Circuit awarded costs to Medtronic on the appeal. In April 2005, the District
Court ruled invalid certain claims in the patents Cross asserted against MSD’s Crosslink and cervical plate products.
The Court also ruled that Cross cervical plate products infringe MSD’s valid patents and that MSD’s redesigned pedicle
screw products infringe one claim of one of the patents owned by Cross. Cross thereafter moved for an injunction against the
redesigned screw products, which the District Court granted on May 24, 2005. The District Court then stayed the effectiveness
of the injunction until August 22, 2005. On July 27, 2005, the U.S. Court of Appeals for the Federal Circuit granted
MSD’s motion to stay the District Court’s injunction pending a full hearing on the appeal. In granting the further
stay, the Federal Circuit stated MSD had shown a “…likelihood of success…” on the merits of its appeal.
The Federal Circuit heard oral argument on this appeal on March 10, 2006, but has not issued its ruling as of the date
of filing this report. The trial court held a status hearing on December 19, 2005, to determine further proceedings in
light of the appellate rulings, and it held a second status conference in May 2006. No trial date has been set. The Company
has not recorded an expense related to damages in this matter because any potential loss is not currently probable or reasonably
estimable under SFAS No. 5. Separately, on February 1, 2006, MSD filed a lawsuit against Biomet Inc., the corporate parent
of Cross (Biomet) and its subsidiary EBI Spine, L.P., for patent infringement. The suit, which involves seven Medtronic patents
and seeks injunctive relief and monetary damages, was filed in the U.S. District Court for the District of New Jersey. Three
of the patents were purchased by Medtronic from Michelson and involve single-lock anterior cervical plating systems used in
cervical spinal fusions. Medtronic claims that a cervical plate marketed by Biomet under the trade name VueLock Anterior Cervical
Plate System, and openly promoted as a plate that has a “Secure One Step Locking” mechanism feature, infringes these
patents. The other patents involve rod reducer instruments and surgical implantation methods commonly used in spinal surgeries
to implant pedicle screws. The lawsuit alleges that Biomet’s pedicle screw systems utilize a rod reducer instrument in
a variety of lumbar and thoracic spinal fusion surgeries.</P>
<P style="font-size:10pt"> On September 4, 2003, Medtronic was informed
by the Department of Justice that the government is investigating allegations that certain payments and other services provided
to physicians by MSD constituted improper inducements under the federal Anti-Kickback Statute. The allegations were made as
part of a civil qui tam complaint brought pursuant to the federal False Claims Act. On November 21, 2003, Medtronic was
served with a government subpoena seeking documents in connection with these allegations. On September 2, 2004, Medtronic
received a copy of a second civil qui tam complaint brought by a second relator asserting similar allegations under the False
Claims Act. The Company views the second complaint as having arisen out of essentially similar facts and circumstances as the
first qui tam complaint, and believes that the second complaint does not materially expand the nature of the existing inquiry
in which the Company is cooperating. The cases remain under seal in the U.S. District Court for the Western District of Tennessee.
The Company is cooperating fully with the investigations and is independently evaluating these matters, the internal processes
associated therewith, and certain employment matters related thereto, in each case under the supervision of a special committee
of the Board of Directors. The Company has not recorded an expense related to damages in this matter because any potential
loss is not currently probable or reasonably estimable under SFAS No. 5.</P>
<P style="font-size:10pt"> On October 2, 2003, Cordis sued Medtronic Vascular
in the U.S. District Court for the Northern District of California, alleging that Medtronic Vascular’s S7 stent delivery
system infringes certain catheter patents owned by Cordis. Pursuant to stipulation of the parties, the Court has stayed the
suit and referred the matter to arbitration. The arbitrators have not yet been selected. The Company has not recorded an expense
related to damages in this matter because any potential loss is not currently probable or reasonably estimable under SFAS No.
5.</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">34</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt"> On October 15, 2004, Dr. Eckhard Alt filed suit
in U.S. District Court for the Eastern District of Texas against Medtronic, Inc. Dr. Alt alleges that certain Medtronic pacemakers
and defibrillators infringe four patents Dr. Alt claims he now owns. Dr. Alt is also seeking injunctive relief and monetary
damages. On February 15,
2006, Dr. Alt filed a second lawsuit in U.S. District Court for the Eastern District of Texas against Medtronic, Inc. alleging
that certain Medtronic defibrillators infringe one other patent in which Dr. Alt claims to have certain rights. Medtronic was
served with a complaint for this second lawsuit on March 3, 2006, but no trial date or other deadlines have been set for
this second lawsuit. On May 8, 2006, the parties informed the Court that they had tentatively settled their disputes,
and they jointly requested the Court to remove the previously scheduled May 15, 2006 trial date from the Court’s
calendar. On June 9, 2006, the parties advised the Court that they had been unable to finalize their tentative settlement,
and the Court scheduled a status hearing for July 13, 2006 at which the Court may seek to enforce a settlement if the parties
are still unable to finalize a resolution. At the time of this filing, the parties remain unable to resolve their dispute,
and there can be no assurance that a satisfactory resolution can or will be reached or whether a settlement may be imposed
by the Court. The Company has not recorded an expense in either matter because any potential loss is not currently probable
or reasonably estimable under SFAS No. 5.</P>
<P style="font-size:10pt"> On February 11, 2005, Medtronic voluntarily began
advising physicians about a potential battery shorting mechanism that may occur in a subset of implantable cardioverter defibrillators
(ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds), including certain of the Marquis VR/DR and Maximo VR/DR
ICDs and certain of the InSync I/II/III Marquis and InSync III CRT-D devices. The Company provided physicians with a list of
potentially affected patients and recommended that physicians communicate with those patients so they could manage the potential
issue in a manner they felt was appropriate for their individual patients. Subsequent to this voluntary field action, later
classified by the FDA as a Class II Recall, a number of lawsuits were filed against Medtronic in various state and federal
jurisdictions. The cases were brought either by individuals claiming personal injury or by third party payors seeking reimbursement
of costs associated with the field action. The personal injury complaints generally alleged strict liability, negligence, warranty
and other common law and/or statutory claims; and seek compensatory as well as punitive damages. Cases filed in federal court
(either personal injury or third party payor) have been consolidated before one federal judge under a process known as a Multidistrict
Litigation case (MDL). There are 209 federal cases, most of which have been consolidated in the MDL. We expect all federal
cases will be transferred to the MDL. There are 28 state court cases that are not part of the MDL. Separate master complaints
were filed in the MDL for the personal injury and third party payor claims. The third party payor master complaint contains
class allegations and lawyers for the plaintiffs have indicated that they will request the court’s permission to amend
the personal injury master complaint to add class allegations which were omitted from it. The Company intends to challenge
any attempt at class certification because it believes individual issues far outweigh any common issues in the various cases.
Cases claiming personal injury will be subject to dismissal in connection with Medtronic’s summary judgment motion based,
in part, upon the legal theory of federal preemption. The motion is scheduled to be heard on July 10, 2006. Discovery
limited to issues associated with federal preemption has been completed. Medtronic also filed a motion to dismiss the third
party payor cases in March 2006. Additionally, five putative class actions have been filed in Canada. The Company is unaware
of any confirmed injury or death resulting from a device failure due to the shorting mechanism that was the subject matter
of the field action though certain of the lawsuits make such allegations. The Company has not recorded an expense related to
damages in connection with the various Marquis related lawsuits because potential losses are not currently probable or reasonably
estimable under SFAS No. 5.</P>
<P style="font-size:10pt"> On October 24, 2005, Medtronic received a subpoena
from the Office of the United States Attorney for the District of Massachusetts issued under the Health Insurance Portability
& Accountability Act of 1996 requesting documents the Company may have, if any, relating to pacemakers and defibrillators
and related components; monitoring equipment and services; a provision of benefits, if any, to persons in a position to recommend
purchases of such devices; and the Company’s training and compliance materials
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">35</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt">
relating to the fraud and abuse and federal Anti-Kickback statutes. The Company intends to fully cooperate with the Office of
the United States Attorney for the District of Massachusetts with respect to this subpoena.</P>
<P style="font-size:10pt"> In the normal course of business, the Company periodically
enters into agreements that require it to indemnify customers or suppliers for specific risks, such as claims for injury or
property damage arising out of the Company’s products or the negligence of its personnel or claims alleging that its products
infringe third-party patents or other intellectual property. The Company’s maximum exposure under these indemnification
provisions cannot be estimated, and the Company has not accrued any liabilities within the consolidated financial statements.
Historically, the Company has not experienced significant losses on these types of indemnifications.</P>
<P style="font-size:12pt;font-weight:bold">
<A name="toc7"></A>Item 4. Submission of Matters to a Vote of Security Holders</P>
<P style="font-size:10pt"> Not applicable.</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">
<A name="toc8"></A>PART II</P>
<P style="font-size:12pt;font-weight:bold">
<A name="toc9"></A>Item 5. Market for Medtronic’s Common Equity, Related Shareholder Matters, and Issuer Purchases
of Equity Securities</P>
<P style="font-size:10pt"> The information in the section entitled “Price
Range of Medtronic Stock” is incorporated by reference herein to Exhibit 13 hereto and will be included in our 2006
Annual Report.</P>
<P style="font-size:10pt"> In October 2003, our Board of Directors authorized
the repurchase of up to 30 million shares of our common stock. An additional 40 million shares were authorized for repurchase
in October 2005. In April 2006, the Board of Directors made a special authorization for the Company to repurchase up to 50
million shares of the Company’s common stock in conjunction with the $4,400.0 million convertible debenture offering.
There were 55.8 million shares repurchased by Medtronic during the fourth quarter of fiscal year 2006. As authorized by the
Board of Directors each program expires when its total number of authorized shares has been repurchased.</P>
<P style="font-size:10pt"> The following table provides information about the
shares repurchased by Medtronic during the fourth quarter of fiscal year 2006:</P>
<DIV align="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM" style="font-size:8pt">
<TH colspan="2" align="left">Fiscal Period</TH>
<TH> </TH>
<TH> </TH> <TH nowrap colspan="2">Total Number of<BR>Shares Purchased</TH>
<TH> </TH>
<TH> </TH>
<TH nowrap colspan="2">Average Price<BR>Paid per Share</TH>
<TH> </TH>
<TH> </TH>
<TH nowrap colspan="2">Total Number of<BR>Shares Purchased as a<BR>Part of Publicly<BR>Announced Program</TH>
<TH> </TH>
<TH> </TH>
<TH nowrap colspan="2">Maximum Number<BR>of Shares that May<BR>Yet Be Purchased<BR>Under the Program (1)</TH>
<TH> </TH>
</TR>
<TR>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD width="34%">01/28/06 – 02/24/06</TD>
<TD width="1%"> </TD>
<TD width="1%"> </TD>
<TD width="4%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="10%">3,501,100</TD>
<TD width="1%"> </TD>
<TD width="4%"> </TD>
<TD width="1%">$</TD>
<TD align="right" width="10%">55.54</TD>
<TD width="1%"> </TD>
<TD width="4%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="10%">3,501,100</TD>
<TD width="1%"> </TD>
<TD width="4%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="10%">39,089,045</TD>
<TD width="1%"> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD>02/25/06 – 03/31/06</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">3,355,400</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">53.51</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">3,355,400</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">35,733,645</TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD>04/01/06 – 04/28/06</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">48,981,191</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">51.04</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">48,981,191</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">36,752,454</TD>
<TD> </TD>
</TR>
<TR>
<TD colspan="2"></TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt;padding-top:12pt">
<TD>Total</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">55,837,691</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">51.47</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">55,837,691</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">36,752,454</TD>
<TD> </TD>
</TR>
</TABLE>
</DIV>
<P style="font-size:12pt;font-weight:bold">
<A name="toc10"></A>Item 6. Selected Financial Data</P>
<P style="font-size:10pt"> The information for the fiscal years 2002 through
2006 in the section entitled “Selected Financial Data” is incorporated herein by reference to Exhibit 13 and
will be included in our 2006 Annual Report.</P>
<P style="font-size:12pt;font-weight:bold">
<A name="toc11"></A>Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations</P>
<P style="font-size:10pt"> The information in the section entitled “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” is incorporated herein by reference to Exhibit 13
and will be included in our 2006 Annual Report.</P>
<P style="font-size:12pt;font-weight:bold">
<A name="toc12"></A>Item 7A. Quantitative and Qualitative Disclosures About Market Risk</P>
<P style="font-size:10pt"> The information in the sections entitled “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” and “Market Risk” as well as Note 3
to the consolidated financial statements is incorporated herein by reference to Exhibit 13 and will be included in our
2006 Annual Report.</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">36</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:12pt;font-weight:bold">
<A name="toc13"></A>Item 8. Financial Statements and Supplementary Data</P>
<P style="font-size:10pt"> The Consolidated Financial Statements and Notes thereto,
together with the report of independent registered public accounting firm, are incorporated herein by reference to Exhibit 13
and will be included in our 2006 Annual Report.</P>
<P style="font-size:12pt;font-weight:bold">
<A name="toc14"></A>Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</P>
<P style="font-size:10pt"> Not applicable.</P>
<P style="font-size:12pt;font-weight:bold">
<A name="toc15"></A>Item 9A. Controls and Procedures</P>
<P style="font-size:10pt;font-weight:bold">Disclosure Controls and Procedures</P>
<P style="font-size:10pt"> As of April 28, 2006, an evaluation was carried
out under the supervision and with the participation of the Company’s management, including the Chief Executive Officer
(CEO) and the Chief Financial Officer (CFO), of the effectiveness of our disclosure controls and procedures (as defined in
the Exchange Act Rules 13a-15(e) and 15d -15(e)) as of the end of the period covered by the report. Based on that evaluation,
the CEO and CFO have concluded that the Company’s disclosure controls and procedures were effective as of April 28,
2006.</P>
<P style="font-size:10pt;font-weight:bold">Management’s Report on Internal Control Over Financial Reporting</P>
<P style="font-size:10pt"> Management is responsible for establishing and maintaining
adequate internal control over financial reporting for the Company. Management conducted an evaluation of the effectiveness
of internal control over financial reporting based on the framework in <I>Internal Control</I> – <I>Integrated Framework</I>
issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this evaluation, management
concluded that the Company’s internal control over financial reporting was effective as of April 28, 2006. Management’s
assessment of the effectiveness of the Company’s internal control over financial reporting as of April 28, 2006 has
been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which
is included herein.</P>
<P style="font-size:10pt;font-weight:bold">Changes in Internal Control over Financial Reporting</P>
<P style="font-size:10pt"> We continue to implement a new enterprise resource
planning (ERP) system using a multi-phased approach. As previously disclosed, during the third quarter of this fiscal year,
the European geographies implemented the new ERP system which resulted in some changes in internal controls. As a result, management
could not test or rely on some of the recurring internal controls from previous quarters. However, management performed other
procedures and analysis to ensure the financial statements were materially correct for the fiscal year ended April, 28 2006.
There have been no other changes in the Company’s internal control over financial reporting during the period covered
by this Annual Report on Form 10-K that has materially affected, or is reasonably likely to materially affect, its internal
control over financial reporting.</P>
<P style="font-size:12pt;font-weight:bold">
<A name="toc16"></A>Item 9B. Other Information</P>
<P style="font-size:10pt"> None.</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">
<A name="toc17"></A>PART III</P>
<P style="font-size:12pt;font-weight:bold">
<A name="toc18"></A>Item 10. Directors and Executive Officers of the Registrant</P>
<P style="font-size:10pt"> The sections entitled “Proposal 1 —
Election of Directors — Directors and Nominees,” “Governance of Medtronic — Committees
of the Board and Meetings,” “Governance of Medtronic — Audit Committee,”
and “Share Ownership Information — Section 16(a) Beneficial Ownership Reporting Compliance” of our Proxy
Statement for our 2006 Annual Shareholders’ Meeting are incorporated herein by reference. See also “Executive Officers
of Medtronic” on page 24 herein.</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">37</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt"> We have adopted a written Code of Ethics that applies
to our Chief Executive Officer, Chief Financial Officer, Corporate Treasurer, Corporate Controller and other senior financial
officers performing similar functions who are identified from time to time by the Chief Executive Officer. We have also adopted
a written Code of Business Conduct and Ethics for Board members. The Code of Ethics for senior financial officers, which is
part of our broader Code of Conduct applicable to all employees, and the Code of Business Conduct and Ethics for Board members
are posted on our website, <U>www.medtronic.com</U> under the “Corporate Governance” caption. Any amendments to,
or waivers for executive officers or directors of, these ethic codes will be disclosed on our website promptly following the
date of such amendment or waiver.</P>
<P style="font-size:12pt;font-weight:bold">
<A name="toc19"></A>Item 11. Executive Compensation</P>
<P style="font-size:10pt"> The sections entitled “Governance of Medtronic —
Director Compensation,” “Report of the Compensation Committee on Fiscal 2006 Executive Compensation,”
“Shareholder Return Performance Graph,” and “Executive Compensation” in our Proxy Statement
for our 2006 Annual Shareholders’ Meeting are incorporated herein by reference.</P>
<P style="font-size:12pt;font-weight:bold">
<A name="toc20"></A>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder
Matters</P>
<P style="font-size:10pt"> The sections entitled “Share Ownership Information”
and “Executive Compensation — Equity Compensation Plan Information” in our Proxy Statement for our 2006 Annual
Shareholders’ Meeting are incorporated herein by reference.</P>
<P style="font-size:12pt;font-weight:bold">
<A name="toc21"></A>Item 13. Certain Relationships and Related Transactions</P>
<P style="font-size:10pt"> The section entitled “Proposal 1 —
Election of Directors — Certain Relationships and Related Transactions” in our Proxy Statement for our 2006
Annual Shareholders’ Meeting is incorporated herein by reference.</P>
<P style="font-size:12pt;font-weight:bold">
<A name="toc22"></A>Item 14. Principal Accounting Fees and Services</P>
<P style="font-size:10pt"> The section entitled “Audit and Non-Audit Fees”
in our Proxy Statement for our 2006 Annual Shareholders’ Meeting is incorporated herein by reference.</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">
<A name="toc23"></A>PART IV</P>
<P style="font-size:12pt;font-weight:bold">
<A name="toc24"></A>Item 15. Exhibits, Financial Statement Schedules</P>
<P style="font-size:10pt;font-weight:bold">(a) 1. Financial Statements</P>
<P style="font-size:10pt;margin-left:30pt">The following report and consolidated financial statements are incorporated herein
by reference in Item 8.</P>
<P style="font-size:10pt;margin-left:30pt">The sections entitled “Report of Independent Registered Public Accounting Firm”
and “Consolidated Statements of Earnings” — years ended April 28, 2006, April 29, 2005 and April 30,
2004 are set forth in Exhibit 13 hereto and will be included in our 2006 Annual Report.</P>
<P style="font-size:10pt;margin-left:30pt">The section entitled “Consolidated Balance Sheets” — April 28,
2006 and April 29, 2005 is set forth in Exhibit 13 hereto and will be included in our 2006 Annual Report.</P>
<P style="font-size:10pt;margin-left:30pt">The section entitled “Consolidated Statements of Shareholders’ Equity” —
years ended April 28, 2006, April 29, 2005 and April 30, 2004 is set forth in Exhibit 13 hereto and will
be included in our 2006 Annual Report.</P>
<P style="font-size:10pt;margin-left:30pt">The section entitled “Consolidated Statements of Cash Flows” —
years ended April 28, 2006, April 29, 2005 and April 30, 2004 is set forth in Exhibit 13 hereto and will
be included in our 2006 Annual Report.</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">38</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:10pt;margin-left:30pt">The section entitled “Notes to Consolidated Financial Statements” is set
forth in Exhibit 13 hereto and will be included in our 2006 Annual Report.</P>
<P style="font-size:10pt;font-weight:bold">2. Financial Statement Schedules</P>
<P style="font-size:10pt;margin-left:30pt">Schedule II. Valuation and Qualifying Accounts — years ended April 28,
2006, April 29, 2005 and April 30, 2004 (set forth on page 44 of this report).</P>
<P style="font-size:10pt;margin-left:30pt">All other schedules are omitted because they are not applicable or the required information
is shown in the financial statements or notes thereto.</P>
<P style="font-size:10pt;font-weight:bold">3. Exhibits</P>
<DIV align="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%">
<TR VALIGN="TOP" style="font-size:10pt">
<TD align=right width="5%">3.1 </TD>
<TD width="5%"> </TD>
<TD width="90%">Medtronic Restated Articles of Incorporation, as amended (Exhibit 3.1).(a)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">3.2 </TD>
<TD> </TD>
<TD>Medtronic Bylaws, as amended to date (Exhibit 3.2).(j)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">4.1 </TD>
<TD> </TD>
<TD width="93%">Rights Agreement, dated as of October 26, 2000, between Medtronic, Inc.
and Wells Fargo Bank Minnesota, National Association, including as: Exhibit A thereto the form of Certificate of Designations,
Preferences and Rights of Series A Junior Participating Preferred Shares of Medtronic, Inc.; and Exhibit B the
form of Preferred Stock Purchase Right Certificate (Exhibit 4.1).(c)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">4.2 </TD>
<TD> </TD>
<TD >Indenture, dated as of September 11, 2001, between Medtronic, Inc. and Wells
Fargo Bank Minnesota, N.A. (Exhibit 4.2).(d)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">4.3 </TD>
<TD> </TD>
<TD >Five Year Revolving Credit Facility dated as of January 24, 2002, among Medtronic, Inc.
as Borrower, certain of its subsidiaries as guarantors, Bank of America, N.A., as Administrative Agent and Banc of America
Securities LLC as Sole Lead Arranger and Sole Book Manager (Exhibit 4.5).(e)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">4.4 </TD>
<TD> </TD>
<TD >First Amendment to Five Year Revolving Credit Facility, dated as of August 21,
2002 (Exhibit 4.7).(f)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">4.5 </TD>
<TD> </TD>
<TD >Second Amendment to Five Year Revolving Credit Facility, dated as of January 23,
2003 (Exhibit 4.9).(g)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">4.6 </TD>
<TD> </TD>
<TD >Credit Agreement ($1,000,000,000 Five Year Revolving Credit Facility) dated as of
January 20, 2005, among Medtronic, Inc. as Borrower, certain of its subsidiaries as guarantors, Citicorp USA, Inc., as
Administrative Agent and Bank of America, N.A. as Syndication Agent, and Citigroup Global Markets Inc. and Banc of America
Securities LLC as Joint Lead Arrangers and Joint Book Managers (Exhibit 4.1).(l)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">4.7 </TD>
<TD> </TD>
<TD >Form of Indenture between Medtronic, Inc. and Wells Fargo Bank, National Association
(Exhibit 4.1).(k)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">4.8 </TD>
<TD> </TD>
<TD >Indenture dated as of September 15, 2005 between the Company and Wells Fargo
Bank, National Association, as Trustee, with respect to the 4.375% Senior Notes due 2010 and 4.750% Senior Notes due 2015 (including
the Forms of Notes thereof) (Exhibit 4.1).(q)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">4.9 </TD>
<TD> </TD>
<TD >Form of 4.375% Senior Notes, Series B due 2010 (Exhibit 4.2).(q)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">4.10</TD>
<TD> </TD>
<TD >Form of 4.750% Senior Notes, Series B due 2015 (Exhibit 4.3).(q)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">4.11</TD>
<TD> </TD>
<TD >Indentures by and between Medtronic, Inc. and Wells Fargo Bank, N.A., as trustee dated
as of April 18, 2006 (including the Forms of Convertible Senior Notes thereof) (Exhibit 4.1).(r)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.1 </TD>
<TD> </TD>
<TD >1994 Stock Award Plan, as amended (Exhibit 10.1).(b)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.2 </TD>
<TD> </TD>
<TD >Medtronic Incentive Plan (Exhibit 10.2).(h)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.3 </TD>
<TD> </TD>
<TD >Executive Incentive Plan (Appendix C).(i)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.4 </TD>
<TD> </TD>
<TD>Form of Employment Agreement for Medtronic executive officers (Exhibit 10.5).(a)</TD>
</TR>
</TABLE>
</DIV>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">39</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<DIV align=center>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%">
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.5 </TD>
<TD WIDTH=5%> </TD>
<TD WIDTH=90%>Capital Accumulation Plan Deferral Program, as restated generally effective January 1,
2005 (Exhibit 4.1).(o)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.6 </TD>
<TD> </TD>
<TD >Stock Option Replacement Program (Exhibit 10.8).(a)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.7 </TD>
<TD> </TD>
<TD>1998 Outside Director Stock Compensation Plan, as amended and restated
(Appendix B).(n)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.8 </TD>
<TD> </TD>
<TD>Amendment effective October 25, 2001, regarding change in control provisions
in the Management Incentive Plan (Exhibit 10.10).(b)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">10.9 </TD>
<TD> </TD>
<TD>Director and Officer Indemnity Trust Agreement (Exhibit 10.11).(j)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">10.10 </TD>
<TD> </TD>
<TD>Asset Purchase Agreement and Settlement Agreement among Medtronic, Inc., Medtronic
Sofamor Danek, Inc., SDGI Holdings, Inc., Gary K. Michelson, M.D. and Karlin Technology, Inc. (Exhibit 10.13).(m)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.11 </TD>
<TD> </TD>
<TD>Form of Restricted Stock Award Agreement (Exhibit 10.3).(l)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.12 </TD>
<TD> </TD>
<TD>Form of Non-Qualified Stock Option Agreement 2003 Long-Term Incentive Plan (four year
vesting) (Exhibit 10.1).(l)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.13 </TD>
<TD> </TD>
<TD >Form of Non-Qualified Stock Option Agreement 2003 Long-Term Incentive Plan (immediate
vesting) (Exhibit 10.2).(l)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.14 </TD>
<TD> </TD>
<TD >Form of Initial Option Agreement under the Medtronic, Inc. 1998 Outside Director Stock
Compensation Plan (Exhibit 10.17).(m)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.15 </TD>
<TD> </TD>
<TD >Form of Annual Option Agreement under the Medtronic, Inc. 1998 Outside Director Stock
Compensation Plan (Exhibit 10.18).(m)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.16 </TD>
<TD> </TD>
<TD >Form of Replacement Option Agreement under the Medtronic, Inc. 1998 Outside Director
Stock Compensation Plan (Exhibit 10.19).(m)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.17 </TD>
<TD> </TD>
<TD >Form of Restricted Stock Units Award Agreement 2003 Long-Term Incentive Plan (Exhibit
10.20).(m)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.18 </TD>
<TD> </TD>
<TD >Form of Performance Share Award Agreement 2003 Long-Term Incentive Plan (Exhibit 10.21).(m)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.19 </TD>
<TD> </TD>
<TD >Medtronic, Inc. Supplemental Executive Retirement Plan (as restated October 19,
2005 generally effective May 1, 2005) (Exhibit 10.2).(p)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">10.20 </TD>
<TD> </TD>
<TD >Purchase Agreement by and among Medtronic, Inc. and the Initial Purchasers named
therein dated as of April 12, 2006 (Exhibit 10.1).(r)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">10.21 </TD>
<TD> </TD>
<TD >Registration Rights Agreement by and among Medtronic, Inc. and the other parties named
therein dated as of April 18, 2006 (Exhibit 4.2).(r)</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.22 </TD>
<TD> </TD>
<TD>2003 Long-Term Incentive Plan as Amended and Restated</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.23 </TD>
<TD> </TD>
<TD >Form of Option Agreement under the 2003 Long-Term Incentive Plan effective June 22,
2006</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.24 </TD>
<TD> </TD>
<TD >Form of Restricted Stock Agreement under the 2003 Long-Term Incentive Plan effective
June 22, 2006</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.25 </TD>
<TD> </TD>
<TD >Form of Restricted Stock Unit Agreement under the 2003 Long-Term Incentive Plan effective
June 22, 2006</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">*10.26 </TD>
<TD> </TD>
<TD >Form of Performance Award Agreement under the 2003 Long-Term Incentive Plan effective
June 22, 2006</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">10.27†</TD>
<TD> </TD>
<TD>Form of Confirmations of Convertible Note Hedge related to Convertible Senior Notes
issued on April 12, 2006, including Schedule thereto</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">10.28†</TD>
<TD> </TD>
<TD >Form of Warrants issued on April 12, 2006, including Schedule thereto</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">10.29†</TD>
<TD> </TD>
<TD >Form of Amendment issued on April 13, 2006 to Form of Warrants issued on April 12,
2006, including Schedule thereto</TD>
</TR>
</TABLE>
</DIV>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">40</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<DIV align=center>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%">
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">10.30</TD>
<TD width=5%> </TD>
<TD width=90%>Named Executive Officer Compensation</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%"> 12.1 </TD>
<TD> </TD>
<TD>Computation of ratio of earnings to fixed charges</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">13 </TD>
<TD> </TD>
<TD >This exhibit contains the information referenced under Part II, Items 5,
6, 7, 7A and 8</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">21 </TD>
<TD> </TD>
<TD>List of Subsidiaries</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">23 </TD>
<TD> </TD>
<TD>Consent of Independent Registered Public Accounting Firm</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">24 </TD>
<TD> </TD>
<TD>Powers of Attorney</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">31.1 </TD>
<TD> </TD>
<TD >Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">31.2 </TD>
<TD> </TD>
<TD>Certification of Chief Financial Officer pursuant to Section 302
of the Sarbanes-Oxley Act of 2002</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%">32.1 </TD>
<TD> </TD>
<TD >Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:6pt">
<TD align=right width="5%"> 32.2 </TD>
<TD> </TD>
<TD >Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002</TD>
</TR>
</TABLE>
</DIV>
<BR>
<HR noshade color="black" align="left" size="1" width="20%">
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%">(a)</TD>
<TD WIDTH="96%">Incorporated herein by reference to the cited exhibit in our Annual Report on Form 10-K for the year ended
April 27, 2001, filed with the Commission on July 26, 2001.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(b)</TD>
<TD>Incorporated herein by reference to the cited exhibit in our Annual Report on Form 10-K for the year ended April 26,
2002, filed with the Commission on July 19, 2002.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(c)</TD>
<TD>Incorporated herein by reference to the cited exhibit in our Report on Form 8-A, including the exhibits thereto, filed
with the Commission on November 3, 2000.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(d)</TD>
<TD>Incorporated herein by reference to the cited exhibit in our Report on Form 8-K/A, filed with the Commission on November 13,
2001.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(e)</TD>
<TD>Incorporated herein by reference to the cited exhibit in our Quarterly Report on Form 10-Q for the quarter ended January 25,
2002, filed with the Commission on March 8, 2002.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(f)</TD>
<TD>Incorporated herein by reference to the cited exhibit in our Quarterly Report on Form 10-Q for the quarter ended October 25,
2002, filed with the Commission on December 6, 2002.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(g)</TD>
<TD>Incorporated herein by reference to the cited exhibit in our Quarterly Report on Form 10-Q for the quarter ended January 24,
2003, filed with the Commission on March 7, 2003.
</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(h)</TD>
<TD>Incorporated herein by reference to the cited exhibit in our Annual Report on Form 10-K for the year ended April 25,
2003, filed with the Commission on July 14, 2003.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(i)</TD>
<TD>Incorporated herein by reference to the cited appendix to our 2003 Proxy Statement, filed with the Commission on July 28,
2003.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(j)</TD>
<TD>Incorporated herein by reference to the cited Exhibit in our Annual Report on Form 10-K for the year ended April 30,
2004, filed with the Commission on June 30, 2004.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(k)</TD>
<TD>Incorporated herein by reference to the cited Exhibit in our registration statement on Amendment No. 2 to Form S-4, filed
with the Commission on January 20, 2005.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(l)</TD>
<TD>Incorporated herein by reference to the cited Exhibit in our Quarterly Report on Form 10-Q for the quarter ended January 20,
2005, filed with the Commission on March 7, 2005.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(m)</TD>
<TD>Incorporated herein by reference to the cited Exhibit in our Annual Report on Form 10-K for the year ended April 29,
2005, filed with the Commission on June 29, 2005.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(n)</TD>
<TD>Incorporated herein by reference to the cited appendix to our 2005 Proxy Statement, filed with the Commission on July 21,
2005.</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">41</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD width="4%">(o)</TD>
<TD width="96%">Incorporated herein by reference to the cited Exhibit in our Form S-8, filed with the Commission on November 21,
2005.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(p)</TD>
<TD>Incorporated herein by reference to the cited Exhibit in our Quarterly Report on Form 10-Q for the quarter ended October 28,
2005, filed with the Commission on December 6, 2005.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(q)</TD>
<TD>Incorporated herein by reference to the cited Exhibit in our Form S-4, filed with the Commission on December 6, 2005.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(r)</TD>
<TD>Incorporated herein by reference to the cited Exhibit in our Current Report on Form 8-K, filed with the Commission on April 18,
2006.</TD>
</TR>
</TABLE>
<P style="font-size:10pt">*Items that are management contracts or compensatory plans or arrangements required to be filed as
an exhibit pursuant to Item 15(c) of Form 10-K.</P>
<P style="font-size:10pt">†Confidential treatment requested as to portions of the exhibit. Confidential portions omitted
and filed separately with the Securities and Exchange Commission.</P>
<BR>
<BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR>
<P style="font-size:10pt;text-align:center">42</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">SIGNATURES</P>
<P style="font-size:10pt"> Pursuant to the requirements of Section 13 or
15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</P>
<DIV align="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="top" style="font-size:10pt">
<TD valign="bottom"></TD>
<TD width="2%"> </TD>
<TD colspan="3" valign="bottom"><B>MEDTRONIC, INC.</B></TD>
<TD> </TD>
</TR>
<TR VALIGN="top" style="font-size:10pt">
<TD width="47%">Dated: June 28, 2006</TD>
<TD> </TD>
<TD width="4%"></TD>
<TD width="2%"> </TD>
<TD width="45%"></TD>
</TR>
<TR VALIGN="top" style="font-size:10pt">
<TD></TD>
<TD> </TD>
<TD><B>By:</B></TD>
<TD> </TD>
<TD>/s/ <B>Arthur D. Collins, Jr.<BR>
<HR align=left style="width:70%;height:1;color:black;background-color:black" noshade>
Arthur D. Collins, Jr.<BR>Chairman of the Board and<BR>Chief Executive Officer</B></TD>
</TR>
</TABLE>
</DIV>
<P style="font-size:10pt"> Pursuant to the requirements of the Securities Exchange
Act of 1934, the report has been signed below by the following persons on behalf of the registrant and in the capacities and
on the dates indicated.</P>
<DIV align="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="top" style="font-size:10pt;padding-top:12pt">
<TD width="47%">Dated: June 28, 2006</TD>
<TD width="2%"> </TD>
<TD width="4%"><B>By:</B></TD>
<TD width="2%"> </TD>
<TD width="45%">/s/ <B>Arthur D. Collins, Jr.<BR>
<HR align=left style="width:70%;height:1;color:black;background-color:black" noshade>
Arthur D. Collins, Jr.<BR>Chairman of the Board and<BR>Chief Executive Officer<BR>(Principal Executive Officer)</B></TD>
</TR>
<TR VALIGN="top" style="font-size:10pt;padding-top:12pt">
<TD>Dated: June 28, 2006</TD>
<TD> </TD>
<TD><B>By:</B></TD>
<TD> </TD>
<TD>/s/ <B>Gary L. Ellis<BR>
<HR align=left style="width:70%;height:1;color:black;background-color:black" noshade>
Senior Vice President and<BR>Chief Financial Officer<BR>(Principal Financial and Accounting Officer)</B></TD>
</TR>
<TR VALIGN="top" style="font-size:10pt;padding-top:24pt">
<TD></TD>
<TD> </TD>
<TD colspan="3"><B>Directors</B></TD>
<TD> </TD>
</TR>
<TR VALIGN="top" style="font-size:10pt;padding-top:12pt">
<TD></TD>
<TD> </TD>
<TD></TD>
<TD> </TD>
<TD><B>Richard H. Anderson<BR>Michael R. Bonsignore<BR>
Arthur D. Collins, Jr.<BR>
Denise M. O’Leary<BR>Robert C. Pozen<BR>Jean-Pierre Rosso<BR>Jack W. Schuler<BR>Gordon M. Sprenger</B></TD>
</TR>
</TABLE>
</DIV>
<P style="font-size:10pt"> Terrance L. Carlson, by signing his name hereto, does
hereby sign this document on behalf of each of the above named directors of the registrant pursuant to powers of attorney duly
executed by such persons.</P>
<DIV align="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="top" style="font-size:10pt">
<TD width="47%">Dated: June 28, 2006</TD>
<TD width="2%"> </TD>
<TD width="5%"><B>By:</B></TD>
<TD width="2%"> </TD>
<TD width="45%">/s/ <B>Terrance L. Carlson<BR>
<HR align=left style="width:70%;height:1;color:black;background-color:black" noshade>
Terrance L. Carlson<BR>Attorney-In-Fact<BR>Senior Vice President,<BR>General Counsel and Secretary</B></TD>
</TR>
</TABLE>
</DIV>
<BR>
<BR>
<P style="font-size:10pt;text-align:center">43</P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<P style="font-size:10pt">
<A href="#toc">Table of Contents</A>
</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">MEDTRONIC, INC. AND SUBSIDIARIES<BR>SCHEDULE II —
VALUATION AND QUALIFYING ACCOUNTS</P>
<P style="font-size:10pt;font-weight:bold;text-align:center">(dollars in millions)</P>
<DIV align="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM" style="font-size:8pt">
<TH colspan="2" align="left"></TH>
<TH> </TH>
<TH> </TH>
<TH nowrap colspan="2">Balance at<BR>Beginning of<BR>Fiscal Year</TH>
<TH> </TH>
<TH> </TH>
<TH nowrap colspan="2">Charges/<BR>(Credits) to<BR>Earnings</TH>
<TH> </TH>
<TH> </TH>
<TH nowrap colspan="2">Other<BR>Changes<BR>(Debit)<BR>Credit</TH>
<TH> </TH>
<TH> </TH>
<TH nowrap colspan="2">Balance<BR>at End of<BR>Fiscal Year</TH>
<TH> </TH>
</TR>
<TR>
<TD colspan="2"></TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD width="38%">Allowance for doubtful accounts:</TD>
<TD width="1%"> </TD>
<TD width="1%"> </TD>
<TD width="4%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="8%"></TD>
<TD width="1%"> </TD>
<TD width="4%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="8%"></TD>
<TD width="1%"> </TD>
<TD width="4%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="8%"></TD>
<TD width="5%"> </TD>
<TD width="4%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="8%"></TD>
<TD width="1%"> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD>Year ended 4/28/06</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">174.9</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">39.3</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD nowrap align="right">(23.6</TD>
<TD>)(a)</TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">183.6</TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD nowrap align="right">(7.0</TD>
<TD>)(b)</TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt;padding-top:6pt">
<TD>Year ended 4/29/05</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">145.3</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">43.2</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD nowrap align="right">(21.0</TD>
<TD>)(a)</TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">174.9</TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">7.4</TD>
<TD>(b)</TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt;padding-top:6pt">
<TD>Year ended 4/30/04</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">99.5</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">70.2</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD nowrap align="right">(28.2</TD>
<TD>)(a)</TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">145.3</TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">3.8</TD>
<TD>(b)</TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
</TR>
</TABLE>
</DIV>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%">(a)</TD>
<TD WIDTH="96%">Uncollectible accounts written off, less recoveries.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(b)</TD>
<TD>Reflects primarily the effects of foreign currency fluctuations.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>Commission File No. 1-7707</TD>
</TR>
</TABLE>
<BR>
<BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR>
<P style="font-size:10pt;text-align:center">44</P>
<HR color="gray" size="3" noshade>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>a62430crdm.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a62430crdm.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@`M`(]`P$1``(1`0,1`?_$`+8``0`"`@,!````````
M```````%!@0'`@,(`0$!``,!`0$```````````````$"`P0%!A```0,"`P0#
M"0D,"`4#!0```@$#!``%$1(&(3$3!T$B%%%A,I.C9587*'&!0E)R([05")&A
ML6*",W/$=84W1Y*BLB0T=!8VTD-38[/!T<)$5(24)1$!``(!`P,#`@8"`@,!
M``````$"$3$#!"%1$D%A,G$3@<$B,Q0%D='P0J&QX?'_V@`,`P$``A$#$0`_
M`-M\M.7&A)_+G2LZ;8H<B9*L\!^3(<;0C<=<BMD9D2[U(E556@LGJJY<>CD'
MQ(T#U5<N/1R#XD:!ZJN7'HY!\2-`]57+CT<@^)&@>JKEQZ.0?$C0/55RX]'(
M/B1H'JJY<>CD'Q(T#U5<N/1R#XD:!ZJN7'HY!\2-`]57+CT<@^)&@>JKEQZ.
M0?$C0/55RX]'(/B1H'JJY<>CD'Q(T#U5<N/1R#XD:!ZJN7'HY!\2-`]57+CT
M<@^)&@>JKEQZ.0?$C0/55RX]'(/B1H'JJY<>CD'Q(T#U5<N/1R#XD:!ZJN7'
MHY!\2-`]57+CT<@^)&@>JKEQZ.0?$C0/55RX]'(/B1H'JJY<>CD'Q(T#U5<N
M/1R#XD:!ZJN7'HY!\2-`]57+CT<@^)&@>JKEQZ.0?$C0/55RX]'(/B1H'JJY
M<>CD'Q(T#U5<N/1R#XD:!ZJN7'HY!\2-`]57+CT<@^)&@>JKEQZ.0?$C0/55
MRX]'(/B1H'JJY<>CD'Q(T#U5<N/1R#XD:!ZJN7'HY!\2-`]57+CT<@^)&@>J
MKEQZ.0?$C0/55RX]'(/B1H'JJY<>CD'Q(T#U5<N/1R#XD:!ZJN7'HY!\2-`]
M57+CT<@^)&@>JKEQZ.0?$C0/55RX]'(/B1H'JJY<>CD'Q(T#U5<N/1R#XD:!
MZJN7'HY!\2-`]57+CT<@^)&@>JKEQZ.0?$C0/55RX]'(/B1H'JJY<>CD'Q(T
M#U5<N/1R#XD:!ZJN7'HY!\2-`]57+CT<@^)&@>JKEQZ.0?$C0/55RX]'(/B1
MH'JJY<>CD'Q(T#U5<N/1R#XD:!ZJN7'HY!\2-`]57+CT<@^)&@>JKEQZ.0?$
MC0/55RX]'(/B1H'JJY<>CD'Q(T#U5<N/1R#XD:!ZJN7'HY!\2-`]57+CT<@^
M)&@KR<O=$)S!*V)9(B6X[2,DHO#3AJ\$E0%S+NS()*F-!8>4_P#"S1O[#MOT
M-N@M5`H%`H%`H-+\\KUJ.VZZT3'LW;I27"+?3DV:'-?AI+.#"%^.*JTXVJ*#
MA*O55").KMV)01L_F->=`Z@U5;\\_4`6IRT,9YD@I*-1I,:7(.2C`-\;$$9$
M7B$BQ\/!,N50DPY]W618;OJ*%:H3MFM,D[<\\Y,X+BR@2-E,6S%"<;>[0XK8
M#UB1ONG@@=.DN9=XU5S'TN2\6!'=9OL.XV\''.SO.VUYMMM[A'ERKUU7`DS)
MC@JKA01=XN&I--Z^U9IJ9=+C/L[5N'6,1])\D93%M@JYVB`T2.;WGA1I%W\-
M5)5S(.`9MT^T/J&VV"%<9-@C<6;%=N,?+*SB]%;B,RAR-`A/"BJZ;:NF.1%#
M-N-$0+CHOF-J35.K+C`CVB,S8K6;02IQ2263_>8@2F<K/#R_#REU^_0:SYJ:
MRU/IB[ZOF6#5STYR/;#:DVUUYE1CSI$IM02%''KAV6$I$9KBB+ABJDJH@0%_
MYF\P(=VU'9F;K*C6O3SNH7+3<%<(W'C@(P<=EUT\Q/(R3RC@2JA(2(6."4%W
MY<\VK]?N9`1-0LNM-7"=<K58HL5Y6V8[MGCMNRBEL(@D:O"^B@KAEE7#`4\*
M@WO0*!0*!0*!0*!0*!0*!0*#3O,;7NJ;+S3A:?A3)0VJ=:@D*U$9B&;4AV<$
M,7E-YEQ>$".9C3;[U!@6WG=<M.OS[7JLBN=R"[/6UN1E9AQ&W(\6.:LB^@H.
M+QND37%RX[4Q3*E!8PYXQ7K4-Z8L<GZBDOI&M]V>=9:CF:3'89H\I+G:5"84
MD3*6(D.Y5PH.OE]S+GZRUH^W&<<CV&7IZ%=8<5P&N,P_(>=:<ZZ(6;\WLS8I
M^"@JS7-C6&G3U)"U=,>=>T5-[7=)C#,0`F6V4@-VUAL<B(#DAUU%,L>H(EUL
M53`++</M`6NW/1&IUEF1U?<X;BNX-JN,Y(*''!Q`-T,2%W,H@F0D^$N6@L6A
M^8DS55VNT(+!(A1+/*EV]^YN/,&P<R$\+1L@(EQ>LA9D)01,$7WPUMJ#7W-'
M3UUGP7KRS<H$VZVJUP[F$5AA8LB4]A/9BBJ&+XQPRCG<0LI&B%B2*E!6[7]H
MG7<R$,XL!2R-Q$G,(RWA<3D78H)ECEQ#[email protected]\OSF..*8#0;/Y<:MUG<M?WR
MU:H6=`5MIV5;+/)A1VXZQ%DH#;K4QHS-T@'`2$L/"Q]P-I4"@4"@4"@4"@4"
M@4"@4"@\\V?F1S#F2M71!O4HI&FIU^1IYR'"6,Y`LRQVT%<K+*G*59?$V.".
M`X*B9L:"?MOVC]/QK6T-S9E2)<2U0)LU]198>?.;&8<;-N-G\%UV4`8B2B)8
MXJ@HBD$W<N=\.TW6W6N\V"?;I<UUM@A?)@>L],*$!,8FBOAQ`0R443!LA+#;
MA08%BO\`S)U)R:N%TL]R3_5\65/"$\K#"H^,*4XV+)MY.'BXV&"**)UL%W8I
M00^GN>[JVZSWV2%PN;%^@K]6V9IJ,3QN6QI/K.4BM@V9*3_S33?PB$BP053*
M$_)^T'IZ/.OD,[7,XUDBS)KC:\,7#:M[HM/8@1"K9$AHXVA>$&W9CA069K4-
M]O\`HN1=(C:Z2?)2)N9=19?1J(.!K*0&G5;5":Q4<YHB+M7%$VAI.Z\^>9ED
MM;/UFC'UC:[&W?9P\!&REB_?&8#(/-%B3&>&YQ<HY2S$*[NK03-B^T+<F;J$
MN_&T%HNS%Q.#&=X<88KT.X=CC-F^6&471).*;BKE+:F`[*#8/(O6]UUIH!J]
MW:0P_<#ERV7NS(*-@C;Y(V"(G<;RX8[53!5WT&P*!0*!0*!057^:?[C_`%N@
M<I_X6:-_8=M^AMT%JH%`H%`H%!"76WZ/F:@MJ7.!#F7UL7';8Z]&!^0R#:HI
MN`XH$3(H1"F;%$S*B;UH,`-/<NM2C(O:V6#.<-Y]B5,=A#V@WH+CD-T3SMHZ
M:MDVXVF/1NV+01ULM7*+5LN8Y&LD"=(E08<F6X_;\BNPY"N)$)5>:#,F,4DP
MWCEP7#!*"?M>A-$VF4W,M>G[=!EM$X;,F/$8:=`GDRNJ!B*$.<=A8+M390<R
ML.EI&HGISEFC'>PC@CEU<ACQ"9>XC7"&60=?JMDAMH?5%4S(B$F(1Y<JN691
M6HI:5M*QF"=)EE8;"B)/H@N*B9=Y((I[R=Q*#G(30^AHDN>U:VK3%&*<J?*M
M\`LO`@@*?/'&:7P`+J"6W*BY=@K@&!9+7RLFW>X+:M/0OK`W9D&YRPM2-9G`
M1M933[ZLBB\3CIL,L'-N&;!:":/1&CG(,:`Y9()PH;A/18Y1VR!MPRS&8HH^
M$9;27IZ:#X-MTA#U0,@8,5C44]MQP9:,(+KHCD%W![+@I8(&9,V911.@=@3E
M`H%`H%`H%`H%`H%`H%`H*U+TGHUS6K6I)&<=3QXBBV]VV2"##$DS(L<749X>
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MT.0,!ZZRAER69,U]UQV5/=X(N(LAUP\[[O5ZN\N_05[3/*WDHJR5L41J6<T`
M?==2=+E&HMRE(76W''W"!4DL+UVU1<P[Z"?#E5R_!;8H6=L/J@`;A"+CR#E:
M>[2VCHH>#^5]5=3BYNNJEO5:#OTGI#1NF77H%A9X#S38YX[DA^2;++ID8BVD
MAQU6FC-"7*&`JJ+TI062@4"@4"@4"@4"@4"@4"@4%+BZ0Y:V:VW>&T0QX6HY
MKC%U1RX2"5^=.5&G6T-QXB!YY<HJ@*A+LH(N[\J.3L.$S#O3+;4!R,=NA1Y\
M]]6Q:%H",6.,ZJBH-0Q+$5Q%`S;.LM!W.\EN6EY*)=G`ESG58C]GN*7.<9NM
MLN]H8<5U'_G,I+B!8[$W=%!:;%I33VG+(]:K4T<.VF;S[HK(?(A-]5-TT><<
M)P,252Q$DP7:F%!7+;RDY9'8[&U:(S@6RV*[*L4F'/F9@;G)F>X,D7E<X3XK
MBHH>5<<:#K7D/RR5^4\MND(DT93<AD9TT&B;G&CDAM`!X1$#),<HX)]Z@S;Z
MQRPNFFCTK=;A&.S,@C+L/ZP<:/)%?[+D<<!X'B09`<)4(MIIE7;085NY/<IW
M8L5+=;@=C0'76,0E2'D,[email protected]")TU>1N7%%5!Q5RD&'=2@FH'+;1,&YS+D
MS:VBDS>(CHO*3S0H\[VAU&FG%)MM''OG#R"F)>XE!EZ.TUI;3MC;MVF&&X]I
MXCCS8-.$\*FX:JX7$,G"7K=_9NH)N@4"@4"@4%5_FG^X_P!;H'*?^%FC?V';
M?H;=!:J!0*!0*!04#7&C+W=KQ.>@/(`76VQ(2*YBK(G;YQ3"9>$44N%,:=)D
MR1%P1-RXHBA7X'*#4+#J..%;@3M8RH@-&[C;>'>I-U481(RW^?:E]G<V#L!%
MZP]1`P[AR;UE,L:6Q7;8*%;;?;'")UYQ,(*7%%=%"CX(JE<0)$5%\!414)1,
M0[(/)*]-DDV0-L2]N74;D_<0(S(Q%MH$!Q'(ZHZB*+I(G5)")"$P5%Q"QZLY
M=W*\ZJ?N21K=)M<A;2LB)*,TXOU:Y,-Q7`1AT"X@S1!,578&WO!'WSE5>+KH
M72NGI+=NE2[%;G8,EZ0;A-DXMM."VZWBR:K\X0NKBB8**88KMH(MSDWJI(MZ
MC1AM<=JZ1+K%9!MYX182Z0(L9<!2-M0'HINKNS9UZ<<0RI_*?5DV=<9/%M\=
M;A(N$@E1UYS$)G8R&.:*PWG;+L1`YM\$UV+N4.)\FKLE^9NK3=MQ;FQYL8%,
MT6"+5U;G.,Q51CP39;,/@[7#V9=X9VD>7%]LQV"!()KA6JZNW@Y$=<1%I;65
MO&*KA-M&Z9.O$6<AS<,$0R4^L0;2H%`H%`H%`H%`H%`H%`H%!KC4%FU,6H[L
M42.]):FRK=*,&7UC'(MK#!,O16WT4,A-2"XRBICF$E3':J4%8M7+[F7$LL:W
M&K@N1HX-MD$U2C]D&UG%[email protected]*:`9N3,'D<4-Q8Y\10:#E-T9S.C,N#:(CC1.
MS(\LB9G"P2=GM=MB(A"+@@>+L%U.MCU539UE40F+1HW7$.=8YB/SLXSI+MX9
MEW%Z0TL=R4IM;Y!93;CB`B@B8EUA(4QST'#6>C==7.ZW4[>Y/",Z](>MY,W-
MV,(YK3P&4R@\.5$GBCB#A@B8KAM5%#-UWI;6MWN$"3;WIC8,6HFW0C3W(B=O
M67%<`R%IUL2RLMOBJ[4ZR)[@1`:)Y@=H1IT9+]N8E17HS$B:CR"U$U-]9-_G
M'3ZXVX&V\R[5(<JK@F-!RC:.Y@Q\&P:D#;5=%Z;;VYJ-J\VMUE27FF<CJ"V;
MD>0TI+F%#R*!%@N-!A,Z%YL-/D^Y.N$@T!6V<+J8J++EMG,9.L:MJZV^]$7B
MJVN)-J>U?""T:/M.J&KY8_K4"X]J@7-BXRL3RN#+F,G"!45Q\<_#8(R`'#1K
MP47`DH-B4"@4"@4"@4"@4"@4"@4"@TDWI?74JS:?MX1)#J6QNR))(9*,-LW6
MV71)-UD2&'#9[2DD&Q<:)1-,>LF&;-09#6DN9*I:G)S$J:,;L3DZ.],:D%V]
MJ%-8FRF#>>P!EXI#&1M,NXER!\((_P#TOS?:CL1&(L]B(S;8\$6HMR;;RFW&
MA"ICA*;$,KD=\>H./6QS$AX`%ZTI8-56R\WT)KLV587&!"UC(F&])%0S#D!P
MWW,5($0N*7#/,N!*6&>@K^C]/\S8U[T]+NWUEA&;A,7E7KB+T=P6[0ZQ*/@)
M(<$B.?P7,V3-L5>E<0Q+YI7F<[=KQ*B+=EXS]R*W<*ZJVP(DD9;>J,K*`!$3
M!Y5')N7`D5-E!PF:2YA2TFE*MLJ2;HW1J*3TJ,X0L2;PS*B-*1R%7!N*SAAC
M@F&%!FCI[FHX9(I3V@%YY;8JW`<8^-Z=D"4K!X^T-E;G6FD`L^7AD."9D*@B
M8.E^=$>U@T)7`IR=F?(I-S1UHWVQE`\VX22>*#9BXROS:X(0H2MG@J*&S-$L
M/B[J&9E)NWW"[.2;6V:$.#/9F&G3$2P5!=E-/.I\;-FZ:"S4"@4"@4"@JO\`
M-/\`<?ZW0.4_\+-&_L.V_0VZ"U4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@JO\T_W'^MT#E/_"S1O[#MOT-N@M5`H%`H%`H%!$WW5VE[`"%>
MKK%@*28MMONB+A_(;QSG^2BU,1,Z)B)G11+E]H[ES$(DB]NN2#LS1H^1%7O=
MJ*/6]>+N3Z-J\:\^B!=^U#:L2X%@D$F'5XK[8*JX=*"+B)]VM/X5_9I_#O[)
MVU\[G)UOBS5L:`W):!Y`&7F)!<%"1-K((I8+W??I'"O,9S#@MN1$X2L;G%8S
M)$DVV?%1/#=46703;T(TZ;B_T*I;B;D>A&[58+3KG25U<!F'<VED.*B-Q7LT
M=\E7XK+R-N+[PUA:EJZPO$Q*=JJ2@4"@4"@4"@4"@4"@4"@4"@4"@@M0:ZT?
MIW$;S=XT-Y$S=F)Q"?5%Z19#,Z7O#5JUF=$Q69T4:Y_:3Y?Q5)(;,^Y;T$V&
M!:%5[_:38-$_)K:O%W)]&]>+>?1"2?M26T`,V=/OF@IB*.2`!51.[E!S#[]:
M?PK^R_\`#M[++&YS..--NN63`3%"46Y2&2(J8[$)IM%^ZE/X5_9Y_P!V$C&Y
MPZ=/#M<*?"'X;AM-O"B_)CN/.+_0JEN)N1Z)C<JL=HUCI>[N(S;[DP[)),4B
MD7#D8)TJPYD=1/R:PM68UA>)RF*JDH%`H%`H%`H%`H%`H%`H%`H%!&7_`%1I
MS3T1)=]N<:VQU7`#DN@UF7XH(2HI%WAVT&L;W]IW1,52"S09]Z-/!>%I(C']
M*2K;G]%M:WKQKV]&U>/>?14)WVHM6NJO8-/0(8_!61)>E+ALWH#<;\-;1P;>
MLMHX5O66'`^T7S2FWB%;Q;L;(S73;0UA2S4$!EQ[_P"]#-^:PZ.[WJF>%B8Z
MZL^1L?;KY9RN+/-?F4TJ*\S9IB)O0&I43';W5>EY=FS<O=[U3/`GTEP_>]DG
M"YXW!I12\Z6>$=B&]:Y34L4_&R/I"<P[PHJ^[65N'N1[K1NPMVG.:&AM02!A
MP;F#5R+=;9@'#E*O3E9D"V9X=T$5._7/:LQK"\3E:JJDH%`H%`H%`H%!5?YI
M_N/];H'*?^%FC?V';?H;=!:J!0*!0*"JZYYEZ6T9&0KH^KDYP<T:V1\#DN)M
M3-E540`V+US5!Z-^RKTV[7G$+TVYM.(>?=8<^-<W\C9@O_45O78C$(EXZI^/
M*P%S']'D[BXUZ&WPZQ\NKOV^'$?+JUT2D;ANFJFZXN9QPE52)>Z1+M5?=KLK
M6(T==:Q&CY4I*#:>F/\`;5I_R4?_`,0TI\8?+[OSGZI.K,W!UIIYLFW0%QLM
MA`:(0K[J+43&4I2S:EU'9%%+9/-(X_\`T,G&1&P[@@2H;:)T(T8IW46N;<XE
M+:=&E=V8;)TMS-M-W=:@SP^J[JZJ"TPX6=EXL,<&'L!S+^*2"7<14VUYN[L6
MIKHVK>)7*L5R@4"@4"@4"@4"@4"@4"@I&ON;NE-'(L:0XLZ\*F(6N,J*XF*;
M">+P6A7\;K+\$5K3;VK7GHTV]JUYZ-`:OYU:[U(1M)+6T6XL42#`(FU45_ZD
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M.?[ML?\`F'OH4BL[ZU^OY2X/[']O\6V:V>$4&/-@09S"QYL=N2RNU6W10QQ3
M<N"]-5M6)C$IB<)*Q:KUGI?(-JEK=;4WX5EN3A&J"G1&F%G=:7N(YG#H1!WU
MQ;O"B>M6M=WNV[HOF!8-6,.)"(XURBHG;[3)1`E,*6Y2%%5"`O@N`JBO0M>=
M:DUG$MXG*RU5)0*!0*!0*"J_S3_<?ZW0.4_\+-&_L.V_0VZ"U4"@4"@U1S@Y
MTMZ7)RPV'(_J(A19#Y8$U"$T0A4A78;I"N(AN1.L6S`2Z-C8F\^S?8V)O/L\
MTRY<N9+>F3'CDS)!JY(D.DIN&:])$N_N>YLKUJ4BL8AZM*16,0ZJLL4"@4&T
M],?[:M/^2C_^(:4^,/E]WYS]4G5F90*#@ZTT\V33H(XV:8$!(BHJ=]%J)C*5
MWT-S#DVYUNUZ@DJ_;2P")<WE4G&55=@27"7KM]".+M'X:JG63S.3Q?']5='1
M3<STEMBN%J4$+.UKI2!<%MTNYLMS1<99-G%24'9!(++9J**@&XI)D$L%7HH.
MAKF%H=V$_-;OD,XL9L'I#J.C@#3A*`.%^(1(J(6[&@[QUKI$@$TN\3`I(0<%
M=%%&4[^;8-%7$'#^")8*O109K5[M#MV>L[4MH[I&:%^1#$D5UMIQ<`,Q3P4+
MHQWT&;0*!0*!0*#2G.'G>5L=?TYI5X2N(8MW&Z#@21R38K3.\2=3X1+L#=M+
M'+U<?C>?6?BZMCC^?6='GIPW''#==,G'7"4W73)2,R)<2(B+%255WJM>K6L1
M&(>G6L1&(<:E)0*#@_\`F7/DK^"HG1$Z-QPO\&Q^C#^RE6C1\K+NJ4%`H.#K
M0.CE-%V*A"0JHD))M0A(<"$A7:A(N*=%5M6)C$IB<-B:"YBO\9JRZB?0S<(6
M[==#P%7")<!8D88"CBKL`]Q^"O7PS^5R.-X=8^+IIN9;+KD:%!`2M?:,B27(
MTB\1FW63<:=Q/$1<8`G'6U-,00VP;(C''$4WT'U->Z,**LH;S$)@7F8QD+@J
MHO2$Q8;(4VH3J+U$5.MT4'?'UAI62<((]VBNE<G'&8*`Z!<5UD5)QL,%\,$1
M<P[TH,J%>K3/ES8<.6U(E6XQ:GLMDA$RX8YA!S#P24=N%!FT"@4"@4$=J+4-
MHT[995YN\@8UOAAG>=+?W!$4WD9DJ"(IM55P2@\B<PN8U^U[<TDW#-%LT<\]
MKLJ+U&N@77\-CC^'3N#</2J^IQ^-%>MM7I\?C>/6=59KL=90*!09NG/]VV/_
M`##WT*16=]:_7\I<']C^W^+;-;/"*!0*#&DQ'"DQY\*0<"[PE4X%Q9V.M$N]
M%Z#;/<;9=4DWUEN[,7C$K5M,-N\L^8I:FCNVV[--PM46\46;%;5>$^UBB#+C
M9MJM&NQ47:!=4NA2\;=VII.)=5;1,+Q6:SKDR8\6.[)DN@Q'9%7'GG"0``!3
M$B(BP1$1-ZK00C?,'0KG@ZAMR=80ZTID,2,2,$3,28Y@;(D[J(J[J#N?UIHZ
M.C*OWZW-)(9&3'4Y;`\1@RR@Z&)]8")<$)[email protected]$8W;<(G<&Q>
M;4HX&*F!/(BXMH0BI(I88I0=T&=!GPV9L"0U+AR!1R/)8,7&G`+:A`8*HDB]
MU%H*Y_-/]Q_K=`Y3_P`+-&_L.V_0VZ"U4"@4%&YO<Q!T7IKBQ5$KW<%)BUM%
M@J"2)BX^0KO!I%1>^2B.S'&M=G:F]L--K;F]L/)+KKSSSC[[AO/ND3CSSA*1
MF9KB1D2[5(E7%5KV:UBL8A[%:Q$8APJRQ0*!0*#:>F/]M6G_`"4?_P`0TI\8
M?+[OSGZI.K,R@4"@^$(F*@:(0DBH0JF**B[T5*#8G*K5;BK_`*8GN*3C+:N6
MEXUQ(V`V$PJKO)G%,O2H?():\?E;'A.8TEU;=\PV37*T4:R6345DN%[BE:H]
MTM]TNYW>/-5\6U%'5;-1>;,"+BL$U\THXHN`;0PQ0-<0N4VOH6F)T%V(-PEW
M*TA;XZN26Q6WDU+XQL`F*-FP]L<S_G$),JXCA@%BU?RRO>K;Q.N,^$D%BZA"
M@\".\V3K`0TE&,]XL0%7FWI8\,04L!#?MRH$KR\T?JNTZPGWJ_@#TRZ6F$U<
M[BT89';@R\^XX@`BY^&VU(;9;513%&^C9B&R:!0*!0*#6//+F2YI:R#:K6[D
MOUU$D;<%>M&C^";_`'C7P6^_BOP<*WX^SYV]F^QM>=O9Y;^^N]57:JKWZ]B(
MP]:(P5*2@4"@X/\`YESY*_@J)T1.C<<+_!L?HP_LI5HT?*R[JE!0*!0<'6FW
MFR:=%#;-,"%=RHM1,9Z2EM;EAJY^YQ'+-<G5=NMO%";D&N)28RKE%Q>ZX"]1
MS\DOAX)XO(V?"WLZJ6S"\U@NU9"T;JFW\O9^BBM,>X*VW<AA7<Y`)Q%F<<F7
MN&8*8O9I&5S%</"5#78*A#1>7FN($'LY05N;[EQL-S[>Y):%\6K4\TXY"=%2
M1OYI&BX)MI@2&F?`D55#*O\`RVU=<Y=SNC,=F'=;A/2\6PF7A)N#+@QF6HA.
MJ2`IE()A1?R!@@%AUMZA9^66D+KIN?J?MP8C=)K$UN6A`O:'>QLLRGE`5505
MR2TXY@O02=]$"]T"@4"@4'E#GES"/5NJSM4-S'3M@>-IE!7JR)P*H//KT*+2
MXMM_E%TI7H</9_[3^#OXFS_VG\&O*]!WE`H%`H,W3G^[;'_F'OH4BL[ZU^OY
M2X/[']O\6V:V>$4"@4"@QI*7"/*BW>T.(S>[8:O0'2V`6*8&P[AO:>'JFGOI
MM1*PW]F+UQZKTMB6_M):F@ZFT["O<)%!F8&)LGAG9=%5!UES#X;3@D!=]*\6
M8PZV!S*TU<-2Z)N-GMY@$U[@.L(ZJBV91Y#<CA.$B$J`[PLA+@NQ=U0*QK73
MVK=5.6:5;[:[IRX1)S+KUTXD)V6VVW#G,(N3%ULP:=G(0)FQ5%/8"X9@P+%H
M_5=I*`@Z=8=")IQVQG$*4!Q')#DD34S-PC>X#@BI%B"GMRY5WT$;'Y/:GAC%
MBL.(;`0&;)?7S,56XVYB$QE%L5+J+VF,;.!X?-/%MQW!L_E_:9UGT)IVSSP1
MN=;+;$A2@0D(>)'8!HU$A54454,4[U!B?S3_`''^MT#E/_"S1O[#MOT-N@M5
M`H%!Y`YO:K/4NO;C($U*#`)8$`<<11M@E$S3H^<=S%C\7+W*];B;?C7/K+U.
M+M^-<]U,KJ=10*!0*!0;3TQ_MJT_Y*/_`.(:4^,/E]WYS]4G5F90*!0*#YQY
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M1IP<%:4G,#4%SICB@[*"YT"@4"@^&8-@3CA(``BD9DN"(B;5556@\5:WU4]J
MK55POIJJM2G%&$);%"*WU6!P7<N3K$GQE6O9X^WXTAZ_'V_&J#K=N4"@4"@X
M/_F7/DK^"HG1$Z-QPO\`!L?HP_LI5HT?*R[JE!0*!0*#M@W=RR7*)>V\<;>?
M$?$=JG&+JR`PZ<6\5%/CH*]%<_)V_*D]U]NV);>YD76^0=#7&?IMUGZT%L7(
MA.&`H09A)WA$>(*XK*'P\=F;"O%=:CV;G"<V[Z,MK4U7&I\QV)>7I$0V'G'2
MCS>''0,JB)L/QFP>(=BDO5ZN;`)Z'KRZ3-?RK48.1K3VMVSVAYL&7&G)S,!)
M[IRL2XR#PU7A(&5%R[27,F`1=MUEKV;I?0&H"4$M=W""FHI3",\9)$]YEEE!
M9='*C2FYE-0+,F;%$V4%COMYU9!U_8XY(+>DKBO91>85MQTIO">>R/BX*$#2
M@UU2;5=J;<,=@72@4"@4%+YQ:M>TMR]NMQB.<*Y/`,.VFF]),HD:`Q_1(2N?
MDU:E?*8A:E?*8AX^89!ED&@\!L4$<=JX)LVK7NUK$1B'MUC$8ASJ4E`H%`H,
MW3G^[;'_`)A[Z%(K.^M?K^4N#^Q_;_%MFMGA%`H%`H%!:>35U6WZHNNG35$B
MW5KZV@BJ[GVE!B8*?*$F3P3ISKW:\GF[>+9[NG:MF$[S0UEJ/3E]TX41]J+I
M]]]QN\2>$DDP)6'381YI%1T6%5HB)QO:.555<$P7C:N>A^9:ZMOVHHMNDQ'&
M8T:/(LL?%<Z"XKP$4G#K=8@;)1P100D%>MC01]UU)S$M^D[_`'9J:U<&K-((
MXDQB$"%)BMM-$ZX32O8<%MWCBI-XF2"F7'X02.C]<W>[:_NUEE%_<6!EN07$
M:5&'PC26V,8KR)UR8S\.4)KB+JCEZN-!*:1O=_?U1J.QWD\YVP8<B*2L"SF:
MEH\F=M0-U":XD<A#,N=,JYNB@[/YI_N/];H'*?\`A9HW]AVWZ&W06J@4$1K"
M[G9M)WF[-K\[`@R)#7?-MHB!-O=)$2IB,SA,1F</$8"@`(IBJ"B(BKM797O1
M&(P]R(Q&'VI24"@4"@4&T],?[:M/^2C_`/B&E/C#Y?=^<_5)U9FR[8,(I@]L
M<1MD44NLA$*DB=42R(I8*N_#HJE\XZ)A:;D%FR3E:(#!7GW7Y#)`"+DR*TPH
MJ.;(>*HF54Q7NX5RT\NGX?\`ZUG#$O!VZ3:<XD#3N97";`6A-,1S-`67:J(A
MH*"F[I\&K[<3%E;8PJU=3,H-I<K58N&BW[7-:"4Q&DR(KK3HH;9MNJD@0(23
M*HB$A`PW;*\3DUQN2Z]N<PGH>AM'0SB.1;+#:<@"@1'!9#.""2$BH2ICF0DS
M9EVX[=]8+NB!RXT'"=C2&;!;RF0R,HTUR*R<ALG'3>+(ZH9@^<=(D051$QV(
MB4'<WH/13:QU"Q01[*1''PCM]0C$`++L^*PV.'<`?BI@'>&D=+!<TN@6F*-Q
M$B<26C((YG,U<(LV&.93)2Q[JT$M0*!0*"G<X+J=KY:7^2"Y3<CI$$TWBLQP
M8V*=].-BE7VJ^5HA?;KFT0\?5[KVR@4"@4"@X/\`YESY*_@J)T1.C<<+_!L?
MHP_LI5HT?*R[JE"6TP-N^MV3G.`#8$"@+J$H$2FB8%@B[$3%=NSN[*QWO+QZ
M+UQGJER2RQX;3R(CS,<D?<("'+(=[3E5DP(4/8UUA3'##HVUE^J9_P"=.BW1
MCZA2$<!HA='CM8HX((TBD\F02SY,%5<$7O)A^-5MK.46T5JNEF4&V=%PK9J+
MEM;[?=XK<Z$+90G&GQ0T)(3I1P/;N/YE"0DVHNU*\#=KXVF';6<PL*:;L(VZ
M/;0M\<(4-"2&PC096<[9LD3:*BH*JVZ8JJ;T(D7>M42Q[7HO2ML[.L*UQVW(
ML9N&R\H(3G`::1@!4RQ(OF@0,5VY4PW4')C1NDH\F'*CV:$P_;VT8@FTPV'!
M:$B(0;041!$2,E1$W8KW:!;M':3MLP9MOL\.)+`4`'V6&P-$05!,%1-G551]
MS903%`H%`H-$?:IN!)%TM:<>J_)E3B';M6*T+*8^YVRNKAUS?Z.GB5S=H2O6
M>J4"@4"@4&;IS_=MC_S#WT*16=]:_7\I<']C^W^+;-;/"*"=L06I+?-5]]H)
MAM.((.B2Y1%$45!411Q)??V=]:PW?+,8CHO7&&9'N[9R(;<OAO/*RID_@`BT
M3KB.%N3#!&01%P3%,5PVU2=OI./^?\E/DCM2A#26#D9P2$Q3*(Y$%`0!RX(W
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MFG^X_P!;H'*?^%FC?V';?H;=!:J!04SG(:ARRU`J+E18Z"2_BDX*$GOHM:;7
MSCZK[7RCZO(%>X]LH%`H%`H%!L[1\@']-6_+_P`EE(Y?*8^:5??R8U%-'S._
M7%YCW3%78E`H%`H%!LODOA]3WO#?]:+C_P#I1:\?F?N.K:T;!KE:%`H%`H%`
MH%!K7[0ZX<L)J8X(LF(B]_\`O`*GWZWXW[D-N/\`.'E>O9>P4"@4"@4'%P<P
M$/QD5/NU$HEMNRRFY=HAR6]@NL@6"[T7*F*+WT794UGH^6M7$S$LVK*E`H%`
MH%!MCE&2+I!$1<1&7*1$3<GSRJO]95]^O$Y/[DNO;^*Z5@N4"@4"@4"@4'GG
M[52HEXT<B],>[(G]."M=G"^?X.OA_/\`!I.O4>F4"@4"@4&1:9`Q=16:27@-
MS!;+_P#(;.,/]9Y*SOZ3[_\`QQ<^N=MMZMG@%`H%`H%!U"8C?=.(JX*=ZMR#
MWU[2"_@2N7F?MRTVOD](UX[J*!0*!057^:?[C_6Z!RG_`(6:-_8=M^AMT%JH
M%!1N>.?U3ZER>'V7J^[Q!PJU/E"U/E#R(TX+C8.!M$T0A7O*F*5[L3E[<3ER
MJ4E`H%`H%!<.74W`YUO+I49+6/3BB-N(G>3*'W:BO27B_P!EMXM%NZ[5=YI0
M*!0*!07OD!*[59=3/HN(+?GFP3O,PHC7WU#&O%Y7SEU[>C:-<ZY0*!0*!0*!
M0:M^TJYPN4\YW'!&Y4(R^2,D%7[R5KLSB\--GY0\OU[;VB@4"@4"@4%[Y>3N
M);9$$EZT1W,";_FW\33RB'45]8>#S]OQW,]UKJ[A*!0*!0*#9'(65VOEZW+1
M<1D3ISK:_B'),@_JJE>%O_.7931L2LEB@4"@4"@4"@\W?:[?5B]Z#<7P/_Z@
M.>XXL,$_K$E='%G%\NCC3B[3U>P]8H%`H%`H.B>CJPW59V/`G$97N.-]</ZR
M)5-R,UEGNU\JS#<T"8U-@QIC7YJ2T#S?3U7!0D^\M:5G,9?,3#OJ4%`H%`H(
M&X3E]8.@[<"[2O4:6]W@;=%H47Y1/?>KAYT_IPVVM7JJO+=!0*!0*"J_S3_<
M?ZW0.4_\+-&_L.V_0VZ"U4"@J?-J(4OEEJ=H1SD-ND.B.W%59;5U,,.GJ;*M
M2<6A:DXM#Q5:'L62CJO697J_(+%1^YM3WJ]ND^CV:[email protected]<
M@4YSH9;4+@N=F5U!(B1XVG6C!5RB@KUAWYDZ:RW9M&C+<F8T3!:1T_`A6=R:
M8NO2.UM/N(X3C3DM&VBCLY8W$<1L2<5"44Q)>E$4<*?<M,SA3[DS,X1VOM-0
M;3):.`C3<51`5;%PW'%,T5S.2KF;[email protected]=5MJ\SJJ5;-DCI
MV;V*_0GUV`;G9W>C$'^HGO(>4E]RJV])<7/V_+;GV;5K1X!0*!0*"-U#=?JR
MU/21P60OS<4%^$Z>P/>3PB[R+5;SB$PV+]FJ&4;0L[''ANW-PVB7>HC&CM*N
M/RFUKQ^5\\=G3M:-LUSM"@4"@4"@4"@UO]HB$4KE'>LHJ1LE$>1$[@RVL^/>
M0%*M=F?UPUV9_7#R3:G^)%1LEQ<8^;+'>J(G5+WQ^_7L4GICL]:D],=F95UR
M@M&E;;8KA:;FPZ&>^\)QV`KZ.#'1MEM2/*ZVZV@N[<WS@J&Q.[66Y:8F.S*]
MIB8[+`YH[3$&X6>-)1'EFP?FU5PR;D2@N#C+SB<!541[.&+>*@.[,NPJS^Y:
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M:6ESOMO.-DG`=//'00Q+(`N=5/C5CFWE,?X8YMY3'^%AAZ/T8_?)\!EL'C;?
M)X&C=D``Q"1@XV5S!$%'4=,24R(QV;-A%64[EL1+.=RV(EKBZ0BASG&%)L]@
MF)-9\F5T$<'+Q4$_!)/"3&NJLYATUG,,2I2V!RZE<72T=A5Q.";L1>\+1KP_
M)*-4VM,=GS7)IX[DPLU:L"@4"@^$0B*D2H(BF)$NQ$1*"D:$=+4O-RP3AS*S
M)N32PDPVI$M[;LD2[R.$V1^X25YW(MFDV[S_`.&]-<=GL2O.;E`H%`H*K_-/
M]Q_K=`Y3_P`+-&_L.V_0VZ"U4"@ZID5B9$?B2!SL2&R:=#N@8J))]Q:#P#>+
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M87+'R_LT%YM6I),]IDMDF!"[*)7S`N^"N9/>KQ=RWE:9=E8Q&%KJB2@4"@4"
M@4"@B=6V(+_I>[64U1$N,1Z,)+N$G`40+\DL%J8G$Y3$XEX(19$"87&;)MQI
M5:EL+X2**JA)L^$!8_?KV(MI:'KQ;_M":`Q,$,%0A),1)-J*BUO$MHE]H,H;
MI<Q@E;QEO#`,LYQ$<-&5)<,25O'+CU4Z.BH\8SGU1XQG+@D^</"PD.IP6S89
MP,NHTXIJ;8[=@EQ3S"FQ<R]U:8@Q#Y*FS)9BY+?<D&`"V!NF1J@#L$44E78G
M0E(B(T(B(=-2D1QYHA>9_/,D+K71UVU0AQ]]*K:,PSW:>59CNW#$E,RXK,IE
M<67VQ=;7NB:(2?>6KQ.8R^8F,.VI04"@ZY$AB,PY(?<%IEH5-QPEP$11,555
MJ)G"6MKI<Y%VGE,X9**_-0(V'70%5,$P7_F.EABGR1Z*RSB)M)[0]AZ2LB6/
M3%JL^Q2@Q66'2'<3@`B.'^4>*UXDSF<NV(2U0%`H%`H%`H%!KK[0&EG=0\KK
MJ$9OB3;9DN<043$E**N9P13XQ,*X*=]:O2WC:)7I;QM$O%[,E8CZ3&L38<1$
MD`.W$?@N"G='[Z5ZN<3Y1IZO4F<3Y0L+;C;K8N-DA@:(HDBXHJ+TI6\3EM$Y
M<JE*1'4>H0*.0726)1`X44D?=16F\N3(WUNJ.7JX)T;*KX5[*^$=F.-RN(.F
MZ$IX77'$><<1PD(G1QRFJXXJ29EP7?MJ?&$^,.EUUUYTW7C)QUQ5)QPU4B(E
MVJJJNU56I2X4%HY:2N'<+M`5<$<1F8VG=545ES[B-!5*]+3'XO$_L:8OGNOU
M:O.*!0*"AZWO_;W'-/0#Q81<MXD@NQ!W]F%4^$?P^X.S>M87GRGQC3U_TO'3
MJO/V<-.%.U?/OY!A#LD;L<=<.JLJ5E(\.^TP">,KAYM^L5[-=F.F7H^N)L4"
M@4"@JO\`-/\`<?ZW0.4_\+-&_L.V_0VZ"U4"@4'FC[4/+YR+<V=:P6L8DQ`C
M7=13P'Q3(R\7><!$;5=R*(])5V<3=Q^F79Q=S'Z9:'CONQ75<!%-LOSK/=_&
M''<7X:[NL3F';I.83+#[3[:.-%F%=G?1>XJ+N6M8F):1.794I*!0*!07?EU-
MS1)D!=\=Q'F^YD>QQ3^F!*ONU%=9AX7]AMXW,]UOJ[@*#@\^RPR;SQBTRVBD
MXX:H(BB;U55W5$SA*AZ@U(Y=\T6-F:MB+UR7$3D8=U-XM]Y=I=.";%S^7T,X
M3?*C1IZIUA'8=;S6NWJ,NYDO@J`K\TROZ8QP5.D$*N?E[OC7'K*^U7,Y>L*\
MIU%`H%`H%`H%`H%!Y-^TCR^.PZK_`-10VL+3?C4W53'[email protected]$XB=U<_
M<KOXFYT\9=_%W.GC+4L26<0L,,T<E52!/"%5WD/_`*I]SO\`9$^/T=6GT3#3
MK;K:.-DA@6XDW5I$Y:1.7*I24"@4"@V#H&=Q[(L4EQ<A.$UM^(7S@>\B%E3W
M*BG9\]S=OQW)]^JRU=R%!TS)L6%&.3*=%EAM,2,EP3O)WU7H1-]1,Q&J5!O=
M_D7D\F0F;<!(33!;#<4<%%QU.C!=HCT;UVX9::ZDRNW(S1CM]U:%VD-JMIL9
M(\1KX)S-BL-I^C_.EANP'XU<?,W<1XPUV:^KTU7FN@H%`H%`H%`H%`5$5,%V
MHM!XGYR\NG="ZR>C,-JEAN9'*LSB)@`BI8NQ?=8(MGXBCWZ]#B[N8\9>AQ=W
M,>,J)&??MYJ3(J[%)<SD=-XJN\F\?OC71UKIIV_TWQ-=-.R;BRX\IKBL&AAN
M7H5%[A(NU%[RUM6T6C,-:VB='=5EB@4"@D=*RNR:MMQKL"4+T,UZ.N'%''\I
MA$3W:SMTM$_A_P`_P\[^RIFD3V;5K9XA0?#,``C,D$!15(E7!$1-JJJK042_
MZV>GYX.GS4(Z]61=TW*G2,7'PE_[G@IT8]&$WFW2NG?_`$MC&J!B0G`2-;K7
M&*1,DN"Q!B!M-U]Q>JF*]U=I$NY,56E[5VZD1-I>O^6^BF-&:1AV0'$?E#F?
MN,I$PXTIY<SQI^+FZH)T"B)7BVM,SF77$86>H24"@4"@JO\`-/\`<?ZW0.4_
M\+-&_L.V_0VZ"U4"@4&)>+1;KQ:Y5KN3(R(,QLF9#);B`DP7OHJ;T5-J+M2@
M\6<T.65WT%?.R2%*1:I*D5LN.&".`GP#PV(Z">$G3O39N]38WHO&/5Z>QO1>
M,>JF"IMN<5DE;<W*2;E[Q)TUOCUAOAG,7=/!DAPU_P"H&)`O_P`A_!WZF+]T
MQ?NSVW6W00VS$P7<0JBI]U*O$Q.BT3ERJ4E`H)?24WL>HHI+^;DH49Q>A.)@
M0+[N<!'WZK/28EP?V.WFF>S9QF`"IF2"`IB1*N"(B=U5K1X:OW#6MK811A8S
MWNA6EP9]][!15/D9E[U4\^W4PJ=RN,^Z.(<]Q#`5S-Q@3*R"IN7+MS$GQBQ[
MV%1XYU1EWV.Q7:_75FTVACM$^1CD!5P`13PG'2P7(V./6+WDQ541:[N[%(S*
M:UF9>K]`Z)MVC]/M6R*O%D&O%GRU3`GWU1$(\.@41,HCT"B=.VO&O>;3F796
M,1A8ZHDH%`H%`H%`H%`H(C5FEK3JG3\RQW5OB1)895),,[9IM!UM5QP,"P)/
M_:IB9B<PF)F)S#Q-KK0U\T7J!ZSW5M51%4X<P45&I+..`NAOP_&''$5V=Q5]
M79WHO'N]3:W8O'NK[9NLFIL'D)?"%=HE\H?_`%WUKCLUQV9[%W:7!)`JR72>
M]O\`I='Y2)4Q?NF+]V<!@8H0$A"NXD7%%K2)6B7VB2@4%AT).[/?5C$N`3FE
M!$[KC.)A_45RJZ2\O^RV\Q%FPGGF66B=>,6V@3$W#5!%$[ZKLJ\R\A7;CK>"
MVA!;@6:[T.[083\M4Q/\A%3OU7SSH*I-F3;@^C\YWC."JJV")E:;Q^(&*X>Z
MN)=^HBOK*)E):5TK>=4WIJT6EO,\6!R9!)\U'9QP5UU?[([R78G2J9[^]%(]
MUJ4\GK32NF+7IFQQK/;048\=.LX7ANN%M-UQ>DC7;]Y-B)7C6M,SF77$82U0
MDH%`H%`H%`H%`H*YS`T)9M;Z:D6.Z(HB:H[$E`B*Y'D`B\-YO'I''!4^$BJ*
M[%J8F8G,)B9B<P\5:PT=J#1U]<LE^8X4D<2C201>!*:1<.*P2[TW9AWBNQ:]
M39WHO'N]/9WHO'N@B9P<XS)DP_NXK>Q53N$BXH2>[6DT]8Z2TFGK'264S>9;
M6`RV.**?\YC?^4V2X_<5:F+VC6,_0B]HUC/T9S%VMSZY6Y`H?_3/J'_1+`JO
M&[6?5>-RL^K+JZY0=4F0446YP^%!=;E)AOP8-'"3WQ%4K/=^.>W5AR:>6W,-
MNS[[9;>VCDZ<Q&$D11XK@@JHN[*BKBN/>J]KUC67S<1,J]-YBPUQ"T0WIY]#
M[B+&C_TG$SE^2"U7[F?C'Y)QW5BY2+K>2QO$GBL8YAM[**W&3#=F'%2=_+54
M[R57[<S\NO\`Z/+LXNNML@F**N*B#;8"I$1$N`@`"BJ1*NQ$1*O:T5C,JQ$R
M]#<DN4;]A5-4:C:1-02&U"#"7`D@,.(F9%5-BON)X9)X*=5/A*7D;^]-Y]G7
M2GC#;U8+E`H%`H%!5?YI_N/];H'*?^%FC?V';?H;=!:J!0*!01NHM.674=H?
MM%YBA+@2$Z[1[T5-HF!)M$A7:A)M2IB<=83$XZP\H\SN0FIM(NO3[6#EXTZF
M)));%%D,#OPD-CO1$_Y@)EZ50:[]KE1/2VKOVN3$]+-7(J*B*BXHNY4KK=;C
MD%"SCB)_'%5$ONI@M1B$>,.X)4T/!?)43<AH))]W!"^_4]>YU[NQ+E.Z5:7W
M`)/_`)U.;&9?5N4WHX7]`O\`BIF3,NLYUP7`T?X9@J&"MBB8$"YA5,V==BIW
M:K;.-66]F:3GLMDA7))9I;KDDD7%.,9.(B]T1)5$?>2M/&'SF9?*LA9=%<O=
M3:PD(-K8X<`2ROW5Y%2.W@N!(*[.*:?$#\I1WUS;W)K3IK+2FW,O2VA.7UBT
M;;5C6\.+,>P6;<74'C/$FY%5$ZH#BN4$V)WU557R]S<F\YEU5K$:+-5$E`H%
M`H%`H%`H%`H%!!ZRT5I_6%E<M%[C\:.2YV707*\RZB8"ZT>W*28^XNY45%5*
MM6TQ.836TQ.8>2N97);5>B'791-K<;`BXMW5@=@#T)(!,5:7\;P._CLKT-KD
MQ;I/27H[7)BW2>DM?UU.EQ0$$LP*H$N\@515?=RX8U7QA7QAWC,G!N?S=XQ%
M4_JH*_?J>O=/7N[$N4[I5I?<`O\`CJ<V,R+<IW0K2>Z!?\=,V,R^QI]Q&;&<
M"033@O-Y2:01PQ)!7!50EW*J;ZK.>[GY<3]N<K,ZBO.(Y(,Y#@KB)O&3I#\E
M34L/>K3QA\_F2K(7#0?*W4NL'&WV&^Q655Q<NSP]0D3H8#$5=7OIU$^-BF"\
MF]RXKTCK+6FU,ZO2ND-&V+2=I"VVEG*/A2)+F!//N=+CIHB9E[G0B;$1$V5Y
MEK3:<RZ8C"<JJ2@4"@4"@4"@4"@4"@@]9:)TWK&S.6B_1$DQB7,RXBY7F7,,
M!=9<3K`:=U/<7%,4J8G"8G#RGS&Y":ST>Z[*@M.7_3Z8D,V,WFDLCW),<,5V
M?]1M%'I5!W5W;7*]+.W:Y7I9K0'`<',!(0KTHN*5V1,3H[(F)T'&FG!RN`)C
MW"1%3[])B)U)B)U=0PHX?FT)K]$9M_V%&J?;JK]NKFC3B;I,A$[G&<7\)+4^
M'O/^9/#WG_,NJ3&!8[F8W3P`O#==--W<(EJMJ1B?]RK;;C$_[E:[3`A,1&'&
M8[;;A-BI&`"A*JBF*JJ)BM:[=(B(Q#YRTSEG5HJS],Z=U%JN8L/34`[@8%E?
ME_FX;"_]Z0J*"*GQ!S'^+7-N\JM?>6E=N9>A^67)*SZ2="[W1T;OJ7*J!+(,
MK$7,F!#$;7'+BBX*X777O(N6O-W=VUYZNFM(ALNLEB@4"@4"@4%5_FG^X_UN
M@<I_X6:-_8=M^AMT&=?]8VFQW:R6R:I(_?)!1HY"G4!1'83B]"$Z;;0]TC&@
MQ+=KJ/,U.Y8.Q.M/-OS&$?(@4%6$W&<(L$7'KC-'#W%QH,%SFC;FU68<%]-/
M#<ULJWG,VH=J1[LRGPD+/P.T?,\3?F^#EZU!SLW-C1UTN21`FM1FWX<:?;GY
M)BSVEB4VZ[F`#RD.0(YJ6;#<J[DH)6-KO1DJ;&@Q[W#=G3",(T07@5XR:7`T
M1O'-U5W[*"=H-<:XY":"U43LH8ZVBZN8JLV"@@ADNW%UE4X9XKO7!"7XU:TW
MK5T:TWK5T:3U+]F/F#;#(K04>^QTQRJT8QG]GQFGR0$]YU:ZZ<R/6'57EQZP
MUY==#ZSM"E]9V*?$`<<77(SJ-;-^#J#PU]XJWC?I/JWC>I/J@S,`<5LR07$W
M@JX*G3N6KQ:.Z\6CNXJ\RF&+@ICNVI3RA/E"4@:8U+<\1MMHFSE79_=HSSV&
M.S;D$L/?K.^[6(U8;VY7QF,^C;EBY(<Q+JHD[!;M4<L%XTYT1)17N--<5S-^
M*:#5;\VL:=7AQLSZMH:6^SUI6VD$B^/'?)(JB\(QX,1%3_LBI$??1PR%?BUQ
M[G*O;VAK7;B&T6666&@99`6F6Q06VP1!$11,$0438B)7.T<Z!0*!0*!0*!0*
M"K7/7T"WZ[M>E'6MMR9,EFJ8H+<A4(X["BNU5>;COECT913X:4&-I/7LN]7%
M(LN"U$#LLF23H/$[@46>[#(<";;ZN#6;-W]R4$(_SF.!IVUZMNMJX>F+T$AV
M$Y'=5Z6`,Q7IC*NLJ`#\\Q&->J?47!%5=I($A`YQZ863<6+NIVLHCJI&5QJ0
MHO-<*,:8&K0CQLTT!5D54TV4$QI_F)I;4,X(-I>D27R822:]DE`TVV1&`\1T
MVQ;`E)HQ05+%5%>Y0654145%3%%V*B[L*#5>M_LZ:$U$3DJW`M@N1XJKL,16
M.1+TN1ERAXM05>E5K;;W[5;;>_:K2^H_LU\RK4;A0&6+W&'%0<BN"V[E3I)I
M]6\"_%`BKJKRZSJZJ\NLZJ!<](ZKM1*ESLLZ$B?#?C/-@ON&0H*^\M;QO4GU
M;1O4GU0ZNM(2@IBA"JH0XIBBIL5%2KQ:.Z\6CN(ZTI("&*F2H@CBF*JNQ,$I
M-H[DVA-V;2>JKG)CK;K-.F`CK9*XQ&><!$0T55(A%13WUK.V]2/5S<F]9I,1
M/5MJQ<A^8-S(2EL,V>.N&+DMP3<P7I%IA7,5[QD%4OS:QI&7C1LSZMJ:3Y"Z
M.LQM2KGFOL]O:A2A08PEW0C)B*][B*>"[4KCW.1>^NC:NW$-E(B(B(B8(FQ$
M3=A6"Y0*!0*!0*!0*!04/UKQ7H.I'X<%3?T]*99X+SG#21&?,6@EM$@'\V1H
MZ@?&R;TQH,B3S%*+IN3='8`E.2\'8H$`'^J_*6;V%C%XP'()E@9KD7*./A8;
M0P;ES=9L]WF6"[VPF[\RB%#8BFY)C/-N1)$IHR?1D":1>Q.@>+:Y<,VT<50,
MR)SBT&=NB2IUQ2`_()MER*^S(`VWC;8<5"$V@)&T&8TO%5$#`D7'"@L.G=3V
M;44-R9:7'78K;A,JZ['D1T(QPS9..VUG1,<,PXICBF.*+02M!1-9<DN7&K''
M),^UC%N3B+C<H"]FD*J_"-0ZCJ_I!*K5O-=)6K>:Z-1WW[)5Z:4CT]J%B4&/
M4CW)DF21/QGV.(B^\RE=->7:->KHKR[1KU4JX_9ZYOPE++9&YXCO.'+CJF&W
M:B/G'-=WQ<:UCF5]8;1RZ^L(L^3?-@"`2TI-Q-<!RK')/?4750?RL*M_+HM_
M*H[VN0_."8)M!IEUE"115Q^3#;%,47NO*2^\E5MRZX]5;<JN/5?K)]G'F,^R
MRW<)ELM30B(D:&]-=3!,%7A"$=ORM5_FS$8B'D_9;$T]]G#1$%1=OCLC4+Z+
MFX<DN#%Q[G9V<@F/>=(ZY[[][:RO6D0VC#APX49N+#8;C164RM,,@+;8#W!$
M41$3W*Q7=U`H%`H%`H%`H*K_`#3_`''^MT#E/_"S1O[#MOT-N@QM6<N(^I'K
MH[,G*V]-9C,6QT0Z\$HKBOBXRN=$(U=^<Q5-XCO0:#E:=`RX6J4O[UT%\U=E
MONL#'X:$4QF.R29N(>&7L;:IL^-W4P#BO+.&N6%VYW_3PW5;W]4Y1_Q2O]JR
M<7''@=J^>R9<<VS-EZM!7_44P[:F[1+OCTBW!$BV_+P&P=[+$AR8(!Q!+#,K
M4T\2R[T3OXA8M+\O3L5X9N:W$9)A&>C.MC$8BB9/DR1.(,=&Q%?[L'P5VJ6W
M:B"%QH%`H%!P>88?#(\V+H8XY3%"3'W%H.+$.)'5588;:4O"X8B..'=P2@[:
M!0*!0*!0*!0*!0*!0*"FWG1&CI=P5NX2^'>KC.;ND1]7&`FH[#1M`2,2AGX;
M:-!B*8[/"QS+B&3I;2^G+=<')5KN!S'X[;T5X%=:=0./).4XA(V**)*\X6_W
M*"+D<L]"'":M$R6XY:5;F0K1:79`(S&66VY'D#%P072,0=-L<YGPT54'+0=1
M<IM%7-"`KA+EO1'S<-T)+:NM2U!@.(I-@B@XVL)HQ[A#CAOH++I[2]OM4R7<
M(TV3-?F`VQ)=DNB]F6,;B[T%,"1QYS%-R;L$1$1`G:!0*!0=;\6-(1$?:!U!
MVHABA(B^_0&(L:.BHPT#2%M5`%!15]Z@[*!0*!0*!0*!0*!0*!0=,R.4F(]'
M%YR,3P$"2&5%'`S)AF!20QS)T8HM!0@Y2:&==>:M4MR`Y&AM6FYM6]8@9T:(
M)('*%&2^?V"69<%P79L)<0F'-':;33<FWS)SCT&?.^LVISKK0.-RWI"26G&'
M&P;%%%_`V]B[=FU-E!@W/EAIF7,<GS[C+6\F:R7;F3K`OJT$1V$H9.$C(L@S
M+<W-I@18XXK08\7E;I:WRUU%'O<^.ZXV`O7`)++0.1TCQXW#(P;`<AMPV>LF
M!(J8B28K06[3=BC6*SLVN,^[(CLJ:MN/J"G@X:FJ8M@V.&)+ALH).@4"@4"@
M4"@4"@4"@4"@4"@4"@JO\T_W'^MT#E/_``LT;^P[;]#;H*QSBCS_`*ZTS.@1
MI5QE0SDY+2++QQ92.,JI#QV4QCRAX?S+A;$Q55ZJ$J!&::NVI;1,NWUJ#I3[
MJC[17%Z'(%UBYR)Q1K?$1]<[91B`@5O*B`"(A$O7Q4*9<[/JMRSB%LB38\/L
M,`9#4F/)4"N8VV4,_B!PC<229$P(2$'`7DVYBZJA=]'W35,#64R=?8DEYJ8[
M-&3Q8<AY^!%;<CMVUME]M#%P'@<S."`8Y\YJO4*@G>6UO>CZFU)*9>DW"V7`
MFY3-RN$5V)*!]QY]7H>#H,YVV>J0X-CES9=NS`-AT"@4"@4"@4"@4"@4"@4"
M@4"@4"@4&J=?Z=O;W-'3]]M-F>EFRVRQ/?-&G(CD1F2CRX9C`F)$?B..-%\,
ML!ZVW*'9I6VWG3EOEV:SQID2/>GE;T\[<`9-V$0PE==*88*KA`AMD+:EQ"S;
M%ZJHM!&1]!WYC3%NLAVU1NT*^/7"#+!`DQ^S!>UG`W)D/JD@$5%XF(*A$@CC
MB6(4$QH#2^HM/ZAD29(NR[0$:/9K<8LA'?<;;?D2"E2@)\LPAQLB'@ADJDO#
M1-JA9.6]ODV[3TB$_".!DNMW=88(1%.SRKE(DQR!`54059>'9T;NB@M-`H%`
MH%`H%`H%`H%`H%`H%`H%`H%!H>S:0UH-WUE$LUI[-:KC,=>F'<S[/++M#++K
M\:/,8%_BM.N8HGS?5%%P-#+$0[]2VG4UYT#I_3K-OD0KUI^*P,UP&4F,HKUI
M?9!K(J"I\15X3JY<S2EBFS`Z#GJ71VOYMPG2I-M!2EV@XK3\.2;YQFPFQ'([
M8,N-")N,`V;JAQ"XI9MN"H-!)Q['??\`0UGM\B'(2\V2<[=&\L+C1;BX<B8V
M(N,*\SP5D`YVA0,P!DB!/@Y:"_:#LD^Q:+LEFN#R/SH$-EB2X"J09P!$(04M
MJ@'@CCMP1*"=H%`H%`H%`H%`H%`H%`H%`H%`H*K_`#3_`''^MT#E/_"S1O[#
MMOT-N@M5!\(`)14A0E!<PJJ8X+AABGO+0?:!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!057^:?[C_`%N@UOH+U[_Z&T[]3?5'U/\`5D+ZM[1FXW9N
MSAP>+EV9^'AFPZ:">]H[S'Y2@>T=YC\I0/:.\Q^4H'M'>8_*4#VCO,?E*![1
MWF/RE`]H[S'Y2@>T=YC\I0/:.\Q^4H'M'>8_*4#VCO,?E*![1WF/RE`]H[S'
MY2@>T=YC\I0/:.\Q^4H'M'>8_*4#VCO,?E*![1WF/RE`]H[S'Y2@>T=YC\I0
M/:.\Q^4H'M'>8_*4#VCO,?E*![1WF/RE`]H[S'Y2@>T=YC\I0/:.\Q^4H'M'
M>8_*4#VCO,?E*![1WF/RE`]H[S'Y2@>T=YC\I0/:.\Q^4H'M'>8_*4#VCO,?
ME*![1WF/RE`]H[S'Y2@>T=YC\I0/:.\Q^4H'M'>8_*4#VCO,?E*![1WF/RE`
M]H[S'Y2@>T=YC\I0/:.\Q^4H'M'>8_*4#VCO,?E*![1WF/RE`]H[S'Y2@>T=
MYC\I0/:.\Q^4H'M'>8_*4#VCO,?E*![1WF/RE`]H[S'Y2@>T=YC\I0/:.\Q^
M4H'M'>8_*4#VCO,?E*![1WF/RE`]H[S'Y2@>T=YC\I0/:.\Q^4H'M'>8_*4#
MVCO,?E*![1WF/RE`]H[S'Y2@>T=YC\I0/:.\Q^4H'M'>8_*4$./KN_U>YF^J
8O]0_5X<+#-V?L7&//C\+B<7)AWL:#__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>a62430cs.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a62430cs.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@`M`(]`P$1``(1`0,1`?_$`+```0`!!0$!`0``````
M```````&`P0%!P@"`0D!`0`#`0$````````````````!`@4$`Q```0,#`@(#
M"P8*!0H&`P$``@$#!``1!1(&(0<Q(A-!46$RDZ,49587*'&!0B,5")&A4H*T
MQ'6%-T=B<C,D%K'!DJ+20U-C<S71LL*#-%3PTT0E$0$``@$#!`("`00#`0``
M`````0(1,0,$(4%1$F$R(A-QL4(4!8&14C/_V@`,`P$``A$#$0`_`-M\M.7&
MQ)_+G:LZ;@H<B9*P\!^3(<;0C<=<BMD9D2]*D2JJK023W5<N/9R#Y$:![JN7
M'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<
MN/9R#Y$:![JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJ
MY<>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=
M5RX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B-`]U7+CV<@^1&@>
MZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B-`
M]U7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y$:
M![JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R(
MT#W5<N/9R#Y$:![JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(/D
M1H'NJY<>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0?
M(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B-`]U7+CV<@
M^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y$:![JN7'LY
M!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<N/9
MR#Y$:![JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>
MSD'R(T#W5<N/9R#Y$:![JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C01Y.7N
MR$Y@EC$PD1,<>)&247LT[-7@DJ`N:>C4@DJ7H)#RG_A9LW]AXW]#;H)50*!0
M*!0>'FA>9<:-20'!4"4"("1"2RZ3!1(5[RHMTH.5]M;HWF]R.E[RGS\T,C'P
MD=7)#DG4]/61DI,4Q!'/2&F#C"PU94:NMUNBZD5`V%+^\%)B[ED;?>QC;,D\
MLUA\:X\3B`X#\I8[<XG1#LS9TMD2Z%14/ZM;>-0)G.W.AN-G:V3P[$23)5K'
MSEAS%?./)DPW'U)'VA0`5LVE'LU5#^FBVH+&4]O#+_=IQ6Z86<FL;AQ./7+/
MR4DNM^EM1]1R&I"@0J6IH%LO2BHEE2ZT%Q@N:6;8SD-(^/=G%N7'QMSO1I$X
MR"'C)+X16VHW;%V8DVVI27KJB*2Z$X:;!:Q_O*95Z!,D!@6#?9"`]';22:-$
M$Z:4)0[9&S$^S,45'6T4"3HH)MS`F9@>6CDW/Y0]JY)M"[;[)D#J<D+K;C,,
MR'A"R..*!+P3O*J#J6@TX]S.YDPI@&&37*Y#"O[8QK+49WM(L\I\:5]H*J!U
M'E-]O2CMN"A<>%[A;8?F[S-&'C,;!R2S,ANH,(UZ=+)%2'+R;TH72;(@<!OM
M`CB@AH41Z1'N*'0G*O=$'=.P,/GH+4EF/-;<5&IKI2'T-MXVW-3IJJGUP+2O
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M+7H*.-YS.X_(SL/DX,_*Y*(@RYR1VVB6&W-C/38L9>R$`7LV&0`W3)+N'PN-
M](>6?O#P9,)EZ#@9$Z0_DXN'".Q(95"D3HBRXZ@X?9B0J(D)*MK*G#4E!F>9
M^4WX&RXF4VW+7!9HP;)O$''9FR9$U[1V<#BIMHG$T<,.BVK4@B5!JC/_`'A]
M\X;*9&4J,RHS,K)XQK'-`!L"Y`QK4AN2+B#VIBKYD1]?3V?0B+QH,B_S7YI%
MB,M$@C,GNX.7$=GYN%"B2'QA2,<,DQ6,2L-$0NEP44\7IX\5#?6W9:3=OXR8
MDDIJ28C#WIAMHT3W:-B7:DV/5!3OJTIT=%!D*!0*!0*!0*!0*!0*!0*#6O.[
M=6X=MQ]IR,-.>B#E-P0\1/;CLL2''(TM#4U:%UMU>V'LOJ[<./%%X6"*1.<F
M9V]+8F[CF2<AB9>W6<]%B^BQP,&YLR.RT4J0SV>DF/2-#FEG3:Y]-AH)1"YY
MXZ<DIS'X'(Y"/CHX2,F["["1V/;179C`II<LXCC+/CBNG48#QNM@Q$/G2]N/
M<^U&,(I1(<G+R<9F8Y+'D-O"./28T33P:UX:A\51XZD5%X4'W=6Z^8.%YH.[
M7+(N+C]T0C/9\D68FF)*8(#E^D*;5W`CLZG>*\0ZO$U0D"M$^\+A"V^&5'%9
M%^$1--Q<B^+;3+XFCZ(X;HV:;-5B+=M$\8P3A==(9G!<Y8N>SF-Q>)P.0DAD
M(4+)G+18XA'B3D+2XZ).H?4,-)(*+WTOPN&)YC[SW_M3<Y3XDR'-P+&.R&0F
MX16-*QX\2*11WW9>K5KD2Q[,!LB+T#=1(J#7^.Y^[[F3V=MD^`3I,?'9!,N+
M#2DV$S`KE'&4!1[+A('2*J*KHNG$NM09["?>%F9_<G+S&1'H<4<Q8=RLJ8*]
MZ2<3M0:;;)5-MHC,5$U\95THO5*X;\H%`H%`H%`H(K_-/]Q_K=`Y3_PLV;^P
M\;^AMT$JH%`H%`H/$@6"8<&0@DP0DCPN64%!4ZR%?A:W3>@BD:%RR3"8W#QL
M1`'!;C>((&/''B,22Z#3DK4379(WQ:C$X)&EB1$457A066Y,=RCV_#FQ<QAH
M;427#D3YK(X]7@<C0B%UXR[-HQ^K-U#MTW75;I6@RQ<LN7)20E%M?%+(!6U!
MU83&I%9'2W9='T!X)07LK";8@[9?QA8B.NWV&7"/#L0Q=9)L;N$`0V@)#4BX
MH`@JD70EZ"D>P]D$N.4L!CO_`/(O]EBD5E$C7+4O8H@V#K=;J]WCTT%I'Y5\
MLHZ$C.T\0"&*`2)!CV44/M$144.X?6^6W>H+'.YWEGF7(F(W%CVYIJ<%8T')
MXQTT;<R:NM15T2&;-J2QW!55MIM9;+PH,QBMM[/<#&92%A(T5R(R(XU2A)%>
MC-*A6`6C!LV=*.$FG2FG47?6@^ELK9C4*6PF#A#%E.#)ELMQ@5''6UU`:B(W
M4Q7B-N*+T<:"^P)84L-#7"`TWB>R'T)N."--BVG!!%M$'1IZ%&R67@M!?T"@
M4"@4"@4"@4"@4"@4%CG<9C<IAIF/RFK[-E,FW,077(]VE3KHKK1-F**/38DX
M4$739/+5_"X3:::CQ\=0R>#Q_P!H3.TTQ5%6W6R[;M2;:5P;(I**<.%!CY7+
M_DWCY<?'R$;BY-IR&[$,LC*;GME_\*&C3_;I(`2_L@`3L7>6@N)'(GE;(?DO
M.8AQ#EE).0C<Z>V)+.1$D]0'Q%$=04U([email protected]]J;,F[/;V[GQ5-MAZ+$1E
MR7(90K&#,=MQX'`=/4XH#US745KW6@MI7*?84N0[(DXXWG9$),;+4Y4M4D1@
M;)H!D#VNEX@`UTN.(1CTH5T2@QZ<F^5N):&=Z"]&9Q[S.2[4LCD-#;L!E6F7
MRU2--VF4TW7Z-`WKB.4>\UC!N66Q-^SBD)';;R#\=`,(X2)%QC/-:B".0F6J
M^D5[B+09*-ROY>#(2<SAF"5R.<=$53-E67HX13^J(E:U.1VQ;(].I1X*O%:"
MSD<J.6<&*U*>A%%:QQ.R/3?3IK9BCK3;+JO/H\AFVK+(`HN$HZ4M:U!-66F6
MF0:9`6V6Q06FP1!$1%+"@HG!$1.B@]T"@4"@4"@4"@4"@4"@4&`W;M7:FX/L
MO_$(*?V?-;EXJTI^+IFA?LC'L7&M;@\=-[]VU!CYFR=A;CS3V612?R^/;3$/
MR8<Z0!,"T02?1B!IU&Q5"4#(5&Z\-5T6@P6-Y8\EY;TG'8I6S*3`7'SX$+(O
MHC\:*I1;R&FGOK"9(B;UFBJ)<+W3@&4PG);EYAI\;(084E)<.0,N,X[/FNH#
MXLI'[32;RB2DTFE=2+=.'1:@RV7VSM#*;MP^2R*=IN3$-/O8<4E/-FVT>EJ0
M8QVW``Q+6(.*0*BW05[E!A%Y&\M_0F(*09`0XLA94..$Z8(1R)'$((Z"\G8M
MEVQZA"R+?P)8+O"[)Y=[%D1Y\9?LY\HHXMF1,G/F)1XP'(%E!D.DW]6#;A\$
MX"A+T7H,:[LCDUF=V?XA=]'R.?F&#:.%D'W@<)V*;C;:1^W)A=443,0T>)UD
M3NT%\UR9Y>,XM<<WCC%I7&G1?21(](%6(WH;0A(U]J(!&^J04*VGP\:"^=Y?
M\OARF"DEBXK&1PM_L/LU5D@0&D:L(`0H[H;%$36A:>Y:@E%`H%`H%`H%!%?Y
MI_N/];H'*?\`A9LW]AXW]#;H)50*!0*!08O=.(=S6V,OAFGO1W<E"DPVY"=+
M9/M$VA\/R5*]!K',<K-V9Z5Z:#\?&N/A8);BGZ?`OA9&)<C,*`$)M(_(])$A
M<&ZWMW"H/61Y1[F?8RX0QQ<%K+P<I$2`PZ\$:*>2@QHFMD48XIVD4G31!"ZE
MW5N1!:Y/DMN7*[FDY#(CB9&+FSV)<S'F3A"XW'F.2!$Q*.NLE9?)I=2KX+"J
M`(9V)RNRL?8V\-NB4-'-PMR!@I<B!ER0TH=H;G8BX2`X6MM"0S%$0>T6R6"\
MVQL',8S?;VY7V8#0R_M-)91W'"?,9SL-UC4JL-Z^Q6(:64OIJJ=U%"+,<D\U
M'G,36(F':D-2HTHG`-Q#7L,L].<#4D:_UL5_T=5[R6\7A07<3E1NUK[*%S[-
M-O'MX-IT>W>5#'"R9CYV18_^^&:B(G<T]V]!19Y+;C7$M0Y$B"LAMB,V$H2<
M5QH8T5Z.40")JZQY"N(1]%M1]4N"J'K%\GLYC9F.DM#CHD;'9%O(=A'(W11L
M6,:T^`LE'$5-X\>Z]J'28N$*ZE36AAL/8F&FXG`$S,16Y$N=D,B4=5$NP3(3
M7I8L7'JJK8O()654U7MPH)!0*!0*!0*!0*!0*!0*!01[F#CIV1VAD(D)I7WB
M[(RC"MB>::>!QYA/"ZT!!9>F]!KW,[2YA9'/N9>$VX2B<HF9JSC;!_'R),1]
MN*RRI`4=Q8L=Q@BTA8BU:N*J@>EV+O@I3;KS#DAD9,-^*+\D'76(T;<+62&,
M;AN$1DW$9THNHDU6'4J)JH*."V;S,>RC"9Q)[,`912718R[J#_\`%=;0=0/]
MH0^D(TYUDMTKI2ZA02#';<WTSL$L;(=D.YAO(QG8[WI1"^<1J0R;G;&KS@ZC
M:!Q"`7%`[WTCJ41!LG:^\,8YETGG-5B;"<1I)&0<E&DKTN60=F3CKBM+Z,ZP
M.H23B/'BEU"+Q.7_`#.BXR,`2<BN2"(VU(>++/&)/%A'XSY#K?6U\DK#HK9+
M(-TMT*%Y)V+OHVY1M1W6YKLAV6S+;E`VZ+A;:9Q0%V@N(:'Z6RI71?%X^"@\
M9S9O-:8Q-6)*F1I[BN&DAO(D#3D9QIE(\86Q<3LG6'1)2,4%%1"ZQ=H24%]B
ML%OK#YV)-G>E2-OPBR`R8[TDYJE#=E3GHR`".FZ;PLO1FM!BXAV3B*MBI!.]
MB8W(XO96"QV2X3X<".Q)%3[11-MH14%/Z>FUM7=Z:#.T"@4"@4"@4"@4"@4"
M@4$'Y@P=PNY2#)Q"Z7TQ>8AXYY4508RTIMA8#Y\"041&G@UEPZ^GZ5!"PV;S
M*1W..8^/D,8UDUDOXX#RB./L9`H&.CQ),IY'S5]EMV(_J`E/J*GU:WL(5G-J
M\PX\V5)A8IX7C=R"H^W)894@FYF/+U!V<@#ZT9LU4-87\76E[T%"-M#FN]A9
M)OO9:/G&H\./&4LFIL.$TTJ2")MN8VGUKC07<U"XB$I)==0D$GWWB-]S'(:8
M@)UBQ+L>:L.<C`I,*5#<:,5)Z.2D#3,@5<0;V)$[JH@>'\#O=S9F,QJ_:/I3
M.><<E:<@H2UP_ISSC8'+%\3-4ADV"_6:K_AH([B]M<UXXXP'F\HZVVL4\F,C
M)-O]JHP9K,D;'*.XF\Y&)!\7JJ7!>D/L+:/,V(W#'%Q7\9,"-$C.25DQU816
M<%(A(3K0/%VHM3G&'$107@*JGA"EEMI\VW30\>658BHP\3$,LOJ="7Z''0%<
M=61<VUD@:H)&2=-T1"TT&8:Q6^%E.1\D+ZN2L]`GX5QUY7G6([,XY$\3[-QY
MIMI(EV0).S0D-`4+I<PVO0*!0*!0*!017^:?[C_6Z!RG_A9LW]AXW]#;H)50
M*!0*!0*!0*!0*!0*!0*!0*#%YG<V&PST1B<ZYZ3.4TB18[#TI]SLD17"%J.#
MKFD$)-1:;)=+KQH+C#Y?'YC&L9+'N$[#D(JM&0&T2Z245N#H@8JBHJ6)$H+?
M+[GPV)EQX<UUP94MMYZ,RTP^^3@1D%7=*,@YQ%#3AT]Z@RE`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%!3E2HT2,[*E.@Q&8`G7WW"00``341$2\$$42ZJM!BL)
MO#`YIX&<>X^1N,)+:5Z)*C"XPI(*.-D^TT)C<D\55Z47HH,E/G1H$&1.E$H1
MHK9//F(D:H`)J)4$$(BLB=")04L7EH63861#5PF4440W&G64)#;%T2#M1#6*
MBXG6&Z7NE[HJ(%Y0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#$Y_<L#"K!:>!V3-
MR;_HN.@QQ0GGW4`G"0=2@`B#8$9$9(*(G30>8>Z\2\"),/[*E$;P)!GFTT^O
M8*NLA%#-""PJ6H55+<:"RRG,/:\$X`!+;G%D7'&H_HCT=RW9-NN$1:G0ZG]W
M,=2<$+@MJ#(Q=SX)]A'"G1V'$C!,?CN/L]HRRX(DANZ#,4&QIUD51[RK09"-
M*C2H[<F*Z#\=X4-IYHD,#%>@A(;HJ+X*"I017^:?[C_6Z!RG_A9LW]AXW]#;
MH)50*!0*!0>7'&VFR<<)`;!%(S)404%$NJJJ]")0:^W'SYY=88C::F'EY(<%
M:QPH\/ER4&%[RV-5\%>U-B]M(>M-B]M(:]ROWH,N9$.(P3$<$\5V6\;ZK\K;
M:,Z?]-:Z*\&>\NBO"GO*-ROO"\S)"JHR(<6Z+9(\9+)?_K$^O#Y:]8X-?,O6
M.%7S*U3GOS2147[91?`L6+_^JK?X5/E;_#I\K^)]XOF1'+ZQ8$L>ZC\<D6W#
MH5EQG_)59X->TRI/"KVF4HQ'WH7140S6`0A3QWX+_67^JP\*)^%ZO&W!M&DO
M*W"MVEL;;/.3E[N$P8C9,8<URR##G)Z.XI+]$"+ZMPO`!E7-?:M76'/?:M76
M$VKS>90*"*Y_;F9+>&+W5AECO28<.5C94"8ZXRVXQ*<9>0VW6VW]#@.1T_W:
MZD6UTM00;=O*O?6>S&0FK]D"SD(SD<@%U]I11]@$)"_N[I.=F^TAIUQ$O&T`
M5U(+?-<D\\_D9*XYC$-0]$YN$^1N-/@U+99"/'4`C$*-PR87L['T6ZHK05WN
M4^]%W)D,KIQ,F%-FE+D8Q]Y]&)C2.R^S:DH,9>(MSA-"+M+.-#;JJB-AMK%0
MUA8N'#+1JC,-LKV:$@7;!!ZB&3AZ>'#42KWU6@NJ!0*!0*!0*!0?#,``C,D$
M!15(E6R(B=*JM!KO<_/GE]A"-EB4>8EA=%9QZ"X"*G#K/DH,]/3I)53O5[4V
M+VTAZTV+VTAK7,?>;W2^9)B,5"@M="%))R4=N^FE8PBO@LM=5>#YEU5X7F44
MF<[>:4DO^_&R'3V;+$4$O_6[)3_UJ]HX=(>L<2C'^\_F'[0SO+%5O\7;\?U6
M_P`7;\+B+S@YG153L=Q2;)W'08?X=[ZYMQ:B>)M^$3Q:>$BQ7WC>8,0D28$+
M)-);5VK)-.K;O&R0`E_^FM>5N#':7G;A1VE/MO?>7VM,46\YCY&(<+I>;7TR
M.GRD`@]^!I:Y[\2\?+GOQ;Q\MIX7/X3.0TFX><Q/BJME=CF)HA6OI*R]4DOQ
M%>-<TQASS&%_4(*##[QVZWN7:F7V^X\L8<K#>B+(%-2M]L"@AZ;I>U[VOQH(
MCNO:>_=S;6:Q,UG#LR&E;1TP>?,'405$G`U1]+/'22-J#B=XA5!.@CGN8W"L
M)UYR)AGLI)>-9C3KSYM.-.8\8HJKWHVK6P^A/@BMJBJ2\1+K4'C(\H-^.,"U
M!=Q;">FM9!/KWD4'6(V-9$@+T8[*9XYPB5!0OK$ZW`A,)WRXV?DMN19(9((1
M371::=R$-7>UFJPKEI4I#01%YQ'.L@HO'Z9)I00F-`H%`H%`H%`H+;)93&XN
M&<W)2V84-KBY(D&+38_*1*B4&KMQ_>1V=CR)K#1I&:>%;(X*>C1KIT_6.(KG
MSBTJ>&NFG%O;X=%.+>WPUYE?O([^EJ0P6(.-:7Q5!LWWA\&MPNS7R5=->#'>
M717A1WE&Y7.+F?*5>UW#(05^BTW'9LE[V16FP+\=Z]8XFV]8XE%K[S^8?M#.
M\L53_B[?C^J?\7;\+^'SJYI122V?<=#I5MYB*XB_G*UK_`55GAT5GB42G$?>
M8WA&5!RF-A9%M.%VE<B.*G?4KOA?Y`2O&W!\2\K<+Q+8VV_O";!RQ`S/<=PD
MDK)_?13L%7NV?;4@$?"YHKFOQKU[.:_'O7LV3'D1Y+#<B.Z#S#HH;3K9(8$*
M\4(22Z*BUX/%4H%!']U;6D9B7A\E`G)C\K@Y)2(CYM+(9,'FB8?9=90V5(3;
M/@J&BB2(O@4(MNOE5N'<669R<C<$5MUMD63;^S34%LDH%MIEMJH]E-LB.J>D
MAU"J:S%0H^YW(MFP,;,PVXS:QG3CGC5(5?C0'8%PTR@TMN`]K(%U=:_6ZRT&
M/3D3FAFP9@;H;!['-QPC(F/)`(HHX]6U>!)2"XG:8EM2X(:BNG7U6U`-HX3'
MN8_&,Q'3:<>#43QQV1C-*XX:F:@R*GH'42V12)>^1+=5"^H(K_-/]Q_K=`Y3
M_P`+-F_L/&_H;=!*J!0*!0:YYC\[-O[2)S'1!3*YX4LL1LD1IA52Z>D.<=*]
MW0**7?LBWKVVMBU]-'MM;%KZ:.=-W;_W9NUU5S<XG8VK4WCVD[.*%ENEFD5=
M2IW"-2+PUI;7&K3YEH[?'K7YE'JZ'N4"@4"@4!4145%2Z+P5%H)ELKFSO/:*
MMLPY7IF*;LBXN6JFR@IW&B\=GP:5T]U16N7=XE;:=)<NYQ:VTZ2Z1Y?\SMO[
[email protected]$<ASS;5PL?)32:BBZ5<9+Q7F[_3'N*ET2Z5F7VYKJRYZ3A+ZH-:<W]Q
MY["%'EP<@<?%Q(<E_,,1.R2:V!&T+4YH'Q49#<==2.,B0KUT6]]-!;3><658
MR+F.CXV"_+&4<)&CF&THFF:9Q+9G9ETA$O21<\7N%TVXA2+G3FT>FL_84>\:
M8N+[=9A-LI."5(CJV3CS++:@HQ>TU(?#6`*FI5L%8N;NX&X4O,R<+$;P&,F0
MX>5>C3#FOMI-B1I2.M@TP+;@`LT`4A<X\23A0;*QCL]W'17<@R$><XT!2H[9
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M<45%KE>;%;ME28NU\L_%FM8V6$-_T7(2$NRP\K:HTZYP+J`:HI<%X4&K8O-S
M,X.#D6<JP2Y*$4U9<7(OM69=A,0G$8CR6`0)#;P2B=`R$32^DAX4&4D\WMRM
MO,-LX"(^4Z;DH6-;"<X1.EBIZ07>TM&7LM>I71+B*"*ZE15&@0><&?RDN#'Q
M>%A']JSEA0#?R0BHZ69CQK);::><:)/L]4TD/C%;Z*K02C8>[\IN09_IL`8+
MF,=6#-`2(M,YIQP7FQU"&H$:1IP3^DA^"@EE`H%`H%`H%!J3F5S\Q>`=>Q.W
M!;RF9;56WY!*JQ(QBMB$E%45TT7@H"J(BWU$BIIKHV>-:_72'1L\>;]=(<][
M@W+G]Q3O3LW.=G2$55;[1>HVB]QIM+`VG]5$OW:T]O9K31H[>S6FC&5ZO4H%
M`H%`H%!GMI[]W5M%[ML)/)ABZF]"=^LB.=U5-I51$5>Z0*)?TJ\-WCUO\2\-
MW8K;XETSR\YK0-T18S60C%A\P^-VXCRW;?1+]9@UM>Z)JT$B&B=Q42]9>YLV
MIKHR)F,S$3E.Z\AK_G#)EL8O'G$R`1'H[SDM8C\B1"8F@RP:%&*7&(#9<Z_:
M,JMTU@ET6@A\CG#N+$8YZ(#;#<B#%UQH^49>]+5O['AS&"E$+H"KA2'GFCTH
MFI1LB(J+<+C(\X-W0,[E<5VF(EKB=/:.`TXUVC;H0S"0V'I3SI``2GG74$"T
M@UP)56]!<1^97,"3%R\F.[A9)8&$QD9,:-&F&LQ@GG^V**XZ^P0_W=@2"[9(
MI&EE45$B#9VW)F1FX.'-R(@W*E-]NK38$V@`ZJFT!"9&J&+:BA\?&O:R<*#)
M4$5_FG^X_P!;H'*?^%FS?V'C?T-N@E5`H%!I+G1SI/'./[8VN_IR(*K>3R;?
M_P#.O=997_B_EE]#H3K^)U\?C^_6='5Q^/[]9T<]<555555252)5XJJJMU55
M7I55K4B(B,0TXB(Z05*2@4"@4"@4!51$NO102;9NT'<P;<R6P1PBXQHNE5*1
MW=1#T]GWD^E_5\:F<]9^K(YG,S^-&PUQTI6VWFVGFNR53CR6D,";)M%N3;@V
M45%.E46IO%;1B69&8ZMG<O-_O98OL;-*(YAL5*/)%$`)C8\5)!3Q703QP3@O
MC#PN(9._L3MS\.FE\LUO;+[9P>*3,YR(W)2.X#<05:!QQ7G%L`-JY9!553I4
MD2N==CSSNQ)&4.&_CV?3FX_VGE?2([0+#:)"L[+-S2@DO9%P12*R:K:>-!'<
M6G+K%1PW&WBYLZ'G'>P;F2&`?3L)LILA<<1;.*VY)=#2CR$[W=-KK02+<8;8
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M=`(N_>6ST+*?W$&\9A)QP0-8H*R],16VR;CB*+]:KCPAI5$5>GQ;K06&YX7+
M+(2S')8]UD\1CWIV9AQP8[.-$>%'C62(*8]HXD9/[!5<LB=RRT&>3<FR7,#/
MW$[CP9;@2D&3=J.KR3"4$`A<;(VE,E>"SB.62_$DLM@RNQ_LI=NM.8TI!M./
M2.W<FEVDDI#;QM/]LY<D,A<!1U"JC9$TJHVH,]0*!0*!0*#GWG9SFDO29&U=
ML2%:CM*3.7R;2]<S2XG&9)/%0>APTXWZJ6LM^WC<;V_*VCLX_']NLZ-'(B(B
M(B61."(E:;2?:!0*!0*!0*#X1"(J1*B"B755X(B)02W:NSC><;R64"S(V.+"
M)+*J]*..HOX1#YUX\$K$>VNC%YG,]OQKHF[K3;H:#2Z7145%5%146Z$*I945
M%XHJ<4J]JQ,8EG1+9/+K?TJ2^.!SKR.2RX8R>7!9`HBDK3MDT]J`I=%^FGA1
M;Y'(X_I.8^KII?*:;DSL;`8&=F93;CL>`T3SH-(BGI'I7BJ)9.E57H3C7*]$
M3Q'-_"SRV]$>:;@9;/QFYH0Y,I@`;8<)``A=O=TG351:``U$J+J0++08F#NS
M;L7/9!R'MY]-Q?:#[:Q$F`XSVJ0O2WWK(ZY'8>[%$!Q!'5K)$5=*J2!D-Y[[
MVC*V]!>G0',IA9N,_P`1/AK1M!QS),:C($).U6TH55KQ2%"1>XA!L2@4$5_F
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M<M.8C$-V0<NO-/E>[Z$L1F9)`XN4@RVED1QD"WUFR2Z$*:B!ULTXHFE;7X5C
M;E)K.)>UZ36<2PLG[OK$J`]CY.61X)+:`]DC859X:83T'LVGS<,NQ[)X4T&I
M+851575<:*,F7*%UV#[email protected]+DYC,]\8T,FEBOQV8[(/0-+J"RX21R)2MTD
MG2B*A!(LKM/)YK(8N1E'H))B9B38DEB,X$ELFWS)`;<)XT$78_9MN\.MU^'6
M'0$JH%`H%`H%!@M[[M@[3VS-SDM-?HXH,>/?2KSYKI::3^L2\5[B77N5:E9M
M.(6K6;3B'&N6RN0R^4E93(NJ_/FN*])=7NDO!$1.X(BB"*=P41.Y6WM[<4C$
M-G;I%8Q"TJZY0*!0*!0*!09C;FV9.9?1US4SBVR^M>1;$ZHKQ;;\'Y1]SH3C
MXM>LZ:,[F<SU_&OV;=VRQ!8D-15AM'$;&Y`2$B-L,BIN:$`AXZ!X5&Y&*].C
M'B<SU9O'X_$S<8ZZRP(NHWI0R0R)'5)!-1%"L5NU!!3N=55[M>5[VK9:(B81
M9W2V1HI(H@JW-%ZMD[MU[E=.7FF7)G?^+E27MH)-"045M7\60EJ3L46SD82\
M5>Q544$0N`+:R(%9'*VXK;,:2ZZ1;US,/A<E,E)W'D<W.R41UQ[(Q\@Q$;BF
M,:0L<&@US6.T5M7507!U`G26M;W0!Y5E&']W]83*M0\P$5XB20F3:C6EL2$Q
M[L!`CFKG4CB+@$+:WMITWZUQ#,P>54^#M&?M:%-BQL-D''7EQXL/&TRAK'7T
M9E3?4DCNJT^KHK=;N]73IZP2S96VUVUMJ)A$?[=N&KR1_&5&V#>-QF."F1DH
M,-F+076^D4H,W0*!0*!0:QY[<Q'-L[?#%XUU6\WF$,&G`*QL1QX.O);BA+?0
M"]^Y)XM>_'VO>WP]]C:][?#EH1$1012PHED1.A$2MF(:\0^T"@4"@4"@4'PB
M$14B6PIQ55I,HF<)?M+:#I.!D\JVH"*H42$:<;IQ1UU._P#DCW.E>/`:Q&>L
MZ,7E\SW_`!K]?ZMFX&>[$*02&`M-M&Z0D@W,T30V/%+K8S1;)W+U&[7.'#6<
M,NS)Q<K#J!J$5>S`>S0VT-&QT`XHJJ7ZQ@IJG$EXI]*]>,Q:+>5LQA"Y[T1F
M,3LJ0D5L%0AD*:-*V8KJ`Q-5320DB$*]Q:Z+Q$QB=%*YST;<V'NYG?FT"*/D
M"8R<1T6)LB.B"7:LD)BX@.#;LWQ1%5--K*0HO"]8FY3UMAV8F-8PP^`Y#X;$
M8J+`;GNZ59BM95!;;07_`$.9Z>UV2(B=BB/J?1>XDM^OUJ\QE'.58.3"RYY9
MQ-QFOUF4".R`F'H[L91)@40%51D$>J_CH/T4T4%:?RIP61Q.-P>14)F$Q1-#
M!C.QV">;C,-,@$8)&G6+9$QJ<4>N5].I!2RA-J!017^:?[C_`%N@<I_X6;-_
M8>-_0VZ"54"@X[YK[I+<N_,G.$]<.,:P8%ENG81B4=0KW4<<UN)X"K6XFWZT
MSY:O%IZTSY1&NITE`H%`H%`H/A$(BI$J(*)=57@B(E!+-I;2<?(<CE&E!D50
MHL0TL1*G0XZ*]"?DBORKWJK$>VNC%YG,]OQKHFLN;$AL*_+>!AD>"N.$@I?O
M77NU>9B-6=$3.B*Y/F$P-V\7'5\NCTAZ[;:>%`\<OGT_+5?:9T=VU_K[VUZ0
MB62RF2R9*N0D$^"K=&$ZK*=ZS:<%MW%*Z^&H]?/5I[7$VZ=LRMJLZFTON\;J
M/%;V^QW3M"SK:M:57@,E@2<:+P:@0P\*J/>2N'F[?2+.+F;?3V=05FLXH%`H
M%`H%`H%!SE]Y?<YR]P0-MM%_=L:VDN2B="R7T401?"VS=?\`W*[^%MZV=W#I
MK9IJM%H%`H%`H%`H%!F=L;:>S+_;/(3>*;6QN<1)XDZ0;7\E/I'\R<;J-/MI
MHS>9S/7\:ZME---,M`TT`MM-B@MMBB((BB61$1.A$KTB&,LLCN/$8M5&5+%M
MZW]@%S=5%_Y87*WAM:HFT0O3:M?ZQE%Y_,::5V\9&[$$NB/25U+QZ;--E;CW
M]?S57,R[]K_6VG[3A&)\^?D5O/DN24O=&S5$;3O6;%!#Y[7IZ^>K1VN+MTTA
M<[>SDK`9W'YN(BK(QSXOB"=)BG!QOC;^T;4@^>J;VW[5F%]ZGM68=NQ)<>9$
M9EQC1R/(;%UEQ.@@-$(5^=%K$8RK0*!0*!0*!0*#C;F=N<]R[ZRN3U:HP.+$
M@=Y(T95`%'P.%J<_.K7XNWZT_EK<6GK3^46KI=!0*!0*!0*#X1"(J1+9$Z5I
M,X1,X3+:&TSNWE,HUI)%0X<,TXCW4<=1?I?DC]'I7K>+6(SUEB<OF>_XU^O]
M4UKT9[!Y'>>`A*0(_P"E/CP5F-9Q45.E%*Z`*^`B2J>\=NKWV^->^D(QD-^Y
MF1<88-P6UZ"X/._+<D[,?DTE\M1UGX:&U_K8_NE'GW'9#W;R7#D/IT.NDIDG
M@%2OI3P)2*PT-O9I3ZPV+R#W.>%W^Q#,K0LX'H;Z=SM1N<<U\.O4VG]>N3F[
M>:^WAX<RF:^WAU768S2@4"@4$5_FG^X_UN@<I_X6;-_8>-_0VZ"54&)W;E7,
M1M3,Y9O^TQ\&3*"_Y3+)&GXQJ8C,IB,N(@%!`1155!1$NO%>'?K>B,1AN1&'
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M@4"@4"@RV!PT:8*Y#)O#$PK965UPT;[<DZ1`E5.KWR[O0G?2DVS_``S>7R\?
MA35(YN_L7&;1G%QBDH"((*J=@R*)PLETU\$Z+!;PU/MXAQ[?`W+:]$:R&Z,_
M/NCLI6&E_P!S%NTG^FBJY_K6\%,3.LM#:X&W77JQ(``(J`*"BK=;);BO=J8B
M(=L1$=(>JE)0*#KKDEDCR'*[!.&MR8:<AHBVN@Q'CC@G^@V/S5A[U<7F/EB[
MM<7F$XKS>90*!0*!0*#$[OR;F*VEF\FTMG8$"5);5.X3+)&GXQJ8C,IB,RXA
M;`0`0'Q11!3Y$X5O1&&Y$8>JE)0*!0*!0?#,0%2);"G2M1,X1,Q$9E*,%C<7
MB4:RFX'0CR5Z\.`?6<%.XX38W(C[R(G5^7HKF-9_Z8W)Y%MZ?6D=%UD>8A+<
M,9$OWGY*V3Y4:!=2I\I"M6]IG0VO]=:?MT1C(9;*Y)%2=*-YM>EA+`U;O*V-
MD+\ZZU'KG7JT-KA[=.V96J(B(B(ED3@B)5G44"@JQ,@[C9D?)-7[:`ZW*:T]
M.M@T<&WYPUY[M<UF/AY[M<UF'=@D)"A"J$))<23BBHM8;%?:!0*!017^:?[C
M_6Z!RG_A9LW]AXW]#;H)501/FRJ)RTW*J\$3'OJJ_FU?;^T?ROM_:/Y<<UNM
MLH%`H%`H%!3)MWTAMX7B;1KB(#9.MW"U*BK=.Y:UEX]-JI:N7GN;<7Z3H]H*
M(1%TF:ZC-552)>^1+Q5?"M6B(A:M(K&(C#[4K%`H%`H*<E12.ZI>*@%?Y+5%
MM$6T=VXLB+&1")5(B9;4B7BJJH)Q6L!A+F@4"@4"@4"@4'#NXB0MR9E?6$Q%
M^5)!HM;>Q](_AL['TACZ]7J4"@4"@4%-]I70T:R!+HJJ-KJB=SK(J66HM&8P
MK:N8P]DBF8FX2N&*:0(U4E$4X((W\44[R<*B*Q"NWM5II#[5GH4"@4"@4'5'
MW>%1>6,.W_V9:?@?*L;D_P#TEC\C[RV57@\2@4"@4"@4$2YM$@<LMS$O0F/?
M5?DT+>K[?VC^5J?:''5;K<*!0*!0*!0>%`^W;>%TP5OB"`J)8ORD*VI"3N*B
MI:JVKEY[FU%]='I!1"(NDS6YFO$B7ODJ\57Y:F(B%JUBL8B,/M2L4"@4"@IR
M%1&'%7@B"2JOS5%M$6T=V8G_`+5#_P"@U_Y$K`82ZH%`H%!%?YI_N/\`6Z!R
MG_A9LW]AXW]#;H)500_G$*ERLW4*+95QLA$7O7!:M6.L+5CK#CF.\CS#;R<$
M<%"MWKI>MVLYC+;K.8RJ5*2@4"@4"@4"@4"@4"@4%GEW-&-D=Q3!6T7PGU;_
M`#7JFY]94W/K+O3$_P#:H?\`T&O_`")6$Q%U0*!0*!0*!0*#A3+.7W+N!KNM
MY6;\MCD&?^4E2MCC?2(:_'^D0H5T/<H%`H%`H%`H%`H%`H%`541%55LB<55:
M#J#[M)JYRF@.+_O)4T_DUR3*WS7K$WOO+%WOM+:5>3S*!0*!0*!00_G$&OE9
MNH+VU8V0E_E!:M2,S"U8S,..(KW;1FG>Z8HJIWEMQ3YEK=K.8RVZSF%6I24"
M@4"@4"@4"@4"@4"@L\NYHQK_`!LIBK8_*?5_%>]4W9_&5-SZR[TQ/_:H?_0:
M_P#(E83$75`H%`H(K_-/]Q_K=`Y3_P`+-F_L/&_H;=!*J".<R893.7FYXH"A
M..XJ:+2+^7Z.>CH_I6J:SB4UG$N'\0];7&7Z*JXWX1)>LGS$OXTK;I/9LT\,
MC7H]"@4"@R0[=RY8I<H+*+$%M7U76&OL4=[!7>SOK[-'>IJM:]5]XSA7WC.%
MTFRMR]JXTL1`-EIIYU''&FD$7VU>;%5<(4UJV)%H\;@O#@M5_;57]E6+R$&1
M`G/PI*(,F,9-/")":(8+8DU"JBMEX<%J\3F,KQ.8RMZE)0*!0*!08S(-N9"8
MUC8_6<,D!$_YKO4;'_6_&E>&[/2?AX[L])^'Z"HB(EDX(E8S'*!0*!0*!0*!
M0<+[_9<Q?-#<C3J:1>RDM22UK(\^;S*_)9RWSUJ\>WXQ/_#4V)_&)6M=;J*!
M0*#*Q-L9J7CTGQV$-@M2@FL$,A`Q;,Q!50E$3<$56W^1;4F\1.%)O$3A7+9>
MX4>5H66G$1MMY'PD1U9('C5MO2]K[,E(Q44%"OP7O5'[:H_9#&9''R<?->A2
MD$9+!:'1`Q<02MQ'4"D-TZ%X]-7B<QE>)S&5M4I*!0*!0*"RRSVF/V*+UW[C
M^9]-?P</E6J7GICRI>>WEUY]WZ$<3E'@0,4$W4DOJJ=T7I;I@J_F$-8^].;R
MR-Z<WEL.O)YE`H%`H%`H,!S"A.3]A;DA-)J=DXN:TTEK]<XYB/XUJ8G$IB<2
MX9Q#Z(1QEZ.+K2]]"7K)\Q<?GK;I/7#9K/7#)UZ/0H%!5B19$N4S$C-J[)D&
M+3+0])&:H(BGA55J)G'5$SAF0V3N`ST@VR6IE7V220QI=`5<14977]82*PXF
MD;K<:I^VJG[(47-I9YK'%D76`;B"T+Y$3S*&C9Z-"JUK[1-7;`HW'BA(O14_
MLC.$_LC.&'JZY0*!0*!0*#&3VW9\UK'1^+A$@"G?==Z@)^`OQI7ANVZ3\/'=
MGI/P_00```$`%!`41!%$LB(G0B)6,QWV@4"@4$5_FG^X_P!;H'*?^%FS?V'C
M?T-N@E5!\,`<`@-$(#11(5Z%1>"HM!P'NO`2MM;HR.'5%%_%2G&6U)5ZS:+]
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MW%>^TIIJG#1%5'$4D[Q.Z`_.KDY%O6F/+EY%O6F/+MJLQFE`H%`H%`H%`H.2
M?O.[97'<POM-&[1<[&![5T(KS`HPZ/S`+9?G5W\2V:S5W\2V8FK6V-F*Z/8.
MK]>VG2OTQZ-7_CX:[J6[3J[*SVE>U=<H%!)L7NT8NWG<2^A/JZ)QF35IN\:.
M^X#CZMFJZS(]%D%;"-U7NUY6V\VR\K;>9RO1W^3$V,;6MZ-%B"P2&RRTLAUA
M7EC&X`ZQ!&A?T=554A2U[%PK^GHC]71B-X9V'FLN4N''2,QUM(:`;*Q.$:(2
M!TZ!-`U$JJ5KKTV2^W2:QB5MNLUC$L'7H]"@4"@4'AUUMELG'"T@*75:B9PB
M9PQ++,W)Y!IIAM7)DQP(\2/?BI.$@-M_*1%^&O&UL1-I>5K8B;2[[V[AF<)M
M_&X9A;M8Z*S%`K6NC+:!J^?3>L:98\RR%`H%`H%`H%!\(1(5$D0A)+$*\45%
MH.!]Y;>D;9W9D\+90<Q<HVXZE?BU?4R2^!QDA7YZUMJWM2)[M7:M[4B>[[$E
M-R64<#@O08+TB2=*+716V8>];95JLL4%QCIK\'(1IL=Q69$5T'F7A1"4#;)"
M$D1>"JBI>RU$QF,(F,QA,4W[`'*1YK;)--0(I1&[email protected]@^3IR>V2]F>U-V
MW4$K#P\*^/ZIQCR\?U3C#QC.8#36'6#D8_IKND"[5QIDD4F=#8-JA):RL-:%
M=5%.RJG&R*BVSUS!;:ZYA":]WN4"@4"@4%O-F#&:NG6=/@T'?7OKX$[M5M;"
MMK82#DCMMS/<S<+'5.T:B/?:<PU[@Q51Q"5.\3W9A^=7)R;>M,>7+R+>M,>7
M;59C-*!0*!017^:?[C_6Z!RG_A9LW]AXW]#;H)50*#G7[T7+YS6QO>`U<$$(
MF:04XIQTQWU_#V9+_4KKXN[B?6>[KXNYB?6>[GEIUV.[VK7&_!QM>@T_S*G<
M6N_2<P[M.L,Q&E,R0UM+T<#%>!"O>5*]*VB7I%LJU624"@4"@4"@4"@MYDYJ
M,*(O7=+Q&DZ5\/@3PU6UL*VMAB")QQPGGBU.%P_HBGY(UYQ'>58CO+JK[M'+
MXL)MMS<T]M1R6=$5C"72W!'K-\.XKQ==>^.BLSD;GM;XAF<C<]K?$-SUX/`H
M%`H%`H%`H%!K[G?R^/>>RW683:%FL<7I>,Z$4R%+.,W_`.:%T3C;5I5>BO3:
MW/2V7IM;GK;+B\A-"144FG07@MK$))THJ+^!46M;6,PU=8Z,G"R`/JC3B(W(
M_)[A6[H_^'<J];=IU6K;M.J\JZY0*!0*!0*!0*"F_(98;5QTD$4X>%5[R(G%
M5\%1,Q&J)F(8>1)=E&A&FAH5NVUW4\)6[O\`DKSZSJIKJW+]V?E^>7W*>ZIK
M5\9A548BDG!R<0\+=]&0+4O])1MT+7%R]W^V''RMS^V'5-<+A*!0*!0*!0*!
M0<]?>AY>NNC'WOCVK]B`Q<T(IQT:K,/V3\E2[,U[VGN(M=?%W<3B>[JXNYB<
M3W<Z-.NL.]LTO'H,%\4T[R^'O+6A\PT)CO#,19;,D-3:\4X&"\"%>\J5>MLK
M1;*M5EB@4"@4"@4"@4%M,G-1D1%Z[Q>(TG2OA7O)X:K:V/Y5M;#$D;CCBNO*
MA.*EN'0B=X?!5(CO*L1WEU;]VGE^Y@]L.;CGM:,EGD$HXDG6;A#Q:^1757M%
M_HZ+\4K+Y&Y[6^(9G(W/:WQ#<E>#P*!0*!017^:?[C_6Z!RG_A9LW]AXW]#;
MH)50*"A/@0LA!?@3F1D0Y39,R&'$N)@:6(53PI0<8<V>5>4V'FE'23^`EF7V
M7/7CPZ>P=7N.@G^DG63Z2#I[&_[1B=6EL;WM&)U0-$(31QLE!Q."&/3;O+W%
M3P+71,.B87S&644M*"W_`#6T51^<>))^.IB^-3VF-5^T\TZ&MHQ,/RA5%3\5
M7B8G1>)B7NI24"@4"@I/RH["(KSB!?Q47I7Y$Z5^:HFT1JB;1#'OY5YSJQQ[
M,?\`BFG6_-'_`&OP52;3.BDVF=%H@V5255(BXD9+=57PJM1$8(C#:W([D](W
MCDPS.784=JPSZVNZ>FN@O]B'?;%?[0OS4XZM/'R-_'XPY.1OX_&'78B(B@BB
M"(I813@B(E<#@?:!0*!0*!0*!0*!0<V?>$Y,OQY4K>NWF-<1Y5>S<)M.LVXJ
MW.4`IT@72ZB="];H4M/9QM_'XSHZ^/OX_&6@"$22R\>ZB]Y4Z%1:[YC+OF,K
MEC(R6407$5]O\K@CB)\]D+\7STBTQ\D3,?+(QYL9_@TXBETJ"\"3Y16RU>+1
M*T6B5:K+%`H%`H/+CK;0*;AB`)TD2HB?A6HF8C5$SA8/9<?%C`IK_P`0T403
MYO&+_P#.-4F_A7W\+$E-P^T=)7'.XJ]">`4[E1A&$GY><O\`,[YW"&)QWU3(
M(CD^>0J3<=E5MJ*W2165`"_67O(BJGCO;T4CY>6]O12/EVOMK;F)VW@XF$Q+
M78P80:&A5;D2JMR,U[IF2J1+WZRYG,YEES.9S+)U""@4"@4"@4"@4%&;"B3H
M;\*8R,B));)F0PXB$!MFBB0DB]**BVH.-.;O*;);#S"FTA2-NS#+[-FK<E#N
M^CO+W'!3H7Z:<4XZD33X^_[1B=6EL;_M&)U:^LJ&A@2@X/BF/!4\'A3P+71,
M.B87K&6,;#)"Z?\`&;153YPXDGS7J8O,:D6F-609?9>'6T8N#WQ5%_R5>)B=
M%XF)T>ZE)0*!0*"D_*CL(BNN(*KXH])+\@IQ7YJB;1&J)M$,>_E'G.K''LA_
MXAI<OS1Z$^?\%4FTSHI-IG1:(*(JK=5(N)$JW55\*K41&"(PVUR+Y.N[PR`9
MS,-*.V(3O]F2*GIKH+_9!WVA+^T+N^(GTM/'R=_'XPY.1OX_&'7"(B(B(ED3
M@B)T6K@<!0*!0*!017^:?[C_`%N@<I_X6;-_8>-_0VZ"54"@4%AG,%B,]BI&
M*R\5N9`DCI>8<2Z+W4)%Z1(5XB2<47BG&IB<)B<.4N:'('<6TW'<AAA=S&W4
MN7:@.J3'%.-GP!.L*)_O`2WY2#W>_9Y43TL[MKDQ/2S52*BHBHMT7BBI76['
MG0.K6EQ/\L542_"EEIB$3$*X3)H>*]J3N(X*$GXM)?CIU\G7RJIE):=(-G\F
MH/\`;J?:3,OOVO(_^N'E5_V*>T^$^T^'DLG-7Q4;#Y4(O\XT]I1F5$Y$QQ+&
M^5EZ1"P)^%.M^.HZ^3$^5(6P%5)$ZR^,722_*J\5I$1!$1#VB*1((HJD2H(B
MG%555LB(G?5:3.-29PW;RK^[EE<NZSEMXMN8[$HJ&WBUN$J0G39WZ3#:]"IX
MZ_T>"UP[W*[5<6]RNU73T.'$A16HD-D(T5@$;88:%`;`!2R"(C9$1.\E<3B5
M:!0*!0*!0*!0*!0*`J(J67BBT'/7-O[N"O./9S8[0BX2J<K`HH@"JO2455L(
M]]6UX?DJGBKU;/)]>DZ.K9Y'KTG1SQ*BR8DEV++9./*8+0_'=$FW`)/HF!(A
M"ORUH5M$QF'?6T3&842`#MJ%"MQ2]3,93,9>P>DM_P!F^:)WB76G^OJ7\%,3
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M**BI=%3BB\4XTB2)<J\TON_;@VLZ[D<"#N7V]Q-=*:Y49.\Z`I=P$_X@)_61
M+77OV>5$]+._:Y,3TLU(BH2(J+=%XHJ5V.Q\4!U:TX&G08JHE^%.-)B$3$*P
M2IK?BOJ2)T"XB$GX>!?CIU\G7RJIDYJ=(ME\B$/^<JGVDS+U]KR?_K@GA[15
M_P#13VGPGVEY+)S5\5&Q^42+_P!0T]K(S*BX_+<\=\[?DA8$_"*(7XZCKY,3
MY4A;`%511$4O&7NK\J]VD1$$1$/:(I$(BBJ1*@B*<5556R(B=]5I,XU)G&K=
M_*O[N&4RSC66WDVYCL4BH;6*OHE2$Z?K;<66UZ%3QUX^)P5>'>Y7:KBWN3VJ
MZ=BQ8T2,U%BM`Q&8`6V66Q0```2PB(I9$1$2R(E<3B5*!0*!0*!017^:?[C_
M`%N@<I_X6;-_8>-_0VZ"^E;QQ,;>$+:KBDF1G17)31V^K30O5;4ORW!!TQ3\
MELJ"RVOOV)GI;\;T1R&L=@I+ANF"B@A+D0R2XJO040B^1:#$^^3!Q\=`S64A
MR,=MW+,R)&+RCF@T<;C,G)NXTVI.-]JPT3C266Z)UM)6&@RN+YE;6FSLI!>F
M,PI>+>("8?=!''&A!DT?$+WTEZ4"6Z;[email protected]+*3PQ^-S$.9.<922,5
MAX''.Q7Z:B*JJ)\M!#]]\@]B[K,Y;;*X;*FJD4R"@B+A+W7F530?A5+$OY5>
MNWO6KH]=O>M71HO=/W;^8V%(G(#+6=ACQ1V&2`\B=\H[JH5_`V1UV4Y=9UZ.
MNG+K.O1K;*8C+8AWL<M!D8YV]NSEM.,%\R.(*U[UW*SI+HKN5G25I7HN4!51
M$NO!._09'"[;W#G#0,-C)6155MJBLN.BG]8P11'YUKRMO5C67G;=K&LMH[4^
M[#OK*$V[G'6,%$6RF!*DF5;IX-M+V:7\+ET_)KGOS([0Y[\N.T-[[%Y-[&V;
MH?Q\/TK*"G_=)EG9"*J671P$&OS!2_=O7)?<M;5QWW+6U3BO-0H%`H%`H%`H
M%`H(<?,:*N\<MMAJ.BR8$`I<1\W4$)#[(H<B.ED(A[('V%4K+?47#J+06V*Y
MG@[M[,YW)PQBP\/C(N6<1EQ72-N1"]+(+$(6(>(ITWH+7(\UY.WG\:&Z<5Z.
M&8C!)@KCW#F$+A28T4V'15MI;@4YI=8\"XHB7LBA5QW.C:90'W<PX>.G1GGF
MCA]C(<U]G(D,`L<NR#M[I$-55M%TV6]K4$CV[O7;^XI$EG#NO2$B(';/K&D-
M,7<`71$7G6P;,NS<$M(JJV5%H++>W++9N\V4'-P!.4`Z6,@RO926T[PN)THG
M3I*X^"K5O-9S"U;S6<PT-NW[K.Z()N/;9G-9>+TA%D*D>4B=P=2_4N+WR50^
M2NRG,_\`4.NG+_\`4-59W96[\`1)F<-,@@*V5YUD^Q5>\+R(K1?,5=-=^D]W
M37>I/=A!(22XJBIWTXUZ9>F7VI24%>!`GY%_T?'17ITA5LC$9LWG%5>X@-H1
M?BJEMRL:RI;<K&LMB;9^[SS-S9";T$,/%+BK^0/LRMW;,@ANW\!"/RUX7Y=8
MTZO"_*K&G5NW9'W;]C[?5N5E[[AR(675*!!BB2=T(R*0K_[A'X+5Q[F_:W\.
M3<W[6;91$1$1$LB<$1.BU>+Q*!0*!0*!0*!0>776F6C>=-&VFQ4W#);"(BEU
M557N(E!!L3S2#+8:#D(>-)MV3E_L>5"E.*T['(M1-.$B-G?M&E;<T\+(?2JI
MQ"LSS&=?P>U)+&.`\QNTQ;AX]9&AIO2P<E\S?5M2TM--%T-W(K)9+W0,1,YW
M0H19''RL6Z.X<44A)D-M778R#&<BH1#*%GCJ:GMN"BMIQZBV51N&=<YN<O&E
M8%W+(T[([5`9-B2+HDP;[email protected]$$T12(;(BK02'!YO'YO&,Y/'$X
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MZX[[EK:N.^Y:VJ;U10H%`H%`H%`H(K_-/]Q_K=`Y3_PLV;^P\;^AMT%EDN6[
M>1R#F47):,PWEF<I&G"U<V!8;1L(NG7IT*S<"X)=#+NE>@K[4V`>"R+\M[(#
M-;D1CBFQV'9I9R6_,4E7M'/IRW!M^3;NHMPQDWDWCYV`C[=EY.0YA,;#EPL-
M&TCK8&7&<AB9N+?M2CQWB!JZ)PXEJ+C06^3Y,GE7'W9^=-QUZ2Y-[08K2*CY
M%#-LE$E-LA!S&M+I4+$BDB]*6"2;1V3_`(=GS9(S$D!,9895D8[<<0[`WG+B
MC.D$12DGP0>"6Z5NJA)Z!0?#`'`4#%#`DL0DET5.\J+08*7L#8<Q=4O;>+D*
MJW5784<UNB6OU@6IB9A,3,+(>4W+$7>T3:N+5;JNE8C*AQ_H*.C\53[V\I][
M>61A;(V7`45@X#&Q5'Q58B,-VXWX:03NU$SE$RS2(B)9.")4(*!0*!0*!0*!
M0*!0*!00=_8FR?3HS13^QSF/.3DBDBY&"<0S.T%\W_J[DT7:FEE'3_HI8+S#
M[1VA`P<X1D^F83(0F8,HI#S9L%$C,>BB/:"@);L^J2WH,;(Y<[,G`Q#FY61-
ME'&8;PSCLEHI#$:,^U+;]%TB.M.TC-D3AH9%I342I046N66Q9+HY")EI'I6)
M(U;GQY;6N*XK[TEPE,15!55ENB2'PT$J6H)3M7!XG%Q9+N+EN3(V0>223SCH
MOHIBV#%Q<1+EU&11;JJW2Z\;T&;H%`H,3D-H[4R)$60PL"81WUE(C,NJM^"W
MUBMZ9,L4[RFY8NEJ7:N+%42UFXC+:?@`12K>]O*WO;RNHO+OE_$+5%VSB6"X
M=9N#&%>'1Q0*B;3*)F6=8CQX[0LQV@99#@#;8H(HG@1+)4(5*!0*!0*!0*!0
M*!0*#'[@PK.;PTK$OONQX\P%:?-A00U;+QP^L%P;&/5+J]"T$0;Y>[':G/YC
M%9)<9%=FQG3BP#A-PAFP-3`((=B2"YJ4A<2]U7@O0E@RX[#PL?`X7%I*D-K@
M'0/$9+6T,EIRQ,IQ[/LBUMNDTHDVJ$B]%^-!B)/*C9\E]]Q,C*;R1))+)RP>
M95Y[TQUAYPGQ-LP&Q0FD'2`H@C;HH/$;EAM.*4R?&SDYAK/D[Z8;<I@&I9RW
MWI`^*[email protected]%#3THNDM0\*"<8K'AC<9%Q[;AO-Q&@9;<=TZU%L4$=6@0&]D
M[B4%U0*#X8`X"@8H8$EB$DNBIWE1:#!2]@;$F+>7MS%R5O>[L*.?'O\`6!:F
M)F$Q,PL4Y3<L4=[3_"N+5;JNE8C*AQ_H*.FW@M4^]O*?>WEDH6R-EP%%8.`Q
ML51\56(C#=N-^&D$[M1,Y1,LTB(B63@B5""@4"@4"@4"@4"@4$5_FG^X_P!;
MH'*?^%FS?V'C?T-N@U-C(67^SN9D%B#DY2.Z)$2<3$MJ<4AYAEQ(CK()9TVM
M2==M5NG$NJ0W"2Y21/QF^9&:DL3!6)F')DR<C#[C:;=#!*B@'9@MP]-1/JD1
M2[6Y6[M!C@=RB9C/2]P8V=G(,MS(NR(S4&8;[<:/,93$1H[C7:=I&E,%K<;`
M.G6I^*=!9X''9N#N?:SH-9"3CH,>&$@Y,6:U(72L]'%C=NR+K3#&L4<;=L3@
M=GT<$,-BPL1"E[_BY:'&D-,A`+(29;POMD\]/5&H[:H[;3V++#NIJR:=071%
MZ0FU`H%`H%`H%`H%`H%`H%`H%`H%`H%!I'>.PLME>8^9=CXV1'Q67AJ.6R!M
M-RA0VXALL285C0]:Z&V'(ZIU@4EZO`B#/X!C+0,9.Q>X\5(D9#/296:08,=A
MQF(BR&&FT5IYZ2`OB1#)4?K!0M5B)1XA&<7L+>6+S&VW'83[D3&0XC,N-'[-
M$?"*$]MMTG$>3L)4=N0%A!=!F:\5LB@&9B[6S,+EYN+;4#%3GX&21]<$U(6.
MW)8:6*SU9!@XV1&CVOL=5U72@F2)9:"8<LL;F<=MDH^7U'+*;,>]*=!&G9(/
MR#=%]UD5(6C<UW(!LB=Q!Z$"64"@4"@4"@4"@4"@4"@4"@4"@4"@HS=?H;^A
MHGC[,]+(D@$:Z5L*$JH@JO1=5H.:XW+S=I;0=Q6/Q4B'"B3,B&.F/Q0.8ZP8
M3&O1)K`$B.H[V@@DH1%0U<%LFJ@V7N=C=NXW<4]C,>@1-OY.$DF`_(<9(I3$
MIE7'1)MI\7V&VB5$+4ENNJBI"*($<F[#RIS92XYC)Q]LY+*1)V;[6/&+(JY_
M?3?%!)IWTF.,DXKB@X+B>-INET0,YN;';AW#RZ8QF3Q3R[O;A@V,A8C+K!2U
M8:>,$5#T,@XY9LW!4=*H6E42RJ&UDO9+]/=M0*!0*!0*!0*!0*!0*!0*!0*!
M0*"*_P`T_P!Q_K=`Y3_PLV;^P\;^AMT$JH/A@#@$VX*&!HHF!)=%1>"HJ+0?
M:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!017^:?[C_6Z#6^PO?O_
M`(&V[]C?9'V/]F0OLWTC5VWHWHX=CVNGAK[.VJW=H,]\1WJ/SE`^([U'YR@?
M$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y0/B.]
M1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.
M4#XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4?G*!\
M1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE`^([U
M'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y
M0/B.]1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1^<H'Q
M'>H_.4#XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4
M?G*!\1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE
M`^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE`^([U'YR@?$
L=ZC\Y0/B.]1^<H,./ON_Q>YJ^RO\0_9X=E;5Z/Z%VQZ[_2[3M=%O!>@__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>a62430diabetes.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a62430diabetes.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@`M`(]`P$1``(1`0,1`?_$`+0``0`!!0$!`0``````
M```````&`P0%!P@"`0D!`0`#`0$!```````````````"!`4#`080``$#`P("
M`PL&"0<*!04!``(!`P0`$042!B$',4$346$B,I.C%&56%RAQ@4(C%0B1H5*T
MQ'6%-T=B<H*BTC,DL=&2LD-38X,T%L%SLU24X41T)395$0$``@("`0,$`00"
M`P```````0(1`S$$(4%1$F%Q(C(3D;$4!:%"X5(S_]H`#`,!``(1`Q$`/P#;
M?+3EQL2?RYVK.FX*'(F2L/`?DR'&T(W'7(K9&9$O2I$JJJT$D]U7+CV<@^1&
M@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B
M-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y
M$:![JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'
MR(T#W5<N/9R#Y$:![JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(
M/D1H'NJY<>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.
M0?(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B-`]U7+CV
M<@^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y$:![JN7'
MLY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<N
M/9R#Y$:![JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY
M<>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5
MRX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B-`]U7+CV<@^1&@>Z
MKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B-`]
MU7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y$:!
M[JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R(T
M$>3E[LA.8)8Q,)$3''B1DE%[-.S5X)*@+FGHU()*EZ"0\I_W6;-_4>-_,VZ"
M54"@4"@4'AYH7F7&C4D!P5`E`B`D0DLNDP42%>XJ+=*#E?;6Z-YO<CI>\I\_
M-#(Q\)'5R0Y)U/3UD9*3%,01STAI@XPL-65&KK=;HNI%0-A2_O!28NY9&WWL
M8VS)/+-8?&N/$X@.`_*6.W.)T0[,V=+9$NA45#^K6WC4"9SMSH;C9VMD\.Q$
MDR5:Q\Y8<Q7SCR9,-Q]21]H4`%;-I1[-50_IHMJ"QE/;PR_W:<5NF%G)K&X<
M3CURS\E)+K?I;4?4<AJ0H$*EJ:!;+THJ)94NM!<8+FEFV,Y#2/CW9Q;EQ\;<
M[T:1.,@AXR2^$5MJ-VQ=F)-MJ4EZZHBDNA.&FP6L?[RF5>@3)`8%@WV0@/1V
MTDFC1!.FE"4.V1LQ/LS%%1UM%`DZ*";<P)F8'EHY-S^4/:N2;0NV^R9`ZG)"
MZVXS#,AX0LCCB@2\$[BJ@ZEH-./<SN9,*8!ADURN0PK^V,:RU&=[2+/*?&E?
M:"J@>`\IOMZ4=MP4+CPO<+;#\W>9HP\9C8.269D-U!A&O3I9(J0Y>3>E"Z39
M$#@-]H$<4$-"B/2(]2AT)RKW1!W3L##YZ"U)9CS6W%1J:Z4A]#;>-MS4Z:JI
M^&!:5_)M9$3@@2N@4"@4"@4"@4"@4"@4"@PN]9LV!L_.3X+RQYD.!)DQWA$"
M47&6B<'P7!,52X\;I0:4PO-'?TO;>`S[V2DLQWIF(@95MZ+#57G9ZL/=I&$6
MF]+#@.FTJJ:DG`DXT$HQ?WB,7EC9BXS"R)66EN/M0\6CK82%<BL/2'VGP-!)
MET18TB*HJ$1)8K:E0+;>//A686X,9CH;^+ST''Y"3$<>5AUQI['M-.D,AA%<
M$$+M_!XE>R]'"@R/,?=^\-O;0VUO:',)<1&.$YNV)&Y#DZ$-YI3`B$@,K
M:1Z47JM>@HXWG,[C\C.P^3@S\KDHB#+G)';:)8;<V,]-BQE[(0!>S89`#=,D
MNX?"XWTAY9^\/!DPF7H.!D3I#^3BX<([$AE4*1.B++CJ#A]F)"HB0DJVLJ<-
M24&9YGY3?@;+B93;<M<%FC!LF\0<=F;)D37M'9P.*FVB<31PPZ+:M2")4&J,
M_P#>'WSALID92HS*C,RLGC&L<T`&P+D#&M2&Y(N(/:F*OF1'X>GL^A$7C09%
M_FOS2+$9:)!&9/=P<N([/S<*%$D/C"D8X9)BL8E8:(A=+@HIXO3QXJ&^MNRT
MF[?QDQ))34DQ&'O3#;1HGNT;$NU)L?!!3OJTIT=%!D*!0*!0*!0*!0*!0*!0
M*#6O.[=6X=MQ]IR,-.>B#E-P0\1/;CLL2''(TM#4U:%UMU>V'LOJ[<./%%X6
M"*1.<F9V]+8F[CF2<AB9>W6<]%B^BQP,&YLR.RT4J0SV>DF/2-#FEG3:Y]-A
MH)1"YYXZ<DIS'X'(Y"/CHX2,F["["1V/;179C`II<LXCC+/CBNG48#QNM@Q$
M/G2]N/<^U&,(I1(<G+R<9F8Y+'D-O"./28T33P:UX:A\51XZD5%X4'W=6Z^8
M.%YH.[7+(N+C]T0C/9\D68FF)*8(#E^D*;5W`CLZG>*\0\'B:H2!6B?>%PA;
M?#*CBLB_"(FFXN1?%MIE\31]$<-T;--FJQ%NVB>,8)PNND,S@N<L7/9S&XO$
MX'(20R$*%DSEHL<0CQ)R%I<=$G4/P##22"B]U+\+AB>8^\]_[4W.4^),AS<"
MQCLAD)N$5C2L>/$BD4=]V7JU:Y$L>S`;(B]`W42*@U_CN?N^YD]G;9/@$Z3'
MQV03+BPTI-A,P*Y1QE`4>RX2!TBJBJZ+IQ+PJ#/83[PLS/[DY>8R(]#BCF+#
MN5E3!7O23B=J#3;9*IMM$9BHFOC*NE%\$KAOR@4"@4"@4"@BO\4_V'^ET#E/
M^ZS9OZCQOYFW02J@4"@4"@\2!8)AP9""3!"2/"Y904%3PD*_"UNF]!%(T+ED
MF$QN'C8B`."W&\00,>./$8DET&G)6HFNR1OBU&)P2-+$B(HJO"@LMR8[E'M^
M'-BYC#0VHDN'(GS61QZO`Y&A$+KQEV;1C]6;J';INNJW2M!EBY9<N2DA*+:^
M*60"MJ#JPF-2*R.ENRZ/H#P2@O96$VQ!VR_C"Q$==OL,N$>'8ABZR38W<(`A
MM`2&I%Q0!!5(NA+T%(]A[()<<I8#'?\`ZB_V6*1642-<M2]BB#8/"\+P>OCT
MT%I'Y5\LHZ$C.T\0"&*`2)!CV44/M$144.H_"^6W<H+'.YWEGF7(F(W%CVYI
MJ<%8T')XQTT;<R:NM15T2&;-J2QW!55MIM9;+PH,QBMM[/<#&92%A(T5R(R(
MXU2A)%>C-*A6`6C!LV=*.$FG2FG47=6@^ELK9C4*6PF#A#%E.#)ELMQ@5''6
MUU`:B(W4Q7B-N*+T<:"^P)84L-#7"`TWB>R'T)N."--BVG!!%M$'1IZ%&R67
M@M!?T"@4"@4"@4"@4"@4"@4%CG<9C<IAIF/RFK[-E,FW,077(]VE3PT5UHFS
M%%'IL2<*"+ILGEJ_A<)M--1X^.H9/!X_[0F=IIBJ*MNMEVW:DVTK@V1244X<
M*#'RN7_)O'RX^/D(W%R;3D-V(99&4W/;+_HH:-/]ND@!+^Z`!.Q=Q:"XD<B>
M5LA^2\YB'$.64DY"-SI[8DLY$23X`/B*(Z@IJ1$LM!F=S[4V9-V>WMW/BJ;;
M#T6(C+DN0RA6,&8[;CP.`Z>IQ0'PS745KW6@MI7*?84N0[(DXXWG9$),;+4Y
M4M4D1@;)H!D#VNEX@`UTN.(1CTH5T2@QZ<F^5N):&=Z"]&9Q[S.2[4LCD-#;
ML!E6F7RU2--VF4TW7Z-`WKB.4>\UC!N66Q-^SBD)';;R#\=`,(X2)%QC/-:B
M".0F6J^D5ZD6@R4;E?R\&0DYG#,$KD<XZ(JF;*LO1PBG]41*UJ<CMBV1Z=2C
MP5>*T%G(Y4<LX,5J4]"**UCB=D>F^G36S%'6FV75>?1Y#-M660!1<)1TI:UJ
M":LM,M,@TR`MLMB@M-@B"(B*6%!1."(B=%![H%`H%`H%`H%`H%`H%`H,!NW:
MNU-P?9?_`'""G]GS6Y>*M*?BZ9H7[(Q[%QK6X/'3>_7:@Q\S9.PMQYI[+(I/
MY?'MIB'Y,.=(`F!:()/HQ`TZC8JA*!D*C=>&JZ+08+&\L>2\MZ3CL4K9E)@+
MCY\"%D7T1^-%4HMY#33WUA,D1-ZS15$N%[IP#*83DMR\PT^-D(,*2DN'(&7&
M<=GS74!\64C]II-Y1)2:32NI%NG#HM09;+[9VAE-VX?)9%.TW)B&GWL.*2GF
MS;:/2U(,8[;@`8EK$'%(%1;H*]5!A%Y&\M_0F(*09`0XLA94..$Z8(1R)'$(
M(Z"\G8MEVQZA"R+?O)8+O"[)Y=[%D1Y\9?LY\HHXMF1,G/F)1XP'(%E!D.DW
M]6#;A\$X"A+T7H,:[LCDUF=V?]PN^CY'/S#!M'"R#[P.$[%-QMM(_;DPNJ*)
MF(:/$\)$ZZ"^:Y,\O&<6N.;QQBTKC3HOI(D>D"K$;T-H0D:^U$`C?5(*%;3W
M^-!?.\O^7PY3!22Q<5C(X6_V'V:JR0(#2-6$`(4=T-BB)K0M/5:@E%`H%`H%
M`H%!%?XI_L/]+H'*?]UFS?U'C?S-N@E5`H%`H%!B]TXAW-;8R^&:>]'=R4*3
M#;D)TMD^T3:'P_)4KT&L<QRLW9GI7IH/Q\:X^%@EN*?I\"^%D8ER,PH`0FTC
M\CTD2%P;K>W45!ZR/*/<S[&7"&.+@M9>#E(B0&'7@C13R4&-$ULBC'%.TBDZ
M:((74NM;D06N3Y+;ERNYI.0R(XF1BYL]B7,QYDX0N-QYCD@1,2CKK)67R:74
MJ]ZPJ@"&=B<KLK'V-O#;HE#1S<+<@8*7(@9<D-*':&YV(N$@.%K;0D,Q1$'M
M%LE@O-L;!S&,WV]N5]F`T,O[3264=QPGS&<[#=8U*K#>OL5B&EE+Z:JG6BA%
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M5YP=1M`XA`+B@=[Z1U*(@V3M?>&,<RZ3SFJQ-A.(TDC(.2C25Z7+(.S)QUQ6
ME]&=8'4))Q'CQ2ZA%XG+_F=%QD8`DY%<D$1MJ0\66>,2>+"/QGR'6^MKY)6'
M16R60;I;H4+R3L7?1MRC:CNMS79#LMF6W*!MT7"VTSB@+M!<0T/TME2NB^+Q
M[U!XSFS>:TQB:L25,C3W%<-)#>1(&G(SC3*1XPMBXG9.L.B2D8H**B%X1=H2
M4%]BL%OK#YV)-G>E2-OPBR`R8[TDYJE#=E3GHR`".FZ;PLO1FM!BXAV3B*MB
MI!.]B8W(XO96"QV2X3X<".Q)%3[11-MH14%/Z>FUM77TT&=H%`H%`H%`H%`H
M%`H%`H(/S!@[A=RD&3B%TOIB\Q#QSRHJ@QEI3;"P'SX$@HB-/!K+AX>GZ5!"
MPV;S*1W..8^/D,8UDUDOXX#RB./L9`H&.CQ),IY'S5]EMV(_J`E/P%3ZM;V$
M*SFU>8<>;*DPL4\+QNY!4?;DL,J03<S'EZ@[.0!^%&;-5#6%_%UI>]!0C;0Y
MKO862;[V6CYQJ/#CQE+)J;#A--*D@B;;F-I]:XT%W-0N(A*2774)!)]]XC?<
MQR&F("=8L2['FK#G(P*3"E0W&C%2>CDI`TS(%7$&]B1.M40/#^!WNYLS&8U?
MM'TIG/..2M.04):X?TYYQL#EB^)FJ0R;!?K-5_PT$=Q>VN:\<<8#S>4=;;6*
M>3&1DFW^U48,UF2-CE'<3><C$@^+X*EP7I#["VCS-B-PQQ<5_&3`C1(SDE9,
M=6$5G!2(2$ZT#Q=J+4YQAQ$4%X"JIWPI9;:?-MTT/'EE6(J,/$Q#++ZG0E^A
MQT!7'5D7-M9(&J"1DG3=$0M-!F&L5OA93D?)"^KDK/0)^%<=>5YUB.S..1/$
M^S<>:;:2)=D"3LT)#0%"Z7,-KT"@4"@4"@4$5_BG^P_TN@<I_P!UFS?U'C?S
M-N@E5`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H(K_`!3_`&'^
MET#E/^ZS9OZCQOYFW02J@4"@4"@4$0W-S9V#MPW&)^5;<FM70H,6\A]"3Z)B
MWJ1M?_,4:G37:W$)TUVMQ#7&8^]"RA$.%P!N#T"].?%I4[_9-"]?RB5:KTK3
MS.%FO3M/,X169]Y#F*^JHRWCHH<416X[I&ETZ;N/&/#J\&NL=&/676.E'K*S
M]_\`S-_]^S_\9G^S4O\`"I[RE_A4]Y7$7[Q?,EA4UE`E)U]O&*]O^2XS7D]&
MOI,O)Z5?>4CQ?WH<@*B&6P#3H\-;T1\FU[]FG`<OY1*Y6Z,^DN5NE/I*?[>Y
M\<N,R0-.3BQ,D^AG)!V*)\KZ*<?YNTO5:^B]>85[Z;UYAL!MQMUL7&R0VS1"
M`Q5%%15+HJ*G2BUR<GJ@H9"=&Q\&1.E$0QHK9//D(&X2`"*1*@`A&5D3H1+T
M&$QG,':F3!"A27G#-EJ4U'*)+;?<COF+;;[;#C0NN-*1I<Q%13K5*#+3<QCX
M,W'PY3BMR,J\<>".@R$W6V7)!`IB*B"]DR9)J5+VX<:"Y>D,,`AON"T"D#:$
M9(**;A(`#=>LC)!%.M5M0>Z!0*!0*!0*!0*!0%5$155;(G%57HM00/<?._EU
M@U)I<C]I2AX+'QP^D+?K17446$5.XKB+76FF]N(=*:;6XAKW*_>AE$I!B,``
M#]!^8^I+_29:%$_`[5FO1MZRLUZ4^LHU*^\9S(?5>S7'Q1ZNPC&JHE[]+SKR
M7[O"NL=&OK,ND=*OK,K;W_\`,W_W[/\`\9G^S7O^%3WE+_"I[RNX?WCN8["H
MCH8Z4/6KL=Q#Z^A6GFQ_JU&>C7TE&>E'I*48G[T2:A#,[?5`3QWX3Z&2_(RZ
M+:>=KE;I6CB7*W2MZ2V)MGG)R]W"X+$;*#$FFJ(,2<BQG%)>@04_JW"[S9%5
M:^JU>85[ZK5YA-:YN90*"-L<Q=H/9)[&^F.-26)OV8Z4B+*892:H(8Q^W=:!
ME3,3%01#\*Z:;W2@R4O<6*AX"1GY9NQ\7%8<E2776'P<!EI%(S)D@1Y-(BJ^
M)>U!D&G6WF@=;74VX*&!<4NA)=%XT'F-*C2H[<B*Z#\=U-33S1(8$*]8D-T5
M*"I0*!0*!0*!0*!04Y$F/&8<D27088:12=><)``13I4B*R(E!KK</[email protected]>)4
MFXLAW,R!^ACP0V^]]>XK;1)_,(J[4Z][<0[4T7MQ"!9/[T&9<4AQ>"C1D3Q7
M)3YR+_*#8L6_TUJS7HSZRL5Z4^LH](^\1S+>*Z.PHW7I8C+;SQO+72.C7WET
MCI5]Y4O?_P`S?_?L_P#QF?[->_X5/>7O^%3WED(?WD^8+*HDF/C9+?7=AYL_
M](7M/]6HST8])1GI1Z2E>(^]#CC(1S.!?CHO!783P2/G4'4C63Y"6N-NE>./
M+C;IVCCRV3MCF=L7<QBUB<LT<L_%A/:H\A5XWTM.H!G:W2**E5KZ[5YA6M2U
M>82BH(E!\,E$")!4U1%5!2UU[R75$H(1"YN8&1%9D.09T,)C<L\8LD8X#+.`
MAJ^RVZCQ-`Y]4>E'C"Z(JWLEZ#+9W?VVL+'!^7*`KR8<22VTXR1QEG.BTTY(
M13'0VA.(I%W./&@N<AO/:6/AG,F9F&S&;C+-4U?;6\9/]J(HJD0=2**+=>"4
M%==S[:07B7+0D&.#;L@ED-6;!^W9&?A>"+ETTJO3U4&1$A(4(50A)+B2<45%
MH/M!%?XI_L/]+H'*?]UFS?U'C?S-N@E5`H%`H(KOOF5MG9<03R;RNSGA4HF-
M8L4AVW#5951`"_29*B=7%>%3UZYO.(3IKFTXASCO;G)O3=2N,%(7%XD[HF.A
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M\<\<XWF9K\Q'I;<&3#?6/)8LZP`Z89@+EG"L5K)X:D%1ODON5(.G7CVLH,QN
M2[D4?E/>EFT+S:29#,@'6A<)N0HD#:(5_"1Y+"@ANB@4"@4"@4"@4$`YB\Y-
MM[-UPA3[2SVE%'&LDB(WJ2Z%(=L2-(J+=$LI+U#;C775IM?AUU:;7X<Y[QYD
M[PW<9CEYJI!)?!QD>[45$ZD(+JKGRN*7>M6EJZM:_66CKZU:_648JRL%`H%`
MH%`5$5%14NB\%1:"7[+YK;SVD;;<&6LO&!9"Q<M2<8TIPLTJKK9MU:%T]T5J
MKMZE;<>)5MG5K;CQ+I'E]S2P&\X;9,"<#(D*DN/D\")!X$;!\!>;14Z1XHGC
M(-TK-V:YKRR[1B9CV3*N;QK67RZW'D%SN/EG":P^>SS&:DN@XX[(%F*$-`8!
MLF@`3<*"EW-:Z$+@BKQH(OD^2N^)D9J*#^+:;&!+QZNBZ\AH$R)D(Y"O^&52
M`3GM.Z4,1\#B-[$@7T+DIE&,O&DFSC2Q7I"2`PJ/RPCXUT`C)V\/L08[8G3B
MF;C9(V*J=KJFK6%CAN1FXX>-9@RTQL@X^,3'1IK<N<PXP*1W(SK;8,@V!!)[
M3M24[Z#(O!<X+0;8V7A\CAMLPL9D76GID9#%QU@4!M45PB"R"#0W0%1"T@(W
MO813@@9J@4"@4"@4"@U3S%Y^83;SKV+P0!E\RVJ@\=U]$CDG!4<,>+AHO2`=
M]"(5JQIZ]K_2'?5U[7^SGS<^\=S[HD^D9W(.3-*W:C^)';_\MD;`*_RK:NZJ
MUI:^O6G'+1UZ*UX8:NSL4"@4"@4'Q1%4LJ(J7OQ[J<4KR8SR\F,MA;*YX[QV
MPH,S)"YG#AP.+,-5=`4Z5:DKJ-+)U'J'J33TU3V]2L^:^%3;U*SYCPZ2VAO;
M!;J@#*QQFT\@`<B!)'LI+*&EQ[1M>I>-B&XKQLO"LZU)K.)9N6>-#4"0%1#L
MNE52Z(O5=+I?\-1&KRY,Y&3MN-@<EG69$7'ID',=V<`FT23D0?:5Y\2DN]KV
M(2W-`BH<>*JMJ"WE<D,M*S`Y%_<4<T!Z.^$=<<>B\>7%EH!"DO1I(H>DK"A*
MA7)25+T%$_N^,+!RD`,LRD7*,244S@ZWHTF4RZR9Q35_2TS9[^ZT*NGP4<1%
MH+R3R5FRBFF_FHROR9#TIB6$!P)++DI_TIQ!D#+[70$CPFA$AL/@GVB4&S($
M8XL&-&-U7C8:!HGE1!4U`4%241L*7M>R4%>@BO\`%/\`8?Z70.4_[K-F_J/&
M_F;=!*J!0*#7'-WFU&V;#^SL?ID;DEMZH[1)J;8;6XH^]\Z+H#Z2]Y%KMITS
M>?H[:=,WGZ.7,AD)V1GOY#(2#ESI1JY(DNKJ,R7N]Q$Z$1.")P1$2M>E(K&(
M:M*16,0MZFF4"@4"@4"@4&:VIM2=N6:C$=#&*A*#CP60B).D&U+P>'TB7@-0
MM;^BAV^W\/QK^W]FU(&T%6",*$PPL`%[``U@C9>+J1-:IJLKB:B[JUY-ZQ&)
M8N)F<IAL/F#*AS&<#G7U?ANJC6-RKA*1B?0+$DS6Y:NAMU>*KX)>%92S^SUO
MC^4<.VO9GQ+YO/<>;B<U\3C&\T]'Q&0BG"&-![`W(TYQQG2[)9>`E-LP>!`(
M2N*\;:4-5INJQR<_<,7!SI$;><IAY_*28.VEF)"NZ[&T,$4@U9$/1VGF9+AV
M%-0:;%>VH)'M_<:?]\Y-H]T-S\2+(B<=\HS8-S79"(VU%01!S0VVX#9ZR*YD
M*7UZD0+O8F3S+NX=QXS(2W9\:-Z'*QLLE8<;<8E-FBDV;`@@W<8->R6^@=*W
M5"H)K0*!0*!0*!0::YS\Z#PKCVVMM.I]L(ELAD$1"2*A)?LV[\%>5%NJ]`?+
MT6NOU_GYGA9Z_7^?F>'.9$9F;CA$XXX2FXX9*1F9+<B(BNI$2K=57BM:M:Q$
M8AJ16(C$/E>O2@4"@4"@4"@DVS=D2=PNMON@JX];FVU?3VXBFI2(EMI91$NJ
M_2_F]/.9B8S_`-?[LKM]S_K3^K9K.VY<AIM8Z`#;:J4=]MU&2#L;7=:)%`Q[
M._C#T=5+VK,8EEQ$\PV!R]Y@/9%T<'G#3[602*),04`)0#Q451/!%\!XD*<"
M3PAX(0CE]CKSKGZ+%+Y5.;V4SF-PN.DXB=Z,K<]@IT5MQIF3*BHMG&HSCPDV
MC@J0G8K(HBMR0;WKIHAB>:VXW\F[-**_D(4PG(>`CLZB<;-F-'=])G0HS).V
M>]([55!PM(:4%N_%0ML;OS?[K6VY)OR97VH]`AP21EJ.W(?3(/#E?26'4!]!
M&#H-LFQ41TJM^!4$RD[YGO\`,K"8R(3PX"0#XBXW%><:F&L<7A>"4C9-=BWJ
M0443\;5JX:;AL&@4"@4"@4"@YUYQ\[)$]^1MO:TA6L<VI-9'*-$J&^2+8FXY
MBO@M)T$:<3ZO!XE>ZW6S^5N%WK];/Y6X:6$1$4$41!1+(B<$1$K2:+[0*!0*
M!0*!0?#,0%2-4$4XJJ\$2DSAY,X37:&Q93R)F,BR79,6-F*26$%Z1<>5>&I;
M>`'5T^-P&',^6+V^W-_QK^J=GC\S`<;R30OX^5&5/1YHCI(%/Z/A)I)"T>$!
M(J+;BE>7BFR,2HQ,U\ML;$WPUN&.<66(L9N(*+*8&Z`Z"\$?8NJKH5?&&ZJ"
M\%NFDBR-VF:3B5FMLPC/->9.A;LVM+C3'W@"0C3F!8??BNO]MJL^P32Z'C:0
M%UM&)7%;7%"75R21YTIK\/<C;6\1[&?(C2\=N`G\F#3I&4J06*LW+'T56^Q'
M5Z(;9*!")!?@H5=N9_,P.88R<N<B#A0@BK\!Y^4X]#5K%1731UITS$HB$AZ7
MM/:*_J%5X\0SFR)^=<WJTR](D.NN#GBW%&?-P@8)K*-ABD%M2(&KQB/LM-M;
M?A<>F@VC0*"*_P`4_P!A_I=`Y3_NLV;^H\;^9MT$JH%!'M_;QA;0VO+S4E$<
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MBM==2I72)B(QRZ:]%]D_C#9G)/>F.W=&7[2C-KNC!`K#4QRSD@X+RIH-'51"
M4O`07>^B*OC5D;]4TM]%K9JM3Q+9,G"864VTW*Q\9]MG5V(.LMF@:UN6E"1;
M7MQM7%S&\'A6G7'F\?&!UTD)UP66T(B0T<125$NJH8H7R\:"M#@P832LPX[4
M9I24E;9`6QU+TK841+T%>@4"@4"@4$"YR<PRV=MF\(A^W,DI,8T51%T61.UD
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MV4FLXE,`@P0E%,".T,LQ1LY"`*.*"6L*G;4J<.BH(/C6-QS,A)#45EN0C?8H
M\#8B:-ZE/1J1+Z=1*MN[0>FH<-H61:8;;&.FF.(@*(V*I:P63P4MW*"M0*!0
M*!0*#3_W@N8KN&Q@;7Q;RMY/*-J<UX%L3,-54;(O43RHHHO4*%T+I6K/6T_.
MWGB%CK:?G/GB'-J(B(B(ED3@B)6NUB@4"@4"@4"@^&8@*D2V%.E:\F</)F(C
M,IKM39Z#V62RK7UR*CD6(?\`LUZ4-Q/R^XGT?YW1Y$9\RP^WW)O^-?U_NV=C
M\O":PRPWA%5%9)JV38FIN.-"+!@:I<5;,;KQZ.[T5"^N9MF/I_Y4XGPJ9/<F
M)=Q#JS$`7TU.NO$BB&MQ"(E0E+P=)G>Y=^W`K5&-<UG/H]FV6N9',F-BY\:=
M@M4G(PW-;+Z>`Q;H,#)453!P?!72*IUHJ*B*GNZL;*X6M'3V3.>(=.;7W#C-
MSX"!G(/&/*#M`$[*;3B7!P"MT&!:@6U8UJS$XE[:)B<2RU>/"@4"@4$5_BG^
MP_TN@<I_W6;-_4>-_,VZ"54"@YH^\AN@LCNV/@&CO%PC2&\"+TRI(H:ZD_D,
MJ&E?Y15H=+7S9?Z>OFS4E:"^4"@4"@4"@4&;VUM>1F'1D/W:Q0*NLTNAO*G#
M0"]0_E'\R<>*1Y^S-[G<^/XUY;&_PL.,B>!'C,"B)T```*63N(B)4_$0QN4;
MR?,#&,7#'ME/<_WB+V;"?\Q452_H"J=^H_//"WJZ6R_TA$LGN'-9.XR9*@PO
M_P!LQ=MNW\JRJ9=]")4[U>?'/+3U=&E.?,L<(B`H(H@B*604X(B5*(74CY>[
MH+:V\\9FM:A&:<[&?U(41ZP/7[NA+.(GY0I5?LZ_E3[*_9U_*GV=H5CLDH%`
MH%`H%`H%!R%SCW2>XN8&1>$]4/'$N.A(G1HCDJ.%W%UO*:WZQT]RM7IZ\5S[
MM3J:\5S[H55M:*!0*!0*!0%5$155;(G%56@E&U-HN2C#(9-O3$2Q1HIIQ<7I
M0W$Z@[@]?7PX+&(^7V8W<[N?QKPG$N9$AL*_+>!AD>EQPD$?DNM3F8CEFQ$S
MPBN3YA1QN&+CK(+H](>16VT[Z"J=H7SH/RU'Y3/"]J_U][<^(1/)97*9-5^T
M))/-K_\`;IX#*?\`+3@MNK5=>_7GQSSY:>KIZZ>F96M26FQ^0>Z7,)OYB$9J
MD'.!Z&^*K84>&YQC7OZ]3:?^95+NZ\U^7LI]S7FOR]G5=9C-*!0*!0*!0*#Q
M(?9CL.2'S1MED2<=<+@@B*7)5^1*#B7=6XY.Y=QY#.R-2%/>5QILNEME/!9;
M[G@-"(K;I7CUUM:-?QI$-G13XUB&*KLZE`H%`H%`H"K;NJJJB(B(JJJJMD1$
M3BJJO0E>3.'EK1$9E.-H[2.,H9+)MHDOICQELJ,I^45KHKG^K^.O(B9\RPNW
MVYV>(_5(\AE<=CFNUFR`8%?%0E\(E[@"GA$O>1*E-HA3K2;3B(RB>3YAN%<,
M5&L/_N9-_P`(M"J+Q_E$B]ZH_*9X:&K_`%UI\V\(M-FS9[J.SI!R3%;@CB^`
M*]T02P#\J)>GQ:>KK4IQ"C4G=NW[L^ZB8RF1VN^:]C+#TZ$B]`NMZ0>%/YX*
M)6_DJO76;W=>)BS.[E,3%G0M45(H%`H%!%?XI_L/]+H'*?\`=9LW]1XW\S;H
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M_P`EQQM+E;N#:R=)<>"<YF)Y_HR>QV+;9^&OA>9/F!/>NWC6$BM]';O6-U4_
MD@BZ!^55+Y*EF9^AJ_UL\WE&9#S\E[MY3IR'^-G724E2_2@]0IWALE(K#2UZ
M:4_6'BI.I0*#VQ,>@R&9['_40W`DL=5G&21P%^8A2H;*YK,(;*YK,.[&'FWV
M6WFUU-NBA@O=$DNE83$>Z!0*!0*!0*"%\YLD6/Y8;@>%;*\P,15X]$QT(Q6M
MWGJZ:JYM$?5TU5S:(<@UN-HH%`H%`H%`5>*(B*I$J"`HBJ1$JV011.*JJ]"5
MY,X1M:*QF>$FQ+.&V^YZ9F'D>RZ)]3CV;.DQJ3Z2(NE'"1?&)41.A.M5AGSY
MY]F/NV;-\XK'XJ>3WUF)=PAB,!E>@TLX^J?*J:`[Z(B]XJEYGZ.VK_6QS>4=
M-2<>)YPB<>/QW7"4S7Y2)56O8K$-&FNM8Q6,%>IE`H)+RSR9XWF'MR6"V)9[
M,9>YIEEZ*5_Z+RU7[5<ZY5^S7-)=FUCLDH%`H%!%?XI_L/\`2Z!RG_=9LW]1
MXW\S;H)50*#@Y50E54Z%XI6[J_6/LV]?ZQ]GRIIE`H%`H%!2D,*\"!K4!NBG
M9!74B?174BI9>NHVKF,(WK\HPJ*ES5PE4W%1!5PU4BLG0FI;K9.I*]BL0\IK
MK6,1&'VO4R@4"@4"@ZVY&*B\K,);H_Q*?@EO5B;OWG[L7=^\_=/*Y.90*!0*
M!0*"-<SB0>6V["7H'#9!?P17*E7F$J\PXRK>;A0*!0*!0*"DZP3CK1]J0(TN
MI!&R7).**JVOX/5;KXU"U,N>S7%_$\*B"B$1=)FNHS7B1%W2)>*KWUJ41$)5
MK%8Q$/M>I%`H%`H/BJB(JKT)TT';VT__`.6PW_X,;_T1KY]@LK0*!0*!0*!0
M:U^\0>GE?-XKI*3#%4[O^("U_GM7?K?_`$AVZ_[PY7K9;!0*!0*!0*"DC)I+
M20C[@*(J("!:$&_C*BC8KJG#IZ.'6M0FF9S+E?5%Y_+RJ"`@EA1!3ILB63C4
MHC#I$1'#[7KTH%`H%!D-N*B;DP]__P#0B?CD!7+?^D_9RW?I/V=Q5B,8H%`H
M%!%?XI_L/]+H'*?]UFS?U'C?S-N@E5`H.!83FH'07QFG7`5.]J51_JJE;6C]
M(;.G]87%=G4H%`H%`H%`H%`H%`H%!Y<<!MLG#6P`BD2]Q$2ZUY,X>3.'67W?
M]7N@VZI^.K<A3^593JK^.L/9^TL79^TMA5!`H%`H%`H%!&.:8H?+'=XKT%A,
MBB_/$<KVL9E[6,RXNAO*]%:<7QB%-?>).!)\RUNUG,-NLYA6J210*!0*!0*!
M0*!0*!0*"VR+FB"\J<%(=`K_`"C\$?QK4;SX1OP[FVG_`/RV&_\`P8W_`*(U
M@L-E:!0*!0*!0*#5GWER4.4L]Q.*MRH1HB=:A)`K?/:NNG]H=-/[0Y?14)$5
M%NB\45*VVT^T"@4"@4"@4"@4"@4"@4%QB'-.Y,`"+97<K!3YAD`:_P"K:N'9
M_27#L?I+NJL9D%`H%`H(K_%/]A_I=`Y3_NLV;^H\;^9MT$JH%!P/EF3Q>\,O
MCW40.SFR8Q(GBHXP\8<+<++94_!6OHMXCZPUM,^(^RM5E8*!0*#)#MW+EBER
M@LHL06U?5=8:^Q1WL%=[.^OLT=\#5:UZC\XSA'YQG"Z396Y>U<:6(@&RTT\Z
MCCC32"+[:O-BJN$*:U;$BT>-P7AP6H_RU1_DJQ>0@R($Y^%)1!DQC)IX1(31
M#!;$FH545LO#@M3B<QE.)S&5O7KTH%`H%`H+#+/HC8QD\9WB?>`>G\/17.\^
MB%Y]'9_)R&<3E=MILQ02<@MR$1.Y(N\GSV<XUC;)S:?NQ]DYM/W3*H(%`H%`
MH%`H,3NZ"[D-J9J`RFIZ7`DL-CTW)QD@1/PK2"'!^'DIJ)B_@FG:L_(OC)^'
MC\];E)\X;5)\LI71T*!0*#)N;;S#>+')DQ_A2$#2Q"IHVZ9-MN*VBZT`S`A1
M;=/RI>/SC.$?G&<+M-C;H66]$]#0)#[email protected]=N()VACJ+LTNHIQ3K
MJ/\`+7&4?Y:\L-*CN1I+T9Q15QDR;-0)#'4"V720W0DX=*5.)RG$Y4J]>E`H
M%`H%!BLL;C[H1&4UF/A**=*F26`?QW_!7'9/_#ELG_A^@$"*D2#&BI9$CM`T
MB"EAL`H/!.YPK%8RO0*!0*!0*!0:^Y_0W9?*+<#37C`,9Y?YK$MET_ZH+733
M.+PZ:9Q>''^(?U,+'+QV.`]\%\1?FZ/FK8USZ>S7I/HOZZ)E`H+G'X^7D)8Q
M8H:WC0RLJH*(+8J9D1$J(@B`J2JO4E>3,1&9>3.%Z[M;.-E-0HUQ@,-RI+@D
M)!V+^GLC$T722.(X*CIZ4^1:C_)']4?G#UD]I9W%Q#E3V`9:;,6C3MF3-'#4
MT0"`#(Q)%:.Z*G"W&E=D3/@KLB>&'J:90*!0*!0*"YV.R63YF;;C@B&VUE(:
M**]!($@''OZH6^9:J=B?QF57?/XS+NFLIEE`H%`H(K_%/]A_I=`Y3_NLV;^H
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M)#<=HG7%L*=2=*JO0B=]:\M.(>3.%CA<3/S^=AXUA/\`'91]J,U;B@=H2"G]
M$$+42_*M5[V^-9M/+A>WQK,R[^A0X\*%'A1@[.-%;!ED$^B#8H(I\R)60R5:
M@4"@4"@4"@4'!W,/;3NV-[YC#@/9)!E&4*R<$8<^L8^7ZEP4*W?2M73;Y4CW
MAJ:;?*D>\+>'*"2RAIX))P<#K$NY_FJS6V5BMLJ]22*!03#&\P',=A6HGHK4
M^:`MLB[*;T"U'9,W6VP-D@=-4=-'$)232HHEE2N-M.9<;:LRNX_,AAG<"3TA
MJF/$(VF`"VNXVVTR\:.&3K@*K3:B*@74*KT+>,Z?QQZO)T^,>J*Y_(L9')N2
M6&Q;;)!%$%MMG5I2REV;7@!?\E+V3A=>FNU*XAUI&(8ZI)%`H%`H+>;+&,UJ
MMJ=+@T'=7_,G74;6PC:V&9Y/[9=W%S'PL(A5UMN2,^>:IP[*,J.EJ_DF0BW_
M`$D2JG8M\:?=6[%OC3[NX:S&84"@4"@4"@4%AG\1'S6"R.(D<&,C&>BNKW!>
M!054^352)(<"2HT_%9)Z/(;[.?!=<CRF/Y;9:'6^-OI#PK9K;,1:&Q6V8BT,
MJP\V^T+K:W`NCJ^94[M=HG+K$Y>Z]>E!?X+)NXS*LS6W%:T:P,T;![ZMT";<
M'LW%$20@-15%7KJ-ZYC"-JYC"5R^93$AK)1DQ++,9^*D6!H5U'`[-&`:5U0<
M:`M`1[I8.!='!51>,:<8\N4:<8\J4W?S$W`N09<;TB:2$2RC:936X^+BO%P3
MZJSCB&FA+FHHJV55O[&G$Y@C5B<PA5=W<H%`H%`H++(S59#L6E_Q#B<%_('K
M-?\`P[_SU"]O2.4+3Z0V1]V/;)9'F$F34+Q<#'-Y37BG;2!)AH5[ZB3A?T:H
M]NV*Q53[5L5BKK>J"@4"@4"@BO\`%/\`8?Z70.4_[K-F_J/&_F;=!*J!0:RY
M_<O'MW;.61CV>US>&4I,,!2YNM*GU[`]/$Q%"%.LA1.NNNG9\+9==.SX6RXY
M15N+K1:7!XMN)QZ?\J+6KSYAJ3&?,,M#R`/V;/ZN0G2'45NL5ZZG6^?$\I5M
MZ3RNZFF4"@4"@4"@4"@HR9;,8-3B\5X`"<2)>XB5&UHA&;88AYYZ0XCCMDM_
M=MIT#_G+OU#S/F4>?,M^_=>Y?./37][3VK1XZ'%P^KZ3I>"^\G>`;MHO=4NY
M5#M[<S\84>ULS/QATE5-3*!0*!0*!0*!0:(^\]R[=R&.9WECFM4C&-]CE@%/
M"*)?4#O_`"2)=7\DK]`U9ZVWXSB>)6>ML^,XGB7,H$XT\CS*V<3@2+XIC^27
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MRV6)3:!FLBJ2\JO2HF2>`S?_`(06%;<-6I4Z:R=NSY6RRMNSY6RG]<W,H%`H
M%!%?XI_L/]+H'*?]UFS?U'C?S-N@E5`H%!S)]X'DR_CI<K>6WV-6*?57LQ#;
M3C'=5;G(%$_V1])_DK<O%7P;G6WX_&5SK[\?C+1!")I9>/6B]:+W45.BK\QE
M>F,KEC(R6?!=3MV^I>".)^&R%^+YZ1,Q]2)F/JR$>=%?72VXFO\`W9>"?^BM
MEJ<6B4HM$J]22*!0*!04GY,=A+O."%^A%7BOR)TK7DVB.7DVB.5B_E7#N,8-
M*?[UQ/\`5#I_#:H3>9X0FTSPLK*IJ9DIN%XQEQ7_`.B=Y*\B"(3KE3RJRV_<
MQH#5&P40Q^T\C;H3@O8M7X$Z0_,*>$O4A5]^_P",8CEPW[_C&(Y=G8O%X_%8
MZ-C<<P,:#$;%F,P'B@`)9$X\?G6LQF+J@4"@4"@4"@4"@\O,M/-&R\`N-."H
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M:66:X"_W8_\`"$D^L+K\5/I*-/L;\?C"IV-^/QAUJ(B(H(H@B*6$4X(B)5!0
M?:!0*!0*!0*!0*"QSN#QF=P\O#Y1A)$":VK3[2]:+T*B](D*V(23BB\4KV)P
M]B<.*N97+;-[#SBP9J*_CWU(L9DD2P/MIU+;@+H)XX_.G!:T]&Z+Q]6GIW1>
M/JB":@<1QLE;<3AK'K3N+?@J?+7?#M,+YC+*B(,D+?\`%;15'YQXDGXZ]B\Q
MR]^4QROV7V7AUM&+@]T51?\`)4XF)X2B8GA[KUZ4"@4"@MG\C$9)0(]3J?[(
M/"+YT3H^>HS>(1F\0L'Y\I_P1^H;7J%;FJ=\OH_-^&H3,S]$9F96XB`#9$01
M3C2(P1&'0WW?N2KROQ=Y[D8T-A9W"8]U/"4ND)3@KT(G2TB_SOR:S^QO^7B.
M%#L;_EXCAT9514*!0*!0*"*_Q3_8?Z70.4_[K-F_J/&_F;=!*J!0*`J(J*BI
M=%X*B]%J#GOFQ]V[MW'LWL9L0=-5<DX)50`55XJ44B5!#C_LR73^2H^+5K3V
M9KXGA:T]F:^)X<\384R#+=AS6'(LQ@M#\9X";<`NX0$B*E:%;1:,POUM%HS"
M@0`:6,4).XJ7KV8R]F,O0./M_P!V\X'>OJ3\!ZD3YJ8]C'LK#D)X\-8$G=(%
MO_5(4_%3,F9>OM*9_P`/_1+^U7N9,R^+D9Z]!-I_0*_^M3-C,J1ORS\>0:IW
M!L'XP05_'7GGW,?52%L!5204U+XQ=:_*O2M(B((B(?5)!2ZK9$Z56DR3+;O+
M+[O6X]RN,Y#<`.X;`K8T$TTRY`]2-MDGU0K^6:?(*WNE/;VHCQ54V]K'BKJ?
M!X+$8+%Q\5B(H0X$8=++#:61.ZJKTD1+Q(EXJO%:HS.5&9ROJ\>%`H%`H%`H
M%`H%`H*,V%#G0WH4UD)$20!-/L.BA`8$EB$A7@J*E!S'S2^[?E<0X[E=FMN9
M'$\3<Q=U.5'3ILU?PGP3J3Q_Y_35W3VO2R[I[7I9I$A(#(#11,%43$DLJ$BV
M5%1>A4J]$Q/"[$Q/#P38%;4**J="]:?)28B28B50'Y0<`?<1.XJH?XS0EIB?
M<Q]54<C/3@I-EWU!;_B*O<V,R]?:<S_A_P"B7]JF9>YEY+(3UX:VQ3NB"W_&
M1)^*O,R\S*D;LAS^\?<).XBZ$_J(-,>\F%,&P!+`*"G79+4B(@B(A4::===!
MED"=>=)`::`5(S)>""(C=25>I$KR;1$9DFT1&9;WY6?=LGS'6LOO<%B0AL;.
M%1?KGNM/2"%?JP_D(NM>O3:RT=W:SXJH[>SGQ5TI&BQHL9J+%:!B,P`MLL-"
M@``"EA$1&R"B)P1$JFIJE`H%`H%`H%`H%`H%!C=Q[;PNX\0_B,S%&7`D(FMH
MKHJ*G$3`DL0D*\4)%NE>Q,QYA[$X\PY2YF\@MS[3=>GXH',SMX;FDAL=4E@>
MFS[0I=4%.EP$T]:H-7]7:B?%E_5VHGQ9JU%14146Z+T*E6UMY5L%)#M8TZ#3
M@2?(2<:3$/)B%4),P/%?.WY):2_&J:OQT\^YB?=53)3DZ5:7^@7]NO<V,R^_
M:4S_`(?^B7]JF9,R\E/GEP[0`3N@%E_K*?\`DKS,^YY4'"==2SSIN)UHJV%?
ME$=(_BKS&>7GQ]WP1$1011!%.A$X)7L0]B%UC<9D<I.:Q^-C.S)SZV9C,"IN
M%;IL*=2=:]"==1O>*QF7EKQ6,RZ/Y3_=P9QKK.;WH+<F>"H<?"II=8:7J*07
M$733\E/`1>LN%L_=V)MXCAG[NQ-O$<-\U65B@4"@4"@4$5_BG^P_TN@<I_W6
M;-_4>-_,VZ"^S^\<3@\MA,9-4D?SD@HT<A3P`41X$XO4A.FVT/=(QH+3';ZC
MS-SN8#T)UIYM^8PCY$"@JPFXSA%9%OX8S1M\BWH+%SFCCFU68<%]-O#DUPJY
MG4VH>E(]Z,I]DA:^P](^I[3IU?1T^%0>\-S8V=E,DD0)K49M^'&GXY^28L^D
ML2FW7=0`>DAT!'-2U6Z%7H2@RL;?>S)4V-!CYN&[.F$81H@O`KQDTMC1&[ZO
M!7IX4%'=_+S9^[V$:SV-;DN`FEF6-VY#:=-@>#2:)?Z-]*]:5*MIK.82K::S
MF&C-U_=2RS"N/[6RK<UE+J$*>G9/(B=2/-HK9DO5<`3OU;IW)]86J=N?6&KL
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M&0V)MOP;-:M7?Z$H,(_SF.!MW%[MRN*[/;&:"0["<CNJ]+`&8KTQE765`!^N
M8C&O@GX"V157B2!D('./;"R<BQEU/%E$=5(RN-2%%YKLHQI8U:$>VU30%615
M33A09C;_`#$VMN&<$'$O2)+Y,))-?1)0--MD1@/:.FV+8$I-&*"I7517N4%C
MO?E#L7>2D_E8'99%4LF4B*C,G@EDU$B*+EDZ$<$D2ITV6KPG39:O#1NZ?NL[
MN@JX]MZ<QF8Z+<([O^%DV5>`IJ4F2MUDIC\E6Z=SWA;IV_>&M,QR]WWAB),G
M@)\<1\9WL#<93_G-H;7]:K%=])]7>N^D^J.J8(:@I)K%;$-^*+W%2ND6B76+
M1+[4GKX)@3B-B2*X2V$$7BJ]Y*C-HCU1FT0DN&Y;<P,T:#C=O3WD+Q739)AE
M;]QY_LVOZU<[=BD>KG;?2/5LW:OW5MRS%![<N19Q3%[G%C?XF0H]Q3\%IM>^
MFM*KW[G_`*PKW[?M#>>R>5FR=F@A8;'CZ:J*)Y*1];*)%Z4[0D\!%ZQ!!'O5
M4O>;<JM[S;E+:@@4"@4"@4"@4"@4$#]Z\5Z#N1^'!4W]O2F6>Q><[-)$9\Q:
M"6T2`?U9&CJ!^5HZ4O07$GF*47;<G*.P!*<F8/!0(`/^"_*6;Z"Q=XP'0)E8
MS70ND;^-;B%CDN;K.'R\S`9?&$WGF40H;$4W),9YMR)(E-&3Z,@32+Z$Z!W;
M73;5Q&ZH%Y$YQ;#/'1)4[(I`?D$VRY%?9D`;;QML.*A";0$C:#,:7M51`L2+
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M5K]N9X5[]N9X;SVGL;:FTX?HN`QS4,21$=>1%-YVW^\=/4X?SKPZJJVM,SF5
M2UIF<RSM1>%`H%`H%`H%!%?XI_L/]+H'*?\`=9LW]1XW\S;H+7=?+F-N5_*G
M+GJ#\MB*UCG`#ZR`L9U7A=:\-$(U>\.Y#TB/2@T'O$[!EPMTIGWLH+YJ[+?=
M8&/V:$4QF.R2:NT.VGT-M4X?E=U+!Y7EG#73"].=_P"WARJYO[)TC_U2O^E:
M.UO?L/2OKM&F^KAJT^#01_W%,.XIO$2\X](QP1(N/T]@V#OHL2')@@':"5M2
MM33N6GI1._<)%M?EZ>"S#.37(C),(ST9UL8C$43)\F2)Q!CHV(K_`(8/HKQ4
MN/%$$)C0*!04Y$6-);[.0T#S?3H<%#&]K="W[M!CEVEM1515PL"Z="^C,_V:
M"[A8K&04M"AL146Z?4M@WP7BOBHG<H+J@4"@4"@4"@4"@4"@4"@AN9V1LZ7D
M%;R$OL\UD9S>4B/JXP$U'8:-H"1B4-?9MHT%Q2_#QKZEN%WM;:NWL?*7(XJ<
MY,4&WXI$KK3H)VTDI;J+V8IX7:NJO3P3A08F1RSV(4%K$S);CF(4)<'$XIV0
M",QBF`Y'D#%L@N*:`Z;8H9GV:*J#IH*!\JMC9)XXAY*3*FPW"D.:93?I#+Y@
MP`O+V8H0&*PFB#HL0W[M!(]KX##PI,O)X_)/9)R8#<>4^Z^$A"6.3AIX0IP+
M4^=TO9+V1$1!1`D-`H%!0EX^!,#1+C-20M;2Z`FEE[Q(M!8_]I;4NJ_8L"Z\
M%7T9F]D_HT%_%@PHC?9Q([<=O@FAH!!+)T<!1*"M0*!0*!0*!0*!0*!0*"C,
MCE)B/1Q><C$\!`DAE11P-26U`I(8ZDZKHM!KYSE7R_#TA8,]<6,.$UB\LD(H
M;0D+1!(`YB=B2=MXI:BMP7N$MPSSFR<`FW9>-F2WGH<R:64&8ZXT#C,HY"2@
M=9<;!L14'T0PNB]Q;IPH,9.Y;[2R$I_(2LK)=RZ$,J5E>W81Y&5AO1``A1M&
M`9["2[:S:<54KWH*47E9M;'S%W"QFY\9XVP!Z>$EEH7(Z1X\;LR(&P'000V>
M*6)%2XDEUH)=MO!1L%AV<7&?=D1V5-6W'U!3LX:FJ7;!L;7);<*#)T"@4%I,
MQ&*F_P#6PF)71_?-`YT='C(M!:IM+:B*JIA8"*O%?\,SQ7H_)H,DRPRR&AEL
M6@Z=((@I=>\E![H%`H%`H%`H%`H%`H(K_%/]A_I=`Y3_`+K-F_J/&_F;=!`H
MT::'-O=8C$GRX<_%D;TEQJ2R]%(#D-`TT;::'V7NS4FM):N*(B>"=@MEA;D0
M,&90YWVJWCMJCAW#9?LP3$PES(FFB[9^C?WR'Q,=*)=:"XW9)RN7RSNZ=COS
M<C.=Q,@68TB"^V,-"Q[KL:5!-X&!)TW7!;5LE*Y&J<-!(@8>3M_=SS#<;$->
ME$U(3'X.83,R(_93A27,R:N"[]8!(ZR\;I`3FBR*NK20;(RF,Q^9W7M^=$C2
M>T)]Z5,FNA(:T,8U%:!A!<0>S[22\!HED[01)>*<:"<4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4&I>9&TLOD^9.$R.-Q;[J$PW"R4XD;<BK"&1VA$*ZD<8DQNU<=
M:)$\,K#8N.D/FSL/N_;[$N*@JW+S@1\5@9*1A8!AO%P#$)DUCMG^S)T0TCI0
MO%#4(WTB&!3EUO6)B9.,.`KRRV,K!Q#C+O;)#>E9M9K<EUQY4/B!"YKXK9H;
M^&J)03':^%DXJ?N!YO%9-S`YM05R'*]'66,IPY*RS1Q'1<5@D4+7,EU%<.%Z
M#)<LL<<4,S*/`O;?/)2PE%",([30:6`C@VT$=QQ/!;8%3-;:B5;<*";4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4'/(;)W.N3W0SCL7*Q\*1F6)[>4D,-2)D.01Q7
MWB;$249\:^NS>E=*)TJ2JB!()^(>R_+G&;3E8G)1<Y@8D4XPQ66I$3TU(;@L
M"Z,A76S;7H,'4L"JEU3@=!]S>TVLKGI+B8.3B9<)D4+(1X/;1ICPS8N0>)T4
M<;.0T;T,66VU7@!&O`;6"^C8[)8K8"XO+[;<RV2>DR<BS`&.$B%&/)RY)BRK
M8N."0Q&G/#!%4>A!+BBH$_V=";@;3P^/;;D--0H;$5H)FE)'9L-HV"O(*JB&
M0BBDG=H,Q0*!0*!0*!0*!0*!0*!0*!0*!017^*?[#_2Z!RG_`'6;-_4>-_,V
MZ"54"@^``-@+;8H``B"`"ED1$X(B(E!]H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H(K_%/]A_I=!K?87OW_[&V[]C?9'V/]F0OLWTC5VWHWHX=CVN
MGAK[.VJW709[XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4
M#XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4?G*!\1
MWJ/SE`^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE`^([U'
MYR@?$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y0
M/B.]1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1^<H'Q'
M>H_.4#XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4?
MG*!\1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE`
M^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE`^([U'YR@?$=
MZC\Y0/B.]1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1^
M<H'Q'>H_.4#XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y08<??=_P!WN:OLK_N'
6[/#LK:O1_0NV/7?Z7:=KHMWKT'__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>a62430ent.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a62430ent.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@`M`(]`P$1``(1`0,1`?_$`+(``0`"`P$!`0``````
M```````%!@0'"`,"`0$!``,!`0````````````````(#!00!$``!`P(#!`0(
M!PP%"@<!```"`0,$``41$@8A,1,'05$B%&$RDZ-E5A<H<8%"4B,5")&A8G*B
MM,1UA18W1[$S4R0T@I*RPD-C<].4&/#!T=*#1"4G$0$``@(!`P0!`P0"`P``
M`````0(1`P0A,1)!46$R<2(3!8&Q0A12,Y&A8O_:``P#`0`"$0,1`#\`VWRT
MY<:$G\N=*SIMBAR)DJSP'Y,AQM"-QUR*V1F1+O4B555:"R>RKEQZN0?(C0/9
M5RX]7(/D1H'LJY<>KD'R(T#V5<N/5R#Y$:![*N7'JY!\B-`]E7+CU<@^1&@>
MRKEQZN0?(C0/95RX]7(/D1H'LJY<>KD'R(T#V5<N/5R#Y$:![*N7'JY!\B-`
M]E7+CU<@^1&@>RKEQZN0?(C0/95RX]7(/D1H'LJY<>KD'R(T#V5<N/5R#Y$:
M![*N7'JY!\B-`]E7+CU<@^1&@>RKEQZN0?(C0/95RX]7(/D1H'LJY<>KD'R(
MT#V5<N/5R#Y$:![*N7'JY!\B-`]E7+CU<@^1&@>RKEQZN0?(C0/95RX]7(/D
M1H'LJY<>KD'R(T#V5<N/5R#Y$:![*N7'JY!\B-`]E7+CU<@^1&@>RKEQZN0?
M(C0/95RX]7(/D1H'LJY<>KD'R(T#V5<N/5R#Y$:![*N7'JY!\B-`]E7+CU<@
M^1&@>RKEQZN0?(C0/95RX]7(/D1H'LJY<>KD'R(T#V5<N/5R#Y$:![*N7'JY
M!\B-`]E7+CU<@^1&@>RKEQZN0?(C0/95RX]7(/D1H'LJY<>KD'R(T#V5<N/5
MR#Y$:![*N7'JY!\B-`]E7+CU<@^1&@>RKEQZN0?(C0/95RX]7(/D1H'LJY<>
MKD'R(T#V5<N/5R#Y$:![*N7'JY!\B-`]E7+CU<@^1&@>RKEQZN0?(C0/95RX
M]7(/D1H'LJY<>KD'R(T#V5<N/5R#Y$:![*N7'JY!\B-`]E7+CU<@^1&@>RKE
MQZN0?(C0/95RX]7(/D1H'LJY<>KD'R(T#V5<N/5R#Y$:![*N7'JY!\B-`]E7
M+CU<@^1&@>RKEQZN0?(C0/95RX]7(/D1H'LJY<>KD'R(T#V5<N/5R#Y$:"O)
MR]T0G,$K8EDB);CM(R2B\-.&KP25`7,N[,@DJ8T%AY3_`,+-&_J.V_F;=!:J
M!0*!0*#X>:%YEQHU)`<%0)0(@)$),%RF"B0KU*BXI0<KZ:U1K-[D=+UE/GWH
M9%OA(ZMR&Y.IW]9%RDQ3$$<[PTP<86&L%1K%<5Q1<R*@;"E_:"DQ=2R-/O6Q
MMF2=V:L]M<>)Q`<!^4L=N<3HAPS9RMD2Y%14/Z-</&H$SG;?0U&SI:YV=B))
MDJU;YRPYBOG'DR8;CZDC[0H`*V;2CPU5#^6BX4&#*>UA=_LTVK5,*^36-0VF
MWK=GY*276^]M1\QR&I"@0J69H%P7>BHF"IBM!D6+FE>V+Y#2/;W9Q:EM\;4[
MT:1.,@AVR2^$5MJ-QBX8DVVI27L51%)<B;,N`8L?[2EU>@3)`6%@WV0@/1VT
MDFC1!.FE"4.,C9B?#,45'6T4"3=07;F!,O`\M')M_NAZ5N3:%QOJF0.9R0N=
MN,PS(>$,$<<4"78G4JH.9:#3CW,[F3"F`87-;K<+*_IBVLM1G>)%GE/C2OK!
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M"X_9VEC@N[902/,?5^L-/:0TUK:',);1&.$YJV)&Y#DY$-YI3`B$@,L,H
M[T7HPQH/&V\YG;?<9UGN<&?=;E$09<Y([;1+#;FQGIL6,O"$`7AL,@!NF28N
M'LQ''*'RS]H>#)A,O0;#(G2'[G%LX1V)#*H4B=$67'4'#X8D*B)"2KA@J;,R
M4$SS/NFO`T7$NFFY:V*]	-V@X[,V3(FO9.'`VJ;:)M-'##=AFS((E0:HO_
M`-H?7-FNEQE*C,J,S*N=L:MS0`;`N0+:U(;DBX@\4Q5\R(^WEX>Y$7;02+_-
M?FD5HNT2",R>[8Y<1V?>X4*)(?&%(MPR3%8Q*PT1"Z6Q13Q=^W:H;ZT[+2;I
M^V3$DE-23$8>[X;:-$]Q&Q+BDV/9!3QS94W;J"0H%`H%`H%`H%`H%`H%`H-:
M\[M5:ATW'TG(LTYZ(-TU!#M$]N.RQ(<<C2T-35H76W5XP\+Z/#9MVHNS`*I$
MYR7G3TMB;J.9)N%IEZ=9OT6+W6.!@W-F1V6BE2&>'E)CO&1S*SEPQ/?@-!:(
M7/.W3DE.6^PW&X1[='"1<W87`D<'C179C`IE<P<1QEGQQ7+F,!VXK@$1#YTO
M:CU/I1BR*42')N\FV7F.2QY#;PC;TF-$T\&==F8?%4=N9%1=E!^ZJU7S!LO-
M!W2Y7%Q;?JB$9Z/DBS$RQ)3!`<OO"FUBX$=G,[M7:'9VFJ$@>T3[0MD+3X74
M;5<7X1$TW%N+XMM,OB:/HCANC@TV:K$7%M$\8P39BN4)FQ<Y8M^OEMM=IL-P
MDA<(4*YG+18XA'B3D+*XZ).H?8,,I(*+UICLQ")YCZSU_I34Y3XDR'-L+%NN
M%PFV16,JQX\2*11WW9>;-GD2QX8#@B+N'%1(J#7]NY^Z[F3V=-D^`3I,>W7!
M+N+#2DV$RPK='&4!1X6R0.45457)BFTNU03UD^T+,O\`J3EY;(CT.*-XP'4K
M*F"O=Y.)Q0:;;)5-MHC,5$U\95RHO9+$-^4"@4"@4"@4%5_FG^P_TN@<I_X6
M:-_4=M_,VZ"U4"@4"@4'Q(%@F'!D(),$)(\+F"@H*G:0L=F&&_&@JD:%RR2R
M6VSQK1`&Q:C>((%O&WB,22Z#3DK,37"1O:U&)P2-,"1$4579086I+=RCT_#F
MQ;Q9H;427#D3YK(V]7@<C0B%UXRX;1C]&;J'AOQ7-AO6@EBY9<N2DA*+2]J6
M0"MJ#JPF,R*R.5O!<GR!V)09LJR:8@Z9?MA6B.NGV&7".SL0Q=9)L<7"`(;0
M$AJ1;4`052+<F-!Y'H/1!+;E*P6[_P#(Q^JQ2*RB1L2S+P40<`[7:[/3MWT&
M)'Y5\LHZ$C.D[0"&*`2)!CX**'Q$144.@^U\.'508-]OO+.\N1+1J*WMS34X
M*QH-SMCIHVY<U=:BKDD,X-J2QW!55PRX8+@NR@F+5IO1[@6RZ0K)&BN1&1&V
MJ4)(KT9I4+`!:,&S9RHX29<J9<Q=:T'Z6BM&-0I;"6.$,64X,F6RW&!4<=;7
M,!J(CBIBNT<-J+NVT&=82LI6:&MD!INT\(>Y-QP1IL6TV((MH@Y,NY1P3!=B
MT&?0*!0*!0*!0*!0*!0*!08-]MEMNEFF6^Z9OJV4R;<Q!=<CXM*G;176B;,4
M4=^!)LH*NFB>6K]ELFDTS';XZA<[';_K"9Q,L515MULN-Q2;:5P<$4E%-FR@
MCY7+_DW;Y<>WR$;BW-IR&[$,KC*;GME_@H:-/\=)`"7]4`">!=2T&1(Y$\K9
M#\EYRT.(<LI)R$;G3VQ)9R(DGL`^(HCJ"F9$3!:"9U/I31DW1[>G;^*IIL.Z
MQ$9<ER&4+`P9CMN/`X#IYG%`>V:YBPQQ6@QI7*?04N0[(DVXWG9$)+;+4Y4M
M4D1@;)H!D#Q<KQ`!KE<<0C'>A8HE!'IR;Y6VEH9W<7HS-O>9N7%*XW#(V[`9
M5IE\LTC+BTRF7%?DT#6MHY1ZS6,&I9;$WZN*0D=MNX/QT`PCA(D8C&>:S$$<
MA,LV.45Z$6@DHW*_EX,A)S-F8)7(YQT15,V59>CA%/Z(B5K,Y';%LCRYE'8J
M[5H,.1RHY9P8K4IZ$45JW$[([[WZ:V8HZTVRZKSZ/(9MJRR`*+A*.5,,,*"Z
MLM,M,@TR`MLMB@M-@B"(B*8"@HFQ$1-U!]T"@4"@4"@4"@4"@4"@4$!JW2NE
M-0?5?[P@I_5\UN7:L)3\7+-#'A&/!<:SN#MRXX].%!'S-$Z"U'>GKLBD_=[>
MVEH?DPYT@"8%H@D]V(&G4;%4)0,A4<5V9L46@@K;RQY+RWI-NM2MF4F`MOGP
M(5Q?1'XT52BXR&FGOI"9(B;SFBJ);,<4V!*63DMR\LT^-<(,*2DN'(&7&<=G
MS74!\64C\3*;RB2DTF5<R+BFS=A02UWTSI"Z:ML]RN*<34EH:?>LXI*>;-MH
M\K4@QCMN`!B6<0<4@5%Q05Z*"$7D;RW[DQ!2#("'%D+*AQPG3!".1(XA!'07
MDX+9<8\PA@BX^!,`R[+HGEWH61'GQE^KGRBC:V9$R<^8E'C`<@64&0Z3?T8-
MN'L38*$N[&@C7=$<FKSJS]X7>[W&_P`PP;1PK@^\#A.Q3<;;2/QR87-%$S$,
MGB=I$Z:#.:Y,\O&;6MN;MQBTKC3HOI(D=X%6(W<VA"1GXH@$;Z)!0L,OAVT&
M<[R_Y?#=+%)*UQ6+C9<?J/AJK)`@-(U@(`0H[D;%$3.A9>C"@M%`H%`H%`H%
M!5?YI_L/]+H'*?\`A9HW]1VW\S;H+50*!0*!01>J;0[>M,7>S-/=W=N4*3#;
MD)O;)]HFT/9\U2QH-8WCE9JR_2N^@_'MKCX8!+<4^_P,;+(M+D9A0`A-I'Y'
M>1(7!Q7'#H*@^KCRCU,^Q=PAC:X+5W@W2(D!AUX(T4[E!C1,[(HQM3B12=-$
M$,5+I7$B#%N?);4MUU-)N%Q&TR+7-GL2YEO,G"%QN/,<D")B4=<Y*R^32YE7
MP8"J`(3L3E==8^AM8:=$H:.:A;D#!3$B!ER0TH<0W."+A(#A9VT)#,41!XBX
M)@&9IC0-XMFNWM2OLP&AE_6:2RCN.$^8SG8;K&958;S\%8AI@I?+54Z44*LQ
MR3O4><Q-8B6=J0U*C2B<`W$->!=GIS@9DC8_2Q7^[JO4F'B[*#+B<J-6M?50
MN?5IMV]NQM.CQWE0QLLF8^>"+'_VPS41$Z,O3C0>+/);4:VEJ'(D05D-L1FP
ME"3BN-#&BO1RB`1-8K'D*XA'NPS'V2V*H?5KY/7RVS+=):&W1(UNN+=PX$<C
M=%&Q8MK3X"R4<14WCM[KV8<IBX0KF5,Z&&P]"6:;:;`3,Q%;D2YUPN)1U42X
M"7":]+%C$>RJMB\@E@JIFQPV4%@H%`H%`H%`H%`H%`H%`H*]S!MTZXZ0N$2$
MTK[Q<(RC"N!/--/`X\PGA=:`@P7?C0:]O.DN85QO[EWA-N$HG*)F:LXVP?M\
MB3$?;BLLJ0%'<6+'<8(LH8$6;-M54#Z70NN"E-NO,.2&1DPWXHOR0==8C1M0
MM7(8QN&X1&3<1G*[email protected]>-BT;S,>NC"7Q)[,`912718N[J#_A76T'
M,#_$(>\(TYVDPWKE3%0H+!;M.:Z9T"5MD.R';PW<8SL=[O1"^<1J0R;G&-7G
M!S&T#B$`N*!XXY1S*(@T3I?6%L<NZ3SFJQ-A.(TDBX.2C25WN60<,G'7%:7N
MSK`YA)-H[=J8J%7B<O\`F=%MD8`DW%;D$1MJ0\5V>,2>*R/QGR'.^N&-R5AT
M5P3!!Q3#<H9DG0NNC;E&U'=;FNR'9;,MN4#;HN%IIFU`7$%Q#0^]LJ6*+XNW
MP4'Q?-&\UIC$U8DJ9&GN*X:2&[B0-.1G&F4CQA;%Q.$ZPZ)*1B@HJ(7:+B$E
M!G6JQ:ZL]]B39W>I&GX17`9,=Z2<U2ANRIST9`!'3=-X67HS60Q<0\$VBK8J
M07O0EMN-KT58K=<MD^'`CL214^(HFVT(J"G\O+AAFZ=]!.T"@4"@4"@4"@4"
M@4"@4%'Y@P=0NW2#)M"Y7TM=XAVYY4508NTIMA8#Y["041&G@SEL[>7Y5!2P
MT;S*1V^.6^/<+8U<UDOVX#NB./L7`H%NCQ),IY'S5]EMV(_F`E/L*GT:XX"'
MLYI7F''FRI,*U/"\;MP5'VY+#*D$V\QY>8.'(`^U&;-5#.&/BYTQQH/"-I#F
MN]99)OO7:/?&H\./&4KFIL.$TTJ2")MN8VGTKC08N9A<1"4DQ7,)!9]=VC7<
MQR&EH"=@5I=CS5ASD8%)A2H;C1BI/1R4@:9D"KB#C@2)TJB!\/V'6[FC+9;5
M^L>],WYQR5EN"A+6S]^><;`Y8OB9JD,FP7Z3-C]V@KMKTUS7CC;`>;NCK;:Q
M3N8R+DV_Q5&#-9DC@<H\1-YR,2#XO94MB[P_86D>9L1N&-KBOVR8$:)&<DK)
MCJPBLV*1"0G6@>+BBU.<8<1%!=@JJ>$/*[:3YMNFAV\KJQ%1AXF(97?,Z$ON
M<=`5QU9&)MK)`U02,DWXHB%EH)AJU:X64Y'N0OJY*OT"?97'7E>=8CLSCD3Q
M/AN/--M)$Q9`DX:$AH"ABF)AM>@4"@4"@4"@JO\`-/\`8?Z70.4_\+-&_J.V
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MA),1)-J*BU4K?M`H*MS#U3/TY;;=*AB!++N46`]G8>E$C<DU`B;98(7#,=Z"
MF..Z@K%PYH7^T*U,ND9D;"ZR8R+F49^,<.0](D,P7)4=UPC%ASNZ"YBHJ!$F
M*HBKE#,MNJ]>RK]9;616K-=;4Y>25&)`H+3,B(V32%QB[1MRR)%RX"2(G:3;
M0;$H%`H%`H%`H%`H%`H*OJ?F=H73)FS=KLT$L/&A,YGY"8[LS32&0X]98)4Z
MZ[6[0G6EK=H:XO'VH+6VI#9K$_)PV(Y,>",F/6@M))54^%4KIKPKSWZ.BO#M
M/?HJTS[2^NW%5(D*V1P7Y[3[II\!<8!Q^$:MC@QZRMCA1ZRPO^XKF5\Z!_TQ
M?\VI?Z-?>4O]*OO+(C?:3YAM*B/1[8^&.*JL=\3^#$7T'\FO)X,>DO)X4>ZQ
MVK[42XH-XT\J`GC/0I"$2_`RZ`(GQNU5;@V])56X5O25_P!.<[N7-\(&0N:6
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M!4;IJG7MEN45YIR7<H<9)\F\6>6W![_W&,41KB,K#!`)T>\D^`_+#L89MM!Y
M,736LYW2W<=8/N1M5=\.+)2)!R@TS#5Y@\JQ\2S.#B6[LKAL7M4&WJ!0*"J_
MS3_8?Z70.4_\+-&_J.V_F;=!:J!0*!05S6W,#36C8"2KQ(5'7<>ZP640Y#ZC
MO1L,4V)TD2H*=*I4J4FTXA*E)M.(<YZWYXZSU*9L1'BL=J5508L,U1XQ_P!]
M(3*?^2&5.A<V^M'5PXCK;JT-?$B/MU:[1$3'!,,555\*KM5:[(B([.N(P_:]
M>E`H%`H%!8M)<P=7Z3=!;+<#;B"6)6Y[%V(?2J*TJIDQZ2;42\-<^SC5M\2Y
M]G&K;XET3RWYV6'5Z)"EMK:[R)"TK#BYF'G"3'*P]@B*6&WAE@?4BIMK-VZ9
MI+,VT\+8EL>J4%4O=VY>7EV3;;G<H[CVGS&X2FAE$R<8XZ['25HP+Z(B3';V
M55,=N%!BVR)RN=)R/&DL2UU$P33K#\MZ3WMIPG5[0/N'GS*#N5<,<$)$V(M!
M,6>U:3ER(5]M*A)*%&=M<*8P^XXV+#;B`ZRF!JV6#L=$)515Q'?LH)>'-AS6
M$D0W@D,*1@CK9(0J39JV:8IL[)BJ+X:#VH%`H%`H%`H%!6=<<Q-,Z,@H_=GU
M*2ZB]UM[&!R7L/F@JBB"G29*@IUXX5.FN;3B$Z4FTXASGK7G;K74Q&PR^MEM
M2XHD*$9(X8K_`&TCLF7P#E'H5%K1U<.L=;=9:&OB1'VZM?"(BF`HB)U)LKKB
M,.J(P_:]>E`H%`H%!9=(<QM8:2=#ZGGFD(53-;7\78BBB[D:54X>/6VHKUUS
M[.+6WQ+GV<:MOB71?+?G-8-8MC&>!;9>4+AE%<7,RXX@YE&._@(FN7;D7`\-
MN&&VLS;IFD]69LIX6PV%52"'OUXTPT;5CO$YAAV\HL5F(X[PG'N*BAE'!1),
M_BBJ*F);$VX4$$]:N6ED%N7(ECQQXP$_<))#$)`0F6<IO$@Y@,5R8=H<,
M45,*#);@<N[JX5H8*.;KDL;T4-AXV366"M2$D96R`LPDXTX2=9"2IBN-!-6W
M4NGKI.F0+=<HTR;;R09T9AT''&555'!P155'M"J?"BIT4$E0*!0*!0*!0*"&
MU5J_3^E;85QO<L8S&.5H-I.NGACD:;3M&7P;MZX)MKVM9F<0]K69G$.=];_:
M`U9?#<BV-2L5K7LH3:HLUQ.LWDV-?`UM3YZUHZN'$=;._5PX[V:O)2(S<-5)
MQQ<SCA*JD1+O4B7:J^%:[:UB(Q#MK6(Z0_*]>E`H%`H%!,Z8UEJ?2\GCV*X.
MPT5<SL9%SQW%Z>(R6+:JOSL,W4J53LX];]X4[-%;=W0?+CGU:M1&-NOK"6JZ
MIE3O`YEA.$:Y13B+CP2-?%!Q=NY")=E9F[CVI\PS-VK]N<9;6JA4KD^\Z,O5
MWD:0N#+=RD-J/>H<B*3\87$;20`&9@3'$X9"X@JN."HM!'6B?RJ9D6NYV>+`
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M+E\N-?2/LW,UR_;@LC:6Q:;C`V)F*@XH+Q301P5157%(E55-,>E<:JC;7Q[=
M&+:)F<S/5;]):UFVBZ,Z;U`^LF,YE;@7<U+$75_^O((\%+M=@'>DDREVL%+@
MW:,1Y5^JVE_240N@[[^^>IY#]B63IBZA_?+8W+%"D/%+1UN1#>,FG&"R!Q'F
M^*`Y\,,?&KE6/:V\N=8L/Q8TQU9@NR[/-=NKCZ&\PW:9#CRQGC+Z1XE:X;:&
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M\0%7Y76OR?AV57:W?X</*Y<4_37[?V;?CZ`;CLE:F$:9C,&C(`X+H(IHB.JJ
MYA4DPQ1<Y;R5%\-0_=KX]NC&F)F<YZK=HC7TN+<@TY?WE?;,N%:[NYBA&OR&
M9*E\H_\`9N+XWBEV\%/@W\?Q_5';^RVE\])97,'2VH+AJJP7:P,<&?#D,"Y<
MU<%6.[(KI/M2HQHN=!$D5D@3,ADO:#'%>58KK'*_5$6'>X-U!N^_6,QN9`N-
MN)RU269PPN$MP-PI;I(JNJJ$(8[R)!450$"1LVC];6C7,S4"M+<.(TX+K2OM
MA$>(H\1H76!+%QF29QBXRJ.0APPVT%BTU;+RFK[E=+A9F[>QW<8%M=;?;)!B
M,.J;8(RV/C.$X1FJE@/9%$7:2A<:!0*!0*!0*"I<Q^8MIT19DER4[Q<).8+;
M`%<"><1-JDN"Y&PQ13+HW)BJHBSUZYO.(3UZYO.(<G:EU/?-379R[7J2LB8:
M911,1::#?PV055R`G5O7>JJNVMC5IBD=&MJU12.B+JU:4"@4"@4"@4&99[1,
MN\SNL7LH&"R'U3$6A7I7K)?DCT_!MJ,SZ0Y>3RHUQ_\`3<MLY>M6J!'@,J*M
MOLK(?(Q(U/-E%5,LN#AD1H&`XHF[8E5UV1$2P[S:TYF>JU::U9+TC*:M%ZD]
MYL1((LR^V2PR)?$4S3,;"8IC_9;O$\3BW:(F/*O_`(3K?TE(Z@Y;76\Z[<O#
M,H;1;I4<HUPF6YP@ES(Y1B:%A]HP-DB!TN(#RXJ@H@(.U5KB6EOY;WV!$T]%
M&<W,"T:EGWUXWU%I>[RRFH#30L,`.?+.SEBB)GS(.`Y<H2NGK3KB->IUTN;5
MKXUP=:"0XR](<-(C/$X33>=IH1X6=51-N8C,L1V#036FK,_;(\TI1B[.N$V3
M-DNAC@O%/*R&U$5>%'!IO'\&@EZ!057^:?[#_2Z!RG_A9HW]1VW\S;H+50*"
M%UEJJ!I73<V]S>T$4/HF47`G7B[+;0^$R5$\&_<E2K6;3B$JUF9Q#C6^WNYW
MV\2[Q='>-.F'Q'2^2*;A`$Z``<!%.KPUM:M<4KB&QKUQ2,0P:L6%`H%`H%`H
M%!*6#3LN]/XBJLP&RPD2>E<-X-8[RZUW#\.RHSF>D.#E\R*?IK]O[-FPHL6$
MPU'CM($=E$06DQ1,-Z[=^WI7?4XC$=&',S,YEEW'6L*S]W===2(RP#@QH^<C
M,E-5)<!'M.925%RX8;-O355J1Z]Y64K:TXK"BZQYFW+4!&U&CC"BF*B9.8.N
M$A(@E@)9FP'`41$[6SJ6HTUXC'HTM7\?GK>?Z-V\A^8[NI;(=ENCRN7RT`**
MZ:XG)B^*#RX[5,%[#B[=N!+XU9G(T^%OA'?J\+?#:=4*"@4"@4"@4"@4$#KG
M5\#26F9=[EIQ."B!&CHN!//GL;;3X5WKT#BO14J5FTXA*E9M.(<;W>[W&\W2
M5=;D\K\^:XKLAW<F*[$$4Z!$4013H1*VM>N*1B&SKUQ2,0PZL3*!0*!0*!0*
M"6T]IN5>7T-<6K:V2H_(381J.]MKP_.+HW;]T>L](9_+YGA^FOV_LV?;V84(
M6F0CCW5E,HL"J@F&&"8*GW:ECIB&)G,YEDS-?QK))&9*=$%0&@8BJI&I`P@B
MB<,>T>(#E)<-B*NZJKZZXQ*W76UI_3&6O-4\P[E>W71CM=TC.#D4W%1U\A1,
M-JKF`57I\;P85[%.F/1I:?X_UO+??(WF.[JJP';KF[GOUI00?<)>U(8+8V_^
M-LRN?A;=F9$K*WZO"V/17OU>%OALRJ%)0*!0*!0*!0*#"O=XM]EM,N[7!SA0
MH31//GABN44QP%$VD2[A1-Z[*]B,O8C+C36.K;IJS4$F]7%<IO=B/&1<188%
M5X;(_BXXDO22JO36SHTQ2N/5KZ=7A7Y0M7+B@4"@4"@4"@SK+9Y=XF]VCX@T
MW@LF2J8BVB[D3K->A/C7PQF>N(<G*Y4:XQ_DV;;+7"MD08L-M&VA7%5WD1+O
M(EWJ2]=2BN&!>\VG,]TG/U9`M34=UTAAPV'''`9)PE4R=04,$P[1(J-IV43&
MJYK'K/=*L3,XB%-U9S9N5Y1MJ"PD<`3`I;W:,URB"D+2XB..3-VL=JKB.VHT
MICMT:.K@3;K?HV5]GCF,[.BKHZZNYY4)KB6E\MYQ@P0F%W)F9Q3)A\C9AV*S
M^5H\)S':4N1H\)Z=F[*Y7,4"@4"@JO\`-/\`8?Z70.4_\+-&_J.V_F;=!:J!
M0<Y?:4U6<S4$+3+!_P!VM@)*EBFY93XJC:%X6V5Q3_B5W\+7WL[N'K[V::K1
M:!0*!0*!0*!02^G--/WMQ3(B9MK9977QV$X2+@3;:_>(NC<FW='OTAG\OF>'
MZ:_;^R^RKA9+%":;=<"*P`Y6&!3$E0>@&QQ(O#@E2S%6/6EKSTZRJ-VU[<9.
M9NVM]R979QW$$WE^`>T`?'F^*HYF?AI:?X[UO/\`1634C=)YPB<>/QW7"4S+
M#K(L56O8B(:=-=:QB(P5ZFGM"ZI=TMJRW7P2468[J#-1/E17.R^BITX`N9$^
M<B51R=?E25'(U^5)=J(J*B*BXHNU%3=A6,R"@4"@4"@4"@4'-7VD-5.3]5Q]
M.M&O=+,[email protected]<@$),4_`8(<J_AE6APM?>SOX>OO9J*M!WE`H%`H%`H%!,Z
M;TP]>SXSA$U;`+`W1V$ZJ+M!M>A.@CZ-R;=HQ^W;LSN9S/']->Z]S;I9;'%;
M;><".V(Y6(P)B2B.S`&QQ)43X*E,Q#(I2UYZ1F50NVN[E*S-V\.XL+LXI93?
M5/R@#\KX4J/6?AIZ?X[UO/\`16B4B<)PR(W37%QTU4C)?PB+%5^.O8B(:5*5
MK&(C!7J:R<N]6'I76-NO"GDB"XC%QZ$6(\J"[C^)L<1.L4KGY6ORI^'/R=?E
M3\.SJQV24"@4"@4"@4"@T7]IK51ML6S2K!X=X_O]P1-BJV!*$<5ZQ)P3+X02
MNSAZ\VS[.OB:\VS[-`UJ-,H%`H%`H%`H)"R6*=>97#8^BBMDB2I:IB@)OR`B
M^,:I\2;UZ$6,S,](<7*Y<:XQ'V;%0K-8+:#9&$2(WL',NTB7:OX1F6_I5:ET
MK##_`%7M[S*J7;F!+>S-6EKN[>[O;Z(KBIU@UN'P*?QC4<S/PT-/\=,];]%6
M=-UY]9$APWY!;">=52/#J15W)X$V4BL0U=>FM(Q6'Y4EC,LMXFV2\0KQ!7"9
M;WAD,ICAF45[0*OS7!Q`O`JU7MU^=9A7MIY5F';EJN42Z6R'<X99XDYAN3&/
M=BV\"&"_&)5AL5E4"@4"@JO\T_V'^ET#E/\`PLT;^H[;^9MT%JH%!Q7KVYG=
M-<7^>2YN+/D`!8XXM,N*RUYIL:V>-7%(:_'KBD(&KUY0*!0*!0*#,MD2"YA+
MNK_=;6*JB*F/%DD/C-L".)DB?+(4\";<5&N;.#D\F<^&OK9*SM:S%8&'9HXV
MR$V*`V:B).H*;$0`3,VW^5\5>QGTZ0HT_P`=,];RKQ*1NDZX9.O'X[KA*9EA
MUD6*K4HB(:=-=:QB(P5ZF4"@4'8_*FYG<N7.GI+A*;HPVX[KB[R.-BP1+X2)
MO&L+97%IAAWKBTPM=01*!0*!0*!0*#B/5US.Z:KO-Q)<>]SI#C>.U4;5TD:3
M'\%M!2MKCUQ2&QHKBD(FKEQ0*!0*!0*#.M4*WO!WV[/=WM2*J`**O%E$.\61
M'MJ*?*(?BZ52N;1/X9_)Y,S/AKZV25PUM/=:&+:61MD(!0&UP$GLJ)@B"*8M
MMI_G?%7O6?B%.G^.];RKRHJN&Z9$X\YM<=,E,R7\(BQ)?CJ45B&G376L8B,/
MVO4R@4'XJ(2*BIBB[%1:#M#EQ=7+KH*P3G24WW8+`R#7'%7FP1MU=O68K6#>
M,3,,.T8F86.HHE`H%`H%`H%!R)SJN9W#F=>S4E)J*;41C''8++0H:;>CBJ:_
M'6MPZXIGW:G$KBGY4BNIU%`H%`H%`H,JWP&YF9V3)&%;FBROS"PQ4M_"91?&
M<5.I%PZMR+"UO1Q<GD^/Z:];IR1K((L0(&GXJ18K290D/)B6'20MKMQ7'',X
MN..\:1GM'1R:OX^UIS>5<?>?DOK(DNG(D+L5UQ<Q8=2=`IX!P2I17#3UZ:TC
M%8?%>K2@4"@ZMY`W,IO+.`T:XN0'7XA+^"+JFVG@RM."E8O(KB\L??7%Y;%J
ME24"@4%5_FG^P_TN@<I_X6:-_4=M_,VZ"U4"@X6N2HMQEX;?IG/O&M;FGZ1^
M(;6KZ1^&-5BPH%`H%`H/*0T;K>07%:153,0HBJJ=28XX8U&T9A&U<QAZ9>UF
M55(\$',2JJY1V".*]"="=%>Q6([/*:ZTC$0_:]3*!0*!0*#K+D&)CRHLJ'L7
M/-5,>I9SZI]ZL7?]Y8V_[RV!5*HH%`H%`H%`H.#B5%)53:BKBBUNZ_K'X;>O
MZQ^'Y4TR@4"@4"@\I#).@@(XK:8HI**(JJB=':14V].RHVKF,(VKF,/3#$E,
ME4C5$13)5(E1-R8KBN"=%>Q6(>4UUK&(C#]KU,H%`H%`H.M^1A(O*RQJBX[)
M*?<EO)6)N^\_EB[OO/Y7NJE90*!0*!0*!0<6\P3SZ\U&N*KA<YB;?P7S3_RK
M9XO_`%PU^-_UPK]7KR@4"@4"@^'FS<:(`-6R+9G'#%$Z<,>FO)C,/)C,/QID
M&P`452X8Y`4EQ5!WJB8[D5=N"=->5I$=D*:JU[0]*DL*!0*!0*#IG[-"I^X<
MWP7-['R#%9'+_P"R63ROO+;-<SG*!0*"J_S3_8?Z70.4_P#"S1OZCMOYFW06
MJ@4'!SKF:?<!7:3<R0*_&Z1)^225M<?Z0V-'TA^5<N*!0*!0*!0*!0*!0*!0
M?A$(BI$N`BF*KX$H.LN0)D?*+3YGXQA((OA*6ZM86S[2Q-GVEL&H(%`H%`H%
M`H%!P-#<S`X*KVFW7`7P(A+E_)5*V]'TALZ?K#WJU:4"@4"@4"@4"@4"@4"@
M^7#%MLG"7`012)?`FVO)G#R9PZR^S_F7E#IY3\=0D*7PK*=5:P]GVEB[/M+8
M500*!0*!0*!0*#B37#G_`/1-6M+O"[RR1/P2=+_61:U^)]&KQ?HB*Z724"@4
M"@4"@4"@4"@4"@4'2/V6W.)R]GN8XH=WDJ*_@\)E!_)1*QN1]Y8_(^\MPU0I
M*!0*"J_S3_8?Z70.4_\`"S1OZCMOYFW06J@4'!NHF5MFN[[!-,K8W&7'1,<4
M16I!H&"KMP(>OP5K:+?IC\-71/Z8_!74Z2@4"@E8^E[Y)MXSF(W$9,4<`!(5
M=)M7DC\06L<ZAQEX>;#QJA.R(G"$WB)PR"T3J%),B.+3#CD5$623<J*;8$2&
MJ-JZ+BMJYE:)<B%FP3=7G[M7G[D(JX09$"<_"DH@R8QDT\(D)HA@N!)F%5%<
M%V;%J<3F,IQ.8RQZ]>E`H%`H%!@W9Y$82.GC/["3\!/&^[XOQU"\^B%_9V/R
M/ANQ.5&G&W-[D99`_B2'3>#\EQ*QMLYM/Y8^V<VG\KS5:!0*!0*!0*!0<"SV
M5MFJKK;C1`1N9(C$*+L%V.Z;:IMZT'#XDK7T3TCYAK:9Z1\PR*Z704"@4$X&
MBM2&D;)%15DJ`B*NM"H*ZSWEOC9B3A(3"*XBG@F5%7H6J_W:J_W*OV+HG4,H
MU2.TPZ".*TCPRHW#(@R(?#/B97!!710B!51,=])VU@G9$(-4P54WX=-6+'Y0
M*!0*!0*#`N[V#0QD\9Y>WX`'QON^+5=Y]$+^SM#D[#=B<K]--NCE,X+;^7J1
M_%X<?#@:5C;)S:?RQ]DYM/Y7&H(%`H%`H%`H%!Q/S?;<MO-[4(NI@+DI"<7H
MRR6P>;+9U<1/NK6GQK8K#2XT_IA"UVNPH%`H)*+IV[RK<=Q890HP(ZJ=L4,A
M802>(&U7.0MHX*DJ)_0N$9O$3A&;Q$X9AZ'U&,PH2LLK*;!#>:23&7A9C1L0
M=)',K;A&2"C9*AX]%1_=KC*/[M<915QMTJW3#ARD$9#:"K@B0FB9A0D3,"D.
M.!;=NRIUG,9A.)S&6-7KTH%`H%`H,6Y2%9C*@+@Z[V&^M%7>O^2FVH7GHC>>
MCJ;[,L%8W*N,[E00F2Y+P8=*`?=]OQLK61R/O+)Y'WEM:J5)0*!057^:?[#_
M`$N@<I_X6:-_4=M_,VZ"U4"@X\^T?IHK5S+F24%1BWIIJ<R2;D-!1IU$7YW$
M;SK^,E:'%MFN&AQ;9KA1;?-XX*VXJ=X;1,Z;L4Z"3P+7;2V>D]W76WI/=EU-
M,H%!;+1K,(EA&UOJZIKECA+:;:%V+$[RDIQ&',<YF;HXIF44';U[*;:\SE3;
M7F<LH.8K[5U;E*;TQIF.TV1OH"/27V1-L'W2Q<)LA;>(<1)55$02Q15KS]GH
M\_9Z('5-XAW6ZE*B,)'8P5!%&P:Q13(TQ!OLIE0T!-JK@*8K5FNLQ'592LQ'
M5#U-,H%`H%!\/O-LM$ZXN`"F*_\`HB=*K7DSB'DSA&6^#<+U=H\.,&:?<7FX
MT5O>B$X>1L5PZ$4L27X>BJ+VQ$VE3:V(FTN_K3;8UJM4*V14RQH+#49@>IMD
M$`?O#6.R&50*!0*!0*!0*#C3[0NFCL_,ZY$@J$:["W<8I#T*XF5U<?G<=LR^
M-*T>+;-,>S1XULTQ[*=;YG>&U$\$?;P1P=V/42>!:[*VS^776V?RRJFD4"@N
M@:[1RW18CDB5%E`K3TB[Q&VVY.>)'*-%;'*;:F#;;A(I$>8L=R=-'[77/_I1
M^UURR(7,H&[M/ERHZN19;I\&-D:)&P?1>,9>)G4R$5)O'(>)8X+@M>3HZ1#R
M=/2%-NDMN9/=D-MHV!JF`H@BJY10<RH"".8L,Q8)O6KZQB%]8Q#%KUZ4"@4"
M@\WWVV&B=<7`1^-57H1$ZUKR9P\F<,&SVN??[[$MS"?WVZ/M1F43:@<0D`?\
MD,V8E^%:Y[V\:S:5%[>-9M+OZ#"CP84>%&')'BM`RR'4#8H(I\2)60R7M0*!
M0*!0*!0*#EK[56FBBZN@7P6_[K=XO!>+>BOQEP7-^,T8(GXJUW<2W>KMXEN]
M6H[9,4T[NZN+H)V"7Y8)T_"G3]VNZD^DNZL^DL^K$R@4%HL&[email protected]<
M%]B,O#;_`+LW,$0DN-N*N=2-L<J!L%%VX]%57UYG*J^O,Y9;NOW4GPW./(GL
MPXY,D]-%LGI*@XX]'%[$G,!;(T'%#S9<<%3%$2/[/1Y^UT16L+_"O5P21$C\
M!OM$N8`$\37'*JAX^5$\<ES$68EPQP2>NDUCJEKI-8ZH&K%A0*!0*#Y<<!L"
M<<)!`4Q(EV(B)7DSAY,X0KKSLJ1Q$`E5>PPTB8E@J]7SB7H^!*JF?65<SZR[
MOT#IU=-Z+LUD)$1Z%%;"3@J*BODF=Y4PZW2):QK3F<L>TYG*?KQX4"@4%5_F
MG^P_TN@<I_X6:-_4=M_,VZ"U4"@UIS[Y=N:PT<KT!M7+W9E*3``?&=`D1'V$
M\)B*$/60BFZK=.SPME;IV>-LN.$4D(76RRN#M`_AZ%3I1>E*U>_6&IWZPE85
MP!_Z,TX<A$VAT+X17I2IUMGI/=*MO2>[+J:90*!0*!0*!0*#RD268[>=TL$W
M"F]57J1.FO)M$/)M$(>0\[)=1QU,HC_5-8XH/X2]9?T?TU=YS*OO.9;Q^S%R
M]*X7EW64YK^Y6M29MB%N<E$.#CF"[T:`L$_"+K&N+E[/\8<?*V?XPZ>KB<10
M*!0*!0*!0*#5GVA.7;NJ](I<+>RKM[L>=^,V.TG6"1.\,HG26`H8IO51P3QJ
MNT;/"WPNT[/&WPY`$B0A>9)!<%,6W-Z8+T+UHM:DQGK#3F,]82T.>W([!)PW
MT3M-KT^$5Z4J=;9_*=;9_+*J:10*!0*!0*!0*#RDRF8X9W5PQV"*;2)>I$KR
MUHAY-L(9]UV2ZCKNQ!_JFMZ#X?"2]?\`X6KO.95XS.9;Z^R_R^.5<7M;3F\(
ML//&M"$GCODF5YX?`V"JVG0JD72-</+VYGQAQ<K9F?&'2U<;C*!0*!0*!0*!
M04SFYH,=:Z*EVII!2Y,JDJUN%L09+2+E%5Z$<%2;5>A"QJ>N_C;*>N_C.7$<
MF,^R\XP^!QY4<R!P"3*XVZVJB0JB[B%45%1?@K6B8M&8:T3%HS#/A7%'51E_
M`']PK\D_Q?#X*LK?TE*+>DLZIIE`H%`H%`H%`H/AYYIEM7'20`3I7^A.M:\F
M8CN\F<(>3+=E%M3(P*X@VN]53Y1?^2?^$KF<H=VTOL[\O2U+K`+S,:S6:P&#
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MC3#(]")M555=JD2XJ1+M5=J[:S)G+,F<LZO`H%`H%`H%`H%`H.6^?W)E^R39
M.K;`QFL<DE=N41M/\(Z2]MP43_8FNU?F+^#AE[>-O_QEV\??_C+2)`)88[T7
M$538J+UHJ;4KNF,NV8RRF+G(:[+R<8.@QP0T^%-B+]ZD6F/DB9CY2$>9&D?U
M3B$2;P782?"*X*E3BT2E%HE[5)(H%`H%!\//LLCF=<%L>A25$Q7J2O)F([O)
MF([H]^[&79BM[/[5Q%1/B#82_'A4)O,]D/*9[,+`B-7'"5QU=BF6_#J3#8B>
M!*\B"(77E;RQN^O+ZD9A"8L\4A6ZW'<C8KMX;:JBH3QIN3H\9>A%Y]^_PC$=
MU&_?XQB.[M*T6FW6>V1;7;6!C0(;8LQV`W"`I@FU=JKUJNU5VK68S&70*!0*
M!0*!0*!0*#G[[0W)J1-<=UGIN,KLE!S7N`TF)N("?XEH43M&@I](*;TVIMQS
M=7'W^/2>SIX^_P`>D]G-JH#@=!`6U.E%Z4K1[M'NR6)\IC`2^G:ZE7Z1/@)=
MA?']VD3,?)F8^4@Q/BOJ@B>#B_[,NR7W%W_%4XO$I1:)9%22*!0*!0?+CC;8
M*;AH`)O(E1$^ZM>3.'DSA@O7<-T8%<7^T+$0^_M7^CPU";^R/G[,`U<=<XCQ
M\1Q-RKL0?Q4Z/Z:CCUEYCUE8=#:&ONM+ZW:+0WVMARY9HO"CM8X*XXJ?DCO)
M?C5*]NV*1\J]NV*1\NU=&Z1M&DM.Q+%:@5(\8>VZ6'$==+:;KBIO(U^YN38B
M)65:TS.995K3,YE-UX\*!0*!057^:?[#_2Z!RG_A9HW]1VW\S;H+50*!0?A"
M)"HDB$))@0KM146@YZYL_9N)UQZ]Z&:%"-5.38<1`<5VJ40EP$?^$6SYJI@@
MKU:>3->D]G5IY,UZ3V<\RHLJ'*=B2V'(TI@E!^.\!-N`2;Q,"1"%?A2M"MHF
M,P[ZVB8S#Q(`/#,*%AM3&O9C+V8R^P>DM_U;[@IU*J'_`*:%]ZF/DQ\O8;C.
M38I-EX5!<?O%7N;&9?7UK+_LV_NK3RE[F7XMSFKNX8^!1(O]8:>4O,R\CDS'
M/&?)$7>((@I]W#-]^O.ON8GW>*-@A9_&-=BF2J1?YRXK7D5@BL/I51$Q78B;
MUJ3UM#ECR%U-J\V9]Q%RSZ>+`^].#@^^*[<([9=!)N<),O2B%7)MY41TKW<F
MWDQ'2KJ[36FK+IJS1[/9HPQ8$9,`!-I$J^,9DNTC)=I$N^L^9F>LN"9F>LI.
MO'A0*!0*!0*!0*!0*#Y<;;=;)MP4-LT43`D11453!45%WHM!SKS7^S<\+CUZ
MT,WG`E5R18<4'+CM58I*J)A_NE_R5W#77IY..ENSKT\G'2W9S](CR(TAV-):
M./)8)0?8=$FW`--XF!(A"J=2I7?6T3&8=U;1,9AXD`'AF%%PW8]%>S$2]F(E
MZ`]);V-OFB=2JA_Z:%3'R8^7L-QG)O5M4_$+'_2KW-C,OKZUE_V;?W5IY2]S
M+\6YS5W<(?`HD7^LE,V>9EY')F.>,^2)TB"(*?=1,WWZ\Z^YB?=XHV"$IX8F
MN\R52)?A)<5KR*Q!%8A]*J(BJJX(F]5KUZVKRQY`:DU6;5PO`N6;3ZX%Q'!R
MRI`]3+9)V17^T-,/FH5<FWE1'2KCV\J(Z5=5Z?T_9]/6B/:+1&&)`BCE::'[
MY$2[2(EVD2[57?7!,Y<,SE(UX\*!0*!0*!0*!0*!0*#1_-S[.\6^.R+]I%`B
M7AQ5<EVTE0(\DUVJ3:[FG2Z?D$N_*JJ2]&GD37I/9T:>1->D]G-%TM5SM,]V
MW72*["G,+@[&?%0-.I<%WBO02;%Z*T:7BT9AH4O%HS#$(`-,IBA#U*F*5*8R
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M#E/_``LT;^H[;^9MT&=?]8VFQW:R6R:I(_?)!1HY"G8!1'83B]"$Z;;0]9&-
M!B6[74>9J=RP=R=:>;?F,(^1`H*L)N,X18(N/;&:.'P+C08+G-&W-JLPX+Z:
M>&YK95O.9M0[TCW=E/A(6?@=X^AXF_-\G+VJ#[LW-C1UTN21`FM1FWX<:?;G
MY)BSWEB4VZ[F`#RD.0(YJ6;#<J[DH)6-KO1DJ;&@Q[W#=G3",(T07@5XR:7`
MT1O'-V5W[*#&UGRVT;K%C)?+>#L@1RLSV_HY3:=&5T>UACMREB/6E2K>:SF$
MJWFO6&BM6?95OT4G']+W)JXQTVA#F_02$3YJ."BM.+X51M*ZZ<S_`)0ZZ<O_
M`)0U9>^7&OK&2I==/SHXCL)X6E>91?\`C,\1K\JNFO(I/JZ*[Z3ZJWF',H8I
MG%<"'I14Z%2K8M$K8F)?M>O7X1"*8DJ(G6NRO,O,I.SZ:U'>B0;/:Y=PQP[4
M5AQT4QZ2(!413PJM5VW4CO*%MM8[RV/IG[-',6ZF!W06+%%5>T4@Q>?RKTBR
MPI"OP&X*U1?EQ':%%^7'HWAH;D)H/2I-RCCK>+J&!)-G()H!)TLLHG##;N7!
M23YU<FS=:W=R7W6MW;(JI44"@4"@4"@4"@4%6N>OH%OUW:]*.M;;DR9+-4Q0
M6Y"H1QV%%=JJ\W'?+'HRBGRTH,;2>O9=ZN*19<%J('=9,DG0>)W`HL]V&0X$
MVWV<&LV;P[DH(1_G,<#3MKU;=;5P],7H)#L)R.ZKTL`9BO3&5=94`'Z9B,:]
MD^PN"*J[20)"!SCTPLFXL7=3M91'52,KC4A1>:X48TP-6A'C9IH"K(JIILH)
MC3_,32VH9P0;2](DODPDDU[I*!IMLB,!XCIMBV!*31B@J6*J*]5!YZTY8Z*U
MBW_^W;@.6*96K@S]%)!$W(CH[2%/FEB/@J5+S6<PE6\UG,-%:K^RMJ.(3CVF
M;BS<XZ8J$67_`'>3AT"AHBLF7A7AI773F?\`*'73E^\-6WOEYKNQJ276P3HP
MCXSW!)QE/_F:SM?E5TUWTGU=%=])]5=SCF4<4S"JH0X[45-Z+5L3$K8F)?M>
MO7X1B*8DJ"G6JX5Y,O)E*6C3&I+RHI:+3,N"'A@<:.ZZ&"]*F`J*)X56J[;J
M1WE"VZL=Y;(TQ]F;F%=5!RZJQ88I>,KY(_(PZQ9951W=!."M47Y<>D.>_+CT
MAO+0O(G0>DC;EC'6ZW8,"&?.07%`DVXLMHB-MX+N5$S?A+7)LW6MW<E]MK=V
MQ*J5E`H%`H%`H%`H%!0_:O%>@ZD?AP5-_3TIEG@O.<-)$9\Q:"6T2`?T9&CJ
M!\[)O3&@R)/,4HNFY-T=@"4Y+P=B@0`?[+\I9O<6,7C`<@F6!FN1<HX^-AM#
M!N7-UFSW>98+O;";OS*(4-B*;DF,\VY$D2FC)]&0)I%[DZ!XMKEPS;1Q5`S(
MG.+09VZ)*G7%(#\@FV7(K[,@#;>-MAQ4(3:`D;09C2\540,"1<<*"PZ=U/9M
M10W)EI<==BMN$RKKL>1'0C'#-DX[;6=$QPS#BF.*8XHM!XZJT5I?5<'N5_MS
M4UI,>$X2*+K2KO5IT<K@+^*M>UM,=8>UM,=8:*U;]E*:V9OZ3NH/M+BJ0;CV
M#3IP%]H5$NI$)M/"5==.7,=W73ES'=J>^\K>8MC,DN.GIH@*KB^PVLEK#YRN
M1^*`I^,J5TUY%)]717D4GU58^PX31]ET5P(%V$B^%%VU;%HGLMBT3V*DD_%5
M$3%5P3K6O!G6NRWJ[&@6FWR;B1;AB,N/KOP7^K$JA.VL=Y5SMK'>6P]-?9RY
MEWE1.7%:LL5=[LYQ.(H]8LM<0\?`>2J+\NL=NJFW+K';JW5HK[.&A+`K<FZ"
M6H+B&"YY8HD82ZPC)B*__(IUR;-]K?AR;-]K-K"(B*"*((BF`BFQ$1*I4OV@
M4"@4"@4"@JO\T_V'^ET#E/\`PLT;^H[;^9MT&+JOES&U*_=3ESU!^6Q%:MS@
M!])`6,ZKPNM=M$(U>[>)#O$=Z#0?=IT#+A:I2_O707S5V6^ZP,?AH13&8[))
MFXAX9>YMJFSYW6F`?*\LX:Y87?G?W>&ZK>_JG*/^*5_O63BXX\#O7TV3+CFV
M9LO9H*_["F';4W:)=\>D6X(D6WY>`V#O=8D.3!`.()89E:FGB67>B>'$+%I?
MEZ=BO#-S6XC),(ST9UL8C$43)\F2)Q!CHV(K_=@^2NU2V[400N-`H%!BS+5:
MYO\`C8;$K=_7-@YNW>,BT$9^X.A?5RU_]%'_`/97N9>YEE0M+Z:@JBPK3"BJ
MFY68[3?3C\D4Z:\>).@4"@4"@4"@4"@4"@4"@IMYT1HZ7<%;N$OAWJXSF[I$
M?5Q@)J.PT;0$C$H9^&VC08BF.SQL<RXAE:6TKIZW25N-KG.3.&V_%(E=:=;3
MC22ENHO#%,"XKJKOV)LH(0>7_+B=;F[8MR[Y9<DN#:;9WMHF(Q3&3:?&,H(C
MBFC+Y""&9Y!+`<J4'U(Y2:+FO=T?GRWYL<RE_P");20VZX#`#([`"0D*PFB!
M=R$./70633^F+?:I\V9'FR9DN2#4>8<ET7BQ94W!S8"BB6,@BPW8$B(B"@H@
M3M`H%!B3+1:IO^-A,2MW]<T#F[=XR+01G[@Z$]7+7_T4?_V5[F7N99D/3.FX
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MX897FQ<3#?\`*1:"++0>AR)2+3ML(B55(EAQU557>J]BO<R]R]XFDM*PUS0[
M-!C+BJXLQF07%4P7Q13HKQXE41$1$1,$38B)NPH%`H%`H%`H%`H%`H*K_-/]
MA_I=`Y3_`,+-&_J.V_F;=!0HT::'-O58C$GRX<^UD;TEQJ2R]%(#D-`TT;:9
M'V7N&I-92S;41$[)X!C+"U(@6,RASOK5NW:5&SN&R_@P3$PEO(FF3%L^[?UR
M'M,<J)BM!.:FLL+5KZ7+3[K\%)MHEW%;V8R@P<?C)#B-Y%4#$4;)UPVQ1%$A
M$L,RXT%-<LVMDCW9]RVR(0SPENZ'M\87S9@S%?B@R28MLDPKAMD^/$`%%LG,
M<.VE!<+W<=2RN8\*X0F79-M;*!'MT&3"E<(FW9CK-TDH1<,67X[8"8DX/B89
M=AKB&UJ!0*!0*!0*!0*!0*!0*!0*!0*!0*#4O,C25WN?,FR7&VVM]U"8;A7*
M<2-N15A#(XA$*YD<8DQN*XZT2)VRP'`MN4/C2EGNVGX5QB7J#+F0[ZPU:;>U
M;F1BR.[6VW.`DA]OO)<%U\`X8*!8[`Q0,<HA%O<LM6.6UB#;G'&P><.#'2;'
M:XK%K[ZQ*"2X\TXRC<EM65R8"9'V,XBHD2!-\O;7KRP=\B/1Y3Y2P<*5(E#%
M-I+N\^\12D-LFGG(Q-HVI8YB1,HCM0T$)_E=I[4%B9O\>\`&,FYE*9D(X3I/
MJY&9%UXE40\=P%7<FW'!$3"@N]`H%`H%`H%`H%`H%`H%`H%`H%`H%!SR&B=3
MK<]4,VZURK?"D7EB>W=)##4B9#D$<5]XFQ$E&?&QSX-Y5RHF]2540)J9;-13
MM+Z6L(PY]N<TRRR=R;B,LR0[SW!Q8)(T^D@71!\$SMDF+9$"KL3.@3K>C+\[
M<W;G%M<*W7Y+4PS*FCA&X\RXO(]=B&0T#[F8`8$635"RD:]";0Q(=@>=Y80-
M'WZSW*)ERJ2VL`D@WA(><90D='`T!604A)I4[0>'`-C:5CW&-I>SQKF#;=R8
MA1FYS;`@#0O@T(NBV#?8$4-%P0=B)NH)2@4"@4"@4"@4"@4"@4"@4"@4"@JO
M\T_V'^ET#E/_``LT;^H[;^9MT%JH%!^``-@+;8H``B"`"F"(B;$1$2@_:!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"J_S3_8?Z70:WT%[=_W&T[]3
M?5'U/]60OJWO&;C=V[N'!XN79GX>&;#IH)[WCO0?G*![QWH/SE`]X[T'YR@>
M\=Z#\Y0/>.]!^<H'O'>@_.4#WCO0?G*![QWH/SE`]X[T'YR@>\=Z#\Y0/>.]
M!^<H'O'>@_.4#WCO0?G*![QWH/SE`]X[T'YR@>\=Z#\Y0/>.]!^<H'O'>@_.
M4#WCO0?G*![QWH/SE`]X[T'YR@>\=Z#\Y0/>.]!^<H'O'>@_.4#WCO0?G*![
MQWH/SE`]X[T'YR@>\=Z#\Y0/>.]!^<H'O'>@_.4#WCO0?G*![QWH/SE`]X[T
M'YR@>\=Z#\Y0/>.]!^<H'O'>@_.4#WCO0?G*![QWH/SE`]X[T'YR@>\=Z#\Y
M0/>.]!^<H'O'>@_.4#WCO0?G*![QWH/SE`]X[T'YR@>\=Z#\Y0/>.]!^<H'O
M'>@_.4#WCO0?G*![QWH/SE`]X[T'YR@>\=Z#\Y0/>.]!^<H'O'>@_.4#WCO0
M?G*![QWH/SE`]X[T'YR@>\=Z#\Y0/>.]!^<H'O'>@_.4#WCO0?G*![QWH/SE
M`]X[T'YR@>\=Z#\Y0/>.]!^<H'O'>@_.4#WCO0?G*![QWH/SE`]X[T'YR@>\
E=Z#\Y00X^V[][W,WU5^\/U>'"PS=W[EQCSX_*XG%R8>#&@__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>a62430fy06pi.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a62430fy06pi.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@`Z0#Z`P$1``(1`0,1`?_$`+0``0`"`P$!`0``````
M```````$!@,%!P(!"`$!``(#`0````````````````($`0,%!A```0,#`@(#
M"`T)!@4$`P$``@$#!``1!1(&(1,Q(@=!4124=196%V%QL=$R0M+4%56U-C>!
MD:%28B,SE0ARDD-STR2"HK)3L\&C5#5C-"4F$0$``@(!`P($!0,#!0``````
M`0(1`P0A,1)!42(R$P5A<8&1,['!4O#A0M'Q(R05_]H`#`,!``(1`Q$`/P#L
M4K%Y/<7:1N#'%N#*8N#BX.,<C1\<\VR"G*65S2/6VXJJO)&AAL?5B_Z9;D\<
M8^;T#U8O^F6Y/'&/F]`]6+_IEN3QQCYO0/5B_P"F6Y/'&/F]`]6+_IEN3QQC
MYO0/5B_Z9;D\<8^;T#U8O^F6Y/'&/F]`]6+_`*9;D\<8^;T#U8O^F6Y/'&/F
M]`]6+_IEN3QQCYO0/5B_Z9;D\<8^;T#U8O\`IEN3QQCYO0/5B_Z9;D\<8^;T
M#U8O^F6Y/'&/F]`]6+_IEN3QQCYO0/5B_P"F6Y/'&/F]`]6+_IEN3QQCYO0/
M5B_Z9;D\<8^;T#U8O^F6Y/'&/F]`]6+_`*9;D\<8^;T#U8O^F6Y/'&/F]`]6
M+_IEN3QQCYO0/5B_Z9;D\<8^;T#U8O\`IEN3QQCYO0/5B_Z9;D\<8^;T#U8O
M^F6Y/'&/F]`]6+_IEN3QQCYO0/5B_P"F6Y/'&/F]`]6+_IEN3QQCYO0:+>>V
M<KMC%1LO"W9G9#S>2QK*L2I++C)MR)S++@F*,BJHH.*G30=3TIWJ,8A2MO\`
MXL;Q\G87W9M&5UH%`H%`H%`H%`H%`H.3%D<W&E;LR[R/OQXF8:AQ75R4L4$2
M>AARAAAI:$41PEU(5UZ%2RK036>U').Y,L6\YC<>ZDV0PY/?(CA-@T@DRRCX
M.:'9#X%JMJ#3I)%&Z)<(&0[0YF8W*WB&"0(D/,0%:D,J33A!X:[&>9?#F&7P
MFK]9`U)\6UE4)&Z,YN/;VXLHH279>,QPQLLQ')Q475E'B@\M\B4$\%BDV[(T
MJ2)Q%+H@7H/2]K.69E86,_%BJ_/<0)33;C9HK3KSK+$AAQM]P21>3J-L>9HZ
M"(>"J&QG;M4NS''[@W+/^B)&3:CO,-XQU&3-V2WK9BMN2$+K+JZQ+9.%UL*+
M057);QWM%;UL91)^XHS,,(F-C(VY&G,N8Y7I4P!$;N"DA#L8K9-"#\:RACG;
MUW#':<BP,TDO`*]K'<$E\&5<5N"W(<A-R0:<$3<=-=-@NG$$XI:@[+BY93,9
M$F$RY'*2RV\L=[@XVK@(6@_VAO9:"30*!0*!0*!0*!04KM?^Y[7E;#_:D>@N
MM!2MO_BQO'R=A?=FT%UH%`H%`H%`H%`H%`H,'A<#4P'.:U2[K&'4-W=(ZE4/
MUK"E^%!CD3,2PZ,60\PTZXHD+!D`D2F:`*H*].IQ4%/9H)/+;NJZ4NJW5;)T
MT'PC8YJ-$0\UP55`54U$(JB$MNE434E_;H/J,M(@H@"B#P%$1.">Q08)<C&L
MHTU,<9;1PD%EMU1342D+8H*%TJI&(\.ZJ)W:#["DXZ4T+L)UE]I!'0;)"0Z#
M%#&RC?@0JA)[%!FY;>G3I33>^FR6O>]_ST`'&W!U`2&**HJHJBI<5LJ<.\J6
MH/5`H%`H%`H%`H%!2NU_[GM>5L/]J1Z"ZT%*V_\`BQO'R=A?=FT%UH%`H%`H
M%`H%`H%!`W!%ER\#DHL-=,M^*^U'*]K.&V0@M^YUEH.=S=J[WEY!B;CQ.*$=
MM\L;S)'+".P]#;::C#'LO+=`D,5<MPOJX]"!Z<V9O-_(M3S;0A:=9.&Q+D\Y
MUIIF<U(%IU[K$?!LRO=;(J#=;4&2#MKM&=BE](SIC"ML3^0W%EHKB.OK&\'1
M5,U1SEVD:=;G!%3BBVL&RR.#WQ,@89!<\%EM0U8R2L23U(X4R$9:'34W%7P=
ME]+ZEXK:ZWO0><IMW?$C;\*%'G/MRX[N34W@E$#I-J$E,;K=3K'I4F%+5WNM
M?C009.S]ZNY&`CCY28$6<S(_W$CF&C8N8Q\^)7);.QY2BE^%T1."I8(<'9_:
M)`Q#4-EP@!N&U'89C2T85J6&/BL-OF:)UVFGFGM3?'5=%TET4$V;MOM&1B43
M4^0[(?\`"C40E:05P9PN0Q$5-M6FBC:A-&S$K<+JJ4%MVG#FQPR9RF?!UDSC
M>;9155$_<M-N$-^.DWFW#15XJBZN[0;V@4"@4"@4"@4"@I7:_P#<]KRMA_M2
M/076@I6W_P`6-X^3L+[LV@NM`H%`H%`H%`H%`H%`H*[G]QS8&XL/B(S0$.1;
MD.NO$V^ZHI'<8#2@LB6G5X1?6=A2U!4F.US*2\7S&<:Q'R;<.?D'XS[AJ"L1
M$`V#;4112%]LUZWQ2$AXVH.B8A^;(QD9^:C:2701PT9U<M-7%$35QZ*"70*!
M0*!0*!0*!0*!0*!0*"E=K_W/:\K8?[4CT%UH*5M_\6-X^3L+[LV@NM`H%`H%
M!7=VY+)1IF#A0I804R4MUF1),!<T@W#?D)9#5!XDRE_8H*E'[7CBXV3,R#(R
MG(X@2M,*H(ZR".J[)CI9Q5$@;%Q$-41$).M09@[5)&.1QC(PUF2'\AD(N.<8
M-"U)&R110!X&P(FD$3"Q6)2LO=Z0S.]JDYB4ZT_@W!4_`QA1=9>$J[)C.R3!
MX!;/1I&.2#:]UMT=P+)MO=:9F;/AN0SQ\B%RC2-(6SY-/(NAT@0=""J@J)I,
MN**BV5+4&_H/#[[+#+C[YBTRT*FZX:H(B(I<B)5X(B)05IS);.S,C$9$S>\+
M<1T,80I+CNJ"FUS4(`T%RU(6KZTT]%!";;[+'6F7`6(0-`6`8-"._+R!#_MD
M6]R%XA32O1^JO306AW)8G'R<?BW7VV),W6UCHI+UW.0VKAH"=*Z&QNM!-H%`
MH%`H%`H%`H%`H%`H%!2NU_[GM>5L/]J1Z"ZT%*V_^+&\?)V%]V;076@4"@4"
M@C3L9C<@V+4^(S+:`M8`^V+HH5E34B&BV6RJE!5W\_MB5!R<]S!E+@8I\V7I
M'(CFA>""0.N(ADA(C*@8=9$6W0FE:#-](;9*2_%7`FDC(QEF$R4-M"F`!-D:
M+?X1-G('4CEN*^W0>)V:V4FW6<S(Q@/8U]1BF*Q6R)OD.$VC1ME95Y3HDB`.
MI;_!1:"SQL?`BN.N18S3#CZZGS:`04R3H4U%$U+[=!GH,4ME'XKS"B!HZ!`H
M.CK;74BI8QX:A[Z4%'@=GF5"%CV)$UEIR))5X'6>>;L5CF-GX'$><<UHR:-:
M21S4EELB6040(L+;<6+D@VL_DT+*I$Q,B(@QR`%QV"F"0W53)"=(CL=EX:A6
MUJ#>R]D/3-TX_<3V2<&5!D$?(;$>4L=&GVFVA0]9`7^X17"0K%;H3AI"U4"@
M4"@4"@4"@4"@4"@4"@I7:_\`<]KRMA_M2/076@I6W_Q8WCY.PONS:"ZT"@4"
M@4"@JI;`B/9')S9DMQU<F]&)]IMMID28B'S09=0!_>W-50C+K*%@Z+W#-*V?
M)?GY2<&:E,2,DRD9MP`8UQ6DMU8QJVJ@G!56][JM^X-@@YS:L*+M1V)-R,E,
M)"CISX\:,R9<IH2OR0;9-U#LOP@ZR*EQXT%DPF=PV<QK62P\QJ?`>2[<A@D,
M5MTHMN@D[J+Q3NT$Z@4"@YUVG9C$8;,[6W,<YAI[$Y!(D]LG00_`,FB1WE4;
MZE1MWDNKWD&@L#O:3L=JU\LT=^A6T-S_`*!*L91F]?=A'M3V$1**98;BNDKM
M/I9;7XW#ATU.M+3&8@\H]TYC?FS'RTAFH:%:^EQT6UM[1J-)K,=X9S#<1Y<6
M2WS(SP/M_KMDAI^<56HLLM`H%`H%`H-"]O7#-M2'Q"2]&CNC'\):8<)IQ\GQ
MBHTT5K&7.-`X<+WX\%H([?:+MEPP03?Y1`T;TA6'4:8Y[SD<$?)1_=KS63!=
M70J<;4&6/O\`VL^<0&I:DY.R$C$QPY9H2RXNOFBJ*G5%.4O67@MTMTI06&@4
M%*[7_N>UY6P_VI'H+K04K;_XL;Q\G87W9M!=:!0*!0*!0*!0*"FYOLY9+(NY
MW:LPMN;B=75(D,`AQ):IW)L15$'?[::7$[A4&L'M<:PDSZ%WS"^BL[U4CG$+
MPB#,U+I%6'ETJT1+_AR-"]Y2Z:C:T1&99BLSV3)&[-PSG'&HB1\6+=D<0E25
M*'4EQU"BBTVJIQ^/7-V_<HCY8_=?U\&9^:54WK%GGC$G/9"9+2,XARVW'B1L
MF"ZIKR6N6UU+H?P>A%K5Q^=>U\6[2QS>'$:IFGS0HNYX3:;;R;,;'K*-V.8>
M#1D`'2U):XJMNL/PD[O#A74CN\WKM\49E$[/=R93<.VV\ED&!C/*X3"`*DJE
MR40#,M5K*3B%P[E+1AG=2*VQ#;1E7GS./^.O_C"NUP/X_P!6VGRPSKQ2R\4[
MRU=98PCLMN(ZT/)=3H=:56C_`+P:2_34+:ZV[Q"46F&]QN]=W8Y41C)G(:3_
M``)J>$"OL:U47O\`GJM?A4GMT3C;*XX;M=A'I;SD0H)="RV+OL>V2(B.A_=5
M/9JGLXEZ_BVUV1*^0YL.;&"3#?;DQW$NV\T2&!)[!#=*JMC-0*`JHB75;)T<
M?9X4%2+8;A8<\`Y.%S!>$M26(Q,+S@%N8$Q62=1Q$(.HH)U$5$7I54XA$8[-
M'&6G(0Y2^*D1XT*5'Y"<TXT1]]UML7>98=3<CEFNA55$O=%6@\0>RJ+$R+$_
MZ0-QYAYF2(JVB`CP/*X^XB:N!/MHVV7>T7[M!>Z!04KM?^Y[7E;#_:D>@NM!
M2MO_`(L;Q\G87W9M!=:!0*!0*!0*!08I4J-$C.RI3H,1F14WGG"00`12ZD1+
MP1$H."[]_J&>>E^`;4!4Q[9VDY$[@Z^"+UA8NB\I"3H<5-7>1.FK%>+:U9ZX
MGT7]/!M:,VZ?@W^VYVU=R;?<6$PV_#D7#(0I`HX?,5.L,E#U*9+^L2KJZ46O
M*<FFW7L^//E[_P#1T*5KX^.,?@K79WV69K9^Y,EDRSPS\?E!TO8]6##0K:_N
M.69.N\&@ZB)^K4N1RJ[*Q&,3#5IX\TMG/271'6FGFC9=%#:<%0<!>A1)+*B^
MVE4XG"U,9<PEF]B6)4=T"?>QIHSI2^HP54Y1\$)>+9B1+;OUZ/3L\ZQ;W>,Y
M7'^GMFOHBMYV$!(&@0$A1WF`2*VI'I)5141+HNOX5N*HO=K;AI^G+-%(2=ED
M*H0D_<23BBHK065*[7`_C_5NKVA(JZR4"@4$G%93*8>4LK$R2B/$NIT$34R[
M;_NM<!+^TEB[RUHV\>M^_=.MYAU?9_:#`SI#!E`D',(*KX,I7;>0?A$P:VU=
M]17K)[7&N5MTVI/59K>)6RM*2I=I<*5+P+7@;+DN5&E-/,P0;YK3[B(2-MR0
M0VR1I3)%UHO4)!/H&@BQ!R6-W=D)Q094F'/4&W72`2<!]PV6@".0N=:.+8F9
MJ0)IMP55*U!62P6[)'/D0H$^$U)5_P"C<:;NE(,R\<8TEPN:NH5!MPW+*J(I
M*-EO=0L6,@96.]N%@H<U8.25U&9Z"T,T77?"''+?O5$FF[@+):46ZV5+)=`W
M6Q(F0B8`8\V-X,K;K@QA5-+IL(7[MQX$)Q!<)/A(A>SPZ$"PT%*[7_N>UY6P
M_P!J1Z"ZT%*V_P#BQO'R=A?=FT%IRN8Q^*8!^:XH"ZX++(`!NN..G?2`-MH1
MD2V7@B4'M[)0V6">,UT@*&0")$XB$J(G[L44^[WJ#(4J*(D1/`@@J":J2(B*
MO0B\:#7.[IPK3$]]QTA;QTD84FS9D2OF+9"``*$1J7."VE*#8PY<:;$8F17$
M=C26Q>8=3H)MP4(22_?1:#+0*#%+EQH<5V5*=%B,P!.//&J"(`*7(B5>A$2@
M_+':MVKSMX3CA0C*/MM@_P!PQQ$I!"O!YY/^@.YTKQZ.AHT8ZSW=CB<3Q^*W
M?^CGU6G0;+;^XLK@,B.0QKFAU.JZT5U;="]]#@ITI[/2G<JKR^'3?7QM^D^S
M7>F>L=W;HV\DW%M9^7@%5K)AR@DQE3F/1T-P1=-`1.OI;U$"HG&W?X5X_;Q)
MT[/'9V_JU7O.)B.EF("W4+(2FU=5D1-KDESE(F@<4>?I/4XBF*H:(JZ[71*Q
M_P"/M/\`;_7]FJ//NQ[HBON#CLNZV<1R:V$:<V!*)-N<3974G'X6H/RI5C@[
M(BTT_9SONVF9I&S'6.[3+BX*Q@C(W9EM$%L4544;$AHJ+TZM27O73R\_YRP0
MFVVBDM-B@MMNH`"G0@BTVB)^:NWP/X_U6*STA*JZR4"@4"@\F"%;BHD)(8&*
MJ)@8K<3`DXB0KT*E1M6+1B68G"X8OM9S\Y6]H8N.W-WHX*(U->5!B-1]*JLJ
M6@JA:Q1/X0<7.E-(WT\;?I\+8CLM4MF%_P!G[0C;<BOJLE[)9;(&C^6RTE;O
M27D32A*B=5L!3JMMCU1'@G?K0FW]`H%`H%!2NU_[GM>5L/\`:D>@NM!2MO\`
MXL;Q\G87W9M!O]TX4LSB'(`A'-3(23PH'#$5%;H8*T;1B8KQ$A)%2@HD?LKS
M$E_(^'36PO*UQYY-(<N4/@L=E3?<$T301,D6BR=:R]SB$J1V2/+&E,QL@RT,
MX2":"QKB]JDRI&HE0T+4GA8HA(M^K:]EM02Y'9FZ_MF3A7IXR`E2V)4A'0-&
MWA8BLQU;=T."YQ-A'4(22Q6Z;+<+-M;$3\1A6H,^<[email protected]#EZ]9J2?NT
M4A!!%4%!'@EN%!MJ!0?G_P#J&[0C?E>9V.=M'8TN9@P7X;BV)MA;=P4L9>S9
M.XM6^+JS/E+H\#C^4^<]H<2J^ZY0*"9A\QD</D6LCCGE9E-="](D*](&/QA+
MNI_ZUHY/&INKXV0O3R_-W[96^,;NB$I-VCY)A$\+A*MU'N:P7XS:KW>YT+7B
M^;PKZ+8GMZ2A6WI/=N,OC6\EC),$UT\\%0'/U#3K`:?V31"JMKO-+1:/1C;K
MB]9K/JH$9UQUD2='EO(J@^W^JZ"J+@_D)%KT<3$QF'B-FN:6FL^B+&_CS/\`
M/7_QA7<X'\?ZM]/EA(JZR4"@4"@T<[+3)TMS%8,D1YI=.0R:IK:B_L`B\''^
M\/0/27>73:\S/C7]9]O]TXC'66PQ>+CXJ.VWCR-E]MQ)`S%76^LA%OSS-?AG
M?IOW.'1PK,Z:^/B><YR[WLO<H;AP;<PA1N8TJL3V1Z`?!$U6O\4D5#'V%2N+
MLI-;3$K43F,M[4&2@4"@4%*[7_N>UY6P_P!J1Z"ZT%*V_P#BQO'R=A?=FT$O
MM"Q68R</$L8EUV/);R;#RR6;_ND:!PA)Q$5-3?,04,>ZBVH*GAIG:>@XZ"W"
MD8TY+DXIQO@$AEHI+TUQLQ)1(K,N(RB7.Q`26'NH&3Z:WZDH,ODH[F*AS`82
M2J--$_#:5U\5:!#4A<-5!LBNBJ@FJHG"@UD?<7:IFL$+D<)K:2,<XXDIMED#
M)T.4XTZQ8-(JZ.L-"D7'N#U54-VW,[06,Q-;CQGQBG.;+'?[=M6Y(&X"2"EF
MO6906>L"CINM^FVF@F8?=66P,))V^IO@L!V#!=*7*:!@6ISY/"]'_=):PH`+
MUNB_3W@G9+M7V(S@)^5Q^=QV0*&P;H1V)3+AF8CU`TB2E<BLG168C+,1F</R
M-/G/R9$C(3W=3\EPGI+YK9%<=*Y%=>^15UZQ%:X]'HZUKKK$>D,=2;$@,=D#
M8!\(SIL.FC3;H@2B1JMD%%1.*JO<K&81\H>BQ>3!30HCPJ!BT=VR2SA6TBO#
MI6Z6IY0>4>Z+T<*RDD8_(3L=-:G07BCRV%U-/!TIWT5%X*B]U%X+6K=HKMKX
MVC,(7I%G>=A]H$+<T;D/(,;,LC=^*B]4T3I<9OTCWTZ1_37C.?\`;[:+>]?2
M4*VF)Q/=$W'"\"SQF*68R8\\.\C[:(+J?\0Z2_O59X&WRIX_XO/?>>/XVB\>
MK11OX\S_`#U_\85ZK@?Q_JY]/EA(JZR4"@\NNMM-&ZX2"VV*F9+T((I=5_-6
M)G#*HXK=!;TBHF#<<@XX;#DIA620)*E^0P/&Q*G2ZO!$^#QZ*U=L[8^'I'JG
M-?'NM,&##@1&H<-H6(S*6;;'H3NJJJO%55>*JO%:L5K$1B$)G+/4F%G[-<PN
M.W4$8BM&RP*P:=Q'VD5QDORCK#\U<_G:^D6;]-O1V6N:WE`H%`H*5VO_`'/:
M\K8?[4CT%UH*5M_\6-X^3L+[LV@W&]<KE\7@7)F+:YCK9AX0[RU?Y#%_WKW(
M$@)W0GQ!*]N*7M:@PQ-QS']QMPFRC2L8]#\+\(9UB3&OEHQS2)5%?"-1J`I9
M;#W:"K;G[1IF-P.3<F0X4]QB2K4)Y1<2$\+`"<A5U:^+)*K:67K'P2UBL&]V
MWOQK-;JR^'C`T$2!'9<@FJD+KI$Z\RZI`J(@@A,IH[JIUNA4H-ML_,S<Q@&9
M\UMIN43LEET&-2MWCR'&+CJZUEY=^-!N:#C']2<'`,;2B"N-B+.FS0!)!,-*
MZ@-@3I:345)+J(WXUNX]<WZK7#UQ;9$3V?F>=@,?*B.QQ#P?FHB*;=TM947X
M**@K^6KU]%9C$='4V<2EHQ'1+@PVH45N,TIDVVED5PE(OSK6RE(K&(;M6N*5
MQ"T8//8W$Q&N6+YRW'=4]-(:":%"$!:+5<5#7KNH\2MT(E1M691OKFTI,;>C
M4<P91A78+##,1GF""NZ`$!<->*C<E:%4'H]FL3KRC.G/YJ[D'HS\UYV,UR6#
M*X-61+<$1>"<$NO&R<$Z*VQ'1OK$Q'5'HRR1I,B+(:DQG28DL$ALO-K8@).A
M46H;-=;UFMHS$HVK%HQ+K6*WNUNW!E`DH+6YH%I44$ZH2E91=?*[Q&VI"0>S
M=.'1Y;=PK<7;%HZZY_UU4.7IG9KFD]_1AA.-NG*=;74VX\A`7?$FFU1:]/P/
MX_U>9K'2$FKK(B*JHB)=56R(G2JK0;@]M2@TZCNO*$R%!ZW-(R!&1U**$5VU
M[M:?K0GX(>4VUS<>\T\B2HKS2B^VET0A)%UCP6^G3W>]6?.+=),3'5IL9A</
MBFR;QD)B&!VUHP`AJMT:E1+KT]VI5I6O:,(S,RFU-@H/GA+D0VIK?\2&ZW)"
MW3=DT<_3IM6K?7-)C\$Z3B8?HU%0D14XHO%%KA+90*!0*"E=K_W/:\K8?[4C
MT%UH*5M_\6-X^3L+[[email protected]^,R\(X.2CA*B&J*31]%Q6Z+PXT$1S:.V7)12
MRQD=)3CC;KCP@@F9LJ*MJ:C;5I5L;7[R=Z@RP]M;>A07<?$QL9B`^FEZ*VT`
MM$EK64$33:@DNXW'/21E.Q6G)(J"B\0"IHK6M6[$J7ZG-/3WM2]^@R1HL:*T
MC,9H&6D(B1ML4$=1DIDMD[I$2JOLT&6@X;_5`Z:1-NM(G4)V49+[(BVB?]2U
M:XGS?HO_`&[YY_)P2N@[)0*!0*!0+\4'XQ<!'NJOL)29B.[%K1$9GHL>+V)O
M-]GZ2:@NP(L>SOTC*58H!I7JF*G9Q5O\'0*JJ]%5]NVDQ,3UA0W?<-,=/F_)
M8-J)E(Z9/'9:R9*%,-'D2R=5P4(."(EK6452W!4J7`M6=>([.#R*XMGTEOJO
M*XBJBW3@J="T$L,OD@T(CY+RQ00U6*UB4Q5-2+Q0B547I2H?3JEY2QMSI3;9
M-@XJ`0J))9.A;W_+UEX]/&LS6&,L%28*!01\BML=+7O,._\`0M1MVEF'Z*Q)
MF>*A&?PR8:4K]]02]>?74J@4"@4%*[7_`+GM>5L/]J1Z"ZT%*V_^+&\?)V%]
MV;076@4"@4"@4'`_ZISTN[2[Q'/'V/@,JGN58XTXNN<&<;'#JZ3N%`K(R1(L
MJ8^D>&RY)D%P1ED"</\`N@BK4+7B.\M>S=2GS3$+MA>Q??F3TF]%;Q;*_P")
M-/2=O\H-9_GM6FW(CT<_;]VUU^7-E]PO]/VWX^D\Q/?R!]UIE$C-?G13<7^\
ME:;;[3^#G;?NNVW;X5[QNVMH[;C&_!@1<<TR*F[*TIK01Z5)T]1_IK5,^ZA?
M9:\]9RE8R#(RDMK+Y-LFHC!<S%X]Q%0A7_Y,@5_Q+?PP7X"<?A_!Y7*Y/E\-
M>RYIT^,9GN_.V,RZO;LE3#6PY9^0I?VG72=;][\M=SA?!B/P=#[AQ_\`UZ6_
MQ_NMU=1P2@4"@4"@4&IW9+\%VSDWD51)([@`J<%U.)H&WY2J&SY9A*O=^F,5
M_P#5P_\`(;_Z$K@+B50*!0*"E=K_`-SVO*V'^U(]!=:"E;?_`!8WCY.PONS:
M"ZT"@4"@4"@X#_5HT:8_:\L>EF3)!%]DVP)$_P#;J5)Q.6_1.+=''L+@LYG%
M'Z'Q\B=J[K+9$*?VCX`-O96NG]:N,Y=>_-U5C,ROV%[!-V2])Y23'Q;2](7\
M(>M_9!1!/[]:K<GVA0V_>*Q\D9_-?L)V&[(@*)S`?RSR?_)/2W?_`"FM"?WE
M6M-MMI]7.V_<-U_7'Y+UC\7C\:PC&/B-0V$X<MAL6Q_*@HEZ@IS.>[/1AY==
M:::-UTQ;:;%3<<-401$4NI*J]"(E!KL?#=SDAK(S6U;Q#)(YC8+B65XDXA*?
M%4NB)TM-KT?"+K60>7RN3GX:]E[1IQUGNG;NR'T=M;,3[V*/#?,5_:Y:Z?\`
MFM5/77-HA9QGH_)HHXTV'*6SK.DFE_;;LH_I2O2=GHMVF+ZYI^#I$62W*BLR
M6_X;X"X/M$E[?DKJUMF,O$3&)PRU)@H%`H%`H*1VDY%#89P[9==W]Z_["<1;
M1?;557\E9I&9F?2L3+92'Z]@M*U"CM+TMM@*_D%$KSD+3-0*!0*"E=K_`-SV
MO*V'^U(]!=:"E;?_`!8WCY.PONS:"ZT"@4"@4"@Y5_4MA#R/9D]+;2YXF2S,
M7O\`+NK+GYA=U?DK,-FJ<6A1.P/=@P,3#P,US3#G$9P#)>#<DG"U-+?H1WI'
M]KA\:MD*6_K>7;T156R)=>]4FEK=R09,O#OQVB<!Q5;-!`=2N(VX)DTHZFE4
M7$'05C3@J\:Q+,3U5`-L;MCQXLA)!E(4267&'K\I@GD5(K:DY8T!M;H*KTBO
M6XI6,)^4+Q"=EKCF'<B@,RN4)RT%?W8'IN?67A9*DURA0XQ[A=;ER!4<`T2'
M#CDBHLPQ6XON)_V!7BV"_#^$O#2E<WE<G_C5=T:<=96:N<M*+VU3O!NSV:W?
MK378\9/:)U#+_D;6K/#KG9#=QZ^6RL?B_.E=YZ);-GRM>/<BDO6BN+I3_P#&
MYUQ_,6I*O<:V:X]GDON>GPW3[6ZM]5ESB@4"@4$3*9.-C(+LV2MFVTX"G29+
M\$!]DEK$RS$94'9T*5NGM"Q+$A-;DZ<VY(1.*(TTO,-$O\46VU2MG)CZ7'GW
MG^LMU8ZOVK7FF\H%`H%!2NU_[GM>5L/]J1Z"ZT%*V_\`BQO'R=A?=FT%UH%`
MH%`H%!%RV,B97%R\9,#F1)K+D=\.^#@J)?H6@_)[6WI>`!W;T]+RL:XY'=7B
MFI$-2;<3N]<"$T7V:VQV4MTSYS*U0.T/([QQ1[%:<#Z0F:HA[H==-IEL1XIH
M5I0-V8-N`@2"2I=5Z1IE*(QUG]EV[(=@Y+9FV7(>8GGDLS*D./2Y1N&ZF@54
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MT)7(;"@4"@4%*[7_`+GM>5L/]J1Z"ZT%*V_^+&\?)V%]V;076@4"@4"@4&OS
M^>QF!Q+^5R;JM0XZ)K(0-PU4R0```!",B(B01%$NJT'%>T/9&\-[L/;LD8TL
M/!8;$!P"*OTE-BBJES)9-JHMD*+<6`N2C="*]AK,2A>N8Z=U`:9B^#`TR`)%
M041L`1$!!Z4THG16U1S.5[VIVH3\:(0LXCD^"-A;FCUI32=YQ/\`&%._\/\`
MM42B8E?L?*B;Q0EA/"[MEDE;E.@O&8Z/2PB<"!H%X.71%->K\&]Z7*Y/C\,=
MUK1I]98^U'M+QW9UMM,Q*QTJ<"DC+#44+-"?0"/._`9%>A._W$KGZM4WG"W:
M<,NR,7C,CMC'YLHI1G\WCVGGHR.FX#`RK27&65+H'F&JTV7F)Q[$0W^-PF-Q
MKLEV&TK92BU.IJ543K&>D$7X(ZW3*R=TEJ%K3/=*(<:[;,E$+?N)CRA5V'CX
M[3DIH;747GU(Q]M6VDKJ?;Z_#,NE]OK,Q:8[]F@7<V&&6J/"DAEU$*23:.:%
M+F6`6P=2^EMO22(MD0KZ>FKWC*U]&V%7RYQ_#C=QY*J)H<`^M;G"B$2BI]?3
MS$X:N-3C,-FS5-]<UGUC_LO<62W*BLR6_@/@+@^PA)>WY*ZM;9C+Q4QB<2RU
M)@H--G-UXO$H0&7A$M.B*VJ:D7]M>@$]OC[%(S:<5ZRE%7.,SG,AEY'.EGU1
M_@L#P;;3]E._WR7C5S5HBO6>MO\`79-L-C[,RN[]PL8?'BHH2H<N5:XL,(O6
M<+W!3NK4.9RHTTS_`,I[)5KE^S<#A,=@L/$Q&-;Y4*$VC3(=*V3I(E[I$O%5
M[]>5M:9G,]V]/K`4"@4"@I7:_P#<]KRMA_M2/076@I6W_P`6-X^3L+[LV@];
MXS&X<;GL.]C%-V$Q%GS,ICP!"60RR48%0%LJHZV+Q.-HB]94T]V@K.&[4=S)
MAVR=@!(6'C8LB2^^8@^[KCL.G*Y2*AJT2O$G5;L*I>_2B!LC[3,PZ\9Q8L4<
M:!D"SW5=5L0+)2(+3Y:41.4C<='"6_QDZ!ZU!`9[1<\$Z5*=%N.S):C\MR7S
MO`FU;"4NMNR(?^[Y(JW?N=];(H9)':?FGW4CE!&"XZ*FN/4C&?'Y,F&W^^N*
MAI=&41)9/@I[=@E2^U*?'QD.;R8[LF4]^]Q8(?-8;$P!QATR(422'-^"@<;+
M8;(I4%IV%)F2MH8Q^<Z;\HVU5UUVZF2H9)=;^U0;^@X_VD]E3X//YS;C*N@Z
M2N3L6VER0EXD['3V>DF^[TCQX+*MFC;JSUCNY4!B:(0K=%]U."I[:5L5)AZP
M4V?CE&9CI3L*7J-%>8+2I(CA<#%;@:>P:+5#;&9G+HZ_EAO8_:=.SFY(8[DA
MAD\+MTS(PCB+?A$]QO2)NM.*K;G@S1EP11365_BUJ^E$1TZ3+9Y.KX7M'V`[
M'9BQYK>,!H1;9B2@6*("*6$14D1JR)T:2JM;5;\TXM"TQI464VCD5YN0VO0;
M1BXGYQ5:US$PEE^:.U*=X;V@YMQ%N++P1A]IAH`7_GU5W.'7&N':^WUQKS[R
MHFX7LNQBW'\4B'+;45Y1#KUBJV5$3O\`&]6+9QT;>5:]:9IWA[Q$YZ0P+4RS
M>3;2\J.@Z=*JO!115+4/[2+:LUGW[L\?;-HQ;YX[PN6VLYCHV.=C3)33"Q7%
MT(X:(O+<ZR62]^!*25>XVR/''L\U]RT^.Z<=IZD_M!PC"*D9')AIT:4T!_>.
MR_F2K=:7MVC]^BCXJME=[9N>BM@:0V%X*VQ="5/9<7K?FM5BO%_RG+,1$-!_
MZ\5JU6L1&(9;S9^S,_N[+AC,.QS#X+(D'=&6`7X[I=SV$Z5[E5N5RZZ8Z]_9
M*M<OUQV?=G^%V5A4Q\!.;)=L<^<:6<?<1+77]44^*/<]NZKYC=NMLMY6[MT1
MA9ZU,E`H%`H%!2NU_P"Y[7E;#_:D>@NM!2MO_BQO'R=A?=FT%UH-'N/<WT-,
MQ$;D":923X.K[KB,LM]6]N8J$G,-?X8+;5Q1%O08RWC%9@[AF2XKL=O;SQLO
MC<#)U!CMR!-O2JIUQ>1$0E]NU!$9W^SX7%BRX#D4W),J'.<)QL@C/18RR[$J
M+<Q-E-2$*>W00L7NC;<J#(W;$A*<UYUF'';)U"?+PPV@CBHD2C'1XC`E3O65
M;T%IP67:R^,;F@T3"J;K+S!V4FWH[I,N@JC=%TN-DETZ:"?0*!04;>W91A]P
M..9""28W,GQ-\1NR\7<Y[:6NO[8V+V^BLQ.$+ZXLX+N_#[BV9%2-DX?*G2'5
M8QKJ+KC//.FJBHN\.`HNHD)$*R+PK1>N;9]$ZQB,,&,Q[>/@M1&R4^6ES=+X
M3CA+J-PO9,E5:U3.64GN6[B]-8'@6&1/6`(V?ZX=0N/LC9:SD<UR\N6F7F6D
M.]60Y:[AK\=>FZ\?RU=US\,+VF]HK&)E&+(3R'24ERWL$J?I2U3S+;]2WO/[
MHTH"E(*O.&1MHJ-NZE4QOTV5;]/=3NUB6NT>7=]@/DRZ02D1-6E`D(E@);JB
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M<3ITHT*61%3K(A=-!\9V;@&FV`5DGE8>>DZWG#<)QV2T3#I.J2KS-3;BCUNY
M[5!'9V!MUF.3`#(T&H*I+)>4KLZ.0NI2O=CE#ROU>YTK0;G&8V%BX#<*(*MQ
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M,%?2ZT2&"VX+8A54J#+Y)FPXNCPI]MCF*2-\PA#4H`3A(FI4O8`(E]A%6@S(
MJ*B*BW1>**E!B=F1&7FF'7VVWW[HPT1")FH\5T"JW*WL4&6@4"@4"@I7:_\`
M<]KRMA_M2/076@I6W_Q8WCY.PONS:"ZT"@4"@4'EUMMULVG!0VW$43!>***I
M946@Y-YM=I&.@&6.CK])Q=.-QL@'F5_V&.$EB$X)&`JDDW%YB*MQLG57N!O(
ML;?HYHDF)->PJ37C1UEV.W(-#458U-J:B,=I-8EH)"/JJH]-!KG,9VE2"AN2
MXAR7\433C2./QP%V0#&2;<=;(5510^?&%%)$7V."T&YV?C=\%/;<W%(?\#9B
MO-C'(F=+IG,?Y9/""NDI#$Y7Q[=^ZT%NQN-Q^+Q\?'8Z.$6#$;%J-&:%!``%
M+((HE!)H%`H%`H%`H%!HMVX1_(8,XL!IHG$DL2G(KE@:DHR^#SC+BHA?QA!1
M551?9X7H*SN?&]H4]Z*Y@8_T.T#+B&T,D1768O`2.`!*UW6R`A%2O?BEN(0<
MQLG>K[C8,O/22BM/^`S'YI$@*[AWHB`397U.^&.J?-_5+O)IH)#F%[2BRTQY
MPS^B3=:(X$>839.MMN.HJ,.D6IE2`FB.R@BZ5%+=*AM]Q;>S4G,0)V&;*+-\
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M+/:#N/Z,*:Z32#$R3,5XS:`.<R8L+(TMH\9*K!O$"<K6JK;ATW#88/?V9T9=
M,K%YTN$#'*B1V^N4Q[FJY#:Y9O\`.1H&P/6*7T%J4:#>=GV>GY[:D3)9#0LX
MSD-2%::<9;4F7S:Z@.]=$L'=H+'0*!0*!0*!0*!0*!00-P/36<'/>@OL1IC;
M#A1Y$M;1P<05TDZO<%%Z5H.;Q^T;,-!C4:"1*BL1T5P3*.Y-R$A9+L7EL*V'
M*?;;5I#(V4%5$D+AT*'H-_YU[:R3$G-AEVY;&L6U8-EX'@:<<9C!HUO*RCFA
M6A5'-7QZ"SR]S/+O+#18$]J3C)Z.MR(S1-.&)`VX0GH$>:(:FK$XIJ-^KINM
MT"W4"@4"@I7:_P#<]KRMA_M2/076@YW#W!@<3VL[M3*Y*+CU>QV&Y*2GVV=>
ME9NK3S"&]KI>U!9_/[8OI'B_'8_RZ!Y_;%](\7X['^70//[8OI'B_'8_RZ!Y
M_;%](\7X['^70//[8OI'B_'8_P`N@>?VQ?2/%^.Q_ET$9S=O9JY-;G.9K#G,
M9`FFI)2HJN"V=E,1)2NB%9+I0$W;V:HC")F<-:,MXR>$Q?W:_L=;J_DH/;>\
MNSII!1O.8<$`B,$&5%2Q%?426+@JW6ZT&0-];!;'2WN'%`/%=(S(R)=5NO0?
M?H/7G]L7TCQ?CL?Y=`\_MB^D>+\=C_+H'G]L7TCQ?CL?Y=`\_MB^D>+\=C_+
MH'G]L7TCQ?CL?Y=`\_MB^D>+\=C_`"Z!Y_;%](\7X['^70//[8OI'B_'8_RZ
M!Y_;%](\7X['^70//[8OI'B_'8_RZ!Y_;%](\7X['^70?%W[L14LNXL6J+TI
MX;'^70>&M[=GS+3;3.?Q+;30H+382XPB(HED040[(EJ#UY]["X?_`.AQ7!;I
M_O(_2O\`QT'WS\V'?5YQ8J]K7\,CWM_?H/OG]L7TCQ?CL?Y=`\_MB^D>+\=C
M_+H'G]L7TCQ?CL?Y=`\_MB^D>+\=C_+H*CVH;NVGD-LQXD#-0)<IS+8CEQV)
M3+CA6R<=5T@)*2V3CPH.ET&MG[9VYD7T?R&*B3'T1!1V0PVZ>E.A-1BJVK.4
M?"$;S&V5]08[Q1CY%,GC!YC;*^H,=XHQ\BF3Q@\QME?4&.\48^13)XPYQB,1
MN+/_`$A+Q.W-H,8^-D9T!@)4-U7E&%*<CZC5M--RY=^%,GC"?YB[X^HMD>)2
M/>ID\8/,7?'U%LCQ*1[U,GC!YB[X^HMD>)2/>ID\8/,7?'U%LCQ*1[U,GC!Y
MB[X^HMD>)2/>ID\8/,7?'U%LCQ*1[U,GC!YB[X^HMD>)2/>ID\8/,7?'U%LC
MQ*1[U,GC!YB[X^HMD>)2/>ID\8/,7?'U%LCQ*1[U,GC!YB[X^HMD>)2/>ID\
M8/,7?'U%LCQ*1[U,GC!YB[X^HMD>)2/>ID\8/,7?'U%LCQ*1[U,GC!YB[X^H
MMD>)2/>ID\8/,7?'U%LCQ*1[U,GC!YB[X^HMD>)2/>ID\8/,7?'U%LCQ*1[U
M,GC!YB[X^HMD>)2/>ID\8/,7?'U%LCQ*1[U,GC!YB[X^HMD>)2/>ID\8/,7?
M'U%LCQ*1[U,GC#%`Q,V#O+#X/<FW-KN1<PS,-MW'1"1P"B"!=;G"HV+F4R>,
M+[YC;*^H,=XHQ\BF3Q@\QME?4&.\48^13)XP]L[,V@PZ#S.#@-/-DA-N!%9$
MA)%NBHJ#=%2F3PAM]`]ZF3PA]K"10*!04KLF_P#H,KY?S?VF_076@4"@K6\L
MG(AN8EDI98W%RY!MY')AH16A1HR:!3,2!M''$0=:I['224%=RO:3DL<[+CP8
M[60"*G*C$XX2O."C+3@3'%;'3R'5=T(0I\+\J("=VGYC'O&S)QS3SC!3F#".
M1F;S\05-O0W_`!&VR!+DXHDB+=.]<(4[?N<+*XMYL5?81R1&,8!*L>9HE04%
MUE3$K]5XV[=_58N[01FNU++PX^6R[ZLS=;D+P2$R1JR`K#5]]D3/3I=2RHO?
M+XM^%!MHW:'N0,A&QST./+?>R$Z.XX!)'06HT[P<&D1USB]R21ZR7U#:P\;H
M$(-Z;@R.(W=DVI(QG6,#&DP68MW%AR7/#%,#%P=/A#>@$-+6X)=*#&?:/N[&
MY:=`E0TE38BQ8;HNDW'B\]&I#JNMNFK8HDP`;T7+JK=+*HV4-V[G]QR]M9IT
M\C"@S(.6>B@9%X*G@S,BR-&Z[SA;==:^"YI5.*+;NT&GR7://EMAC<>#[&J+
M"D^$.)HEMFLF%K;=%%L7,:E_"$4'@2(J\;!+A]J>8>"/(?QK,6&]-:C.J3P.
M26D=(A5I8H'S5=`D'5PX7OHLBT&W7+9).T&;B"R!*$N'?'M1E9="+RP%2.4R
M0\T'",U4#U:"2PJETXA%Q&Z,TK.S)N1FH,7)8IZ3F-30`*N-1VWE>(D1.7:Y
M=5+)01LKN_(GE,FF&S33V.A"R604UB`Y'UNMJ0Q>:@(1"R76YUQU$*(NJXT#
M![VR)S\*&4R+<:0</PG/8]\66D9;,%2.2<$=1]TM)D&I1$=5T3JW#8;$W)G<
MKDY;.0/FB+`O2&M`AX')60\VL2XHBK9ML5Z]R[O024%VH%`H*3N?\4=D?Y&8
M_P#$Q07:@4"@4"@4"@4'+-H[HG;9C97%SMKYU]U<SE9+;\6%S63:DSG7FC`T
M-+H0&BT&]]:*>B6Y/Y<O^I0/6BGHEN3^7+_J4#UHIZ);D_ER_P"I0?%[4!7@
MNTMR6\G+\N@>M`?1+<G\N7Y=`]:`WOYI;DOY.7Y=`]:">B6Y/Y<ORZ!ZT$]$
MMR?RY?ET#UH#Z);D[_\`]<ORZ#[ZT4]$MR?RY?ET'Q>U`5Z=I;D_ER_+H'K0
M'T2W)QZ?_P"<ORZ#[ZT$]$MR?RY?ET'SUH#>_FEN2_DY?ET'E.TME'5>39^X
MT>(4`G/HWK*(JJH*KKO9%):`[VF,NMFT[M#<;C3B*)@6-N)"J65%13XHM!Z]
M9X>B.Y/Y:ORZ!ZSQO?S2W)?O_1R_+H'K03T2W)_+E^70??6BGHEN3^7+_J4#
MUHIZ);D_ER_ZE`]:*>B6Y/Y<O^I0:QK,3]R=HVV9C.`RV/AXMC)>%R<C%\';
M19#;0MB*ZBNJJ"T'2:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
+!0*!0*!0*!0?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>a62430neuro.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a62430neuro.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@`M`(]`P$1``(1`0,1`?_$`+(``0`!!0$!````````
M```````&`P0%!P@"`0$!``,!`0$```````````````(#!00!!A```0,#`@(#
M"P8*!@<&!P$``@$#!``1!1(&(0<Q(A-!46$RDZ,49587*'&!0B,5"%)B<I*T
MQ'6%-T>1H8(S)!:QP:+20U-C\.&R<T15T<*#-)0E)Q@1`0`"`0,$`00"`@,!
M```````!`A$A`P0Q05$287$B,A-"%*$%@9$S8O_:``P#`0`"$0,1`#\`VWRT
MY<;$G\N=JSIN"AR)DK#P'Y,AQM"-QUR*V1F1+TJ1*JJM!)/=5RX]G(/D1H'N
MJY<>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/
M=5RX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B-`]U7+CV<@^1&@
M>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B-
M`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y$
M:![JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R
M(T#W5<N/9R#Y$:![JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(/
MD1H'NJY<>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0
M?(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B-`]U7+CV<
M@^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y$:![JN7'L
MY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<N/
M9R#Y$:![JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5RX]G(/D1H'NJY<
M>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B-`]U7+CV<@^1&@>ZKEQ[.0?(C0/=5R
MX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B-`]U7+CV<@^1&@>ZK
MEQ[.0?(C0/=5RX]G(/D1H'NJY<>SD'R(T#W5<N/9R#Y$:![JN7'LY!\B-!'D
MY>[(3F"6,3"1$QQXD9)1>S3LU>"2H"YIZ-2"2I>@D/*?^%FS?V'C?T-N@E5`
MH%`H%!X>:%YEQHU)`<%0)0(@)$)++I,%$A7O*BW2@Y7VUNC>;W(Z7O*?/S0R
M,?"1U<D.2=3T]9&2DQ3$$<](:8.,+#5E1JZW6Z+J14#84O[P4F+N61M][&-L
MR3RS6'QKCQ.(#@/RECMSB=$.S-G2V1+H5%0_JUMXU`F<[<Z&XV=K9/#L1),E
M6L?.6',5\X\F3#<?4D?:%`!6S:4>S54/Z:+:@L93V\,O]VG%;IA9R:QN'$X]
M<L_)22ZWZ6U'U'(:D*!"I:F@6R]**B65+K07&"YI9MC.0TCX]V<6Y<?&W.]&
MD3C((>,DOA%;:C=L79B3;:E)>NJ(I+H3AIL%K'^\IE7H$R0&!8-]D(#T=M))
MHT03II0E#MD;,3[,Q14=;10).B@FW,"9F!Y:.3<_E#VKDFT+MOLF0.IR0NMN
M,PS(>$+(XXH$O!.\JH.I:#3CW,[F3"F`89-<KD,*_MC&LM1G>TBSRGQI7V@J
MH'4>4WV]*.VX*%QX7N%MA^;O,T8>,QL')+,R&Z@PC7ITLD5(<O)O2A=)LB!P
M&^T".*"&A1'I$>XH="<J]T0=T[`P^>@M268\UMQ4:FNE(?0VWC;<U.FJJ?7`
MM*_@VLB)P0)70*!0*!0*!0*!0*!0*!087>LV;`V?G)\%Y8\R'`DR8[PB!*+C
M+1.#U7!,52X\;I0:4PO-'?TO;>`S[V2DLQWIF(@95MZ+#57G9ZL/=I&$6F]+
M#@.FTJJ:DG`DXT$HQ?WB,7EC9BXS"R)66EN/M0\6CK82%<BL/2'VGP-!)ET1
M8TB*HJ$1)8K:E0+;>//A686X,9CH;^+ST''Y"3$<>5AUQI['M-.D,AA%<$$+
MM^KQ*]EZ.%!D>8^[]X;>VAMK>T.82XB,<)S=L,&F2-R')T(;S2F!$)`96TCT
MHO<M>@HXWG,[C\C.P^3@S\KDHB#+G)';:)8;<V,]-BQE[(0!>S89`#=,DNX?
M"XWTAY9^\/!DPF7H.!D3I#^3BX<([$AE4*1.B++CJ#A]F)"HB0DJVLJ<-24&
M9YGY3?@;+B93;<M<%FC!LF\0<=F;)D37M'9P.*FVB<31PPZ+:M2")4&J,_\`
M>'WSALID92HS*C,RLGC&L<T`&P+D#&M2&Y(N(/:F*OF1'U]/9]"(O&@R+_-?
MFD6(RT2",R>[@Y<1V?FX4*)(?&%(QPR3%8Q*PT1"Z7!13Q>GCQ4-];=EI-V_
MC)B22FI)B,/>F&VC1/=HV)=J38]4%.^K2G1T4&0H%`H%`H%`H%`H%`H%`H-:
M\[MU;AVW'VG(PTYZ(.4W!#Q$]N.RQ(<<C2T-35H76W5[8>R^KMPX\47A8(I$
MYR9G;TMB;N.9)R&)E[=9ST6+Z+'`P;FS([+12I#/9Z28](T.:6=-KGTV&@E$
M+GGCIR2G,?@<CD(^.CA(R;L+L)'8]M%=F,"FERSB.,L^.*Z=1@/&ZV#$0^=+
MVX]S[48PBE$AR<O)QF9CDL>0V\(X])C1-/!K7AJ'Q5'CJ147A0?=U;KY@X7F
M@[M<LBXN/W1",]GR19B:8DI@@.7Z0IM7<".SJ=XKQ#J\35"0*T3[PN$+;X94
M<5D7X1$TW%R+XMM,OB:/HCANC9ILU6(MVT3QC!.%UTAF<%SEBY[.8W%XG`Y"
M2&0A0LF<M%CB$>).0M+CHDZA]0PTD@HO?2_"X8GF/O/?^U-SE/B3(<W`L8[(
M9";A%8TK'CQ(I%'?=EZM6N1+'LP&R(O0-U$BH-?X[G[ON9/9VV3X!.DQ\=D$
MRXL-*383,"N4<90%'LN$@=(JHJNBZ<2ZU!GL)]X69G]R<O,9$>AQ1S%AW*RI
M@KWI)Q.U!IMLE4VVB,Q437QE72B]4KAOR@4"@4"@4"@BO\T_W'^MT#E/_"S9
MO[#QOZ&W02J@4"@4"@\2!8)AP9""3!"2/"Y904%3K(5^%K=-Z"*1H7+),)C<
M/&Q$`<%N-X@@8\<>(Q)+H-.2M1-=DC?%J,3@D:6)$115>%!9;DQW*/;\.;%S
M&&AM1)<.1/FLCCU>!R-"(77C+LVC'ZLW4.W3==5NE:#+%RRY<E)"46U\4L@%
M;4'5A,:D5D=+=ET?0'@E!>RL)MB#ME_&%B(Z[?89<(\.Q#%UDFQNX0!#:`D-
M2+B@""J1="7H*1[#V02XY2P&._\`U%_LL4BLHD:Y:E[%$&P=;K=7N\>F@M(_
M*OEE'0D9VGB`0Q0"1(,>RBA]HB*BAW#ZWRV[U!8YW.\L\RY$Q&XL>W--3@K&
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ME_R;Q\N/CY"-Q<FTY#=B&61E-SVR_P#LH:-/]ND@!+^Z`!.Q=Y:"XD<B>5LA
M^2\YB'$.64DY"-SI[8DLY$23U`?$41U!34B)9:#,[GVILR;L]O;N?%4VV'HL
M1&7)<AE"L8,QVW'@<!T]3B@/7-=16O=:"VE<I]A2Y#LB3CC>=D0DQLM3E2U2
M1&!LF@&0/:Z7B`#72XXA&/2A71*#'IR;Y6XEH9WH+T9G'O,Y+M2R.0T-NP&5
M:9?+5(TW:933=?HT#>N(Y1[S6,&Y9;$W[.*0D=MO(/QT`PCA(D7&,\UJ((Y"
M9:KZ17N(M!DHW*_EX,A)S.&8)7(YQT15,V59>CA%/ZHB5K4Y';%LCTZE'@J\
M5H+.1RHY9P8K4IZ$45K'$[(]-].FMF*.M-LNJ\^CR&;:LL@"BX2CI2UK4$U9
M:9:9!ID!;9;%!:;!$$1$4L*"B<$1$Z*#W0*!0*!0*!0*!0*!0*!08#=NU=J;
M@^R_\P@I_9\UN7BK2GXNF:%^R,>Q<:UN#QTWOW;4&/F;)V%N/-/99%)_+X]M
M,0_)ASI`$P+1!)]&(&G4;%4)0,A4;KPU71:#!8WECR7EO2<=BE;,I,!<?/@0
MLB^B/QHJE%O(::>^L)DB)O6:*HEPO=.`93"<EN7F&GQLA!A24EPY`RXSCL^:
MZ@/BRD?M-)O*)*32:5U(MTX=%J#+9?;.T,INW#Y+(IVFY,0T^]AQ24\V;;1Z
M6I!C';<`#$M8@XI`J+=!7N4&$7D;RW]"8@I!D!#BR%E0XX3I@A'(D<0@CH+R
M=BV7;'J$+(M_`E@N\+LGEWL61'GQE^SGRBCBV9$R<^8E'C`<@64&0Z3?U8-N
M'P3@*$O1>@QKNR.369W9_F%WT?(Y^88-HX60?>!PG8IN-MI'[<F%U11,Q#1X
MG61.[07S7)GEXSBUQS>.,6E<:=%])$CT@58C>AM"$C7VH@$;ZI!0K:?#QH+Y
MWE_R^'*8*26+BL9'"W^P^S562!`:1JP@!"CNAL41-:%I[EJ"44"@4"@4"@4$
M5_FG^X_UN@<I_P"%FS?V'C?T-N@E5`H%`H%!B]TXAW-;8R^&:>]'=R4*3#;D
M)TMD^T3:'P_!4KT&L<QRLW9GI7IH/Q\:X^%@EN*?I\"^%D8ER,PH`0FTC\CT
MD2%P;K>W<*@]9'E'N9]C+A#'%P6LO!RD1(##KP1HIY*#&B:V11CBG:12=-$$
M+J7=6Y$%KD^2VY<KN:3D,B.)D8N;/8ES,>9.$+C<>8Y($3$HZZR5E\FEU*O@
ML*H`AG8G*[*Q]C;PVZ)0T<W"W(&"ER(&7)#2AVAN=B+A(#A:VT)#,41![1;)
M8+S;&P<QC-]O;E?9@-#+^TTEE'<<)\QG.PW6-2JPWK[%8AI92^FJIW44(LQR
M3S4><Q-8B8=J0U*C2B<`W$->PRSTYP-21K_6Q7_1U7O);Q>%!=Q.5&[6OLH7
M/LTV\>W@VG1[=Y4,<+)F/G9%C_\`&&:B(G<T]V]!19Y+;C7$M0Y$B"LAMB,V
M$H2<5QH8T5Z.40")JZQY"N(1]%M1]4N"J'K%\GLYC9F.DM#CHD;'9%O(=A'(
MW11L6,:T^`LE'$5-X\>Z]J'28N$*ZE36AAL/8F&FXG`$S,16Y$N=D,B4=5$N
MP3(37I8L7'JJK8O()654U7MPH)!0*!0*!0*!0*!0*!0*!01[F#CIV1VAD(D)
MI7WB[(RC"MB>::>!QYA/"ZT!!9>F]!KW,[2YA9'/N9>$VX2B<HF9JSC;!_'R
M),1]N*RRI`4=Q8L=Q@BTA8BU:N*J@>EV+O@I3;KS#DAD9,-^*+\D'76(T;<+
M62&,;AN$1DW$9THNHDU6'4J)JH*."V;S,>RC"9Q)[,`912718R[J#_\`:NMH
M.H'^T(?2$:<ZR6Z5TI=0H)!CMN;Z9V"6-D.R'<PWD8SL=[THA?.(U(9-SMC5
MYP=1M`XA`+B@=[Z1U*(@V3M?>&,<RZ3SFJQ-A.(TDC(.2C25Z7+(.S)QUQ6E
M]&=8'4))Q'CQ2ZA%XG+_`)G1<9&`).17)!$;:D/%EGC$GBPC\9\AUOK:^25A
MT5LED&Z6Z%"\D[%WT;<HVH[K<UV0[+9EMR@;=%PMM,XH"[07$-#]+94KHOB\
M?!0>,YLWFM,8FK$E3(T]Q7#20WD2!IR,XTRD>,+8N)V3K#HDI&*"BHA=8NT)
M*"^Q6"WUA\[$FSO2I&WX19`9,=Z2<U2ANRIST9`!'3=-X67HS6@Q<0[)Q%6Q
M4@G>Q,;D<7LK!8[)<)\.!'8DBI]HHFVT(J"G]/3:VKN]-!G:!0*!0*!0*!0*
M!0*!0*"#\P8.X7<I!DXA=+Z8O,0\<\J*H,9:4VPL!\^!(*(C3P:RX=?3]*@A
M8;-YE([G',?'R&,:R:R7\<!Y1''V,@4#'1XDF4\CYJ^RV[$?U`2GU%3ZM;V$
M*SFU>8<>;*DPL4\+QNY!4?;DL,J03<S'EZ@[.0!]:,V:J&L+^+K2]Z"A&VAS
M7>PLDWWLM'SC4>''C*634V'"::5)!$VW,;3ZUQH+N:A<1"4DNNH2"3[[Q&^Y
MCD-,0$ZQ8EV/-6'.1@4F%*AN-&*D]')2!IF0*N(-[$B=U40/#^!WNYLS&8U?
MM'TIG/..2M.04):X?TYYQL#EB^)FJ0R;!?K-5_Z:".XO;7->..,!YO*.MMK%
M/)C(R3;_`&JC!FLR1L<H[B;SD8D'Q>JI<%Z0^PMH\S8C<,<7%?QDP(T2,Y)6
M3'5A%9P4B$A.M`\7:BU.<8<1%!>`JJ>$*66VGS;=-#QY95B*C#Q,0RR^IT)?
MH<=`5QU9%S;62!J@D9)TW1$+309AK%;X64Y'R0OJY*ST"?A7'7E>=8CLSCD3
MQ/LW'FFVDB79`D[-"0T!0NES#:]`H%`H%`H%!%?YI_N/];H'*?\`A9LW]AXW
M]#;H)50*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"*_P`T_P!Q
M_K=`Y3_PLV;^P\;^AMT$JH%`H%`H%!CLWN3;^"CI(S.1CX]HKHV4AT6]:IW`
M0EN2^`:]B)GH]B)GHUYE_O'\OX1*$()N55.&N.RC07\*R28*WA05J^O%O/9=
M7C7GLBTS[TDB^F'MH-/<<>FK?\P6/_FJZ.#;O*Z.%;O+'K]YS="JJIB((IW$
M57EM\^I+_P!%2_H_/^$OZ/S_`(7$;[T68!425MV.^G02M2C9[O2B$T]W.Y?Y
MZ\G@SY>3PI\I#B_O.;6>5`R6*FPB6UW&NRD-)W[KJ:<_H"JK<.\?*JW$O'RG
MVW>9>Q-Q*S,=V2Y9`B.JK$@E7\%EY&W"^9*Y[4M7K"BU)KUA)JBB4&IN9
M6Z=W[>W#F9T*2X_MN'AHQY.$R(E(ANRG)8-Y!C@I*#91@1T%OU54DZ+*%-KG
M3,8DLP_08[D1J=%Q3TQ^8VDA#*9'A.NNL"BF(_XGM4(D0;6X]9*"I@N<^:RP
M1'PQ4)F))3&M=NLMPE%_*2'6&]0HS9`%6"3Q[D2BG"ZV"EA>:N8F9Q1%IK7E
MEAQHS#\C_`Q'D;R1.N(\#>HFY"XY$;73UM2+X*"UF<[\ID\-ECA8;T88F%>R
MDO\`QBM26`3&,SP)LTCO-$I%(5H4X+U==M))09G*\Y%B,SWVFL<HQILG',QG
M9JC*[:)*..7:LHTJ"CHMJXVJFB:5156UU0,ERMW7-W)+W),=>(XB2(#D&.1"
M:1VY6)B2C:$A0;Z77SH)[0*!0*!0*!0*"TRN8Q.(B+,RLUB!$%;*_)<!H+KW
M-1JB7I$#7N:^\/RZQY$$5V5EG!X*D-FPW_+D*P!)X15:OKQKSV7UX]Y[(G.^
M](J$J0-MZQ6^ER1,T*G>50!EQ/FUU='!MWF%L<*W>6,/[SNYE)5##P@'N"1.
MFJ?VD4+_`-%3_H_/^$_Z7RJQ_O0YT%3TC;\60EUOV<EQBZ6X=+;]>3P9\O)X
M4^6>QGWG]ON$(Y/"3(JE]*,;4D4X]W6L<K?(*U7;AWCY5VX=X3G`<W>7>=(6
MX>:9:D'9!C2[Q7%)?HBCR!K7\A5KGOMVKUA1;;M7K"85!`H-1[PW+O##YW*H
MS,>E;<F9*%C!<CH"OXJ6Z,5Q-:HB_421D$*ZD50+3W"H/@<\I1,-2_L^&SCY
M#CK3+STYM7`)N'.DB,AL-1,EKQW9JAVNIK;B"W"ZB\W\[*(5;Q4%IB0^Y%A/
MN37-).,XT<DJ&J1](ZP+2*:NX2\=/6#'X_F_DF0S,M8RNBZ+^7B19[W8]A&C
M83%3G((D(+]:1Y`U&Z<-)7H+QSFSD\C,EQFL9Z+`@96!"E2TE$T^V3F::@H*
MBK!MF+@+VAH)\!56RL7&@I3^>XQ=OQ<TW'Q[S<P!D-0QFEZ2VUV;CA-2`[+2
MT\'965"*U[HEU1$()OL')2LAC,B[(E++5K+9*.RZ2BMF69;@-"BBB)801$2@
MDM`H%`H%`H%`H(]N+F%LK;ADWF<Q'C2!34L5"5V19>[V#2&[;^S4JTFW2$JT
MF>D-?Y3[S6T6%(,;C9TXD\5PT;CM+\Y$;B?.W717AWGX7UXEY^$=E?>CRI*J
M1=N,,IQ02=EF[\BJ(LM?T7^>K8X,^5L<*?*T_P#].;I_]I@KX+O)_P#/7O\`
M1^?\/?Z/S_AD(GWI)>I!F;:;457BXS-)%1/R"86_YU1G@V[2C/"GM*3XC[R6
MPY:B$]B=BR7@3CK2/[email protected]!*IMQ;QV56XMX[-A8'=FV=P-*YA<G&GH
M*:C!EP2<!%_YC=]8?(2)5$Q,=5$Q,=65KQXP^\WYL?:.9D09JXZ:Q"D.QIR"
MVYV+C;9$)J#J$V2(J<4).B@U@'-G>&+R4['9;'E*W!"^S\9]E]I'APGIDE)[
MWIK4IX1LU(8A!H$CZIKHMJH,@]SQEA&,@PD=98@Z0QER(EQ;;A.HBFTPX-E'
M(^,*DG4X*J+>@H;GYK;@3"Y*.$0,9.:3(11F1'UD&S-Q8-NNZ@>C@/8NZ[`:
M\;*/!%/JAD)W.9V(I&6);6,\<AN(]Z2JJ'HF69Q+JRFQ9(F^M)%P1#6I(BCT
MI>@I1N:^42<TW+QK<+(Y-G'K%@3)W9Q63DQYLFSCJQ1<;<)(BA8D*Y6X#8J"
MA-YLS<G-/&P4;A.1<CAD23%?&0+S,C,1H4IDM;()90?7K-JOY5[I0;:H(K_-
M/]Q_K=`Y3_PLV;^P\;^AMT$JH%`H%!B-T;MV]M?&KD,Y,")'OI;%;DXZ?3H:
M;&YF7@%.CBO"O:UF9Q#VM9F<0Y_WK]XG<V5)R+MQO[%QZW'T@]+DTT[BWZS;
M/#N#J7O&E=^UPN]G=M\/O9JB5)DRY1RY;SDJ6[_>R7S)UT_RG#4B7YUKNK2*
M](=M:17I"G4DB@4"@4'ESLT;)7+:$2Y7XIPXUY.,:O+8QJW-R\W/OS;^+:5[
M(N2A-=:8N>JO-MMV32V+BKVK96[Q*(_@K:N6W#K:,QI+Y_=WXF\^L?:W+M/F
M'A\^8Q'!7'Y>UU@O$BZ[)<E8<2PNBGS$B<2$:S]W9M2=7M;1*0_9^/\`2'9/
MHS7I#X=F\]H'68=&DBM<DX="U4DCTO/;6#=A[77'>DY&5&:E9!6V&S`65=[%
MA7[]8QU\$5!)![MDH/+6:V2NV,CN0H3;&,965'G]I&$7#^SY!Q7&R;MJ+ZUA
M1`5Z>'"@HQL_LR5*BP7,3V4S*3',0]&>BM*H2(44I?92"#6W9&&=3?66Z6MX
M`QF.Q?+G)Y#+[N[,Y<*&Z\^_.DZ'8BN,LK'?<:%=3I`#;:CUD[/NA?IH)!MO
M(;8SK<I(V-&,^P499<22PT#J79!Z*9(.L53LC31QZO$>"HJ(&;@XO&0$-(,1
MF(CENT1AL&]6G@E]*)>U!<T"@4"@4"@L<UG,1@\<[DLO+;A064^L?=6R77H%
M$Z2(N@13BJ\$KV(R]B,M#;W^\CDY1N1-H,>A1D54^U)0(;YI;QFF2N#?'H5S
M4MND16NW:X4SK9V;7#F=;-.Y+)Y+*3%FY.6].F+=/2)+A.FB+]%"-5L/@3A7
M?3;K7I#NIMUKTA;5-,H%`H%!\5$5%14NB\%1>BU!M'E=G-Z87'I+C91T(3NE
M8>,DW?C=DGTNS)4($.]T1HQX65>FU<MN+6^O1@\K?K[_`&QHW;M7F?C,J\W`
MR;7V7E'%TM"1:H[Q*O!&7E0>LOX!H)?@ZK7K@W>/:G7HA6\2EK>.Q[1/&U%:
M`I)(<@A;%%<)%NA&J)UE\*U0FP.],MM/:V`DY;+0FCB*\CAM`RV1.R2NHE8M
M(J:V\8EH,2>\]A-/R(;N))H3>%N6BP@5%G>BE/",;8W<)_L$4QZBI?@A:E1*
M#RF]]GFP_++;TM'69G9Y(#@-]HQ,!P6V^U*^@G#5X5;4")50KT%,MO[%V]NR
M,V_BI$J3FGW08FO-`_&:>F&<LV]9==5<..17L>FW%11>(39S"89T"!R!&,#,
MG3$F@5%<--)&J*G$B1;*M!5AP(,)LFX<9J,V9*9@R`MBIJB(I*@HG'ATT%>@
M4"@4"@4$-W[S6VKLQM6IKJRLL8:F,5'L3RHOBDY?JM`OX1]/'2A*EJLV]JUY
MQ"S;V[7G1SYO'G7OG<I.-!*7#XTE73"@$0&HJG0[(32X?=OITBOX-:&WPZQU
MU=^WQ*QUU0%!1+V2UU55MW55;JM=<1$='5$1'1]KUZ4"@4"@JPAFE/C#CU,,
MB1Z8CC1DV8FJ74D<"Q`@HEU5.XE0W(B8Q,94\B]:US9T#M?F'NS!QV(^1?7<
M$9L1%TG]+<OAP(FW4L)^`7$NJ]+B5R;G!T^V6!&]KJVCAL_MS=>-<[#1):ZJ
M2X$@$[1LNE!>9*_=2Z+T+TBJIQK/M2:SB5T3E?S,-B)K)L38,>2RX(`XT\T#
M@D+2J38J)(J*@*2J/>O47J'9G=7+.#N3(XZ?CFSG0H9RLM-2"+H-,L1TD:7G
M$%27Z@;CP5."#?59%`]O/E\]):1<6,G+99TH!0QCQSDN>C"TXHF6K0;8"ZT7
M`R1+IWEL%S(Q&S-Z1\E"B1U&.$H!F9..RP+;TF&=NS7M@<&2C1C9=39!=+7U
M#P"IM'&<OI6/R&)P\&/)BX:8N/FJZP!(4EL0E+Q(;$@K(14LFE%\7@B4&?+;
M>W3E'+/%0RE.$IG(6.TKA$JHJDIZ=2KU!X^!*#(T$5_FG^X_UN@<I_X6;-_8
M>-_0VZ"54"@4$-YE\R\5LC%(ZZB2<O)14Q^/1;*:IP4S5/%;'Z1?,G&K-K:F
M\XA9M[<WG$.4=Q;DS>X\JYE<U*65-<X(MM+;87NC;0<4`$[WSJJK=:U]K9K2
M-&KM;44C1C:M6E`H%`H%`H))LK;_`*=*3)R1O#BG_AA7H<>%?'_);7H_&_)X
MQC6?AD\_D_PC_EM--OY4D;5&DZ^E5ZX]1#;5X5<X]5%;12X]RG[:LOUE:9+%
M/1E!N6*"1?6-*#B*0J!*B&)-K<20AZJHMZ9K>,=C6$ZV'S'?64Q@MPN:W'E1
MO'94K)VIJMA8?LB(+B]`'T'T+8[:\OD<:::Q^+HIN99O<6Q)>9WIA<^LUIAG
M#JIM:&2&6BJ;:FTCXN"BLO""B8F*]*]-T4>58M)>P]P%M]W;C.2CK!R$W*39
MTM8Q"XUZ=)=G1T:'MB0B:E/(A:N!@B^*O2%Q#Y?S&LE#RCF0:26&<>S\\`8)
M0=<=QSF,%EM5=16T!@T74NJY)T)>@PF%Y+IB\;,Q3,V../G8P<#+%N,H&]!'
MTF[CBHY8I6F2(]HJ*G57J]:PA+-H[5EX=Z?-R$MN9D<@D5MUQEI66Q;AL(R"
M(*DXMR+6:\>&JW<NH2.@4"@4"@4$?WOO?"[/PIY/)G=5N$2("IVK[MKH`(O]
M:]")Q6I4I-IQ"5*3:<0Y,WGOC<&\,K]H9AZXMJOH<)NZ,1P7Z+8KTDJ>,:\2
M\"61-?9V(I'RU=G8BD?+`5>O*!0*!0*!09C:^`^V)ZJ\-\=&5%DWZ'"Z19^3
MNGX.'TN$9UG#.YW)]8]8ZRV^.W\HJ-Z6DL>F_6%-"&VKPJ?'J(K0J7'N)3]M
M6-ZRM<EBG8Z(Q-;`A>%5T:@<11NH\=*DG2BU[%HM!,82?9?,>1AW&<9GGB?Q
M!KH8R;I*3D55L@B^2\29_P"HO$/I7'K#G<GB^OW5Z+MO<SI*?[YVY*W%MR5B
M8[L</20,'6YC"2&'1)LA0#&XD-C(3$Q6XD*<%Z%X5R+8[E`4&;C9S633TW$Q
M_P##/F$AP7YPQSBLR9;12=+@L-.*#8^/ILBN+:@RN*V+EFL5`@9;)QYWH^4#
M*3'8\0HJ22:17@5P3?DKVJS-#Q'JT]72(BEJ"KD]G97,Y?%3<M(@&.(E>F0Y
M$:(XU,`A=-4:%XGW$$'&5`'>KUK%PZR:`EU`H%`H%`H%!J#G'SI3`*YM_;;H
M'G52TR99#"(BIXJ(O5)Y4Z$7@/22+T5T\?CS?6>CHV./-]9Z.;WGGGWW9#[A
MO2'B5QYYPE,S,NDC(KJ2KWUK5K6*QB&I6L5C$/%22*!0*!0*#X1"(J1+842Z
MKX*3+R9PV)L':LAOLY#C*EE9^EMAE>!-MFJ:6^/01+93^9.Y>HQI]TL#E\B=
MVVG1-!V_DRN0@"MZ$<%WM`0"0E)$TDJHBJO9EP\"UY^VKE]96:C/QF31^*^4
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M4A&D[$&(;$1!^J!M%)48Z;(FE!2UT52"5T"@BO\`-/\`<?ZW0.4_\+-F_L/&
M_H;=!*J!08C=NY\;M?;TS-Y!5]'B!<6Q\=QPETMM!?Z1FJ"G<[J\*]K69G$/
M:UF9Q#C7<6X<KN+-2LSE7>UFRRN2)XC8)XC3:+T`"<!_I7BJK6UM;44KB&QM
M;<4C#'5:M*!0*!0*!07N&P[^7R`PVE4&D1#E/)_PVKVX?C'T#\Z]Q:C/B')R
M^1^NNGY2VK&CL1H[<=@$;9:%`;!.A!%+(E3B,/GYG+/KN1[T:/'%5U(H+*D*
MVWK,0;5D6[65#06S(>O>_@JG].LRE[*>;S;62;;TL=FXEM:K95ZNI$ZWC%<2
M1%OWDKW;V_4M;*,Y?)XB%'4<D^#3;HJB-DJJ9HG3H`>N2_DI5EIC&)*4M:=(
MU;4Y,\RF-V8R1CI#IGE<4J"KCR:7)$8N#3ZI^%]!SP]9434B5B[^UZ6^';;;
MM7'M#8]4HE`H%`H%`H%`H+;*9.#B\=)R4]U&(4-HWY#Q7L+8)J);)Q7@G0E!
MQQOW>N1WCN-_+S-3;"7;QT-5X,1[]4>%TUEXSB]TO`@VV./L^D?+7V-GTCY1
MVNA>4"@4"@4"@K08,K(3&H45+OO+XRI<0!/&<+P#?YULG=J-I\=5'(WXVZY;
M6QF-C8V"U#C(J--):Z\2(EXD1+WR7BM3B,0^<O:;3F>J2KN1[T:/'%5U(H+*
MD*VWK,0;5D6[65#06S(>O>_@JG].LR]]E/-YMK)-MZ6.S<2VM5LJ]74B=;QB
MN)(BW[R5[M[?J6ME'Y\^!"85V<^VPRO5NX2(A*OT41>E?`E6S,1U>5K,SB$W
MY)<SH&5>>VF;KAE%;[3#OO"H*Y''@;'6ZRJS]'4B*H=SJ*JX_)VO6<Q^,N[]
M5ZUB;0V]7,B4"@4"@4"@4"@UYSIYC+M#;J1X#B)G\IJ:@<$7L@&W:R%1>'40
MD0;])*G!40JNV-KWMCLMV=KWMARB1$1$9DIF:J1F2J1$1+<B)5XJJJMU5:V8
MB(C$-B(B(Q#Y7KTH%`H%`H%!(MF;?7(2TR,D?\#%/ZD5Z'7A7I_);7_:_)6H
M]9^&5S^3_"/^6RH<AR-+9D-N$TXT8F+@HA$*BM[HBV1?D6I6C,89,2S([J()
M8&VUHBL-B#$<1`4U"I+K72B:5NZ:]7Y%NEZI_1I\I>[&Y>:S,F*ZRVC3?%!%
M!$>"DI=`\.&K2G@2K=NLQ&KR9RCN1W=`P<MJ2Q-1K,0S[2,#**ZX)V\5P!5.
MH8KI)"445%Z:KWJUO'K*W9VKVG[8=";(W?C]V[:AYN$G9H^.F1&5;DR^'!QH
MOR2Z%[J65."UC6K-9Q+IM6:SB6=J*)0*!0*"*_S3_<?ZW0.4_P#"S9O[#QOZ
M&W02J@4'.7WE-V'+S\/;+!KZ-C`25,%%X%)?'ZL23OML\4_\RN_A;?6SNX>W
MULTU6BT"@4"@4"@4'T&W776V605Q]XD!EI.DB7H3_6J]Q.->3.%>YN12LS+:
M.W<&SA\>,=%0Y!KKE/(EM;B][\44X"G>\->UKA\YO;L[EO:64J2I@<EO7!0E
M4`=68^G!6HUCLO>([HV-N\I7\%0]X[:NC:XU[](13);USDRXLD,!E?HL]=Q4
M\+A)_P"$45._7FLM+:_UU8_*<L$J7,G"53=/B;IJI&2]\B*Y+\]>Q$0[Z4K6
M,1&$@V%NMS:F[L=FT-1CLN=G/1+KJB.J@O(J)Q72/7%/PA2J.3M^U/HKY&W[
M4^CM)%14146Z+Q14Z+5CL@H%`H%`H%`H%!I#[S&[#8Q^.VM&-1*<OIN0TK;Z
MADK,@2=XW;E_].NOA[?M;/AU<3;S;/ASY6JU"@4"@4"@4'PELG0JJJHB"B75
M55;(B(G%55>")7DSAY:T1&9;(VCM[[*A*[(1%R$E$)]>G0*>*TB]X>[WU\%J
M5CO/5\YR=^=RV>S/U-SL/E-V83'$3;K_`&TD>"QF/K'$7O%;JA_;5*A-X7;>
MQ>_XPBF2WWF)5PA`,!GN'P=>5/E)-`_)8OEKS6?AH[7^MC^<HZX3CKROO&3S
MY<%>=)3.W>U$JK;P5[%8AH[>U6D8K&%WALQ.PN7AYB`6F;`>%]B_!%4>D"M]
M$Q50+P*M0W:>]9@W:>U9AVWA\I$RV)A92&6J)/8;DQR7@J@Z"&-T[BV6L-BK
MN@4"@4"@4"@4'&O,W=A[IWMDLHAJ<,#]%QR7N*1F%40(?`X6IW^U6OQ=OUI\
MRUN+M^M?JB]=+H*!0*!0*!07F'Q,C+Y`(3*J`VUR7D_X;5[7[VHN@?Z>A%J,
MSVAR\OD?KK_]2VK%BQXD9N-'!&V&10&P3H04X)4XC#YZ9R]/OL,-$\^X+30)
M<W#5!%$\*KP2DS@1G);_`,8QJ"`V4YU.@T^K9O\`^8J*J_*`JE1]_#KVN#N7
M^(17);FSF1U"])5EA?\`@1KM#;\8D57"\/6LO>KS$SU:6UP*5ZZRQ8@`#I`4
M$>\B62O8C#MB,=&W?NX[L/';K?VZ\=H>:`G&`7H26P"E=.]K9$M2_BBE<'-V
M^EG#S-OI9TM6>X"@4"@4$5_FG^X_UN@<I_X6;-_8>-_0VZ"54"@XIWUE"RN]
M<]D"+6C\^0C9WO=IIQ6F>*?](!2MGC5Q2&QQZXI#!U>N*!0*!0*`JHB*JK9$
MXJJT$QVGC(F*B?;N7<",;PZ8J/*@=FV7'H7_`(CENCIM9.G54(GO+"Y>_.[;
MUKTA5R7,..-PQ<<GRZ.W?NTVGA0%^L+Y%0?EJ7M,]#:_U][==$5R69RV354G
M22<:7_TX?5L_)H'QD_+4J\]<]6EM<+;IVS*S1$1$1$LB<$1*DZR@4!414LO1
M0=D<JLH>3Y=;?E.%J=2&##IKTD<:[!$OY1-WK"W*XM,,.]<6F$JJ")0*!0*!
M0*!0<C\\,H60YGYCK:VH78PV%O>PM,B1C\SSCE:O#KBF?+4XE<4SY06NMU%`
MH%`H%`H)/L[$1T__`'^2(&8;%_0U=5`!2Z%>)2LEDZ`OX5_!6H==9Z,;G<CV
MGTJRF2Y@XYJX8YDYKB?\1;M,_G$BD7]D;+WZE[YZ*=K@[ENND(KDMQ9O)7&3
M*4&5_P#3Q[M-_/95,O"A%;P5YZYZM+:X.W7KK+&B(@*"*((IT(G!*E$.R(P^
MT>E`H.J?N^9,YO+6*P:ZCQTB1%U?BZ^V!/[(/(/S5C<BN+RQ^17%Y;)JA24"
M@4"@4"@P',#+.8C8^>R+1]G(C09!1S1;*CRMJ+5E_+5*]K&9B'M8S.'%8B(B
M@BEA%+(G>1*WVZ^T"@4"@4"@^B#KC@-,@KKSI(#30])$O0B?]N%>3.$-S<BE
M<RV!COL3:>-%F;*!)KWULG3<W'#7AU&Q13T#T#P^7BJUY$Q7KU?/WF^]?,1E
MB<ES"ENW#&1D8#_GR+$?S-BNE/`JDOR4S,_#KVO];,_E.$8ERI<UU'IK[DIQ
M%N*N+=!7\4$L`?V42GK#1VN/2G2%.I+R@4&2VUDSQ6X\5DP6RPIC#Y>$&W!(
MQ_M!=*JWZYI*K?KFDNX*Q&,4"@4"@BO\T_W'^MT#E/\`PLV;^P\;^AMT$JH%
M!PMDE1<E+MQ^N<_\:UN;/X1](;6U^$?1;58L*!0*!0*#PZV9Z-)J&DT-;()7
MT\;*A(26OWTJ-JYA#<I[1A4>-U]Y7Y#AOOK?ZUTE,K+W$4KV3P)PKV*Q#S;V
MJT_&,/E>K"@4"@4"@ZRY"`X/*C"HYXVJ:J<;\%G/J/\`4M8N_P#G+&W_`,Y;
M`JE44"@4"@4"@4'&G,]47F'N+P3GK_G5L<7_`,X:W%_\X1BNAT%`H%`H%!3?
M;)UHFQ-6U+AK&UT2_&U_!7EHS&$;1F,*SSCSY`4APGB;1$:UK<01$LB-@EA!
M+=P41*\BL0KV]BE.D/-27%`H%`H%!TI]V,'!V-E%+Q2R[JAQ[GHL9/\`2BUD
M\O\`]&5R_P`VWJY7,4"@4"@4"@A?.543EEGE7@B,A=?_`*P59M?G'UA9M?G'
MU<@UN-HH%`H%`H%!\:*2S*](9D&R2`H)V=A5-7C*AVU"JIPN*HO]-1FN9RIW
M-F+_`)=!!%%(OI&MS)>*DO?)5XJORU[$1"RM8K&(?:]2*!0*!0>'P<-AP&_[
MPA5`XVXJG#C4;_C*-_QEWK6"PR@4"@4$5_FG^X_UN@<I_P"%FS?V'C?T-N@E
M5`H.#77-60R`*MR;F2!7YW%)/]DDK:X\_9#8V/P@JY<4"@4"@4"@4"@4"@4"
M@^&8@!&2V$4527O(E)EY,NLN0!&7*+;QFEC,)!$GA*6ZJUA;GY2Q=S\I;!J"
M!0*!0*!0*!0<6<QW/_Z;NMI5XCD#-/R21$_TBM:W#G[&IQ/P8"NIU%`H%`H%
M`H%`H%`H%`H%!TC]UMWM>7L]WI0\O(TKWQ1EE!7YQ1*QN3.;S+'Y$YO+<-4*
M2@4"@4"@4$&YX(2\I]RH*V)8J:5\/:!4J?E"5/RAR&RZ+K(.CXK@H2?(J7K=
MB<QEMQ.8R]UZ]*!0*!0*!0*!0*!0*!049;N@`1/&<<!M$_*)-7^S=:JWY^R5
M6]/V2[XK$8Q0*!0*"*_S3_<?ZW0.4_\`"S9O[#QOZ&W02J@4'!NZ(Y8G?V=A
M&FEL<C*C^!-$@T:5/`0\/G2M;8M]L2U=B?MB2NITE`H%!DV]MY=S%KDQ918J
M!VUU,$/L4=[!7="KJ[-'ET*5K7J'O&<(^\9PK!L_<!R9<88X]I!TI)4GF1`5
M,%<$4<(T`B4`)4057@B]ZG[*O/V0QV0@R($Y^%)1!DQC)IX1(31#!;$FH545
MLO#@M2B<QE*)S&5O7KTH%`H%`H+#+/HC8QA7K/>/X&TZ?SNBJ[SV0OX=E<DH
M1P^5.VVSZ78GI(W_``9)D^'^RXE8VY.;3]6/N3FT_5-Z@@4"@4"@4"@4'%G.
M^.6*YPYXU32RX\TXJ]Q6Y$=IPB_LN*M_GK2XUOMB?#1XT_;$^&`KN=I0*!09
M-O;>7<Q:Y,646*@=M=3!#[%'>P5W0JZNS1Y="E:UZA[QG"/O&<*P;/W`<F7&
M&./:0=*25)YD0%3!7!%'"-`(E`"5$%5X(O>I^RKS]D,=D(,B!.?A2409,8R:
M>$2$T0P6Q)J%5%;+PX+4HG,92B<QE;UZ]*!0*!0*"TR4A68ZB"V==ZC=NE+]
M)?V4XU"\Z(7G1U']V"`4;E<V]:S<R;)>:3\5M1CK_M,+61R)^^65R)^^6VJI
M4E`H%`H%`H([email protected]:[[email protected][.D.-CWS:;5P4_I"I4G$Q*5)Q,2XEQ#]M<
M4OHW-KPB2]9/[)+_`%I6U2>S8IIHR56+"@4%6)%D2Y3,2,VKLF08M,M#TD9J
M@B*>%56O)G&KR9PR3VU<TRI:FFR`8QS4=!UHP)ALU;,@)"5#TF*BJ#Q14J,;
MD(Q>'US:6>:QQ9%U@&X@M"^1$\RAHV>C0JM:^T35VP*-QXH2+T4_9&<'[(SA
MAZFF4"@4"@4"@M8C)Y3<N-QK/%793$8+<;O2'!;3\W5;YZY]ZVD_$.?>G2?B
M'?E8[)*!0*!017^:?[C_`%N@<I_X6;-_8>-_0VZ"54"@Y#^\OM8L7S%=R&BT
M//L!);)."=JR(LOBGA32!K^76AQ+9K-7?Q;9K-6N\=-[5.P>7_$`E[_ABGTD
M_P!==M+=IZNRMNTKZIIE`H)-%W<K.U7<,8]J\ZWZ(T^33:>CQ2D))<`#\=Q3
M<2]B5$'CTWX53M_=E5.W]V5Z&^VHFXY>1B=L[!?[-T(KH-@JOMM=BA*2*XH:
M1,^(KQ\54LJU']6:XE']6:XEA-TYB'E<J4J(PD=BRH(HV#5T4R-+@WU4TH:`
MG%5L*76K-NLQ&JRE9B-6'J:90*!0*"E)DM1VE<<7AT"*=)+W$3PUY:V'DSA9
MX3$9'<&=AXR/QGY1]N,TJ<4#M"THOY+:*I+\ZUSWMZUF9ZJ+V]:S,]7?D"#&
M@0(T&*.B-$:!A@/P6VQ013YD2LADJ]`H%`H%`H%`H.9OO7[8-G-XC<K8?X>:
MRN/DDG0CS*DZW?PN-F?S!7;P[ZS5V<2^LPTIC)B#IB.KQ3@P2_21$\7Y1_T?
M/7?2<:.ZLXT9*K%A0*"31=W*SM5W#&/:O.M^B-/DTVGH\4I"27``_'<4W$O8
ME1!X]-^%4[?W953M_=E>AOMJ)N.7D8G;.P7^S="*Z#8*K[;78H2DBN*&D3/B
M*\?%5+*M1_5FN)1_5FN)83=.8AY7*E*B,)'8LJ"*-@U=%,C2X-]5-*&@)Q5;
M"EUJS;K,1JLI68C5AZFF4"@4"@\.NMM-DXX2"`\55:\F</)G##*4B9)0A;(W
M7%1N.P/$NLMA%$3Z1+_\*IF?Y2JF>\N\=B;<3;6SL/@UMVL&*VW((?%)]4U/
M$G@)TB6L>TYG+(M.9RSM>/"@4"@4"@4'EUIMYHVG10VG!4#!>**))947Y4H.
M!-U;>E[9W/D<*XJC)Q,DV6S+Z0)Q:-?`ZT0E\BUK;5O:L3W:NW;VK$]U6)*;
MDM:PX$G!P%Z1+NHM=%;97UME6J2107&.FOP<A&FQW%9D170>9>%$)0-LD(21
M%X*J*E[+7DQF,/)C,82N7O3&2WW1)DX\1O&/8^*C++2*;K[A/./.`)-B&IPU
MZHWLEDX]*TQM3'_:J-N8_P"WO&<P&FL.L'(Q_37=(%VKC3)(I,Z&P;5"2UE8
M:T*ZJ*=E5.-D5%MG7,/+;6N80FKUY0*!0*!06>0F]@'9M*BR#3JI^"GX:_ZN
M_4+6QI'5"UNT=4V^[QM8\US*@/*&N'AA/(22*_$Q32RE_P`)7C$_#I6N/E6Q
M7'ER<JV*X\NR*SF>4"@4"@BO\T_W'^MT#E/_``LV;^P\;^AMT$JH%!`^<_+S
M_.VS7HD41^V8*^E8HRLEW114)E26UA='J]-D+2J]%6;6YZ6RLVMSUMEQ6ZTZ
M#A`:&P^T2B2*B@XV8K8D5%XH2+P5%^1:UM+1F&KI:,K^'DQ-4:D6!Y>`ET`?
MR=Y?!4HOVE*+=I7]6)E`H%`H%`H%`H+>7-9C(FKK.%XC0^,O_=X5J-K81M;#
M$NN.ON]L]932Z`*>*"+W$OW>^M0QWE#'>70GW7^73A/.[XR+5FA$XV$$DXJ2
MKI?D)\G%H?[?@K/Y6[F?6.SAY6[F?6.SHRN1R%`H%`H%`H%`H([S!V;#WCM*
M?@9"HV<@-420J7[&0'6:<[_`O&MTC=.[4J6FLYA*MIK.8<,Y?$S\7D96*R3)
M1Y\)TF9+*KQ!P%[A)W.Z))TI94K7K:+QEK5M%XR]Q,GH1&I9>`7UX(OY?>7P
M]%3BV.J46QU9.K%A0*!0*!0*!0*"E)E,QPU.E:_`13B1+WD3NUY:T0\FT0P\
MA]V4:&ZFD!6[;73;PEWR_P!']=5]=95]=9;A^[?RZ<SNYDW-.:OA\&=V-271
MZ;:X(G@914<7\;1X:X^7N_QAR<K=_C#JZN!PE`H%`H%`H%`H-`?>>Y<N2HS6
M]L:UJ<A@C&9;!.*L(OU4CAT]FJZ3_%5%Z!KJXV[ZSB>DNKC;OK.)Z2YM`W6G
M$=9+2:<%1?%).\7^I>Y6CCO#0F.\,M$G,R4TIU'42Y-%TIX4[Z>&IUME*+97
M-22*!0*!0*!0*!064S)"TJM,6<?3@OX(?E6_\/\`HJ%K]H0FW:&,1%U$9*IN
M&MS)>*JO_;H2H=-4=(U=E<B>73FS=GH4]M`SF649.014ZS0VLS'5?^F*JI?C
M$7<K*WMSWMEE[VY[VRV152HH%`H%!%?YI_N/];H'*?\`A9LW]AXW]#;H)50*
M!0:#Y^\D9.3>>W?M>.KL]40LMBVAN3^E+>D,BG2[;QP^ETIUKH73Q]_UTGHZ
M=C?]=)Z.:502%45$45X*BUI:3#1TE58ERX]D`NU:3_AN*MT_)/BO]-Z1F.CS
M6.B_:RL0^#BJP7><X)^<EQ_KJ4;D=]$O>.^B[14)$5%NB\45*FF^T"@4"@MW
MLA#951)Q%-."MAUBOX4&]OGJ,WB$9O"Q?R<IW@RG8!W2*Q'\R<13^NH3:9^$
M9F9^%J@HBJO%2+B1*MU5?"JTB,$1ALSDWR<G[YGI.GH<7;$4[2)"7$Y!CTLL
M+_XS^CT)UNCEW^1ZZ1U<V_O^ND=78,.'%A1&8<1H&(L8!:88;1!`&P32(BB=
M"(B62LYG*M`H%`H%`H%`H%`H-0\]N3*[OC)GL$`CN2&WI-C@(S&1XHVI+9$=
M#CV9+P7Q2X64;]G>])^%^SO>D_#D^1'?CONQI+1LR&2)M]AT5`P,5L0&)642
M1>"HM:=;1,9AI5M$QF'QA^3&LC!(K:?\$^(_V5Z1_P!'@I&8Z&)CHOVLO'+@
M\BL%WRXA^<G#^FU3B_E+W\KT#`Q0@)"%>@A6Z?U5.)RE$OM'I0*!04'YL1A=
M+CJ(:<="=8_S4N51FT0C-HA9/Y5\TTQP[-/^8YQ7YA1?]*_-49M,]$9M,]%G
M95-7#)3<7@IEQ7_N3P)7D01":\K^5^9W[F?1H^J-B8RHN2R2C<6Q7CV;=^!.
MDG0G<Z5\-&]OQ2,=U&]OQ33N[-V]@,5M_#1,-BF4CP(0(VRVG3WR(E^D1$JD
M2]U5O69,Y9LSED*\>%`H%`H%`H%`H/+S+3S1LO`+C3@J#C9HA"0DEE$D7@J*
ME!R'SHY+SMF3G<MB6CD;4D'<#2Y%"(RX,NKT]G=;-N+^276LI:''Y&?MEW\?
MD9TEJL@0K*MT5.(DBJBHO?14XI77,9=<QE<L9*4UP=3T@/PDL+G^H2_JI%IC
MY,S'ROF<C#=5!1Q!->@#ZI?,BVO\U3B\2E%X7-22*!0*`JHB*JK9$XJJT%F[
ME8@<&R5\N\UUD_.\7^NH3N1VU0]X[:K%^9+?NBEV+2_0;5=2_*?!?Z+5&<R\
MUGJHH@`-D1!$>XG!$IT.CHOD)R0=:=B[QW.PH&%GL/C'!LHKTA)>%>@DZ6Q[
MGC+QM;/Y&_[:1T9_(W_;2.CH>N1RE`H%`H%!%?YI_N/];H'*?^%FS?V'C?T-
MN@E5`H%`H-1<U_N_8C=CCN8P1MXO<)]9Y"14BRE[[HBBJ!_]04X_20N"I?M;
M\T^B_:WYI]',>Y]H;EVO/]!SV/=@OJJHT1I=IU$[K3HW!Q/R5X=VU:&WNUMT
M:&WNUMT8>K5CR+8@MV[MJO2K:J"K\NE4J/K"/K"J,B8/`9!HG>727]9"JU[K
MY>XGR]^F3?\`GE^:'^[37R:^7DI4U?\`U!(G@0/]VFODU\J1H1_WAFXG=$B)
M1_-5;5YZO/4$1%$$4043H1."5[$/<*L:-)E26HL5ER1*>+2S'9`G'#+\$`!%
M(E^1*\M:*QF7EK1$9EO?EI]V6?*<:R>]U6)$2Q!A6CN\YWNW=!;-C^*"J7?4
M>BN'=Y6=*N+=Y6=*ND(4*'`ALPH3(1HD8!:88:%!``%+"(BG!$1*XW&K4"@4
M"@4"@4"@4"@4"@UQS3Y)[?WRV4UI4QNX@&S61`;BZ@]`2`2VM.\7C#WU3JK;
MM;TTG1;M[LTG1RSO/EYN[9LM6,[`)EE2TLSV[N17>]H=1$2Z_@EI+P5H[>_6
MWU:&WOUM]4;JY<\]F"$I"F@UZ3!5$OZ1LM1]8>>L*HORP\20XB=Y;'_6:$M>
MZ^3'R]>F3?\`GE^:'^[37R:^19<U>B02?(+?^L::^37RI$KA_P!XXX??13*R
M_**+;^JO,//5\$`!+`*"G>1+5[$8>Q&'H4(B$!12,U00%$NI$O!$1$Z56DS$
M=29B.K<G+?[M^XLX;.0W0CF%Q"V-(BI::\/3;0O]PB]\^M^*G37%N\KM5Q[O
M*[5=.X+`XC`8IC$XB*$/'QDTLL-]"76ZJJK=2(EXJ2\57IKBF<N*9ROZ\>%`
MH%`H%`H%`H%`H/#[#$AAQB0V+S#HJ#K3@H0$))91(5NBHJ=R@YUYG?=F?%UW
M*[%1#:*YNX)T])"O=]%=-;6_$<5+=PN@4Z]KE3&EG7M<F8TLT%.@3L?,<A3X
MSL28RMGHSX$VX"_C`2(J5WUO%HS#NK>+1F%N0B2*A(BHO2B]%>I`(H?W9FVG
M<$"(1_-1;5YZH^L*J2IJ?^H-4[RH'^[7NOE[KY>O3)O_`#R_-#_=IKY-?+P4
MB87`I!JG>32/]8BBTU\F)\J1-B:W<NXO<5Q5.WR:E6O/6'GK#U4DF3V[MG/[
MDR0XW!07<A,6RD#2=4$7Z3IK8&Q\)JB57?=K7JKONUKU=+\J_NZXS;KK&9W.
M;>3S;2BY'BA=8L8QXH2:D177$7BA$B(G<2Z:JS]WD3?3I#/W=^;Z=FYZYU!0
M*!0*!0*"*_S3_<?ZW0.4_P#"S9O[#QOZ&W02J@ASW,["I`W1*C,NR#VJXK<M
MA-($Z(IQ<;4E\3M!=;OW2;*U!<2.8..B[<G9M^*\@PY[F+;AAH)Y^4,OT)MM
MJY"-W7E33<DLBW6W&@M"YH8J)E7\'EXSL#/MJVC$"XNC(1YA^0T3+H=6Q#$=
M%=:#8A[RHJA=X7F;LK*8.%EART1AN6+2$V;[>IIUUMMSLG%OP44>"Z]'%.^E
M!>M3=F;RQ\N(T[!SV/;<5B8TBMRF4<'I$O&'4E!K#=7W6MH9`S?V_-?PCQ<4
MCE_BXR+X!,A=&Z_]2R=Q*Z*<FT?+HIR;1\M6YO[M7-#'JJPX\7+M_16)($"M
M^,,GT?CX$5:Z:\NO>'17EU[PB4SE?S(B$HO;8R9$*V7L8CSZ7\"LBXB_*E61
MR*3W6QR*3W8[_*6[?_8\C_\`AR/]RI?NIYA+]U/,+F+R_P!^R^,?;65,>E#]
M!DH"V6W`E!!_KKR=^GEY._3RDN)^[]S7R1#?#I!:+H?F/LMBGR@)./)^95=N
M72%=N52&Q=M?=.1"%W<^;U(EE*)C0MT?]=Y.A?\`RD7PU1?ES/311?ES/31N
MC:>P-G;395O`8MF&9)I=DV5R0:=-C?<4G"2_<4K)W*YK6F=9<UK3/5(*BB4"
M@4"@4"@4"@4'PS``(S)!`452)5LB(G2JK0:_P_-EO+X0,C#@H+R9J/B9$1YZ
MQ@Q,=#T63U1+^]COM.:%M:ZC>X\0NDYB2CVYMZ:$!M<ON.;]GQ(2O*C(.#VQ
MN&;NC4H`U',N`7);#PO>@P^5YUMXES,XJ?BR3<6'"8X;#1&Y$<;AL1I/:(^C
M>H=;,UM4%0X%U57Q54,\G-W87:L,+/<"0^X;/HY190O-F#ALZ7FE;UM*3C1"
M*&B77HH,UB,M@]V8`9D=DI6(GAU`F1G61>:)$5"[*2`*39HMQ738DZ*#7&[?
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M5RVO-NLN6UYMUE+*BB4"@4"@4"@4"@4&$WIN@-L;<EYA8CD]YA$2/`95$=?=
M);"V%[_*J]Q$5>Y08'+\S1C.1W,=#:GXZ9#@3XTSMR;4VI\UN*BZ.R+Q1>0T
MZW6Z.KTT%YF-[9%K.97#X3%MY*1A(#60R)/2O1419"N=@PW9I]2<,8[A+JTB
MG5X];@&!C<^]I2AC3&F9088D<*;/=CR+LB,!G(":-M-.J8=E(^L*Z:+77JJA
M4&<E<V^7T:7)AEE5>EQ7$9=CQH\J2XKBF;6EL6&G%<LXV0+HO8N"\52X9+<^
MRMI[LABQGL8U.!!^J<<%0>;0NGLW1T.M^'225[6TQT>UM,=&F=S_`'3XIJ;V
MV,T3*](P\B/:#=>XC[2"0HGA;)?#753EVCKJZ:<NT==6M\O]WSFOC2+3B!R#
M07N_"?:<%;?@@X33R^3J^O+I/5T5Y59ZHS+Y>[^B761MK*@*=)^A2"!.-N)"
M"CT^&K(WZ>5D;]/*U_RENW_V/(__`(<C_<KW]U/,/?W4\PR$/ECS&F$@L[8R
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M1&D.9<C=C,A$2\2.X*QTBQHIII?1X4<7T!DQ<1.J5^%EM03C:N!/`X8<:<GT
MI1>D/]MH[.ZR7SD$FG4?03JHG'HH,O0*!0*!0*!0*!0*!0*!0*!0*!0*"RS>
M)8S&(EXN0XXU'FM$P^;*H)]F:6,44D)$U#<>CY*"(.;/Y?G/D9>+DFX0>D0P
MEMQ'HS4;TO&NJXPC@(&E'1<5=2=*^*O!$2@RSNQ\`W@<;AC?>;#&R1DXJ8K@
MC(:E(1D)@6G01?6&.DA5"%5145*#`9/EQR]D"^_.RK@RQ*6UEL@4MD'7CR`,
M@\,E=*`*J,1I`$1'2@H@I:]!7#E[LN+)>SS.8DQ5RKAE*E-RVVV91.ND^`%8
M4`T!TS($3\(D6XJJ4$RPV*CXC$0\5&(RC0&6XS"N*A'V;0H`(2HB7L*(EZ"\
MH%`H%`H%`H%`H%`H%`H%`H%`H%!@MT;?P&3]%G9\P/%XE79+D66C"PE56B#M
M7T>`O[H")174EJ",Q.4VUXK$7%LYN<@`P(0HZNPU)&&9@[email protected]`\B6[B#
MU>BU!G<WM3"9+)SI0Y%_'3I,$8>6]#=:`G8:*XK?:HX#BAH[1S0X.DDNO6[P
M8!_E'L9YIV-$G2(6/RS+S34",\PK)-OX]O'N]AVC;A\8K(=!<+7H+R'RUP$%
MZ-!8S4\$C2OM2'CBD,D#;G:DZX0-$TO4-TU5?P>@-**J4$YH%`H%`H%`H%`H
M%`H%`H%`H%`H(K_-/]Q_K=`Y3_PLV;^P\;^AMT%]O>,LK:N1BHY*960VC/;P
M6E??;[0Q'M!9'K."%]1BG%1O:@UARZ#-O;:Y=O)C9$)Y@I;:DV,HHJLECW19
MD."8Z6A<<4+:TM?Q%45H*FQ9/V6V47+,9*'!R>#QL":GH\LI+N>!F:[D2$F@
M4U?5H`U.#XY:=*JM!\Q6VL;D]N@U'QF1BN93,HW%ARX\Z*.-B/*#\EMMN2+6
MF\:*5W1'0CQZ0):"ZV;*W?"R&87)-NO9/))+0YCL&1VD::<TF8,87OK`**K-
MC'2B``IK)>O=0RG)Z)/CG*4HTJ+"7%88)#<H'&U++@T\F1.SB(1&J*PCI\=1
MHO%5O0;*H%`H%`H%`H%`H%`H%`H%`H%`H%!Y<(Q;(@'6:(JB%[76W!+KT7H.
M=\'RXW7%Q<]C'XAR*$-]UC;L3(1VW3<;E,2XKT>8Z#[8JS'!X2;DWO8C1$=^
MD$^GX_(RX6T\:S`DRI.TLW"C3YK@MIVC<:#9V4V6LE5LU?'\:Z+=.%!:,[>)
MW)[ER3&RUC3`B+'PK4EN(L9YV,3J,/G9QPC=><E&1$8]5M/PE*@OMX[4;>V"
M>R(6*FNK&@?9F-G@S$=;)?1=**JO&JMBYI[,SL)(O02>-0;%C>D>CM>D:?2-
M`]MHOIUVZVF_<OT4%2@4"@4"@4"@4"@4"@4"@4"@4"@4$&YV8<LQRUS$`8DN
M61M*X`0="O"XRBNM'H._:!V@"A@B*JHO"@@N-V]O"%NW$;AG8GL&(0-NSL=&
M9$&'$:8GCZ8TYVA)%<$7Q%8JGI)3\%T#-/1L1E=U%FDVID6HZ0G4)_T$=<LY
MO8/&<E#)"=%E6``&E1>.KAI%*#`XW8.[(C11#@DZXZ6/';\X6D:]%&-GY$V0
M\\"*0QS<C.M.J*61;=F@HJ:*"0?8VXIW-O&;D;QTF/BU)IQV'*:%--\=(966
MKXD79.-*[Z.4>ZB6K7:_60-KT"@4"@4"@4"@4"@4"@4"@4"@4$5_FG^X_P!;
MH'*?^%FS?V'C?T-N@E5`H/A`!**D*$H+J!52ZHME2Z=[@JI0?:!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"*_S3_<?ZW0:WV%[]_\C;=^QOLC['^S
M(7V;Z1J[;T;T<.Q[73PU]G;5;NT&>^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.
M4#XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4?G*!\
M1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE`^([U
M'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y
M0/B.]1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1^<H'Q
M'>H_.4#XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4
M?G*!\1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE
M`^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE`^([U'YR@?$
M=ZC\Y0/B.]1^<H'Q'>H_.4#XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1
M^<H'Q'>H_.4#XCO4?G*!\1WJ/SE`^([U'YR@?$=ZC\Y0/B.]1^<H'Q'>H_.4
A&''WW?YO<U?97^8?L\.RMJ]']"[8]=_I=IVNBW@O0?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>a62430spinal.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a62430spinal.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@`M`(]`P$1``(1`0,1`?_$`+4``0`"`@,!````````
M```````%!@0'`@,(`0$!``,!`0$```````````````($!0$#!A```0,"`P0#
M"0@-"0<$`P$``@$#!``%$1(&(3$3!T$B%%%A,I.C9587*'&!D4)2(Q4(H6)R
M@K*TQ#5UA18W1[&2HC-#4W,D=,'APM*S-"7PT8-$\6-DM1$!``(!!`$#!`("
M`@,```````$"$2$Q`P0205%A(C)"$W$%@3.A%/"1L?_:``P#`0`"$0,1`#\`
MVWRTY<:$G\N=*SIMBAR)DJSP'Y,AQM"-QUR*V1F1+O4B555:"R>JKEQZ.0?$
MC0/55RX]'(/B1H'JJY<>CD'Q(T#U5<N/1R#XD:!ZJN7'HY!\2-`]57+CT<@^
M)&@>JKEQZ.0?$C0/55RX]'(/B1H'JJY<>CD'Q(T#U5<N/1R#XD:!ZJN7'HY!
M\2-`]57+CT<@^)&@>JKEQZ.0?$C0/55RX]'(/B1H'JJY<>CD'Q(T#U5<N/1R
M#XD:!ZJN7'HY!\2-`]57+CT<@^)&@>JKEQZ.0?$C0/55RX]'(/B1H'JJY<>C
MD'Q(T#U5<N/1R#XD:!ZJN7'HY!\2-`]57+CT<@^)&@>JKEQZ.0?$C0/55RX]
M'(/B1H'JJY<>CD'Q(T#U5<N/1R#XD:!ZJN7'HY!\2-`]57+CT<@^)&@>JKEQ
MZ.0?$C0/55RX]'(/B1H'JJY<>CD'Q(T#U5<N/1R#XD:!ZJN7'HY!\2-`]57+
MCT<@^)&@>JKEQZ.0?$C0/55RX]'(/B1H'JJY<>CD'Q(T#U5<N/1R#XD:!ZJN
M7'HY!\2-`]57+CT<@^)&@>JKEQZ.0?$C0/55RX]'(/B1H'JJY<>CD'Q(T#U5
M<N/1R#XD:!ZJN7'HY!\2-`]57+CT<@^)&@>JKEQZ.0?$C0/55RX]'(/B1H'J
MJY<>CD'Q(T#U5<N/1R#XD:!ZJN7'HY!\2-`]57+CT<@^)&@>JKEQZ.0?$C0/
M55RX]'(/B1H'JJY<>CD'Q(T#U5<N/1R#XD:!ZJN7'HY!\2-`]57+CT<@^)&@
M>JKEQZ.0?$C0/55RX]'(/B1H'JJY<>CD'Q(T#U5<N/1R#XD:!ZJN7'HY!\2-
M`]57+CT<@^)&@>JKEQZ.0?$C0/55RX]'(/B1H'JJY<>CD'Q(T#U5<N/1R#XD
M:"O)R]T0G,$K8EDB);CM(R2B\-.&KP25`7,N[,@DJ8T%AY3_`+K-&_H.V_B;
M=!:J!0*!0*#@\T+S+C1J2`X*@2@1`2(28+E,%$A7N*BXI0>5]-:HUF]R.EZR
MGS[T,BWPD=6Y#<G4[>LBY28IB".=H:8.,+#6"HUBN*XHN9%0-A2_K!28NI9&
MGWK8VS).[-6>VN/$X@.`_*6.W.)T0X9LY6R)<BHJ'\VN'A4"9SMOH:C9TM<[
M.Q$DR5:M\Y8<Q7SCR9,-Q]21]H4`%;-I1X:JA_'1<*#!E/:PN_U:;5JF%?)K
M&H;3;UNS\E)+K?:VH^8Y#4A0(5+,T"X+O143!4Q6@R+%S2O;%\AI'M[LXM2V
M^-J=Z-(G&00[9)?"*VU&XQ<,2;;4I+V*HBDN1-F7`,6/]92ZO0)D@+"P;[(0
M'H[:231H@G32A*'&1LQ/AF**CK:*!)NH+MS`F7@>6CDV_P!T/2MR;0N-]$R!
MS.2%SMQF&9#PA@CCB@2[$[BJ@YEH-./<SN9,*8!A<UNMPLK^F+:RU&=XD6>4
M^-*^D%5`ZCRF^WE1W#8H8CLQQ#&L_-WF:,.V6V#<EF7#5061KMTLD5(<NYO2
MA=)LB!P&^($<4$,BB.\1Z%#T)RKU1!U3H"SWZ"U)9CS6W%1J:Z4A]#;>-MS,
MZ:JI]<"RK\G#!$38@6N@4"@4"@4"@4"@4"@4"@A=:S9L#1]\GP7ECS(<"3)C
MO"($HN,M$X/5<$Q5,1VXI0:4LO-'7TO3=@O[URDLQWIEH@75MZ+#57G9ZL/<
M2,(M-Y6'`=-I54U)-A)MH+1:_K$6N[&S%MEED2KM+<?:AVM'6PD*Y%8>D/M/
M@:"3+HBQE$514(B3`L,RH&-K'GPK,+4%LMT-^UWZ#;[A)B./*PZXT];VFG2&
M0PBN""%Q^KM+'!=VR@D>8^K]8:>TAIK6T.82VB,<)S5L,&F2-R')R(;S2F!$
M)`9891WHO1AC0=-MYS.V^XSK/<X,^ZW*(@RYR1VVB6&W-C/38L9>$(`O#89`
M#=,DQ</9B..4.+/UAX,F$R]!L,B=(?N<6SA'8D,JA2)T19<=0</AB0J(D)*N
M&"ILS)03/,^Z:\#1<2Z:;EK8KT8-DW:#CLS9,B:]DX<#:IMHFTT<,-V&;,@B
M5!JB_P#UA]<V:Z7&4J,RHS,JYVQJW-`!L"Y`MK4AN2+B#Q3%7S(CZ^7A[D1=
MM!(O\U^:16B[1((S)[MCEQ'9][A0HDA\84BW#),5C$K#1$+I;%%/!W[=JAOK
M3LM)NG[9,224U),1A[MAMHT3W$;$N*38]4%/'-E3=NH)"@4"@4"@4"@4"@4"
M@4"@UKSNU5J'3<?2<BS3GH@W34$.T3VX[+$AQR-+0U-6A=;=7C#POF\-FW:B
M[,`JD3G)>=/2V)NHYDFX6F7IUF_18O98X&#<V9'9:*5(9X>4F.T9',K.7#$]
M^`T%HA<\[=.24Y;[#<;A'MT<)%S=A<"1P>-%=F,"F5S!Q'&6?#%<N8P';BN`
M1$/G2]J/4^E&+(I1(<F[R;9>8Y+'D-O"-O28T33P9UV9A\%1VYD5%V4'W56J
M^8-EYH.Z7*XN+;]40C/1\D68F6)*8(#E]H4VL7`CLYG=J[0ZNTU0D#NB?6%L
MA:?"ZC:KB_"(FFXMQ?%MIE\31]$<-T<&FS58BXMHGA&";,5RA,V+G+%OU\MM
MKM-AN$D+A"A7,Y:+'$(\2<A97'1)U#ZAAE)!1>ZF.S$(GF/K/7^E-3E/B3(<
MVPL6ZX7";9%8RK'CQ(I%'?=EYLV>1+'A@."(NX<5$BH-?V[G[KN9/9TV3X!.
MDQ[=<$NXL-*383+"MT<90%'A;)`Y1515<F*;2ZU!/63ZPLR_ZDY>6R(]#BC>
M,!U*RI@KW:3B<4&FVR53;:(S%1-?"5<J+U2Q#?E`H%`H%`H%!5?XI_J/\KH'
M*?\`=9HW]!VW\3;H+50*!0*!0<)`L$PX,A!)@A)'A<P4%!4ZR%CLPPWXT%4C
M0N6262VV>-:(`V+4;Q!`MXV\1B270:<E9B:X2-[6HQ."1I@2(BBJ[*#"U);N
M4>GX<V+>+-#:B2X<B?-9&WJ\#D:$0NO&7#:,?FS=0\-^*YL-ZT$L7++ER4D)
M1:7M2R`5M0=6$QF161RMX+D^(.Q*#-E633$'3+]L*T1UT^PRX1V=B&+K)-CB
MX0!#:`D-2+:@""J1;DQH.H]!Z();<I6"W?\`B,?HL4BLHD;$LR\%$'`.MUNK
MT[=]!B1^5?+*.A(SI.T`AB@$B08^"BA\1$5%#H/K>[AW*#!OM]Y9WER):-16
M]N::G!6-!N=L=-&W+FKK45<DAG!M26.X*JN&7#!<%V4$Q:M-Z/<"V72%9(T5
MR(R(VU2A)%>C-*A8`+1@V;.5'"3+E3+F+NK0?2T5HQJ%+82QPABRG!DRV6XP
M*CCK:Y@-1$<5,5VCAM1=VV@SK"5E*S0UL@--VGA#V)N."--BVFQ!%M$')EW*
M."8+L6@SZ!0*!0*!0*!0*!0*!0*#!OMLMMTLTRWW3-]&RF3;F(+KD?%I4ZZ*
MZT39BBCOP)-E!5TT3RU?LMDTFF8[?'4+G8[?](3.)EBJ*MNMEQN*3;2N#@BD
MHILV4$?*Y?\`)NWRX]OD(W%N;3D-V(97&4W/;+_LH:-/\=)`"7]4`">!=Q:#
M(D<B>5LA^2\Y:'$.64DY"-SI[8DLY$23U`?$41U!3,B)@M!,ZGTIHR;H]O3M
M_%4TV'98B,N2Y#*%@8,QVW'@<!T\SB@/7-<Q88XK08TKE/H*7(=D2;<;SLB$
MEMEJ<J6J2(P-DT`R!XN5X@`URN.(1CO0L42@CTY-\K;2T,[L+T9FWO,W+BE<
M;AD;=@,JTR^6:1EQ:93+BOQ:!K6T<H]9KLMB;]'%(2.VW<'XZ`81PD2,1
MC/-9B".0F6;'**]"+024;E?R\&0DYFS,$KD<XZ(JF;*LO1PBG\T1*UF<CMBV
M1Y<RCL5=JT&'(Y4<LX,5J4]"**U;B=D=M[=-;,4=:;9=5Y]'D,VU99`%%PE'
M*F&&%!=66F6F0:9`6V6Q06FP1!$1%,!0438B(FZ@YT"@4"@4"@4"@4"@4"@4
M$!JW2NE-0?1?[0@I_1\UN7:L)3\7+-#'A&/!<:SN#MRXX].%!'S-$Z"U'>GK
MLBD_=[>VEH?DPYT@"8%H@D]F(&G4;%4)0,A4<5V9L46@@K;RQY+RWI-NM2MF
M4F`MOGP(5Q?1'XT52BXR&FGOG"9(B;SFBJ);,<4V!*63DMR\LT^-<(,*2DN'
M(&7&<=GS74!\64C\3*;RB2DTF5<R+BFS=A02UWTSI"Z:ML]RN*<34EH:?>LX
MI*>;-MH\K4@QCMN`!B6<0<4@5%Q05Z*"$7D;RW[$Q!2#("'%D+*AQPG3!".1
M(XA!'07DX+9<8\PA@BX]Y,`R[+HGEWH61'GQE^CGRBC:V9$R<^8E'C`<@64&
M0Z3?S8-N'L38*$N[&@C7=$<FKSJS]H7>SW&_S#!M'"N#[P.$[%-QMM(_')A<
MT43,0R>!UD3IH,YKDSR\9M:VYNW&+2N-.B^DB1V@58C=C:$)&?BB`1OFD%"P
MR]_;09SO+_E\-TL4DK7%8N-EQ^@^&JLD"`TC6`@!"CN1L41,Z%EZ,*"T4"@4
M"@4"@4%5_BG^H_RN@<I_W6:-_0=M_$VZ"U4"@4"@4$7JFT.WK3%WLS3W9W;E
M"DPVY";VR?:)M#V?)4L:#6-XY6:LOTKMH/Q[:X^&`2W%/M\#&RR+2Y&84`(3
M:1^1VD2%P<5QPZ"H.5QY1ZF?8NX0QM<%J[P;I$2`PZ\$:*=R@QHF=D48VIQ(
MI.FB"&*ETKB1!BW/DMJ6ZZFDW"XC:9%KFSV)<RWF3A"XW'F.2!$Q*.N<E9?)
MI<RKWL!5`$)V)RNNL?0VL-.B4-'-0MR!@IB1`RY(:4.(;G!%PD!PL[:$AF*(
M@\1<$P#,TQH&\6S7;VI7V8#0R_I-)91W'"?,9SL-UC,JL-Y^"L0TP4OCJJ=*
M*%68Y)WJ/.8FL1+.U(:E1I1.`;B&O`NSTYP,R1L?G8K_`&=5[B8>#LH,N)RH
MU:U]%"Y]&FW;V[&TZ/'>5#&RR9CYX(L?^V&:B(G1EZ<:#I9Y+:C6TM0Y$B"L
MAMB,V$H2<5QH8T5Z.40")K%8\A7$(]V&8^J6Q5#E:^3U\MLRW26AMT2-;KBW
M<.!'(W11L6+:T^`LE'$5-X[>Z]F'*8N$*YE3.AAL/0EFFVFP$S,16Y$N=<+B
M4=5$N`EPFO2Q8Q'JJK8O()8*J9L<-E!8*!0*!0*!0*!0*!0*!0*"O<P;=.N.
MD+A$A-*^\7",HPK@3S33P./,)WW6@(,%WXT&O;SI+F%<;^Y=X3;A*)RB9FK.
M-L'[?(DQ'VXK+*D!1W%BQW&"+*&!%FS;55`Y+H77!2FW7F')#(R8;\47Y(.N
ML1HVH6KD,8W#<(C)N(SE1<Q)FP',J)FH.FQ:-YF/71A+XD]F`,HI+HL7=U!_
M[5UM!S`_Q"'M"-.=9,-ZY4Q4*"P6[3FNF=`E;9#LAV\-W&,['>[40OG$:D,F
MYQC5YP<QM`XA`+B@>..4<RB(-$Z7UA;'+ND\YJL383B-)(N#DHTE=KED'#)Q
MUQ6E[,ZP.823:.W:F*A5XG+_`)G1;9&`)-Q6Y!$;:D/%=GC$GBLC\9\ASOKA
MC<E8=%<$P0<4PW*&9)T+KHVY1M1W6YKLAV6S+;E`VZ+A::9M0%Q!<0T/M;*E
MBB^#M[U!POFC>:TQB:L25,C3W%<-)#=Q(&G(SC3*1XPMBXG"=8=$E(Q045$+
MK%Q"2@SK58M=6>^Q)L[M4C3\(K@,F.]).:I0W94YZ,@`CINF\++T9K(8N(>"
M;15L5(+WH2VW&UZ*L5NN6R?#@1V)(J?$43;:$5!3^/EPPS=.^@G:!0*!0*!0
M*!0*!0*!0*"C\P8.H7;I!DVA<KZ6N\0[<\J*H,7:4VPL!\]A(*(C3P9RV=?+
M\:@I8:-YE([?'+?'N%L:N:R7[<!W1''V+@4"W1XDF4\CYJ^RV[$?S`2GU%3Y
MM<<!#N<TKS#CS94F%:GA>-VX*C[<EAE2";>8\O,'#D`?6C-FJAG#'P<Z8XT'
M1&TAS7>LLDWWKM'OC4>''C*5S4V'"::5)!$VW,;3YUQH,7,PN(A*28KF$@L^
MN[1KN8Y#2T!.P*TNQYJPYR,"DPI4-QHQ4GHY*0-,R!5Q!QP)$Z51`X/V'6[F
MC+9;5^D>U,WYQR5EN"A+6S]N><;`Y8OB9JD,FP7YS-C\-!7;7IKFO'&V`\W=
M'6VUBG<QD7)M_BJ,&:S)'`Y1XB;SD8D'P>JI;%WA]A:1YFQ&X8VN*_;)@1HD
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MPP:+N5+_`*5\[P\>>D\6,^J?9YR6Q2ROV>>&*^&VL8Q1._F>`O@&HST^2'A^
MV$O!YGZ)EJ@G<$A'N5)S;D447Y/%=$6B7[DUKQMPWKO"46B5H:=:>;%UHQ<:
M-,0,%0A5%Z45-BUYI.5`H%`H%`H%`H%`H%`H%`H%`H%!CS[C;[=%.7<)34.*
MW_62)#@M-C[IFJ"E!0KUS^Y:VPB!F:[='AWA`:)P5^Y>/ALE[QU[5Z][;0]J
M\%YVA59?UHK6A+V+3\ET,=G:'VV2P[N#8R$^S7M'2O\`#UCIW^'RR?60N-VF
ME$:TNRV0M$[F*XDJ8"0CALB?;UW_`*4YQEX=CCGBB)GU69GG&ZBXR;(J!TI'
MDBZ?O"XVP/\`2I/1O\*W[H2T+FUI-_!):2K<2[422PI#ATJ3D=7VQP^V)*\;
M=:]?1*+Q*UVZZ6RYQDE6V6S-C*N"/QW`=!5^Z!22O!-DT"@4"@4"@4"@4"@4
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M1*U"0D*$*H0DF(DFU%1:\DGV@4"@4&)-O%H@O,L39T>*_)7".T\Z#9.+B@X`
M)*BEM)$V=V@[9,R'%1M93[;"/."RRKIB&=UQ<`;',J8D2[D3:M!W4&-$N=NF
M,N/1)3,AEDR:><:<$Q`V_#`E%51"'I1=U!]@7&WW"*,N!):F13Q0)#!BZV2B
MN"X&"JBX*F%!7?XI_J/\KH'*?]UFC?T';?Q-N@M5`H%`H.B?/@V^&[-GR&XL
M-@<[\AXD!L!3I(B5$2@T?K;ZR8"3D/1T5'438MVF"2!_\,?JFO>)S#;\54JY
MQ=.;:VT6^+J3.LZ-+W_4^HM1/\>^7%^[email protected]/O12K]."E=H7
MJ<-:[0C*]7J4%JY=_G.=_@M_AE7(W9/]G^/^5\J;)*#E;GIEJ>X]HE.VUU54
MB[,60#)=Y.,JA,N+WS!:\>3KTMO"<7F%\T_S<?:4(^I8Z*WL1+I$$E%.^]'Z
MQ#]TVI)]J*5G\O3M76-8>U>6)W;)B3(DV*U+AO!(BOBALOM$A@8KN(2'%%2J
M;U=M`H-/ZXM<\>8S=X@V]^8]Q(T=[M$(S;CM,,F\,^%<$'AL\(S4767%5'%3
M=BNT(*S:BYG72S6>]JLRZH[;AG09AVME#:GOV5\W4:RQ@7A)(5H&C1,#XA#F
M--P20ZKYJ1G+<S):NLD$GM=M=6UH0N0W';<KXGP8RX<-IZ6@8("]7PB(40@S
M+I$OS7):!8H=OD,.W)URWS"['(>.%'<-X^,<-H>,X"J(-J*#A@>94445%"Q<
MFI%W72_8[K"F6V5#46EM\N/P@93#:++J-L@^)$BN9FTRBA""895H+[0*!0*!
M0*#%N=TMMJ@/7"Y26X<*.F9Z0\2``INVJO=78E!HK6_UDY#A.0]&QT;:W?2\
MP%SEWV8Y89>\3OOA5WBZ<SK;1<XNI,ZVT:9O%ZO%ZE]LO$Y^X2DQRNR#4\F.
M]&T7JMC]J"(E7Z<5:[0O4XJUVAA5Z/0H+'H#\_N?Z5S_`*C5<_)E_P!G]M6P
MZFQR@XM"3$E)<5QR),3!$E1S)IW!-R*8*BD/VJXHO2E>=^*MMX2BTQLNE@YK
M7B"H,WUKZ2B)L6:P(A*!/E&T.5MU.[DRKAN$EJAR]*8UJ]J\ONV?:KO;+O!;
MG6V2$J(YB@NMKCM1<"$DWB0KL(5VHNQ:HS&'LRZX%!KOG-;7[A;+<,>.Z_)B
M.O2XS:V]VZ0W708)M(\R.R)F@/"\2"X."@28I04>XW+F#+M5]L\%J6X$",Y#
M<TV[`8G1F&RT['EL,J^4<T?>2XOBRH&99FU4B39FH)R?J3F7%NL\V%NTFW//
M26XX);!PC@$^"$=QM1B*X2'&?E*2D+JX!B@*J8$&1RYEZK;+4^H;C9Y1WB1:
MK:[V9R.<,I<V)'?%YL>(`"ADY@F*)AMQ3901W)T=2P-4W!BXQ;BU$NCCTX91
MV]^/'D./_/J+B/-"<98QFXVO%-2>Q!1)1'"@W30*!0*!0*#6W,3GAIS2CCMN
MA"EWOH=4XK1Y66"__>ZB%E)/D"BEW<$7&O;BX+7VV>W%P6OML\]ZOYC:PU:9
MI>9Y+#+=;8^+,1$[BM(J\3W7%)>_6EQ]6E?F6AQ]:M?E6JL+!0*#;-E_,\#_
M`$[7X"4IM#Y2=V;4G"@R+1=+Q9#0[)-."..8HJ(CD4]N*H3!=5,R[R;RG]M5
M?DZM+?$O2O),-EZ5YI0+B\U;[RVELN3BY&7,V:*^2[$0'%PR&7R#Z=@J=9G-
MU[4_A[UO$KS7@F4"@USS&TWJ.XW^)/L4%\Y;###!/JY%*!(8<E(4B/,8>,'1
MX0@+K;K*9D7=CNH*KIX-?75N/=+:]<[C:QN*A,S3HQH\D6[NBIL(;X\,`AMJ
M!CU5-5!<JX*5!CR;-ST:L#D6$Q=3N#D5IP'W;C$-0GI#DB>^4*JWQU8ZN?(A
M)FR&F**%KBVC6D?16J([%H=;N%VO4E]N(3L17BM\Z2'&-HN*;".C&(U!'#1,
MR;=F\/O)C3NJ]/L3K=?84QD`+"%*>D,.L.M#AE<)L)#YC*<S+QNKPQRH@+A0
M6+^*?ZC_`"N@<I_W6:-_0=M_$VZ"U4"@4$1JO5=FTM9'[S=W5;BLX"(`F9QU
MPM@--#BF8R^QO7!$5:[6LS.(=K69G$/*','F3J#6T_B3C6/:V34H5J;5>$WM
MV&Y_>.X?&7=\5$Q7'6X.M%-9W:G#UXIK.ZIU962@4"@M7+O\YSO\%O\`#*N1
MNR?[/\?\KY4V2[_H^?G`.S.YW1SM#D+$AWXBF&U*CYQ[NXE\"'+,%,&'"!"4
M5)!)40D3%4QPWX4\H,.FI.)#3FH[MIJ8K]N7B0W2S3;82_-.X[S;QV-/?;)L
M+XZ+L4:G/U8OK'W/6G)ANK3VH+;?[4U<[>:DPYB)-FF5QMP=AMN#\4Q7?\*8
MI@M9-JS$XE9B71K&\S[)IFX7:WQ0FRX32NM1'#X0NJ/Q,^!95+<BJE<%4B\V
MK',MDVYW)E&+"S&`9D<VW79;,DED#+B2XX@0AP$BGFQ7;\&8,KUB:-M5O<M]
MF;&*W;26,U&"*\W&:%M(Y8H+#996B"<RH$(Y>LFW#&@S9'-31C$F9&*0^3L+
MB<7)%D$"\&24-W*XC>3J2&R`NMLP5?!VT$<O.32JSD#BE'M[;Q@]/DLR`:<9
M"TI=U<9,6R'JL$)*+BBN&."+LQ#*F<X-#0I"19DB3'E(;@/QW(<H39X2,$9O
M)P_FP0)C)9BV8$E!=*!0*!0*"&U;JVR:4LKMWN[W#8#JM-#@KKSJHJBTT*JF
M8RP]Q$VK@B*M2K6;3B$JUF9Q#R;KWF'J#6MR[3<CX,%HE6#:VR5664W(2[N(
MYAO-4[N&5-E:W!UXIKZM3AZ\4_E6*L+!0*!06/0'Y_<_TKG_`%&JY^3+_L_M
MJV'4V.D&K+(<;;=1QL6C8.2IJI8"#9*"YL!5<<VS9C7G/)$)>+(72T\",776
M6LBGM)35%;;7`G441+J>[M[VRH_OAWPE#U[(,FT7:ZV.>MQM#J-2"P21'/'@
M2!3<+PITI\4TZP_<XBM?GZ\7CY3I>8;KTMJFW:CMW:HBJV\VJ!+B&J<1ES#'
M*6'0N\238J;:R+TFLXE:B<IBH.M;6[FU)=O/T)<H#=OND>X2H\QHB<<1V!':
MDNC/AY0S.B2PB;(,,1/8O1B$E;=>\OF9;IVYA6)MS-QV23,,FW'Y$=YF(X+A
M""<1X3D-#@JJ6"]R@Y0.:VF2;AMS9!=MF%E1N-%F.(.>2_&9SBK2.!G.(X/7
M%,%%<<$PQ#$N'.;3`Q9)6]7776(4Z8XZ[&DHS'^CVH[QI)%MLW@3)-:)<`51
MQVX+LH)6X\T-'6YQT)4A]%;<<8;5N+(=1YUB0$5X&5;;+B$T^Z($@]/N+@$[
M8[U`O=K9N<`C**_G0>(!-&A-F39B8&@D)"8**HJ4&=0*!0*#0O.7G:^+\C3.
ME)*MDT1,W2[-+@2$.(FQ')/!(5V&XF[<.W:ESK];RUG9;Z_7\M9V:'1$1,$3
M!*TXC#2B,%==*!0*#;-E_,\#_3M?@)2FT/E)W34>VH[`6:;XMM#(;C&BH2J/
M$$RSK@FY$!=B;:Y-\3CX=B-&>&ES>5%C24=!0;(5R&BYGLZ@*BF*IU6E)5[F
M%><\^-X=\$7<(10Y1L$JD@^"YE44-/E#CO%>A>FO6ELQE&8PQ7&VW6R;<%#;
M-%$P)$5%1=Z*BUV8%QT/S"D6=QNV7Q]7;,6`19[JJ3D8E7!`>-<<S.Y$-=H?
M&Q#:&9V>KX_579[\?)G26W:HO9BW5V4S;);L0@"2VRX;)N@KC:&(JHJ0"3:D
MF.]$)/=H-:63F]=5FMP[_$:BSX$,SOUMC@N?C%(B,Q9,5]Y]MOLL@)F=,Z8C
ME)%+$5H)-.<5HF12&!!GMRW[>U<87$:CEBQ(BR'T?X:R6\P,E$)MU,P]=11%
MP)"H.0\Y+",@H:PYLAZ-&61+?`8S38H$:-))2%V2)@BI-;1%7JXX]94%2H.E
MCF_#N)@Y"B2(L`'[>V]+>;:<7&9*>BFT38O@H93CX<05/NY5V8A]=YW6$$B(
M%GNCKL]AF;"9`8:$[$D19,QJ0*E)$4$FH#VPE0D5,%%,4H,WZ8A_MQ],];L7
M[-=LW=?A=HXF[NY>B@SN4_[K-&_H.V_B;=!:J!0<'WV([#DA]P6F&1)QUTU0
M1$!3$B)5V(B(FV@\@<S^84O6VHBEHI-V>)F;M,4DPRMKAF=-/[QW#%?DI@/0
MJKK=;@\(S.\M7K</C&9WE3ZM+)0*!0*"U<N_SG._P6_PRKD;LG^S_'_*^5-D
MK0=PA#;7817-MXWVBRR,LC$77'67',V9L505%E!1!Q[JX8U5\)\LX_\`GR],
MZ;N\M2VV0]-1U1!MQ7PBN8."J@X3CF9W)CAG)S*N5,<.Y@BU']-HB/\`#OE"
MJ25960ZK"*+"F2M"N]`QZJ;>]5N,XU><NNNN)'36II&F+M](AF.WO8!=HPXK
MF:3<\`I_:,[]GA#B._*HU.UP>49C>'KQWQHW5=K;#OUF<AE(-(<T!7CQB#$F
MUP),I*AC@2=*5D+*L:DY?<OKK<WX]P-(UTO9-R)#33Z,.RBB,NQLZ@GA_-22
M$E1/DJF"BBH'-K0^A9]LF.PI*&U(B1;=,N4=\'"5JV$N1"<P,$-,$1PL,5RI
MCX*4%:LG*ZWR"G7&Z7QF7:KS,*8CT%QL1D279BO1S1[*I)D4R;!M'#'$MF"H
ME!,M\G-#.$L,WI,EEA$[1`<D(8?.6U+5BX*)F%3A#P]BIW4VIC0=DOE-H^](
MY*=F2I;SP/QI,T7VS)Q"[.RZ)$@*.(I;V@7!$P45^,1*H7U$5$1%7%4Z5WK\
M%`H%`H.#[[+#+C[YBTRT*FZX:H(B(IB1$J[D1*#R!S0Y@RM:ZD.6)$-FBJ35
MIC+BF#>.UXA7^T=PQ79L3`>A576ZW!X1F=Y:O6X?&,SO*GU:62@4"@4%CT!^
M?W/]*Y_U&JY^3+_L_MJV'4V.E(]Z1E(:"T:=E;-HT%Q$1P7#(U0NJO5ZV"I7
ME/'G/RE%F1&U9/;DR)#N9PI!D:BAJ(AF$D^;%4(1)"420L/BIWZC/!&(CV=B
M\HB5(*1)<?),%<)25,57#'OKM6O:L8C",RZJZXRK/>IU@NK=W@BKA@B!+BBJ
M)VF.BXJVN.S,.*DVJ[BZ<I%C6['!YU^7I2^);ZMUPAW*!'GPG4>B2FQ=8=3<
M0&F*+MVI[BUC+2I7[0^APMT61J&2J)`.:,>ZRGA8>!;LVZQ(#C`C6QSM)8)T
M%@J;DH.RS\N=%P#A1F5*4_;)7TK$!YY#-MQQI6,^4<OS:X8HF&7,B*G@I@%4
MD\OK1'U,ER8U%&;MME;%N<3[S*R(R/27Y$H7"RY6NT]I44-%;,.C'902L?DU
MH-N'V=B;,1JXQ'X2*DS'CQ942/&>;'%%0A*/!9VHGQ<:"3?Y8Z4DON-D^^L@
M'3FB".-J3#TJ2$IY\`4%05D2(R&N*9?"041%)*"QV"QQ;';`MT5QQQD''G<[
MRB1J;[I/.*JB(IM-Q5W4$C0*!0:IY]<R'=.6=NQ6IY6[W=@52>!<"CQ,<I.(
MJ;4-Q<0!?NBWC5CK\/G;XA[]?B\[?#S$(H(H(I@*)@B)T(E;$0UWV@4"@4"@
MVS9?S/`_T[7X"4IM#Y2=TN$\AM;MOX:*#KP/JYBN9";$A1.YA@:USQ^K)G3#
MM2\21FG+$1$R;1H!VY1$00!P3'XHCL^&N?KC&'?)UW2Y/7&64ET1`B4ERCBJ
M)F,C7PE5?"):[2GC&"9RQ*FBC[M?+3;&_P#//B!&BY&/#<-/M6QQ)4]["HS:
M(>E..UIQ6,K[R*YFQ[T,C2\A#:=@#Q+03Q)G<B#@*MK@JIF95=FW:"I\DJR.
MSP^,YC:5ZW#>D1Y-LS8;$V&]#D(1,2`)IT1(FR4#3`D0P42'8N]%JL\U0U1;
MN5\1RUV_4/`9DR&PA6PWG71D*W%<"4"<="XHHTXP!HX1["Z<2VAFVK3.@7XS
MUOMC##K=J:?L;R,NF1L-OHV^_$5Q"SCO!<N;$=R84%*MNB^7$A^\7I;XW-TZ
MKC;,ML'Y(MHHM-1V([SZ2%:=1O(VK>5M',V55)5WA8[7H_E8Y='8-M9%)T-P
M77669,H,3C22>15P<0759D/%COR$65<-B4'"T::Y2WL5B6?@RDA"#B#$ER$5
MIIQM]AI`)MQ%%GAO/@V`KD1"-!3:M!W?0]O_`&Z^AN&OT=^S78^#G/-P.T</
M+Q,W$QR;,V;'OXT&;RG_`'6:-_0=M_$VZ"U4"@U#]9#5A6[2\;3\<\LB^&7:
M<%VI$8P5Q/\`Y#(![XYJL]7C\K_$+'6X_*W\/-=:[6*!0*!0*"U<N_SG._P6
M_P`,JY&[)_L_Q_ROE39)0*!0*"/G:@LL$E"5,:!U-[*%F<\6.8_L5&;1"=..
MUMHRV=R)UG#O=CFVE@R+Z&=%(^<5`NR/HI-)@6W`#%P!3#8*#6/V:>-M-I7/
MUVK$>4..M=,W1[F1`N]OM+\MAZ&D6\DXC#L-^&T^#F44)P'69+><B;4?"V)M
M3,HUW'58I;UOB75)>A[@CVH9#DHK4V$%(^:-$$6V%$7\,A!'`%<),"<)45$'
M!*")31>M)$*V2(%K&&U&O35T*V3"%E1EO31D29(@PKH<%ILN$VF9"RYR5%(T
MP"SZ%LVKK#J*]OWF&,Q;P]$5VX1#0D-Y&3XKQBZK:BT&"`@IBHIE%$5$QH)O
MEI;Y-NTRY%?@G;E^D[L^S$,0'(Q*N<B3'P$%(43@O!L3=NH+30*!0*#4OUC=
M6G:])L6*,YDE7XR![#?V-G!7T^_(P!47>)%5CJ\?E?\`A8ZW'Y7_`(>9ZV&L
M4"@4"@4%CT!^?W/]*Y_U&JY^3+_L_MJV'4V.4"@4$-/U?I^&I`4L7WAV*S'^
M=+'N+DQ$5^Z5*AYP]N/@O?:%>G<PYIJHV^&#(_%=DKG+WVVU1$_GK3,RO<?]
M;/Y2V[]6_6<NXPKII^>[Q'X9]MADJ".+4@UXP(@X;`=ZWW]97;X_&V?=WGX(
MX\1&RT\Z;#.O&F8@V^#*EW"'.9E0G8?",F'DQ:SN,/$`O-D#I`0X]..Q$S)5
M>#&MJW73UUD7RX6`P5C35N9F,VL&E;.9&-U78T9#<!3R(Z(MXKM38BJNR@J+
M^@-<E<;RX$:2RQ)G))BO`39NV]1O13.)!0GE&0CH%QS%X4RKU43^RH);3>D]
M>6ZYZ1NDVWM.L6>WNQ2B,NKQ66TBBA!D<,VU>?>%5QXJIX(J75S*%ULT28G,
M6^7,K<[%B3[1:FAD&+:(<B,]--T"4"+$@"4T..[8J(NR@ME`H%!\(A$5(E01
M%,2)=B(B4'BG6NIWM4:JN5],E5N6ZO9!7XD8.HP.'1\VB*7VRJM;/7X_&D-?
MKT\:0A*]WN4"@4"@4&V;+^9X'^G:_`2E-H?*3NS:DX4$/=M56:V$33SO&DI_
M]5C`W/OMJ"'WRI4)O#VXN"]_MA4+IK:]3<S<?"WL+L^;7.\J=]Q41!Q^U'%/
ME5S66GP_UT1K:<J_E3.1KB3CBXN.$JD1+W2)=JKWUKL1$-&M(K&(C"2T[?IF
MG[]`O</'M%O>%X039G%-CC7N.-J0+[M>?-Q^=9A#FIY5F'MJ!-C3X,>=%-'(
MLIH'V'$W$VX*$))[J+6(QFO^:&C]2WJ_Z=N%@89:G6]X\EX5W*3#;C#PO-OL
M$!MO,.XMIA@I;T3#-F0)1EC4=FGZBE,VH;A].WIEZ.RC_#RQOHZ-#)UPLAY<
MIPU)47XI)MS=6@IUPY0ZDF:==@VI]JQPTF),M^G9)'/88+A,!U'<X<-`,'C!
MM,P)GQ1!7#*$OIG1>K;%K6ZWY6FY@3U?%]I7A;859$UDFWH@*+AQU[,CAR@5
M<'71%4[J!<=/VB7&NM[N4P`!V?(;;AB"HN2#%:%MD-G=<5UW#HST&#_%/]1_
ME=`Y3_NLT;^@[;^)MT%JH%!Y5^L%=3F\RY<95ZEKC1X@CT8D':57W5[1A[U:
M?2KBLRTNG7Z9EK>KJX4"@4"@4%JY=_G.=_@M_AE7(W9/]G^/^5\J;)8TVYVZ
M"*%-E-1D7P>*8AC[F*[:C-HC=**S.R!E\P+*UBD8'I9)LQ`.&*+WU=R+AWQ1
M:YY^T+5.CR6],?RA9>O[R]BD9AF(*[,5S/'AW45>&*+[HK7/J6Z?UD?E*$EW
M6ZS<>US7GA7>"ED!4[BMMY`7X*>/NN4Z?'7T8@``#E`4$>XB8)78C"Q$8;,^
MKU=C@\R6(F9>'=(TB*H="D`]I$O=1&"3WUJGW:_3$JG=K],2]3UF,TH%`H%`
MH%`H%!Y<^L5=#F<Q5BYEX5MAL,('0CCF9\B3[H703WJT^C7Z9EH]*OTS+6%7
M5TH%`H%`H+'H#\_N?Z5S_J-5S\F7_9_;5L)51$Q78B;UJ;'0D_6>GX>(I([4
MZF/S49.*N*="DGS8K]T25#SCTU>_'UKWVA7IW,*XNXC`BA&!=SCZ\0\/N!41
M%?OBKF9GX7N/^MG\I_\`2O3KC<I^*3I;LD5WMDJ"WXL$%O9W<N-/'WU7N/J<
M=-H8Z(B(B(F")L1$J2R4%ZY(74K=S.LZHN#4WC0GU3Y#K2D">^\VW53N5S3/
MLJ]NN:9]GKBLIEE`H%`H%`H%!4>;=S.V\MM02&URF<0HP$F\5E*D="3OCQ<:
MGQUS:(3XZYM$/'=;K;*!0*!0*!0;9LOYF@_Z=K\!*4VA\I.Z*NFN+-#4FXY+
M.D)LR,8*"+]LZO4]U!Q5.Y7//VU6.'J7OM&BH7/55\N6(F]V5A?_`*\95#9]
MLYL,O>P1>Y7,3.[4X?Z^E=;:RB1``'*`H(]Q$P2NQ&%Z(QL^UUTH%!ZSY$W,
MI_+"T(98N0^-#)/DBR\0M#[S.2L3GKB\PQN:N+S"_P!>3R*!0*!057^*?ZC_
M`"N@<I_W6:-_0=M_$VZ"U4"@\><WUQYGZC55Q7M((OO1VD3[%:_4_P!<-7J_
M9"H5962@4"@4"@SK1>IUI?>=B"T1O`@*KJ$2)E553JBH8[^[49B<Z*G9ZO[9
MC7&'*9J&_3,4?GNH"_V;*HR*>XK>4U^^):>/O+E.CQU],HU&P0B-!1#+:9=*
MKWUZ:[%8C9:K6(VC#E74B@4"@N'*`E'F?IQ47!>TFB*G?CNHOPHM5NW_`*Y5
MNU]DO859#**!0*!0*!0*!0>0^=I8\V=2)CCE<B)[G_CXR_[:UNG]C4ZGV*35
MI:*!0*!0*#)M]RGVZ24B$8`X;1,DIAG5$(A+$=J)BF3I1:C,3E7['7CEQGT<
M)TR;/7&?(<E;<<CA=3'NHVF#:>\-/&/74X^KQTVATU)8*!0*!06/EQQ?V_T[
MP\<WTC%QP^3Q1S?T<:\.U_KEX=G_`%R]GUC,@H%`H%`H%`H->?6`5$Y37G'9
M\Y`__P!"/7MU_OA[<'WP\H5M-@H%`H%`H%!D2;E<Y<9J-+DDY':`6QCA\VU@
M(Y=HIX6[XZK4(IIKJJ<73I37>6.B(B8)NJ:V4"@4"@4'I[ZMZ.>KYW,J**W!
M[AX=`\-K?[^-8_:_V2R>U_LEM2JZN4"@4"@JO\4_U'^5T#E/^ZS1OZ#MOXFW
M06J@4'C3FNYCS7U6TN\931I]R49I/Y16M7IS]#4ZGV*Q5M:*!0*!0*!0*!0*
M!0*!06CE.XJ<U]*-IO*4Z2_<C&=3^4DJIW)^A5[<_0]E5E,LH%`H%`H%`H%!
MX[YT.8<YM5M*OQX+B>_;XXK^"E:G2^UI=/[51JXN%`H%`H%`H%`H%`H%`H+#
MRW=4>96E6TWG<6U)/M11?]JI57N3]"MVY^A[1K)910*!0*!0*!0:U^L<9!R;
MOS@XXMN0#1$WKEN,<L/?PKTXONAZ<7W0\K(J$B*BXHNU%2MQM/M`H%`H%`H%
M`H%`H%`H%!Z9^K(XKG+0G.@[C*45^U51R_8K%[$YO+&YY^N6V:\7D4"@4"@J
MO\4_U'^5T#E/^ZS1OZ#MOXFW06J@4'C'GFT5OYS7QPD5&9!QUQ7I%V*RN;9T
M"YBGN5I=6<5B6CUI^F)5NKRZ4"@4$Q`TC?Y\1J5#B\8'U%&00PXAH3X1D(05
M4)1X[HACAO6H3R1$ZH3R1&[L'1>HC(N&P!M"".I(1]E&2$N)AD=(T`U^8<V"
MN/5+N+7/VU<_95%W"#(@3GX4E$&3&,FGA$A-$,%P),PJHK@NS8M3B<QE.)S&
M6/772@4"@4"@LO(UHKASGL1BBJS&.0JDG0C45Y<VWNN8#[E4>U/TRI=J?IE[
M-K-9Q0*!0*!0*!0*#Q]]8ID[?S?FRS3*$IB*\JITM*R+"DON&Q\"5H=6V*Y]
MI7^K/TY]I4ZM!?*!0*"3#3EV.U+=1:'L:"KBDK@(7#1T6%<R*N;(CK@AFPWK
M4?.,X1\XSAW!H_4!R9<88X\2#E22I/,B`J8*X(HX1H!$H`2H@JNQ%[E<_95S
M]D(ZX09$"<_"DH@R8QDT\(D)HA@N!)F%5%<%V;%J43F,I1.8RQZZZ4"@4"@4
M$YR@:=N7.#3S;6T69)**]&$=LWG5]_AY?>JEVI^F5/LS],O:U9C-*!0*!0*!
M0*"A<]X92^4NH6A%"R--/JBX[$CR&WE79W$;QKTXIQ:/Y>G%.+0\>6E_-'5A
M?#8P'[Q?`7X-GO5LTGT]FO2?3V9U33*!0=D:._)D-1F`5Q]\Q;:;3>1FN443
MW56N3.')G":31&H5>)D6V5-&B?;_`,PQ@X(DZ)(UU_G"0H[B91V]5>]4/VU0
M_;#I<TE?FK<5Q=8!N(+0OD1/,H:-GDR*K6?B)FXP*.([4)%W5W]D9P[^R,X0
M]33*!0*!0*#%N4A68RH*X.N]1ONXKO7[U-M0O.B%YT>J_JUP2C<IX#BHHI*D
M2G1%=F`B\3*8)W%X6-9'/]\LGG^^6T:\7D4"@4"@JO\`%/\`4?Y70.4_[K-&
M_H.V_B;=!:J!0>8?K7Z;)C4=JOXAC'N,4H<A438CL<E(<W?-MW!.\%7>I;>J
M[U+;U:=MDM7![.ZN+S:;"7XX;D+W4W+_`+ZT*3Z2O5GTEG5-,H%!>M+\PXED
MLL6`<8Y*1GQD]G+!`5X9+;G&![-Q&U5D%:R(.7XV^J_)PS:<O"_#Y3EUP^8#
M=N&W1(:/.VRUQR;::=%L3=?-Y]SB*J*:M91EF*9"7'#`MA*E=GASF9WDGBSF
M9WE`ZIO$.ZW4I41A([&"H(HV#6**9&F(-]5,J&@)M5<!3%:]..LQ&KTI68C5
M#U-,H%`H%[email protected]<!I<'W$VDGQ!Z2]WY/\`NJ%Y](0M/I#<7U4--$]J.ZW\
M@PCVZ*,..JIL5V02$67O@VU@O>.L_MVVJH]NVU7IZJ2D4"@4"@4"@4"@\Y_6
MRTT7&L>I6PQ`A.V2S[Z9GXZ>YM>JYU+:S'NM]2VLQ[M$6N7@B1'%ZPI\R2_&
M%/B^Z/\`)[]:%)QHOUG&B1KT>A0*"U1]6PPT2YIQUMPA<Q/+E$A%]7P-)`&I
M(8_,BK:MHF5?"WUXSQSY^3RGCGR\F2&NVHFHY=QB<9V"_P`-T(KH-@JOMM<%
M"4D5Q0RB9[17;X*I@JUS]6:XE']6:XE":IO$.ZW4I41A([&"H(HV#6**9&F(
M-]5,J&@)M5<!3%:]..LQ&KTI68C5#U-,H%`H%!A7*8K0\!I?GW$WI\0?E>[W
M/]U0O;TA"T^D-M_54TR4G5EPOI-_Y6TQ>SL*J?V\E<$45^U:;-%^Z2J';MM5
M1[=MJO4E45(H%`H%`H%`H,*]VJ/=[-/M,G_MKC&>B/8?(?;5LOL%0>`Y<6=:
M+H_&D!DFP77(TMG[9HU!P-O<(=E;%;9B+0UZVS$6A*-.MO-BXV68"3%%KWB<
MO:)RYUUTH,BWOLQY\9]X%=99=!QQH24%(1)%44)-HJJ=*5R8S#DQHNTOF%!?
MO[=]-'G9S<8HS^>.P@3`<)W,+PYR%KYHP;4@15)$5=ZUX1PSC'_D/".*<88]
MLY@--6=8-QC]M=R@7%<:9)%)G(V#:H288*PUD5U44\%5-N"*G;<.N8=MQ:YA
M2:]WN4"@4"@^&8@!&:H(BBJ1+N1$I,N3*%-QZ;*0@`B(U1N,RB=9<R[-GRC7
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MD&60.1,DN"``*8FXX:H("*)TJN"(E0F8K&91F8K&9>W^5.A6]%:+AV=<"G'C
M)N;H[4.4ZB9\%Z4!$%L5^2*5D7OY3EDWOY3E;Z@@4"@4"@4"@4"@@->Z0AZO
MTG<+!)5`[6W_`)=]4QX3X+G:<P^U-$Q3I3%.FI5M-9S"5;3$YAX6N]HGVRXR
MK7<F2C7""Z34AI5ZP.`N\23>G2))L5-J;*UJVB]<M:MHO&7="N6;*S)5!=W"
MYN$__8N]\%>E;>DIQ;TE(5Z)E`H%`H%`H%`H,*;<A:56F<''^GY(=\O_`&J%
MK^D(3;TA'QX[[SX,LB<B7)<$``4S..NN*@B(HF]254043W*\YQ6,RCI6,R]O
M<I]"-Z*T7#M)"/TB[_F;JZ&U#E.(F9,>E&Q06Q7N#63R7\IRR>2_E.5QJ"!0
M*!0*!0*!0*#RY]9KE\Y;+^&KH+7_`(Z[*+=PRIL:F"."$N&X7@'^<BX[22KW
M4Y?QE=ZO)^,M*1Y+L4U($SM$N+C7_$/?_EJ[K&R[MLF&'VGVT<:+,*[.^B]Q
M47<M>D3$IQ.79772@4"@4"@4"@X.O-,MJXZ2``[U6N3.')G"'ERCEDF**$<5
MQ%M=Y*FXB_V)_P"D\I^K^'G.K:WU<^7Q:BU>-]F-9K18#%Y"7P7)J8$P"?X?
M]:O<P''855>WR8CQA5[7)B/&'K>L]0*!0*!0*"J_Q3_4?Y70.4_[K-&_H.V_
MB;=!:J!0*#0/UB.3K\]7=9Z=CJ[,`4^FH#0XDZ`)AVEM$VD8BB(8IX0[4VIU
MK77Y_'2=EGK\WCI.SS6J"8[=J;T7^146M'26CI+)8N,EG`7$X[:=.Q'$]]=A
M>_A[](F8^2)F/E(1YT5]<K;B9_[LNJ?\U<%J<7B4HM$N^I)%`H%`H,>1/BL+
ME,T5S^['K%\"5&;Q",VB&!(N$EY%%OYAM>G8KBI[J;!]['W:A,S/PC,S/PQ4
M0&P7<(IBJJOPJJJM-(-(>E/J\\FWH2LZSU''5N628V6`Z.!-"2?]RX*[C)%P
M`5\%-J[5ZN=V.?RTC9G=CG\M(V;_`*JJQ0*!0*!0*!0*!0*#3G/GDRYJIC]H
MK"V/[0Q6\LB,F"=L9#P1QW<4$\%5WIU5Z,/?@YO"==GOP<WA.NSRDZTHD;3H
M*)"J@XV:*BH0K@0D*[45%V*BUIQ,3#3B8F'8Q-E1\!1>,TGQ#7K(GVI[?L_#
M78F8V-8V2#-SB.J@J7"-?B.=5<>XB[E]Y:E%X=B\,JIIE`H%`H,9^XQ&E45/
M.XF]L.L6/?PW>_49O",WA@/SY3Z91^8;7H%>NONDG@^]\-0F9GX1F9EC(@-C
M@F`BFWN)32(-(>F/J_\`)61;'&=8:E8X<]0S6BW.#UV$-,..ZB[G"%<!'XJ;
M5ZVP<[L<_EI&S.['-Y:1LWW556*!0*!0*!0*!0*#`O\`8K7?[-+L]T921`FM
MJT^TO<7:A"O00DB$))M14QKL3AV)P\5<R>7%ZT)?BMTU"?@NXG;KD@J+;[?\
M@N#\<,=F_<J+6IP\T7CY:?#S1>/E4A4VW.*R2MN;E)-R]XDZ:]L>L/;#.9NX
MILD@H+_>!B0K[R=9/_6VNQ?W=\_=GM.M.AG:,3!?C"J*GV*G$Q.R43ERKKI0
M*!0<7'6V@4W#$`3>1*B)\*UR9B')G#!>NX;4C`KJ_++J@GP[5]Y/?J$W]D?/
MV8#A..FCCY\0T\'H$?N1Z/Y:CCUE''K*P:'T/?M:7UNSV=M,^PY<LT7@QF57
M!7'%3^B.\EV=U4\^;FBD?+SY>6*1\O;&C])VC2>GHMCM3>2+&'K.%@KCKA;3
M=<5-Y&6U?@3!$1*RK6F9S++M:9G,IFN.%`H%`H%!5?XI_J/\KH'*?]UFC?T'
M;?Q-N@M5`H%`H-(<W?J\1KZ[(OVDD")>7%5R7;25`CRC7:1@NYITNGXI+ORK
MB2V.'L372=ECA[$UTG9YHNMIN=HN#MMND5V%/87!V,\*B8X[EP7>*]!)L7HK
M1I>+1F&A2\6C,,,@`DP(4).XJ8U*8RE,9<@<D-_U;[@IW,<Z?`>;#WJ8]I<P
M[AN$\=F<"3ND"X_T2%/L4S+N9<OI*;A_9X_<E_S5W,F9<2N$\MF<!3NB&W^D
M1)]BN9DU=)F^Y_6O.'WLV5/?0,J+[]<Q[N8]W$0$4P%$%.XB85V(P[$89EJM
M-SN]P:MMKBNS9[ZX-1F14C+#>N";A3I)=B=-1O>*QF4;WBL9EZ5Y1?5W8L;\
M>_ZMR2KNTJ.Q+:*H;$8TVH3A;G71Z,.J*[4S+@59_-V)MI&S/YNQ-M(V;QJL
MKE`H%`H%`H%`H%`H%`H-4<V^0UJUBKEWLY-VS4F'7<5%2/*PZ'T%%43[C@HJ
M]U"V8>W%SS3^'MQ<TT_AY;U-I74.F+DMNOT%V#*V\/B)U'13>[email protected]>*K
MAT[:TN/EK;9H\?+6VR)5$5,%3%%WI4WH^`A-_P!49-IT(!*@_P`WP?L5SQ1\
M7<,R</\`;J7W0A_PH-=U]W=?=R^D;A\IK^87_/7<V,RXK,G%_;Y?N1'_`(D*
MN:^YK[NH\[G]:X;G=0B7*OWO@_8KF'/%\$1%$041$3<B;$KJ20L=AO5^N(6V
MS0G9\YSP6&1S*B+LS&O@@/=(E1$[M1OR5KNA?DBN[TQRE^KQ`T\XQ>]4\.X7
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MGPX9OLUS7W-?=T\,5/.6)FFXS52+X2Q6N>,'C#E4G6P.6W);5FMG&I0MK;;`
MJHIW9\5P,?\`^=M<%=5?E>!]MCLJKR]F*Z1K*MR]F*Z1K+UGHO1&GM'68+59
M8_":3K/OG@3S[G2XZ>"9B^PB;$1$K/M:;3F6?:TVG,IZHHE`H%`H%`H*K_%/
M]1_E=`Y3JB<J]&JNQ$L5M_$VZ#H@<SK/<K%'O-N8=?8?NK=H5M<H&!O/HTTZ
M2$O@N`XVZ/3E,:#M7F'"+3U@NC,-YZ5J5QMBU6T2!'"<<;-Y<YJJ"(-M-$9E
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MY0R8<.9.)!A,.2B78@L`3BJN*)L0$7I6N3R5CUA&>2L>JV67DYS.O!#V73LM
MH%VJY,%(8HG=_P`RK2K]ZBUY6[-(]7G;LTAM/2?U47E,']67<1!-I0;:BJJ]
M/6D.BGN*B-^X55[]N9VT5K]N9VT;RTMHO2^E878[!;FH+18<4P12=<5-RNNE
MF<<7[HEJI:TSK*K:TSK*:KCA0*!0*!0*!0*#$O%TBVFU3+G+54C0F3?>PVKE
M;%25!3I5<,$2@H[7-:1)TY9;M&MK7:+@-P:GPG)&V+-ML9YUV.I@!H:<6,09
M]FS`D1<:"5DZVF')TY;;=#:<NNH8;EPP?=(&8\=AMHG"51`R-5.0`"*(G2N.
MS!0KK7/.":+%<M4ANZPY+$:[Q@%Q]MI7+F[:W.SFTV12"1V.2@*`BDF[:BH@
M3)\Z.7`MHZMT(F^S+,(@CR3RMHTCZH:"VJB:-+G4%ZR)T4%OM\YJ?"9F-`\V
MV^.<6Y#3D=U$7H-IT0<!>\0HM!T7NPV6^P#M]XA,SX;FTF'P0QQZ"''P23H)
M-J5V)P1.&E]6_55LDIQR1I>YN6PEVI`E(LAC'Y(.8HZ"=\L]6*=JT;ZK-.U:
M-]6J[W]7WFI:C+"TC<61QQ?@/`Z*^X!JV]Y.K->W2=]%FO:K.^BHS-&ZP@JJ
M3;#<8N'QGH<AL=^&PB!$6O6.:D^KTCFI/JCB@S1<X91W$<QPR*!9L>YAA4OV
M5]X2_97WAG1-):LF+A#LEPE+CA\Q$?=V_>`51GFI'K#D\U(]5KLO(7FI=3%!
MLI062_\`L3G&V!'[H,2>^!M:\[=JD;:O*W:I&VK:.D_JHPFB!_5=V*4J;2@6
M]%:;Q[A/G\X2+]J`+WZK7[=IVT5[]JT[:-V:<TMIW3<#L%BM[-OBXYC!D<%,
MMV9PUQ,R^V)56JTS,[JTS,[I2N.%`H%`H%`H%`H*WKK7,#1]OBSIC)OMOR6V
M74;WLL*N+\H]B_-L-]8O>3IH,.5KR4QJI+']'MDRL^-![4CZYLLJ&]*1SA\+
M#%%8R9<_3CCT4&)>.9SL%O4EPC6L95BTH^$:\35DY'LR--OR5881IQ'.`T^"
M]9P,RYD3=M#A`YR:;EW=J*33\:WOJXPS/>8D)C*;N*VU&S%&E%MLWD%!<,T3
M$LJY214H,^%S;Y?SY3,6!<RFR)#PQV6XT64\I&8B8E\VT6#:@:%Q%ZF&*YNJ
M6`6^@UKK?D!H'5!O2VXY6>ZNJI%,@X`)FNW%UA4X18KM)4027Y5>O'S6KL]:
M<UJ[-*ZD^K'S"MCAE:2C7V,G@*T8QGU3[9I\D!/>=*K=.Y'K"U7MQZPU_<]"
M:VM9*EPL%PC"FSBG&=X6.[!'4%6U]XJ]HYZ3ZO>.>D^J!=(63R/*C9_)/JK\
M"UZ><>Z?G'N^-F#A\-LD,U^(*XKL[R4\X]SSCW3=LT7K&Z$B6ZQW"6BX)Q&H
MKQ`F/=-!R)[ZU">:D>J$\U(]5_TY]6CF1="`[BW'LD<L%(I+@NNY5Z1:85Q%
M7O$8UX6[=?2'C;MQZ0W-HGZNF@].DW*N#97ZY!@O%FBG9Q).EN,F(;]J<135
M.A:J\G/:RK?GM9M-$1$1$3!$V(B;L*\7B4"@4"@4"@4"@JO\4_U'^5T$;HFU
M/W?D?IJULRBA'-T];F%E".<@`X;2'E3$=JABB*BXIOH/CG*UINXRI5IN`P8D
MJ3;IIP$85QE)-K5,AI\Z)?.9``]O@BB)@J8T&='Y>-,Z=T];$GGV_3+HOVNY
MBV@JA@!LJCC6*H0&PZ39IBF..*8+A@$/=.3;,TIDH;R\U=+H$]N[3%9;-'QN
M'9$(1!5^;%H+>T#>"[$WXJJK0$Y-M)>)-W^EO\Y+-PW\8;#@8K*>F,\/B\1Q
MOANRG$)0-%(%PQ140J"[Z>M/T/8;=:.-QTMT9J*+RCD4Q9!&Q)1Q+!50=M!(
M4"@4"@Z>PPN-Q^SM\?''BY!S8]W-AC0=U`H%`H%`H%`H%`H%`H%!'7ZR0KS"
M")-,AB@\S)=;')E<[.:.B#B&)HH9P123IP[F-!4&M#<OWE[;!NO"AW24^_%:
MB2(R12D28JPG>SB(*.),EAE%?"ZWA;:"=N&D;.X%G%)CT&X69HV;5<&3;20+
M1-BV\.5P#:<$@`5)";5,40MBHBT%=C:#Y:A(CW"!=>$L98S;CC4QHQ=?9F.3
MV3?4\^9TI#SAKMZV*[-V`%Y3Z&L]O>@%=)<"WW$$8?C',!II]SAJRCBB0HA.
M\'!OW$%<,PH2!L0!40$5)35$1%)<,5[ZX(B4'V@4"@4"@4"@4"@4"@4"@4"@
M4"@4%6U?HW2EY=*9J1P'(Y13ML=J6D=6&3F&(\5GC-DHOF2`(KF7H3"@P+;R
MYL4.X0U"]3I$J`[%>!IYV*9DL&.<9I',&4-?F750EQQ7?CCMH.^]:*TG->N_
M:Y[D:#=#:D7^V`\T$>03*`&=Y"%7`S@VV#F0Q0D1,>^$>_RCTB\Z[!6Y2Q"0
M92DMZ.QU1!6Y)=%RH31.9.U[=I+L7+09]ET#9+1/M+<>\SGG;*!A;X4B0TZ@
M1U;1M&LA-Y\@!L0L<V[,2X)@%RH%`H%`5$5%14Q1=BHN["@^``-@@`*``I@(
MBF"(G<1$H/M`H%`H%`H%`H%`H%`H*K_%/]1_E=!U\KER\I=(K@2X6"W+@WX:
M_P"3;\'O]R@T_;;)J0=,OQ(D)^Y,PG93,();,N+(N;DE)+#9/`K9H$R&Y@1O
M8"W@76("!5$+!K,[]<&NQLK*N%UM-F>MD>2VQ(RMZE`H;@NXH&PB!P3!['+D
MSX+AGH,EB%K%^=K"=J>POO/+$BR[;&1\G8IRVTE-L16D;P$@%'AS]"$F<D12
[email protected]%BN+>F+=9K(+UTFV*$Y;`A/-RP5^5(ABW&F,R!;-M76"3/Q%7*.8L3`
MMM!M6W-2F;?%:F.(]+;:;"0\FXW!%$,DV)O+;09%`H%`H%`H%`H%`H%`H%`H
M%`H%`H(O5,%NX::NMO=B.3V9L1Z,]"9<%IQUMYM6S`'"41$B$EP553;TT&A;
M=H3F$MHLO_BG&EB.O`VBM-M.3HZNV]P&+B`N#P,W9G$5X$1<&A543-E(-G36
M7=1ZPTM>`L[X6YAN\PKBLD&D4$(DCB)Y3/,#I,D0X*O55%7#&@K=ZT)=&GYE
MT8L?&8N!7N,MHC"R&1'XS<&WN9<PAD-N,:JN/5XZJ6'6P"6O.G[Q<5TR"P[C
M^T5@5AH+D?9S@/@#[`33>$S<V.MM*X"Y4<[G6ZM!LZ@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@UMSSLDNZV&U=C@R9<V%<XDJ(3#;<ED'1?!O"5&-15UDFW#QP5,
M,-I"E`@V>)8KQ^U$O3C<)RUV=EMY+<RV;KTVX.BLP`+%">X'`;05S*JYR1,5
MV4$4&CV0FZF<&!/*UWHA<4Y4!B3*8N+KTCBN-BHYGF!`T(4<SB"J.3I00C=-
M:6UC9=6V6Z3K8XY'MT".,RWQPX@HY'L[C/:6'U<7YSB)V18Q&HKF1SHS4%RT
MW8G6^9%SU!%BS&(MPCOMW1;BRR)=I:=8",L5Y$XRLFRVYB.=1V!X*[*"_4"@
M4"@4"@4"@4"@4"@4"@4"@4"@JO\`%/\`4?Y70.4_[K-&_H.V_B;=!:J#X``"
M*@"@HJJ2HB88JJXJOOK0?:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!057^*?ZC_*Z#6^@O7O^PVG?H;Z(^A_HR%]&]HS<;LW9PX/%R[,_#PS8=-!
M/>T=YC\I0/:.\Q^4H'M'>8_*4#VCO,?E*![1WF/RE`]H[S'Y2@>T=YC\I0/:
M.\Q^4H'M'>8_*4#VCO,?E*![1WF/RE`]H[S'Y2@>T=YC\I0/:.\Q^4H'M'>8
M_*4#VCO,?E*![1WF/RE`]H[S'Y2@>T=YC\I0/:.\Q^4H'M'>8_*4#VCO,?E*
M![1WF/RE`]H[S'Y2@>T=YC\I0/:.\Q^4H'M'>8_*4#VCO,?E*![1WF/RE`]H
M[S'Y2@>T=YC\I0/:.\Q^4H'M'>8_*4#VCO,?E*![1WF/RE`]H[S'Y2@>T=YC
M\I0/:.\Q^4H'M'>8_*4#VCO,?E*![1WF/RE`]H[S'Y2@>T=YC\I0/:.\Q^4H
M'M'>8_*4#VCO,?E*![1WF/RE`]H[S'Y2@>T=YC\I0/:.\Q^4H'M'>8_*4#VC
MO,?E*![1WF/RE`]H[S'Y2@>T=YC\I0/:.\Q^4H'M'>8_*4#VCO,?E*![1WF/
MRE`]H[S'Y2@>T=YC\I0/:.\Q^4H'M'>8_*4#VCO,?E*![1WF/RE`]H[S'Y2@
M>T=YC\I0/:.\Q^4H'M'>8_*4#VCO,?E*"''UW?M>YF^BOVA^CPX6&;L_8N,>
,?'XW$XN3#O8T'__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>a62430us.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a62430us.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````4```_^X`#D%D
M;V)E`&3``````?_;`(0``@("`@("`@("`@,"`@(#!`,"`@,$!00$!`0$!08%
M!04%!04&!@<'"`<'!@D)"@H)"0P,#`P,#`P,#`P,#`P,#`$#`P,%!`4)!@8)
M#0L)"PT/#@X.#@\/#`P,#`P/#PP,#`P,#`\,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,_\``$0@`PP);`P$1``(1`0,1`?_$`,L``0`"`@,!`0$`````
M```````'"`4&`P0)"@(!`0$``@,!`0``````````````!08"`P0!!Q```00!
M`P("!`D'!P<)!0D``@$#!`4&`!$'$@@A$S%!(A31,A655Q@H:*A182.U%C<)
M0E*%%T?'B'&!<C-S-'618H*2LD,DM#:#D]0E5F/31%1DE#4G9Q$!``$"`@4)
M!@0%!`(#``````$"`Q$$(3%1$@5!87&!D;'!T3+PH>$B$P;Q4G(S0B,4)#2"
MDK)#TE-BXA7_V@`,`P$``A$#$0`_`/1K@'M[X1S'B;&,FRKB_'\@R&Y=LW[6
MYG1`>D2'/E*4/6XX6ZDNR(GCH)C^JKVX_0OBGS>W\&@?55[<?H7Q3YO;^#0/
MJJ]N/T+XI\WM_!H'U5>W'Z%\4^;V_@T#ZJO;C]"^*?-[?P:!]57MQ^A?%/F]
MOX-`^JKVX_0OBGS>W\&@?55[<?H7Q3YO;^#0/JJ]N/T+XI\WM_!H'U5>W'Z%
M\4^;V_@T#ZJO;C]"^*?-[?P:!]57MQ^A?%/F]OX-`^JKVX_0OBGS>W\&@?55
M[<?H7Q3YO;^#0/JJ]N/T+XI\WM_!H'U5>W'Z%\4^;V_@T#ZJO;C]"^*?-[?P
M:!]57MQ^A?%/F]OX-`^JKVX_0OBGS>W\&@?55[<?H7Q3YO;^#0/JJ]N/T+XI
M\WM_!H'U5>W'Z%\4^;V_@T#ZJO;C]"^*?-[?P:!]57MQ^A?%/F]OX-`^JKVX
M_0OBGS>W\&@?55[<?H7Q3YO;^#0/JJ]N/T+XI\WM_!H'U5>W'Z%\4^;V_@T#
MZJO;C]"^*?-[?P:!]57MQ^A?%/F]OX-`^JKVX_0OBGS>W\&@?55[<?H7Q3YO
M;^#0/JJ]N/T+XI\WM_!H'U5>W'Z%\4^;V_@T#ZJO;C]"^*?-[?P:!]57MQ^A
M?%/F]OX-`^JKVX_0OBGS>W\&@?55[<?H7Q3YO;^#0/JJ]N/T+XI\WM_!H'U5
M>W'Z%\4^;V_@T#ZJO;C]"^*?-[?P:!]57MQ^A?%/F]OX-`^JKVX_0OBGS>W\
M&@?55[<?H7Q3YO;^#0/JJ]N/T+XI\WM_!H'U5>W'Z%\4^;V_@T#ZJO;C]"^*
M?-[?P:!]57MQ^A?%/F]OX-`^JKVX_0OBGS>W\&@?55[<?H7Q3YO;^#0/JJ]N
M/T+XI\WM_!H'U5>W'Z%\4^;V_@T#ZJO;C]"^*?-[?P:!]57MQ^A?%/F]OX-`
M^JKVX_0OBGS>W\&@?55[<?H7Q3YO;^#0/JJ]N/T+XI\WM_!H'U5>W'Z%\4^;
MV_@T#ZJO;C]"^*?-[?P:!]57MQ^A?%/F]OX-`^JKVX_0OBGS>W\&@?55[<?H
M7Q3YO;^#0/JJ]N/T+XI\WM_!H'U5>W'Z%\4^;V_@T#ZJO;C]"^*?-[?P:!]5
M7MQ^A?%/F]OX-`^JKVX_0OBGS>W\&@?55[<?H7Q3YO;^#0/JJ]N/T+XI\WM_
M!H'U5>W'Z%\4^;V_@T#ZJO;C]"^*?-[?P:!]57MQ^A?%/F]OX-`^JKVX_0OB
MGS>W\&@?55[<?H7Q3YO;^#04P_J5XH_;;Y+_`&!I_D[ZQ7[*>Y>[IY?R)^Q?
MRI\G=/H\CWS]/T>CK]KTZ"Y_:Y^XK!OZ3_6<O03_`*!H&@:!H&@JYWH<F9GP
MUVU\E\I8!9-5F585'AS*TY,9J5'=\V:Q%-IYIU%W%1>5=Q45143QVW10KDSW
M#\GTTWBK(KK-KES!N0,XCXU%JI6&Q1N77J>)<NW,:0P3]>['8FHS&=ANMLNN
MIT$A!L:=8;AB_P#$-XUS>DQR=AF`9;E^09>W<2<<PBE6JG6C[%!5-6]DA,LS
MR\N0TV^#*1B5'C?5``";5'5#&<J]]]!5,<KX)C./Y%BG*&.8AG-OB4B[B0Q$
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M%U4.$U.BF4@^CH<(3:-M6Q51(,K'_B3YC69!8<@W]`T]Q@N:<DX6F`Q@:66P
MW@N-UUS$F,SE$2)^7)?>:=0]VT;)M0`2;)7`NMV>=P%ISM192_F=F<+DVC:I
M)^7<;-UH086/PL@AE94RQ'NN0[+&5$-")XWUZE#<66/BD%RM`T#0-`T#0-`T
M#0-`T#0-`T$=\N9-=85Q;R)F>.^Y+=8?CEE>0&[%AR1%<.NC'*5IUMEZ.:HX
MC:ANCB=*KU>UMTJ'F[B??7RMD/#2<R(YQVY2PJRB_;$3JKZ.SCUS?7$"+$AO
MN19=D]*!R&](7S`8;0'O)$O9(M!<")WC\&6*615UW86+<7)6,.J7(U>^ZEM?
M29K]>U75_2BJ;Q/Q7=T/HZ6Q\\E1@@=(.E4]Z7`^2V^+X[1Y+8!9YH_35E-,
MF4E@VQ&MLD9EOU$&8VX#+H.2`@ODB;("("]3@;CN$9TO<=SSFW9*WW'8'B&+
M6G)]<M]-M<(<8G'`FP*"XL*Z0$)`EH^#ZL1$>%"(^HD)M!W,2$,=B??;B[U1
M0<EYA?US7$>68NS(QEROHIX7,R]K*WY4RL@!)TMOW&F8%4=)!5?.(HP&XXS^
MG"8H_>IV_3<D<QBOR>98RS:O"J)L6NE/1;)[&JR/<6\:$X`*KCL:%*;>5%%$
M-"V;(RW30;?QMW#8MS?AN493PY4W.1N4L1EVDCWM;/QR-:/3(B2H?D2K&,"$
MRYU(A.M@?2GM()(H=84^B=Z?,\.Y>XNR3!</'E"3R1<811954OV$C%I4>AI5
MN+!]L7O*?-V.71&<!'1Z7#7?Q;4"#4<0_B<+G-ACEQ48-#A83&N>-L8Y`C2'
M7G+%JTY"CV+I.07T5MKR:TH0H2&TI/=1;*ULFX3QVJ=U&8=P?)G)U':3,$K<
M:Q('WJ?#8,?(8F8QV'IB#7O6;5K%CPR;6.BHX<0G!\U1V415.H+[:!H&@:!H
M&@:!H&@:!H&@:!H(MYOS:WXTX<Y2Y(H8T.=:\>XM:Y-&KYZ.+'DI417)KD<U
M:,"'S09($)%]E50E0D3I4*1XIWHY_DF"8%R,RUQV_C&7VN*XW<3FW;I0J,DR
M)JEL%I'5AL3R<=2%;*(O=`-!(:)MY6UZ4,+$0^\S@"RJY%Q6Y/964)+>/15"
MQ:2T>.VGRG9S3;-8`1E64J+6R5/HW\L0ZW.@"`B#JM]YG!%W*ATF)9FMC>Y#
M!AGBS[U79!`=G6U,M]5Q'GS8;%MR1!V?0#(54=QW1Q%%`B@NZSEZZ[(:#NPP
MCCJCN<A2NDWF5X`X[*4!JX<U^-*>AO`J$I1VF?/(33Q!#V5%1$(-BIN]KCP1
M:S#)<G@CQ1D=2$_C^_K:BR?G6(5T)B3D5B\S&.8C$&L<>1EPS3='O,9\29ZG
M0D4N\GMW"WRVH+.7E<PF)D4Z[GM5-H_$5G$>CY>6,^S%,7U@H8JXC74JBO4'
M6/CH-KQ'G;'N7<#R3+^#(LG.Y56;46EBVD2=CL:9(EQV),5[S[.*R:Q%:D@\
M3S3;BJWNK0.'T@04B/OZY,K(Y8ED?%E#7<G-Y3R71!/AV,J7C4N-QEC_`,N6
M,B(\K3,@U><(8@HHIT%UD7M`3*!WL6_B15N7Y3A;\#"!K..\BRSCW!K.7.DK
M\I1[;D&DFV[#XJ*(S[O"..W'<ZO$^HW!41%!(+)\"]S?]>?+O<%@4#%CI<:X
M>;Q)W&[^09>\W4;)X4N<W-5A41&67&66G&$5>M0-"-!)>@0MCH&@:!H&@:!H
M*`_VB_XJ?[O-!/\`VN?N*P;^D_UG+T$_Z!H&@:!H&@C;EKBC#N;<$N.-L_CR
MYV(9`K*75=#EO0BD`PX+P-FZP0'T]8"2HBIOLF@C/-^(N#^1ZGB#',FR1R:E
M%+=E\4/L9"3,[email protected]?F*7Q]@ZB+PW701W?]K?:SBM]691D5
MT[A_(,2UEY95\@.Y2[2WWZ&"Q!GD,MM^.11UA,MM2%5%ZAW-TE<(G%#D>["^
MW&UL[C(O<\FDEE,G*+&<(95;N175S:$$*\5L%E$*)-9`4,D]HMAW)1$40)XL
M.$,!LN&&>`9,6<G&C./1\4&J;G/A(6GBLC&;BK+0O.5/)!`5>KJ5/2N@B^@[
M8.!;9.)<WP^=:O,X)A\;$\*RG'LFFBW9X@!I(AU<J7"D(DZ$)()`)$J$FVZD
M.^X19`[%>SV)39O1Q';%RB@4DC%\XKRS*Q<8K:LK3]I2A2468J10;D&KZ(73
MX$3A]1&IJ$Z9S6<"<IX"O"&2\BP)^/V+,.GE4\#*DAV4P&(R2FHSKT22W(<\
MV.WYIAO^D;W(D4-]!H%9V6=L5[B%$Q65,S(L;L(\F2SD`9#/GN7=5=C#>>CR
M;+WEQR9$D##C$**XJ((#Y9(*KN&\R^TC@&PR7(,FGX(S,<R5+H[&C<??^2TD
MY)`CU=S,9A"8MM/S(<5IEQP414%%Z.DC<4PV7A7A?BSBFOM+7C1LYPYQ'J#G
MY4_/.S>GP:B`U7T[8RB(D-F-";!MGI]([F2D9$9!-N@:!H&@:!H&@:!H&@:!
MH&@:#4L]Q")R!A.68+864ZGKLPJ9=-8V-:K"2VHTUHF'E962S(:0E`U1%)LM
MM]]M]!6YSLOXV<[?&.W!,IRIG#VTJ&G\C:*G"]D1:*<-E`BO24J_)-MJ0*$B
M^3U[;CU]*JF@CZU_AY<96UW99@>=956Y])NZ3)J[-JP:J%*CW=#*ERHMD\TS
M`%B7(+WUQMQR0V:F&W5NYU.$&9RGL9H<QY1J.7K[FKD"PS"DN,:O:Z3(2@>;
MCS<;:>9;6*#E0216I"/F;S#'0R;BHX;9$#?0%@N&>%*3@SBF!Q)A^2WTNFJC
MM7:N^M2@/6;#MO,D3WC$FH3,8E!^29`AL$GH0D(4VT%;X7\/KC"FP;A/"J+.
M<NBEV_V=]/XYR.>W0V<IEC)B([2%)[email protected]@6VQ;(B:#H!_#QX
M^'DD>3EY5SYZ]CRLC=K_`#W*5\HL;)J;Y$E0VGWJIQU6&8Z(D=HR)MGQ\L!4
MW",+387Q!!X_X7I.%,6S+)*ZLQN@3':',T<KUO8L<`5MET'/<?=/-:!4$"6,
MJ>"*2$6ZJ%;JSL$P.IHZJN9Y;Y,L[C&)C,O"<IMK.ND2Z1!BSH<AF$VS6QXZ
M!*"P>)]3:(W'.EPCZD\0[,#^'WP736F,2:!R[I*6@/$9EAC;#[!L6ME@S,QB
MCGS'7&#>\UM)IJXC9@#JB'4.R$AA-?%G`T3CB[_:NZY"RKE;,6:),8@99EQU
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M.5KC+3B5X$TR\CGF*RST-(6ZJ!'TF`3[QKV_4_%W;Y#[>:#)[.10U]/8TL+(
MYC<<YXL63C[CA*(MBR1#[P2"O1MZ-T700-![`L,J,:X,HJ?D6_BS>!&KNOQ>
M\E0*>Q*55Y`YYLN+,ASH;\1P@/VF7?*W!=E5"5$V#7G_`.'1C,K+LSRR3S-E
M\M[-X&:4UFS)C53SK=5FD-(3T-N6<57NB(")[NBDH-[(@`"*YUA;>FXD?QO@
MJDX0QK/;O'QQS%8>)4>?P@BC<1HD&.$1E]M39)@7T8;0>M&_`O;'8MM@JXQ_
M#XQ5O&\>J9?+^:W=[AK-M689E-FE<\Y54M_42*6UK(T5N*U'$'V)1N=?1U^<
M@.$IH/009$?X=G`X7%<*#9.X#&?QNRLN.'C:*'-M,3I95!5S')(@$@=HDLR=
M`"3S'A!W<5ZT,),X.[/>(NWODKDSDCCF-/@2.1X577_($B4[(AU<:N:0'&XA
M/$;I>\N"+AJ\9J*ILVH!N*A:K0-`T#0-`T#04!_M%_Q4_P!WF@G_`+7/W%8-
M_2?ZSEZ"?]`T#0-`T#00UW$4F69)P9RM0X,CYY5;8U/C5,>*:MR'U-I4<8CF
M)`HNO-]3;9=2;$2+NGIT%'>6,-[C,ZSBLR;B+&K!6,7LKZRX1SAJTK8V,U]+
M8\<RZ>J:&H?ELO,2V;F6?F*[!(A%?%Q6A%H0R>9\9\^Y&.3>ZX)EEQB\ZJS6
M'@F/Y!>4\VWJ$O,0C5Z1I4V5;&3C;]JKZM;O.]`[JIBVK8B'4R7&^[R5D]M&
MH,9Y$J,4LH+,5$@9+CS?NQ,3L4)HH:G<M@P@P8]NVHMQQ+S'$\QV2B@;86+X
M9Q?F3&<_Y2B9D>2W''Q0Q:X_MKFY:ES^F,^]&;80/?I+;AN1VFWTDJ$8U\SH
MD"ZZ)/*$%<<X=W8UV4\>6>25>;1*RFA\?P;>M/(Z9VO16$O&<L=E0F;0VWD5
MMR`2*($:DG4TG4):#/\`)O%G/3G*O)V4<:#E%4.27$>8S)@W%:Q2V50WAGR:
M]'.&_*$_?5L6649<<:%`Z4/S!;4^H(ZF</\`/\_-*S)GN,[T'AR_$<@FV@VV
M/))$:WC2VQR:\*_*J_I6[*8V*>G=-S'<4WT&4J\0[T5Q*@A3VLFKLYK:#&&(
M]FQ>U:U_ND3#TB9%7S(X3U8<L'[M'78\E&UV5R.2/BTT\`!W*G#>[RNFX^W$
M:SAZMJLCI+67#R#)*N0DM@ZFA9MFCF1K9Q\!;G!/?!MQM^.NSC:1U%UA6PME
MV]Q+)BBY!G.-N1\6O^0<BM>.XSB**)32GQ+SF@40Z6I,Q),EKPV)MT3%5$D5
M0GW0-`T#0-`T#0-`T#0-`T#0-!TK(IH5T\ZUL7K$(SI0&CV02>0%5L5W44V4
MMD\530>3\V9R-<X;PM3#CV66=;#3A[.E>K\:>MTN,PC9BU(SQW([!BMEO5\N
MO2*CA`+C!;J^WTN"GE`&U-Y%SEF$WA][D[$,JO*F)9X/<9I&F8;)%ZARIQVS
M9R"!!2!`17ZMEL6]I!(\/20;R7/,V0(LP?DWN2XTX_XWQ#%<#Y&IZFBPV:Q-
MJUP"TE(-D]593*B."B4\EU3&T8JV2%QUI`%SQ8<;<\]L+>\/99SZ/).&T.;2
M<HR_#+S$6IUG?6>/-4A5UL[&"<XW/0:B$TJ(KZ1FO*?1T2;('HJ_Z_00K=9Y
MSQC4NP8PB#G='6UUUR%:VD"KXW=-FUDLYE4)4*Z0T)*[\HULV>\XZPJ&[Y?F
M=:$BJH2-S97\KU/<<QG7&$;((LN=@&.U4%Z#0?*-5:O!E)G/K[62Y$=2((0'
MR=Z_.8,?!4(^E6R"MT:FR.RI*FPN>(,GC9`%34_*'N?'UI"_2UW*83FB\F)5
M-MHZ%>*R/9'JZ%)S;VE50E:LS/N-I($VDPO%LDI0A7&3S,'BM86D.#D%B]R+
M:"3%ZAUC206)-*_$EC)`HR/$Z^ZKJFV8Z#6Z[F#N[CXU8N&SGMSD$V&W9Q8E
ME@$F$K!1KC(([]?&D1L>,&C?@18#@%(CO[N.#_JFG5<:"YO"\FS//N8HS423
M"QA?V<L78+X"#<7*+*`<B_CMB"J`$HK$>>!OV?/=</=3<<706/T#0-`T#0-`
MT#0-`T#0-`T#0:KG4C(X>$YC+PZ.DO+HM'8/8M$)!5';((SA1`5"W14)U!3Q
M\-!Y?YC><BV-=P)C^,T&59!7XY/XTS+#685%+L8.0RY"R9=_96]X$21Y+[,H
MA\X3>8(?,-UU'$<3RPWBNR+E;D&_X>E<A8KD.38Q7WF*6]S*F8A,BR:FWM,<
MR1C**9Z*Q"12@Q'?<D1QT2'J>1HGGR%5`(KJN8.YOCKC/CO#L4Q7-FYV-\)5
M-?&HI6`6\MUG)86#NRV!ZQ@/$\Z=M%;BFKKP(*JX"QUZ4D*%S.,LNYG#G6ZP
M;,95QEF`,8^Y*I<P<Q[Y%CE*5BGDBDL7(K*@>\N0#:M/."?2XR;33T1TW0KU
M!S_N-QNPK*_'J#)*K%Z>UR&=8U</CZ8+%IYO*;D)LW=H"N-^]X_).<7DJ)K_
M`*_JVZMPDSE5>6L8[D[S(>,0LXXY'CG&$*54M8Z[/J[]IC)<BCY`3]HC)-Q'
M:NJEA)W\P3/]`WL>X-D%6DQC.K2ZXQNG.*<GJY$6FX"<M!A89:08\*?09Y9.
MW2C'"$`LK#KB;5U$1.EA13XFV@EG!.2NY*NIJ2DBX9;8K/C'6/XOCB8=(B5]
M\]8YK:1<A"Q-R(BU_NM5[M+:)#:W\PWR]X'<!#%CS1W?5V(K.>K,JO;=ZLQ6
MYD12P*962VY4R+DZ7-/"4ZUU@G&'*^L<1)`CYIOK&%Y@I+!M!='AJ;9.9QS]
M51T>3"*C+82XNV[LH19LVGA3+F(P2&:*#<QXG#1/`'G'@3XNR!8+0-`T#0-`
MT#04!_M%_P`5/]WF@G_M<_<5@W])_K.7H)_T#0-`T#0-`T#0-`T#0-`T#0-`
MT#0-`T#0-`T#0-`T#0-`T#0-`T#0<+,>/'\WW=AMCSW"=>\L4'K<+XQELB;J
MNWBJZ#FT#0-`T#0-`T#0<+$>/%`FXS#<=LG''2;:%`%7'C)QPU043Q,R4B7U
MJJJOCH.;0-`T#0-`T#0-`T#0-`T#0-`T'7C1(L)LF8<9J(R;KSYM,@+8J[(<
M)YYQ4%$3J<<,C)?2I*JKXKH.QH&@:!H&@:!H&@ZL.#"KF/=J^&Q!C>8Z][O'
M;%H/,?<)UT^D$1-S,R(E]9*JKXKH.UH&@:!H&@:!H*`_VB_XJ?[O-!+7!N88
MU@';%0YGF-NS0XQCD6VF7%J^A$+306DI/`&Q(S(E5!$`%2,E01125$T$FXMS
M-A>3WD[%7BL,1RV!"C6AXKD\1RJG.UTPG`CS&`?V%ULC:,"Z"4FR3H=$"V30
M;@SFN'R)UE6,934O6%/%BS;:($QE3C1II&$9UU$+V!=)LD!5].WAH-3S7F+#
M>/<)SOD'+CGT^-\>E(&Z?=BGYKPQV`D$<-I/:?$@/<5'T[%ZD5=!)"S8V\P&
MG1DR(`H4J(R2&\"D/6(J"+NBDGB*+Z=!$^+\YX3F-1@U[1,74BKY$O)V/8U)
M<K)#75-K0E.2?/$Q160!(,CVW$055M41551Z@[*<TX8YR+(XRCA:R[V#;,T-
MI8,P'BKH=I(IROFHDB7L@@9P4%P5^(JF#:%YBJ*!+6@:!H&@:!H&@:!H&@:!
MH&@:!H&@:!H,=;V]7C]3:7UW8,5-+21'Y]O:2C1IB-%C-DZ\\ZX2H@@`"I$J
M^"(F@BO%^>./LHN:F@&18X[9Y)3KD.(LY#`?JDN*H7&6RE0BDB"%TE(:ZVBZ
M7@0P(VQ$A50W_P#;3$%M1HTR>K*X.`[:I7#+:5U(3+J,N25%"W1M'/9ZE\-T
M)/Y);!C;3D+'*2OS*WMBE0*C!X@SK2U=CFD>1'*+[VAPC3?WGV/9_1[^W[";
MEH,GBF6T>9T&/Y'1RT=@Y+40KRM9=V"1[E8,B^P;C6ZD&XDGI]?AH([K>><&
MMH$RQA1[QQBOS1<`EBM9($PO!>6.;/2J(JM@[L"NI[&ZI[6WCH.[?\UX;CV<
MAQ])8N)UZVM&EH_`KGY,.O7(YKD"J]\D`G2VDAYEQ$+Q$>GVU%2;0PES0-`T
M#0-`T#0-`T#0-`T#0-`T#0-`T&M9CF&-8!B]WF>8V[-#C&.13F7%J^A$+30>
M'@#8D9D2J@B`"I&2H(HI*B:#3<6YFPO)[R=BKQ6&(Y;`A1K0\5R>(Y53G:Z8
M3@1YC`/["ZV1M&!=!*39)T.B!;)H-Q:S/$'YUA6LY15.SZF)%G6D09C*G'C3
M3<;C/.HA>R#I-$@JOI5/#0:QEO+6)X-AF>9YDZ6%9CW'8S'+QTXAJZ\U!BC,
M==AM?&?#R54A4?2@DOH1=!(*SXJE-::>"3*KP0Y<)DA-X.H5($($7=%-$]G?
MTZ"*\7YOPS,:G"KV@C7<NKSZ[G8_CTLJR0"+,K1E%)5]"%%9;'W)]$<<V$E!
M4%54@Z@_1<W81_6._P`8,K92;Z%:QZ*UGM0W"KH5I*J2NX\.3*79&S=A(+@*
MJ=!*8-H7F+TH$O:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@H#_:+_BI_N\T&SX;
MQ<US/V<5O'1VY4+]RKLNJNA:\](MA59"=E!><90V_-;&3%;4PZQZQW'J3??0
M<F>=NO(7).;5O*^07F,0LSQ2-C,/$<988DR:@0J;V/=V;TF4X+<CKG*P+38B
MWLP";*KRF2H$*Q^Q?.HN$#B'[4XPZ\[14D)R\C,RH<N/8TI7B,R&%-N4RXR0
M6K:.,R&7`=`#:)!0A,`[>9]D_(N44_(U6QDN&Q6N08V60'X+T.2Y#C%D\2C9
M6WCL@`(U-:<IB,MNI"20:(8].YA87@SM^O.+LZS/,+^QHKN;D+MTK.00V[,+
M24Q<W+ET+,U),UV*(Q''G&P\EI%-%ZU4%ZD,.SQSPSR!@5-BF)!D%')H..K[
M)<@QBS1J3[U8N7/RJD.+81UV!D(Z6I*X;3I*Z38*(M(I#H,`YP'R%)YDI.9!
MM\7H<LK7W2OLAI&YL1W(:LJ8XK-%<0P469+,>P,7V9+IF\VTV#0BA;GH+:UB
M625M>ER48KA(S7RJ4)#&,LGH3SE81Q5-`Z]^GJ7?;;?QT'>T#0-`T#0-`T#0
M-`T#0-`T#0-`T#0:'RC@%7RKQMGG&=U)?A56>T%A0SIL9=GF&Y\<V%=;W\%(
M.OJ1%\%5-EW3?05:S_MHY&Y8@8H6;Y3C,:WXUQ.72XB-;#DG%GV\M^N=<LYO
MGKYD9M`K1`([2N*!.$:O'T`.@T%>S#-W(V3#+OL8?=RZQM[&Q]P]_JY$([#-
MQS!CY-FM"Z3+D95(&S-LQ0A!3:<!3!0QL/LJY(A,R17(\)L?>(-=!EU;]>XS
M62RCX:YB;TLH49AIEET%/SV4`5%!(VMAW0D"3>WWM2R3B#,:O(\BO\?R=RDK
M@B5V0LLV@6R`[3UM;)@]+LXH@1O,KFW!5&5-1!IM=NCJ4)#Q[A'+*.YO:PKJ
MIDX1;\HR>3FYR`^-J#DAT)OR:K.RLJ@RQ7]/YGBU[/E(?MZ#6\EX"Y"S/DO`
M>3+JSQ2CS##K:EEKGN-MSX%K\CQ#1RWQYQM"49L&PV)!&2XOD*XX8H:]*"%K
MJ%+Y*B"F3E`.^0%^4BJQ=&(I]2[>2CRDXB=.WQE].@R^@:!H&@:!H&@:!H&@
M:!H&@:!H&@:"*N;N,DYBXORGCP;H\=E781'ZN]%E)"1)U=,8L(;IL*0>:`R(
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M]4XWB/[04$[&^/\`(<ER#$['R9*3IORRMFL.)/:W1MI(WRH?F.M&2N]`](-;
MEH-?F<!<B6/,V,\R)=8SC664[Z_+^1T`3HSU_4K3''&@MH6_DRF&;(TD-2'3
M)X&@%L!`_;T%M:I+-*RN2[**=RD5E+<X(F,5970GG*P+BD:-J>_2A*J[;;KO
MH._H&@:!H&@:!H&@:!H&@:!H&@:!H&@H#_:+_BI_N\T$_P#:Y^XK!OZ3_6<O
M03_H//CDOD&_QCNNHZFRY.E-85D4&=4PHM#91&G\4FA5Q)+IW=5.!6'XI@Y[
MVW*1#<;550T%AHMPZE/S3F''?#W=--7(F,HS+"KV]D<0C97C=_&E0V\>@6S2
M1)O0P_.:B"ZY,DM(UULBI-#N``2A"=[W%<L8ZY?8C,?9M*KA^!DF4<CY6&82
MVTY#=I:VAG#!QZW8@BL1Q6;CJ<AQ&F11\`!LT;5X2"Q';QS7G.;\N64+.8OG
MNYJ&<2,=J85H^)8E!PZ_BTJ5=Q1JRVTS(D"\V\DDG77#/S1!184!$+[:!H,;
M;W-/C]?(MKZUATE5$'JE6<]]N-':'\INND(BG^5=!53+N^OMDQ,SCM\@IETP
M5)&V,9AR;-ESIW15"<T"0E3?P1?/\?2GANNNRUP_,7/31/=WNNWD+]STT3W=
MZ#;3^)[Q2TIA2<;9I8&**@NSDJX;1%_)V5J=*/I_*JANGJ1==E/`\S.O".OR
MQ=E/!<Q.O".OR9;"?X@T'.G;1NKXJD1TIQCG+63<`BD,E74'RT&&2*J>26_4
MH^KQ_)G'`;\S,8TZ.>>?FYD9Q"U.1JBFYIF8QT?'!*\+O(Q5P_*LN.LMAEXK
M[Q'6ID,;>&R;K8-.]7I\$;V_/K"O@>:IU1$]$^>#AC-VY231]S7"5V8LGFS.
M.O*O3TY'&DTK?7_,&1/:88<)?4@.%OZM<%W)7K7KHF.K1VMU-VBK5*=&'V9+
M+,F,\$B/(`78\AHD,#`TW$A)-T5%1=T5-<S8Y=`T#0-`T#0-`T#0-`T#04)[
M@<^R7"NX_B1Q,XEOX1*#'X%KQ[06#,2X@3+6Z?B,V;\%].BRA6.R1'6_%UD6
M7'(Z=:D2!L/#6=NUV:<WX]DG*XV6*&N.2N,\ZFY#`N8$E+B%/0BBS#9CM-S#
M*O.2[`$":9;5HVNIIU=!7#/.7^7<0XE[JJ?%;O)KE*=;RXQ3EJLF_M9#I:=G
M$XM@P#%JTPT8/RI:JXJ.-B$1MUPFSV:8\P+(8YRYG.2=UV*T-A3Y7BF!V^#Y
MH%)B5G4O1&I#]388PK=W*=(=MS25(9;%55&@5K?I=DFV(74T#0:GF6>X/QU4
M'?Y]F%+A5(VJB5M>3F($=21-^E')!@*DOJ1%W704LS/^)1VW8V3[&,.Y-RC,
M9)0Z<:J3:C*7Y1FVQU\9P/RDTX:?DW7PUV6N'YB[Z:)[N]UVLA?N^FB>[O5]
MNOXJ-J1.!BW;\)M%OY4J^R@8K@IX;*4>'6S15?3NB/)_I:[J.`YB=<TQU^4.
MVC@=^=>$=?E#5J_^)GS->9-C]#!XHPNN3(YON,8G[.QD^421W7U,S%AC=%\I
M4V0/7K*K@5RF:8FJ-,X<NR9\'/G^'59.U]2J8G3AH6#B]Y?-D56UL.',+N&T
M01?6'EEA`<545.HVP=HY0KNF^P$:?[3UZSJ^WK\:JJ??Y(.,[1LENM/WTUS9
M-MYQPGF>.@J"KUK2N5N00FU_E;@Q)9G%MZNB(6_YO1KDN<'S5'\./1./Q;*<
MU;GE3]Q_W+\%\G3F:?$^1ZP\D?V1O#K7S::[55\-DJ[-N-+79?!51I4W\-]1
MU=NJB<*HF)YV^*HG4G36#TT#0-`T#0-`T#0-`T#0>;G+7([email protected]
M=AV14%W45T2EFQ0+%;$8%5(.1>U<]$CR(J`^DMN0/4X/42%TLLEU!G./\_NL
MHXHYTK^(^=X&:9-E$NQ>[=4OKR%+O&8XU+6Z/..#L!O2HLR7';>;)6&#:)T1
M!%:`(?D<N6\[#[B=(YKON(AG9]*KNW&%DN0U@E)KH3%2=K97-HX]/:LJZOEA
M/`3]Z=!X"1H2<=*-L$S=O?)^<Y+W(\FXSD602[3%W!S5_#GDE><S,;HLL"K<
M;E5QO*52[5"ZW$90&T&>TJRR7S!5-!Z`Z!H.M,F0ZZ+(G6$IF#"B`KLJ9(,6
MFFP'Q4C,U011/6JKH*NYAWL]LN&D\P_R?#R.:TJB,3&6)%T)FGI;]Y@MNQ0)
M/7YCH[>CTZZK62OW?31,]W:Z;63O7?33,^VU`MM_$YX?BN$U3\?YO;**KO(=
M:JXK))ZNE?E!QS_E!-=M/`\S.N(CK\L7;3P7,3KB(Z_+$P_^(C79M9/U55Q1
M)CR(\8I1G+N0`%`3`%1%"&XN^YIZM;/_`,&_CAC3VSY<[AXCEJLC%,W,)WL=
M7-TX;4NP^\G'E)`L^-<I8(D39V"[526A79>KJ5Z=%/T^C8%W]>VL:N!9F-41
M/7YX(V,Y;E(M)W1<+6ZBU,RAS%)"(GO`Y%#DUL=E5]`G/>;2$J^KV7R37#=R
M&8M>JB>_N;:;U%6J4ZUMG6W,&-:4]A&M:R:'F0[&&Z#[#H;[=3;K:D))NGI1
M=<C:[V@:!H&@:!H&@:!H&@H#_:+_`(J?[O-!/_:Y^XK!OZ3_`%G+T$_Z#&O4
MU1)GA:R*J'(LVXCL`+%QALWQBOD)NL(ZHJ2-F0"I#OLJHFZ>&@_4:IJX;$6+
M$K8L6-!0A@QV60`&4-%0D;$41!ZD5=]O3H.`:"B"-$AA20`B0'O>(,5(S2-L
MO(JKYC8=.PENJKNB;Z#MLU\"/*E3H\&.Q-G=/OLQMH!=>Z$V'S#1$(NE/!-U
M\-!BLJRS&<'H+'*,OO86.8]4M^;86\]T666T5=A3J)?$B)4$13<B)4$4551-
M>Q$S.$:WL1,SA#R=YL_B36TQV51<"T85L$2-H^0,@C^9(='941R!6DJ"UX[$
M)RNI?44=/3J>RG`JZ_FNSNQLY?@G,IP2NO3=G"-G+\'FGF>;YGR-:C=Y_E5I
MF5JV9.1Y=M(.0C!%\9(S2[-1Q7?XK(`/Y$U8<ODK-CT4QCMY>U/V,G9L^BF,
M=O+VM7UUNHT%D.W+_?,X_P!C4_\`:FZPH_<GHCQ43[L_>H_3XK1:WJH:#MXS
M:Y!@TA96`Y'882\1=;K%48)">)2W,GZ]X'8;I$FZ*9LJ:(OLD*[+J/S/#,O?
M]5.$[8T3[=+?1F*Z-4K>\?\`=RVV3%9R]5L4Z%[*9W3@Z58FR*JG.B&3K\,?
M0G6)O-^DW"9'5:SO!;MCYJ/FI]\=7D[[6;IKT3HE=2',AV,.)85\MF?`GLMR
M(,Z.X+K+S+HH;;C;@*HD)"J*BHNRIXIJ%=3LZ!H&@:!H&@:!H&@:#H/U59*G
M0;.3719%E5HXE98NL@;\='AZ'?)<)%(.L?`NE4W3P70<;%+3QHP0HU3#CPVW
M2>"(VPV#0N'OU&@(*(A+U+NNV_BN@Y(]761('R7$KHL6LZ":^3FF0!CH--B'
MRA1!V5%\4VT';5IHG0?5H%?;`FVWE%.L0-14A0O2B$H"JIZ]D_)H-.Y!Y'P7
MBG%I^:\BY1!Q'&*WI&3:SW.D2</?H9:`4(WG7%38&VQ(S7P$577L1CHA[$8Z
M(>._-?\`$DY$R]Z32\$5']6V-;D'[<WL9J5?2A]'7$KW?,C0Q]:*^CQJGI;:
M74[D^!UW/FN_+&SE^";RG!:[GS7/EC9R_!YUW<RTRFZ+)LPN[+-,F-.DLCOY
M;UE-1-]^EMV01JT&_H!OI!/4*:L.7R-FQZ*8QVZY[4_8R-FQZ:=.WE<.NQUF
M@SV$_O+XQ_X^7ZOF:YK_`*K?ZO"4!]R_X<],/137:^<&@PUYCM!DT/Y/R*E@
MWD+?J&+.8;?`2]1"CB+TDGJ5/%-:[EJBY&%41,<[*FJ:=4MKPKD+F7B,FOZO
M<YD9%CL<D(^-LWD/VE<3:(OZ*%9.*Y805\?9V-YD-DVC[>&H/-\`MUZ;4[L[
M.3SCVT.NWG*H]6E?CACNGP/EF>SB-C&D<=<H^23SG'MX8>9*!M-W'JF8'Z"P
M:%$555I?,!-E>::WVU6,SE;F7JW:XP\>A(47*:XQA9O7.S-`T#0-`T#0-`T#
M08F30T<RQ;N)=+`E6[4)^M:M'HS1R1A2B`WXR.D*FC3I-`1AOTDHBJHNR:#B
M7&L<**[!*@K2A/(:/0UBLJT:.#T'U!T]*]0^"[IXIX:#GD4E++]W][J(4KW0
M$;B>=';/R@3T"'4*]*)MZ$T'.S6UT:7+GQX$9B?/0$G36V@%YY&T5`\QQ$0B
MZ45=MU\-!^;2UJZ.NFW%U91:>HK&3D65I->"/&CLMIU&XZZXH@`BGBJDJ(F@
M\MN<OXD=?`=F8[P)3-7TAM39>Y#O&G0KQ)-DW@0-VGI&RJNSCI-`BHBB#P%O
MJ;R?!;EWYKGRQ[_AU]B9RG!KEWYJ_ECW_#VT/+SD'E'D;E><-AR1FMKF+S9^
M;&BSGMH3![_&CP&4;BL%ZE5IH579-]]6/+\.L6/33IVSIGVZ%@R^0LV/33IV
MSIGVZ&AZ[7::"=.W_P#]8V?_``9[_P`Q'UA_V1T3WPIWW;JM?ZO!;[6]2C0<
ME+*M,7L';?$+JPQ"V?<5Z1.IWUCH^YMLARF-BCRMO4DAMP?S:X\QD+&8]=,8
M[=4]K;1>KHU2M1@7=K=4Y,UW*]3\KU:;#^V]%'+WED4\.N=5AU*XB(FY.1-R
M4EV&,([KJMYS@5RW\UJ=Z-G+\?;0[[6<BK15H7BH;^DRFG@9!C=M$O:.T:\Z
MNMH+P/[email protected]'`517945%\?!45%\=0,Q@[&7UX&@:!H&@:!H&@H#_:+_BI_
MN\T$_P#:Y^XK!OZ3_6<O03_H&@:!H(BYLYKPK@;!Y>;YJ^\;"[email protected]
MIKB*K<6*V9`*DJ"I$1$@@*$9D@HJZVV;-=ZN**(QF6VS9JNU133&,R^>[G#G
MSD+G_)ROLUG^[U4-TRQC"X9G\FU3:HHIY8EMYKZCX./FG42JO2C;?2T-TR'#
M:,K&.NK;Y+AD>'49:,==6WR0MJ22)H&@:"R';E_OF<?[&I_[4W6%'[D]$>*B
M?=G[U'Z?%:+6]5#0-`T$@<7<JY3P[8B5(!W>$RWU<O\`!#<01'S"ZG9541J@
ML2/%25M5%EY=^ORS+SA@N)<'IOXUV]%?NGX^TNRQFIHT5:GJ'BF5X]G&/UN4
M8M9M6]':@1Q)C6Z>($K;C3@&@FVXT8D#C9HA@:$!(A(J:IU5,TS,3HF$G$XZ
M6Q:\>F@:!H&@:!H&@:!H&@:"OG<=W'81VV80&4Y2#UQ=W#Q0<)PF"0I.N)R#
MU*VVI;BTTT*];SQ^RV/Y24`+9:M57:HIIC&9;+5JJ[5%-,8S+YZN5^5^0N=<
MP7.>4+<;*Q84QQW'8O6-11,.;;L5[!JNQ*B)YCY[NN;>TJ"@@-SR'#*,M&,Z
M:]NSH6_(\-HRT8SIJV^30-2B3-`T#09["?WE\8_\?+]7S-<U_P!5O]7A*`^Y
M?\.>F'HIKM?.#0-`T&%O<?J\CAMP[1@R]V?;EU\V.ZY&EPY3*]34F))9('6'
MFR\0<;(2%?0NM-ZQ1>IW:XQAE17-$XPMKV[=S5Y6W%1Q%SC<#8S+5T87&G*[
MP`PENZO@W57'0@M-V"HGZ)T1%N5\5!!Y.ERE<2X95E9QC31/+X2EK&8BY&'*
M]"M1;H-`T#0-`T#0-`T#0-`T&C<C\CX?Q/B%MG.=7#=-C]0"*Z\?M./.FO2U
M'CMI[3KKI;"`#XJNLJ**JZHIIC&9944375%-,8S+Y]NXSNBSON+MR;L_-QKC
MR"^CN/<?-/=;8JVJ*$FQ,-ADR-TZD](-?%;W7J=<N'#N%4Y>(KKTU]W1YK;P
M_A=-B(JKTU]W1YJU:F4N:!H&@G3M_P#_`%C9_P#!GO\`S$?6'_9'1/?"G?=N
MJU_J\%OM;U*-`T#0;+@>=Y9Q3>.W^%/"[%FN^=DV&27%;KK?84%3)4$_=Y/2
MB(,@!5=D$71=`1%(GB/"J,S&]3HKV[>GS=-C,3;T3J>H7&O).,\JXK%RO&'G
M4CFX46TJI8HW-KIS2"[email protected]]2+X*HD*BXV1MF!E2;MJJW5--483"6IJ
MBJ,8;]K!Z:!H&@:!H&@H#_:+_BI_N\T$_P#:Y^XK!OZ3_6<O03_H&@:##9%D
M%-B=!=91D4]JJH<=@R+*YLGEV;8BQ6R=><+\PB*KKV(Q(C%\V'<'SED'<#R-
M89K;>?"HXOF0L&QIU4VK:SK110A%5'WA]11R02*NY;`A*VVWM=^&9",M;QGU
MSK\ETX;D8RU&,^J=?DA#4FDC0-`T#060[<O]\SC_`&-3_P!J;K"C]R>B/%1/
MNS]ZC]/BM%K>JAH&@:!H)1X6Y5<X?RY'+&2K?'6626VLR8)?T5=*-$:8N`1?
M`4'86Y2^">5LZJ_H-BKO&^'Q73]:B-,:^>-O5W.[*7\)W9U/535221H&@:!H
M&@:!H&@:!H--Y"SW&.+L)R;D+,[!*O&,[email protected]%M+5-RZ&TV%MH-TZW'346VP3
MQ,R$4\537L1B1&+YF.5N5LNYTY#NN4<W(F9]GO&QO'>OK9HJ@24H]>QZE)-^
MM\T1/,=4B^*@"-VX7D(RU&,^N=?-S+GPW(QEZ,9]4Z^;F:#J429H&@:!H,]A
M/[R^,?\`CY?J^9KFO^JW^KPE`?<O^'/3#T4UVOG!H&@:!H,5>4E7DE1/HKJ(
M,ZKLVE9F1251ZA7Q14(50A(51%$A5%%4145%36%RW3<IFFJ,8EE35-,XPO/V
MC<VW&70K;B#D.S.SY(X]B-2:_(7U_39%CIEY,:R<\$19+)[1Y>WI<Z'=A1\1
M2@\0R4Y6[-/)R3S)BS=BY3BNGKA;C0-`T#0-`T#0-`T'&ZZU':=??=!EAD"<
M>><)!``%-R(B79$1$3=570?.SW;=R$WN"Y`<2GF.AQ=B#SL;!J\25&II(J@Y
M<.AZSD)NC/5XML[)L!N/(5PX/P^+-'U*H^:?='Q6SA.0^E3]2J/FGW1\54M3
M::-`T#0-!.G;_P#^L;/_`(,]_P"8CZP_[(Z)[X4[[MU6O]7@M]K>I1H&@:!H
M-NX[Y%L^(\N:S&`V_-I)8MQ<\Q]A",IM>"DJ/L-COO)B=9.-;(OF#UL^'F";
M<-Q?A\9BC?ICYX]\;/)U9:_N3A.J7K776,"WKX-M5S&;"LM([4NNGQS1QE]A
M\$<:=;,=T(3$D5%3TIJDI9W-`T#0-`T#04!_M%_Q4_W>:"?^US]Q6#?TG^LY
M>@G_`$#0-!Y:_P`2[EIVKQS$N%JJ0H/9<:7^8""IO\FP7D2"P:;[[/RP5Q%3
M_P#+JB^"[+-<$ROU;V_.JGOY/-,<&RWU+N_.JGOY'CEJXK<WW`L`E<@39M;`
MOZ>FGQH[K\2+:.20*7Y,=^2X+2QX[X@@ML$I./*VT/AUF.^M-Z]%J,9B9CF]
MN[2TWKT6HQF)F.;V[M+;ZO@O(KVII;>CR7&[9JPF!"NXS$M]'*0SKI%LIV!.
M1@;4&X<1]UPHYO='ED!;.;`NJK.4TS,3$QLY].&C3MF->#55FZ:9F)B8V<^G
M#1US&O!JF=\>3\`2C^4;JMLSOXYS(+,%)@.#%0D%M]QN9%C$(NEUB*;=2*!H
M8BJ>.RS?B[CA$QAT>$RVV;\7<<(F,.CPF4?:WMQH+(=N7^^9Q_L:G_M3=84?
MN3T1XJ)]V?O4?I\5HM;U4-`T#0-!QNM-/M.,O-B\R\*@ZT:(0D))LHDB^"HJ
M>E->3&(]$NU7-963\8M8_;2W)M[QU*7'I4Q]5)V3";;!ZMD&1JIN%[JX#3CA
M?'>;=77S[B&5_IKU5')KCHGVP3=BYOT1*R^N)M-`T#0-`T#0-`T#0>-O\3GE
MMZRR'!^!*F8J5M8PWF?(##:^R\\3ALTL1U4]0$T])(%7XPL'M\5=37!,K]6[
MOSJI[^3S3'!LM]2[OSJI[^3S>76KBMS*4U1*O;*-5PW([+TGK7SY;[<9AL&@
M)QQQQUTA$1$!55W7U>&Z[)K&NJ*8QEC55%,8RD*5PSFD-W*V'EJ/>,0CN3)T
M8+2&3DF,S&:F.OPP1U5?`8[X.JH_R5\-R1431&:HG#7IYIZ-/6T1FJ)PUZ>:
M>C3UN.[X<SG'*.PR&[C5]?7U0,?*+9V4,Y+,B0C!-Q#C-ND\C_1)`R;Z=P'J
MZ^E0)$49JBNJ*8QQGFGMZ-#VC-45U13&.,\T]O1H1;KI=!H,]A/[R^,?^/E^
MKYFN:_ZK?ZO"4!]R_P"'/3#T4UVOG!H&@:!H&@PLW)Y_&MYB_,5,R3]EQA,*
MQL8C:*IS:%\4:NX6R(JDKD3J<;'9?T[;);>RFHKC&5^O8F8UTZ8\?<Z<K<W*
M^:7MI`GPK2#"LZV4U.KK%AN5`FLDAM/,O"AMN`2>"B0JBHJ>K5%2[MZ!H&@:
M!H&@:!H&@H3_`!#.67\!X7;PJGF%$R#EF4Y4*XT2BZW31Q%RU,53U.";<4DW
MWZ7U)/BZD>%Y7^HOQ$ZHTRD.&9;Z]Z(G5&F7@]J]+LW'!<.=SK(86.,7M902
MK%UF/"DVBRE;=D2'@8:9`(4>4\1$3B?%;5$1%4E1$UJO7?I4[V$ST8>,PU7K
MOTZ=["9Z/C@W:KX0R*\@O.4>08_<WT:SAUC^'1)+YV`K86*5<5_K6.D10<DD
M(HB2%<1"$B!!7?6FK-TTSIB8C"9QY-$8SRXZN9JJS=-,Z8F(PQQY-$8SSZN9
MA\UXNGX135MY*R6CN85Q+<BU:5IS%.0C`]3SS:28D=%:#J!.K?VNL"#J!>K6
M=K,1<JF(B8PVX>;*UF(N3,83&&W#S1AKH=!H)T[?_P#UC9_\&>_\Q'UA_P!D
M=$]\*=]VZK7^KP6^UO4HT#0-`T#07=[/\S<DT.2<9S"3JP=UF;C6ZI__``]H
M3I`P*+LJ^[26G@1!3I!HF`U1N,Y7Z%^9C55I\TOE;F_1IUPN1J)=)H&@:!H&
M@H#_`&B_XJ?[O-!/_:Y^XK!OZ3_6<O03_H&@:#YRN\_+G<R[E^392N^="QZ5
M'QNJ3JZE;:JV`:?;W]2>^+(+;U=7Y=7/@=K<R^/YIF?#P6_@MK=R^/YIF?#P
M5=U,)=)_%G(;?&%Z&60X%C)R2M?C/T;\2S]RAJ+1$3\:QCI&=*7'?]A#;1UK
MP1455ZO#GS-CZU.[,QARZ,>S3HF.MSYBQ]:G=G##ET8]FR>UE9')M+&QG$*7
M%<:M<2ML8>22]D4&^,7'Y+P],R4`MQ6B;?>%!;$E,Q;;3I0%55)<8R]4U535
M,3$\F'9&O4QBQ5-54U3$Q/)AV<K*<A\[6N?XU&QQVK*KCL&8N`,M7V#9&4Z_
M'56B:%2D-M*Q'*09D9-,`GLJ3BGA8R<6JM[''\.[7.&V>AC8RD6JM[''V[M<
MX;9Z$#Z[78:"R';E_OF<?[&I_P"U-UA1^Y/1'BHGW9^]1^GQ6BUO50T#0-`T
M#06'[4;EVMY>MZ1#,8>6XHZ_(ZO$/>:28S[L(^/@1-V,A5\/%!_YJ:J_W%:]
M%?3'C'BD,C5KAZ/:K"0-`T#0-`T#0-`T#0?+_P`_98]GG<!SCESQDXDS-+*J
M@DJKM[GCYI21NE%^*)MP4<V_*2JOBJZNG!+6YEXG\TS/AX+AP:UN9>)VS,^'
M@BC4NEF:QY^LC7,&3;OS8L&.9.%*K@:=DM."*JR8-O$`'TN(*J*DFZ;INB^.
ML*XF:='O85Q,QH3W*YPK7[G-,J6+8/7.6T"XW;U;S$)8-LU\C-UHV$XD3J;D
M>\BLPA:!44^E.M"17%XHR<Q333HPB<>7&-..$<V&CVP<<928BFG1A$X\N,:<
M<(YL-#MP.X=%PR7C]_4O7]S)%F6_=R0BG[S-!Q]'&W@5O;RG659$S3=XO_$)
MU_\`BC4?*LC\^]3.$;-.KVQYM6QY.2^?>IG"-GM^&K8J_J12!H,]A/[R^,?^
M/E^KYFN:_P"JW^KPE`?<O^'/3#T4UVOG!H&@:!H&@_#C;;S9M.@+K3HJ#K1H
MA"0DFRHJ+X*BIKR8Q'H%V7WSUSVZ8)72G2>F8&Y9X4\1JI&K6-6$BKB$1+XJ
MKD6.R>Z^/M>/CKYOF;7TKM5&R9A.VZMZF)6FUI9F@:!H&@:!H&@:#P<_B,9:
M]?\`<&UCR.FL#`\<@P`C$NXA,GJ<^0Z";[)YC+L<5\/'H3\VK5]OVL+=5>V<
M.S\5HX#:PMU5[9P[/Q4+U84\W;`LGKL/O6\@E1;EZPKQ1VBET=LE/(BRA,51
MU7EB2E(5!"!0%`54+XR:TWK<W*=V,,.7&,?&&J];FNG=C##EQC'QAOMQS#`M
M:C(3:Q6339MDV0/Y/9Y/6VQQ8ORDY+.2RX$%J.)B,47#%@?>-@(E/VE\-::<
MK-,QIQIB,,)CDPV\_+H::<M-,QIQIB,,)CDPV\_+H9/)NX6^R3"Y6&O0I(LO
M(3(V#]D[)<>8-F&"^^]8(4IP78[SP$9=(')>40^)T8V\C317O^'3JV:XCJAC
M;R5-%>]X=.K9R=D*\Z[G::"=.W__`-8V?_!GO_,1]8?]D=$]\*=]VZK7^KP6
M^UO4HT#0-`T#02SV_P!T[1<X8)T+^CRAFUQR9U%L`M.PSLQ/Q\.I7JQL!_TU
M3UZ@/N"UO68JV3[I]H=N2JPKF-L/4S5/29H&@:!H&@H#_:+_`(J?[O-!/_:Y
M^XK!OZ3_`%G+T$_Z!H&@^73FUYQ_F_F\W35PAY&RYM"7Q]EN[F`*?YD%$U?.
M&1_;4="\<-C#+T=",]=[N-`T#0-!^HX.S)85\&._8V+@];==#:.1((=]NI&F
MD(^E%]*[;)Z]:ZKE-,X3KV<O8YLQF[67C&Y5$+:\'X9DN,!D<_(JY*E;D800
MX+CK;CZ)&60I$XC)&`H7G#TIUJOIZD'7MJ)FJ:IC#1'NQ\WS_CW$+6<NTS;Q
MPB,-/2GO6]!&@:!H&@:"7N`/#FG`33P-7+)M23TJ!5<LE'?\BJ`KM^5$_)J!
M^X?V*?U1W2[,EZYZ'J/JG)0T#0-`T#0-`T#0-!\E+I/N3KER6RD>8[;V1S8P
MJA(V\4QY7014545!-53=%\?3J^\-_P`:CH7GAW^/1T/YKN=IH&@:!H.E.LJ^
ML;%ZPFLPVS)!;)XT'K)?!!%%\2557P1/'6NY=HMQC5,1'.UW+M%N,:YB(YTF
M\78=F5[FN%Y&SB\^LQFAL#GR[NU;]Q1T/='V1%B,]TR34B>38E;0-OY6N?>F
M]53--,[L3CC.CDG5$Z>79@J''N+Y>_9FU;G&<8T\B^6I!3#0-`T#0-`T%R^Q
M9]7./N4(XFAL0>2[9J.B;+T^97ULAQ%5/2OFNGZ?1Z/5J@<5C^ZKZ?!,Y;]N
M%VM1[>:!H&@:!H&@:!H/G-[VR)>['FI%5509E"@HOJ3]FJE=D_SKJY\#_P`:
M.F5PX+_CQTRJUJ82QH&@:!H/R)=<AB&R!R9LI=HL!@">D/+^1IEM",U_,*+K
M"JY33KEIO9BW9C>KJB(YUG>#\+RBFMIU_=U#E-!DUY1H;,H@22XKCK3B&K(J
M1-HB!Z'.DM_Y.O*,:JM[#",)U\^'ERJ)]P\3LYR:*;4S.[CIZ<-78LOKH5HT
M#0-`T#0;7Q^X3'(W',ALNA]K*:@&C_,_+;8<3;U]3;AC_GW].HKC4?VE?5WP
MZ,K^Y'MR/7K5%3!H&@:!H&@H#_:+_BI_N\T$_P#:Y^XK!OZ3_6<O03_H&@:#
MY6^5)"N\V]P3!$A'"Y7S9HE3\AWLQX?^07$35XX1/]M3&S\?%=.%3_;TQL_'
MQ:9J321H/PZZTRV3KS@M-`FYN&J"*)^557P37DS$1C+R9B(QEN..X!FN5HVY
M2T#HPG/BV]BJPHFR^@A(Q5QP53T$TV:?GUK^I-7IC'GU1V^6*$S?W!E;&B)W
MIYO/4G?'>WFK9Z7\NNY%TYX+\F0.J#%3U[$X)+(-47^4)MHOK#7OTJJO5/5&
MCWZ^Y5\W]RYF]HH^2.;7V^2=:7'Z/&X:5]!4Q*>&B]11XC0M(1;(G6?2B*1+
MMXD6ZKZUUMHHIHC"(P0%=RJN<:IF9YV8UFP-!DZJFL;IY]FNCH\L5@I,QTS!
MIIED-D)QUUPA`!W5$W)4\51$\51-:[EVFW&-7+H94TS5J9<,)R5UB)(CUWO8
M3S9"&VPZTX\:27#:8-&4+S$%PP)!)11%_P`Z;Z_ZJW$S$SAAX:].K0R^G4ZE
MOC-O1L,R;%N.#,EQ6HYL2X\E#(6P=7I5AQS=$!P%W]'M)K*W?HN3A3CV3'>\
MJHFG6P&MS`T&[\$VBCW-<4TH%U"]69'-D@B_%5N%Y;*JG_.ZW-O\BZKOW%5_
M+ICG\/Q=V1CYIZ'K=JI)(T#0-`T#0-`T#0-!\GN4(RQR#RQ5LBC84F?9/!!I
M/0#8VLAQD?'?;9IP-7KA4_V\4[-'C'NF%VX9/\B(V:/&/=,,5J12!H/X1"`D
M9D@`"*1F2[(B)XJJJNO)G!Y,X/Q2!;98\4;"J"PR]T24#D5[:)";)-T5'9[Q
M-Q15%3Q'S.K\@KKF_JJ:M%N)JGFU?[M7O16;XUELOKJQG9&E-^/]N>6VO0]F
M>4L8W$+Q*GQX4DRU1=_`Y\MM&Q7T;H$=?7L?KU[].]<]4Q3'-IGMG1[NM6<W
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MUGJ]^_75MF>SD]R<LQA1$<ST3URMAH&@:!H&@:!H&@^;GO0DJ7>'W`0S7=6)
MN-/M_F;>Q:I%$_ZS1+JW\!J_DS'/CV_@MG`ZOY,QSX^W8K=J<31H/X1"`D9D
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M9F<(9?\`9"]*"_9,QV9$-CS/TC,ADR<%DVVW#9;0^MP1-T44@14\?R(NVO\`
MJ:-[=F=/1/OV,OISAB_5OAF0T49^7:Q6(S4=UMAY!E1GC%UQ711M0:<,D)%9
M<145/9421=E3;7EO-6[DX4S[IYO..TJMS3K:OKH8&@_%%9>Z\N<"5[9IYMIG
M]8CC*;*JL,HX9GX^A!<\M%5/62?EU#<=G^VF.>._\'5E/W'M1JDI8T#0-`T#
M04!_M%_Q4_W>:"?^US]Q6#?TG^LY>@G_`$#0-!\JO/<8L;[I>=ZY]LHX76<7
MTE`-479V1/D3FB\/0CK;ZJF_J04U<>$UX6J)VQAUQ,_'W+?PNK"U1.V,.N)G
MV[&M5T.?<RRKZ2OE74\%1'8D%HGR;ZO!%=44Z6A55^,XHC^?4M5=IB<-<[(T
M_AUNO-<0L9:/YE<1S<O8FG'N`LJL^E[)+&/C$0DW6'&Z9DY45/%"+P8:)%]:
M*\FF%RK_`.,=L^4>]6,W]U<EBGKJ\OBGO&.*<'Q5QB7"IPGVL=4)N[L5]ZE"
M:?RVR-.EE5_^R$$_-K*FS3$XSIG;/MHZE9S7$+^9G^97,\W)V)&UN<1H&@:!
MH-_P?,`QAJZBN/RX0VR0R^4(``X\*PY"/>40.&VA-NINA)U?DW0DW37'F\M]
M::9T3ACHGGC#'IAMMW-W%N-MRO%>HQA4D1^HDQ)Z3Z2$+;9,0'_>I+SA`\3A
M$Z!MO^7Y)M]`^*IZ^KFM\/F*\:YQB8PG;.B(U<FF,<8G%LJOZ,(8;*L^J[VC
M6J8K-GV!2)%EO1HX&K#1LFTZA!NK)(C9CY32("(XJ(2B(BFS+Y.JW7O3//KG
M7IT<_3.G0QKNQ5&"*-2+0:#'=H%D[FG>`EQ#57:^CI+4(9HFXK`@A[FKJ=**
MFSDJ<1":KLH*'CXHFJSQRK>M1.VK1T1$^,SU.[)^O#9'D]MM59)&@:!H&@:!
MH&@:!H/E$YPB.8CW4\Z43[218=[F=Y(@-;KL+J37GF43?UN13%?^AJY\/KW=
MS973'^ZF/&/^*X9&O=BC953'^ZF/&/\`BU-RSBI-;JXZ/65P\F[%+7LN3)KG
MYQCL";FWY]MOSZD;F8MT3A,Z=D:9[(TNS,9VSEXQN51'?V)2Q_ACE')T!V1#
MAX#6N>/O5NOOD]17?Q"!%<0$_P#:2!5/6'I36.]>N>F(IC;5IG_;'C/4K>;^
MZ:*=%FG'GGR3KCG;IQ_4DW*R%N3GMDVJ$CMZ0N1`)%W_`$<!H6XOAX;*;9$F
MWQO3KV,G3.FY,USSZO\`;J]RLYKBV9S/KJG#9&B$[,L,QF6H\=D([#(H#+#8
MH``(IL@B*;(B(GJ377$8:(1SEUZ\-`T#0;1A5U%QS+*"\FM$[&JYC;[J`(F8
M]*^!B)^RJ@OM(B^E4USYJU-VU51&N89VZMVJ);58912).&QAJ)6</'GHA2HL
M88L>5:RG#8<E(R(@C:C%=3VNA%)QM%VW7JUST9>O=W9U35CIG&8IC3AC^J.R
M6<UQCCS>_P#!F:CD"C=IWHF2QAFS)$>.CY#'56S&&49AIDD0QZB*.POI_1H7
MEELA"JKJN9.N*\;<X1C/+MQG'MGIPQVLJ;L8:4*:E7.:"*>9\N=Q'`;5VO>1
MK(;_`&I,73TDDZ<A`#J)ZT8#K?+_`)H+KFS=R:;>%/JJT1TSY:^ILMQC.,ZH
MTKZ_PS,>9H>V5LXL=6(5KE]^Y")>K](U7OC4(2;^'LK`4/9\/9_G;ZHF>B(O
MU1&J)P[-"7L8S1$SRO0;7(VF@:!H&@:!H&@:#YJ>_5EVB[TN2K%XU2+D04/5
MNG2@@='71FRWW7JV>C]._AMU+^3?5IX-7A;B>>8GKPP]_>L_!ZL+43SS$]>&
M'O[T`1FWILL*^OBR+*P-$4:^$RY)?Z5W]KRFA(D'P7<E39/6NIZJY33.$Z]F
MN>Q+9C.6<O&-RJ(]MB8L>X*S6X47KIR-B4-?%6W5&;-7\J>4R:-!NGH)725/
M6&G\RK5&'3IGLCSZE:S?W513HLTX\\ZNS\$\8WPQ@>.DS).M+(+)E4(+*X(9
M)"2>@P9Z1CMDG\X&Q+\^O8L4ZZM,\_EJ]RL9OBN9S7KKG#9&B.Q*VMZ.-`T#
M0-!N.%9*&,S[-YQV5%"UJY-:MA"V63&5_I5'6D4V]U101%3K'P5?'7-FK'U:
M8C1HF)PG5.'(V6Z]V9Z$@V/*M=*I+RLB1),-;%YQ]J.+32`4O>*3<[S1<0F#
MZHW4;8`0FJ[JJKXZXJ.'U1735,Q.'=I^7GUZ)G3#;-Z)B8]NEC;#DB#98Z[5
M3*Y)<_RC49;L*(@N/RV3]Y-!%$&/TO&ABK0[GY8$722EOLHR-5%S>B<(Z9U1
M.CIT;=6,\SR;T33@A_4DYS01WQC.',N\/B"HBN$[$QNX.,PH*GM28D9ZUG**
M_%5!2&V!>M%!P4\=07&:L;-<]$1VQ,]T1U2Z\KZXCK>].J:E30-`T#0-!0'^
MT7_%3_=YH)_[7/W%8-_2?ZSEZ"?]`T#0?.1_$JXZ>QON@=ND9)BKY4C4-M&E
M@(^7[S'-FKE-B*ILIA[JVZ?A_P!ZBKXJNK%PJOZEF;>RJ.R9A+V+\QD;L1KI
MB9CVZ4D<69'3WV,,,5U=#HYU/M&NJ"$T##,=]4W\QIL$1/*>^."_DW%?;$T2
MS6)C#=PB)C7$>VJ?;2I=<S,XXXXI*UO8&@:!H&@:!H&@:!H&@ASEW-BHZO\`
M9NHE*UD=\TJ*\T6SD&"2J+LG=/BF6RMM>OKW)-T;/6B]5,_)&N?='MHCMY&4
M:-,K,_PT\#WN^1^1BBJS!IX$7$:)X!V!3D$$ZP:]'_=@S#5-OY^JMQZ[&_3;
MC^&._P#!WY&G1-4\KUOU`.]C7;FH9>E1GK6&U(A-^;,8-]L39;]GVW!4MQ3V
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MV*L;]7IIB=WQJZ]4<W2W3&JB-<Z_)]&7;9QL_P`1<$<7<>SFQ;N:&B8/)4#X
MJV\U2FV9)XKX%,?=+T^O5%KJFNJ:IURF8C",$P/6E9'DK#?L8K$M&E>6*X\`
MN>4**JGT*J+THB*JKMMX:Q>N:-,AS(PS(DIF5$-"4)3)B;:H*JA;&*JB[*BH
MOCH.1A]F2RS)C/!(CR`%V/(:)#`P--Q(23=%147=%30?ER5&:>CQW9#34B6I
M)%8,T$W5!.HN@57<NE/%=O0F@Y]`T#0-`T'@W_%PP%^OSG!N2V67%@93B\K'
MYKHI^C;EU#SDAOK7;P-YJ<J#X^*-+^1=3?";OR7*)V8^?@FN%7?DN43LQ\_!
MJ'"-Y3/8\N,QX$*HNZ$1&PCQ&6V$F-?%:G=((G43B)LZOJ<W_DJ*K:\OA3&Y
MAA,>_G\^=2;E<USO3..*;M=+6:!H&@:!H&@:!H&@:".N2<X##:5!B$V[D=OU
ML4$,O:1#1$ZY#@[HOE,HJ$7HW7I#?<[email protected]=3;/X>&#/7
MG-L_*'/,D0..J&1+D3C/=PK2Z(HL<G5\.M7F4FD2_P`Y-UU7>.W(HMT6HZ?;
MITNS(T[U4U2]OM5A),:Y<5#+\F*[:PVI4-OSI<8WVQ<:;1$)3,5+<1V5%W7\
MN@YRGP1A'9E-8&M;960=@K@HP+(CU$XKF_2@H*;JN^VV@[2*A(A"J$))NBIX
MHJ+H.%949)(PUD-),-HG@B*:>8K8J@D:!ONHHI(BKMMNJ:#GT%`?[1?\5/\`
M=YH)_P"US]Q6#?TG^LY>@G_0-`T%"_X@W!$CE_B&NRF@B%+S'AZS;R.N8;%3
M=DU2.,E;Q6Q3=5)661?$112,V1;'X^NS(9CZ-V)G5,QCT8Q+WZE5-%<1_%3,
M/%REN;+'K6+D=`\'OS+:@3)F21IL<O%6'^C?<5]($B*H%[2;IU"5ZJIQPJIU
M]_-/MH5ZFK#1.I;_``S.:7-H!R*\UCV$1`2WI'U1)$0S1=D)/Y0$J+T.#N);
M+LNZ*B;+=R*^:8UQ[=[*8P;GK:Q-`T#0-`T#0-`T$;9]R/6X:TD&.(VF32V^
MJ#4"7@V*[HC\HD_U;2*FW\XE\!1=E5--R[A.[&F?;3+*(Y9U*HDMI;V;LEP9
M%[D602VPZ&0ZGYDMY19888:1?22J+;0)^8?3K55539HFNJ>>9]O<\TUS$0^B
M[MUXG#A;B+$\&=5MV[89.?E<QK8A>M9Q*_*Z3V13!HB\EI5\?*`$]6J#F+TW
MKE5<\LIRW1%%,4QR)NUI9J.\K8I8U_-7,&0IQ]:9!7<K\)5V&X[95%45@$B^
MA3[PW8<UQD22*AM3HJB]*4&50-B<3RT301#R%%[E*F+RWC&-R,NMJ#Y)RC',
M`Q5O&:R;2JP&$5)U0@)U"BXV[?\`OD1%D$8DS\=.A?-4$Z7W1U62WM;1SN2*
MS'+[(I]JU?QL=@79,ON4^/.TD"/&F.0O)A&X-BT_UD+;1@T+A-]3IZ"0>#X/
M*USW+S<ZY)Q/)JRSCX#?8Y?V5C`88IV)(Y2,FMB54I@$&0PL`1,20W/6IJCI
M.;A?_0-`T#0-!1#^(?PLO+7;]97-56/V67\5S(^4T3,0$<D.Q(K[1VD<!W12
MZHP$Z@CN1&T`BBJNR]>4S'T:M.J<,>J8EG%RJFBNF/XHP>'E=9VU195V<8-/
M8&U%D$<;,E6%;0"]M(TE1W]E>KJ;<1%)LEW3=%(2NURB:L+EJ?F]U4;)\)Y%
M?HJW?EJU=RYO'_)&/<AUSDBK,X5M`Z0OL;E[[email protected]$O2#@[@:>(KK
M?9OTW8V3&N)UQ[;=4E5$T]"0-;V!H&@:!H&@:!H&@X7WV(K#TJ4\W&C1FR=D
M2'20`;`$ZB(B+9$1$3=577DS$1C+U3+DCDQ[D]7<<QIQR-QR!I\JW2*3;M]T
M^F.P*HBC#5?CFOB]\4?T2J1Q]54YK1&BW_S_`/K_`,NC7LF?I_J[OCW)M[..
M&2YDYPI"F5ZN<?<0NQ,ERQY0VC/6+!>92UB>I25\$E&.RIY;*"6R.CO$\=S<
M4TQ9IY=,]')#HR5K&=^7T%ZJZ351Y&J'L>[EN.N59N%6>0XJ'&^5XA9VU+5.
MV\ABRGVE'+@M2(\5MU\6W68LD$<Z/+!55'"`3W4*\TU+W!X"Y@&)5LG,:G$L
M8Q7#:.SQ&JHJZ=3L.GB]NS=F#K=7()\F;$8![J\:*X9)L;:$`A'^+KW;4-;3
M0WQS_'(][1X#7Y/95&-P;!*$8V''&G!65?3&;;\N_#9UM@5`07S.GR2W()=P
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M(FMK$T#0-`T#0-`T#0:1F^=U.$5Z/2MYUM+$TIZ)DD1Z48I^794;;%=NMPDV
M'T>)*(EJN7-S1KGDCVY.=E$8]"H%S<3KBQL<DR"6)S)`J3I=2HQ$CM[J+#*%
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M@68X'?XW?64^%&:J(T@<H276Q:V3'!!>86`(D!=;B[[JXJ.DYN%_M!0'^T7_
M`!4_W>:"?^US]Q6#?TG^LY>@G_0-`T#0>%_>1VTO<,Y.[G6(UY+Q1ELS=&XX
M+Y=!923_`-S<04V;C/F2>[%\427R/9V9\RT<'XE$Q%FY.G^&?#R1F;R^'ST]
M:EC12(LR+9UTU^KM8*JL*SBD@/-H6W4/BA"8%LG4!B0%LFXKLFI^NW%6G5,<
MO+[>YPTU3"=<8YP5I&H6<P%9-5Z!R*L:<=CEZ-E?BIUO,JJKMN'F#Z2)03PU
MY%VJCUQCSQXQK[,>IGHG4GBKMJJ[AMV--91;:`]OY4V&\#[1;>G8VU)%V_RZ
MWTUQ5&,3C#R8F-;(ZR>&@:!H&@PUWD-'C<1)U[:QJJ,2]#1R'$!7#VWZ&A^,
M9KMX"**J^I-85UTT:YP>Q$RK]D_-=A9@Y#PN(Y513W$LAL&D200_SHT0]^C?
M?P)]-T5-E97TZT[]=>K1&V=?5')U]CV<*>=#&R"<F2\Z;TB4X3\Z:^:N.NN*
MGB;KAJI$NR(FZKX(B)Z$UE31%$:&N9F7J9V+]L$I)=?SOR-5.Q/(17.+,=E#
MT$J.@HK=2&]]_:`E&*!HFR*KZBJJR05/B_$OKS].B?EC7SSY)7*9?<C>G6]6
MM0;M-!6KN-YMO>%8N'V,6J@1\9O),V/DO(-TW-=IJ)[email protected](
MTLHT\IC92-"W$5#!1^[W`8-7EUCEU/<X\Q@N1,8QD%DVP$RO665-!N'WV);#
MA-FRVW.`0\?,=7I\ILU-$T':K>[_`(KES/DRQCWE-:%EMMB3=:[!)][S*>Y*
MA?FD,97=HZS!Z=TW(1ZG#$6VW2`)BXOY3Q+E_'7LJPI]^71MS3A-3'FT;1TA
M::>Z@1"+PZ7A0A+8VS0VG0!T#`0D;0-`T#0-`T'A%WE=KS_`U]9\H85!3^H_
M)IJ/6\)GT8G:3'=B%0_DU\ETT5M4\&'"5M4%HF^FP<(XG%O^5<G1R3LYNCN<
M&;RV]\U.OE4I>A.>_1+NIL)-#D5<BI6Y!`)`D-BJ[JV2$A`ZT2_&;<$@+UIO
MLNK)=L1<PG55&J8U_&.:="/HN33HY-B:,7[@Y%6B0.4JKW)MI$0,XJ&G'X#J
M)_*E10\Q^*7Y53K;]?6*>&L(S-=K1=C1^:-77&N/?'.V;M-7IGJE9*GNZ?(:
M]BVH;6)=5<I-XUC!>"0R:?\`-<;4A7_EUUT5TUQC3,3',US$Q.$LIK-X:!H&
M@:!H(ER_FC"<4?D5;,L\GR9CP+&:7IDR&S]227.I&8R?G>,?S(OHUS5YJBF=
MVGYJMD>/)'6V1;G#&=$*Q97D.5\D/(68O-0L?`T<B8)`<(X>XJA"4]XD`IAB
MJ)X*(M(J;HVJ^UK3]&J[.-W5^6-77^;NYGDW(IT4]OMJ9G"L(S/E#,*KCCC:
MJ"WS"Y!7&_-ZA@UD,%0';&Q=%%\J,RJIOM[3A;-MH1DB:U9_/TY6C;5.J/;D
M>V+$W9YGT.<"<(8KV_\`'%7@&,*4QT#*?E&1OB@RK>VD"*2ITC;UGTH(#Z&V
MQ!L?9!-4>Y<JN5355.,RFZ:8IC"$SZP>H*[@N5KGA[#JC*ZZD6?5OWL>OR[(
M2AR[&-CU6ZQ(<<MY<.`GO#K#;K33+GEJGEH[YI;BV2*$;TG=YB8U-U(RVGE1
MW\0QS&;K)KZ@)NTH'W,A@OST*NL$,`*,#48B%Y_RD/P!$\Q1$PY?KH\0,KE)
MSV;Z'&QV^^18;HUYON63;=566[\V(PTI.FVRS:L=0=/G+U#T-DI(F@F_C_E?
M#N3I.61\1ENSQPVTD4]O*4$1KWN+)D1'VQ(2)4('HKB*!H)]/0YT^4ZT9A).
M@:!H&@:!H/'_`+Y>V67CUQ:\Y8'6'(QJZ<.7R74QAW^39A>+EL()_P!P^OC(
MZ4_1N;O%N+CI-V#@_$8M_P`JN=$ZIV<S@S>7WOFIU\KS8-O=R/(;==BRX;B/
M0IL=PFGV7$\$-MP%0A7951?'Q151=T54U:*Z(KC2C::IC4FG%>:[&O\`*@YO
M$*SBCX)D]>U^F%$3TRH3:;EZ/$F$555=D9%$WUC%=='JTQMC7UQY=C/15S+`
M4>1462P_?Z"VBVT5%07'(S@FK9JF_0X*>T!(B^(DB*GK36ZBY37&-,XO)B8U
MLSK-X:!H&@:#H6=K64L-VQN+&-50&-O.FRW09:'?T;F:HB;_`.76-544QC,X
M0]B)G4@?*>;5<!R%@\+SC5>DLBL6C;8%/6K$95!UU?#;<^@?02>8G@NF;E57
MIC#GGPCSPZWNB-:"73DRI4BQL)C]G:3%19EG*)#>=VWV151!$13=>D`1`'T"
M*)KVBB*>G;RL*JIE?SLF[9'^1;RNY?S:"3?'^-3?.Q2M?$A^6[.(XBC(5%1-
MXD5T?\CKH]/Q`-#K?&.)8XV;<_JGP\^Q(93+X?/5U/:;5;2)H*U]QO-EYPG$
MPNTC5,%C%;V?*A95R%<-S'JB@(8ZG!6Q2"!NL,RW]F5E%^B8^,YNA)H-8:[Q
M^.JVDRNZS.LM\<A8/?LXYD=TRR,ZJ&1\APKV3*:GL&3*QFF9@H)$2&[[/E`9
M&(Z#*5G=[Q7+F)66#-S2VKF67.*,U;T/SI"G27/R#(G$$<G%2.LU4!%3<D'J
M,A1MITFPF'B_E/$N7\<?RO"GWYE$U.=@-3GFT;%XV@;<4V]B+=$1Q!)%V-LT
M-IP0=`P$)&T%`?[1?\5/]WF@G_M<_<5@W])_K.7H)_T#0-`T&+NZ2GR2GL\?
MR"LC75'=1G8=M4S&A>CR8[PJ#C3K9HHD)"JHJ*F@\7.Y7LIRCC&58YCQ="F9
MAQLX9OR*-@3DVU""^*@H)UN3(P^.S@[[email protected]:"3VK-P[C.JB]/15Y^?:C<Q
MD_XJ.Q1!IUI]L'F'`>9=%";=!4(2%?0J*G@J:LD3$QC&I'S&#\L-%#EG85LF
M346+G3YMA7ON1'G.CXJ.&R0JX*?S3W'\VM=5FF9QU3MC1/N917,)!K.4^0ZU
M4!RZB7C'AU?*D$%=1$]0'#.(G_6$M(IN1JJQZ8\L'N_&QN$;G6Y1$&9A\(U3
MXS[-FX*%^=&RAET_Y.M=9;]S9';/D8T\[N_UZ2/_`*2;^<5_^%TWZ]D=OP,:
M>?VZV.D\Z7[B=$/$Z^(2_P#XIZP=D(/_`+$8K.__`+Q--ZY/)$=<SX08T\[3
MK/DWD"U$FW+UFH:).E6ZB*+'4*^GJ<D%)<1?S@0Z\W:YUU=FCSGWF_')#1#:
M1V4Y/DN.S;!U.EVQENG)DD.^_2KSQ&:BGJ3?9/5KVFW33.,1IV\O:QFJ9<[3
M;S[\:)%CO3)LYX(\"!&:-^1(?<7I;989;0C<<-?`0!%)5\$37ER[3;IWJIP@
MIIFJ<(>HO:_V,S/>ZGD;G6O%AN*8R\=XM=Z7.HA\6G[K;J%=EV(8HJJ)[/GJ
MJ]3(53B7%YO8T6]%.WEGX)3+Y2*/FJUO5O4&[30-!`/+5#Q)FV05V*9IR$N,
MY.[C%['''X=ZW6RYF.V/NJ6_G1B+=QA4B@BN=.X;$H$*[J@0]"[8.U+E:/<O
MX3D3MQ3J^HSX>'9<^[!B.O44?'R!`AR7`:)R#$8%=_:+RQWW%2$@S<+AWMHH
M,@AYC`Y#?J9USDMW'ZV<WD,1K6QN9Z6%G3N@,P1D(<Y%?*/XEUD8E[!D"A-/
M&^#<;\96>5XYB4]I<FR62UD>4P9$T'[)Y4CL5S,I]K=#V\J,VWYI#U.$BDX9
MN$1*$MZ!H&@:!H&@Z=A7U]O`FU5K!CV=98L.1K"NEM`\P^PZ*@XTZTXBB8D*
MJBB2;*GIT'BYW'=AN4\;/66:<"ULG,N/%(I$[B]HB>N:4-NHODGK55FQAV\(
MZEYP>AKS4V`9SA_&*K.%%S33MY8\X<68RD5Z:=$J`PYT6>VXY%=\Q&77(\AM
M44'&GFBZ7&G6S1";,"38@)$(5\%1%U:[5VB[3O43C"+JHFF<)8]NBCPISMM1
M2YV*W#R]3]I227(+CI)ZWQ:5&WO\CH$FM5>4HF=Z,:9VQH[=O7BSINU1&&N.
M=(%7RER_2(+97M/F$8=D4;F"L66J)Z/_`!,`VVO'U[QUUY%-^C55%73&GMI_
M\7N_1.N,.CX^;=8G<+D+2(-OQDIJB)U.5%PS)0EV7Q09;$)4\=O!5_SKMXY?
M6O1KH[*O.*7N%$\ON_%E@[C8"@"N<99@#BBGF")41"A;>*(JVX[I^?9->_U-
M?_KJ[:?_`"-VG\T>_P`G7?[BC+K^3^,;Y53XGRA+JXZ*NWK6/+E*G_)KS^HN
M3JMSUS3X3)NT_F[VMS^<>2IR*-7CF.XT*[H+\N3*N#V]1*VVW7BB_FZR3\^F
M]F*N2FGMJ_\`%YC1&V?=YH[N;++\I0PRS-;6TB.>!TT,QJX"IOOTDU#1MQP?
MS/.&FL9R\U_N53/-JCLCQF3ZN'IB(][IPH$&MCA$KH;,&*W\2/';%L$_R"*(
MFM]%%-$84QA',U35,SC*6N&>$.3^X:W2MXSJQCXY'?\`(R#E*S:/Y"KNE51T
M62106?(';;R&"\"V\UQI%ZM1&>XQ19QIM_-5[H==C*55Z:M$/=S@#MWP#MWQ
M1V@P^.Y/NK<FY&99M/0"L[F6"*@N2#!$06VT)1:9!$!L?`4W4B*I7;M5VJ:J
MIQF4K33%,81J3QK6R-!$/)T/C^XL\&ILHSXL'RH[)]W!?<KAJLL9DAR&_&>9
M9:<54D@K3I*K:MF/4@%MU".@A->T3MFFO+C=44VN+#X=(Q.QNJR::T<1JJB3
M8L)V6T$E74-R+/D`KKJ]9(2D)(?MZ##8OPMVI3??LAPKE5Z0=#)A.7E]09^\
MGD%+JXM"K<EZ',06OE&/6L`?Q2,V0)M1,$V"PO'G%O'''>5YS88DJ?M7E#%8
M65@[+1^4,.,[..M%T/C]`G(DBT;O4:@GDH?E,--MA+V@:!H&@:!H/PXVV\V;
M3H"ZTZ*@ZT:(0D))LJ*B^"HJ:#R([G.QFQQ]ZPSW@FI<M,?<4Y%UQC%$G)<$
ME52<<J!W576?'=(J)UM^ACK%09;G^'<8FWA1=TT\D\L?!P9C*;WS4ZWFKO[3
M@*BBXRX;3S1(HF#C9*)@8KLHD)(J$BINB^"ZM-%=-<;U,XQ*,FF8G"7"D=L)
M86$<G8-DV/0W9PW7(LH1]/2C[!`X@KZTZMEUY5:IJG&8T[=4]L:7L5S&IO57
MR5R'4"#89$W<LCX(W<Q&WU$4]0N1EBN*OYS(EUY%-=.JKMC'NPEEOQ.N&Z1>
M=+]M$";B=?*)/3*8L'8Z+Z/^Y**]M_[Q=9;]R.2)ZYCPDQIYV2_KTD?_`$DW
M\XK_`/"Z;]>R.WX&-//[=;HR>=;I448>(0FR7XK[UFX:#X^E6QACOO\`Z:?Y
M]-^YLCMGR,:>=J5ERIR#9;@W<1*5I-^GY,A`CBHOJ,YA2T_ZHCKS"N==79'G
MB;\;&@2?,G2AG6,F1:S@W\N;.><E.@A>D6S>(E`5_FCLGYM*;5,3CR[9TS[V
M,US+\FX#0];AH`[H/42[>)*@BG^555$365544QC,X0\B)F<(>A7;7V-WN=OP
MLSYJK)6-8**HY`P60CD:TN$V14*8B*#D.-ZE!=GG/'=&@1%=K/$>,[T3;LZN
M6?+S267R>'S5]CV2A0H59"B5U=$9KZ^O9;C0($9L6F6&6A0&VFFP1!`0%$01
M1-D3P35<2#M:!H()Y0Q;BWD/)Z;"LHS=VDS*QQV[@0<8K;D(-A8T5H40+5LH
MNZFZT?NS0J2#N.RJ!"7B@13:=GO;3R".20(16!0/>'J^\HL?R26U#AO'C\;'
M7XQQH[Z@T9U\6.+B$G670/4JB1B8<DKA3MIP0XO),_D27B%?:V]JZ[D,G.),
M"MM3N9A6=C7/N',!E]I^6TY(-O?J4O-15Z%,=!,7%.&\4X%8YS2<?VT2=D5C
M8L6&>14L&I<\)+<9J$P4QILNH#\B.`*;@^8YT]3A&:J2A,V@H#_:+_BI_N\T
M$_\`:Y^XK!OZ3_6<O03_`*!H&@:!H&@J%S1V6\1\N29^00HKG'V<3B)V3DU(
M`(S+>)553GP"V9?4E7<G!\MXO!/-V\-=N5XA>RWHG1LG5[=#3=L47-</-CD7
ML<Y]P(I4FJIHO)=''W,;/''$29Y2>"D[622![K5?0W'*0NWK].K!E^/6JM%R
M)IGMCS<%S(U1Z9Q5+N8%CC<]*G):N=C-L2JB5%S%>KI?AZ=X\H&G$_ZNI:UF
MK5WT51/6Y:K55.N)=370UF@*NWBO@B>E=!G,7QC)\XD'%PC&;C,WVBZ)`4,"
M19>2OH_3%%;<1I/SFJ)KDO9ZQ:]5<=\]D-M%FNK5"Y?&_P##^YIRUUF5G+]=
MQ;3*J*XW*<;MK4T\%V"+#=]W!"3PZCD]0KZ6UU$9CC],:+5.///E^#KMY"?X
MI>G'"W;%Q/P8`R\5ICM,K-DF)F=7*A*M7`/;K;;<$`;CMELG4#``);(I(1)O
MJO9C-7,Q5C7./<[[=JFW&%,+":YVPT#0-!Y_<@<2Y?8=X>'YCCW&\FPP[)*V
MSK>69U][C:XS858Q:=D9+#+LA'H,U?:CJ'EDCX,`J`3?GF`;';<><C?U.<YT
M^*8E-Q_DGGN;EK\*56O0(35)'CPBJJ!EZ0KXJP4FO@QT$F&W$:D/&9;)U&H1
M-:\7\BNX5:<?2.!,CSCCJ;>Q*W`@4L.CW^-X37PZN4Y5HDFVK6&B?M6'@8=:
M5QQMD1=-3,&`T$J=O_&_,6"<HWLNX;LXF.Y38YW=\JNV3];,A6=M-O(KF*2Z
ME]AL9OL5/F,N@[L#0M@UT[B!*%X]`T#0-`T#0-`T%6N;^SWA;G-V5=7-,]B6
M>/@@CR+C)!!M"4$V#WM.@V)HCLB(,EIS9/`>GTZW6,Q<LSC15,,*[=-<851B
M\S.1>P+N&P>0\]AGR3S1CZ*1,N0'6J.[`$\4%V#/>]T<5$\.IN6BDJ>#0[HF
MI[+\?F-%VGKCR^+AN9#\L]JG&4Q+C`I(PN0\:O..I9ETMMY36RJEMPE\$1F1
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M#NM9:BWSR])*>FJ,>JX%'054.CI*I@(U73U[#<:+&8;38&F66A$`$4\$$41$
MU'.ADM`T#04<[D./.0KSEKB_,>-<'EVEU63J6#;W$MVNEXW/JD=M79<6U@R7
MFY,<X`FCS$IA%7J?4$0W!`"#!]M."\S<7PVL4SK'LCRW&[2JCPN0F[-RCE-3
M,NM;>>Y=7L<_.!]Z$\PZ#CR.J1]!-`VT3@O`(=OD+A'*K_B[G1VFX]8/,LZS
MZE>Q/%HQ5T58M!BEI`APC:<=>9CMB[&B29PHKB'_`.)(-D+]&@6`QO&KZ%W%
M<J9D[BKU=B^5X#A%7"R178/1+LZ2PR1Z8T;34@I/4#%I&%#-I!7I(4+81W"=
M-`T#0-`T#0-`T%:>:>U#B+FU95I<U)XWFCX(@9U1=$:<:@B('O0$)LRQ1$Z?
MTP$0CX-D"^.NG+9R[EYQHG#FY.QKN6:;GJAYE\D]A'.&%F]*Q$('*M(&Y`[5
MF%=9@*;*JNP)CO0J(B[)Y,ETRV^(FZ)JPY?C]%6B[3ASQICS[T?<R,QZ9Q4Y
MR6CO<+F#79G0V>'3W"Z685]"D5CKOIV5L)8-*:+LNRCNB^K4O:SMF[Z:XGVV
M.6JS73KB6,UU-1H&@R%#47.5S#K<3I;+++)M>ERMHX;]G)'_`[email protected])ZU5
M-DUS7<W9M>JJ(Z_!LIM5U:HE;WCGL0YWSA8\K((<'BZE>5.N7>&DJP\M?0XU
M6Q#557\H/OL%J)S''[=.BW$S.V=$>?<Z[>1JGU3@]+>$^S_B3A=^+>L07,SS
MF/N3>97H@Z[&)?3[A&%$9B[>*(8"KO2O23I)JO9K/7<S/SSHV<COM6:;>J%J
M=<C::!H&@\V><>)>8;7N7:RWA_$9]3+R7$LAJ,@S.U?A2\?4DKZMJNLXA>>D
MNKL&9"^5[#9>:+`$($'GFV$L]M6-<B<;U(\>W>#9`'&!P*FOP^KM3HGWZ1V-
M3J=V$YR(^TK[$F:G0T:"Z;CQ.N$J,D!Z",I_#>;2^(>&<;C\?YEC/+V#?+$K
M"KVJM*@:6EE2;$7/(O6!LW(TJ,^STJ0HP^J-@X+:BZ0@82#Q#PEG6+\\V62R
MY;K/%^$P,SA8<[,B1HEI:S<YR-F_L$?.-*D+)B0G(W2PX\U'<(G%7RR1%=<"
M[.@H#_:+_BI_N\T$_P#:Y^XK!OZ3_6<O03_H&@:!H&@:!H&@Z-C65MQ$>K[:
MOC6D"0BB_"EM`^R:*FRH3;B$*ILOK300]8]M';S:F3LOA+"4?/\`UDF-1PHK
MI^"#[;C#39ELB)MNOAK;3?N4ZJICKEC-%,ZXAK@]H/;<)"7]5=<?2J+T.2)K
M@+MZB`Y"B2+ZT5-EUL_K;_\`[*NV6/T:/RQV-LJNW/@&E<%ZMX5PAB4"[C-*
[email protected]$\47;SW&2<V11143J]6M55VNKU53/6RBB(U0F%AAF,RW'C,A'89%`98;
M%``!3P1!%-D1$_-K6R<N@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:#C=::D-.
ML/M`\P\!-O,N"A`8$FQ"0KNBHJ+LJ+H(1R'MC[<LL?<EY%P1@-I/=^/9NX]7
M)+5/R>\BP+NW_2U[$S&H:1]2'M2^A2C_`.M*_P#O];/K7/S3VRQW*=D.]`[,
M.U.O=5X>`\.L"+;=NUKF[-OV=]MFYWG@GI_)^3\B:QJN55:YF7L4Q&J$ZXQA
M>'83"^3,,Q.FQ&M\/_E]+`CP&/#P3]'&!L?#_)K!ZV;0-`T#0-`T#0-`T#0-
M`T#0-`T#0-`T#0-!UY42+.CNQ)L9J9$?3I?C/@+C9IZ=B`D5%_SZ"(;7MSX!
MNG">LN%<(?E&NY31H8#<A?%5V\]MD7-E4E54ZO7K93=KI]-4QUL9HB=<-27M
M`[;E55_JLKQW7?I"3.$4_,@C(1$3\R)K;_6W_P#V5=L^;'Z-'Y8[&R5O;3V]
M5+@/0^$L)]X;7=J5(I(4EX%V4?8=?:<,?!5WV76NJ_<JUU3/7+***8U1"9(,
M"#5Q&*^LA,5T"*/1&A16Q99;'??8&P1!%-U]2:U,G;T#0-`T#0-`T#0-`T#0
M4!_M%_Q4_P!WF@G_`+7/W%8-_2?ZSEZ"?]`T#00OD?,C=?GMEQIB6$W7(678
M_0L9)E$:J=@1H]=#FN/M06G9$^5'%9,PHSODM#X=($3AMCTJ0?V%W`\2?);,
MS(\[HL(M6:-F]R+&+^SAPK"G9*-'E/M3VG'4\IR,$IKSA7Q#K!5\#!2#-UG-
M'$-T-2=1R=B]FW?/2(],Y&MHCHRG8COD/@THN*A*#GL*B?RO#0:C<=QO&L0\
[email protected]:R1!QVQR85L'G9+?D@_#K7";<5.C91,B%M4)0Z
M]AW*<:5=OQ913KB"W8\F,.3'A;M*QUNCB-X]-R-9=DX$I41A8T$T%YOK;\1+
MK0"$B#90Y\X9<FQH(<EX^3DJKL+AM_WYKR!B54AN),(WE+H$FG74%05>K="\
M/978,+D?<=Q51GQ^S6Y/79=*Y(O*JFH(E)807W>BUFN5[<T@)\2)EN0RXV70
MA'U-N(@?HG5`->R[N>Q3#.2LQXJN,?M6LHH,4/+,6,U8:AY(U&CNRID&ODN.
M""3&&V2-675%5!%<'V!)4#;9O<+Q%25RR,FSJDQ^VB1*N3>8T[/8>G0"M78K
M#+;S+)$7LNS&1,D3I#K$B41)%4,?R3S]1\=YECF!CCEIE62Y/1SLAJZZL<A`
M[)AU[T=E\(3<J0R<V0*2/-\B,)N*V)$@J70!AF<AYRP&GDQH-9;1LNL4RNGQ
M*[KJ67$??JI5S8'5M/3&R>$A;;EM.,GTH1(X!AT]3;G0&3;YLX==%PVN4L5<
M!J:-<Z06\14&4;:O`T2H[X*3:=:>I1\?1H-6RSGJGQ?F3%.%&L8MKW)<EK8M
MPX_#.&V#$"7,=@^\-M2)#3LD8QLDY+\D25AI0,D53`5#KIW#8_\`L[FN2'BE
M^W&P3/XW'EU#)("OC.DR($4):(DQ06.CM@WNHFKG3NOE^K09WF?F`>&<;E99
M+P3(\RHZ:NGW>4S:(82!6556+1RY#I39443-`=ZFV6U)QQ!/I'V%T&B_6@Q^
M1>2L?I\%R:_GR;+):/#VH`03*YM,1M6*:WC-BY+!8R,R'^M')/EMJRVZ\I"(
MCUA+/%G(L/E/#H^6PZ2SQH_E&VIK2@MQ925#L:.QD54]@CC.OLN($F*X@FTX
M0DFRHOI1`D30-`T#0-`T#0-!%_(/*=;@=O@V+-TUCE.9<CSI,+$L9K?)`W!@
M1UE39;[\EQEEEB,TB*9$74JD(@!F2#H,?2\U8DZD*#F[K7%>5SYS\"-AF43H
M#,]TFI2PVGV?(DO-N,R7=DCF)?I.H1V1Q5!`_D+N%X(LJZTMZWF/#+&JI7VH
M]M91;N$\Q'<>;?>;1QQMTA1":BON;[[=#3I[]+9J(=?->?..,/@Y(XQ?0LJO
M,45I;O$J>=#=LV6RG,U[SI,./MKTQWGQ%[;Q!?95.I4%0PV6]R/'N&XG)RFT
MFQ9!)>2Z2JHX-K529<\H5FW5O/L>7+5M1!QUM7`4O,;4Q:<`7E1O0;=(YPXC
MCV,.I_K#HI%E.OF<99A1YC3S@VCZ2E;CN(V1="DL&0"*6P];1M[]8J*!K68]
MRO#>)8#E7(+.>463UN*QY;CM?46U>Y(E2(D/W]8L?S)#;:NG'V=%%-$5M4/?
MI5%T'ZSWG_%>-;;B^/EE=80,=Y/566<T00.NIWS6.$9+4D+JCMOO2FF1>5%;
M%PQ$R'J1=!R4'<#@$JN;?S*XK.-[EZQNJYC&;NTA),<6BGS*Z2Z`MNDA"3T!
M_P`O954A!53Q0D0.CF_<A@&(8!QMR-#=7),>Y:MZVFPJ<S(BP8IOVL9^7'.7
M*L'H[485".0?I%ZO-4&NGK+;0=RV[@L)HL,E9%;@_5Y7"Q%_,)G$DQ^%'R9J
M/%AG-D1BBN2$;\YMMIS?I<450"("(/:T&9KN=>)YL:*LK/*.IM7:>%=S,=F6
M$89\6/.2-Y0NL(XI=?5-8#I3=>IUI$3]*WU!K_*7<)B?&U7QC9Q83V;M\O7,
M"HP5ZHEP6XDTK!`=9<"=+D,QE\UDNME/,_2KZ%0>HQ#H9-W*XGB$[.8&0XQD
M=;(P7"Z#-9++K,1'9K&22Y5?`@QFTE*0REEQ#8(7O+%#5/:Z/;T'>7N$QEC$
MLMR&=2V<2YPW-(?'EIAW5&.8YD=E(@1ZZ)'<1[R3&5\IQ7`-33I;<ZC05$A0
M-):[N<,EY=@V`PJ*6WF677MQCL^FLY];6I6SJ.Q^39;:NR9(C,(B$W6FX?FN
MFTG7Y8J2#H-^X:YXH.;9V>MXQ6K'JL%M3IWK!Z?`=D2)#;KS:J=?'?=E0T46
M4<%);;1D)BHBOM=(3KH&@:!H&@:!H&@T3DSD7&^)\'ON0,M<?"DH`9\UF(WY
MLF1(E/MQ(D6.VI"A.R)#S;+:*2(IDFY(GCH-3C<R0ZM^T:Y/QN7Q!&@Q*V3"
MN<CG5JU\X[!)1'$C2HLIX"D1$B$3[:[=(J)@IM[F@9`>>.$CLY5,WR[ASMI!
MKG;>;!"[@DXS`8B#/<DN(+R]+8Q21]27P\K=SXB*N@R'];_&!2:B!'SV@DVN
M0@BT%.%C%&5,,WGHK;33;CH>V<B.ZR(ELJN-F'Q@-$"-<"[H..LYQU,G-]K&
M('[/5M^Y%M+.J&:TMI-FPF(;T1N6;K;IN1$\LC%&W5<06C,A<00_.,=V'"E]
MQU6\C6F7P,2B3L;DY6_C]G*8.SCUD07W'72CQ7'E-?+C.."+?4I")***B+L$
MB,<U\12#?:#DO&D?B5(WLR,5G&%QFN5&2]Y<%7-Q`4D-=2KZ/,;WVZPW"-K+
MN=QN'P=-YZ@8G>W^+UV13J"335GNDFR<]PR-_&CD1FVWR:D(<EGK;%MQ2,"3
MIW+PT&7J>Y/C*P^5[>9D%72<?PZRHM:3DF?9PV:NU8N8\F4RD;K<%Q";9B.F
MXAB/2(JOH$^D-ALN=>-XN$<I9[4W:9;4\/L63N91*(??);;E7&*2^PTTBIUD
MHBJ"N_0JHOM(@DJ!A\1[A<$OJ"%D61S8F`0+NS&NQ"7;VE:[$O@.)%E#,J9<
M22\U)C[RD9(T)%%T#`D39-P[V+<]8#>A'8N[.-@=Y895<8C3XS?S83,Z9.I[
M%VL+R`:?=`T>=;1&T$E55,0^.J#H.YD_./'F/\891RW!NV,OQ'$V?-L95"^Q
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M&RZ!H&@:"@/]HO\`BI_N\T$_]KG[BL&_I/\`6<O03_H&@:"#+KB"V9Y1M>6N
M/,S:P_(,MHX&/9Y73ZM+6!91JIZ0[`E`V$F$XS+CI+>;%Q7'&U`D0F2Z4700
MAG/9/69[59+CUQR39O4EW-R.[@N.P(Y6,6YRNG*EM9)R639:=:-I^0ZVPC`"
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MX0<\;88OK5J_I'W<>KW;"#8I90;9X7K%%"3(B%)@BHQT-OI0E0C/I;4`WSG+
MMYD<XQF*6ZS4(N-K'K0>C/5#,FQ@SZZ6<I+BCL0>CG73S0D;5U`<!!%-F]!'
MK'9[,',K_*IW*TFU:R"]@W4F#)JD\[:MR:3DL5CWH)@J@B<LXZJ``GE[$(BY
MU$08JL['Z^NQ?&L9;Y!%DL1*%'H,AKL?@U-HS#K6R8B.',K3C.OS$8,F777R
M<CO`O2[$+<^L)@Y:X`7EG-<%R"WRI6:'"KBLOZ^H6$T<V#8U4IN4#U78(HN1
M?>O*!J1NA[M]0@H*:KH/Q)[?#=QGDS'&,P1A.2.0HW(+TTJ_K6)(C2J^6$4`
M]Y%#!3K6D4E5%V4_#Q3I#-<D<59SR`*0PY5&FHVKUJX9HRH(<U@FH\:,,:'(
M1YS9YMJ6TY+133Q,@%?9:3J#2'NUN".59;R)2Y4QB_)5Y3RZ>BS*GI(<4X!6
MAQSM;9Z.!>7*LIONP(<A4`1V_1M#NYY@3CQGAD[`,0K\5FWXY%\F*00Y3<"-
M6M-,>"`RW'C)MLFRD1&1&1*1*7BB(&_:!H&@:!H&@:!H(AY+XL?S:]X^S7'\
MG/$,[XRFS9&-6QQOE""]'LX_NT^%/@^='5YEX!`O8=;,#`"`TV5%"-<I[:I>
M:75M=9)R-)FEFD#&Z_D2"W6M,LRV<2O'[ZJ&MZ7NN"@.RGF3ZR?(FB^,+J>;
MH(OD=B\!_%H>+_UD/MMP:.EI(EJ%:3,R.M"YDKT*;%D1YS3L>0#F3/'UMFB+
MY38$)-$\VZ&R2^S>!*@I4%R%,>J*:3DTK"0E0&W)4`\QO(U_<>]R`?:][19#
M!"Q[#?0+A=?FD($(<.0]GLRVGY-95G*K]))S-^V'(@^1VI+90K._'(Q:C@Y*
M3RG697F"CNY(;9=)MJ0`:!BXG998,Y':Y'+YCFV,NWL(,R8Z]4`CYA"D9&2`
M3PRT5"6-DTED2`10.AHA!!#RU#KM]D!1,=J:NMY2"LNJO%[K!7;N)B]9&";C
MMW!8@/)-CQ295Z>(Q62263FW4&R,B)&*A96^XB@96QCU+E,N)D>(0\2LL0RS
M&9\`3;N8MF$-'7#<%T?)(2A`2((KZ2\=^DA"`\4[*:/#K6DE5N>R[*O@P&Z^
MU^7*FOMK20,2YM+F&]'LYH.N17NJU=9D.`*J\/MCY3NSB!)[W!EXYPU@?$;N
M:U5S$Q*M;I+X;_'&K*FR"J9A.PF8EA4^]LKLWNRXA!(1>MI%7P)4T$&?45<8
M&DA1N:+>32T.*+B<&%;5S<YYJ,]CL['I),O^\M(".!-\U$Z%5%`0(C!&T;#,
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MJJ6CN[F%6!41WH6/N6#L$SBB_)W?5;-Y''/,Z21`$0`0VT$NZ!H&@:!H&@:!
MH(VY=XQI>8^/,AXZOYLVK@WJ176;:N(`EPIE?+9GP9;"N`X"FQ)CMN(ABHKT
M[$BHJZ"/;;A[D3(9V%Y)?<N1I>8<>6?RABC\?'&F*A?-KYE7,]^@+-.0^<F/
M./J5N8T`F+9-M"B&+@1%%['<;KZRIHH.8FY1T;;C<&MGU,>4#HNX._@S@RF_
M,;9=`XKY/D`M`"N>STHW[.@R%%V:Q*2)\D_UEVEC1VDS')V35LYAR49EB&1R
M<DI&:^7)ENR8S3+CXQG$=<D&<=L41P'5)U0QU'V6.XS)P^WH.57X608#6X_7
MXS/<IVGHZ_L_874UM9D<I2*\+X7\IEP0-M4V:,"`@7K#46^P!5I8^.2N:[69
M2LXS98Q[L=1'0FX]O2VU),*.J/\`2TI-VGFIN!%UMHAF8=`MAN*]EJ.+<O/\
ME@=C*NZO+:*[#&:M)\#(*R76V`DLL^MUZO*56-G[FI"NQ$)/GL)"$OT7!]Q3
M\:C@;^=MV5@?(#O(,C(#J4;`I;^5EE[D8(H2DZ6EFDH;JZ1>4JBB]6Q($86W
M9+A#=Y;7F#W28JW990F4,XI85<6\Q^.[(AS(5E&;JY:HT+,GWUR0(@H^4^I&
M.X&3:A*F(<)W6"XIR-BV-\CR8:9=9+:XO:_)<,7J20<=AIS=IKRV)(DXQU]'
MEM@@KY?3TZ"NV0=A,>[I;RH@<H+A\7*+ZZR&\Q['J)N'CX2[6+71VU@5AS'2
MC>4=:+Q(KYHXXZZ6PEY2M!($/M&2-G#.<.Y\Q-E3+.QG9'#EXW73!=;F7CV0
M-#7G,*0L%YB3)=!'A0R5I1\!=`7M!OW&'`4CBGC6[X^QO.9#*6-NQ:5,E(?5
M!K6V6H+1P(T!]]]`B/\`N9*XP#@@/G.BP+`>6`!"V#=AF"T&"\88/DDZ%=0,
M&F,7%N<>K9:DRY;4MFP6OC2W"<*-5E*8!XXS;:&X:*2O)UN"02E<=MTK(L@G
M7E]R&_,#*I>,RN1(;-:S%6T_8V\?NJ06'&71]UZ?-;C25V<5YEH43RC4B4-8
MPOL_J\/PGD3"&\T<?@\F56/4&5R6*_W8KDZU82[$?>7!D6ES#?./-FIT>
M8B-FK6X+UA<I$04011!$4V1$\$1$T']T#0-`T%`?[1?\5/\`=YH(OX;_`*\/
MZO*?]G?K%?(GO=K\F_LK_4G\C>7\I2MO<OVA_P#F?E[^CWKV_P`OAMH)/^T5
M]ZK\/6@?:*^]5^'K0/M%?>J_#UH'VBOO5?AZT#[17WJOP]:!]HK[U7X>M`^T
M5]ZK\/6@?:*^]5^'K0/M%?>J_#UH'VBOO5?AZT#[17WJOP]:!]HK[U7X>M`^
MT5]ZK\/6@?:*^]5^'K0/M%?>J_#UH'VBOO5?AZT#[17WJOP]:!]HK[U7X>M`
M^T5]ZK\/6@?:*^]5^'K0/M%?>J_#UH'VBOO5?AZT#[17WJOP]:!]HK[U7X>M
M`^T5]ZK\/6@?:*^]5^'K0/M%?>J_#UH'VBOO5?AZT#[17WJOP]:!]HK[U7X>
MM`^T5]ZK\/6@?:*^]5^'K0/M%?>J_#UH'VBOO5?AZT#[17WJOP]:!]HK[U7X
M>M`^T5]ZK\/6@?:*^]5^'K0/M%?>J_#UH'VBOO5?AZT#[17WJOP]:!]HK[U7
MX>M`^T5]ZK\/6@?:*^]5^'K0/M%?>J_#UH'VBOO5?AZT#[17WJOP]:!]HK[U
M7X>M`^T5]ZK\/6@?:*^]5^'K0/M%?>J_#UH'VBOO5?AZT#[17WJOP]:!]HK[
MU7X>M`^T5]ZK\/6@?:*^]5^'K0/M%?>J_#UH'VBOO5?AZT#[17WJOP]:!]HK
M[U7X>M`^T5]ZK\/6@?:*^]5^'K0/M%?>J_#UH'VBOO5?AZT#[17WJOP]:!]H
MK[U7X>M`^T5]ZK\/6@?:*^]5^'K0/M%?>J_#UH'VBOO5?AZT#[17WJOP]:!]
MHK[U7X>M`^T5]ZK\/6@?:*^]5^'K050__M_]J_[=??OZ]/\`_(_??E;]E?\`
/]K\J>Z_T=[K_`/KM!__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>a62430vascular.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a62430vascular.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@`M`(]`P$1``(1`0,1`?_$`+0``0`!!0$!`0``````
M```````&`P0%!P@!`@D!`0`"`P$````````````````"`P$$!080``$#`@,$
M`PL%#00'!P4!``(!`P0`!1$2!B$Q$P=!(A1187$RDZ-E5A<(*(%"4B,5D:&Q
M8G*"0[3$=84W1\&B<Q;1DK(S8X,DPE,T1%0E-?#3=)34&!$!``("`0,#!`$$
M`P````````$"$0,$(3$205%A<2(R$P7P0C,4@9%2_]H`#`,!``(1`Q$`/P#;
M?+3EQH2?RYTK.FV*'(F2K/`?DR'&T(W'7(K9&9$N]2)555H))[*N7'JY!\B-
M`]E7+CU<@^1&@>RKEQZN0?(C0/95RX]7(/D1H'LJY<>KD'R(T#V5<N/5R#Y$
M:![*N7'JY!\B-`]E7+CU<@^1&@>RKEQZN0?(C0/95RX]7(/D1H'LJY<>KD'R
M(T#V5<N/5R#Y$:![*N7'JY!\B-`]E7+CU<@^1&@>RKEQZN0?(C0/95RX]7(/
MD1H'LJY<>KD'R(T#V5<N/5R#Y$:![*N7'JY!\B-`]E7+CU<@^1&@>RKEQZN0
M?(C0/95RX]7(/D1H'LJY<>KD'R(T#V5<N/5R#Y$:![*N7'JY!\B-`]E7+CU<
M@^1&@>RKEQZN0?(C0/95RX]7(/D1H'LJY<>KD'R(T#V5<N/5R#Y$:![*N7'J
MY!\B-`]E7+CU<@^1&@>RKEQZN0?(C0/95RX]7(/D1H'LJY<>KD'R(T#V5<N/
M5R#Y$:![*N7'JY!\B-`]E7+CU<@^1&@>RKEQZN0?(C0/95RX]7(/D1H'LJY<
M>KD'R(T#V5<N/5R#Y$:![*N7'JY!\B-`]E7+CU<@^1&@>RKEQZN0?(C0/95R
MX]7(/D1H'LJY<>KD'R(T#V5<N/5R#Y$:![*N7'JY!\B-`]E7+CU<@^1&@>RK
MEQZN0?(C0/95RX]7(/D1H'LJY<>KD'R(T#V5<N/5R#Y$:![*N7'JY!\B-`]E
M7+CU<@^1&@>RKEQZN0?(C0/95RX]7(/D1H'LJY<>KD'R(T#V5<N/5R#Y$:![
M*N7'JY!\B-`]E7+CU<@^1&@>RKEQZN0?(C0/95RX]7(/D1H'LJY<>KD'R(T#
MV5<N/5R#Y$:![*N7'JY!\B-`]E7+CU<@^1&@>RKEQZN0?(C0/95RX]7(/D1H
M(\G+W1"<P2MB62(EN.TC)*+PTX:O!)4!<R[LR"2IC02'E/\`RLT;^X[;^IMT
M$JH%`H%`H/AYH7F7&C4D!P5`E`B`D0DP7*8*)"O<5%Q2@Y7TUJC6;W(Z7K*?
M/O0R+?"1U;D-R=3MZR+E)BF((YVAI@XPL-8*C6*XKBBYD5`V%+]X*3%U+(T^
M];&V9)W9JSVUQXG$!P'Y2QVYQ.B'#-G*V1+D5%0_JUP\:@3.=M]#4;.EKG9V
M(DF2K5OG+#F*^<>3)AN/J2/M"@`K9M*/#54/YZ+A06,I[6%W]VFU:IA7R:QJ
M&TV];L_)22ZWVMJ/F.0U(4"%2S-`N"[T5$P5,5H+BQ<TKVQ?(:1[>[.+4MOC
M:G>C2)QD$.V27PBMM1N,7#$FVU*2]BJ(I+D39EP"UC^\I=7H$R0%A8-]D(#T
M=M))HT03II0E#C(V8GPS%%1UM%`DW4$VY@3+P/+1R;?[H>E;DVA<;[)D#F<D
M+G;C,,R'A#!''%`EV)W%5!S+0:<>YG<R84P#"YK=;A97],6UEJ,[Q(L\I\:5
M]H*J!U'E-]O*CN&Q0Q'9CB%M9^;O,T8=LML&Y+,N&J@LC7;I9(J0Y=S>E"Z3
M9$#@-\0(XH(9%$=XCT*'0G*O5$'5.@+/?H+4EF/-;<5&IKI2'T-MXVW,SIJJ
MGUP+*OT<,$1-B!*Z!0*!0*!0*!0*!0*!0*#"ZUFS8&C[Y/@O+'F0X$F3'>$0
M)1<9:)P>JX)BJ8CMQ2@TI9>:.OI>F[!?WKE)9CO3+1`NK;T6&JO.SU8>XD81
M:;RL.`Z;2JIJ2;"3;02BU^\1:[L;,6V661*NTMQ]J':T=;"0KD5AZ0^T^!H)
M,NB+&415%0B),"PS*@6VL>?"LPM06RW0W[7?H-ON$F(X\K#KC3UO::=(9#"*
MX((7'ZNTL<%W;*#(\Q]7ZPT]I#36MH<PEM$8X3FK88-,D;D.3D0WFE,"(2`R
MPRCO1>C#&@HVWG,[;[C.L]S@S[K<HB#+G)';:)8;<V,]-BQEX0@"\-AD`-TR
M3%P]F(XY0^6?>'@R83+T&PR)TA^YQ;.$=B0RJ%(G1%EQU!P^&)"HB0DJX8*F
MS,E!F>9]TUX&BXETTW+6Q7HP;)NT''9FR9$U[)PX&U3;1-IHX8;L,V9!$J#5
M%_\`>'US9KI<92HS*C,RKG;&K<T`&P+D"VM2&Y(N(/%,5?,B/KY>'N1%VT&1
M?YK\TBM%VB01F3W;'+B.S[W"A1)#XPI%N&28K&)6&B(72V**>+OV[5#?6G9:
M3=/VR8DDIJ28C#W;#;1HGN(V)<4FQZH*>.;*F[=09"@4"@4"@4"@4"@4"@4"
M@UKSNU5J'3<?2<BS3GH@W34$.T3VX[+$AQR-+0U-6A=;=7C#POJ\-FW:B[,`
MBD3G)>=/2V)NHYDFX6F7IUF_18O98X&#<V9'9:*5(9X>4F.T9',K.7#$]^`T
M$HA<\[=.24Y;[#<;A'MT<)%S=A<"1P>-%=F,"F5S!Q'&6?'%<N8P';BN`8B'
MSI>U'J?2C%D4HD.3=Y-LO,<ECR&WA&WI,:)IX,Z[,P^*H[<R*B[*#W56J^8-
MEYH.Z7*XN+;]40C/1\D68F6)*8(#E]H4VL7`CLYG=J[0ZNTU0D"M$]X6R%I\
M+J-JN+\(B:;BW%\6VF7Q-'T1PW1P:;-5B+BVB>,8)LQ7*&9L7.6+?KY;;7:;
M#<)(7"%"N9RT6.(1XDY"RN.B3J'U##*2"B]U,=F(8GF/K/7^E-3E/B3(<VPL
M6ZX7";9%8RK'CQ(I%'?=EYLV>1+'A@."(NX<5$BH-?V[G[KN9/9TV3X!.DQ[
M=<$NXL-*383+"MT<90%'A;)`Y1515<F*;2ZU!GK)[PLR_P"I.7ELB/0XHWC`
M=2LJ8*]VDXG%!IMLE4VVB,Q437QE7*B]4L0WY0*!0*!0*!017^J?\#_:Z!RG
M_E9HW]QVW]3;H)50*!0*!0?$@6"8<&0@DP0DCPN8*"@J=9"QV88;\:"*1H7+
M)+);;/&M$`;%J-X@@6\;>(Q)+H-.2LQ-<)&]K48G!(TP)$115=E!9:DMW*/3
M\.;%O%FAM1)<.1/FLC;U>!R-"(77C+AM&/U9NH>&_%<V&]:#+%RRY<E)"46E
M[4L@%;4'5A,9D5D<K>"Y/F#L2@O95DTQ!TR_;"M$==/L,N$=G8ABZR38XN$`
M0V@)#4BVH`@JD6Y,:"D>@]$$MN4K!;O_`&C'[+%(K*)&Q+,O!1!P#K=;J].W
M?06D?E7RRCH2,Z3M`(8H!(D&/@HH?$1%10Z#ZWAP[E!8WV^\L[RY$M&HK>W-
M-3@K&@W.V.FC;ES5UJ*N20S@VI+'<%57#+A@N"[*#,6K3>CW`META62-%<B,
MB-M4H217HS2H6`"T8-FSE1PDRY4RYB[JT'I:*T8U"EL)8X0Q93@R9;+<8%1Q
MUM<P&HB.*F*[1PVHN[;07UA*RE9H:V0&F[3PA[$W'!&FQ;38@BVB#DR[E'!,
M%V+07]`H%`H%`H%`H%`H%`H%!8WVV6VZ6:9;[IF^S93)MS$%UR/BTJ==%=:)
MLQ11WX$FR@BZ:)Y:OV6R:33,=OCJ%SL=O^T)G$RQ5%6W6RXW%)MI7!P1244V
M;*#'RN7_`";M\N/;Y"-Q;FTY#=B&5QE-SVR_\%#1I_CI(`2_W0`)X%W%H+B1
MR)Y6R'Y+SEH<0Y923D(W.GMB2SD1)/4!\11'4%,R(F"T&9U/I31DW1[>G;^*
MIIL.RQ$9<ER&4+`P9CMN/`X#IYG%`>N:YBPQQ6@MI7*?04N0[(DVXWG9$)+;
M+4Y4M4D1@;)H!D#Q<KQ`!KE<<0C'>A8HE!CTY-\K;2T,[L+T9FWO,W+BE<;A
MD;=@,JTR^6:1EQ:93+BOS:!K6T<H]9KLMB;]G%(2.VW<'XZ`81PD2,1C/
M-9B".0F6;'**]"+09*-ROY>#(2<S9F"5R.<=$53-E67HX13^J(E:S.1VQ;(\
MN91V*NU:"SD<J.6<&*U*>A%%:MQ.R.V]NFMF*.M-LNJ\^CR&;:LL@"BX2CE3
M##"@FK+3+3(-,@+;+8H+38(@B(BF`H*)L1$3=0?=`H%`H%`H%`H%`H%`H%!@
M-6Z5TIJ#[+_S""G]GS6Y=JPE/Q<LT,>$8\%QK.X.W+CCTX4&/F:)T%J.]/79
M%)^[V]M+0_)ASI`$P+1!)[,0-.HV*H2@9"HXKLS8HM!@K;RQY+RWI-NM2MF4
MF`MOGP(5Q?1'XT52BXR&FGOK"9(B;SFBJ);,<4V!E+)R6Y>6:?&N$&%)27#D
M#+C..SYKJ`^+*1^)E-Y1)2:3*N9%Q39NPH,M=],Z0NFK;/<KBG$U):&GWK.*
M2GFS;:/*U(,8[;@`8EG$'%(%1<4%>B@PB\C>6_8F(*09`0XLA94..$Z8(1R)
M'$((Z"\G!;+C'F$,$7'O)@%W9=$\N]"R(\^,OV<^44;6S(F3GS$H\8#D"R@R
M'2;^K!MP]B;!0EW8T&-=T1R:O.K/\PN]GN-_F&#:.%<'W@<)V*;C;:1^.3"Y
MHHF8AD\3K(G307S7)GEXS:UMS=N,6E<:=%])$CM`JQ&[&T(2,_%$`C?5(*%A
ME[^V@OG>7_+X;I8I)6N*Q<;+C]A\-59($!I&L!`"%'<C8HB9T++T84$HH%`H
M%`H%`H(K_5/^!_M=`Y3_`,K-&_N.V_J;=!*J!0*!0*#%ZIM#MZTQ=[,T]V=V
MY0I,-N0F]LGVB;0]GT5+&@UC>.5FK+]*[:#\>VN/A@$MQ3[?`QLLBTN1F%`"
M$VD?D=I$A<'%<<.@J#ZN/*/4S[%W"&-K@M7>#=(B0&'7@C13N4&-$SLBC&U.
M)%)TT00Q4NE<2(+6Y\EM2W74TFX7$;3(M<V>Q+F6\R<(7&X\QR0(F)1USDK+
MY-+F5>]@*H`AG8G*ZZQ]#:PTZ)0T<U"W(&"F)$#+DAI0XAN<$7"0'"SMH2&8
MHB#Q%P3`+S3&@;Q;-=O:E?9@-#+^TTEE'<<)\QG.PW6,RJPWGX*Q#3!2^>JI
MTHH19CDG>H\YB:Q$L[4AJ5&E$X!N(:\"[/3G`S)&Q^MBO]G5>XF'B[*"[B<J
M-6M?90N?9IMV]NQM.CQWE0QLLF8^>"+'_3#-1$3HR].-!19Y+:C6TM0Y$B"L
MAMB,V$H2<5QH8T5Z.40")K%8\A7$(]V&8^J6Q5#ZM?)Z^6V9;I+0VZ)&MUQ;
MN'`CD;HHV+%M:?`62CB*F\=O=>S#E,7"%<RIG0PV'H2S3;38"9F(K<B7.N%Q
M*.JB7`2X37I8L8CU55L7D$L%5,V.&R@D%`H%`H%`H%`H%`H%`H%!'N8-NG7'
M2%PB0FE?>+A&485P)YIIX''F$[[K0$&"[\:#7MYTES"N-_<N\)MPE$Y1,S5G
M&V#]OD28C[<5EE2`H[BQ8[C!%E#`BS9MJJ@?2Z%UP4IMUYAR0R,F&_%%^2#K
MK$:-J%JY#&-PW"(R;B,Y47,29L!S*B9J"C8M&\S'KHPE\2>S`&44ET6+NZ@_
M^%=;0<P/\0A[0C3G63#>N5,5"@D%NTYKIG0)6V0[(=O#=QC.QWNU$+YQ&I#)
MN<8U><',;0.(0"XH'CCE',HB#1.E]86QR[I/.:K$V$XC22+@Y*-)7:Y9!PR<
M=<5I>S.L#F$DVCMVIBH1>)R_YG1;9&`)-Q6Y!$;:D/%=GC$GBLC\9\ASOKAC
M<E8=%<$P0<4PW*%Y)T+KHVY1M1W6YKLAV6S+;E`VZ+A::9M0%Q!<0T/M;*EB
MB^+M[U!\7S1O-:8Q-6)*F1I[BN&DANXD#3D9QIE(\86Q<3A.L.B2D8H**B%U
MBXA)07UJL6NK/?8DV=VJ1I^$5P&3'>DG-4H;LJ<]&0`1TW3>%EZ,UD,7$/!-
MHJV*D$[T);;C:]%6*W7+9/AP([$D5/B*)MM"*@I_/RX89NG?09V@4"@4"@4"
M@4"@4"@4"@@_,&#J%VZ09-H7*^EKO$.W/*BJ#%VE-L+`?/82"B(T\&<MG7R_
M.H(6&C>92.WQRWQ[A;&KFLE^W`=T1Q]BX%`MT>))E/(^:OLMNQ'\P$I]14^K
M7'`0K.:5YAQYLJ3"M3PO&[<%1]N2PRI!-O,>7F#AR`/K1FS50SACXN=,<:"A
M&TAS7>LLDWWKM'OC4>''C*5S4V'"::5)!$VW,;3ZUQH,7,PN(A*28KF$@D^N
M[1KN8Y#2T!.P*TNQYJPYR,"DPI4-QHQ4GHY*0-,R!5Q!QP)$Z51`^'[#K=S1
MELMJ_:/:F;\XY*RW!0EK9^W/.-@<L7Q,U2&38+]9FQ^[01VUZ:YKQQM@/-W1
MUMM8IW,9%R;?XJC!FLR1P.4>(F\Y&)!\7JJ6Q=X>PM(\S8C<,;7%?MDP(T2,
MY)63'5A%9L4B$A.M`\7%%J<XPXB*"[!54[X4KMI/FVZ:';RNK$5&'B8AE=\S
MH2^QQT!7'5D8FVLD#5!(R3?BB(66@S#5JUPLIR/<A?5R5?H$^RN.O*\ZQ'9G
M'(GB?#<>:;:2)BR!)PT)#0%#%,3#:]`H%`H%`H%!%?ZI_P`#_:Z!RG_E9HW]
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MC_\`,HG>[+%_^U4O]*GRG_IT^5Y&]X7F8PJ*4B'*PPQ21&3!</\`!)A=OAJ,
M\&OO*,\*OO*26KWH+L"B-WL3$A%7K/1'C95$[S3@O9O*)55N#/I*JW"GTEL#
M3O/KEU>%%MZ:=GD%^BN0HR.[_OQ4V$^4T7O5KWT7KWAKWT7KWAL)MQMUL7&R
M0VS1"`Q5%%15,45%3>BU2J?5!"^::W2!98FI[<[*4M-2@N$Z#&=<`94`>K,:
M-L"$'%%I5=!"1>L&'2M!`V>9VI-/7)W3IJQ)NAM/2WH]P>=5UF7*:;G!'1U]
MX45IH'B:!,HA@"+Q,1<00R#'.6]2;?+G-C#86`TRZ];I,>2$ER.Y'9>*<.5P
MP"/F<<;VJHHH_P"\5>JH6;O-:8EQ>NK$^,BD#T)MM3<=@X-7XX+,E6>.V`JY
M'03SDX`]9.MAA02OE9KN^ZR1V?(.`%N;B0C6+&!Q7QDRXC$DT)U7C#*T;CC2
MCPT7,.],%2@V#0*!0*!0*!0*!0*"+ZHYFZ'TP1M7:ZM!,#?!9Q?D(JHBIF::
M0R#''8IX)WZG37:W:$ZTM;M#6EY]Z&&!$%DL+KZ;D>G/"QAW^&TC^9/STK9K
MPK3WZ-BO#M/?HB4[WC^8DA51@+?#;^:K3#A'\I.NN#_=JZ.#7UE='"CUEC3Y
M\<T2)52[B"+N$8T7!/NMJM3_`-*GRE_IT^5>-[P/,YC!2FQI*IO1^,W@NW';
MPN"OWZQ/"I[RQ/#K[RD%K]Y[4;1"EULL.6*^,L5QV*J=]$<[5CX,4JJW!GTE
M7;A>TI[I[WAN7UT(6ISC]F?7!$[8WBTJ].#S*N`(IW7,M:]^->OHHOQ[U]&R
M(<V'.C-RH3[<J*ZF9I]DQ<;).Z)"JHM4*%:@Q^H;25XL<[email protected]::FQ7
M7&7V35.HXVXT0$B@6"[]NY=E!I0>9.K+'#@7FY!V:60C994*>Z^Y',[00A<)
M32D\VWG=>=,4<)"-1:QP(<Q(&<B<Y+R_.2#(6!`)QZ4,>:ZR^[&=X*,''B-D
MRZ1$_(:?(AQ1#10459S84&/'FQ=+S(BQ9CK4`X,ZV')6(;S+B.K=Y,.5&=#B
M$I(D:.#A-DFX\53Q:"^T-S>U'JJ\6ZW,O6IOCOF4DD;=(BC-PX4K!H1DEE,R
ME/MB1[N'U@0D(*#<-`H%`H%`H%`H%!X1"(J1*@B*8D2[$1$H()J'G?RXLJDV
MMS2Y21_\O;A[3MZ4XJ*C"*G<)Q%JVFF]NT+*:;6[0@=T]Z(<Q#:=/$0+XCLR
M2C9)X6F@=3SE;%>%;UEL5X5O64?D>\QKXBQCP;4V.W8XS(<7O;4D-_@JR.#'
MNLCA1[J7_P#I;F/_`.EL_P#^M*__`*ZS_HQ[L_Z4>Z_A>\]JEM46;9H,I.D6
M3>C=SYQ+)[_149X/M*,\+VE++/[S6DY!"%VMLRVJN]YO+*9%.^HJ#OW&EJFW
M$O'RIMQ+Q\MDZ=UGI74;:G9+I'G**(3C+9X/`B[N(R65P/SA2M:U9CNUYK,=
MV9K#!0:SUMH^Z'K)I^U0T>MNKHR6C4QH*8,!'/CI(QPQ178Z/,8[.OPNXE!'
M+/KGFNZ,$5MMPR#,BJ_'.U/17"BN-QD-M"<C([email protected])CGZHXJCQ9$SA\7C6
M?-ENP,W&W-W9V9(@RNT0BLAB4:Z!&;-I@!X)&XUQT-!<4<BHN'$)=J!7#4&K
M;/?'&+1;[FQ:Y5\DO3%&TRC`F'Y3#:N(O9W"ZK:N&B)E1?&S%AEH-C<N).H9
MFB[5.U"\\Y>)D=I^:U(B]B<8>-L>*PK*B!)PW$)$4DV[]V%!):!017^J?\#_
M`&N@<I_Y6:-_<=M_4VZ"54"@4"@B.ON9^F=%1D^T'%D7)X%*+:V,%>--J(18
M[&V\4\<N_ABNRK->NUYQ">O7-YQ#F[6W-O6>K3-J3*6WVLL4&UPR(&U%>AYS
M8;VS?FP!=^1*Z.KB5KWZRZ.OBUKWZRA:(@HB(F")L1$K;;3V@4"@4"@8&JB(
M"KCAJ@-MCXQ$2X"*=]5K$SA&]XK&9[-NZ&._Z1M[3=MN)M/JJNR6"578A&6U
M1X!*@H/1F#(:]W;5%^+6T=>[SNSD3:TRW%I'F7;KPZW;[BVEMNY]5MLBS,2"
MW_4.+AUL-O#)$+?AF1,U<[=HM3OV3K>)3%UQ&VS<5%5`%25!3%5P3'8E4)M<
M6SGA:9]A;O#=HF(T^$^3';0XQ*<6V9N.:$CN5'!043ADJ+B7T>M09*3S6M;$
M]89V^3B\D1;>YF8RO]OE!$CXHCBFRCANH0\04S`BJFU,*"_<YAV5G1,G5S[;
MS4.)VD'HBB*R./$>..ZP(BJB1<9HA1<V'3CAMH))&?%^.T^**@N@)BB[T0DQ
MVT%2@4"@4"@4"@4&`UEKG3FD+;VZ\R,F?%(T5O`GWR%-HM-XICWU7`4Z52I4
MI-IQ"5:3:<0YRUOSSUCJ,W8\%TK):"V#'BDJ2#'_`(LA,"V_1;RIT+FKHZN'
M$=;=70U<2(ZVZM<((HF"(B)CCL[J[5K<B,=FW$8>UEDH%`H%!X1"(J1+@(IB
MJ]Y*3.&)G#9G+Z'>].QNW1ILBWW"42.N,-FO"0<,!!U@LS3A8+UE(55-R+L1
M:HMQZWZS'5Y_D<GSOF.S<VEN:T:2;4'40!!F&J`U/;Q2(Z:[$1<RD3!*NY#5
M1[AXKA7/W<:U.O>&*[(EL&M98@]PYKVN%=M2P"M\IT-+,`_<7F^$I?6,J^*B
MT1BYPU%,$<5,N;''!-JA\!S;L[LJQQ&(AF_?9+\:*9/1P85([W!5P'B<R/"Y
M@1MHUF(A3Q<=E!(+)JJ/=V+NY'AR`.SRWH+T<^'Q''6&P<7AY3(,"XB(.))W
M\*#W2FJ&M10I4@(QQ3ARG83S9FTZG$9PS*#C).`0];#8NQ<47:E!FJ!0*!0*
M!0*!0:RYB\]-/:7-VW6P1O%\#$'&6SPCQR39]>ZF/61?T88E]++L6K]7'M?Z
M+M6BU_HY\U;S!U?JQPEO5P-R*JXC;F<6H@]*?4HN!X=!.*1=^NCKXU*_,NCK
MX]:_,H[6PO*!0*!0*"\LMOFS[M'8A.''D`O%68TJB;`"NUP#3!1/H'#I[V-0
MO6+=&IS-T4IU[RW_`*>YC:DLR@S,(KU;A1!4'B1)@(G2#ZX([L^:[M5?TB5J
M;>%'>KBUV^[:FG]26:_PNV6N0CP"N5YM44'6CPQR.ME@0%T[4VIM39MKG6K,
M3B5T3ECN8>K).E-+2;W'A+.*.H(08F@-B:X*\ZK8.GD#>6`^%13$DPRCK'.&
M+_FJWV.6Q%8:EPDN#DP)?&:[+V9U\Y3+J-"TZP!L(TJYD)5+-E04H*OM+OCU
MC&]Q+`BPV[BY`E-29/!DHB3AA-(TTC;N=X\V=6R443Q<RJNP,[J'4UYM-[M,
M9NUA(M=PE,PG)7:,KZ.OHX6+3"`6<61:SN*1CU<53'*M!)*!0*"*_P!4_P"!
M_M=`Y3_RLT;^X[;^IMT$JH%`H-:<X.;K6CHXVRU(W)U'*',(GUFXK2_I7114
M55+]&/3O78FV_1IF\_"[3IF\_#EZ;-F3YC\Z<^<J;)+B2)+JYG#+##$E\"(B
M=")L3977I2*QB'6I2*QB%&I)%`H%`H%`H)AH2P9E2]2@WHJ6\%^BJ8$]^<FP
M/Q=OSJC7K.7$YW)\I\8[0V66F[F)H)(`[#XA*6"!PT#,A8_XH(F&.*KLK'[J
MM#QEC[G;#CN+$EB!$HB1`A(2)C@0[1V8[E3!:E$Q:/@[)QH?7<AT1TW?);B/
M2D)FV7C%.(I$BY6G25,.*GZ,U3K^*77P4^7R>-X=8_%?KV9>L\C+2]!ND:[2
M@FN7J:[,N,A(S0'E=)W'@+BO!=<;>5MQT4S*."#EP%4U%K.7#EO#GRY$N2<5
MUY8CMNABY";)MN*Z^R\@.AF^N)GLK?!)53(NW!<:"G[)]/\`^76M-\5_[&BQ
MR;A,`9,&W)>1\9,I7&%9(R?246<%ZF_`<%5*"76V"U`M\:$T1FW&;!H#=,G#
M5`3!%(S4B)>^JT%Q0*!0*!0*!00[F9S+M6B+2CKJ))NTI"2VV]%P5PAPQ,U^
M:V&*9E^1-JU9JU3><0LUZYO.(<G7Z_WB_P!U>NMXDE+G/KUC+8(#CB+;8[@`
M<=@I]]<5KL:M44C$.MKU12,0Q]6+"@4"@4"@4$CT78.WS$N,@<840_J17<X^
M/3^2VO\`>_)6H]Y^(<G^0Y/]D?\`+:RZ=N29<4!$5%(R4L$;06Q=7.J_B."N
MS'?AOK'[JN7XRM+E;7H;JQ9:`ID.)MHHFF!8I@6&*;4V^"I5M%HZ,3&$FT)K
MT[&3=JO#Q'925`BS'%Q*(JK@(&2[V.A%_1_D>)S^3Q<?=7LOU[,])2+4G*MO
M4%_DW:9=704XIQ82---HZR+H.`XV3N&+C*J[FX:IM7>JHB5H+E:W\M0AQ&;:
M,\1LS<\+HMM9C-MM-R6IG;@2-M+@M<01Q#;TX*BE07]MTC<K9]J+!NW!<NEQ
M?N;I)'`L%>8X7"P,BZHD('CL7$<-RT%]IG3+%B"XD!B<BZRUGS2;;1EI7E9:
MCJK;0J65%".*EM7$L5Z:#,T"@4"@4"@4'/O.+G>](=>T[I*4K<4%5NX7=DL"
M<5-A-1C3<*;B<3?\W9M7=X_&\ONMV;G'XWEUMV:.$1%$041$3<B;JZ<1AT8A
M[1DH%`H%`H'651$!4W#5!;;':1$2X"*=]57"L3.$;WBL9GLVKHS2;\*$3;8B
MY-<079KRD(BBJJ`((9J*914LH]_%>E:QF*]9[R\YOVSMME(/L&Z\-7"8R"F=
M50S`"P;S9URD2%@G#+HZ%I^VJKQE:P9MPML\+E;'UC3FT0<Z)B#@(N/">#9G
M;7N;TWBJ+MJ.[36\=6:WF&TK9=HG,'3$F&K[]GN;:*S/9CF*N-$XV09ASB0.
MLN"2Y5(=O<$Q5!XVS7-)Q+:K:)(W*'1C#K&+!OPV"%Q;<_PW8[CHQW(O$,3!
M27,T\2$"$@+]&H,O/9)IUCA#:Y4NSLM2I,Y&+?V=D%?E*N8_]R2HH`2MMJ*H
MH`N"+07\C0C;][B7<[W=.+#SH#"/-(T0.2%D$"_59T$ERMKE)%4!$5H)/0*!
M017^J?\``_VN@<I_Y6:-_<=M_4VZ"54"@CG,'6<31^EI5Y?1''AP:@QE7#C2
M7$7AAW<-BD6&X45>BITI-IQ"5*3:<0XXN-QGW.X2;C<'RDSICBNR7RWD9=[H
M1$V"B;$3!$V5VM=(K&(=FE(K&(6]33*!0*!0*!09/3EC*\W'@FB]A8P.86[%
M%\5I.^?3W![BJE1GK.&ASN3X5\8_*6TA$1%!%$$13`138B(E6.$D$K5*O.Q3
M%LQ2/B*CG1%5GJ*+"$*(N02#%%7;MK7KHQG^O^4YNQ.JM60":9D3C&(`)AUE
M1<QJ(H2-B*(2YE#-@F*XJM2I6*>K.)O.(AKF]ZZ>EMG&MS/!9+8LE[_>>%L$
M7J+TH1+C^+6;9M&/1T-'\=/>TX=#<E>89ZNTTK,]S-?;5D9GDN"*Z!(O"D8)
ML^L050MW60MB)A7(WZO"V/1C=J\+8;#JE44"@4"@4"@4"@Q^H;[;K!9)EYN)
M\.'!:5UU4VDN&P0%.DC)4$4Z56LQ&9PS$9G#C/56I[KJB_2KW<R_ZF2N`-(J
MJ#+0X\-D,?F@B_*N);U6NSIU12N'8TZHI7#$U<M*!0*!0*!075JM<BZW!N"P
MJ@I]9YY$QX;2+@1;=F.W`4[O>QJ-I](:W*Y'ZZ_/HVM$B1X<5J+&!&V&10&P
M3H1*G$8>=F<SF4D?U0K@PP%LVPBJ@X":(J-9`$F@)!QRJH9MN."]_:M$:<9^
M4O-C]2:HC/Q6WI:MQ&FD173,A$,^5!7+L3#,6*X=]$Z$J5*13U)F;=(:\N_,
M!"0F;2QF1<465(%4'\UK82_G9?`M2\IGLWM/\?:W6W2&W?=[YBNW:W%I6ZO*
MY<K:WQ(#YX9GHB*@Y5PP3,RI(/Y*CW%6N5R=/A/3M*W?H\)Z=FY*UFN4"@4"
M@4"@4"@T[[P/,AVSV\=+6IY6[G<F\\Z0VN!L1"51RBJ;C>5%''>@HNY5%:V>
M-I\YZ]H;/&T^<]>T.;T1$1$1,$38B)77=4H%`H%`H%`H)AH2P9E&]21V*BI;
MP7Z*I@3WYR;!_%V_.J->LY<3G<GRGQCM#8MFN(09!DZG$CF*(ZSE$D<RDAH.
M)+U>L..9,<.XM-E/*&A6<,FSJKB)*[>/%66KF.#;9("&1.#@A89\''%7K>+T
M=-5SH[8]$O/W8!]P77W'!!&Q,B)&QW"BKC@G@J^(Q"##ES"@Z:NS-QM[_:;G
M$50.*QUD=:54XL=XTZ@(6&/67%"1"P7#"M?D4B\8]6SQ]-[3TCHZ3L=YM][M
M$.[VYSBPIK0O,'N7*2;B3H(5V$G0NRN/,86S&%]6&"@4"@4$5_JG_`_VN@<I
M_P"5FC?W';?U-N@E5`H.9/>,U2=RUDW8VC7L=C:1'`Z%E2!1PRV;\K2MHG<7
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MO7Y4S[-;E:_*N?9V+7)<HH%`H%`H%`H%!H7WFM5.(=LTJP>`$/VA<!1=Z9E;
MCBO=3,+A*G=05K=X6O-O+V;G#UYMGV:'KIND4"@4"@4"@+FV((J9DJ"#8IB1
M$2X"(IW578E8F<(WO%8S/9LW2U@&T6_*Y@4Z1@<MQ-J8_-`5^B"+@GRKTTK&
M._=YS?NG9;,LE,G0X3"R)CX1V1V*XX2"F*[DV]*]"5*9B.ZF(F>R)7;F#CF:
MM#.;H[7(14'\QK82_G9?`M0\IGLZ&G^/M;K;I")2Y4N8_P!HF/')>3Q3<7'+
MC]`4P$?S42D5=75HIK_&%*I+F3TUJ"7IS4$"^1,5>M[PNJV.]QOQ76_^8V1#
M\M5;]?G685;M?E68=M194>7%9E1C1V/(`767!W$!HA"2>%%KB.,JT"@4"@4"
M@4%*9+CPXC\R2:-QHS9//.+N$`%2(E\")0<2:DU!,U%?Y]\F8B_<'5=X:_HP
MV"VUL_[ML1'Y*[>G7X5B'9TZ_&L0QM6K2@4"@4"@4&4TW8BO-PX1I_T+&!3"
M[N/BM(O=/I[@^%*C/7HT.=R?"OC'Y2VB(B(H(H@B*8"*;$1$JQPE.3*C162?
MDN@PR'C..$@BGA5=E8F<,Q&47N7,&"WB%M9*8>U.*>+32?=3.7R#@O=J/EGL
MW=7`O;OTA%+E?;S<\4F25X*[XS.+3/@4452).\9+6/'/=TM7"UT^96`B(H@B
MB(B;$1-U2;C?GNRZK,F[EI20>*,I]H6X5Z`(D"2*=Q$<(#\)E7+YFO%L^[F<
MS7BV?=O>M-J%`H%`H(K_`%3_`('^UT#E/_*S1O[CMOZFW02J@4'#FH+F=UO]
MSNA+BL^6_)3IP%UTC$4QZ!%41*[>BN*1#LZ:XI"PJU:4"@4"@4'A$(BI$N`H
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M0*!02?2%NAQFO\Q71P&(P8C`XJH**JXHKNW>I>*WAT8KMQ2H1,=Y[.-S=\WM
MX57-VY@D69JT,[-W:Y"*B>$&MA?*>'Y*U+RF>S&G^.M/6W1$I+\F7([3,>.5
M(VX.NKBHHN]`1,!!.\*(E8BL=_5U-6BFO\8?%27%`H%!UQR/N9W#E?9"<)5.
M*#L-47'8,9XVFT\D`UQ-U<7F'%W5Q>83JJE90*!0*!0*"!<]+F<#E?><BX.2
MT9AHF[,$AX&W4^5I3JW17-XA;IKF\0Y*KMNR4"@4"@4"@J1XTF7):B11SR'R
MR-BNY.E2)4W"*;5K$SA5NVQKKY2V(U)L&EK<W">DBC@IG(4ZS[IEXSG##$MJ
M][!-VZD3%>CS^+[;9QF6`N7,"<]B%MCI&#:G'?P-S\T!7(/RJ7@K&9GX;VK^
M-GO>49E/R9;Z/S'CDO)XKCJYLN._(GBAX!1*16'1U:*4_&'Q4EQ0*"9<GKH5
MMYEV%['!M]]8CJ)\Y)+9-"GE"%?DK5Y=<T^C6Y=<T^CL"N2Y10*!0*"*_P!4
M_P"!_M=`Y3_RLT;^X[;^IMT$JH%!P/"5%A1U3=PP_P!E*[U.T.Y3M"M4DB@4
M"@4"@IN`\IM$VXC?#-#7JB>.&[86(["P7:BU&U<J]FOSC'HJN&XZ\3[[AO/E
ML)YPE,U3N9EZ.]NK,5B#7JK2,5C#RLK"@4"@4"@[!Y/(XG+/3^?''LV(8_04
MR4/DRX85P]OYS]7$V_E/U3&JT"@4"@4"@4"@XEUH>;6VI5QQ_P#>+DF/@F.I
M_97:X_\`CAV./^$,/5RXH%`H%`H*;[9N-Y`)`Q5,RJF.(X[4WIO394;1F,(W
MKF,9PK/.O2'!=D.$\X"90(\,!'Z("B((#WA1$I%8A#5HK3\8?-26E`H%`H%!
MU![N.'L\+#_US_\`LA7'Y7^27(Y/^26TJUU!0*!0*!0*#5OO'?R\'_\`.8_V
M3K8XO^2/Z]%_%_R0Y?KL.N4"@4"@4"@]C/SHSSSC$DF>**!BVF4T#>HHYM(<
M2V]7+T=RH37KG*C9QZWG-NN/1\H(HI*GC$N)DNU27NJJ[57PU*(B%M:Q$8A[
M64B@4"@4&;T,CBZYTUP\<WVO;\</H]J;S?W<:IY'^.5/(_"7:]<5QR@4"@4$
M5_JG_`_VN@<I_P"5FC?W';?U-N@E5`H/S_L;F>TQL5Q4`1M>[U.KM\.&-=S3
M/VP[6K\87U6+"@4"@4"@4"@4"@4"@4'RZX+39N'L$!4B\")BM8F<,3.'8G)Y
M37E;I93\=;;'S>'(F-<*W>7$MWE,*BB4"@4"@4"@4'#NJ7,=<:M;5=K=]N>'
M@*8X7X25*['%_"'6XWX0Q];#8*!0*!0*!0*!0*!0*!0*#IGW8W.)RT5S>AW&
M40K^*JBH_>KB\B?OEQM_YRVS5*HH%`H%`H%!J;WG'.%RS1S<@7"*1+^*BDI?
M>J[1.+PMT3]\.9J[3LE`H%`H%`H%`H%`H%`H%!F=#.J/,#2K:;W+O#1?`+PE
M^%$K6Y<_9+7Y4_8[9KD.24"@4"@BO]4_X'^UT#E/_*S1O[CMOZFW02J@4'Y^
MQVBM]SE6QQ,BMN&V@+O1QE<ABN/3@/WEKLZ;=(^8=?5/2/F&0J]>4"@4&7AZ
M3OTV&$N-'1QIU$,!S@AJVKR1^+D4D+AH\N13W(M0G9$3A"=D1*N6A]2(Z;:1
MVS$&FWN.,AC@D#HD8*#JGD-2%H]@KCU5[BUC]M6/VU8FX09$"<_"DH@R8QDT
M\(D)HA@N!)F%5%<%V;%J<3F,IQ.8RMZRR4"@4"@4%A=WD1H8Z+UGEZWY`[2^
M[L'Y:KO/HA?V=K\J8[L?EII=IU,#^S(IJG<SM":(O?3-MKBWG,RXUYS,I544
M2@4"@4"@4"@X>YCM%;^:VI6G$0!?N,@B1-V+SBO-E^<CFWOK75XT_;#I\>?M
MACJVVV4"@4&6A:5ODV$,R+'XC3BKPA0P1PQ$Q:(A;5<RB)N"*KA^!<(3LB)P
MA-XB<+AS1&HP>X:,M."K3;XR`DQR8('7":#(\CG#)2<`AP0L<47N5C]M6/VU
M8JXV^3;YKT*4@C)8+(Z(&+B"6&T<P*0XIN7;OJ<3F,IQ.8RMJRR4"@4"@4%K
M<I"LQ505P<=^K;5-Z*N]?D3%:A>>B-YZ.K/=LA=FY36T\F3M+\IU$V[4%\VD
M7!=VQO97'W_G+D;_`,Y;0JI44"@4"@4"@U?[R4%9/*>XN(.;LK\5Y4[Q/BTN
MSP.U=HG[X6Z)^^'*5L?5V,@$N+K/4/'>N&XOE2NO2>F'6I/3"[J:90*"K$BR
M)<IF)&;5V3(,6F6AWD9J@B*=]56L3..K$SADGM*WIE2S--D`QCFHZ#K1@3#9
MJV9`2$J'E,5%4':BI48V0C%X>N:2OS5N*XNL`W$%H7R(GF4-&SR9%5K/Q$S<
M8%'$=J$B[J?LC.#]D9PP]33*!0*!0*!09/EBVY<>;.FVF=O`GM*/?X!<=Y?D
M%O#Y*T^3/VRU.1/VR[?KEN84"@4"@BO]4_X'^UT#E/\`RLT;^X[;^IMT$JH%
M!Q+SMTZ[8N9U\8%%;"5(^THCF&\9?UJDB=P75,/DKI\:WE3Z.EQY\J?1@(4L
M9+.;#*X/5=#Z)?Z.Y6W6V6U6V5>I)%`H)5;-71F=/?8TT7'0=1(A/`TRCD>$
M4E)+P,FO6,G#'9FP0<5WX[*;:_NS']2JMKZYA>CKJ%`NR/6Q9+EL;:!&83X-
M`@N-(;32`HJX38@TZ6)(2D98YL4):Q^J9CKW1_5,QU[L!JF\0[K=2E1&$CL8
M*@BC8-8HID:8@WU4RH:`FU5P%,5JS768CJLI68CJP]33*!0*!0?#SS;+1.N+
M@`IBJUB9PQ,X6%GM<Z_WV);F$7M=T?:BLBGS$<)`'Y!S9B7PUK[+8K-I47MB
MLVEW_%C,18K,5@<C#`"TT'<`$013;W$2N0Y*K0*!0*!0*!0*#DKWH-.%`YAI
M<\J]GOL5MWB8X8O1D2.X(_DMBTOYU;_$MFLU;_%MFLU:VMTSC@K;B_\`4-^/
M^,G0:>'\-;U+9Z3W;E;>D]UY4TR@4$GM.K6XNGW+3)0GD=$XS3G";58L=]P'
M)"M&JH9D>38*J(IBJX[:JMKS;*JVO,Y7QZWM\*Y-G:.U%:VF4!J#)%I!0V4<
M[.F]U<!)XS,LV)J1)@B+4?U3,=>Z/ZIF.O=AM87V'>KN4N''2,QULH9`;+`G
M"-$)`WY!-`S$JJ6&*[\$GKI-8Q*>NLUC$L'5BPH%`H%!X1"(J1*B"*8JJ[D1
M*#"//G*?XJ"JCXL=M$ZRHO3AW27HJF;>LJIGUEWCH33ZZ=T;9K*28/08C3<C
M!45%>RYGEQ3NN*2UQK3F<N/:<SEG:PP4"@4"@4"@PFM]/_YATA>+(F'$GQ'6
MF%78@NJ*JT7YKB"M9K.)RS$XG+@P''H<E3)LA,/JY#*I@2(B[45/I`O1X4KL
MQ;^Z'8B?6&:`P<`3`D("3$23:BHM71.5D3E]49*"XMTU^#<(TV.XK,B*Z#S+
MPHA*!MDA"2(NQ514QP6L3&8PQ,9C"5R]:6R6^Z),G'B-VQZWQ499:13=?<)Y
MQYP!)L0S.&O5''!,$V[UIC5,?]JHUS'_`&^[9S`::LZP;C'[:[E`N*XTR2*3
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M'64_Q`\5/I(-6Z=GA;*W3L\;9<9XFBBXT61P=H'X>A4Z47I2NKWZPZD]>L,M
M#GMR$RKU'Q3KMK^$>ZE65MGZIUMGZKJI)%`H%`H%`H%`H/DS!L%,R00%,2)5
MP1$\-)G#$SAB)<PI:Y411C(N*(NQ3PW*J="=ZJIGR^BN9S]&R_=[T">IM;-7
M*2VJVBP$$MX]PG)0LT9KO]8>(7>'!?&2M7E;,1X^[6Y6S$>/N[`KG.>4"@4"
M@4"@4"@Y(]XKEX[IW5SE^B-+]C7]PGLPIU6IJ]9]M?\`$7%T<=^))\VNAQ=N
M8\9;_%V9CQEJJ++<BEL138)<3!-XJN\A_M3_`.EVXG#;[,NTZV\VCC9(8%N)
M*LB<IQ.7W662@4"@4"@4"@4%G-N`,8M-8.2%38/0./2?^C>M0M?TCNA:WI'=
MC$$R<4EQ<><5,51,2(EV(B(GW$1*AVZRCVZR[4Y+<OUT7HIB)*#+=YZ]LNFY
M5%TQ1!9Q3H:!$'9LS8KTUR=M_*V7*VW\K93VJU90*!0*"*_U3_@?[70.4_\`
M*S1O[CMOZFW02J@4'A@#@$VX*&!HHF!)BBHNQ45%H..N=G*:3HF^%-M[!%I:
M>>,)U.LD=PMJQG%Z,/T:KO'9O1:Z/&WYCQGNZ''W9^V>[6>"H:&!*#@^*8[T
M_P!*=Y:VIAM3"^CW91P&4.'_`!@15'Y1VJ/WZS%\=R+8[L@VZVZ"&V2&"[B%
M45/NI4XG*<3E]5EDH%`H%!X1"**1*B(FU57=06+]V:3JQDXQ?3W-I^=\[Y*K
MF_LAY^S'FKCKG$>/B.='0(_DCT?AJ./66,>LI3RYY>WC76H0M5O^JC-97+E.
M5,1CL*N&;#YQE@J`/2O>152K=NBD?*G=NBD?+MC3]AM=@LT2S6ME&($)M&V&
M]ZX;U(EZ2(E4B7I5<:Y<SES)G+(5A@H%`H%`H%`H%`H.7?>'Y1.6:>_K&R,X
MV:8>>Z1P3_PTAQ=KR(FYITEV_1->XJ8;O&WX^V6[QMV/MEH\A1<%VH0KB)(N
M"HO=14K>F,MV8RO(]T=;P&2/$'_O@3K?G`G_`&?N5F+3'<BTQW9!E]EX<S1H
M8[E5%QP7N+W*G$Q/9.)B>RI662@4"@4"@LG[K'#$6?KS_$7JIX3W?<Q6H3>/
M3JA-_;JQSSKT@D)\LV&T6TV`*^#I7OK4<9[HXSW932^F+UJ>^1K+9F%D39*^
M`&VT5,[KI?-`,=J_(F*JB5#;LBD9E'9LBD9EVUH'1%JT7IF-8[?UT;^LER53
M`GY!HG$=+?OP1$3H%$3HKDVM-IS+E6M-IS*15%$H%`H%`H%`H%!AM7Z4M&J]
M/2['=0S190X(8X9VG$V@ZVJ[B`MJ?<796:VF)S#-;3$YAQ1KG0U^T7?7+1=V
M^MM.++!%X4AK'!'&U7^\.\5^15ZNK;%X^75U;8O'RCS9.LN*XP>0U\9-XE^4
M/]N^K,>L)X]89!F[M+@D@>"7T_&#_6Z/EJ47]TO/W7PD)BA`J$*[4)%Q1:LB
M4WM`H%`H%!0D38S&QUQ$+>@)UB7\U,5J,VB$9M$,?(N,E[JM)P&^DMBN+^%!
M^_\`)4)F9^$9F9^%L@B*+AL3>J]_I55I$8(C#H#W>.3CS\B/K744?)%:P=L4
M-U-KA[QEF*[A'>UCO7K]`JO/Y&_RZ1V:'(W^72.SI*M1J%`H%`H%!%?ZI_P/
M]KH'*?\`E9HW]QVW]3;H)50*!06MUM5MNUND6VYQFY<"4"MR([J9@(5[J??1
M>A:#E/FOR!O>EG7KI8`=NFG553(113DQ!WX."F*N-BGZ1-R>-NS+OZ>3GI9O
MZ>3GI9J1%14147%%VHJ5N-QX@()YP50-=Y`JBJ^'#?\`+6/&&/&%<)\\$PX@
MN)_Q!V_=%0_!6<S[G7W5ANS_`,Y@?"AK^#+6?*?9GRE]?:__``"_UAK/G/L>
M4^SQ;N[\V.GYQX+]X5K'G/L>4^RB=PG'L0@;3\4<2^Z2JG]VL9EC,K<T5Q45
MXB=5-J*:XHB]U!\5/D2L>/NQXO:DDG7+3E!JC74D78X+!L8K]?=W@7AJB+@H
ML#LXQ[.A<J?.5%P1=;=R(KTCK+6V\B*](ZRZ\T=HVPZ1LC-GLL=&F&]KKI8*
MZ\YA@3KQHB9C+[B;DP1$2N;:TS.9<ZUIF<RS=88*!0*!0*!0*!0*!0?#S++[
M+C+S8NLNBH.M&B$)"28$)"NQ45-Z4'-'-WW=9EO<>OFBF"E6\E)R39`12>95
M5Q58R)M<;_X?C#\W,FP=S3R<=+-S3R<=+-$JBB1"2*A"JB0KL5%1<%14[J+6
M_$Y[-Z)SV?"@.9#3$338ABJB6'A3!:3$$Q"NW,G-[GLZ=QP4+[XY5^[3K[G7
MW5ANTA-A,@OXR&J?>RK^&L^4L^4OO[77I8+_`%DK/G/L>4^SQ;NY\UA/SCP_
M`)5CSGV/*?92.Y32\7AMHO>4E3P*JHGWJ9EC,K9SB/8\=PGD7YI+U?\`53`?
MO5'QSWZL>/OU>U))*-!\N-4ZWN"1;-&_Z8"1)=R=11C,)TYC^<?<`<2\"8JE
M&W?%/JIV[XI]77G+CEGI_0EH[';AXTY]!6X7-Q$1V08XX=*Y`'%<H)L3OJJJ
MO-O>;3F7-O>;3F4MJ"!0*!0*!0*!0*!0*#`:VT-I[6=E.U7IC.WM*/)#`7V'
M,,$<9-47*7R8+N5%2I5M-9S"5;36<PY(YD<GM5Z'D..R&EGV/'ZF\,"O#1%7
M8CX8DK)?E=5>@EW)T=7)BW2>DNAJY$6Z3TE!*V6R\$$`E)M5;)=Z@JCCX<,,
M?EJ/C"/C"N$Z>&YU#_Q!1?\`9R5G,^[/7W5$NLM-[;9^!5#^PZSY2SF7OVO)
M_P#3@G?XBK_V*>4^QY2^"N4Y?%X8?FD7W\R?@IFS&947'I+FQQ\U3N"N1/[F
M5?NUC'O)CWE\"`!CE%!QVKA2(P1&%>'#F3I;,.$PY*F2"R,1F1)QPR[@@**J
MUBUHK&98M:*QF717*3W<.R/,7W6P`Y(!4<BV)%%QL%3:A2B3$35%_1CB/=4M
MR<_=R9MTCLT-W(FW2.SH%$1$P38B5JM4H%`H%`H%!%?ZI_P/]KH'*?\`E9HW
M]QVW]3;H+Z5K&TQM80M*N*27&=%<E-'A]6F1>JVI?3<$'3%/HME066E]>Q+]
M+?C=D<AK'8*2X;I@HH(2Y$,DQ%5W%$(O`M!B?;)8X]N@7JZ0Y%NT[=F9$BUW
M1S(:.-QF3DXN--J3C?%8:)QI,%Q1.ME+`:#*VOF5I:;.ND%Z8S"EVMX@)A]T
M$<<:$&31\0QQREVH$PWXJG=2@R-MUII*Z3PM]MO$.9.<922,5AX''."OSU$5
M543PT$*U][OVB=5&Y,B@MCNYJI%,ABG#<)>EZ/U0+;M51RDO256Z]UJ]ENO=
M:O9H75?N^\R;`1FS!2]0AVI)MRJZ>'1C'7!['\D23OUNTY=9[]&Y3E5GOT:Z
MD,/QI!QI+1L26_\`>,.BH.#^4!(A)\M;%;1/:6Q6T3VE3J210*`B*1B";3-<
M`%-ZKW$2L3,1W8F8CNF^EN2W,C4A"L2SN0XI?^=N"+%:1%Z<#3BFG?`"K7OR
M:1\J+\FL?+>FA?=DTK9U;F:D=^WIXKF2.HJW"!?\+%2=[G77*OT*U-G)M;XA
MI[.1:WQ#<C++3+0,L@+;38H#;8(@B(BF""*)L1$2M=0^J!0*!0*!0*!0*"''
MS&BKK&[:8:CHLF!`*7$?-U!"0^R*'(CI@A$/"!]A5+!<<Q;.HM!;6KF>#NGK
MS?;G#&+#L]LBW9Q&7%=(VY$+M9!@0A@0[13?C06MQYKR=//VT-4VKLX7B,$F
M"MO<.80N%)C138=%6VEQ`IS2YQV%M1$QP10JV[G1I,H#[MX<.W3HSSS1P^#(
M<S\.1(8!8Y<(./BD0U56T7+@N.&%!(].ZUT_J*1)9L[KTA(B!QGUC2&F,7`%
MT1%YUL&S+AN"6455<%1:#`Z]Y,:(UFIR9L985V),$ND/!MY53=Q15%!W\\<<
M-RI5E-MJ]EE-MJ]G/^KO=MY@V0C=M@-W^"BK@Y%P;D(/=..XN/R-D:UN4Y<3
MWZ-RG+B>[6%PM]PMLGLMQBO0928XQY+9LN;-_4<02^]6S6]9[2V*WK/:5O4T
MR@4'BDB;UPZ-M8F<,3.$LTURJYA:D(?LNR2%8)4_ZN0/9F,%^<CCV1#1/Q,R
M]ZJ;\BD>N5-^12/7+=VA_=:M4,VYFKYOVD\.W[-BJ;49%_'=ZKKF'>R)W45*
MT]G*M/;HU-G*M/;HWA;K=;[;":@V^,U#A,#D9C,`+;8"G0(BB(E:S67%`H%`
MH%`H%`H/EUUIEHWG31MIL5-PR7`1$4Q555>A$H(-:>:07:S0;A#MI-NR;O\`
M8\J%*<5IV.19B:<)$;/'B-*VYEV8(>]53:%9GF,Z_8]*26+<!WC5IBW#MZR,
MC3>5@Y+YF^K:EE:::+<WB18)@F.*!B)G.Z%"*XV^5:W1U#:BD),AMJZ[&08S
MD5"(90L[<S4]MP45M-O47!5'$,ZYS<Y>-*P+MV1IV1Q4!DV)(NB3!O-.`XV3
M:&V?$BN@@FB*1#@B*M!G[1=[7J"T-SX2&];I8D@=H8=8X@8J*KPI`-GE+H51
MP)-J8I0:SUM[M>B;Z3DJS*6GIYXKA&%#B$2])1E4<O\`RR!.\M7Z^1:J[7R+
M5:2U)[OG,ZR&9-VX;M%'=(MQHZN'1BR:-O8_D@J=^MNG+K/?HVZ<JL]^C7]P
MM]PMKW`N41Z"^BX*S*:-@T7N*#B"57UV5GM*^-E9[2MZFF4'A&(IB2H*=]<*
MQ,X8F<)!8]`ZWOI"EHL4V6);!>%D@9Q7_CN9&D^4JJMOI'JJMOI'JVMI+W5K
M_*,'M4W%JVQMY1(>#\E4[BN$B--KWTXE:U^9_P"8:]^7_P"8;XT9R[TAHZ+P
M+'`!ETARO33^LDN]/UCJ];#';E3`4Z$2M2UYM.9:EKS:<RDE11*!0*!0*!0*
M"*_U3_@?[70.4_\`*S1O[CMOZFW065RY;MW&X.71;EDO#=V9ND:<+6)L"PVC
M81<N?+D5G$"V)BAETEC05]*:`.Q7%^6]<!FMR(QQ38X'#3!R6_,4E7B.?/EN
M#A]'#I1<0QDWDW;YU@CZ=EW.0Y9+;#EPK-&RCG8&7&<AB9N+CQ2CQWB!K%$V
M;2S%MH+>Y\F3NKC[L^^FXZ])<F\08K2*CY%#-LE$E-LA!RVM+E4,"121=Z8!
M)-(Z)_R[/FR1F)("8RPRK(QVXXAP#><Q%&<H(BE)/8@[$PWKBJA)Z!06=RLU
MGNC2-7.#'G-)N;DM`\*8]XT)*"+3>2O*N82DYIJ(WCT1D*,/=\5@FTJ<;+1Z
MRG&RT>LL:7N[<GB)26PEB2JJX3IZ)M[B(_@E2_??W2_=?W7L7D;RHC*BMZ=8
M/##8\;SR;.\Z9I6)VV]Y8G;;WE)[1I?35F_^(M,.W8I@O9([3&S_`)8C5<RK
MF63H%`H%`H%`H%`H%`H%!!W]":)[=&:*?P;Y;SDW(I(N1@G$,SB"^;_U>)-%
MQ33!1R_ZJ8!>6?2.D(%CG",GMEDN$)F#**0\V;!1(S'91'B"@)AP^J2XT&.D
M<N-'3VV(DVZ29TDXS#=F==DM$^Q&C/M2V^RJ(#G3B1FB)PT,BRIF)4H*3?*[
M1,A&+O%NDKB0,YQ+FQ*;Q8+CO2'#%Q!4<<TIX2S8IE)46@E&E;':;7&DN6N6
MY,CW!Y))/..H^A&C0,8BXB8EU&11555Q5,=ZK09J@4%"=;X$^.4:=&:EQR\9
ME\!<!?")(J4$5G<G.5TTE)[34%M2QS+';[-CCO7ZA6]M3C9:.TRG&RT=I8IS
MW>.3[AJ96%45=Z#-G"G<W"^B5+]]_=+]U_=<1>0_*6,J</3S98)A]:])>3?C
MMXCIXUB=M_>6)VV]Y26TZ*T?9R$[58X$%P=J.QXS39X]W.(H6/?QJ$S,H3,R
MS-88*!0*!0*!0*!0*!08_4%E9O=FE6E]]V/'F`K3YL*"&K9>.'U@N#@8]4NK
MN6@B#?+W0[4Y^\6JY+;(KLV,Z<6`<)N$,V!F8!!#@D@N9E(7$QQ5=B[DP#*_
MY(L,6RV*S+-?9>LKHE8YZN-#+!T&S#`>IPSQ9,P(5;5%'>F.V@Q4WE/I%QQY
M\[A+8GF,@KE-1YGBO]N>8=(GT<;)L>O!:0,H"B(.5-E!XQRLTO#.;.8O4^.%
M])WMQ!)9!J44M]Z0.*(V@K@[*<4,N]%REF'903:U6\+;;(MO;<-YN(T#+;CN
M7.HMB@CFR"`XX)T)075`H/AYAE]HFGVQ=:/8;9HA"J=]%V4&#E<OM!2US2M-
MVJ0N_%V%'->Y\X%K,3,,Q,PH#ROY:"N9-)V9%QQQ^SXN_O?5[*SY3[L^4^[*
MV_3FGK::';K7$AFF.!1V&FE3'?M`4J*+(T"@4"@4"@4"@4"@4$5_JG_`_P!K
MH'*?^5FC?W';?U-N@U-;(5W^SN9D%B#<Y2.Y)$2<3$MJ<4AYAEQ(CK()@Z;6
M9.NVJXIM+JD.(26Z2)]LUS(O4EB8*Q+PY,F3D8?<;33H6)44`X8+B';43ZI$
M4N+B6'304KQ;(DO4M_D194Z#8;M`*-.N4.%/22S,&:THH?&!X9`/BZXB&#:"
MVT.&*`HE04[1""-<-(=OMEQAWF`JORY\2!<ECE'1'F6X_4;=99[1Q.TO@X:*
M*[%Q)4P#)V2;J=_FB<YQER1!G2%::;DQ)#?9+4EM%]B0PZYD!LG)2JT\"AGS
M+@OB)@&U*!0*!0*!0*!0*!0*!0*!0*!0*!0*#2.L=!7:Z\Q[R['MLB/:KO#4
M;M<#:;E"AMQ#98DPL#0\ZY&V'(ZIU@4EZNPB#,6T+]:K'<H=ZTX=\O%WD2K\
MQ;&&V1B`O'9:;:=%R0Z(.8DD@Q0C''/E(B3:&`MF@[U%;9AA8YAQBD6J1')]
M(PDU$MIOK+C*(NF#?&0S1MM"PROY<<!/`)?IFVRK/;K^W)LLR7:[O.=N$5H8
M\07Q;[-'3(]'0VV\R.`0-H@;4#K;\2#.\MK'/LFF5M\P5'";/?CYQ;;=5F5+
M=D`3H,_5"9<525`1$3=E'<@2F@4"@4"@4"@4"@4"@4"@4"@4"@4%&;G[&_D:
M)X^&>5D20"-<JX"A*J(*KNQ5:#FN-R\U:6D';5;[5(APHDRXA;IC\4#F.L&$
MQKLDU@"1'4=X@@DH1%0S;%P3-0;'U8Y#U"<"*>E[@Y-A2V6Y,]I@7BC]@>:D
M\.+((T%.,Z(@KJ*G50LV!"*4&'F:(O\`*?U(SJN%),+REN<.=93[9Q)<?M3@
MKP9##8<%KZL4`A)$P#,I=8D"]U19=3W"TV:+.LSDDX%BGVR?$CM-I&.Z3+?'
MX#D<17*+0&+S*.940%+H';0;4M3$J/:X;$MSBRF6&VY#N*KF<$$0RQ7:N)4%
MU0*!0*!0*!0*!0*!0*!0*!0*!017^J?\#_:Z!RG_`)6:-_<=M_4VZ"54'A@#
M@$VX*&!HHF!)BBHNQ45%H/:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!017^J?\#_`&N@UOH+V[_Y&T[]C?9'V/\`9D+[-[1FXW9NSAP>+EV9^'AF
MPZ:#/?$=Z#\Y0/B.]!^<H'Q'>@_.4#XCO0?G*!\1WH/SE`^([T'YR@?$=Z#\
MY0/B.]!^<H'Q'>@_.4#XCO0?G*!\1WH/SE`^([T'YR@?$=Z#\Y0/B.]!^<H'
MQ'>@_.4#XCO0?G*!\1WH/SE`^([T'YR@?$=Z#\Y0/B.]!^<H'Q'>@_.4#XCO
M0?G*!\1WH/SE`^([T'YR@?$=Z#\Y0/B.]!^<H'Q'>@_.4#XCO0?G*!\1WH/S
ME`^([T'YR@?$=Z#\Y0/B.]!^<H'Q'>@_.4#XCO0?G*!\1WH/SE`^([T'YR@?
M$=Z#\Y0/B.]!^<H'Q'>@_.4#XCO0?G*!\1WH/SE`^([T'YR@?$=Z#\Y0/B.]
M!^<H'Q'>@_.4#XCO0?G*!\1WH/SE`^([T'YR@?$=Z#\Y0/B.]!^<H'Q'>@_.
M4#XCO0?G*!\1WH/SE`^([T'YR@?$=Z#\Y0/B.]!^<H'Q'>@_.4#XCO0?G*!\
M1WH/SE`^([T'YR@?$=Z#\Y0/B.]!^<H'Q'>@_.4#XCO0?G*!\1WH/SE`^([T
M'YR@?$=Z#\Y0/B.]!^<H'Q'>@_.4#XCO0?G*##C[;O\`-[F;[*_S#]GAPL,W
09^Q<8\^/SN)Q<F'>QH/_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>med_blue.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 med_blue.gif
M1TE&.#EAWP!_`,00`$5XIL+3XH.EQ!=6C_#T^&2/M='>Z39MGJ.\TR9BE^'I
M\56#K72:O++'VI.QRP=+B/___P``````````````````````````````````
M`````````````````````````"'Y!`$``!``+`````#?`'\```7_("2.9&F>
M:*JN;.N*S?',B4"\>*[O?.__P%UC1IP!@LBD<LELZA+%8L-)K5JO6)(B$"T"
M!`U#=DPNFTD$Q&+0;1,!#L5Y3J_SU.Y\]^"XV?^`=@0";$0#"PX!!7D!!@@%
M4$4%<H&5EE6#A0\##&(C"GD(6@Z1,Y.7J*DO"@X"`@A^#:4'HB<+;0<H`;<S
M`P*JP,$D`E$##KP/"0$JQ,F$IBH*R`>>PM:!!#)YQBR+1@T.!<LK`:4.U^AV
M`#,'RYE$!2P$73G-#_'I^60(['XB!IIJI6`0)8&.`(4.^-/'T`F4`0M%$!CR
M8$&T+D=T*-"FL*%')C,8I-`V[H2W*"5Q_V3K][$E$`,S?J$@P$;F"4VE!E#*
M08"719=`>4!#T<QF"2Y$'/!CQV/E`Y%!H[[@-04-*2(I23B(PL">0)[:JDH=
MFP)F3'_-(ATH("#`0GN]D#[(Q0/@IIUD\Y(X^0#`%`)]%&@B0DL$W!ER'U33
M03&CWL>"NWS=5>K-EBZ)S_7@]?7Q6%X!&GB#>$)!`P:%?$5I5\2H#IK)(GH&
MBO0GA*6=2_1T\\7+CZ6N9[M<]P`O%'P0!,@84,`?WS=P'?=X*%MX0U#W2BS*
M:-90-02#^\(=`&2I9NLMO>&%0)'2@B_$!U0C0/!-X@=!H!A$WY*-;1)L0*55
M+SO-8Q]*0&SU0/]6_*6SE%C#(&:"@@?LA,R""/Y@('(-YK,(>2@LQ^!H,BV%
M6(8_W`)BA_FPP6$)D3UPW@CUS46`@2<6P>`.2RW&HC!FY4:"77VM5TX_VA2'
MH@_8:68``%_\J(J"ZYE@@#;<:$=#*??MN`,4%L$V@Y!2VN$-E%ZR<B$U6J)$
MG"%0@E%="XL89&)%909B0`'A.>./`F]V4<!BAP40:!L`P%+/#!!X<XMT><YQ
M9R]%0'78`5#R^48U-2X8J"L%)$G$`@BXU0)2X%5$#*21EM'=%V#<)L!#,;P!
M(03O;"(&=EAQM5,`#%2V22?D4/H`.)NT2@=Q0CXW@)>X>I,`?2BU8</_D*@5
MQ)8`B?CH&U+*GK$A"I4!,.=>6T:!8S)$).`C!`8T<&A!`'3E'7N,AEL&JBAL
M@<`K+SQ'!`0ZRI(4"GN*NDTMQ-"E[QA(0<M#IP,7(<H@\+1`0`#_,@!EICNM
M\]_#5R!U:Q!'%L'K`S9=R1(0ZP1',A5F":C$I*\0X9HW'?VP#JLS4_'08GL"
M0*H/"C\2DPG2&MV6"QL',,[/06>A("?_7CC7NR><)D,"7]0GEUTR*[Q)`2<'
MX(#'X1'W8M54"$R#)%5"H/8:>A"\8'(LGR!F%P-\+&P>7,/=1*WPB(%QNQ\#
M,/A<4`Z&T`,=]WT"D0B(ID=?;"ASFM$2&]Y$_WUX/;GY(8IJ<0L#BRS03(4(
M%^(.`AY#V54`E(`I>AU!FJ"``%!"7J\#A8NPCGR;R.5+[,FP@)W,NX_A8A+$
MN:)804+BMD*/T=.A(O4Z&\!%.Z4DD)ON*GS?O:0SG,S#O#+B^@Q3Z`(]PKCK
MB^L?$EK/@!<"D?A*,U2@H-#E+V[^"\)AYF("`D#!9@-,@7X..`>SO$T(79C1
M"*@V@@B>P#P4G`-QZI:#^RCF!!P40<3(M8ESA;`*2+E@#A1D"*+D2R)+,P%P
M7BA""?G@,/;CW@ADX+#[L8$T/#0#=J;E`ZUI\!,SF!&52E`?,B7Q"LVPF0["
M<RXH%+%W(VC,%>D0%O\>4"1C*6A&2M`'@<CH9(P5/&+Q5/`<]WV"#46LSPV<
M8D4X7F$I;\P!%U=0E#"V#P)N\V,=7N="*[email protected][email protected]"_4I@
M%R3RI6>5I,-H,#F"^VRR!!3Y":]`&4I1$J&/I=1DP`X)@?K`P2U1:^49:+B`
M1J[,<AKKG$3,]C)=0BPUL(P"]%#@#4\,XG%/-*85"/`F`$`K4`84@0).$ARI
M:0Z8TAQ#JKYADB*0<D]1&%D;L^7#<))A<30@U@AHB)\4I$%4"]B.-@,`O"(H
MPYUS^-U@$E``!(BO"`WDI\+$P;=G"<PO`!4$`HC9&@$4(')=J,%[email protected].$3_
MM!)JZI,>#B``KIW$FA\-1KQFQ;B/<<N`XB-A2E'QIF?-=#;"`H!,;_H1CAKB
M6CR-B@F+P*:@`J45H&I<5W9JU*8Z]:E0C:I4ITK5JEKUJEC-JE:WRM6N>O6K
M8`UK6:1&UK*N)VIE+>MCQ)=6LC(U4O#+82SS\)BX@G-F=G7-4`>FE[PF88&`
M\]WFVDD&OY)@KS<DBV�#$W^&A2;HCF%1:KPKSU-0_+U(%=BZ!!N75!BUF@
MK-TLFQ?1^N!Q71@9:F5I!M$BMIZEQ6P2!ML++="V>:V5[6%)2Y9_N>*WO\WF
MJ6Z[-Q'0<W-G<"UO*7C&P=JD?XQ`&/`&<P!2-5(1_Z6`@Q_\^CM0Z2&MN&JK
M6X^BE/6H26$`*.B<MB!>4\F/(PRH&UO%2T(%T`X`H@I<O1"P$\#R1I+$/9G!
M-L>`ZNRF#=SPZVOIBEB;S`^8\J(M0TO@W[TU0*2@-2T"-AN%$4"7KO`B+CBI
M25QW<7*UIE"PB`?68%PI[!>`6G&!(^2&T.CA192-L8@W*.)E''=SR-G(BN5S
M/XH60[8+=L-HW6`#LY54I(,%987'J5OC59E(.Q:!C"'PX?^Z>,4T\$-CP?R+
M)+=AR=8:LZ;`3#^^N0'%O?"'8;&<Y5]&66]9[K)SV\CF+I29S6C&2)_W[.9!
MB\6P1D9NH&_;W-MN3`\+D/_:AR$R9L(``,JM6?1M-3UH=EQZ<W*H\&UMXE?(
MND&_I3`NF(F)Z05Y-CL>=L-$"3?,S>EUN9P>="V<PN1"MZ$`[.RUE7NMYUY\
MQ;X_J33DB*ML&>EA(78V0AYLMN!;@WBWG9;$D$;JZRC@PZ?*Y'&O!\O$%-BU
M-XS&]+E-D.@V9,76F;SV7('<@(GHX58H[K84AECEO";9CB-8+0/,/`,2KQJX
MKH!S%R*R66LK.=[;*,EKL[+9WT5WV-82M[46O*(4Z.$7K29,H[(]:!,T'.)G
M1CG@"(7KS?+SXHCL-V9%W9=B1;?8(=$WR3==@I-C^^$_;X,&1<WP[U:X)(O-
M*\W_3XDO6O_8W4W?^8K7DVB'ISSHCT3E=WNN!XO76.-^!KLR.4Y(RX([Y037
M),+7_MM7WPK>)#`U7[%>*1.\MC.MUGD[DX[9)$NLR_N!0,@=PV:F0]$-')+[
MJ*BX=;KKK(%ZD$ZC'WETL=<=XV$G][G6+8)BVR3DCEW!(""P6LU,;G,EH?,>
M%M-B=NMAQJ='O-Z+&_-3-T!J1OX%SLV'A@WCN0T"4OS>M[$PV4Q$4R.7.EN"
MK0>PD:?U)7@ZF,50^<YG^Q>3SP.F2A'MQVM3#QU_=5\VAZF/T2/M4C]_E=$`
M^LUEI/H0D#YQ9<)A1C1>!*O]CZAC#V;,OS[]"`5]6C=HR8$$?W_#9C*A>K<E
M?[27?$)'`MF'%<*G:`J84;4$@(PB@"4P@=M0#?`7?YW6,NW'%<NE>*RG!^=`
M95EV&X.E..W6?QJX@2/8+BSW=>C29T9A``JG2=L`(Z=F`A^G33CG3S-R8:=6
M$M0R6-;4;!FX?J4A?D7@"Q'Q@<8U@YF&!@\V6+73.!\#6A?%A5'2<V#8A5K`
M`$8&-B7E-RSU4[*Q"PB&"+^R9E[``%/P)&.8*"W`"G&%.M6Q87?(-6GP'G=X
,AV3B-7F0`*02`@`[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>12
<FILENAME>medtronic062430s1_ex10-22.htm
<DESCRIPTION>2003 LONG-TERM INCENTIVE PLAN
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 10.22 to Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR><BR>
<P style="font-size:10pt;font-weight:bold;text-align:right">Exhibit 10.22</P>
<P style="font-size:12pt;font-weight:bold;text-align:center"></P>
<P style="font-size:12pt;font-weight:bold;text-align:center">MEDTRONIC, INC.<BR>
<BR>2003 LONG-TERM INCENTIVE PLAN<BR>(AS AMENDED AND RESTATED THROUGH JUNE 22, 2006)</P>
<P style="font-size:10pt;font-weight:bold">1. Purpose of the Plan</P>
<P style="font-size:10pt"> The purpose of the Plan is to aid the Company and
its Affiliates in recruiting and retaining employees and to motivate such employees and other plan participants to exert their
best efforts on behalf of the Company and its Affiliates by providing incentives through the granting of Awards. The Company
expects that it will benefit from the stock ownership opportunities provided to such participants to encourage alignment of
their interest in the Company’s success with that of other stakeholders.</P>
<P style="font-size:10pt;font-weight:bold">2. Definitions</P>
<P style="font-size:10pt"> The following capitalized terms used in the Plan have
the respective meanings set forth in this Section:</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">(a)</TD>
<TD WIDTH="92%">“<B><I>Act</I></B>” means the Securities Exchange Act of 1934, as amended, or any successor thereto.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(b)</TD>
<TD>“<B><I>Affiliate</I></B>” means any entity that is consolidated with the Company for financial reporting purposes
or any other entity designated by the Board in which the Company or an Affiliate has a direct or indirect interest of at least
forty percent (40%).</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(c)</TD>
<TD>“<B><I>Award</I></B>” means an Option, Stock Appreciation Right, Share of Restricted Stock, Other Stock-Based
Award or Other Cash-Based Award granted pursuant to the Plan.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(d)</TD>
<TD>“<B><I>Board</I></B>” means the Board of Directors of the Company.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(e)</TD>
<TD>“<B><I>Code</I></B>” means the Internal Revenue Code of 1986, as amended, or any successor thereto.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(f)</TD>
<TD>“<B><I>Committee</I></B>” means the Compensation Committee of the Board.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(g)</TD>
<TD>“<B><I>Company</I></B>” means Medtronic, Inc., a Minnesota corporation.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(h)</TD>
<TD>“<B><I>Effective Date</I></B>” means the date the adoption of the Plan by the Board of Directors is approved by
the Company’s shareholders.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(i)</TD>
<TD>“<B><I>Exercise Price</I></B>” means the purchase price per Share under the terms of an option as determined pursuant
to Section 6(a).</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(j)</TD>
<TD>“<B><I>Fair Market Value</I></B>” means, on a given date, (i) if there should be a public market for the Shares
on such date, the closing sale price of the Shares on The New York Stock Exchange, or, if the Shares are not listed or admitted
on any national securities exchange, the arithmetic mean of the per Share closing bid price and per Share closing asked price
on such date as quoted on the National Association of Securities Dealers Automated Quotation System (or such market in which
such prices are regularly quoted) (the “NASDAQ”), or, if no sale of Shares shall have been reported on The New York
Stock Exchange or quoted on the NASDAQ on such date, then the immediately preceding date on which sales of the Shares have
been so reported or quoted shall be used, and (ii) if there should not be a public market for the Shares on such date, the
Fair Market Value shall be the value established by the Committee in good faith.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(k)</TD>
<TD>“<B><I>ISO</I></B>” means an Option that is an incentive stock option granted pursuant to Section 6(d).</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(l)</TD>
<TD>“<B><I>Option</I></B>” means a stock option granted pursuant to Section 6.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(m)</TD>
<TD>“<B><I>Other Stock-Based Awards</I></B>” means Awards granted pursuant to Section 9(a) or 10.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(n)</TD>
<TD>“<B><I>Other Cash-Based Awards</I></B>” means Awards granted pursuant to Section 9(b) or 10.</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD width="4%"> </TD>
<TD width="4%">(o)</TD>
<TD width="92%">“<B><I>Participant</I></B>” means an employee of the Company or an Affiliate who is selected by the
Committee to participate in the Plan. An Award may also be granted to any consultant, agent, advisor or independent contractor
who renders bona fide services to the Company or an Affiliate that (i) are not in connection with the offer and sale of the
Company’s securities in a capital-raising transaction and (ii) do not directly or indirectly promote or maintain a market
for the Company’s securities. Except where the context otherwise requires, references in this Plan to “employment”
and related terms shall apply to services in any such capacity.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(p)</TD>
<TD>“<B><I>Performance-Based Awards</I></B>” means certain Restricted Stock, Other Stock-Based Awards and Other Cash-Based
Awards granted pursuant to Section 10.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(q)</TD>
<TD>“<B><I>Plan</I></B>” means the 2003 Long-Term Incentive Plan, as amended from time to time.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(r)</TD>
<TD>“<B><I>Restricted Stock</I></B>” means any Share granted under Section 8.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(s)</TD>
<TD>“<B><I>Shares</I></B>” means shares of common stock of the Company, $.10 par value per share.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(t)</TD>
<TD>“<B><I>Stock Appreciation Right</I></B>” means a stock appreciation right granted pursuant to Section 7.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(u)</TD>
<TD>“<B><I>Subsidiary</I></B>” means a subsidiary corporation, as defined in Section 424(f) of the Code (or any successor
section thereto), of the Company.</TD>
</TR>
</TABLE>
<P style="font-size:10pt;font-weight:bold">3. Shares Subject to the Plan</P>
<P style="font-size:10pt"> The total number of Shares which may be issued under
the Plan is 60,000,000, of which no more than 50% may be issued in the form of Restricted Stock or Other Stock-Based Awards
payable in Shares, provided, however, that no more than 5% of the Shares reserved under the Plan shall be granted
pursuant to Restricted Stock Awards if such Award (a) shall vest in full prior to three years from the Award date or (b) if
a condition to such vesting is based, in whole or in part, upon performance of the Shares or any aspect of the Company’s
operations and such vesting could occur over a period of less than one year from the Award date. The Shares may consist,
in whole or in part, of unissued Shares. The issuance of Shares upon the exercise or satisfaction of an Award shall reduce
the total number of Shares available under the Plan. Shares which are subject to Awards that terminate, lapse or are cancelled
may be granted again under the Plan. Any Shares tendered by a Participant or retained by the Company as full or partial payment
to the Company for the purchase price of an Award or to satisfy tax withholding obligations in connection with an Award shall
be available for Awards under the Plan. No fractional Shares will be issued in payment for any Award, but instead the number
of Shares will be rounded upward to the next whole Share.</P>
<P style="font-size:10pt;font-weight:bold">4. Administration</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">(a)</TD>
<TD WIDTH="92%"><B><I>Delegation of Authority</I></B>. The Plan shall be administered by the Committee, which may delegate its
duties and powers in whole or in part to (i) any subcommittee thereof consisting solely of at least two individuals who are
intended to qualify as “non-employee directors” within the meaning of Rule 16b-3 under the Act (or any successor
rule thereto) and, to the extent required by Section 162(m) of the Code (or any successor section thereto), “outside directors”
within the meaning thereof and (ii) persons who are not non-employee directors for purposes of determining and administering
Awards to those Participants who are not then subject to the reporting requirements of Section 16 of the Act.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(b)</TD>
<TD><B><I>Authority of Committee</I></B>. The Committee shall have exclusive power to make Awards and to determine when and
to whom Awards shall be granted, and the form, amount and other terms and conditions of each Award, subject to the provisions
of this Plan. The Committee may determine whether, to what extent and under what circumstances Awards may be settled, paid
or exercised in cash, Shares or other Awards or other property, or cancelled, forfeited or suspended. The Committee shall have
the authority to interpret this Plan and any Award or agreement made under this Plan, to establish, amend, waive and rescind
any rules and regulations relating to the administration of this Plan, to determine the terms and provisions of any agreements
entered into hereunder (not inconsistent with this Plan), and to make all other determinations necessary or advisable for the
administration of this Plan. The Committee may
</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD width="4%"> </TD>
<TD width="4%"> </TD>
<TD width="92%">
correct any defect, supply any omission or reconcile any inconsistency in this Plan or in any Award or agreement in the manner
and to the extent it shall deem desirable. The determinations of the Committee in the administration of this Plan, as described
herein, shall be final, binding and conclusive.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(c)</TD>
<TD><B><I>Rule 16b-3</I></B>. It is the intent that this Plan and all Awards granted pursuant to it shall be administered by
the Committee (or a subcommittee thereof) so as to permit this Plan and Awards to comply with Rule 16b-3 under the Act. If
any provision of this Plan or any Award would otherwise frustrate or conflict with the intent expressed in this Section 4(c),
that provision to the extent possible shall be interpreted and deemed amended in the manner determined by the Committee so
as to avoid such conflict.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(d)</TD>
<TD><B><I>Indemnification</I></B>. To the full extent permitted by law, each member and former member of the Committee and each
person to whom the Committee delegates or has delegated authority under this Plan shall be entitled to indemnification by the
Company against and from any loss, liability, judgment, damages, cost and reasonable expense incurred by such member, former
member or other person by reason of any action taken, failure to act or determination made in good faith under or with respect
to this Plan.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(e)</TD>
<TD><B><I>Tax Withholding</I></B>. The Committee shall require payment of any amount it may determine to be necessary to withhold
for federal, state, local, non-U.S. income, payroll or other taxes as a result of the exercise, grant or vesting of an Award.
Unless the Committee specifies otherwise, the Participant may elect to pay a portion or all of such withholding taxes by (i)
delivery in Shares, (ii) having the Company withhold Shares with a Fair Market Value or cash equal to the amount of such taxes
that would have otherwise been payable by the Participant or (iii) paying cash.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(f)</TD>
<TD><B><I>Deferral</I></B>. In the sole discretion of the Committee, in accordance with procedures established by the Committee
and consistent with the provisions of Section 162(m) when applied to Participants who may be “covered employees”
thereunder, a Participant may be permitted to defer the issuance of Shares or cash deliverable upon the exercise of an Option
or Stock Appreciation Right, vesting of Restricted Stock, or satisfaction of Other Stock-Based Awards or Other Cash-Based Awards,
for a specified period or until a specified date.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(g)</TD>
<TD><B><I>Dividends or Dividend Equivalents</I></B>. If the Committee so determines, any Award granted under the Plan may be
credited with dividends or dividend equivalents paid with respect to the underlying shares. The Committee may apply any restrictions
to the dividends or dividend equivalents that the Committee deems appropriate and may determine the form of payment, including
cash, Shares, Restricted Stock or otherwise.</TD>
</TR>
</TABLE>
<P style="font-size:10pt;font-weight:bold">5. Limitations</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">(a)</TD>
<TD WIDTH="92%"><B><I>Term of Plan</I></B>. No Award may be granted under the Plan after the tenth anniversary of the Effective
Date, but Awards granted prior to such tenth anniversary may extend beyond that date.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(b)</TD>
<TD><B><I>No Repricing</I></B>. No Option or Stock Appreciation Right, once granted hereunder, may be repriced.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(c)</TD>
<TD><B><I>Maximum</I></B>. No Participant may be granted Options, Stock Appreciation Rights, Restricted Stock, Performance-Based
Awards, Other Stock-Based Awards or any combination thereof relating to more than 2,000,000 Shares under the Plan during any
fiscal year.</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<P style="font-size:10pt;font-weight:bold">6. Terms and Conditions of Options</P>
<P style="font-size:10pt"> Options granted under the Plan shall be, as determined
by the Committee, non-qualified or incentive stock options for federal income tax purposes, as evidenced by the related Award
agreements, and shall be subject to the foregoing and the following terms and conditions and to such other terms and conditions,
not inconsistent therewith, as the Committee shall determine:</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">(a)</TD>
<TD WIDTH="92%"><B><I>Exercise Price</I></B>. The Exercise Price per Share shall be determined by the Committee, but shall not
be less than 100% of the Fair Market Value of the Shares on the date an Option is granted. </TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(b)</TD>
<TD><B><I>Exercisability</I></B>. Options granted under the Plan shall be exercisable at such time and upon such terms and conditions
as may be determined by the Committee, but in no event shall an Option be exercisable more than ten years after the date it
is granted, except as provided in Section 16 of the Plan.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(c)</TD>
<TD><B><I>Exercise of Options</I></B>. Except as otherwise provided in the Plan or in an Award agreement, an Option may be exercised
for all, or from time to time any part, of the Shares for which it is then exercisable. For purposes of this Section 6, the
exercise date of an Option shall be the date a notice of written or electronic exercise and full payment of the purchase price
are received by the Company in accordance with this Section 6(c). The purchase price for the Shares as to which an Option is
exercised shall be paid to the Company pursuant to one or more of the following methods, except as otherwise provided in an
Award agreement: (i) in cash or its equivalent (e.g., by check); (ii) in Shares having a Fair Market Value equal to the aggregate
Exercise Price for the Shares being purchased and satisfying such other requirements as may be imposed by the Committee; (iii)
partly in cash and partly in such Shares; (iv) if there is a public market for the Shares at such time, through the delivery
of irrevocable instructions to a broker to sell Shares obtained upon the exercise of the Option and to deliver promptly to
the Company an amount out of the proceeds of such sale equal to the aggregate Exercise Price for the Shares being purchased;
or (v) through the withholding of Shares having a Fair Market Value equal to the aggregate Exercise Price for the Shares being
purchased from the number of Shares otherwise issuable upon the exercise of the Option (e.g., a net share settlement). No Participant
shall have any rights of a shareholder with respect to Shares subject to an Option until the Participant has given written
or electronic notice of exercise of the Option, paid in full for such Shares and, if applicable, has satisfied any other conditions
imposed by the Committee pursuant to the Plan.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(d)</TD>
<TD><B><I>ISOs</I></B>. The Committee may grant Options under the Plan that are intended to be ISOs. Such ISOs shall comply
with the requirements of Section 422 of the Code (or any successor section thereto). No ISO may be granted to any Participant
who, at the time of such grant, owns more than ten percent of the total combined voting power of all classes of stock of the
Company or of any Subsidiary, unless (i) the Exercise Price for such ISO is at least 110% of the Fair Market Value of a Share
on the date the ISO is granted and (ii) the date on which such ISO terminates is a date not later than the day preceding the
fifth anniversary of the date on which the ISO is granted Any Participant who disposes of Shares acquired upon the exercise
of an ISO either (I) within two years after the date of grant of such ISO or (II) within one year after the transfer of such
Shares to the Participant, shall notify the Company of such disposition and of the amount realized upon such disposition. All
Options granted under the Plan are intended to be non-qualified stock options, unless the applicable Award agreement expressly
states that the Option is an ISO. If an Option is intended to be an ISO, and if for any reason such Option (or portion thereof)
shall not qualify as an ISO, then, to the extent of such nonqualification, such Option (or portion thereof) shall be regarded
as a non-qualified stock option granted under the Plan; provided that such Option (or portion thereof) otherwise complies with
the Plan’s requirements relating to non-qualified stock options, In no event shall any member of the Committee, the Company
or any of its Affiliates (or their respective employees, officers or directors) have any liability to any Participant (or any
other person or entity) due to the failure of an Option to qualify for any reason as an ISO.</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD width="4%"> </TD>
<TD width="4%">(e)</TD>
<TD width="92%"><B><I>Attestation</I></B>. Wherever in this Plan or any agreement evidencing an Award a Participant is permitted
to pay the Exercise Price of an Option or taxes relating to the exercise of an Option by delivering Shares, the Participant
may, subject to procedures satisfactory to the Committee, satisfy such delivery requirement by presenting proof of beneficial
ownership of such Shares rather than physical delivery, in which case the Company shall treat the Option as exercised without
further payment and shall withhold such number of Shares from the Shares issued upon the exercise of the Option.</TD>
</TR>
</TABLE>
<P style="font-size:10pt;font-weight:bold">7. Terms and Conditions of Stock Appreciation Rights</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">(a)</TD>
<TD WIDTH="92%"><B><I>Grants</I></B>. The Committee may grant (i) a Stock Appreciation Right independent of an Option or
(ii) a Stock Appreciation Right in connection with an Option, or a portion thereof. The Committee may impose such terms
and conditions upon any Stock Appreciation Right as it deems fit. A Stock Appreciation Right granted pursuant to clause (ii) of
the preceding sentence (A) may be granted at the time the related Option is granted or at any time prior to the exercise
or cancellation of the related Option, (B) shall cover the same number of Shares covered by an Option (or such lesser
number of Shares as the Committee may determine) and (C) shall be subject to the same terms and conditions as such Option
except for such additional limitations as are contemplated by this Section 7 (or such additional limitations as may be
included in an Award agreement).</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(b)</TD>
<TD><B><I>Terms</I></B>. The exercise price per Share of a Stock Appreciation Right shall be an amount determined by the Committee
but in no event shall such amount be less than the Fair Market Value of a Share on the date the Stock Appreciation Right is
granted; provided, however, that, notwithstanding the foregoing, in the case of a Stock Appreciation Right granted in conjunction
with an Option, or a portion thereof, the exercise price may not be less than the Exercise Price of the related Option. Each
Stock Appreciation Right granted independent of an Option shall entitle a Participant upon exercise to an amount equal to (i) the
excess of (A) the Fair Market Value on the exercise date of one Share over (B) the Exercise Price per Share, times
(ii) the number of Shares covered by the Stock Appreciation Right. Each Stock Appreciation Right granted in conjunction
with an Option, or a portion thereof, shall entitle a Participant to surrender to the Company the unexercised Option, or any
portion thereof, and to receive from the Company in exchange therefor an amount equal to (I) the excess of (x) the
Fair Market Value on the exercise date of one Share over (y) the Exercise Price per Share, times (II) the number
of Shares covered by the Option, or portion thereof, which is surrendered. Payment shall be made in Shares or in cash, or partly
in Shares and partly in cash (any such Shares valued at such Fair Market Value), all as set forth in the Award agreement. Stock
Appreciation Rights may be exercised from time to time upon actual receipt by the Company of written or electronic notice of
exercise stating the number of Shares with respect to which the Stock Appreciation Right is being exercised. The date a notice
of exercise is received by the Company shall be the exercise date.</TD>
</TR>
</TABLE>
<P style="font-size:10pt;font-weight:bold">8. Restricted Stock</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">(a)</TD>
<TD WIDTH="92%"><B><I>Grant</I></B>. Subject to the provisions of the Plan, the Committee shall determine the number of Shares
of Restricted Stock to be granted to each Participant, the duration of the period during which, and the conditions, if any,
under which, the Restricted Stock may be forfeited to the Company, and the other terms and conditions of such Awards.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(b)</TD>
<TD><B><I>Transfer Restrictions</I></B>. Shares of Restricted Stock may not be sold, assigned, transferred, pledged or otherwise
encumbered, except as provided in the Plan or the applicable Award agreement. Shares of Restricted Stock shall be registered
in the name of the Participant and held by the Company. After the lapse of the restrictions applicable to such Shares of Restricted
Stock, the Company shall deliver such Shares to the Participant or the Participant’s legal representative.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(c)</TD>
<TD><B><I>Dividends</I></B>. Dividends or dividend equivalents paid on any Shares of Restricted Stock may be paid directly to
the Participant, withheld by the Company subject to vesting of the Restricted
</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD width="4%"> </TD>
<TD width="4%"> </TD>
<TD width="92%">
Stock pursuant to the terms of the applicable Award agreement, or may be reinvested in additional Shares of Restricted Stock,
as determined by the Committee in its sole discretion.</TD>
</TR>
</TABLE>
<P style="font-size:10pt;font-weight:bold">9. Other Awards</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">(a)</TD>
<TD WIDTH="92%"><B><I>Other Stock-Based Awards</I></B>. The Committee, in its sole discretion, may grant Awards of Shares and
Awards that are valued in whole or in part by reference to, or are otherwise based on, Shares or on the Fair Market Value thereof
(“Other Stock-Based Awards”). Such Other Stock-Based Awards shall be in such form, and dependent on such conditions,
as the Committee shall determine, including, without limitation, the right to receive, or vest with respect to, one or more
Shares (or the equivalent cash value of such Shares) upon the completion of a specified period of service, the occurrence of
an event and/or the attainment of performance objectives. Other Stock-Based Awards may be granted alone or in addition to any
other Awards granted under the Plan. Subject to the provisions of the Plan, the Committee shall determine the number of Shares
to be awarded to a Participant under (or otherwise related to) such Other Stock-Based Awards; whether such Other Stock-Based
Awards shall be settled in cash, Shares or a combination of cash and Shares; and all other terms and conditions of such Awards
(including, without limitation, the vesting provisions thereof and provisions ensuring that all Shares so awarded and issued
shall be fully paid and non-assessable).</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(b)</TD>
<TD><B><I>Other Cash-Based Awards</I></B>. In addition to the Awards described above, and subject to the terms of the Plan,
the Committee may grant such other incentives denominated in cash and payable in cash under the Plan as the Committee determines
to be in the best interests of the Company and subject to such other terms and conditions as it deems appropriate. The maximum
amount of Other Cash-Based Awards (including those that are performance-based) that may be granted during any fiscal year shall
be $3,000,000; provided, however, that for such Awards with performance periods longer than one year the maximum shall be $3,000,000
for each fiscal year in the performance period.</TD>
</TR>
</TABLE>
<P style="font-size:10pt;font-weight:bold">10. Performance-Based Awards.</P>
<P style="font-size:10pt"> Notwithstanding anything to the contrary herein, the
Committee may grant performance-based Awards of Restricted Stock, Other Stock-Based Awards and Other Cash-Based Awards to Participants
(“Performance-Based Awards”). Any such Awards granted to Participants who may be “covered employees” under
Section 162(m) of the Code or any successor section thereto shall be consistent with the provisions thereof. In such cases,
a Participant’s Performance-Based Award shall be determined based on the attainment of written performance goals approved
by the Committee for a performance period established by the Committee (I) while the outcome for that performance period is
substantially uncertain and (II) by the earlier of (A) 90 days after the commencement of the performance period to which the
performance goal relates or (B) the number of days which is equal to 25 percent of the relevant performance period. The performance
goals, which must be objective, shall be based upon one or more of the following criteria: (i) consolidated earnings before
or after taxes (including earnings before interest, taxes, depreciation and amortization); (ii) net income; (iii) operating
income; (iv) earnings per share; (v) book value per share; (vi) return on shareholders’ equity; (vii) expense management;
(viii) return on investment; (ix) improvements in capital structure; (x) profitability of an identifiable business unit or
product; (xi) maintenance or improvements of profit margins; (xii) stock price; (xiii) market share; (xiv) revenues or sales;
(xv) costs; (xvi) cash flow; (xvii) working capital; (xviii) return on assets; (xix) asset turnover; (xx) inventory turnover;
(xxi) economic value added (economic profit); and (xxii) total shareholder return. The foregoing criteria may relate to the
Company, one or more of its Subsidiaries or one or more of its divisions or units, or any combination of the foregoing, and
may be applied on an absolute basis and/or be relative to one or more peer group companies or indices, or any combination thereof,
all as the Committee shall determine. In addition, to the degree consistent with Section 162(m) of the Code (or any successor
section thereto), the performance goals may be calculated without regard to the negative effect of unusual or nonrecurring
items, extraordinary items, discontinued operations or cumulative effects of accounting changes. The Committee shall determine
whether, with respect to a performance period, the applicable performance goals have been met with respect to a given Participant
who may be a covered employee and, if they have, shall so certify and ascertain the amount
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<P style="font-size:10pt">
of the applicable Performance-Based Award. No Performance-Based Awards will be paid for such performance period until such certification
is made by the Committee. The amount of the Performance-Based Award actually paid to a given Participant may be less than the
amount determined by the applicable performance goal formula, at the discretion of the Committee. The amount of the Performance-Based
Award determined by the Committee for a performance period shall be paid to the Participant at such time as determined by the
Committee in its sole discretion after the end of such performance period.</P>
<P style="font-size:10pt;font-weight:bold">11. Adjustments Upon Certain Events</P>
<P style="font-size:10pt"> Notwithstanding any other provisions in the Plan to
the contrary, the following provisions shall apply to all Awards granted under the Plan:</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">(a)</TD>
<TD WIDTH="92%"><B><I>Generally</I></B>. In the event of any change in the outstanding Shares after the Effective Date by reason
of any Share dividend or split, reorganization, recapitalization, merger, consolidation, spin-off, combination or transaction
or exchange of Shares or other corporate exchange, or any distribution to shareholders of Shares other than regular cash dividends
or any transaction similar to the foregoing, the Committee in its sole discretion and without liability to any person may make
such substitution or adjustment, if any, as it deems to be equitable, as to (i) the number or kind of Shares or other securities
issued or reserved for issuance pursuant to the Plan or pursuant to outstanding Awards, (ii) the maximum number of Shares for
which Awards (including limits established for Restricted Stock, Other Stock-Based Awards or Other Cash-Based Awards) may be
granted during a fiscal year to any Participant, (iii) the Exercise Price or exercise price of any Stock Appreciation Right
and/or (iv) any other affected term of such Awards.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(b)</TD>
<TD><B><I>Change in Control</I></B>. Notwithstanding anything contained in this Plan to the contrary, unless otherwise provided
in the applicable Award agreement at the time of grant, in the event of a Change in Control, the following shall occur as of
the effective date of such Change in Control with respect to any and all Awards outstanding as of the effective date of such
Change in Control: (i) any and all Stock Options and Stock Appreciation Rights granted hereunder shall vest in full and become
immediately exercisable, and shall remain exercisable throughout their entire term; (ii) any restrictions imposed on Restricted
Stock (including Performance-Based Awards in Restricted Stock) shall lapse; (iii) a pro rata payment of all other Performance-Based
Awards equal in each case to the number of Shares covered by the Award multiplied by the performance-based accrual percentage
applicable to such Award, and multiplied by a fraction the numerator of which is the number of months elapsed from the date
of grant through the effective date of the Change in Control and the denominator of which is the number of months from the
date of grant through the originally scheduled maturity date; and (iv) the maximum payout opportunities attainable under all
Other Stock-Based Awards and Other Cash-Based Awards that are not Performance-Based Awards shall be deemed to have been fully
earned for the entire performance period(s). Such Awards shall be paid in cash, or in the sole discretion of the Committee
in Shares to Participants within thirty (30) days following the effective date of the Change in Control, with any such Shares
valued at the Fair Market Value as of the effective date of the Change in Control.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(c)</TD>
<TD><B><I>Definition of Change of Control</I></B>. For purposes of this Section 11, “Change in Control” means: </TD>
</TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">(i)</TD>
<TD WIDTH="88%">Any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Act or any successor
thereto) (a “Person”) becomes the beneficial owner (within the meaning of Rule 13d-3 promulgated under the Act) of
30% or more of either (A) the then outstanding Shares (the “Outstanding Company Common Stock”) or (B) the combined
voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors
(the “Outstanding Company Voting Securities”); provided, however, that, for purposes of this clause (c)(i), the following
acquisitions shall not constitute a Change in Control: (1) any acquisition directly from the Company, (2) any acquisition by
the Company or any of its Subsidiaries, (3) any acquisition by any employee benefit plan (or related trust) sponsored or maintained
by the Company or any of its
</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD width="4%"> </TD>
<TD width="4%"> </TD>
<TD width="4%">
</TD>
<TD WIDTH="88%">
Subsidiaries, (4) any acquisition by an underwriter temporarily holding securities pursuant to an offering of such securities
or (5) any acquisition pursuant to a transaction that complies with clauses (iii) (A), (B) and (C) below; or</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD> </TD>
<TD>(ii)</TD>
<TD>Individuals who, as of the date hereof, constitute the Board (the “Incumbent Directors”) cease for any reason
to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the
date hereof whose election, or nomination for election by the Company’s shareholders, was approved by a vote of at least
a majority of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of
the Company in which such person is named as a nominee for director, without written objection to such nomination) shall be
considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual
whose initial assumption of office occurs as a result of either an actual or threatened election contest or other actual or
threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD> </TD>
<TD>(iii)</TD>
<TD>Consummation of a reorganization, merger, statutory share exchange or consolidation (or similar corporate transaction) involving
the Company or any of its Subsidiaries, a sale or other disposition of all or substantially all of the assets of the Company,
or the acquisition of assets or stock of another entity (a “Business Combination”), in each case, unless, immediately
following such Business Combination, (A) substantially all of the individuals and entities who were the beneficial owners,
respectively, of the Outstanding Company Common Stock and the Outstanding Company Voting Securities immediately prior to such
Business Combination beneficially own, directly or indirectly, more than 55% of, respectively, the then outstanding Shares
and the total voting power of (1) the corporation resulting from such Business Combination (the “Surviving Corporation”)
or (2) if applicable, the ultimate parent corporation that directly or indirectly has beneficial ownership of 80% or more of
the voting securities eligible to elect directors of the Surviving Corporation (the “Parent Corporation”), in substantially
the same proportion as their ownership, immediately prior to the Business Combination, of the Outstanding Company Common Stock
and the Outstanding Company Voting Securities, as the case may be, (B) no Person (other than any employee benefit plan (or
related trust) sponsored or maintained by the Surviving Corporation or the Parent Corporation), is or becomes the beneficial
owner, directly or indirectly, of 30% or more of the outstanding Shares of common stock and the total voting power of the outstanding
voting securities eligible to elect directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving
Corporation) and (C) at least a majority of the members of the board of directors of the Parent Corporation (or, if there is
no Parent Corporation, the Surviving Corporation) following the consummation of the Business Combination were Incumbent Directors
at the time of the Board’s approval of the execution of the initial agreement providing for such Business Combination;
or</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD> </TD>
<TD>(iv)</TD>
<TD>Approval by the shareholders of the Company of a complete liquidation or dissolution of the Company.</TD>
</TR>
</TABLE>
<P style="font-size:10pt"> Notwithstanding the foregoing provisions of this definition,
a Change in Control shall not be deemed to occur with respect to the Participant if the acquisition of the 30% or greater interest
referred to in clause (i) is by a group, acting in concert, that includes the Participant or if at least 40% of the then outstanding
common stock or combined voting power of the then outstanding voting securities (or voting equity interests) of the Surviving
Corporation or, if applicable, the Parent Corporation shall be beneficially owned, directly or indirectly, immediately after
a Business Combination by a group, acting in concert, that includes the Participant.</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">(d)</TD>
<TD WIDTH="92%"><B><I>Further Adjustment of Awards</I></B>. Subject to the above provisions, the Committee shall have the discretion,
exercisable at any time before a sale, merger, consolidation, reorganization, liquidation, dissolution or Change in Control
transaction to take such further action as it determines to be necessary or advisable with respect to Awards. Such authorized
action may include (but
</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD width="4%"> </TD>
<TD width="4%"> </TD>
<TD WIDTH="92%">
shall not be limited to) establishing, amending or waiving the type, terms, conditions or duration of, or restrictions on, Awards
so as to provide for earlier, later, extended or additional time for exercise, lifting of restrictions and other modifications,
and the Committee may take such actions with respect to all Participants, to certain categories of Participants or only to
individual Participants. The Committee may take such action before or after granting Awards to which the action relates and
before or after any public announcement with respect to such sale, merger, consolidation, reorganization, liquidation, dissolution
or change in control that is the reason for such action.</TD>
</TR>
</TABLE>
<P style="font-size:10pt;font-weight:bold">12. No Right to Employment or Awards</P>
<P style="font-size:10pt"> The granting of an Award under the Plan shall impose
no obligation on the Company or any Affiliate to continue the employment of a Participant and shall not lessen or affect the
Company’s or Affiliate’s right to terminate the employment of such Participant. No Participant or other person shall
have any claim to be granted any Award, and there is no obligation for uniformity of treatment of Participants, or holders
or beneficiaries of Awards. The terms and conditions of Awards and the Committee’s determinations and interpretations
with respect thereto need not be the same with respect to each Participant.</P>
<P style="font-size:10pt;font-weight:bold">13. Other Benefit and Compensation Programs</P>
<P style="font-size:10pt"> Payments and other benefits received by a Participant
under an Award shall not be deemed a part of a Participant’s regular, recurring compensation for purposes of any termination,
indemnity or severance pay laws and shall not be included in, nor have any effect on, the determination of benefits under any
other employee benefit plan, contract or similar arrangement provided by the Company or an Affiliate, unless expressly so provided
by such other plan, contract or arrangement or the Committee determines that an Award or portion of an Award should be included
to reflect competitive compensation practices or to recognize that an Award has been made in lieu of a portion of competitive
cash compensation.</P>
<P style="font-size:10pt;font-weight:bold">14. Successors and Assigns</P>
<P style="font-size:10pt"> The Plan shall be binding on all successors and assigns
of the Company and a Participant, including without limitation, the estate of such Participant and the executor, administrator
or trustee of such estate, or any receiver or trustee in bankruptcy or representative of the Participant’s creditors.</P>
<P style="font-size:10pt;font-weight:bold">15. Nontransferability of Awards / Beneficiaries</P>
<P style="font-size:10pt"> No Award or interest in an Award may be sold, assigned,
pledged (as collateral for a loan or as security for the performance of an obligation or for any other purpose) or transferred
by the Participant or made subject to attachment or similar proceedings otherwise than by will or by the applicable laws of
descent and distribution, except to the extent a Participant designates one or more beneficiaries on a Company-approved form
who may exercise the Award or receive payment under the Award after the Participant’s death. During a Participant’s
lifetime, an Award may be exercised only by the Participant. Notwithstanding the foregoing and to the extent permitted by Section 422
of the Code or any successor thereto, the Committee, in its sole discretion, may permit a Participant to assign or transfer
an Award; provided, however, that any Award so assigned or transferred shall be subject to all the terms and conditions of
the Plan and the agreement evidencing the Award.</P>
<P style="font-size:10pt"> A Participant may designate a beneficiary to succeed
to the Participant’s Awards under the Plan in the event of the Participant’s death by filing a beneficiary form with
the Company and, upon the death of the Participant, such beneficiary shall succeed to the rights of the Participant to the
extent permitted by law and the terms of this Plan and the applicable agreement. In the absence of a validly designated beneficiary
who is living at the time of the Participant’s death, the Participant’s executor or administrator of the Participant’s
estate shall succeed to the Awards, which shall be transferable by will or pursuant to laws of descent and distribution.</P>
<P style="font-size:10pt;font-weight:bold">16. Amendments or Termination</P>
<P style="font-size:10pt"> The Board may amend, alter or discontinue the Plan,
but no amendment, alteration or discontinuation shall be made, (a) without the approval of the shareholders of the Company,
if such action would
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<P style="font-size:10pt">
(except as is provided in Section 11 of the Plan), increase the total number of Shares reserved for the purposes of the
Plan or increase the maximum number of Shares of Restricted Stock or Other Stock-Based Awards that may be awarded hereunder,
or the maximum number of Shares for which Awards may be granted to any Participant, (b) without the consent of a Participant,
if such action would diminish any of the rights of the Participant under any Award theretofore granted to such Participant
under the Plan or (c) to Section 5(b), relating to repricing of Options or Stock Appreciation Rights; <I>provided, however</I>,
that the Committee may amend the Plan in such manner as it deems necessary to permit the granting of Awards meeting the requirements
of the Code or other applicable laws.</P>
<P style="font-size:10pt;font-weight:bold">17. International Participants</P>
<P style="font-size:10pt"> With respect to Participants who reside or work outside
the United States of America, the Committee may, in its sole discretion, amend the terms of the Plan or adopt such modifications,
procedures or subplans with respect to such Participants as are necessary or desirable to ensure the viability of the benefits
of the Plan, comply with applicable foreign laws or obtain more favorable tax or other treatment for a Participant, the Company
or an Affiliate; provided, however, that no such changes shall apply to the Awards to Participants who may be “covered
employees” under Section 162(m) of the Code or any successor thereto unless consistent with the provisions thereof.</P>
<P style="font-size:10pt;font-weight:bold">18. General</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">(a)</TD>
<TD WIDTH="92%"><B><I>Issuance of Shares</I></B>. Notwithstanding any other provision of the Plan, the Company shall have no
obligation to issue or deliver any Shares under the Plan or make any other distribution of benefits under the Plan unless,
in the opinion of the Company’s counsel, such issuance, delivery or distribution would comply with all applicable laws
(including, without limitation, the requirements of the Securities Act of 1933, as amended, or any successor thereto (the “Securities
Act”) or the laws of any state or foreign jurisdiction) and the applicable requirements of any securities exchange or
similar entity.</TD>
</TR>
</TABLE>
<P style="font-size:10pt"> The Company shall be under no obligation to any Participant
to register for offering or resale or to qualify for exemption under the Securities Act, or to register or qualify under the
laws of any state or foreign jurisdiction, any Shares, security or interest in a security paid or issued under, or created
by, the Plan, or to continue in effect any such registrations or qualifications if made.</P>
<P style="font-size:10pt"> The Company may issue Shares with such legends and
subject to such restrictions on transfer and stop-transfer instructions as counsel for the Company deems necessary or desirable
for compliance by the Company with federal, state and foreign securities laws. The Company may also require such other action
or agreement by the Participants as may from time to time be necessary to comply with applicable securities laws.</P>
<P style="font-size:10pt"> To the extent the Plan or any Award agreement provides
for issuance of stock certificates to reflect the issuance of Shares, the issuance may be effected on a noncertificated basis,
to the extent not prohibited by applicable law or the applicable rules of any stock exchange.</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">(b)</TD>
<TD WIDTH="92%"><B><I>No Rights as a Shareholder</I></B>. Unless otherwise provided by the Committee or in the agreement evidencing
the Award or in any other written agreement between a Participant and the Company or an Affiliate, no Award shall entitle the
Participant to any cash dividend, voting or other right of a shareholder unless and until the date of issuance under the Plan
of the Shares that are subject of such Award.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(c)</TD>
<TD><B><I>No Trust or Fund</I></B>. The Plan is intended to constitute an “unfunded” plan. Nothing contained herein
shall require the Company to segregate any monies, other property, or Shares, or to create any trusts, or to make any special
deposits for any immediate or deferred amounts payable to any Participant, and no Participant shall have any rights that are
greater than those of a general unsecured creditor of the Company.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(d)</TD>
<TD><B><I>Severability</I></B>. In the event any provision of the Plan shall be held illegal or invalid for any reason, the
illegality or invalidity shall not affect the remaining parts of the Plan, and the Plan shall be construed and enforced as
if the illegal or invalid provision had not been included.</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD width="4%"> </TD>
<TD width="4%">(e)</TD>
<TD width="92%"><B><I>Choice of Law</I></B>. The validity, construction, interpretation, administration and effect of the Plan,
and rights relating to the Plan and to Awards granted under the Plan, shall be governed by the substantive laws, but not the
choice of law rules, of the State of Minnesota.</TD>
</TR>
</TABLE>
<P style="font-size:10pt;font-weight:bold">19. Effectiveness of the Plan</P>
<P style="font-size:10pt"> The Plan shall be effective as of the Effective Date.</P>
<BR>
<BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>13
<FILENAME>medtronic062430s1_ex10-23.htm
<DESCRIPTION>FORM OF OPTION AGREEMENT UNDER 2003 INCENT. PLAN
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 10.23 to Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR>
<img src="medtronicblksm.gif"><P style="font-size:10pt;font-weight:bold;text-align:right">Exhibit 10.23</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">NON-QUALIFIED STOCK OPTION AGREEMENT<BR>2003 LONG-TERM INCENTIVE PLAN</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%">1.</TD>
<TD WIDTH="96%"><B>The Option.</B> Medtronic, Inc., a Minnesota corporation (the “Company”), hereby grants
to you, the individual named above, as of the above Grant Date, an option (the “Option”) to purchase the above number
of shares of common stock of the Company (the “Common Stock”), for the above Option Price Per Share, on the terms
and conditions set forth in this Non-Qualified Stock Option Agreement (this “Agreement”) and in the Medtronic, Inc.
2003 Long-Term Incentive Plan (the “Plan”). In the event of any inconsistency between the terms of the Agreement
and the Plan, the terms of the Plan shall govern. Capitalized terms not defined in this Agreement shall have the meanings ascribed
to them in the Plan.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>2.</TD>
<TD><B>Exercise of Option.</B> The exercise of the Option is subject to the following conditions and restrictions:</TD>
</TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">(a)</TD>
<TD WIDTH="92%"><U>Expiration</U>. Upon vesting of the underlying shares, the Option may be exercised in whole or in part until
the earlier of (i) the above Expiration Date, or (ii) the expiration of the applicable period following your termination of
employment with the Company or one of its subsidiaries, as provided in Sections 2(c),(d) or (e) below.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(b)</TD>
<TD><U>Schedule of Exercisability</U>. The Option shall become vested and exercisable to the extent of __% of the above number
of shares of Common Stock on __________________. Once a portion of the Option has become exercisable, that portion may be exercised
at any time thereafter, subject to the provisions of Paragraph 2(a) above.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(c)</TD>
<TD><U>Death</U>. Notwithstanding the schedule of exercisability set forth in Section 2(b) above, the Option shall become immediately
exercisable in full upon your death, and may be exercised by your Successor (as defined below) at any time, or from time to
time, within five years after the date of your death. For purposes of this Agreement, the term “Successor” shall
mean the legal representative of your estate or the person or persons who may, by bequest or inheritance, or valid beneficiary
designation (as provided in Section 15 of the Plan), acquire the right to exercise the Option.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(d)</TD>
<TD><U>Disability or Retirement</U>. Notwithstanding the schedule of exercisability set forth in Section 2(b) above, the Option
shall become immediately exercisable in full upon your Disability or Retirement (as each such term is defined below), and you
may exercise your Option at any time, or from time to time, within five years after the date of Retirement or determination
of Disability. For purposes of this Agreement, the terms “Disability” and “Retirement” shall have the meanings
ascribed to those terms under any retirement plan of the Company which is qualified under Section 401 of the Code (which
currently provides for retirement on or after age 55, provided you have been employed by the Company and/or one or more Affiliates
for at least ten years, or retirement on or after age 62), or under any disability or retirement plan of the Company or any
Affiliate applicable to you due to employment by a non-U.S. Affiliate or employment in a non-U.S. location, or as otherwise
determined by the Committee.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(e)</TD>
<TD><U>Termination for Any Other Reason</U>. In the event your employment with the Company terminates for any reason other than
those specified in Sections 2(c) and 2(d), the unvested portion of the Option will terminate as of 11:00 p.m. CT (midnight
ET) on the date of termination of your employment. You may exercise that portion of the Option that was vested but unexercised
as of the date of termination of your employment for thirty (30) days following the date of termination of your employment.
At 11:00 p.m. CT (midnight ET) on the date 30 days after the date of termination of your employment, the Option will expire.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>(f)</TD>
<TD><U>Change in Control</U>. Notwithstanding the schedule of exercisability set forth in Section 2(b) above, the Option shall
become immediately exercisable in full upon the occurrence of a Change in Control.</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD width="4%"> </TD>
<TD width="4%">(g)</TD>
<TD width="92%"><U>Expiration of Term</U>. Notwithstanding the foregoing paragraphs (a)-(f), in no event shall the Option be
exercisable after the Expiration Date.</TD>
</TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%">3.</TD>
<TD WIDTH="96%"><B>Manner of Exercise.</B> To exercise your Option, you must deliver notice of exercise (the “Notice”)
to UBS Financial Services. The Notice must specify the number of shares of Common Stock (the “Shares”) as to which
the Option is being exercised and must be accompanied by payment of the purchase price for the Shares in cash, check, or by
the delivery of Common Stock already owned by you, or by a combination thereof, pursuant to such forms and subject to such
conditions as may be prescribed from time to time by the Committee.<BR><BR>Exercise shall be deemed to occur on the earlier of
the date the Notice and option cost payment are received by UBS Financial Services or the date you simultaneously exercise
the Option and sell the shares, using the proceeds from such sale to pay the purchase price.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>4.</TD>
<TD><B>Withholding Taxes.</B> You are responsible for payment of any federal, state, local or other taxes which
must be withheld upon the exercise of the Option, and you must promptly pay to the Company any such taxes. The Company and
its subsidiaries are authorized to deduct from any payment owed to you any taxes required to be withheld with respect to the
Shares, including social security and Medicare (FICA) taxes and federal, state and local income tax with respect to income
arising from the exercise of the Option. The Company shall have the right to require the payment of any such taxes before issuing
any Shares pursuant to an exercise of the Option. In lieu of all or any part of a cash payment, you may elect to have a portion
of the Shares otherwise issuable upon exercise of the Option withheld by the Company to satisfy all or part of the withholding
tax requirements relating to the Option exercise with such Shares valued in the same manner as used in computing such withholding
taxes. Any fractional share amount due relating to such tax withholding will be rounded up to the nearest whole share and the
additional amount will be added to your federal withholding.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>5.</TD>
<TD><B>Forfeitures.</B> If you have received or been entitled to receive payment in cash, delivery of Common Stock
or a combination thereof pursuant to this Option within the period beginning six months prior to termination of your employment
with the Company or any Affiliate and ending when the Option expires in accordance with Section 2(a), the Company, in its sole
discretion, may require you to return or forfeit the cash and/or Common Stock received or receivable with respect to this Option
(or its economic value as of the date of the exercise of the Option), in the event you engage in any of the following activities:</TD>
</TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">a.</TD>
<TD WIDTH="84%">performing services for or on behalf of any competitor of, or competing with, the Company or any Affiliate within
six months of the date of your termination of employment with the Company or any Affiliate;</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>b.</TD>
<TD>unauthorized disclosure of material proprietary information of the Company or any Affiliate;</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>c.</TD>
<TD>a violation of applicable business ethics policies or business policies of the Company or any Affiliate; or</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>d.</TD>
<TD>any other occurrence determined by the Committee.</TD>
</TR>
</TABLE>
<P style="font-size:10pt;margin-left:30pt">The Company’s right to require forfeiture must be exercised not later than 90
days after the Company acquires actual knowledge of such an activity but in no event later than 12 months after your termination
of employment with the Company or any Affiliate. Such right shall be deemed to be exercised upon the Company’s mailing
written notice of such exercise to your most recent home address as shown on the personnel records of the Company. In addition
to requiring forfeiture as described herein, the Company may exercise its rights under this Section 4 by preventing or
terminating the exercise of any rights under this Option or the acquisition of Shares or cash thereunder.</P>
<P style="font-size:10pt;margin-left:30pt">If you fail or refuse to forfeit the cash and/or Shares demanded by the Company (adjusted
for any events described in Section 11(a) of the Plan), you shall be liable to the Company for damages equal to the number
of Shares demanded times the highest closing price per share of the Common
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<P style="font-size:10pt;margin-left:30pt">
Stock during the period between the date of termination of your employment with the company or any Affiliate and the date of
any judgment or award to the Company, together with all costs and attorneys’ fees incurred by the Company to enforce this
provision.</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%">6.</TD>
<TD WIDTH="96%"><B>Conversion to Stock-Settled Stock Appreciation Rights.</B> At any time following the Grant Date,
the Company may convert this Option to a stock-settled Stock Appreciation Right. Upon exercise of a Stock Appreciation Right,
you shall receive Common Stock with a value equal to the excess of the Fair Market Value of the Shares on the date of exercise
over the aggregate of (a) the Option Price Per Share multiplied by the number of Shares and (b) the amount of any taxes required
to be withheld as a result of such exercise.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>7.</TD>
<TD><B>Agreement.</B> Your receipt of the Option and this Agreement constitutes your agreement to be bound by the
terms and conditions of this Agreement and the Plan.</TD>
</TR>
</TABLE>
<P style="font-size:10pt">Accompanying this Agreement are instructions for accessing the Plan and the Plan Summary (prospectus)
on the Company’s intranet. You may also print these documents from the intranet or request written copies by contacting
HROC - Stock Administration at 763.505.3030.</P>
<P style="font-size:10pt;text-align:center">HROC – Stock Administration, m.s. V235<BR>Medtronic, Inc.<BR>3850 Victoria
Street North<BR>Shoreview, MN 55126-2978</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>medtronicblksm.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 medtronicblksm.gif
M1TE&.#EA@P!+`'```"P`````@P!+`(?____1T=%_?W\````-#0UY>7G5U=7T
M]/0("`A=75W2TM+3T],Z.CH7%Q<!`0$/#P]`0$#4U-2GIZ=!04$+"PLL+"PO
M+R\;&QL"`@('!P=%144I*2EV=G;'Q\?U]?7W]_?AX>'EY>7IZ>F.CHYM;6V5
ME977U]?=W=VVMK8C(R,4%!2DI*3DY.26EI9S<W,<'!PJ*BIL;&R"@H(Q,3$X
M.#BBHJ*@H*!*2DHD)"2^OK[V]O8^/CX0$!`T-#3KZ^OY^?F\O+QA86$2$A(_
M/S^WM[?P\/#%Q<4P,#`9&1EJ:FHE)278V-CGY^<S,S,*"@I"0D*PL+#;V]M.
M3DYT='3S\_/Q\?%<7%S]_?W"PL)34U,G)R?)R<GX^/B*BHH,#`P>'A[-S<WJ
MZNJ&AH8M+2V,C(SL[.QE967[^_MF9F;M[>U)24G^_OZYN;D='1W*RLHF)B;Z
M^OI[>WLV-C;?W]\A(2$6%A:ZNKIQ<7'N[NY86%B_O[_(R,A75U<.#@Z;FYN0
MD)!145%D9&1^?GZHJ*@:&AH@("!K:VO,S,R]O;V-C8U@8&!>7EY?7U^/CX]#
M0T.9F9F7EY<\/#S:VMK#P\/\_/R(B(BJJJK6UM9$1$03$Q-B8F*CHZ-I:6D5
M%16IJ:D)"0GHZ.A+2TM45%3.SLZEI:4]/3WR\O*XN+B<G)P#`P,R,C+BXN(W
M-S>QL;$K*RN'AX>TM+3>WMZ2DI*FIJ8H*"C/S\]Z>GI;6UN[N[L$!`01$1'+
MR\M\?'R$A(0B(B)X>'@?'Q^?GY^RLK*>GIYN;FZ`@(!P<'"4E)2AH:%24E*K
MJZMO;V]&1D::FIIG9V=W=W=(2$@&!@;!P<%,3$S<W-S@X.!'1T?0T-#9V=DY
M.3F+BXN8F)AU=7504%!]?7W&QL9H:&B=G9V3DY,N+BX[.SNOKZ_O[^]55559
M65F1D9&!@8'FYN;$Q,2LK*RMK:V#@X-65E:)B8E/3T]C8V.UM;7`P,"%A86N
MKJXU-36SL[-R<G):6EH8&!A-34T%!04````(_P`!"!Q(L*#!@P@3*CQXJ-*`
M`<].+)Q(L:+%BQ@S)GSV\.$YC2!#BAR)\="))KHZ#M"%J<F)0R1CRIQ)\9"E
M)@-\H50Y`!,F7SV?P:1)M&C&$W@$XJGDR]>S1TAQ`7VHZQ&>$X^>Z?*%9JC1
MKV`)'GK6I,DC2S^[%D2)25>3I`-QH7&+"V[8NS0/H42#!J@OB07QX,1D"7#!
M$^=TH<'+.":>Q)8$'OKI=:##G)4#,ZUDM['GBX>X$A1\KO,)3!T?+3RDJ]+G
MUQ9#+QZ(AZQA`)=]I<2U4.ILV,`1/L;$&\"A<SFM#GST$!/RWPFE/NL<O#H`
M2UN[GL!E:6433%8O-_]!L[*XPG.^,EL'?@X\:KB''CUJVX1C3O(#5$]L>7O]
M:UQ-1#:9:P`\4LD)6+7UT'@KZ;<0=@3Z!QL:F,!USC/&I>1+9'A,U01R$%%W
M$![.B2CA7:Q%)M!),!T"8%4`G#8`@SWUAQ!VZIT8UB-O$<077"?!^$AV"]HX
MXG@Z>H;)=`19PA5@>K4F%8V8&&E0;;XDV9@OG!6$76N`8?>,;CQBAJ")3?[%
M6GI:%C666^<HAUMB#Z%17)D#]+623YA48@F:QCF%GBXJMBD34TVAT<236OGR
M"'=I(55)2F0U.-^BW]5UD',;$F:H3'HQ*5!N?Q(T'W$X-0'@@OH=TI=.?*'_
M8<DA)@&E"XF%?BJ2DYV-]8QY!)WFX:KM<9G450VUM55+BSJ*JZXC88G1"1Z&
M5A56OE09+*W<6E)8H+E"JY%4@%V%E$)7H99G6_HA%B!2)A[+7+CB3INI)7TU
M<6!G>+A8"1I9^8*>DPZR=E\EN'`;7ZP4$EKOKC_IHLLS6M5'\3/_+DH572Z!
M9ZI;Y.G6E&[-H2;JPR$1;)EN$@N,AD3'UM=GGI5AIQH>:%R8U".^`(OR2!_:
MM1TN"6_:IUY-E3KJ7P95TL3/,SEMY4&I^G2<3D.=Y."*^D(-:GX6J3L`@2?,
M!9?'!$F5H]<9/59:13@]9!AV*O8Y&H6`LGV15#XG_Z0N)F+!"(!/A@%(K]X:
M/<;T1'%#-SB&U[FDU#EO(TZ2='D'VF!!?4E$+8=,]6TY2$YVF1!S.?6'B\./
MN2;FZ#/U)?J*ZD)>4.BX#8"+<[#/A)BV!YWTD.VC88)&OSJ=,W7O1Z%G>K"U
M(\0WSE5=E3GS%B46T6'J1A@8>@*]NA+QV(.$AY-]WH8Z^2LZS;J+B55>OD@G
MC.GH(3MO55F_/+H%(]%](<[\9'("IV6+<CF9E4W:LY5?#4Y@;A'@`&ER/J?M
M1"=EX=*!EL,534WP*P@:#"X09"/K??`NV*'*(]9V0KS@HCWM61(+6P@6/-CP
MAC:DH0YWR,,>^O"'0`RB$/^':+D3>.N(=N'.$6?7F'X=<5;7"PP.J3/%',9D
M2%N1F%=0(C&66(=Z+-N017#!DQD-I5\IX<G60G*9CGAE*@_)4G5(Q!/O+01$
M/#D>`.A81L>!I(T/V:)*GC9'/#[$C@H1FTK>)KP^Q@20`WCC(+^HJ+*,9WD%
M461'=`&3%)91?C9TD2B-Q"U-H<Z-_0J-2CAIDA@E+&'E0A!M1#G*P]#R6+3R
MH%)>PDM^*8Q;25%E&0<0&4AVA$U[?$9BNLB2K6&%B[HX!RX@22N2\41B37`5
M,U53O^_L\5\L:YDT`1.DEOUI+A*SDU(FU<6>K>@1?6&FQ#[BR3*^!3]EU`5O
MZC?_S,T)Q#ZKU&0U^QE(?(YM,FZ<2S\5DY03Y!&2JMJC(<<6(P7ULT`$_4L:
M\UD70TI,C4LA*$]HM=%ARD4ESS!H2?M9&H>N<I@8XF-'7!,W@EYGI9L<TD*S
MPI.G*#2.NPMH355B$@8&U'B/$>DU6W)-J.1SI;I`RD01-LQL^>16!IW11N$X
M3$6IA&DRU>HF"R.CD>Z16E^U'LZ4FE,$3;0K387D7\*ZH8DFT'HC5*1BN-H1
M&A&4DPC2Y%>'8DQ)]I4@$XTF\E99'(@>HJ<Q&NI<#:DJOA+S,$,EE&!IAM-5
M6K*S<1S*ZLPJ$*[*<8\J;157.2F0[JS2M1V!G"(GJQ),_PCSF-1IY((`D-5#
M`@"T;!WLJ,IHV#C2QJ#(E`IC!7+*CL!V>`(Q)&W[>MLX4@>B&+UF9(`[@',\
M\8G2+4YO58368]+&D+_1[4I4E-5S/%8E!)(N4F:[JCH6I+DSVF,9Y<A=9.XR
M8255U4W*6"57]=$D:TV-CWBB*ITNTJ6QC>XJT3`F-1K3*;2R!,[email protected]@&"T23
M0YU1)>3S"/2X-\36M*=EXY@>0V[MN7&$:F$X;-=A4K6J),OJ4/"K(AC7A[MO
MJ><FE1O<CIQTIE[B+D1BQ&$(B]0UHRUR)%M;TAWSQ!>U";%*]#BI57*FR_;4
M,B<-NL8":7E!77+RDE&[8OBV=D*SAS20G,MEB1&/F)QV-A"'&I+9IYQQP'=M
K;1M;`Y7X@&AB=<&%G"NAGJN4>)",ALM2%EV9:2[:0'GVRJ2Y>HY*!`0`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>15
<FILENAME>medtronic062430s1_ex10-24.htm
<DESCRIPTION>FORM OF RESTRICTED STOCK AGMT UNDER 2003 PLAN
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 10.24 to Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR>
<img src="medtronicblksm.gif">
<P style="font-size:10pt;font-weight:bold;text-align:right">Exhibit 10.24</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">RESTRICTED STOCK AWARD AGREEMENT<BR>2003 LONG-TERM INCENTIVE PLAN</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%">1.</TD>
<TD WIDTH="96%"><B>Restricted Stock Award.</B> Medtronic, Inc., a Minnesota corporation (the “Company”),
hereby awards to you, the individual named above, the above number of shares of Common Stock of the Company (the “Restricted
Stock”), subject to the restrictions, limitations, and conditions contained in this Restricted Stock Award Agreement (this
“Agreement”) and in the Medtronic, Inc. 2003 Long-Term Incentive Plan (the “Plan”). In the event of any
inconsistency between the terms of the Agreement and the Plan, the terms of the Plan will govern. Capitalized terms not defined
in this Agreement shall have the meanings ascribed to them in the Plan.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>2.</TD>
<TD><B>Restricted Stock Period.</B> On ________________________ the shares of Restricted Stock will become yours
free of all restrictions provided that you have been continuously employed by the Company or any Affiliate and all other conditions
and restrictions are met. Until the applicable vesting dates, the Restricted Stock is subject to the restrictions, conditions,
and limitations described in this Agreement and the Plan. In the case of your death, Disability or Retirement, you shall be
entitled to receive that number of shares of Restricted Stock that has been pro rated for the portion of the Restricted Stock
Period during which you were employed by the Company or any Affiliate, and with respect to such shares of Common Stock, all
restrictions shall lapse. Upon termination of your employment for any reason other than death, Disability or Retirement, any
shares of Restricted Stock whose restrictions have not lapsed will automatically be forfeited in full and canceled by the Company
as of 11:00 p.m. CT (midnight ET) on the date of such termination of employment. For purposes of this Agreement, the terms
“Disability” and “Retirement” shall have the meanings ascribed to those terms under any retirement plan
of the Company which is qualified under Section 401 of the Code (which currently provides for retirement on or after age
55, provided you have been employed by the Company and/or one or more Affiliates for at least ten years, or retirement on or
after age 62), or under any disability or retirement plan of the Company or any Affiliate applicable to you due to employment
by a non-U.S. Affiliate or employment in a non-U.S. location, or as otherwise determined by the Committee.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>3.</TD>
<TD><B>Change in Control.</B> Upon the occurrence of a Change in Control, all restrictions with respect to shares
of Restricted Stock shall lapse.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>4.</TD>
<TD><B>Forfeitures.</B> If you have received or been entitled to receive payment in cash, delivery of Common Stock
or a combination thereof as a result of this Restricted Stock award within the period beginning six months prior to termination
of your employment with the Company or any Affiliate and ending when the Restricted Stock award terminates or is canceled,
the Company, in its sole discretion, may require you to return or forfeit the cash and/or Common Stock received or receivable
with respect to this Restricted Stock, in the event you engage in any of the following activities:</TD>
</TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">a.</TD>
<TD WIDTH="92%">performing services for or on behalf of any competitor of, or competing with, the Company or any Affiliate within
six months of the date of your termination of employment with the Company or any Affiliate;</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>b.</TD>
<TD>unauthorized disclosure of material proprietary information of the Company or any Affiliate;</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>c.</TD>
<TD>a violation of applicable business ethics policies or business policies of the Company or any Affiliate; or</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>d.</TD>
<TD>any other occurrence determined by the Committee.</TD>
</TR>
</TABLE>
<P style="font-size:10pt;margin-left:30pt">The Company’s right to require forfeiture must be exercised not later than 90
days after the Company acquires actual knowledge of such an activity but in no event later than 12 months after your termination
of employment with the Company or any Affiliate. Such right shall be deemed to be exercised upon the Company’s mailing
written notice of such exercise to your most recent home
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<P style="font-size:10pt;margin-left:30pt">
address as shown on the personnel records of the Company. In addition to requiring forfeiture as described herein, the Company
may exercise its rights under this Section 4 by terminating this Restricted Stock Award.</P>
<P style="font-size:10pt;margin-left:30pt">If you fail or refuse to forfeit the cash and/or shares of Common Stock demanded
by the Company (adjusted for any events described in Section 11(a) of the Plan), you shall be liable to the Company for damages
equal to the number of shares demanded times the highest closing price per share of the Common Stock during the period between
the date of termination of your employment with the Company or any Affiliate and the date of any judgment or award to the Company,
together with all costs and attorneys’ fees incurred by the Company to enforce this provision.</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%">5.</TD>
<TD WIDTH="96%"><B>Rights of Shareholders.</B> As a recipient of Restricted Stock, you will have the rights of a
shareholder of Common Stock, including the right to receive dividends and to vote such stock, at the time you are awarded the
Restricted Stock. Shares representing the Restricted Stock will be issued and held in custody by the Company for you. All rights
as a shareholder with respect to the Restricted Stock will cease, and your Restricted Stock will be forfeited, upon termination
of your rights to such stock as provided in paragraph 2 or 4 above or pursuant to the provisions of the Plan. Upon such termination,
the Restricted Stock shares shall be canceled by the Company.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>6.</TD>
<TD><B>Restrictive Legend.</B> Each certificate representing shares of the Restricted Stock will contain a statement
substantially as follows:</TD>
</TR> </table>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2" ALIGN="CENTER">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="8%"> </TD>
<TD WIDTH="84%">“The shares represented by this certificate are subject to a risk of forfeiture and other restrictions, conditions, and limitations, including restrictions on transferability, as more particularly described in the
Medtronic, Inc. 2003 Long-Term Incentive Plan and Restricted Stock Award Agreement covering such shares. Such Plan and Agreement
are available for inspection at the principal office of Medtronic, Inc.”</TD><TD WIDTH="8%"> </TD>
</TR> </table>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="96%">Failure to include this statement on any of
the Restricted Stock certificates will not invalidate or waive the restrictions, limitations, or conditions contained in this
Agreement and the Plan.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>7.</TD>
<TD><B>Withholding Taxes.</B> You are responsible for any federal, state, local or other taxes due upon vesting
of the Restricted Stock, and you must promptly pay to the Company any such taxes. The Company and its subsidiaries are authorized
to deduct from any payment to you any taxes required to be withheld with respect to the Restricted Stock. As described in Section
4(e) of the Plan, you may elect to have a portion of the vested Restricted Stock withheld by the Company to satisfy all or
part of the withholding tax requirements relating to the Restricted Stock. Any fractional share amount due relating to such
tax withholding will be rounded up to the nearest whole share and the additional amount will be added to your federal withholding.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>8.</TD>
<TD><B>No Employment Contract.</B> Nothing contained in the Plan or in this Agreement shall create any right to
your continued employment or otherwise affect your status as an employee at will. You hereby acknowledge that Medtronic and
you each have the right to terminate your employment at any time for any reason or for no reason at all.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>9.</TD>
<TD><B>Agreement.</B> Your receipt of the Restricted Stock and this Agreement constitutes your agreement to be bound
by the terms and conditions of this Agreement and the Plan.</TD>
</TR>
</TABLE>
<BR>
<table border="1" cellspacing=6 cellpadding=6 width="100%" style='border-collapse:collapse'>
<TR VALIGN=TOP>
<td width="100%"><P style="font-size:10pt">Accompanying this Agreement are instructions for accessing the Plan and the Plan Summary (prospectus)
from UBS’s Internet website or HROC – Stock Administration’s intranet website. You may also request written
copies by contacting HROC – Stock Administration at 763.505.3030.</P> </TD></TR>
</TABLE>
<BR>
<P style="font-size:10pt;text-align:center">HROC – Stock Administration, MS V235
<BR>Medtronic, Inc.
<BR>3850 Victoria Street North
<BR>Shoreview, MN 55126-2978</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>16
<FILENAME>medtronic062430s1_ex10-25.htm
<DESCRIPTION>FORM OF RESTRICTED STOCK UNIT AGMT UNDER PLAN
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 10.25 to Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR>
<img src="medtronicblksm.gif"><P style="font-size:10pt;font-weight:bold;text-align:right">Exhibit 10.25</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">RESTRICTED STOCK UNIT AWARD AGREEMENT<BR>2003 LONG-TERM INCENTIVE
PLAN</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%">1.</TD>
<TD WIDTH="96%"><B>Restricted Stock Units Award.</B> Medtronic, Inc., a Minnesota corporation (the “Company”),
hereby awards to the individual named above Restricted Stock Units, in the number and at the Grant Date set forth above. The
Restricted Stock Units represent the right to receive shares of common stock of the Company (the “Shares”), subject
to the restrictions, limitations, and conditions contained in this Restricted Stock Units Award Agreement (the “Agreement”)
and in the Medtronic, Inc. 2003 Long-term Incentive Plan (the “Plan”). Unless otherwise defined in the Agreement,
a capitalized term in the Agreement will have the same meaning as in the Plan. In the event of any inconsistency between the
terms of the Agreement and the Plan, the terms of the Plan will govern.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>2.</TD>
<TD><B>Vesting and Distribution.</B> The Company will issue to you on _____________________ of your Restricted Stock
Units (including any dividend equivalents described in Section 5, below) within six months following any vesting date, provided
that you have been continuously employed by the Company and all other conditions and restrictions are met during the period
beginning on the Grant Date and ending on each vesting date (the “Restricted Period”). Notwithstanding the preceding
sentence, if you terminate employment during the Restricted Period due to death, Disability or Retirement, and all other conditions
and restrictions are met during the Restricted Period, you will vest in your Restricted Stock Units ___________________________,
and the Company will issue you a number of Shares equal to the number of your vested Restricted Stock Units (including any
dividend equivalents described in Section 5, below) within six weeks following your separation from service. Upon termination
of your employment during the Restricted Period for any reason other than death, Disability or Retirement, the Restricted Stock
Units will automatically be forfeited in full and canceled by the Company as of 11:00 p.m. CT (midnight ET) on the date of
such termination of employment. For purposes of this Agreement, the terms “Disability” and “Retirement”
shall have the meanings ascribed to those terms under any retirement plan of the Company which is qualified under Section 401
of the Code (which currently provides for retirement on or after age 55, provided you have been employed by the Company and/or
one or more Affiliates for at least ten years, or retirement on or after age 62), or under any disability or retirement plan
of the Company or any Affiliate applicable to you due to employment by a non-U.S. Affiliate or employment in a non-U.S. location,
or as otherwise determined by the Committee.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>3.</TD>
<TD><B>Forfeitures.</B> If you have received or are entitled to receive delivery of Shares as a result of this Restricted
Stock Units award within the period beginning six months prior to termination of your employment with the Company or any Affiliate
and ending when the Restricted Stock Unit award terminates or is canceled, the Company, in its sole discretion, may require
you to return or forfeit the cash and/or Shares received or receivable with respect to this Restricted Stock Units award, in
the event that you engage in any of the following activities:</TD>
</TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">a.</TD>
<TD WIDTH="92%">performing services for or on behalf of any competitor of, or competing with, the Company or any Affiliate within
six months of the date of your termination of employment with the Company or any Affiliate;</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>b.</TD>
<TD>unauthorized disclosure of material proprietary information of the Company or any Affiliate;</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>c.</TD>
<TD>a violation of applicable business ethics policies or business policies of the Company or any Affiliate; or</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>d.</TD>
<TD>any other occurrence determined by the Committee.</TD>
</TR>
</TABLE>
<P style="font-size:10pt;margin-left:30pt">The Company’s right to require forfeiture must be exercised not later than 90
days after the Company acquires actual knowledge of such an activity but in no event later than 12 months after your termination
of employment with the Company or any Affiliate. Such right shall be deemed to be exercised upon the Company’s mailing
written notice of such exercise to your most recent home address as shown on the personnel records of the Company. In addition
to requiring forfeiture as described herein, the Company may exercise its rights under this Section 3 by terminating this
Restricted Stock Units Award.</P>
<P style="font-size:10pt;margin-left:30pt">If you fail or refuse to forfeit the cash and/or shares of Common Stock demanded
by the Company (adjusted for any events described in Section 11(a) of the Plan), you shall be liable to the Company
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<P style="font-size:10pt;margin-left:30pt">
for damages equal to the number of Shares demanded times the highest closing price per share of the Common Stock during the
period between the date of termination of your employment with the Company or any Affiliate and the date of any judgment or
award to the Company, together with all costs and attorneys’ fees incurred by the Company to enforce this provision.</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%">4.</TD>
<TD WIDTH="96%"><B>Change in Control.</B> Notwithstanding anything in Section 2 to the contrary, if a Change
in Control of the Company, within the meaning of both the Plan and Section 409A of the Code, occurs during the Restricted Period,
and all other conditions and restrictions are met during the Restricted Period, then the Restricted Stock Units will become
100% vested upon such Change in Control and, the Company will issue to you a number of Shares equal to the number of your Restricted
Stock Units (including any dividend equivalents described in Section 5, below) within six weeks following the Change in Control.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>5.</TD>
<TD><B>Dividend Equivalents.</B> You are entitled to receive dividend equivalents on the Restricted Stock Units
generally in the same manner and at the same time as if each Restricted Stock Unit were a Share. These dividend equivalents
will be credited to you in the form of additional Restricted Stock Units. The additional Restricted Stock Units will be subject
to the terms of this Agreement.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>6.</TD>
<TD><B>Withholding Taxes.</B> You are responsible to promptly pay any Social Security and Medicare taxes (together,
“FICA”) due upon vesting of the Restricted Stock Units, and any Federal, State, and local taxes due upon distribution
of the Shares. The Company and its subsidiaries are authorized to deduct from any payment to you any such taxes required to
be withheld. As described in Section 4(e) of the Plan, you may elect to have the Company withhold a portion of the Shares issued
upon conversion of the Restricted Stock Units to satisfy all or part of the withholding tax requirements. You may also elect,
at the time you vest in the Restricted Stock Units, to pay your FICA liability due with respect to those Restricted Stock Units
out of those units. If you choose to do so, the Company will reduce the number of your vested Restricted Stock Units accordingly.
The amount that is applied to pay FICA will be subject to Federal, State, and local taxes.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>7.</TD>
<TD><B>Limitation of Rights.</B> Except as set forth in the Agreement, until the Shares are issued to you in settlement
of your Restricted Stock Units, you do not have any right in, or with respect to, any Shares (including any voting rights)
by reason of the Agreement. Further, you may not transfer or assign your rights under the Agreement and you do not have any
rights in the Company’s assets that are superior to a general, unsecured creditor of the Company by reason of the Agreement.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>8.</TD>
<TD><B>No Employment Contract.</B> Nothing contained in the Plan or Agreement creates any right to your continued
employment or otherwise affects your status as an employee at will. You hereby acknowledge that Medtronic and you each have
the right to terminate your employment at any time for any reason or for no reason at all.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>9.</TD>
<TD><B>Amendments to Agreement Under Section 409A of the Code.</B> You acknowledge that the Agreement and the Plan,
or portions thereof, may be subject to Section 409A of the Internal Revenue Code; that it is anticipated that comprehensive
rules interpreting this Code section will be issued; and that changes may need to be made to the Agreement to avoid adverse
tax consequences to you under Section 409A. You agree that following the issuance of such rules, the Company may amend the
Agreement as it deems necessary or desirable to avoid such adverse tax consequences; provided, however, that the Company shall
accomplish such amendments in a manner that preserves your intended benefits under the Agreement to the greatest extent possible.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>10.</TD>
<TD><B>Agreement.</B> You agree to be bound by the terms and conditions of this Agreement and the Plan. Your signature
is not required in order to make this Agreement effective.</TD>
</TR>
</TABLE>
<BR>
<table border="1" cellspacing=6 cellpadding=6 width="100%" style='border-collapse:collapse'>
<TR VALIGN=TOP>
<td width="100%">
<P style="font-size:10pt">Accompanying this Agreement are instructions for accessing the Plan and the Plan Summary (prospectus)
on the Company’s intranet. You may also print these documents from the intranet or request written copies by contacting
HROC – Stock Administration at 763.505.3030.</P> </TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Default" FSL="Default" -->
<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>HROC – Stock Administration, MS
V235<BR>
Medtronic, Inc.<BR>
3850 Victoria Street North<BR>
Shoreview, MN 55126-2978 </FONT></P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>17
<FILENAME>medtronic062430s1_ex10-26.htm
<DESCRIPTION>FORM OF PERFORMANCE AWARD AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 10.26 to Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR>
<img src="medtronicblksm.gif"><P style="font-size:10pt;font-weight:bold;text-align:right">Exhibit 10.26</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">PERFORMANCE AWARD AGREEMENT<BR>2003 LONG-TERM INCENTIVE PLAN<BR>(For
_____ Performance Cycle)</P>
<TABLE WIDTH="75%" BORDER="1" CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER">
<tr>
<TD ALIGN="center" WIDTH="20%"><font size="2"><strong>Awarded to</strong></font></td>
<TD ALIGN="CENTER" WIDTH="13%"><font size="2"><strong>Performance Cycle</strong></font></td>
<TD ALIGN="CENTER" WIDTH="12%"><font size="2"><strong>Target Award</strong></font></td>
</tr>
<tr>
<td width="20%"> <BR><BR></td>
<td rowspan="3" align="center" width="20%"> </td>
<td align="center" width="20%"> </td>
</tr>
<tr>
<td width="20%">
<div align="center">
<b><font size="2"><BR>Social Security Number<BR></font></b></div>
</td>
<td rowspan="2" align="center" width="20%"> </td>
</tr>
<tr>
<td width="20%">
<div align="center">
<b><font size="2"><BR> <BR></font></b></div>
</td>
</tr>
</table>
<P style="font-size:10pt"> 1. <B>Performance Award.</B> Medtronic,
Inc., a Minnesota Corporation (the “Company”), hereby grants to the individual named above (“you”) a Performance
Award (the “Award”) based on the target award specified above (“Target Award”), under the terms and conditions
set forth in this agreement (the “Agreement”) and in the Medtronic, Inc. 2003 Long-Term Incentive Plan (the “Plan”).
In the event of any inconsistency between the terms of the Agreement and the Plan, the terms of the Plan shall govern. Capitalized
terms used but not defined shall have the meaning ascribed thereto in the Plan.</P>
<P style="font-size:10pt"> 2. <B>Performance Targets.</B> The
payout under this Award will be based on the following pre-established performance targets:</P>
<P style="font-size:10pt"> (a) Company performance will be measured
using three criteria: 3-year Cumulative Diluted Earnings Per Share (“Cumulative Diluted EPS”), 3-year Average Annual
Revenue Growth (“Average Revenue Growth”), and 3-year Average After-Tax Return on Net Assets (“Average After-Tax
RONA”) as shown in the grid below. The performance measures will be weighted as follows: Cumulative Diluted EPS weighted
__%, Average Revenue Growth weighted __%, and Average After-Tax RONA weighted __%. The award constituting the payout may be
greater than, equal to, or less than the original amount based upon actual performance relative to these targets.</P>
<P style="font-size:10pt;font-weight:bold;text-align:center">% of Performance Award Earned</P>
<DIV align="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM" style="font-size:8pt">
<TH colspan="2" align="left"></TH>
<TH> </TH>
<TH> </TH>
<TH colspan="2">20%</TH>
<TH> </TH>
<TH> </TH>
<TH colspan="2">40%</TH>
<TH> </TH>
<TH> </TH>
<TH colspan="2">60%</TH>
<TH> </TH>
<TH> </TH>
<TH colspan="2">80%</TH>
<TH> </TH>
<TH> </TH>
<TH colspan="2">100%</TH>
<TH> </TH>
<TH> </TH>
<TH colspan="2">120%</TH>
<TH> </TH>
<TH> </TH>
<TH colspan="2">140%</TH>
<TH> </TH>
<TH> </TH>
<TH colspan="2">160%</TH>
<TH> </TH>
<TH> </TH>
<TH colspan="2">180%</TH>
<TH> </TH>
</TR>
<TR>
<TD colspan="2"></TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:8pt" bgcolor="#D6F3E8">
<TD>Diluted EPS growth %</TD>
<TD width="1%"> </TD>
<TD width="1%"> </TD>
<TD width="2%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="5%"></TD>
<TD width="1%"> </TD>
<TD width="2%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="5%"></TD>
<TD width="1%"> </TD>
<TD width="2%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="5%"></TD>
<TD width="1%"> </TD>
<TD width="2%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="5%"></TD>
<TD width="1%"> </TD>
<TD width="2%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="5%"></TD>
<TD width="1%"> </TD>
<TD width="2%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="5%"></TD>
<TD width="1%"> </TD>
<TD width="2%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="5%"></TD>
<TD width="1%"> </TD>
<TD width="2%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="5%"></TD>
<TD width="1%"> </TD>
<TD width="2%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="5%"></TD>
<TD width="1%"> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:8pt">
<TD><B>CUMULATIVE DILUTED EPS</B></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:8pt" bgcolor="#D6F3E8">
<TD><B>AVERAGE REVENUE GROWTH</B></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:8pt">
<TD><B>AVERAGE AFTER-TAX RONA</B></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
</TR>
</TABLE>
</DIV>
<P style="font-size:10pt"> Across the top of the grid are the percentages of
the Award to be earned based on the actual company performance against these three criteria for the three years of the award
cycle. This performance determines the percentage of the Target Award that will be paid out at the end of the three-year cycle.</P>
<P style="font-size:10pt"> (b) To earn a payout, performance must
meet or exceed the threshold Average After-Tax RONA and Cumulative Diluted EPS targets. The threshold targets for this Award
are an Average After-Tax RONA of __% and a Cumulative Diluted EPS of $____. If Company performance is below threshold for <U>either</U>
of these measures, no award payout will be made.</P>
<P style="font-size:10pt;text-align:center">– Continued on next page –</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<P style="font-size:10pt"> (c) To determine payout, the percentage
across the top of the grid is earned based on achievement of Company performance according to the targets within the grid for
each of the three performance measures, multiplied by the weight. To illustrate, if Company performance results in a Cumulative
Diluted EPS of $____, an Average Revenue Growth of __%, and After-Tax RONA of __%, the payout would be calculated as follows:</P>
<DIV align="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM" style="font-size:8pt">
<TH colspan="2" align="left">Performance Measure</TH>
<TH> </TH>
<TH> </TH> <TH colspan="2">% Award<BR>Earned</TH>
<TH> </TH>
<TH> </TH>
<TH colspan="2">Weight</TH>
<TH> </TH>
<TH> </TH>
</TR>
<TR>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD width="55%">Cumulative Diluted EPS</TD>
<TD width="1%"> </TD>
<TD width="1%"> </TD>
<TD width="4%"> </TD>
<TD width="1%"> </TD>
<TD align="center" width="8%"> ___% x</TD>
<TD width="4%"> </TD>
<TD width="2%"> </TD>
<TD width="1%"> </TD>
<TD align="center" width="8%">__%</TD>
<TD width="1%"> </TD>
<TD width="4%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="8%">= ____</TD>
<TD width="1%">%</TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD>Average Revenue Growth</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="center"> ___% x</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="center">__%</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">= ____</TD>
<TD>%</TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD>Average After-Tax RONA</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="center"> ___% x</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="center">__%</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">= ____</TD>
<TD>%</TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD>% Payout of Target Award</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">____</TD>
<TD>%</TD>
</TR>
</TABLE>
</DIV>
<P style="font-size:10pt"> 3. <B>Calculation of Cumulative Diluted
EPS, Average Revenue Growth, and Average After-Tax RONA</B> </P>
<P style="font-size:10pt">Cumulative Diluted EPS is calculated by adding the Diluted EPS for each of the three years.</P>
<P style="font-size:10pt">Average Revenue Growth is the simple annual growth in revenue over the three-year period excluding
the effects of foreign exchange rates.</P>
<P style="font-size:10pt">Average After-Tax RONA is the simple average of the After-Tax RONA for each of the three years of
the cycle.</P>
<P style="font-size:10pt"> 4. <B>Payment of Award.</B> Your
Award will be paid following the end of the performance period.</P>
<P style="font-size:10pt"> 5. <B>Withholding Taxes.</B> For
employees subject to United States taxes, your Award will be subject to federal, state, and local income tax withholding and
applicable employment taxes. Participants subject to tax outside of the United States will be subject to the taxes of the applicable
taxing authority.</P>
<P style="font-size:10pt"> 6. <B>Termination.</B> In the
event of your death, Disability or Retirement you will be entitled to a pro rata portion of the Award, provided you have completed
a minimum of six months participation in the cycle. Your Award will be paid following the end of the performance period. If
you terminate for reasons other than death, Disability or Retirement prior to the end of performance cycle, you will not be
entitled to any Award payment.</P>
<P style="font-size:10pt"> 7. <B>Change in Control/Fundamental Change.</B>
In the event of a Change in Control, a Fundamental Change or other substantially similar event or occurrence, this Award
will accelerate and vest immediately to the full extent contemplated or permitted under the Plan.</P>
<P style="font-size:10pt"> 8. <B>Beneficiary Designation.</B>
If a participant dies before completion of the Award cycle, a portion of the Award may be payable. The Plan permits each
participant to designate a beneficiary to receive payments that may be due in the event of death. Any beneficiary can be named
and you may change your beneficiaries at any time by submitting a new designation form to Executive Compensation, LC 245.</P>
<P style="font-size:10pt"> 9. <B>Forfeiture of Award.</B> If
you have received or been entitled to receive payment pursuant to an Award within the period beginning six months prior to
your termination of employment with the Company or its Affiliates and ending when the Award terminates or is canceled, the
Company, in its sole discretion, may require you to return or forfeit the payment received or receivable with respect to the
Award, in the event you are involved in any of the following occurrences: performing services for or on behalf of a competitor
of, or otherwise competing with, the Company or any Affiliate, unauthorized disclosure of material proprietary information
of the Company or any Affiliate, a violation of applicable business ethics policies or business policies of the Company or
any Affiliate, or any other occurrence determined by the Committee. The Company’s right to require forfeiture must
be exercised not later than 90 days after discovery of such an occurrence but in no event later than 15 months after your termination
of employment with the Company and its Affiliates. Such right shall be deemed to be exercised upon the Company’s
mailing written notice to you of such exercise at your most recent home address as shown on the personnel records of the Company.
In addition to requiring forfeiture as described herein, the Company may exercise its rights under this Section 10 by
terminating any Award. If you fail or refuse to forfeit the payment demanded by the Company, you shall be liable to the
</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<P style="font-size:10pt">
Company for damages equal to the payment together with all costs and attorneys’ fees incurred by the Company to enforce
this provision.</P>
<P style="font-size:10pt"> 10. <B>Acknowledgment.</B> Your
receipt of the Performance Award and this Agreement constitutes your agreement to be bound by the terms and conditions of this
Agreement and the Plan. Your signature is not required in order to make this Agreement effective.</P>
<TABLE WIDTH=90%>
<TR VALIGN=TOP>
<TD> </TD>
<TD colspan=2><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>MEDTRONIC, INC.</B> </FONT></TD></TR>
<TR VALIGN=TOP>
<TD WIDTH=65%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=2%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>By: </FONT></TD>
<TD WIDTH=33%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
</TABLE>
<BR>
<BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>18
<FILENAME>medtronic062430s1_ex10-27.htm
<DESCRIPTION>FORM OF CONFIRMATIONS OF NOTE HEDGE
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 10.27 to Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR><BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=100%>
<TR style="font-size:1px">
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="72%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="15%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD ROWSPAN="2" STYLE="BORDER:SOLID BLACK 1PX;PADDING:1%">
<P ALIGN=CENTER><FONT SIZE=2>Confidential Materials
omitted and filed separately with the<BR>
Securities and Exchange Commission. Asterisks denote omissions.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=MIDDLE>
<P ALIGN=CENTER><FONT SIZE="3"><B>Exhibit 10.27</B> </FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=100%>
<TR style="font-size:1px">
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="90%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>April 12, 2006</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Medtronic, Inc.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>710 Medtronic Parkway </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Minneapolis, Minnesota 55432</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Attn: Treasurer</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Telephone: (763) 505-2697</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Facsimile: (763) 505-2700</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>With a copy to:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Attn: General Counsel</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Facsimile: (763) 505-2980</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>From:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[_________________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[_________________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[_________________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Attn: [_________________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Telephone: [_________________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Facsimile: [_________________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2><B>Re:</B></FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2><B>Convertible
Bond Hedge Transaction</B></FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><font size=1> </font></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2><B>(__________
Reference Number:________________)</B></FONT></P>
</TD>
</TR>
</TABLE>
<P><FONT SIZE=2>Ladies and Gentlemen:</FONT></P>
<P><FONT SIZE=2> The
purpose of this communication (this “<B>Confirmation</B>”) is to set forth the terms
and conditions of the above-referenced transaction entered into on the Trade
Date specified below (the “<B>Transaction</B>”) between [________________] (“<B>Dealer</B>”)
and Medtronic, Inc. (“<B>Counterparty</B>”). This communication
constitutes a “Confirmation” as referred to in the ISDA Master Agreement
specified below. </FONT></P>
<P><FONT SIZE=2> 1. This
Confirmation is subject to, and incorporates, the definitions and
provisions of the 2000 ISDA Definitions (including the Annex thereto) (the “<B>2000
Definitions</B>”) and the definitions and provisions of the 2002 ISDA
Equity Derivatives Definitions (the “<B>Equity Definitions</B>”, and together with the
2000 Definitions, the “<B>Definitions</B>”), in each case as published by
the International Swaps and Derivatives Association, Inc. (“<B>ISDA</B>”).
In the event of any inconsistency between the 2000 Definitions and the Equity
Definitions, the Equity Definitions will govern. Certain defined terms used
herein have the meanings assigned to them in the Indenture to be dated as of
April 18, 2006 between Counterparty and Wells Fargo Bank, N.A., as trustee (the
“<B>Indenture</B>”)
relating to the USD2,200,000,000 principal amount of 1.625% convertible
debentures due April 15, 2013 (the “<B>Convertible Debentures</B>”). In the event of
any inconsistency between the terms defined in the Indenture and this
Confirmation, this Confirmation shall govern.</FONT></P>
<P><FONT SIZE=2> Each
party is hereby advised, and each such party acknowledges, that the other party
has engaged in, or refrained from engaging in, substantial financial
transactions and has taken other material actions in reliance upon the parties’
entry into the Transaction to which this Confirmation relates on the terms and
conditions set forth below.</FONT></P>
<P><FONT SIZE=2> This
Confirmation evidences a complete and binding agreement between Dealer and
Counterparty as to the terms of the Transaction to which this Confirmation
relates. This Confirmation shall be subject to an agreement (the “<B>Agreement</B>”)
in the form of the 2002 ISDA Master Agreement (the “<B>ISDA Form</B>”) as if Dealer and
Counterparty had executed an agreement in such form (without any Schedule but
with the elections set forth in this Confirmation). For the avoidance of doubt,
the Transaction shall be the only transaction under the Agreement.</FONT></P>
<P><FONT SIZE=2> All
provisions contained in, or incorporated by reference to, the Agreement will
govern this </FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<P><FONT SIZE=2>Confirmation except as expressly modified herein. In
the event of any inconsistency between this Confirmation and either the
Definitions or the Agreement, this Confirmation shall govern. </FONT></P>
<P><FONT SIZE=2> 2. The Transaction constitutes a Share Option Transaction for purposes of the
Equity Definitions. The terms of the particular Transaction to which this
Confirmation relates are as follows:</FONT></P>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=100%>
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="30%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="62%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>General Terms:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Trade Date:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>April 12, 2006</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Effective Date:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>April 18, 2006</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Option Style:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Modified American, as described under “Procedures
for Exercise” below.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Option Type:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Call</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Seller:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Dealer</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Buyer:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Counterparty</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Shares:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The Common Stock of Counterparty, par value
USD 0.10 per share (Ticker Symbol: “MDT”).</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Number of Options:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The number of Convertible Debentures in
denominations of USD1,000 principal amount issued by Counterparty on the
closing date for the initial issuance of the Convertible Debentures; <I>provided</I>
that the Number of Options shall be automatically increased as of the date of
exercise by Banc of America Securities LLC and Morgan Stanley & Co.
Incorporated, as representatives of the Initial Purchasers (as defined in the
Purchase Agreement), of their option pursuant to Section 4 of the Purchase
Agreement dated as of April 12, 2006 between Counterparty and Banc of America
Securities LLC and Morgan Stanley & Co. Incorporated as representatives
of the Initial Purchasers thereto (the “<B>Purchase Agreement</B>”) by the number of
Convertible Debentures in denominations of USD1,000 principal amount issued
pursuant to such exercise (such Convertible Debentures, the “<B>Additional
Convertible Debentures</B>”). For the avoidance of doubt, the Number
of Options outstanding shall be reduced by each exercise of Options
hereunder.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Option Entitlement:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>As of any date, a
number of Shares per Option equal to the Conversion Rate (as defined in the
Indenture, but without regard to any adjustments to the Conversion Rate pursuant
to Section 10.13 of the Indenture).</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Strike Price:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>As of any date, an amount in USD, rounded to the
nearest cent (with 0.5 cents being rounded upwards), equal to USD1,000 <I>divided by</I>
the Option Entitlement.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable Percentage:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[____]%</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Number of Shares:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The product of the Number of Options, the Option </FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>2</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=100%>
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="30%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="62%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Entitlement and the Applicable Percentage.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Premium:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD [__________] (Premium per Option USD
[___________]); <I>provided</I> that if the Number of Options is increased
pursuant to the proviso to the definition of “Number of Options” above, an
additional Premium equal to the product of the number of Options by which the
Number of Options is so increased and the Premium per Option shall be paid on
the Additional Premium Payment Date. </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Premium Payment Date:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The Effective Date</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Additional Premium Payment Date:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The closing date for the purchase and sale of the
Additional Convertible Debentures.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Exchange:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>New York Stock Exchange</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Related Exchange:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>All Exchanges</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>Procedures for Exercise:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Potential Exercise Dates:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Each Conversion Date.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Conversion Date:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Each “Conversion Date”, as defined in the Indenture,
of Convertible Debentures with respect to which Counterparty does not make
the direction described in Section 10.25 of the Indenture (such Convertible
Debentures, the “<B>Relevant Convertible Debentures</B>” for such
Conversion Date).</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Required Exercise on</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Conversion Dates:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On each Conversion Date for Relevant Convertible Debentures,
a number of Options equal to the number of Relevant Convertible Debentures in
denominations of USD1,000 principal amount submitted for conversion on such
Conversion Date in accordance with the terms of the Indenture shall be
automatically exercised, subject to “Notice of Exercise” below.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Expiration Date:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>April 15, 2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Multiple Exercise:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable, as provided above under “Required
Exercise on Conversion Dates”.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Minimum Number of Options:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Zero</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Maximum Number of Options:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Number of Options</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Integral Multiple:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Not Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Automatic Exercise:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>As provided above under “Required Exercise on
Conversion Dates”.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Notice of Exercise:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Notwithstanding anything to the contrary in the
Equity Definitions, in order to exercise any Options, Counterparty must
notify Dealer in writing prior to 5:00 PM, New York City time, on the
Exchange Business Day prior to the first Exchange Business Day of the
“Conversion Reference Period”, as defined in the Indenture, relating to the
Relevant Convertible Debentures converted on the Conversion Date relating to
the relevant Exercise Date (the “<B>Notice Deadline</B>”) of (i) the number of
Options </FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>3</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=100%>
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="30%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="15%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="47%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>being exercised on such Exercise Date, (ii) the
scheduled settlement date under the Indenture for the Relevant Convertible
Debentures converted on the Conversion Date corresponding to such Exercise
Date and (iii) the applicable Cash Percentage (as defined in the Indenture); <I>provided</I>
that, notwithstanding the foregoing, such notice (and the related exercise of
Options) shall be effective if given after the Notice Deadline but prior to
5:00 PM New York City time, on the fifth Exchange Business Day of such
“Conversion Reference Period”, in which event the Calculation Agent shall have
the right to adjust the Delivery Obligation as appropriate to reflect the
additional costs (including, but not limited to, hedging mismatches and
market losses) and expenses incurred by Dealer in connection with its hedging
activities (including the unwinding of any hedge position) as a result of
Dealer not having received such notice prior to the Notice Deadline.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Dealer’s Telephone Number <BR>
and Telex and/or Facsimile Number <BR>
and Contact Details for purpose of<BR>
Giving Notice:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=2>To:</FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=2>[__________________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Attn:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Telephone:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________] </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Facsimile:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________] </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>With a copy to:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Attn:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________] </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Telephone:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Facsimile:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________] </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>Settlement Terms:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Settlement Date:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2">
<P><FONT SIZE=2>In respect of an Exercise Date occurring on a
Conversion Date, the settlement date for the Shares or cash to be delivered
under the Relevant Convertible Debentures under the terms of the Indenture; <I>provided</I>
that the Settlement Date will not be prior to the later of (i) the date one
Settlement Cycle following the final day of the “Conversion Reference Period”,
as defined in the Indenture, or (ii) the Exchange Business Day immediately
following the date on which Counterparty gives notice to Dealer of such
Settlement Date prior to 5:00 PM, New York City time.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Delivery Obligation:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2">
<P><FONT SIZE=2>In lieu of the obligations set forth in Sections 8.1
and 9.1 of the Equity Definitions, and subject to “Notice of Exercise” above,
in respect of an Exercise Date </FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>4</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=100%>
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="30%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="62%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>occurring on a Conversion Date, Dealer will deliver
to Counterparty, on the related Settlement Date, the product of the
Applicable Percentage and a number of Shares and/or amount of cash in USD
equal to the aggregate number of Shares or amount of cash, as the case may
be, that Counterparty is obligated to deliver to the holder(s) of the
Relevant Convertible Debentures converted on such Conversion Date pursuant to
Section 10.01(b) of the Indenture (the “<B>Convertible Obligation</B>”); <I>provided</I>
that such obligation shall be determined excluding any Shares or cash that
Counterparty is obligated to deliver to holder(s) of the Relevant Convertible
Debentures as a result of any adjustments to the Conversion Rate pursuant to
Section 10.13 of the Indenture. For the avoidance of doubt, if the
“Conversion Value”, as defined in the Indenture, is less than or equal to USD1,000,
Dealer will have no delivery obligation hereunder.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Notice of Delivery Obligation:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>No later than the Exchange Business Day immediately
following the last day of the “Conversion Reference Period”, as defined in
the Indenture, Counterparty shall give Dealer notice of the final number of
shares and/or the amount of cash comprising the Convertible Obligation (it
being understood, for the avoidance of doubt, that the requirement of
Counterparty to deliver such notice shall not limit Counterparty’s obligations
with respect to Notice of Exercise, as set forth above, in any way).</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Other Applicable Provisions:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To the extent Dealer is obligated to deliver Shares
hereunder, the provisions of Sections 9.1(c), 9.8, 9.9, 9.10, 9.11 and 9.12
of the Equity Definitions will be applicable, except that all references in
such provisions to “Physically-Settled” shall be read as references to “Net
Share Settled”; and <I>provided</I> that the Representation and
Agreement contained in Section 9.11 of the Equity Definitions shall be
modified by excluding any representations therein relating to restrictions,
obligations, limitations or requirements under applicable securities laws as
a result of the fact that Buyer is the issuer of the Shares. “Net Share
Settled” in relation to any Option means that Dealer is obligated to deliver
Shares hereunder.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Restricted Certificated Shares:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Notwithstanding anything to the contrary in the
Equity Definitions, Dealer may, in whole or in part, deliver Shares in
certificated form representing the Number of Shares to be Delivered to
Counterparty in lieu of delivery through the Clearance System. </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>Adjustments:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Method of Adjustment:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Notwithstanding Section 11.2 of the Equity
Definitions, upon the occurrence of any event or </FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>5</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=100%>
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="20%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="62%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>condition set forth in Section 10.06, 10.07, 10.08
or 10.09 of the Indenture, the Calculation Agent shall make the corresponding
adjustment in respect of any one or more of the Number of Options, the Option
Entitlement and any other variable relevant to the exercise, settlement or
payment of the Transaction, to the extent an analogous adjustment is made
under the Indenture.</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN=TOP>
<P><FONT SIZE=2>Extraordinary Events:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Merger Events:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Notwithstanding Section 12.1(b) of the Equity
Definitions, a “Merger Event” means the occurrence of any event or condition
set forth in Section 10.12 of the Indenture.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Tender Offer:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable. Notwithstanding Section 12.1(d) of the
Equity Definitions, a “Tender Offer” means the occurrence of any event or
condition set forth in Section 10.10 of the Indenture.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Consequences of Merger Events and</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Tender Offers:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Notwithstanding Sections 12.2 and 12.3 of the Equity
Definitions, upon the occurrence of a Merger Event or Tender Offer, the
Calculation Agent shall make the corresponding adjustment in respect of any
adjustment under the Indenture to any one or more of the nature of the
Shares, the Number of Options, the Option Entitlement and any other variable
relevant to the exercise, settlement or payment for the Transaction, to the
extent an analogous adjustment is made under the Indenture; <I>provided </I>that
such adjustment shall be made without regard to any adjustment to the
Conversion Rate for the issuance of additional shares as set forth in Section
10.13 of the Indenture; and <I>provided further</I> that the Calculation
Agent may limit or alter any such adjustment referenced in this paragraph so
that the fair value of the Transaction to the Dealer is not reduced as a
result of such adjustment.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Nationalization, Insolvency</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>or Delisting:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Cancellation and Payment (Calculation Agent
Determination); <I>provided</I> that in addition to the provisions of Section
12.6(a)(iii) of the Equity Definitions, it will also constitute a Delisting
if the Exchange is located in the United States and the Shares are not
immediately re-listed, re-traded or re-quoted on any of the New York Stock
Exchange, the American Stock Exchange or the NASDAQ National Market System
(or their respective successors); if the Shares are immediately re-listed,
re-traded or re-quoted on any such exchange or quotation system, such
exchange or quotation system shall thereafter be deemed to be the Exchange.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Additional Disruption Events: </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(a)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Change in Law:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Not Applicable</FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>6</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=100%>
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="62%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(b)</FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Failure to Deliver:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(c)</FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Insolvency Filing:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(d)</FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Hedging Disruption:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Not Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(e)</FONT></P>
</TD>
<TD NOWRAP COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Increased Cost of Hedging:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Not Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=2>Hedging Party:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>For all applicable Additional Disruption Events,
Dealer</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=2>Determining Party:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>For all applicable Additional Disruption Events,
Dealer</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=2>Non-Reliance:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=2>Agreements and Acknowledgments </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=2>Regarding Hedging Activities:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=2>Additional Acknowledgments:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=2>3. <U>Calculation Agent</U>:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Dealer. The Calculation Agent shall deliver, within
five Exchange Business Days of a written request by either party, a written
explanation of any calculation or adjustment made by it, and including, where
applicable, the methodology and data applied.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=2>4. <U>Account Details</U>:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="4" VALIGN=TOP>
<P><FONT SIZE=2>Dealer Payment Instructions:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=2>[______________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>Bank Routing:</FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>[______________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>Account Name:</FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>[______________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>Account No. :</FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>[______________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="6" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="6" VALIGN=TOP>
<P><FONT SIZE=2>Counterparty Payment Instructions:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=2>To be provided by Counterparty.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="7" VALIGN=TOP>
<P><FONT SIZE=2>5. <U>Offices</U>:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="6" VALIGN=TOP>
<P><FONT SIZE=2>The Office of Dealer for the Transaction is:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=2>[__________________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="6" VALIGN=TOP>
<P><FONT SIZE=2>The Office of Counterparty for the Transaction is:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=2>Medtronic, Inc.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=2>710 Medtronic Parkway </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=2>Minneapolis, Minnesota 55432</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="7" VALIGN=TOP>
<P><FONT SIZE=2>6. <U>Notices</U>: For purposes of this
Confirmation:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(a)</FONT></P>
</TD>
<TD COLSPAN="6" VALIGN=TOP>
<P><FONT SIZE=2>Address for notices or communications to
Counterparty:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>To:</FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Medtronic, Inc.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>710 Medtronic Parkway</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Minneapolis, Minnesota 55432</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>Attn:</FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Treasurer</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>Telephone:</FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>(763) 505-2697</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>Facsimile:</FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>(763) 505-2700</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>With a copy to:</FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="5" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>Attn:</FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>General Counsel</FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>7</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=100%>
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="15%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="70%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Facsimile:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(763) 505-2980</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(b)</FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Address for notices or communications to Dealer:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________] </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________] </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Attn:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________] </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Telephone:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________] </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Facsimile:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________] </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>With a copy to:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Attn:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________] </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________] </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Telephone:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________] </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Facsimile:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[__________________] </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="4" VALIGN=TOP>
<P><FONT SIZE=2>7. <U>Representations, Warranties and Agreements</U>:</FONT></P>
</TD>
</TR>
</TABLE>
<P><FONT SIZE=2> (a)
In addition to the representations and warranties in the Agreement and those
contained elsewhere herein, Counterparty represents and warrants to and for the
benefit of, and agrees with, Dealer as follows:</FONT></P>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=100%>
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="95%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>
(i)
On the Trade Date, (A) none of Counterparty and its officers and directors is
aware of any material nonpublic information regarding Counterparty or the
Shares and (B) all reports and other documents filed by Counterparty with the
Securities and Exchange Commission pursuant to the Securities Exchange Act of
1934, as amended (the “<B>Exchange Act</B>”) when considered as a whole
(with the more recent such reports and documents deemed to amend inconsistent
statements contained in any earlier such reports and documents), do not contain
any untrue statement of a material fact or any omission of a material fact
required to be stated therein or necessary to make the statements therein, in
the light of the circumstances in which they were made, not misleading.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>
(ii)
(A) On the Trade Date, the Shares or securities that are convertible into, or
exchangeable or exercisable for Shares, are not, and shall not be, subject to
a “restricted period,” as such term is defined in Regulation M under the
Exchange Act (“<B>Regulation M</B>”) and (B) Counterparty shall not engage in any
“distribution,” as such term is defined in Regulation M, other than a
distribution meeting the requirements of the exceptions set forth in sections
101(b)(10) and 102(b)(7) of Regulation M, until the second Exchange Business
Day immediately following the Trade Date.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>
(iii)
On the Trade Date, neither Counterparty nor any “affiliate” or “affiliated
purchaser” (each as defined in Rule 10b-18 of the Exchange Act (“<B>Rule
10b-18</B>”)) shall directly or indirectly (including, without
limitation, by means of any cash-settled or other derivative instrument)
purchase, offer to purchase, place any bid or limit order that would effect a
purchase of, or commence any tender offer relating to, any Shares (or an
equivalent interest, including a unit of beneficial interest in a trust or
limited partnership or a depository share) or any security convertible into
or exchangeable or exercisable for Shares, except through Dealer.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>
(iv)
Without limiting the generality of Section 13.1 of the Equity Definitions, Counterparty
acknowledges that Dealer is not making any representations or warranties with
respect to the treatment of the Transaction under FASB Statements 149 or 150,
EITF Issue No. 00-19 (or any successor issue statements) or under FASB’s
Liabilities & Equity Project.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>
(v)
Without limiting the generality of Section 3(a)(iii) of the Agreement, the
Transaction will not violate Rule 13e-1 or Rule 13e-4 under the Exchange Act.
</FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>8</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="95%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (vi) Prior
to the Trade Date, Counterparty shall deliver to Dealer a resolution of
Counterparty’s board of directors authorizing the Transaction and such other
certificate or certificates as Dealer shall reasonably request.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (vii) Counterparty
is not entering into this Confirmation to create actual or apparent trading
activity in the Shares (or any security convertible into or exchangeable for
Shares) or to raise or depress or otherwise manipulate the price of the
Shares (or any security convertible into or exchangeable for Shares) or
otherwise in violation of the Exchange Act. </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (viii) Counterparty
is not, and after giving effect to the transactions contemplated hereby will
not be, an “investment company” as such term is defined in the Investment
Company Act of 1940, as amended.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (ix) On
the Trade Date (A) the assets of Counterparty at their fair valuation exceed
the liabilities of Counterparty, including contingent liabilities, (B) the
capital of Counterparty is adequate to conduct the business of Counterparty
and (C) Counterparty has the ability to pay its debts and obligations as such
debts mature and does not intend to, or does not believe that it will, incur
debt beyond its ability to pay as such debts mature.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (x) The
representations and warranties of Counterparty set forth in Section 3 of the
Agreement and Section 1 of the Purchase Agreement are true and correct and
are hereby deemed to be repeated to Dealer as if set forth herein.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (xi) Counterparty
understands that no obligations of Dealer to it hereunder will be entitled to
the benefit of deposit insurance and that such obligations will not be
guaranteed by any affiliate of Dealer or any governmental agency.</FONT></P>
</TD>
</TR>
</TABLE>
<P><FONT SIZE=2> (b) Each
of Dealer and Counterparty agrees and represents that it is an “eligible
contract participant” as defined in Section 1a(12) of the U.S. Commodity
Exchange Act, as amended.</FONT></P>
<P><FONT SIZE=2> (c) Each
of Dealer and Counterparty acknowledges that the offer and sale of the
Transaction to it is intended to be exempt from registration under the
Securities Act of 1933, as amended (the “<B>Securities Act</B>”), by virtue of Section 4(2)
thereof. Accordingly, Counterparty represents and warrants to Dealer that (i)
it has the financial ability to bear the economic risk of its investment in the
Transaction and is able to bear a total loss of its investment and its
investments in and liabilities in respect of the Transaction, which it
understands are not readily marketable, are not disproportionate to its net
worth, and it is able to bear any loss in connection with the Transaction,
including the loss of its entire investment in the Transaction, (ii) it is an
“accredited investor” as that term is defined in Regulation D as promulgated
under the Securities Act, (iii) it is entering into the Transaction for its own
account and without a view to the distribution or resale thereof, (iv) the
assignment, transfer or other disposition of the Transaction has not been and
will not be registered under the Securities Act and is restricted under this
Confirmation, the Securities Act and state securities laws, and (v) its
financial condition is such that it has no need for liquidity with respect to
its investment in the Transaction and no need to dispose of any portion thereof
to satisfy any existing or contemplated undertaking or indebtedness and is
capable of assessing the merits of and understanding (on its own behalf or
through independent professional advice), and understands and accepts, the
terms, conditions and risks of the Transaction.</FONT></P>
<P><FONT SIZE=2> (d) Each
of Dealer and Counterparty agrees and acknowledges (A) that this Confirmation
is (i) a “securities contract,” as such term is defined in Section 741(7) of
Title 11 of the United States Code (the “<B>Bankruptcy Code</B>”), with respect to which
each payment and delivery hereunder is a “settlement payment,” as such term is
defined in Section 741(8) of the Bankruptcy Code, and (ii) a “swap agreement,”
as such term is defined in Section 101(53B) of the Bankruptcy Code, with
respect to which each payment and delivery hereunder is a “transfer,” as such
term is defined in Section 101(54) of the Bankruptcy Code, and (B) that Dealer
is entitled to the protections afforded by, among other sections, Section
362(b)(6), 362(b)(17), 546(e), 546(g), 555 and 560 of the Bankruptcy Code. </FONT></P>
<P><FONT SIZE=2> 8.
<U>Other Provisions</U>:</FONT></P>
<P><FONT SIZE=2> (a) <I>Right to
Extend</I>. Dealer may postpone any Potential Exercise Date or any other
date of valuation or delivery by Dealer, with respect to some or all of the
relevant Options (in which event the Calculation Agent shall make appropriate
adjustments to the Delivery Obligation), if Dealer determines, in</FONT></P>
<P ALIGN=CENTER><FONT SIZE=2>9</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<P><FONT SIZE=2> its reasonable
discretion, that such extension is reasonably necessary to enable Dealer to
effect purchases of Shares in connection with its hedging or settlement
activity hereunder in a manner that would, if Dealer were Counterparty or an
affiliated purchaser of Counterparty, be in compliance with applicable legal,
regulatory or self-regulatory requirements, or with related policies and
procedures applicable to Dealer.</FONT></P>
<P><FONT SIZE=2> (b) <I>Additional
Termination Events</I>. The occurrence of (i) an event of default with
respect to Counterparty under the terms of the Convertible Debentures as set forth
in Section 6.01 of the Indenture that results in an acceleration of the
Convertible Debentures pursuant to the terms of the Indenture, (ii) an
Amendment Event or (iii) a Repayment Event shall be an Additional Termination
Event with respect to which the Transaction is the sole Affected Transaction
and Counterparty is the sole Affected Party, and Dealer shall be the party
entitled to designate an Early Termination Date pursuant to Section 6(b) of the
Agreement; <I>provided</I>
that in the case of a Repayment Event the Transaction shall be subject to
termination only in respect of the number of Convertible Debentures that cease
to be outstanding in connection with or as a result of such Repayment Event.</FONT></P>
<P STYLE=MARGIN-LEFT:5%><FONT SIZE=2>
“<B>Amendment
Event</B>” means that Counterparty amends, modifies, supplements or
waives any term of the Indenture or the Convertible Debentures governing the
principal amount, coupon, maturity, repurchase obligation of Counterparty,
redemption right of Counterparty, any term relating to conversion of the
Convertible Debentures (including changes to the conversion price, conversion
settlement dates or conversion conditions), or any term that would require
consent of the holders of not less than 100% of the principal amount of the
Convertible Debentures to amend, in each case without the prior consent of
Dealer, such consent not to be unreasonably withheld.</FONT></P>
<P STYLE=MARGIN-LEFT:5%><FONT
SIZE=2> “<B>Repayment
Event</B>” means that (A) any Convertible Debentures are repurchased
(whether in connection with or as a result of a change of control, howsoever
defined, or for any other reason) by Counterparty or any of its subsidiaries,
(B) any Convertible Debentures are delivered to Counterparty in exchange for
delivery of any property or assets of Counterparty or any of its subsidiaries (howsoever
described), (C) any principal of any of the Convertible Debentures is repaid
prior to the final maturity date of the Convertible Debentures (whether
following acceleration of the Convertible Debentures or otherwise), or (D) any
Convertible Debentures are exchanged by or for the benefit of the holders
thereof for any other securities of Counterparty or any of its affiliates (or
any other property, or any combination thereof) pursuant to any exchange offer
or similar transaction; <I>provided</I> that, in the case of clause (B)
and clause (D), conversions of the Convertible Debentures pursuant to the terms
of the Indenture as in effect on the date hereof shall not be Repayment Events.</FONT></P>
<P><FONT SIZE=2> (c) <I>Alternative
Calculations and Payment on Early Termination and on Certain Extraordinary
Events</I>. If, subject to Section 8(k) below, Dealer shall owe
Counterparty any amount pursuant to Section 12.2 of the Equity Definitions and
“Consequences of Merger Events” above, or Sections 12.3, 12.6, 12.7 or 12.9 of
the Equity Definitions (except in the event of an Insolvency, a
Nationalization, a Tender Offer or a Merger Event, in each case, in which the
consideration or proceeds to be paid to holders of Shares consists solely of
cash) or pursuant to Section 6(d)(ii) of the Agreement (except in the event of
an Event of Default in which Counterparty is the Defaulting Party or a
Termination Event in which Counterparty is the Affected Party, that resulted
from an event or events within Counterparty’s control) (a “<B>Payment Obligation</B>”),
Counterparty shall have the right, in its sole discretion, to require Dealer to
satisfy any such Payment Obligation by the Share Termination Alternative (as
defined below) by giving irrevocable telephonic notice to Dealer, confirmed in
writing within one Scheduled Trading Day, between the hours of 9:00 A.M. and
4:00 P.M. New York City time on the Merger Date, Tender Offer Date,
Announcement Date or Early Termination Date, as applicable (“<B>Notice of
Share Termination</B>”). Upon such Notice of Share Termination, the
following provisions shall apply on the Scheduled Trading Day immediately
following the Merger Date, the Tender Offer Date, Announcement Date or Early
Termination Date, as applicable:</FONT></P>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="30%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="67%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Share Termination Alternative:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable and means that Dealer shall deliver to
Counterparty the Share Termination Delivery Property on the date on which the
Payment Obligation would otherwise be due pursuant to Section 12.7 or 12.9 of
the Equity Definitions or Section 6(d)(ii) of the Agreement, as applicable (the
“<B>Share
Termination Payment Date</B>”), in satisfaction </FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>10</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="30%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="67%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>of the Payment Obligation.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Share Termination Delivery<BR>Property:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2><BR>A number of Share Termination Delivery Units, as
calculated by the Calculation Agent, equal to the Payment Obligation divided
by the Share Termination Unit Price. The Calculation Agent shall adjust the
Share Termination Delivery Property by replacing any fractional portion of a
security therein with an amount of cash equal to the value of such fractional
security based on the values used to calculate the Share Termination Unit
Price. </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Share Termination Unit Price:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The value of property contained in one Share
Termination Delivery Unit on the date such Share Termination Delivery Units
are to be delivered as Share Termination Delivery Property, as determined by
the Calculation Agent in its discretion by commercially reasonable means and
notified by the Calculation Agent to Dealer at the time of notification of
the Payment Obligation. </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Share Termination Delivery Unit:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>In the case of a Termination Event, Event of Default
or Delisting, one Share or, in the case of an Insolvency, Nationalization,
Merger Event or Tender Offer, a unit consisting of the number or amount of
each type of property received by a holder of one Share (without
consideration of any requirement to pay cash or other consideration in lieu
of fractional amounts of any securities) in such Insolvency, Nationalization,
Merger Event or Tender Offer. If such Insolvency, Nationalization, Merger
Event or Tender Offer involves a choice of consideration to be received by
holders, such holder shall be deemed to have elected to receive the maximum
possible amount of cash.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Failure to Deliver:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Other applicable provisions:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>If Share Termination Alternative is applicable, the
provisions of Sections 9.8, 9.9, 9.10, 9.11 and 9.12 of the Equity
Definitions will be applicable, except that all references in such provisions
to “Physically-Settled” shall be read as references to “settled by Share Termination
Alternative” and all references to “Shares” shall be read as references to
“Share Termination Delivery Units”; and <I>provided</I>
that the Representation and Agreement contained in Section 9.11 of the Equity
Definitions shall be modified by excluding any representations therein
relating to restrictions, obligations, limitations or requirements under
applicable securities laws as a result of the fact that Buyer is the issuer
of any Share Termination Delivery Units (or any part thereof). </FONT></P>
</TD>
</TR>
</TABLE>
<P><FONT SIZE=2> (d) <I>Disposition
of Hedge Shares</I>. Counterparty hereby agrees that if, in the good
faith reasonable judgment of Dealer, the Shares (the “<B>Hedge Shares</B>”) acquired by Dealer for the
purpose of hedging its obligations pursuant to the Transaction cannot be sold
in the U.S. public market by Dealer without registration under the Securities
Act, Counterparty shall, at its election: (i) in order to allow Dealer to sell
the Hedge Shares in a registered offering, make available to Dealer an
effective registration statement under the Securities Act to cover the resale
of such Hedge Shares and (A) enter into an agreement, in form and substance
satisfactory to Dealer, substantially in the form of an underwriting agreement
for a registered offering, (B)
provide accountant’s “comfort” letters in customary form for registered
offerings of equity securities, (C) provide disclosure opinions of nationally
recognized outside counsel to Counterparty reasonably acceptable to Dealer, (D)
provide other customary opinions, certificates and closing documents customary
in form for registered offerings of equity securities and (E) afford Dealer a
reasonable opportunity to conduct a “due diligence” investigation with respect
to Counterparty customary in scope for underwritten offerings of equity securities;
<I>provided,
however</I>, that if Dealer, in its sole reasonable discretion, is not
satisfied with access to due diligence materials, the results of its due
diligence investigation, or the procedures and documentation for the registered
offering referred to above, then clause (ii) or clause (iii) of this Section
8(d) shall apply at the election of Counterparty; (ii) in order to allow</FONT></P>
<P ALIGN=CENTER><FONT SIZE=2>11</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<P><FONT SIZE=2>Dealer to sell the Hedge Shares in a private
placement, enter into a private placement agreement substantially similar to
private placement purchase agreements customary for private placements of
equity securities, in form and substance satisfactory to Dealer, including
customary representations, covenants, blue sky and other governmental filings
and/or registrations, indemnities to Dealer, due diligence rights (for Dealer
or any designated buyer of the Hedge Shares from Dealer), opinions and
certificates and such other documentation as is customary for private
placements agreements, all reasonably acceptable to Dealer (in which case, the
Calculation Agent shall make any adjustments to the terms of the Transaction
that are necessary, in its reasonable judgment, to compensate Dealer for any
discount from the public market price of the Shares incurred on the sale of
Hedge Shares in a private placement); or (iii) purchase the Hedge Shares from
Dealer at the VWAP Price on such Exchange Business Days, and in the amounts,
requested by Dealer. “<B>VWAP Price</B>”
means, on any Exchange Business Day, the per Share volume-weighted average price
as displayed under the heading “Bloomberg VWAP” on Bloomberg page MDT
<equity> VAP (or any successor thereto) in respect of the period from
9:30 a.m. to 4:00 p.m. (New York City time) on such Exchange Business Day (or
if such volume-weighted average price is unavailable, the market value of one
Share on such Exchange Business Day, as determined by the Calculation Agent
using a volume-weighted method).</FONT></P>
<P><FONT SIZE=2> (e) <I>Amendment to Equity
Definitions and the Agreement</I>.
The following amendment shall be made to the Equity Definitions and to the
Agreement: Section 12.6(a)(ii) of the Equity Definitions is hereby amended by
(1) deleting from the fourth line thereof the word “or” after the word
“official” and inserting a comma therefor, and (2) deleting the semi-colon at
the end of subsection (B) thereof and inserting the following words therefor
“or (C) at Dealer’s option, the occurrence of any of the events specified in
Section 5(a)(vii) (1) through (9) of the ISDA Master Agreement with respect to
that Issuer.”</FONT></P>
<P><FONT SIZE=2> (f) <I>Repurchase
Notices</I>. Counterparty shall, on any day on which Counterparty
effects any repurchase of Shares, promptly give Dealer a written notice of such
repurchase (a “<B>Repurchase Notice</B>”) on such day if, following such repurchase,
the Notice Percentage as determined on such day is (i) greater than 6% and (ii)
greater by 0.5% than the Notice Percentage included in the immediately
preceding Repurchase Notice (or, in the case of the first such Repurchase
Notice, greater than the Notice Percentage as of the date hereof). The “<B>Notice
Percentage</B>” as of any day is the fraction, expressed as a
percentage, the numerator of which is the Number of Shares and the denominator
of which is the number of Shares outstanding on such day. In the event that
Counterparty fails to provide Dealer with a Repurchase Notice on the day and in
the manner specified in this Section 8(f) then Counterparty agrees to indemnify
and hold harmless Dealer, its affiliates and their respective directors,
officers, employees, agents and controlling persons (Dealer and each such
person being an “<B>Indemnified Party</B>”) from and against any and all losses,
claims, damages and liabilities (or actions in respect thereof), joint or
several, to which such Indemnified Party may become subject under applicable
securities laws, including without limitation, Section 16 of the Exchange Act,
relating to or arising out of such failure. If for any reason the foregoing
indemnification is unavailable to any Indemnified Party or insufficient to hold
harmless any Indemnified Party, then Counterparty shall contribute, to the
maximum extent permitted by law, to the amount paid or payable by the
Indemnified Party as a result of such loss, claim, damage or liability. In
addition, Counterparty will reimburse any Indemnified Party for all expenses
(including reasonable counsel fees and expenses) as they are incurred (after
notice to Counterparty) in connection with the investigation of, preparation
for or defense or settlement of any pending or threatened claim or any action,
suit or proceeding arising therefrom, whether or not such Indemnified Party is
a party thereto and whether or not such claim, action, suit or proceeding is
initiated or brought by or on behalf of Counterparty. This indemnity shall
survive the completion of the Transaction contemplated by this Confirmation and
any assignment and delegation of the Transaction made pursuant to this
Confirmation or the Agreement shall inure to the benefit of any permitted
assignee of Dealer. </FONT></P>
<P><FONT SIZE=2> (g) <I>Transfer and
Assignment</I>. Dealer may transfer or assign its rights and obligations
hereunder and under the Agreement, in whole or in part, to any of its
affiliates without the consent of Counterparty. If at any time at which the
Equity Percentage exceeds 9.5%, Dealer, in its discretion, is unable to effect
a transfer or assignment to a third party after its commercially reasonable
efforts on pricing terms reasonably acceptable to Dealer such that the Equity
Percentage is reduced to 9.5% or less, Dealer may designate any Scheduled
Trading Day as an Early Termination Date with respect to a portion (the</FONT></P>
<P ALIGN=CENTER><FONT SIZE=2>12</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<P><FONT SIZE=2> “<B>Terminated
Portion</B>”) of the Transaction, such that the Equity Percentage
following such partial termination will be equal to or less than 9.5%. In the
event that Dealer so designates an Early Termination Date with respect to a
portion of the Transaction, a payment or delivery shall be made pursuant to
Section 6 of the Agreement and Section 8(c) of this Confirmation as if (i) an
Early Termination Date had been designated in respect of a Transaction having
terms identical to the Terminated Portion of the Transaction, (ii) Counterparty
shall be the sole Affected Party with respect to such partial termination and
(iii) such portion of the Transaction shall be the only Terminated Transaction.
The “<B>Equity
Percentage</B>” as of any day is the fraction, expressed as a
percentage, (A) the numerator of which is the Number of Shares and (B) the
denominator of which is the number of Shares outstanding on such day.
Counterparty may transfer or assign its rights and obligations hereunder and
under the Agreement, in whole or in part, to any party with the consent of
Dealer, such consent not to be unreasonably withheld. </FONT></P>
<P><FONT SIZE=2> (h) <I>Staggered Settlement</I>.
If the Staggered
Settlement Equity Percentage as of any Exchange Business Day during the
relevant “Conversion Reference Period”, as defined in the Indenture, is greater
than 4.5%, Dealer may, by notice to Counterparty prior to any Settlement Date
(a “<B>Nominal Settlement Date</B>”),
elect to deliver the Shares on two or more dates (each, a “<B>Staggered Settlement Date</B>”) or at two
or
more times on the Nominal Settlement Date as follows:</FONT></P>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="95%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (i) in
such notice, Dealer will specify to Counterparty the related Staggered
Settlement Dates (each of which will be on or prior to such Nominal
Settlement Date, but not prior to the beginning of such “Conversion Reference
Period”) or delivery times and how it will allocate the Shares it is required
to deliver under “Delivery Obligation” (above) among the Staggered Settlement
Dates or delivery times; and</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (ii) the
aggregate number of Shares that Dealer will deliver to Counterparty hereunder
on all such Staggered Settlement Dates and delivery times will equal the
number of Shares that Dealer would otherwise be required to deliver on such
Nominal Settlement Date.</FONT></P>
</TD>
</TR>
</TABLE>
<P><FONT SIZE=2> The
“<B>Staggered
Settlement Equity Percentage</B>” as of any day is the fraction,
expressed as a percentage, (A) the numerator of which is the sum of the number
of Shares that Dealer or any of its affiliates beneficially own (within the
meaning of Section 13 of the Exchange Act) on such day, other than any Shares
so owned as a hedge of the Transaction, and the Number of Shares and (B) the
denominator of which is the number of Shares outstanding on such day.</FONT></P>
<P><FONT SIZE=2> (i) <I>Disclosure</I>.
Effective from the date of commencement of discussions concerning the
Transaction, Counterparty and each of its employees, representatives, or other
agents may disclose to any and all persons, without limitation of any kind, the
tax treatment and tax structure of the Transaction and all materials of any
kind (including opinions or other tax analyses) that are provided to
Counterparty relating to such tax treatment and tax structure.</FONT></P>
<P><FONT SIZE=2> (j) <I>Designation
by Dealer</I>. Notwithstanding any other provision in this Confirmation
to the contrary requiring or allowing Dealer to purchase, sell, receive or
deliver any Shares or other securities to or from Counterparty, Dealer may
designate any of its affiliates to purchase, sell, receive or deliver such
shares or other securities and otherwise to perform Dealer obligations in
respect of the Transaction and any such designee may assume such obligations.
Dealer shall be discharged of its obligations to Counterparty to the extent of
any such performance.</FONT></P>
<P><FONT SIZE=2> (k) <I>Netting and
Set-off</I>. </FONT></P>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="95%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (i) If
on any date cash would otherwise be payable or Shares or other property would
otherwise be deliverable hereunder or pursuant to the Agreement or pursuant
to any other agreement between the parties by Counterparty to Dealer and cash
would otherwise be payable or Shares or other property would otherwise be
deliverable hereunder or pursuant to the Agreement or pursuant to any other
agreement between the parties by Dealer to Counterparty and the type of
property required to be paid or delivered by each such party on such date is
the same, then, on such date, each such party’s obligation to make such
payment or delivery will be automatically satisfied and discharged and, if
the aggregate amount that would otherwise have been payable or deliverable by
one such party exceeds the aggregate amount that would otherwise have been
payable or deliverable by the other such party, replaced by an obligation of
the party by whom the</FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>13</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="95%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>larger aggregate amount would have been payable or
deliverable to pay or deliver to the other party the excess of the larger
aggregate amount over the smaller aggregate amount.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (ii) In
addition to and without limiting any rights of set-off that a party hereto
may have as a matter of law, pursuant to contract or otherwise, upon the
occurrence of an Early Termination Date, Dealer shall have the right to
terminate, liquidate and otherwise close out the Transaction and to set off
any obligation or right that Dealer or any affiliate of Dealer may have to or
against Counterparty hereunder or under the Agreement against any right or
obligation Dealer or any of its affiliates may have against or to
Counterparty, including without limitation any right to receive a payment or
delivery pursuant to any provision of the Agreement or hereunder. In the case
of a set-off of any obligation to release, deliver or pay assets against any
right to receive assets of the same type, such obligation and right shall be
set off in kind. In the case of a set-off of any obligation to release,
deliver or pay assets against any right to receive assets of any other type,
the value of each of such obligation and such right shall be determined by
the Calculation Agent and the result of such set-off shall be that the net
obligor shall pay or deliver to the other party an amount of cash or assets,
at the net obligor’s option, with a value (determined, in the case of a
delivery of assets, by the Calculation Agent) equal to that of the net
obligation. In determining the value of any obligation to release or deliver
Shares or any right to receive Shares, the value at any time of such
obligation or right shall be determined by reference to the market value of
the Shares at such time, as determined by the Calculation Agent. If an
obligation or right is unascertained at the time of any such set-off, the
Calculation Agent may in good faith estimate the amount or value of such
obligation or right, in which case set-off will be effected in respect of
that estimate, and the relevant party shall account to the other party at the
time such obligation or right is ascertained.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (iii) Notwithstanding
any provision of the Agreement (including without limitation Section 6(f) thereof)
and this Confirmation (including without limitation this Section 8(k)) or any
other agreement between the parties to the contrary, (A) Counterparty shall
not net or set off its obligations under the Transaction, if any, against its
rights against Dealer under any other transaction or instrument; (B) Dealer
may net and set off any rights of Dealer against Counterparty arising under
the Transaction only against obligations of Dealer to Counterparty arising
under any transaction or instrument if such transaction or instrument does
not convey rights to Dealer senior to the claims of common stockholders in
the event of Counterparty’s bankruptcy; and (C) in the event of
Counterparty’s bankruptcy, Dealer waives any and all rights it may have to
set-off in respect of the Transaction, whether arising under agreement,
applicable law or otherwise. Dealer will give notice to Counterparty of any
netting or set off effected under this provision.</FONT></P>
</TD>
</TR>
</TABLE>
<P><FONT SIZE=2> (l) <I>Equity
Rights</I>. Dealer acknowledges and agrees that this Confirmation is not
intended to convey to it rights with respect to the Transaction that are senior
to the claims of common stockholders in the event of Counterparty’s bankruptcy.
For the avoidance of doubt, the parties agree that the preceding sentence shall
not apply at any time other than during Counterparty’s bankruptcy to any claim
arising as a result of a breach by Counterparty of any of its obligations under
this Confirmation or the Agreement. </FONT></P>
<P><FONT SIZE=2> (m) <I>Early Unwind</I>.
In the event the sale by Counterparty of the Convertible Debentures is not
consummated with the initial purchasers pursuant to the Purchase Agreement for
any reason by the close of business in New York on April 18, 2006 (or such
later date as agreed upon by the parties, which in no event shall be later than
April 27, 2006) (April 18, 2006 or such later date being the “<B>Early Unwind
Date</B>”), the Transaction shall automatically terminate (the “<B>Early Unwind</B>”),
on the Early Unwind Date and (i) the Transaction and all of the respective rights
and obligations of Dealer and Counterparty thereunder shall be cancelled and
terminated and (ii) Counterparty shall pay to Dealer, other than in cases
involving a breach of the Purchase Agreement by the initial purchasers, an
amount in cash equal to the aggregate amount of costs and expenses relating to
the unwinding of Dealer's hedging activities in respect of the Transaction
(including market losses incurred in reselling any Shares purchased by Dealer
or its affiliates in connection with such hedging activities). Following such
termination, cancellation and payment, each party shall be released and
discharged by the other party from and agrees not to make any claim against the
other party with respect to any obligations or liabilities of either party arising
out of and to be performed in connection with the Transaction either prior to
or after the Early Unwind Date. Dealer and Counterparty represent and
acknowledge to the other that upon an Early Unwind and following the payment
referred to above, all obligations with respect to the Transaction shall be
deemed fully and finally discharged.</FONT></P>
<P ALIGN=CENTER><FONT SIZE=2>14</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<P><FONT SIZE=2> (n) <I>Waiver of
Trial by Jury</I>. <B>EACH OF COUNTERPARTY AND DEALER HEREBY IRREVOCABLY
WAIVES (ON ITS OWN BEHALF AND, TO THE EXTENT PERMITTED BY APPLICABLE LAW, ON
BEHALF OF ITS STOCKHOLDERS) ALL RIGHT TO TRIAL BY JURY IN ANY ACTION,
PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE)
ARISING OUT OF OR RELATING TO THE TRANSACTION OR THE ACTIONS OF DEALER OR ITS
AFFILIATES IN THE NEGOTIATION, PERFORMANCE OR ENFORCEMENT HEREOF</B>.</FONT></P>
<P><FONT SIZE=2> (o) <I>Governing
Law</I>. <B>THIS CONFIRMATION SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.
THE PARTIES HERETO IRREVOCABLY SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE
COURTS OF THE STATE OF NEW YORK AND THE UNITED STATES COURT FOR THE SOUTHERN
DISTRICT OF NEW YORK IN CONNECTION WITH ALL MATTERS RELATING HERETO AND WAIVE
ANY OBJECTION TO THE LAYING OF VENUE IN, AND ANY CLAIM OF INCONVENIENT FORUM
WITH RESPECT TO, THESE COURTS</B>.</FONT></P>
<P ALIGN=CENTER><FONT SIZE=2>15</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<P><FONT SIZE=2> Counterparty
hereby agrees (a) to check this Confirmation carefully and immediately
upon receipt so that errors or discrepancies can be promptly identified and
rectified and (b) to confirm that the foregoing (in the exact form
provided by Dealer) correctly sets forth the terms of the agreement between
Dealer and Counterparty with respect to the Transaction, by manually signing
this Confirmation or this page hereof as evidence of agreement to such terms
and providing the other information requested herein and immediately returning
an executed copy to Equity Derivatives Documentation Department, Facsimile No.
(212) 428-1980/83.</FONT></P>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="50%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="4%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="46%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>Yours faithfully,<BR></FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<HR SIZE=1 WIDTH="75%" NOSHADE align=left>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>By:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<HR SIZE=1 WIDTH="92%" NOSHADE ALIGN=RIGHT>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Name:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Title:</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="4%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="46%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="50%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>Agreed and Accepted By:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>MEDTRONIC, INC.<BR><BR></FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>By:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="72%" NOSHADE ALIGN=left>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP colspan=2>
<P><FONT SIZE=2> Name:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP colspan=2>
<P><FONT SIZE=2> Title:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>16</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<P ALIGN=CENTER><FONT SIZE=2><U>Schedule to Exhibit 10.27</U></FONT></P>
<P><FONT SIZE=2> On
April 12, 2006, the Company entered into six convertible bond hedge
transactions (the “Convertible Bond Hedge Transactions”). A confirmation was
produced for each transaction. The confirmations are substantially identical to
the form of hedge confirmation appearing herein as Exhibit 10.27 (the “Form of
Hedge Confirmation”). However, the six actual confirmations differ from the
Form of Hedge Confirmation as follows: </FONT></P>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="16%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1><B>Issuer:</B></FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1><B>Deutsche Bank</B></FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1><B>Deutsche Bank</B></FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1><B>UBS AG</B></FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1><B>Merrill Lynch</B></FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1><B>Merrill Lynch</B></FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1><B>Goldman Sachs</B></FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 1,
the following<BR>
names and addresses replace<BR>
the blank that appears<BR>
opposite the heading “From:”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Deutsche
Bank<BR>
AG, London<BR>
Branch<BR>
<BR>
Winchester house<BR>
1 Great Winchester St.<BR>
London EC2N<BR>
2DB<BR>
<BR>
Telephone: +44<BR>20 7545 8000<BR>
<BR>
c/o Deutsche Bank AG,<BR>
New York<BR>
Branch<BR>
60 Wall Street<BR>
New York, NY<BR>
10005<BR>
<BR>
Telephone: (212)<BR>
250-2500<BR>
<BR>
Facsimile: (212)<BR>
797-9365</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Deutsche
Bank<BR>
AG, London<BR>
Branch<BR>
<BR>
Winchester house<BR>
1 Great Winchester St.<BR>
London EC2N<BR>
2DB<BR>
<BR>
Telephone: +44<BR>20 7545 8000<BR>
<BR>
c/o Deutsche Bank AG,<BR>
New York<BR>
Branch<BR>
60 Wall Street<BR>
New York, NY<BR>
10005<BR>
<BR>
Telephone: (212)<BR>
250-2500<BR>
<BR>
Facsimile: (212)<BR>
797-9365</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>UBS AG,
London<BR>
Branch<BR>
<BR>
c/o UBS Securities LLC<BR>
299 Park Avenue<BR>
New York, NY<BR>
10171<BR>
Attn: Adam<BR>
Frieman<BR>
<BR>
Telephone: (212)<BR>
821-2100<BR>
<BR>
Facsimile: (212)<BR>
821-4610</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Merrill
Lynch<BR>
International<BR>
<BR>
Merrill Lynch<BR>
Financial Center<BR>
2 King Edward<BR>
Street<BR>
London EC1A<BR>
1HQ<BR>
Attn: Manager,<BR>
Fixed Income Settlements<BR>
<BR>
Telephone: +44<BR>207 995 3769<BR>
<BR>
Facsimile: +44<BR>
207 995 2004</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Merrill Lynch<BR>
International<BR>
<BR>
Merrill Lynch Financial Center<BR>
2 King Edward<BR>
Street London EC1A <BR>
1HQ<BR>
Attn: Manager,<BR>Fixed Income<BR>
Settlements<BR>
<BR>
Telephone: +44<BR>
207 995 3769<BR>
<BR>
Facsimile: +44<BR>
207 995 2004</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Goldman,
Sachs & Co.<BR><BR>
85 Broad Street<BR>
New York, NY<BR>
10004<BR>
Attn: Tracey<BR>
McCabe<BR>
Telephone: (212)<BR>
357-6076<BR>
<BR>
Facsimile: (212)<BR>
428-3778</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 1,
the following numbers replace the blank after the phrase “Reference or
Transaction Number.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(Internal<BR>
Reference: 104927)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(Internal<BR>
Reference: 104930)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(UBS
Reference<BR>
Number: 1806955)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(Transaction<BR>
Reference Number: 0683242)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(Transaction<BR>
Reference Number: 0683244)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(Transaction<BR>
Reference Number: FDB1620971367)</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="16%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 1,
in the first paragraph, the following
names replace the blank
before the word “Dealer.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Deutsche
Bank AG acting through its London branch (“<B>Dealer</B>”), with
Deutsche Bank
AG, New York
Branch acting as its
agent</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Deutsche
Bank AG
acting through its
London branch
(“<B>Dealer</B>”), with
Deutsche Bank
AG, New York
Branch acting as its
agent,</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>UBS AG, London
Branch (“<B>Dealer</B>”)
represented by
UBS Securities
LLC (“<B>Agent</B>”) as
its agent,</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Merrill
Lynch International (“<B>Dealer</B>”)
represented by
Merrill Lynch,
Pierce, Fenner &
Smith Incorporated
(“<B>Agent</B>”) as its
agent,</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Merrill
Lynch International
(“<B>Dealer</B>”)
represented by
Merrill Lynch,
Pierce, Fenner &
Smith Incorporated
(“<B>Agent</B>”) as its agent,</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Goldman,
Sachs & Co. (“<B>Dealer</B>”)</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Pages 1,
the following paragraphs appear after the first paragraph of Section 1.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>DEUTSCHE
BANK AG IS NOT REGISTERED AS A BROKER DEALER UNDER THE U.S. SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. DEUTSCHE BANK AG, NEW YORK BRANCH HAS ACTED
SOLELY AS AGENT IN CONNECTION WITH THE TRANSACTION AND HAS NO OBLIGATION, BY
WAY OF ISSUANCE, ENDORSEMENT, GUARANTEE OR OTHERWISE WITH RESPECT</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>DEUTSCHE
BANK AG IS NOT REGISTERED AS A BROKER DEALER UNDER THE U.S. SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. DEUTSCHE BANK AG, NEW YORK BRANCH HAS ACTED
SOLELY AS AGENT IN CONNECTION WITH THE TRANSACTION AND HAS NO OBLIGATION, BY
WAY OF ISSUANCE, ENDORSEMENT, GUARANTEE OR OTHERWISE WITH RESPECT</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(none)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(none)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(none)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(none)</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="16%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>TO THE
PERFORMANCE OF EITHER PARTY UNDER THE TRANSACTION. DEUTSCHE BANK AG, LONDON
BRANCH IS NOT A MEMBER OF THE SECURITIES INVESTOR PROTECTION CORPORATION
(SIPC).</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>TO THE
PERFORMANCE OF EITHER PARTY UNDER THE TRANSACTION. DEUTSCHE BANK AG, LONDON
BRANCH IS NOT A MEMBER OF THE SECURITIES INVESTOR PROTECTION CORPORATION
(SIPC).</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 2 and Page 3,
in Section 2, the following amounts replace the blank that appears opposite
the heading “Applicable Percentage.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]%</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]%</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]%</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]%</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]%</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]%</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 3,
in Section 2, the following amounts replace the blank that appears opposite
the heading “Premium.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 3,
in Section 2, the following amounts replace the blank that appears opposite
the heading “Premium per Option.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 3,
in Section 2, in the paragraph entitled “Procedures for Exercise,” the
following dates appear opposite the heading </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP nowrap>
<P><FONT SIZE=2>April 15, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP nowrap>
<P><FONT SIZE=2>April 15, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP nowrap>
<P><FONT SIZE=2>April 15, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP nowrap>
<P><FONT SIZE=2>April 15, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP nowrap>
<P><FONT SIZE=2>April 15, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP nowrap>
<P><FONT SIZE=2>April 15, 2013</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="16%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>“Expiration
Date:”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 4,
in Section 2, in the paragraph entitled “Procedures for Exercise,” the
following addresses replace the blank that appears opposite the heading
“Dealer’s Telephone Number and Telex and/or Facsimile Number and Contact
Details for purpose of Giving Notice.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To: Deutsche
Bank AG<BR>London<BR>
<BR>
c/o Deutsche<BR>Bank AG,<BR>
New York Branch<BR>
60 Wall Street<BR>
New York, NY<BR>
10005<BR><BR>
Attn: Stanley<BR>Rowe or Lee<BR>
Frankenfield<BR>
<BR>
Telephone: (212)<BR>
250-4942 or (212)<BR>
250-4980<BR>
<BR>
Facsimile: (212)<BR>
797-9365</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To: Deutsche<BR>
Bank AG<BR>London<BR>
<BR>
c/o Deutsche<BR>Bank AG,<BR>
New York Branch<BR>
60 Wall Street<BR>
New York, NY<BR>
10005<BR><BR>
Attn: Stanley<BR>Rowe or Lee<BR>
Frankenfield<BR>
<BR>
Telephone: (212)<BR>
250-4942 or (212)<BR>
250-4980<BR>
<BR>
Facsimile: (212)<BR>
797-9365</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To: UBS AG,<BR>
London Branch<BR><BR>
c/o UBS Securities<BR>
LLC<BR>
299 Park Avenue<BR>
New York, NY<BR>
10171<BR>
Attn: Adam<BR>
Frieman <BR>
<BR>
Telephone: (212)<BR>
821-2100<BR>
<BR>
Facsimile: (212)<BR>
821-4610</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To: Merrill
Lynch<BR>
International<BR>
<BR>
Merrill Lynch<BR>
Financial Center<BR>
2 King Edward<BR>
Street<BR>
London EC1A<BR>
1HQ<BR>
Attn: Manager,<BR>
Fixed Income<BR>
Settlements<BR>
<BR>
Telephone:<BR> 44 207 995 3769<BR>
<BR>
Facsimile:<BR> 44 207<BR>
995 2004</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To: Merrill
Lynch<BR>
International<BR>
<BR>
Merrill Lynch<BR>
Financial Center<BR>
2 King Edward<BR>
Street<BR>
London EC1A<BR>
1HQ<BR>
Attn: Manager,<BR>
Fixed Income<BR>
Settlements<BR><BR>
Telephone:<BR> + 44
207 995 3769<BR>
<BR>
Facsimile:<BR>+44
207 995 2004</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To: Goldman<BR>
Sachs & Co.<BR>
<BR>
One New York<BR>
Plaza<BR>
New York, NY<BR>
10004<BR>
Attn: Equity<BR>
Operations:<BR>
Options and<BR>
Derivatives<BR>
<BR>
Telephone: (212)<BR>
902-8996<BR>
<BR>
Facsimile: (212)<BR>
902-0112<BR><BR>
With a copy to:<BR>
<BR>
Attn: Tracey<BR>
McCabe<BR>
Equity Capital<BR>
Markets<BR>
<BR>
Telephone: (212)<BR>
357-0428<BR><BR>
Facsimile: (212)<BR>
902-3000</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 7,
in Section 4, entitled “Account Details,” the following information replaces
the blank therein.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Dealer
Payment Instructions for Deutsche Bank AG, New York
Branch acting as
agent are as
follows:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Dealer
Payment
Instructions for
Deutsche Bank
AG, New York
Branch acting as
agent are as
follows:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Dealer
Payment
Instructions:<BR>
<BR>
UBS AG Stamford<BR>
<BR>
SWIFT:<BR>
UBSWUS33XXX</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Dealer
Payment<BR>
Instructions:<BR>
<BR>
Chase Manhattan<BR>
Bank, New York <BR>
<BR>
Bank Routing:<BR>
021-000-021</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Dealer
Payment<BR>
Instructions:<BR>
<BR>
Chase Manhattan<BR>
Bank, New York<BR>
<BR>
Bank Routing: 021-<BR>
000-021</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Dealer
Payment<BR>
Instructions:<BR>
<BR>
Chase Manhattan<BR>
Bank New York<BR>
<BR>
Bank Routing:<BR>
021-</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="16%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Bank of New
York<BR>
<BR>
Bank Routing:<BR>
021-000-018<BR>
<BR>
Account Name: DBO <BR>
<BR>
Account No. : [**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Bank of New
York<BR>
<BR>
Bank Routing:<BR>
021-000-018<BR>
<BR>
Account Name: DBO<BR>
<BR>
Account No. : [**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Bank
Routing:<BR>
026-007-993<BR>
<BR>
Account Name:<BR>
UBS AG, London<BR>
Branch <BR>
<BR>
Account No. : [**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Account
Name:<BR>
ML Equity<BR>
Derivatives<BR>
<BR>
Account No. : [**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Account
Name:<BR>
ML Equity<BR>
Derivatives<BR>
Account No. : [**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>000021<BR>
<BR>
Account Name:<BR>
Goldman,<BR>
Sachs & Co.<BR>
<BR>
Account No. : [**]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 7,
in Section 5, entitled “Offices,” the following addresses replace the blank
below the heading “The Officer of the Dealer for the Transaction is:”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The Office
of<BR>
Dealer for the<BR>
Transaction is:<BR>
<BR>
Deutsche Bank<BR>
AG, London<BR>
Branch<BR>
<BR>
1 Great Winchester St.<BR>
Winchester house <BR>
London EC2N<BR>
2DB</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The Office
of<BR>
Dealer for the<BR>
Transaction is:<BR>
<BR>
Deutsche Bank<BR>
AG, London Branch<BR>
<BR>
1 Great Winchester<BR>
St.<BR>
Winchester house<BR>
London EC2N<BR>
2DB</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The Office
of<BR>
Dealer for the<BR>
Transaction is:<BR>
<BR>
UBS AG<BR>
100 Liverpool<BR>
Street<BR>
London EC2M<BR>
2RH<BR>
United Kingdom<BR><BR>
Telephone:<BR>+44 207<BR>568 0687<BR><BR>
Facsimile:<BR>+44 207<BR>568 9895/6</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The Office
of<BR>
Dealer for the<BR>
Transaction is:<BR>
<BR>
Merrill Lynch<BR>
Financial Center<BR>
2 King Edward<BR>
Street<BR>
London EC1A<BR>
1HQ <BR><BR>
Telephone: 44<BR>207 995 3769<BR>
<BR>
Facsimile: 44<BR>207 995 2004</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The Office
of<BR>
Dealer for the<BR>
Transaction is:<BR>
<BR>
Merrill Lynch<BR>
Financial Center<BR>
2 King Edward<BR>
Street<BR>
London EC1A<BR>
1HQ<BR><BR>
Telephone:<BR>+44 207<BR>
995 3769<BR><BR>
Facsimile: +44<BR>
207 995 2004</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The Office
of<BR>
Dealer for the<BR>
Transaction is:<BR>
<BR>
One New York<BR>
Plaza, New York,<BR>
New York 10004</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 8,
in Section 6, entitled “Notices,” the following addresses replace the blank
below the heading “(b) Address for notices or communications to Dealer:”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To: Deutsche<BR>
Bank AG<BR>
London<BR><BR>
c/o Deutsche<BR>Bank AG,<BR>
New York<BR>
Branch<BR>
<BR>
60 Wall Street<BR>
New York, NY<BR>
10005<BR>
Attn: Stanley Rowe<BR>
or Lee<BR>
Frankenfield</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To: Deutsche<BR>
Bank AG<BR>
London<BR><BR>
c/o Deutsche<BR>Bank AG, <BR>
New York<BR>
Branch<BR>
60 Wall Street<BR>
New York, NY<BR>
10005<BR>
Attn: Stanley Rowe<BR>
or Lee<BR>
Frankenfield</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To: UBS AG,<BR>
London Branch<BR><BR>
c/o UBS Securities<BR>
LLC<BR>
299 Park Avenue<BR>
New York, NY<BR>
10171<BR>
Attn: Adam<BR>
Frieman<BR><BR>
Telephone: (212)<BR>
821-2100 </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To: Merrill
Lynch<BR>
International<BR><BR>
Merrill Lynch<BR>
Financial Center<BR>
2 King Edward<BR>
Street
London EC1A<BR>
1HQ<BR>
Attn: Manager,<BR>
Fixed Income<BR>
Settlements</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To: Merrill
Lynch<BR>
International<BR><BR>
Merrill Lynch<BR>
Financial Center<BR>
2 King Edward<BR>
Street<BR>
London EC1A<BR>
1HQ<BR>
Attn: Manager,<BR>
Fixed Income<BR>
Settlements</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To: Goldman,<BR>
Sachs & Co.<BR><BR>
85 Broad Street<BR>
New York, NY<BR>
10004<BR>
Attn: Equity<BR>
Operations:<BR>
Options and<BR>
Derivatives<BR><BR>
Telephone: (212)<BR>
902-8996</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="16%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Telephone:
(212)<BR>
250-4942 or (212)<BR>
250-4980<BR>
<BR>
Facsimile: (212)<BR>
797-9365</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Telephone:
(212)<BR>
250-4942 or (212)<BR>
250-4980<BR>
<BR>
Facsimile: (212)<BR>
797-9365</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Facsimile: (212)<BR>
821-4610<BR>
<BR>
With a copy to:<BR>
<BR>
To: Equities Legal<BR>
Department<BR>
<BR>
677 Washington<BR>
Boulevard<BR>
Stamford, CT<BR>
06901<BR>
Attn: David Kelly<BR>
and Gordon<BR>
Kiesling<BR>
<BR>
Telephone: (203)<BR>
719-0268<BR>
<BR>
Facsimile:(203)<BR>
719-5627<BR>
<BR>
and:<BR>
<BR>
To: Equities<BR>
Volatility Trading<BR>
<BR>
677 Washington<BR>
Boulevard<BR>
Stamford, CT<BR>
06901<BR>
Attn: Namuk Cho<BR>
and Bennett<BR>
Lieberman<BR>
<BR>
Telephone: (203)<BR>
719-7330<BR>
<BR>
Facsimile: (203)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Telephone:<BR>
+44 207<BR>995 3769<BR>
<BR>
Facsimile: +44<BR>
207 995 2004</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Telephone:<BR>+44 207<BR>
995 3769<BR>
<BR>
Facsimile: +44<BR>
207 995 2004</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Facsimile:
(212)<BR>
902-0112<BR>
<BR>
With a copy to:<BR>
Attn: Tracey<BR>
McCabe<BR>
Equity Capital<BR>
Markets<BR>
<BR>
Telephone: (212)<BR>
357-0428<BR>
<BR>
Facsimile: (212)<BR>
902-3000</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="16%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>719-7910</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 15,
in Section 8, entitled “Other Provisions,” the following paragraphs appear
after the paragraph entitled “(o) <I>Governing Law</I>.” </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE="2"> (p)<BR>
<I>Method of Delivery</I>. Whenever delivery of
funds or other assets is required hereunder by or to Counterparty, such
delivery shall be effected through Deutsche Bank AG, New York Branch (“<B>DBNY</B>”).
In addition, all notices, demands and communications of any kind
relating to the Transaction between Dealer and Counterparty shall be
transmitted exclusively through DBNY. </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE="2">(p)<BR>
<I>Method of Delivery</I>. Whenever delivery of
funds or other assets is required hereunder by or to Counterparty, such
delivery shall be effected through Deutsche Bank AG, New York Branch (“<B>DBNY</B>”).
In addition, all notices, demands and communications of any kind
relating to the Transaction between Dealer and Counterparty shall be transmitted
exclusively through DBNY. </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(p)<BR>
<I>Role of Agent</I>. Each party agrees and
acknowledges that Agent is acting as agent for both parties but does not
guarantee the performance of either party and neither Dealer nor Counterparty
shall contact the other with respect to any matter relating to the
Transaction without the direct involvement of Agent; (ii) Agent is not a
member of the Securities Investor Protection Corporation; (iii) Agent, Dealer
and Counterparty each hereby acknowledges that any transactions by Dealer or
Agent in the Shares will be undertaken by Dealer or Agent, as the case may,
as principal for its own account; and (iv) all of the actions to be taken by
Dealer and </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(Blank)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(Blank)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(Blank)</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="15%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Agent in
connection with the Transaction, including but not limited to any exercise of
any rights with respect to the Options, shall be taken by Dealer or Agent
independently and without any advance or subsequent consultation with
Counterparty; and (iv) Agent is hereby authorized to act as agent for
Counterparty only to the extent required to satisfy the requirements of Rule
15a-6 under the Exchange Act in respect of the Options described hereunder.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 16
the following names replace the blank below the phrase “Yours faithfully.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>DEUTSCHE BANK AG LONDON<BR>
<BR>
and<BR>
<BR>
DEUTSCHE BANK AG NEW YORK as agent</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>DEUTSCHE BANK AG LONDON<BR>
<BR>
and<BR>
<BR>
DEUTSCHE BANK AG NEW YORK as agent</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>UBS AG, LONDON BRANCH<BR>
<BR>
and<BR>
<BR>
UBS SECURITIES LLC, as agent</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>MERRILL LYNCH INTERNATIONAL <BR>
and<BR>
<BR>MERRILL LYNCH, PIERCE,
FENNER & SMITH</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>MERRILL LYNCH INTERNATIONAL<BR>
<BR>
and<BR>
<BR>MERRILL LYNCH, PIERCE,
FENNER & SMITH</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>GOLDMAN, SACHS & CO.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P></TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>INCORPORATED,
as agent</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>INCORPORATED,
as agent</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=4>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>19
<FILENAME>medtronic062430s1_ex10-28.htm
<DESCRIPTION>FORM OF WARRANTS ISSUED ON APRIL 12, 2006
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 10.28 to Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR><BR>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=100%>
<TR style="font-size:1px">
<TD WIDTH="15%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="68%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="13%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD ROWSPAN="3" STYLE="BORDER:SOLID BLACK 1PX; PADDING:3PT">
<P ALIGN=CENTER><FONT SIZE=2>Confidential Materials
omitted and filed separately with the<BR>
Securities and Exchange Commission.
Asterisks denote omissions.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD ROWSPAN="2">
<P ALIGN=CENTER><FONT SIZE="3"><B>Exhibit 10.28</B> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="90%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>April 12, 2006</FONT></P></TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Medtronic, Inc.<BR>
710 Medtronic Parkway <BR>
Minneapolis, Minnesota 55432<BR>
Attn: Treasurer<BR>
Telephone: (763) 505-2697<BR>
Facsimile: (763) 505-2700</FONT></P></TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>With a copy to:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Attn: General Counsel<BR>
Facsimile: (763) 505-2980</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>From:</FONT></P>
</TD>
<TD VALIGN=TOP>
<FONT SIZE=2>[_________________]<BR>[_________________]<BR>[_________________]<BR>Attn: [_________________]<BR>
Telephone: [_________________]<BR>Facsimile: [_________________]
</FONT></TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2><B>Re:</B></FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2><B>Issuer
Warrant Transaction</B><BR>
<B>(Transaction
Reference Number: </B>_________________<B>)</B></FONT></P>
</TD>
</TR>
</TABLE>
<P><FONT SIZE=2>Ladies and Gentlemen:</FONT></P>
<P><FONT SIZE=2> The
purpose of this communication (this “<B>Confirmation</B>”) is to set forth the terms
and conditions of the above-referenced transaction entered into on the Trade
Date specified below (the “<B>Transaction</B>”) between [_________________]
(“<B>Dealer</B>”)
and Medtronic, Inc. (“<B>Issuer</B>”). This communication constitutes a
“Confirmation” as referred to in the ISDA Master Agreement specified below. </FONT></P>
<P><FONT SIZE=2> 1.
This Confirmation is subject to, and incorporates, the definitions and
provisions of the 2000 ISDA Definitions (including the Annex thereto) (the “<B>2000
Definitions</B>”) and the definitions and provisions of the 2002 ISDA
Equity Derivatives Definitions (the “<B>Equity Definitions</B>”, and together with the
2000 Definitions, the “<B>Definitions</B>”), in each case as published by
the International Swaps and Derivatives Association, Inc. (“<B>ISDA</B>”).
In the event of any inconsistency between the 2000 Definitions and the Equity
Definitions, the Equity Definitions will govern. For purposes of the Equity
Definitions, each reference herein to a Warrant shall be deemed to be a
reference to a Call Option or an Option, as context requires.</FONT></P>
<P><FONT SIZE=2> Each
party is hereby advised, and each such party acknowledges, that the other party
has engaged in, or refrained from engaging in, substantial financial
transactions and has taken other material actions in reliance upon the parties’
entry into the Transaction to which this Confirmation relates on the terms and
conditions set forth below.</FONT></P>
<P><FONT SIZE=2> This
Confirmation evidences a complete and binding agreement between Dealer and
Issuer as to the terms of the Transaction to which this Confirmation relates.
This Confirmation shall be subject to an agreement (the “<B>Agreement</B>”) in the form of
the 2002 ISDA Master Agreement (the “<B>ISDA Form</B>”) as if Dealer and Issuer had
executed an agreement in such form (without any Schedule but with the elections
set forth in this Confirmation). For the avoidance of doubt, the Transaction
shall be the only transaction under the Agreement. </FONT></P>
<P><FONT SIZE=2> All
provisions contained in, or incorporated by reference to, the Agreement will
govern this Confirmation except as expressly modified herein. In the event of
any inconsistency between this Confirmation and either the Definitions or the
Agreement, this Confirmation shall govern. </FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<P><FONT SIZE=2> 2.
The Transaction is a Warrant Transaction, which shall be considered a Share
Option Transaction for purposes of the Equity Definitions. The terms of the
particular Transaction to which this Confirmation relates are as follows:</FONT></P>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=100%>
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="30%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="56%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP colspan=2>
<P><FONT SIZE=2>General Terms:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Trade Date:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>April 12, 2006</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Effective Date:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>April 18, 2006, subject to Section 8(m) below</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Components:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The Transaction will be divided into individual
Components, each with the terms set forth in this Confirmation, and, in
particular, with the Number of Warrants and Expiration Date set forth in this
Confirmation. The payments and deliveries to be made upon settlement of the
Transaction will be determined separately for each Component as if each
Component were a separate Transaction under the Agreement.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Warrant Style:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>European</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Warrant Type:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Call</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Seller:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Issuer</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Buyer:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Dealer</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Shares:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The Common Stock of Issuer, par value USD 0.10
per share (Ticker Symbol: “MDT”).</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Number of Warrants:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>For each Component, as provided in Annex A to this
Confirmation.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Warrant Entitlement:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>One Share per Warrant</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Strike Price:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD76.56</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Premium:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD [___________] (Premium per Warrant USD
[__________])</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Premium Payment Date:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The Effective Date</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Exchange:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>New York Stock Exchange</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Related Exchange:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>All Exchanges</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP colspan=2>
<P><FONT SIZE=2>Procedures for Exercise:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP colspan=2>
<P><FONT SIZE=2><I> In
respect of any Component:</I></FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Expiration Time:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Valuation Time</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Expiration Date:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>As provided in <U>Annex A</U> to this Confirmation
(or, if such date is not a Scheduled Trading Day, the next following
Scheduled Trading Day that is not already an Expiration Date for another
Component); <I>provided</I> that if that date is a Disrupted Day, the
Expiration Date for such Component shall be the first succeeding Scheduled
Trading Day that is not a Disrupted Day and is not or is not deemed to be an
Expiration Date in respect of any other Component of the Transaction
hereunder; and <I>provided further</I> that if the Expiration Date has not
occurred pursuant to </FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>2</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=100%>
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="30%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="56%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>the preceding proviso as of the Final Disruption
Date, the Final Disruption Date shall be the Expiration Date (irrespective of
whether such date is an Expiration Date in respect of any other Component for
the Transaction). “<B>Final Disruption Date</B>” means December 10,
20__. Notwithstanding the foregoing and anything to the contrary in the
Equity Definitions, if a Market Disruption Event occurs on any Expiration
Date, the Calculation Agent may determine that such Expiration Date is a
Disrupted Day only in part, in which case the Calculation Agent shall make
adjustments to the number of Warrants for the relevant Component for which
such day shall be the Expiration Date and shall designate the Scheduled
Trading Day determined in the manner described in the immediately preceding sentence
as the Expiration Date for the remaining Warrants for such Component. Section
6.6 of the Equity Definitions shall not apply to any Valuation Date occurring
on an Expiration Date.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Market Disruption Event:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Section 6.3(a) of the 2002 Definitions is hereby
amended by deleting the words “during the one hour period that ends at the
relevant Valuation Time, Latest Exercise Time, Knock-in Valuation Time or
Knock-out Valuation Time, as the case may be,” in clause (ii) thereof.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Automatic Exercise:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable; and means that each Warrant not
previously exercised under the Transaction will be deemed to be automatically
exercised at the Expiration Time on the Expiration Date unless Buyer notifies
Seller (by telephone or in writing) prior to the Expiration Time on the
Expiration Date that it does not wish Automatic Exercise to occur, in which
case Automatic Exercise will not apply.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Issuer’s Telephone Number<BR>
and Telex and/or Facsimile Number<BR>
and Contact Details for purpose of <BR>
Giving Notice:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=2>Attn: Treasurer</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Telephone: (763) 505-2697<BR>
Facsimile: (763) 505-2700</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>With a copy to:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Attn: General Counsel<BR>
Facsimile: (763) 505-2980</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP colspan=2>
<P><FONT SIZE=2>Settlement Terms:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP colspan=2>
<P><FONT SIZE=2><I> In
respect of any Component:</I></FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Settlement Currency:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Net Share Settlement:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On each Settlement Date, Issuer shall deliver to
Dealer a number of Shares equal to the Number of Shares to be Delivered for
such Settlement Date to the account specified by Dealer and cash in lieu of </FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>3</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=100%>
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="30%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="56%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>any fractional shares valued at the Relevant Price
on the Valuation Date corresponding to such Settlement Date. If, in the
reasonable opinion of Issuer or Dealer based on advice of counsel, for any
reason, the Shares deliverable upon Net Share Settlement would not be
immediately freely transferable by Dealer under Rule 144(k) under the
Securities Act of 1933, as amended (the “<B>Securities Act</B>”), then Dealer may elect
to either (x) accept delivery of such Shares notwithstanding any restriction
on transfer or (y) have the provisions set forth in Section 8(b) below apply.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The Number of Shares to be Delivered shall be
delivered by Issuer to Dealer no later than 12:00 noon (local time in New
York City) on the relevant Settlement Date.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Number of Shares to be Delivered:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>In respect of any Exercise Date, subject to the last
sentence of Section 9.5 of the Equity Definitions, the product of (i) the
number of Warrants exercised or deemed exercised on such Exercise Date, (ii)
the Warrant Entitlement and (iii) (A) the excess of the VWAP Price on the
Valuation Date occurring on such Exercise Date over the Strike Price <I>divided by</I>
(B) such VWAP Price.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>VWAP Price:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>For any Valuation Date, the per Share
volume-weighted average price as displayed under the heading “Bloomberg VWAP”
on Bloomberg page MDT <equity> VAP (or any successor thereto) in
respect of the period from 9:30 a.m. to 4:00 p.m. (New York City time) on
such Valuation Date (or if such volume-weighted average price is unavailable,
the market value of one Share on such Valuation Date, as determined by the
Calculation Agent). Notwithstanding anything to the contrary in the Equity
Definitions, if there is a Market Disruption Event on any Valuation Date,
then the Calculation Agent shall determine the VWAP Price for such Valuation
Date on the basis of its good faith estimate of the market value for the
relevant Shares on such Valuation Date.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Other Applicable Provisions:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The provisions of Sections 9.1(c), 9.8, 9.9, 9.10,
9.11 (except that the Representation and Agreement contained in Section 9.11
of the Equity Definitions shall be modified by excluding any representations
therein relating to restrictions, obligations, limitations or requirements
under applicable securities laws as a result of the fact that Seller is the
Issuer of the Shares) and 9.12 of the Equity Definitions will be applicable,
except that all references in such provisions to “Physically-Settled” shall
be read as references to “Net Share Settled”. “Net Share Settled” in relation
to any Warrant means that Net Share Settlement is applicable to such Warrant.</FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>4</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=100%>
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="30%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="56%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP colspan=2>
<P><FONT SIZE=2>Adjustments:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP colspan=2>
<P><FONT SIZE=2><I> In
respect of any Component:</I></FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Method of Adjustment:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Calculation Agent Adjustment</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Dividend Adjustment:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>In the event that Issuer pays a Relevant Dividend,
on the ex-dividend date for such Relevant Dividend, the Strike Price shall be
adjusted by dividing the Strike Price previously in effect by the Adjustment
Ratio for such Relevant Dividend, the Number of Warrants shall be adjusted by
multiplying the Number of Warrants previously in effect by such Adjustment
Ratio, and the Threshold Amount shall be adjusted by dividing the Threshold
Amount previously in effect by such Adjustment Ratio.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Adjustment Ratio:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>For any Relevant Dividend, a fraction (A) the
numerator of which is equal to the Current Market Price for such Relevant
Dividend <I>minus</I>
the Threshold Dividend Amount for such Relevant Dividend and (B) the
denominator of which is such Current Market Price <I>minus</I> the amount of such
Relevant Dividend.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Current Market Price:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>For any Relevant Dividend, the Relevant Price of the
Shares on the Exchange Business Day immediately preceding the ex-dividend
date for such Relevant Dividend (determined as if such Exchange Business Day
were a Valuation Date).</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Relevant Dividend:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Any cash dividend or distribution that has an
ex-dividend date occurring on or after the Trade Date and on or prior to the
Expiration Date (it being understood, for the avoidance of doubt, that such
term shall not include (i) a distribution of cash by Issuer as payment of
consideration in connection with a Tender Offer or (ii) a distribution in
connection with the liquidation, dissolution or winding up of Issuer).</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Threshold Dividend Amount:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>With respect to each calendar quarter, for the first
dividend or distribution for which the ex-dividend date occurs within such
quarter, the Threshold Amount and, for any subsequent dividend or
distribution for which the ex-dividend date occurs within the same quarter,
USD 0.00.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Threshold Amount:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD0.09625 per Share (subject to adjustment in
accordance with the Calculation Agent Adjustment to account for any Potential
Adjustment Event, and subject to adjustment to account for any change to the
frequency or timing of payment of Issuer’s regular dividend).</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Extraordinary Events:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Consequences of Merger Events:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (a) Share-for-Share:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Modified Calculation Agent Adjustment</FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>5</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=100%>
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="21%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="61%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(b)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Share-for-Other:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Cancellation and Payment (Calculation Agent
Determination)</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(c)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Share-for-Combined:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Component Adjustment</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Tender Offer:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Consequences of Tender Offers:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(a)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Share-for-Share:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Modified Calculation Agent Adjustment</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(b)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Share-for-Other:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Cancellation and Payment (Calculation Agent
Determination) on that portion of the Other Consideration that consists of
cash; Modified Calculation Agent Adjustment on the remainder of the Other
Consideration.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(c)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Share-for-Combined:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Modified Calculation Agent Adjustment</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Nationalization, Insolvency</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>or Delisting:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Cancellation and Payment (Calculation Agent
Determination); <I>provided</I> that in addition to the provisions of Section
12.6(a)(iii) of the Equity Definitions, it shall also constitute a Delisting
if the Exchange is located in the United States and the Shares are not
immediately re-listed, re-traded or re-quoted on any of the New York Stock
Exchange, the American Stock Exchange or The NASDAQ National Market (or their
respective successors); if the Shares are immediately re-listed, re-traded or
re-quoted on any such exchange or quotation system, such exchange or
quotation system shall thereafter be deemed to be the Exchange; and <I>provided
further</I> that the definition of “Delisting” in Section 12.6
(a)(iii) of the Equity Definitions shall be deemed to be amended by adding “,
subject to no further conditions,” after the word “will.”</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Additional Disruption Events:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(a)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Change in Law:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(b)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Failure to Deliver:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(c)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Insolvency Filing:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(d)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Hedging Disruption:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(e)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Increased Cost of Hedging:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Not Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(f)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Loss of Stock Borrow:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Maximum Stock Loan Rate:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>2.00% per annum</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(g)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Increased Cost of Stock Borrow:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Initial Stock Loan Rate:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>0.25% per annum</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Hedging Party:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Buyer for all applicable Additional Disruption
Events </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Determining Party:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Buyer for all applicable Additional Disruption
Events </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Non-Reliance:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Agreements and Acknowledgments</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Regarding Hedging Activities:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable</FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>6</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=100%>
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="16%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="56%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="4" VALIGN=TOP>
<P><FONT SIZE=2>Additional Acknowledgments:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="4" VALIGN=TOP>
<P><FONT SIZE=2>3. <U>Calculation Agent</U>:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Dealer. The Calculation Agent shall deliver, within
five Exchange Business Days of a written request by either party, a written
explanation of any calculation or adjustment made by it, and including, where
applicable, the methodology applied.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="4" VALIGN=TOP>
<P><FONT SIZE=2>4. <U>Account Details</U>:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Dealer Payment Instructions:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>[_______________________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Bank Routing:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[_________________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Account Name:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[_________________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Account No. :</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[_________________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>Issuer Payment Instructions:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To be provided by Issuer.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="4" VALIGN=TOP>
<P><FONT SIZE=2>5. <U>Offices</U>:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="4" VALIGN=TOP>
<P><FONT SIZE=2>The Office of Dealer for the Transaction is:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>[________________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="3" VALIGN=TOP>
<P><FONT SIZE=2>The Office of Issuer for the Transaction is:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>Medtronic, Inc.<BR>
710 Medtronic Parkway <BR>
Minneapolis, Minnesota 55432</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="4" VALIGN=TOP>
<P><FONT SIZE=2>6. <U>Notices</U>: For purposes of this
Confirmation:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(a)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="4" VALIGN=TOP>
<P><FONT SIZE=2>Address for notices or communications to Issuer:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To:</FONT></P>
</TD>
<TD VALIGN=TOP colspan="3">
<P><FONT SIZE=2>Medtronic, Inc.<BR>
710 Medtronic Parkway <BR>
Minneapolis, Minnesota 55432</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Attn:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Treasurer</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Telephone:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(763) 505-2697</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Facsimile:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(763) 505-2700</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>With a copy to:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Attn:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>General Counsel</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Facsimile:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(763) 505-2980</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(b)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="4" VALIGN=TOP>
<P><FONT SIZE=2>Address for notices or communications to Dealer:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[_________________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[_________________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[_________________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Attn:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[_________________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Telephone:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[_________________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Facsimile:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[_________________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>With a copy to:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Attn:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[_________________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[_________________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Telephone:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[_________________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Facsimile:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[_________________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>7</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="95%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> 7.
<U>Representations, Warranties and Agreements</U>:</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (a)
In addition to the representations and warranties in the Agreement and those
contained elsewhere herein, Issuer represents and warrants to and for the
benefit of, and agrees with, Dealer as follows:</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (i)
On the Trade Date, (A) none of Issuer and its officers and directors is aware
of any material nonpublic information regarding Issuer or the Shares and (B)
all reports and other documents filed by Issuer with the Securities and
Exchange Commission pursuant to the Exchange Act when considered as a whole
(with the more recent such reports and documents deemed to amend inconsistent
statements contained in any earlier such reports and documents), do not
contain any untrue statement of a material fact or any omission of a material
fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances in which they were made, not
misleading.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (ii)
Without limiting the generality of Section 13.1 of the Equity Definitions,
Issuer acknowledges that Dealer is not making any representations or
warranties with respect to the treatment of the Transaction under FASB Statements
149 or 150, EITF Issue No. 00-19 (or any successor issue statements) or under
FASB’s Liabilities & Equity Project.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (iii)
Prior to the Trade Date, Issuer shall deliver to Dealer a resolution of
Issuer’s board of directors authorizing the Transaction and such other
certificate or certificates as Dealer shall reasonably request.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (iv)
Issuer is not entering into this Confirmation to create actual or apparent
trading activity in the Shares (or any security convertible into or
exchangeable for Shares) or to raise or depress or otherwise manipulate the
price of the Shares (or any security convertible into or exchangeable for
Shares) or otherwise in violation of the Exchange Act. </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (v)
Issuer is not, and after giving effect to the transactions contemplated
hereby will not be, an “investment company” as such term is defined in the
Investment Company Act of 1940, as amended.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (vi)
On the Trade Date (A) the assets of Issuer at their fair valuation exceed the
liabilities of Issuer, including contingent liabilities, (B) the capital of
Issuer is adequate to conduct the business of Issuer and (C) Issuer has the
ability to pay its debts and obligations as such debts mature and does not
intend to, or does not believe that it will, incur debt beyond its ability to
pay as such debts mature.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (vii)
Issuer shall not take any action to decrease the number of Available Shares
below the Capped Number (each as defined below).</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (viii)
The representations and warranties of Issuer set forth in Section 3 of the
Agreement and Section 1 of the Purchase Agreement (the “<B>Purchase Agreement</B>”) dated as of the
Trade Date between Issuer and Banc of America Securities LLC and Morgan
Stanley & Co. Incorporated as representatives of the Initial Purchasers
party thereto are true and correct and are hereby deemed to be repeated to
Dealer as if set forth herein.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (ix)
Issuer understands no obligations of Dealer to it hereunder will be entitled
to the benefit of deposit insurance and that such obligations will not be
guaranteed by any affiliate of Dealer or any governmental agency.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (b)
Each of Buyer and Issuer agrees and represents that it is an “eligible
contract participant” as defined in Section 1a(12) of the U.S. Commodity
Exchange Act, as amended.</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (c)
Each of Dealer and Issuer acknowledges that the offer and sale of the
Transaction to it is intended to be exempt from registration under the
Securities Act of 1933, as amended (the “<B>Securities Act</B>”), by virtue of Section
4(2) thereof. Accordingly, Dealer
represents and warrants to Issuer that (i) it has the financial ability to
bear the economic risk of its investment in the Transaction and is able to
bear a total loss of its investment and its investments in and liabilities in
respect of the Transaction, which it understands are not readily marketable,
are not disproportionate to its net worth, and it is able to bear any loss in
connection with the Transaction, including the loss of its entire investment
in the Transaction, (ii) it </FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>8</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="95%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>is an “accredited investor” as that term is defined
in Regulation D as promulgated under the Securities Act, (iii) it is entering
into the Transaction for its own account without a view to the distribution
or resale thereof, (iv) the assignment, transfer or other disposition of the
Transaction has not been and will not be registered under the Securities Act
and is restricted under this Confirmation, the Securities Act and state
securities laws, (v) its financial condition is such that it has no need for
liquidity with respect to its investment in the Transaction and no need to
dispose of any portion thereof to satisfy any existing or contemplated
undertaking or indebtedness and is capable of assessing the merits of and
understanding (on its own behalf or through independent professional advice),
and understands and accepts, the terms, conditions and risks of the
Transaction.</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (d)
Each of Dealer and Issuer agrees and acknowledges (A) that this Confirmation
is (i) a “securities contract,” as such term is defined in Section 741(7) of
Title 11 of the United States Code (the “<B>Bankruptcy Code</B>”), with respect to which
each payment and delivery hereunder is a “settlement payment,” as such term
is defined in Section 741(8) of the Bankruptcy Code, and (ii) a “swap
agreement,” as such term is defined in Section 101(53B) of the Bankruptcy Code,
with respect to which each payment and delivery hereunder is a “transfer,” as
such term is defined in Section 101(54) of the Bankruptcy Code, and (B) that
Dealer is entitled to the protections afforded by, among other sections,
Section 362(b)(6), 362(b)(17), 546(e), 546(g), 555 and 560 of the Bankruptcy
Code. </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (e)
Issuer shall deliver to Dealer an opinion of counsel, dated as of the Trade
Date and reasonably acceptable to Dealer in form and substance, with respect
to the matters set forth in Section 3(a) of the Agreement. </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> 8.
<U>Other Provisions</U>:</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (a)
<I>Alternative
Calculations and Payment on Early Termination and on Certain Extraordinary
Events</I>. If, subject to
Section 8(k) below, Issuer shall owe Buyer any amount pursuant to Sections
12.2, 12.3, 12.6, 12.7 or 12.9 of the Equity Definitions (except in the event
of an Insolvency, a Nationalization, a Tender Offer or a Merger Event, in
each case, in which the consideration or proceeds to be paid to holders of
Shares consists solely of cash) or pursuant to Section 6(d)(ii) of the
Agreement (except in the event of an Event of Default in which Issuer is the
Defaulting Party or a Termination Event in which Issuer is the Affected
Party, that resulted from an event or events within Issuer’s control) (a “<B>Payment
Obligation</B>”), Issuer shall have the right, in its sole discretion,
to satisfy any such Payment Obligation by the Share Termination Alternative
(as defined below) by giving irrevocable telephonic notice to Buyer,
confirmed in writing within one Scheduled Trading Day, between the hours of
9:00 A.M. and 4:00 P.M. New York City time on the Merger Date, Tender Offer
Date, Announcement Date or Early Termination Date, as applicable (“<B>Notice of
Share Termination</B>”). Upon
such Notice of Share Termination, the following provisions shall apply on the
Scheduled Trading Day immediately following the Merger Date, the Tender Offer
Date, Announcement Date or Early Termination Date, as applicable:</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="35%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="65%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Share Termination Alternative:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable and means that Issuer shall deliver to Dealer
the Share Termination Delivery Property on the date on which the Payment
Obligation would otherwise be due pursuant to Section 12.7 or 12.9 of the
Equity Definitions or Section 6(d)(ii) of the Agreement, as applicable (the “<B>Share
Termination Payment Date</B>”), in satisfaction of the Payment
Obligation. </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Share Termination Delivery<BR>Property:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2><BR>A number of Share Termination Delivery Units, as
calculated by the Calculation Agent, equal to the Payment Obligation divided
by the Share Termination Unit Price. The Calculation Agent shall adjust the Share Termination
Delivery Property by replacing any fractional portion of a security therein
with an amount of cash equal to the value of such fractional security based
on the values used to calculate the Share Termination Unit Price. </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Share Termination Unit Price:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The value of property contained in one Share
Termination Delivery Unit on the date such Share Termination Delivery Units
are to be delivered as Share Termination Delivery Property, as determined by
the </FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>9</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="35%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="65%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Calculation Agent in its discretion by commercially
reasonable means and notified by the Calculation Agent to Issuer at the time
of notification of the Payment Obligation.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Share Termination Delivery Unit:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>In the case of a Termination Event, Event of Default
or Delisting, one Share or, in the case of an Insolvency,
Nationalization, Merger Event or
Tender Offer, a unit consisting of the number or amount of each type of
property received by a holder of one Share (without consideration of any
requirement to pay cash or other consideration in lieu of fractional amounts
of any securities) in such Insolvency, Nationalization, Merger Event or
Tender Offer. If such Insolvency,
Nationalization, Merger Event or Tender Offer involves a choice of
consideration to be received by holders, such holder shall be deemed to have
elected to receive the maximum possible amount of cash.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Failure to Deliver:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Applicable</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Other applicable provisions:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>If Share Termination Alternative is applicable, the
provisions of Sections 9.8, 9.9, 9.10, 9.11 (except that the Representation
and Agreement contained in Section 9.11 of the Equity Definitions shall be
modified by excluding any representations therein relating to restrictions,
obligations, limitations or requirements under applicable securities laws as
a result of the fact that Seller is the Issuer of the Shares) and 9.12 of the
Equity Definitions will be applicable, except that all references in such
provisions to “Physically-Settled” shall be read as references to “settled by
Share Termination Alternative” and all references to “Shares” shall be read
as references to “Share Termination Delivery Units”. If, in the reasonable opinion of counsel
to Issuer or Dealer, for any reason, any securities comprising the Share
Termination Delivery Units deliverable pursuant to this Section 8(a) would
not be immediately freely transferable by Dealer under Rule 144(k) under the
Securities Act, then Dealer may elect to either (x) accept delivery of such
securities notwithstanding any restriction on transfer or (y) have the
provisions set forth in Section 8(b) below apply.</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="95%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (b)
<I>Registration/Private
Placement Procedures</I>. (i) With respect to the
Transaction, the following provisions shall apply to the extent provided for
above opposite the caption “Net Share Settlement” in Section 2 or in
paragraph (a) of this Section 8. If
so applicable, then, at the election of Issuer by notice to Buyer within one
Exchange Business Day after the relevant delivery obligation arises, but in any event at least one Exchange
Business Day prior to the date on which such delivery obligation is due,
either (A) all Shares or Share Termination Delivery Units, as the case may
be, delivered by Issuer to Buyer shall be, at the time of such delivery,
covered by an effective registration statement of Issuer for immediate resale
by Buyer (such registration statement and the corresponding prospectus (the “<B>Prospectus</B>”)
(including, without limitation, any sections describing the plan of
distribution) in form and content commercially reasonably satisfactory to
Buyer) or (B) Issuer shall deliver additional Shares or Share Termination
Delivery Units, as the case may be, so that the value of such Shares or Share
Termination Delivery Units, as determined by the Calculation Agent to reflect
an appropriate liquidity discount, equals the value of the number of Shares
or Share Termination Delivery Units that would otherwise be deliverable if
such Shares or Share Termination Delivery Units were freely tradeable
(without prospectus delivery) upon receipt by Buyer (such value, the “<B>Freely Tradeable
Value</B>”); <I>provided</I> that Issuer may not make the
election described in this clause (B) if, on the date of its election, it has
taken, or caused to be taken, any action that would make unavailable either
the exemption pursuant to Section 4(2) of the Securities Act for the sale by
Issuer to Dealer (or any affiliate designated by Dealer) of the Shares or the
exemption pursuant to Section 4(1) or Section 4(3) of the Securities Act for
resales of the Shares by Dealer (or any such affiliate of Dealer). (For the avoidance of doubt, as used in
this paragraph (b) only, the term “Issuer” shall mean the issuer of the
relevant securities, as the context shall require.)</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (ii)
If Issuer makes the election described in clause (b)(i)(A) above:</FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>10</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="95%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (A)
Buyer (or an Affiliate of Buyer designated by Buyer) shall be afforded a
reasonable opportunity to conduct a due diligence investigation with respect
to Issuer that is customary in scope for underwritten offerings of equity
securities and that yields results that are commercially reasonably
satisfactory to Buyer or such Affiliate, as the case may be, in its
discretion; and</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (B)
Buyer (or an Affiliate of Buyer designated by Buyer) and Issuer shall enter
into an agreement (a “<B>Registration Agreement</B>”) on commercially
reasonable terms in connection with the public resale of such Shares or Share
Termination Delivery Units, as the case may be, by Buyer or such Affiliate
substantially similar to underwriting agreements customary for underwritten offerings
of equity securities, in form and substance commercially reasonably
satisfactory to Buyer or such Affiliate and Issuer, which Registration
Agreement shall include, without limitation, provisions substantially similar
to those contained in such underwriting agreements relating to the
indemnification of, and contribution in connection with the liability of,
Buyer and its Affiliates and Issuer, shall provide for the payment by Issuer
of all expenses in connection with such resale, including all registration
costs and all fees and expenses of counsel for Buyer, and shall provide for
the delivery of accountants’ “comfort letters” to Buyer or such Affiliate
with respect to the financial statements and certain financial information
contained in or incorporated by reference into the Prospectus.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>(iii) If Issuer makes the election described in
clause (b)(i)(B) above:</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (A)
Buyer (or an Affiliate of Buyer designated by Buyer) and any potential
institutional purchaser of any such Shares or Share Termination Delivery
Units, as the case may be, from Buyer or such Affiliate identified by Buyer
shall be afforded a commercially reasonable opportunity to conduct a due
diligence investigation in compliance with applicable law with respect to
Issuer customary in scope for private placements of equity securities
(including, without limitation, the right to have made available to them for
inspection all financial and other records, pertinent corporate documents and
other information reasonably requested by them), subject to execution by such
recipients of customary confidentiality agreements reasonably acceptable to
Issuer; </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (B)
Buyer (or an Affiliate of Buyer designated by Buyer) and Issuer shall enter
into an agreement (a “<B>Private Placement Agreement</B>”) on
commercially reasonable terms in connection with the private placement of
such Shares or Share Termination Delivery Units, as the case may be, by
Issuer to Buyer or such Affiliate and the private resale of such shares by
Buyer or such Affiliate, substantially similar to private placement purchase
agreements customary for private placements of equity securities, in form and
substance commercially reasonably satisfactory to Buyer and Issuer, which
Private Placement Agreement shall include, without limitation, provisions
substantially similar to those contained in such private placement purchase
agreements relating to the indemnification of, and contribution in connection
with the liability of, Buyer and its Affiliates and Issuer, shall provide for
the payment by Issuer of all expenses in connection with such resale,
including all fees and expenses of counsel for Buyer, shall contain
representations, warranties and agreements of Issuer reasonably necessary or
advisable to establish and maintain the availability of an exemption from the
registration requirements of the Securities Act for such resales, and shall
use best efforts to provide for the delivery of accountants’ “comfort letters”
to Buyer or such Affiliate with respect to the financial statements and
certain financial information contained in or incorporated by reference into
the offering memorandum prepared for the resale of such Shares; and</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (C)
Issuer agrees that any Shares or Share Termination Delivery Units so
delivered to Dealer, (i) may be transferred by and among Dealer and its
affiliates, and Issuer shall effect such transfer without any further action
by Dealer and (ii) after the minimum “holding period” within the meaning of
Rule 144(d) under the Securities Act has elapsed with respect to such Shares
or any securities issued by Issuer comprising such Share Termination Delivery
Units, Issuer shall promptly remove, or cause the transfer agent for such
Shares or securities to remove, any legends referring to any such
restrictions or requirements from such Shares or securities upon delivery by
Dealer (or such affiliate of Dealer) to Issuer or such transfer agent of
seller’s and </FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>11</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="95%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>broker’s representation letters customarily
delivered by Dealer in connection with resales of restricted securities
pursuant to Rule 144 under the Securities Act, without any further
requirement for the delivery of any certificate, consent, agreement, opinion
of counsel, notice or any other document, any transfer tax stamps or payment
of any other amount or any other action by Dealer (or such affiliate of
Dealer).</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (c)
<I>Make-whole Shares</I>. If (x)
Issuer elects to deliver Share Termination Delivery Units pursuant to
paragraph (a) of this Section 8 or (y) Issuer makes the election described in
clause (b)(i)(B) of paragraph (b) of this Section 8, then in either case
Dealer or its affiliate may sell (which sale shall be made in a commercially
reasonable manner) such Shares or Share Termination Delivery Units, as the
case may be, during a period (the “<B>Resale Period</B>”) commencing on the
Exchange Business Day following delivery of such Shares or Share Termination
Delivery Units, as the case may be, and ending on the Exchange Business Day
on which Dealer completes the sale of all such Shares or Share Termination
Delivery Units, as the case may be, or a sufficient number of Shares or Share
Termination Delivery Units, as the case may be, so that the realized net
proceeds of such sales exceed the amount of the Payment Obligation (in the
case of clause (x), or in the case that both clause (x) and clause (y) apply)
or the Freely Tradeable Value (in the case that only clause (y) applies)(such
amount of the Payment Obligation or Freely Tradeable Value, as the case may
be, the “<B>Required Proceeds</B>”). If any of such delivered Shares or Share
Termination Delivery Units remain after such realized net proceeds exceed the
Required Proceeds, Dealer shall return such remaining Shares or Share
Termination Delivery Units to Issuer.
If the Required Proceeds exceed the realized net proceeds from such
resale, Issuer shall transfer to Dealer by the open of the regular trading
session on the Exchange on the Exchange Trading Day immediately following the
last day of the Resale Period the amount of such excess (the “<B>Additional
Amount</B>”) in cash or in a number of additional Shares (“<B>Make-whole
Shares</B>”) in an amount that, based on the Relevant Price on the
last day of the Resale Period (as if such day was the “Valuation Date” for
purposes of computing such Relevant Price), has a dollar value equal to the
Additional Amount. The Resale Period
shall continue to enable the sale of the Make-whole Shares in the manner
contemplated by this Section 8(c).
This provision shall be applied successively until the Additional
Amount is equal to zero, subject to Section 8(e).</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (d)
<I>Beneficial
Ownership</I>. Notwithstanding anything to the contrary in the
Agreement or this Confirmation, in no event shall Buyer be entitled to
receive, or shall be deemed to receive, any Shares if, upon such receipt of
such Shares, the “beneficial ownership” (within the meaning of Section 13 of
the Exchange Act and the rules promulgated thereunder) of Shares by Buyer or
any entity that directly or indirectly controls Buyer (collectively, “<B>Buyer
Group</B>”) would be equal to or greater than 9.5% or more of the
outstanding Shares. If any delivery
owed to Buyer hereunder is not made, in whole or in part, as a result of this
provision, Issuer’s obligation to make such delivery shall not be
extinguished and Issuer shall make such delivery as promptly as practicable
after, but in no event later than one Exchange Business Day after, Buyer
gives notice to Issuer that such delivery would not result in Buyer Group
directly or indirectly so beneficially owning in excess of 9.5% of the
outstanding Shares.</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (e)
<I>Limitations
on Settlement by Issuer</I>.
Notwithstanding anything herein or in the Agreement to the contrary,
in no event shall Issuer be required to deliver Shares in connection with the
Transaction in excess of [_________] Shares (the “<B>Capped Number</B>”). Issuer represents and
warrants (which
shall be deemed to be repeated on each day that the Transaction is
outstanding) that the Capped Number is equal to or less than the number of
authorized but unissued Shares of the Issuer that are not reserved for future
issuance in connection with transactions in the Shares (other than the
Transaction) on the date of the determination of the Capped Number (such
Shares, the “<B>Available Shares</B>”).
In the event Issuer shall not have delivered the full number of Shares
otherwise deliverable as a result of this Section 8(e) (the resulting
deficit, the “<B>Deficit Shares</B>”), Issuer shall be continually obligated to
deliver, from time to time until the full number of Deficit Shares have been
delivered pursuant to this paragraph, Shares when, and to the extent, that
(i) Shares are repurchased, acquired or otherwise received by Issuer or any
of its subsidiaries after the Trade Date (whether or not in exchange for
cash, fair value or any other consideration), (ii) authorized and unissued
Shares reserved for issuance in respect of other transactions prior to such
date which prior to the relevant date become no longer so reserved and (iii)
Issuer additionally authorizes and unissued Shares that are not reserved for
other transactions. Issuer shall
immediately notify Dealer of the occurrence of any of the foregoing events
(including the number of Shares subject to clause </FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>12</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="95%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>(i), (ii) or (iii) and the corresponding number of
Shares to be delivered) and promptly deliver such Shares thereafter.</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (f)
<I>Equity
Rights</I>. Buyer acknowledges
and agrees that this Confirmation is not intended to convey to it rights with
respect to the Transaction that are senior to the claims of common
stockholders in the event of Issuer’s bankruptcy. For the avoidance of doubt, the parties agree that the
preceding sentence shall not apply at any time other than during Issuer’s
bankruptcy to any claim arising as a result of a breach by Issuer of any of
its obligations under this Confirmation or the Agreement. For the avoidance of doubt, the parties
acknowledge that this Confirmation is not secured by any collateral that
would otherwise secure the obligations of Issuer herein under or pursuant to
any other agreement.</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (g)
<I>Amendments
to Equity Definitions and the Agreement</I>. The following amendments shall be made to the Equity
Definitions and to the Agreement:</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (i)
The first sentence of Section 11.2(c) of the Equity Definitions, prior to
clause (A) thereof, is hereby amended to read as follows: ‘(c) If “Calculation
Agent Adjustment” is specified as the Method of Adjustment in the related
Confirmation of a Share Option Transaction, then following the announcement
or occurrence of any Potential Adjustment Event, the Calculation Agent will
determine whether such Potential Adjustment Event has a material effect on
the theoretical value of the relevant Shares or options on the Shares and, if
so, will (i) make appropriate
adjustment(s), if any, to any one or more of:’ and, the portion of
such sentence immediately preceding clause (ii) thereof is hereby amended by
deleting the words “diluting or concentrative” and the words “(provided that
no adjustments will be made to account solely for changes in volatility,
expected dividends, stock loan rate or liquidity relative to the relevant
Shares)” and replacing such latter phrase with the words “(and, for the
avoidance of doubt, adjustments may be made to account solely for changes in
volatility, expected dividends, stock loan rate or liquidity relative to the
relevant Shares)”; </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (ii)
Section 11.2(e)(vii) of the Equity Definitions is hereby amended by deleting
the words “diluting or concentrative” and replacing them with “material”; and</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (iii)
Section 12.6(a)(ii) of the Equity Definitions is hereby amended by (1)
deleting from the fourth line thereof the word “or” after the word “official”
and inserting a comma therefor, and (2) deleting the semi-colon at the end of
subsection (B) thereof and inserting the following words therefor “or (C) at
Buyer’s option, the occurrence of any of the events specified in Section
5(a)(vii) (1) through (9) of the ISDA
Master Agreement with respect to that Issuer.”.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (h)
<I>Transfer
and Assignment</I>. Buyer may
transfer or assign its rights and obligations hereunder and under the
Agreement, in whole or in part, at any time to any person or entity
whatsoever without the consent of Issuer.
</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (i)
<I>Disclosure</I>. Effective from the date of commencement of
discussions concerning the Transaction, Issuer and each of its employees,
representatives, or other agents may disclose to any and all persons, without
limitation of any kind, the tax treatment and tax structure of the
Transaction and all materials of any kind (including opinions or other tax
analyses) that are provided to Issuer relating to such tax treatment and tax
structure.</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (j)
<I>Designation
by Dealer</I>. Notwithstanding
any other provision in this Confirmation to the contrary requiring or
allowing Dealer to purchase, sell, receive or deliver any Shares or other
securities to or from Issuer, Dealer may designate any of its affiliates to
purchase, sell, receive or deliver such shares or other securities and
otherwise to perform Dealer obligations in respect of the Transaction and any
such designee may assume such obligations.
Dealer shall be discharged of its obligations to Issuer to the extent
of any such performance.</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (k)
<I>Netting
and Set-off</I>. </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (i)
If on any date cash would otherwise be payable or Shares or other property
would otherwise be deliverable hereunder or pursuant to the Agreement or
pursuant to any other agreement between the parties by Issuer to Buyer and
cash would otherwise be payable or Shares or other property would otherwise
be deliverable hereunder or pursuant to the Agreement or pursuant to any
other agreement between the parties by Buyer to Issuer and the type of
property </FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>13</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="95%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>required to be paid or delivered by each such party
on such date is the same, then, on such date, each such party’s obligation to
make such payment or delivery will be automatically satisfied and discharged
and, if the aggregate amount that would otherwise have been payable or deliverable
by one such party exceeds the aggregate amount that would otherwise have been
payable or deliverable by the other such party, replaced by an obligation of
the party by whom the larger aggregate amount would have been payable or
deliverable to pay or deliver to the other party the excess of the larger
aggregate amount over the smaller aggregate amount.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (ii)
In addition to and without limiting any rights of set-off that a party hereto
may have as a matter of law, pursuant to contract or otherwise, upon the
occurrence of an Early Termination Date, Buyer shall have the right to
terminate, liquidate and otherwise close out the Transaction and to set off
any obligation or right that Buyer or any affiliate of Buyer may have to or
against Issuer hereunder or under the Agreement against any right or
obligation Buyer or any of its affiliates may have against or to Issuer,
including without limitation any right to receive a payment or delivery
pursuant to any provision of the Agreement or hereunder. In the case of a set-off of any obligation
to release, deliver or pay assets against any right to receive assets of the
same type, such obligation and right shall be set off in kind. In the case of a set-off of any obligation
to release, deliver or pay assets against any right to receive assets of any
other type, the value of each of such obligation and such right shall be
determined by the Calculation Agent and the result of such set-off shall be
that the net obligor shall pay or deliver to the other party an amount of
cash or assets, at the net obligor’s option, with a value (determined, in the
case of a delivery of assets, by the Calculation Agent) equal to that of the
net obligation. In determining the
value of any obligation to release or deliver Shares or any right to receive
Shares, the value at any time of such obligation or right shall be determined
by reference to the market value of the Shares at such time, as determined by
the Calculation Agent. If an
obligation or right is unascertained at the time of any such set-off, the
Calculation Agent may in good faith estimate the amount or value of such
obligation or right, in which case set-off will be effected in respect of
that estimate, and the relevant party shall account to the other party at the
time such obligation or right is ascertained.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (iii)
Notwithstanding any provision of the Agreement (including without limitation
Section 6(f) thereof) and this Confirmation (including without limitation
this Section 8(k)) or any other agreement between the parties to the
contrary, (A) Issuer shall not net or set off its obligations under the
Transaction against its rights against Buyer under any other transaction or
instrument; (B) Buyer may net and set off any rights of Buyer against Issuer
arising under the Transaction only against obligations of Buyer to Issuer
arising under any transaction or instrument if such transaction or instrument
does not convey rights to Buyer senior to the claims of common stockholders
in the event of Issuer’s bankruptcy; and (C) in the event of Issuer’s
bankruptcy, Buyer waives any and all rights it may have to set-off in respect
of the Transaction, whether arising under agreement, applicable law or
otherwise. Buyer will give notice to
Issuer of any netting or set off effected under this provision.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (l)
<I>Additional Termination Event</I>. If within the period commencing on the
Trade Date and ending on the second anniversary of the Premium Payment Date,
Buyer reasonably determines that it is advisable to terminate a portion of
the Transaction so that Buyer’s related hedging activities will comply with
applicable securities laws, rules or regulations, an Additional Termination
Event shall occur in respect of which (1) Issuer shall be the sole Affected
Party and (2) the Transaction shall be the sole Affected Transaction.</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (m)
<I>Effectiveness</I>. If, prior to the Effective Date, Buyer
reasonably determines that it is advisable to cancel the Transaction because
of concerns that Buyer’s related hedging activities could be viewed as not
complying with applicable securities laws, rules or regulations, the
Transaction shall be cancelled and shall not become effective, and neither
party shall have any obligation to the other party in respect of the
Transaction.</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (n)
<I>Waiver
of Trial by Jury</I>. <B>EACH OF
ISSUER AND BUYER HEREBY IRREVOCABLY WAIVES (ON ITS OWN BEHALF AND, TO THE
EXTENT PERMITTED BY APPLICABLE LAW, ON BEHALF OF ITS STOCKHOLDERS) ALL RIGHT
TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON </B></FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>14</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="95%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2><B>CONTRACT,
TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THE TRANSACTION OR THE
ACTIONS OF BUYER OR ITS AFFILIATES IN THE NEGOTIATION, PERFORMANCE OR
ENFORCEMENT HEREOF.</B></FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> (o)
<I>Governing
Law</I>. <B>THIS CONFIRMATION SHALL BE GOVERNED BY
THE LAWS OF THE STATE OF NEW YORK.
THE PARTIES HERETO IRREVOCABLY SUBMIT TO THE EXCLUSIVE JURISDICTION OF
THE COURTS OF THE STATE OF NEW YORK AND THE UNITED STATES COURT FOR THE
SOUTHERN DISTRICT OF NEW YORK IN CONNECTION WITH ALL MATTERS RELATING HERETO
AND WAIVE ANY OBJECTION TO THE LAYING OF VENUE IN, AND ANY CLAIM OF
INCONVENIENT FORUM WITH RESPECT TO, THESE COURTS.</B></FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>15</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="95%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2> Issuer
hereby agrees (a) to check this Confirmation carefully and immediately upon
receipt so that errors or discrepancies can be promptly identified and
rectified and (b) to confirm that the foregoing (in the exact form provided
by Dealer) correctly sets forth the terms of the agreement between Dealer and
Issuer with respect to the Transaction, by manually signing this Confirmation
or this page hereof as evidence of agreement to such terms and providing the
other information requested herein and immediately returning an executed copy
to Equity Derivatives Documentation Department, Facsimile No. (212)
428-1980/83.</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="47%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="46%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>Yours faithfully,</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<HR SIZE=1 WIDTH="50%" NOSHADE COLOR=GRAY ALIGN=LEFT>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>By: </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="80%" NOSHADE COLOR=GRAY ALIGN=left>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Name:</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Title:</FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>Agreed and Accepted By:</FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>MEDTRONIC, INC.</FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>By:</FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="80%" NOSHADE COLOR=GRAY ALIGN=left>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Name:</FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Title:</FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>16</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<P ALIGN=RIGHT><FONT SIZE=2><B>Annex
A</B></FONT></P>
<P><FONT SIZE=2>For each Component of the Transaction, the Number of
Warrants and Expiration Date is set forth below.</FONT></P>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="15%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="15%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="30%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="30%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE="1"><B>Component Number</B> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE="1"><B>Number of Warrants</B> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE="1"><B>Expiration Date</B> </FONT></P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN=TOP>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>1.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>2.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>3.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>4.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>5.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>6.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>7.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>8.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>9.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>10.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>11.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>12.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>13.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>14.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>15.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>16.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>17.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>18.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>19.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>20.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>21.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>22.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>23.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>24.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>25.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>26.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>27.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>28.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>29.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>30.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>31.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>32.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>33.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>34.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>35.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>36.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>37.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>38.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>39.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>40.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>41.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>42.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>43.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>44.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>45.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>46.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>47.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>48.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>49.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>50.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>51.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>17</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="15%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="15%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="30%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="30%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>52.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>53.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>54.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>55.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>56.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>57.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>58.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>59.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>60.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>61.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>62.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>63.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>64.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>65.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>66.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>67.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>68.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>69.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>70.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>71.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>72.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>73.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>74.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>75.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>76.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>77.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>78.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>79.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>80.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>81.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>82.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>83.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>84.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>85.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>86.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>87.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>88.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>89.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>90.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[_________] </FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>18</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<P ALIGN=CENTER><FONT SIZE=2><U>Schedule to Exhibit 10.28</U></FONT></P>
<P><FONT SIZE=2> On April 12, 2006,
the Company entered into six warrant transactions. A confirmation was produced
for each transaction. The confirmations are substantially identical to the form
of warrant confirmation appearing herein as Exhibit 10.28 (the “Form of Warrant
Confirmation”). However, the six actual confirmations differ from the Form of
Warrant Confirmation as follows: </FONT></P>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="13%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="14%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="13%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1><B>Issuer:</B></FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1><B>Deutsche
Bank </B></FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1><B>Deutsche
Bank </B></FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1><B>UBS AG</B></FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1><B>Merrill
Lynch </B></FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1><B>Merrill
Lynch </B></FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1><B>Goldman
Sachs</B></FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 1, the following names and addresses replace
the blank that appears opposite the heading “From:”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Deutsche Bank <BR>
AG, London Branch<BR><BR>
Winchester house <BR>
1 Great Winchester St.<BR>
London EC2N<BR>
2DB<BR><BR>
Telephone: +44 20 7545 8000<BR><BR>
c/o Deutsche Bank AG, New York Branch<BR>
60 Wall Street<BR>
New York, NY 10005<BR><BR>
Telephone: (212) 250-2500<BR><BR>
Facsimile: (212) 797-9365</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Deutsche Bank<BR>
AG, London Branch<BR><BR>
Winchester house <BR>
1 Great Winchester St.<BR>
London EC2N 2DB<BR><BR>
Telephone: +44 20 7545 8000<BR><BR>
c/o Deutsche Bank AG, New York Branch<BR>
60 Wall Street<BR>
New York, NY 10005<BR><BR>
Telephone: (212) 250-2500<BR><BR>
Facsimile: (212) 797-9365
</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>UBS AG, London<BR>
Branch<BR><BR>
c/o UBS<BR>Securities LLC<BR>
299 Park Avenue<BR>
New York, NY 10171<BR>
Attn: Adam Frieman<BR><BR>
Telephone: (212) 821-2100<BR><BR>
Facsimile: (212) 821-4610</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Merrill Lynch<BR>
International<BR><BR>
Merrill Lynch<BR>Financial Center<BR>
2 King Edward Street<BR>
London EC1A 1HQ<BR>
Attn: Manager, Fixed Income Settlements<BR><BR>
Telephone: +44 207 995 3769<BR>
<BR>
Facsimile: +44 207 995 2004</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Merrill Lynch<BR>
International<BR><BR>
Merrill Lynch
Financial Center<BR>
2 King Edward Street<BR>
London EC1A 1HQ<BR>
Attn: Manager, Fixed Income Settlements <BR><BR>
Telephone: +44 207 995 3769<BR>
<BR>
Facsimile: +44 207 995 2004
</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Goldman, Sachs & Co.<BR><BR>
85 Broad Street<BR>New York, NY 10004<BR>
Attn: Tracey McCabe<BR>
<BR>
Telephone: (212) 357-6076<BR><BR>
Facsimile: (212) 428-3778</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 1, the following numbers replace the blank
space following the phrase “Internal or </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>104926</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>104928</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>1805700</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>0683241</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>0683243</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>FDB1620971448</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="13%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="14%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Transaction Reference Number”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 1, in the first paragraph, the following
names replace the blank before the phrase “Dealer.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Deutsche Bank AG acting through its London branch (“<B>Dealer</B>”),
with Deutsche Bank AG, New York Branch
acting as its agent,</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Deutsche Bank AG acting through its London branch (“<B>Dealer</B>”),
with Deutsche Bank AG, New York
Branch acting as its agent,</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>UBS AG, London Branch (“<B>Dealer</B>”), represented by
UBS Securities LLC (“<B>Agent</B>”) as
its agent,</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Merrill Lynch International (“<B>Dealer</B>”) represented by
Merrill Lynch, Pierce, Fenner & Smith Incorporated (“<B>Agent</B>”) as its agent,</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Merrill Lynch International (“<B>Dealer</B>”) represented by
Merrill Lynch, Pierce, Fenner & Smith Incorporated (“<B>Agent</B>”) as its agent,</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Goldman, Sachs & Co.
(“<B>Dealer</B>”)</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 2, in Section 2, the following amounts
replace the blank that appears opposite the heading “Premium.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 2, in Section 2, the following amounts
replace the blank that appears opposite the heading “Capped Amount.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 3, in Section 2, in the paragraph entitled
“Procedures for Exercise,” the following dates replace the blank that appears
after “Final Disruption Date.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>December 12, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>December 10, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>December 9, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP nowrap>
<P><FONT SIZE=2>December 9, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>December 10, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>December 10, 2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 7, in Section 4, entitled “Account Details,”
the following information replaces the blank therein.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Dealer Payment Instructions for Deutsche Bank AG,
New York Branch acting as agent are as follows: <BR>
Bank of New York<BR>
Bank Routing:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Dealer Payment Instructions for Deutsche Bank AG,
New York Branch acting as agent are as follows:<BR>
<BR>
Bank of New York</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Dealer Payment Instructions:<BR>
<BR>
UBS AG Stamford<BR>
<BR>
SWIFT:<BR>
UBSWUS33XXX<BR>
Bank Routing: 026-007-993</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Dealer Payment Instructions:<BR>
<BR>
Chase Manhattan Bank, New York<BR>
<BR>
Bank Routing: 021-000-021</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Dealer Payment Instructions:<BR><BR>
Chase<BR>
Manhattan Bank, New York <BR>
<BR>
Bank Routing: 021-000-021</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Dealer Payment Instructions:<BR><BR>
Chase<BR>
Manhattan Bank New York<BR>
<BR>
Bank Routing:
021-000021</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="13%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="14%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>021-000-018<BR>
<BR>
Account Name: DBO<BR>
<BR>
Account No. : [**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Bank Routing: 021-000-018<BR>
<BR>
Account Name: DBO<BR>
<BR>
Account No. : [**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Account Name: UBS AG, London Branch<BR>
<BR>
Account No. : [**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Account Name: ML Equity Derivatives<BR>
<BR>
Account No. : [**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Account Name: ML Equity Derivatives<BR>
<BR>
Account No. : [**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Account Name:
Goldman,<BR>
Sachs & Co.<BR>
Account No. :<BR> [**]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 7, in Section 5, entitled “Offices,” the
following addresses replace the blank that appears under the heading “The
Office of Dealer for the Transaction.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Deutsche Bank AG, London Branch<BR>
<BR>
1 Great Winchester St. <BR>
Winchester house London EC2N 2DB</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Deutsche Bank AG, London Branch<BR>
<BR>
1 Great Winchester St. <BR>
Winchester house London EC2N 2DB</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>UBS AG<BR>
<BR>
100 Liverpool Street <BR>
London EC2M 2RH<BR>
United Kingdom<BR>
<BR>
Telephone: +44 207 568 0687<BR>
<BR>
Facsimile: +44 207 568 9895/6</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Merrill Lynch Financial Center<BR>
<BR>
2 King Edward Street<BR>
London EC1A 1HQ<BR>
<BR>
Telephone: +44 207 995 3769<BR>
<BR>
Facsimile: +44 207 995 2004</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Merrill Lynch Financial Center<BR>
<BR>
2 King Edward Street<BR>
London EC1A 1HQ<BR>
<BR>
Telephone: +44 207 995 3769<BR>
<BR>
Facsimile: +44 207 995 2004</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>One New York Plaza, New York, New York 10004</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Pages 7 and 8, in Section 8, entitled “Notices,”
the following addresses replace the blank that appears under the heading “(b)
Address for notices or communications to Dealer:”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To: Deutsche Bank AG London<BR>
<BR>
c/o Deutsche Bank AG, New York Branch<BR>60 Wall Street New York, NY 10005<BR>
Attn: Stanley Rowe or Lee<BR>
Frankenfield<BR>
<BR>
Telephone: (212) 250-4942 or (212) 250-4980<BR>
<BR>
Facsimile: (212) 797-9365</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To: Deutsche Bank AG London<BR>
<BR>
c/o Deutsche Bank AG, New York Branch <BR>
60 Wall Street<BR>
New York, NY 10005<BR>
Attn: Stanley Rowe or Lee<BR>
Frankenfield<BR>
<BR>
Telephone: (212) 250-4942 or (212) 250-4980<BR>
<BR>
Facsimile: (212) 797-9365</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To: UBS AG, London Branch<BR>
<BR>
c/o UBS Securities LLC <BR>
299 Park Avenue<BR>
New York, NY 10171<BR>
Attn: Adam Frieman<BR>
<BR>
Telephone: (212) 821-2100<BR>
<BR>
Facsimile: (212) 821-4610<BR>
<BR>
With a copy to:<BR>
<BR>
To: Equities Legal </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To: Merrill Lynch International<BR>
<BR>
Merrill Lynch Financial Center<BR>
2 King Edward Street<BR>
London EC1A 1HQ<BR>
Attn: Manager, Fixed Income Settlements<BR>
<BR>
Telephone: +44 207 995 3769<BR>
<BR>
Facsimile: +44 207 995 2004</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To: Merrill Lynch International<BR>
<BR>
Merrill Lynch Financial Center 2 King Edward Street<BR>
London EC1A 1HQ <BR>
Attn: Manager, Fixed Income Settlements<BR>
<BR>
Telephone: +44 207 995 3769<BR>
<BR>
Facsimile: +44 207 995 2004</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>To: Goldman, Sachs & Co.<BR>
<BR>
85 Broad Street New York, NY 10004 <BR>
Attn: Equity Operations: Options and Derivatives <BR>
<BR>
Telephone: (212) 902-8996 <BR>
<BR>
<BR>
Facsimile: (212) 902-0112 <BR>
<BR>
With a copy to:<BR>
<BR>
Attn: Tracey McCabe</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="13%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="14%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Department 677 Washington Boulevard Stamford, CT
06901<BR>
Attn: David Kelly and Gordon Kiesling<BR>
<BR>
Telephone: (203) 719-0268 <BR>
<BR>
Facsimile: (203) 719-5627<BR>
<BR>
and:<BR>
<BR>
To: Equities Volatility Trading</FONT><BR>
<FONT SIZE=2>677 Washington Boulevard Stamford, CT 06901 <BR>
Attn: Namuk Cho and Bennett Lieberman<BR>
<BR>
Telephone: (203) 719-7330<BR>
<BR>
Facsimile: (203) 719-7910</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Equity Capital Markets<BR>
<BR>
Telephone: (212) 357-0428<BR>
<BR>
Facsimile: (212) 902-3000</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 12 and Page 13, in Section 8, entitled “Other
Provisions,” the following amounts replace the blank before the phrase
“Capped Number.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="13%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="14%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 15, in Section 8, entitled “Other
Provisions,” the following paragraphs appear after the paragraph entitled
“(o) Governing Law.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (p)<BR>
<I>Method of Delivery</I>. Whenever
delivery of
funds or other assets is required hereunder by or to Issuer, such delivery
shall be effected through Deutsche Bank AG, New York Branch (“<B>DBNY</B>”). In addition, all notices, demands
and<BR>
communications of any kind relating to the Transaction between Dealer and
Issuer shall be transmitted exclusively through DBNY.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (p)<BR>
<I>Method of Delivery</I>. Whenever
delivery of
funds or other assets is required hereunder by or to Issuer, such delivery
shall be effected through Deutsche Bank AG, New York Branch (“<B>DBNY</B>”). In addition, all notices, demands
and communications of any kind relating to the Transaction between Dealer and
Issuer shall be transmitted exclusively through DBNY.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> (p)<BR>
<I>Role of Agent</I>. Each party agrees
and
acknowledges that Agent is acting as agent for both parties but does not
guarantee the performance of either party and neither Dealer nor Issuer shall
contact the other with respect to any matter relating to the Transaction
without the direct involvement of Agent; (ii) Agent is not a member of the
Securities Investor Protection Corporation; (iii) Agent, Dealer and Issuer
each hereby acknowledges that any transactions by Dealer or Agent in the
Shares will be undertaken by Dealer or Agent, as the case may, as principal
for its own account; and (iv) all of the actions to be taken by Dealer and
Agent in connection with the</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(none)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(none)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(none)</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="13%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="14%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Transaction, including but not limited to any
exercise of any rights with respect to the Warrants, shall be taken by Dealer
or Agent independently and without any advance or subsequent consultation
with Issuer; and (iv) Agent is hereby authorized to act as agent for Issuer
only to the extent required to satisfy the requirements of Rule 15a-6 under
the Exchange Act in respect of the Warrants described hereunder.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 16 the following names replace the blank
below the phrase “Yours faithfully.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>DEUTSCHE BANK AG LONDON<BR>
<BR>and<BR>
<BR>DEUTSCHE BANK AG NEW YORK as agent</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>DEUTSCHE BANK AG LONDON<BR>
<BR>and<BR>
<BR>DEUTSCHE BANK AG NEW YORK as agent</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>UBS AG, LONDON BRANCH<BR>
<BR>and<BR>
<BR>UBS SECURITIES LLC, as agent</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>MERRILL LYNCH
INTERNATIONAL<BR>
<BR>and<BR>
<BR>
MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED, as agent</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>MERRILL LYNCH
INTERNATIONAL<BR>
<BR>and<BR>
<BR>MERRILL LYNCH, PIERCE, FENNER & SMITH
INCORPORATED, as agent</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>GOLDMAN, SACHS & CO.</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="13%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="15%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="15%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>In the table on Annex A the following amounts
replace each and every blank in the column entitled “Number of Warrants.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P align=center> <FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P align=center> <FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P align=center> <FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P align=center> <FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P align=center> <FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P align=center> <FONT SIZE=2>[**]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD ROWSPAN="31" VALIGN=TOP>
<P><FONT SIZE=2>In the table on Annex A the following dates replace
the blanks in the column entitled “Expiration Date.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP nowrap>
<P ALIGN=CENTER><FONT SIZE=2>Expiration Date</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP nowrap>
<P ALIGN=CENTER><FONT SIZE=2>Expiration Date</FONT></P>
</TD>
<TD VALIGN=TOP >
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP nowrap>
<P ALIGN=CENTER><FONT SIZE=2>Expiration Date</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>Expiration Date</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>Expiration Date</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP nowrap>
<P ALIGN=CENTER><FONT SIZE=2>Expiration Date</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>07/25/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>07/24/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>7/25/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>July 25, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>July 24, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>7/24/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>07/26/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>07/25/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>7/26/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>July 26, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>July 25, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>7/25/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>07/27/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>07/26/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>7/27/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>July 27, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>July 26, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>7/26/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>07/28/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>07/29/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>7/28/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>July 28, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>July 29, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>7/29/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>07/29/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>07/30/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>7/29/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>July 29, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>July 30, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>7/30/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/01/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>07/31/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/1/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 1, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>July 31, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>7/31/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/02/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/01/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/2/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 2, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 1, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/1/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/03/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/02/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/3/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 3, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 2, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/2/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/04/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/05/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/4/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 4, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 5, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/5/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/05/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/06/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/5/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 5, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 6, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/6/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/08/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/07/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/8/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 8, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 7, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/7/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/09/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/08/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/9/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 9, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 8, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/8/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/10/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/09/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/10/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 10, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 9, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/9/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/11/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/12/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/11/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 11, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 12, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/12/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/12/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/13/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/12/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 12, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 13, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/13/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/15/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/14/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/15/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 15, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 14, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/14/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/16/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/15/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/16/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 16, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 15, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/15/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/17/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/16/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/17/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 17, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 16, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/16/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/18/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/19/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/18/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 18, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 19, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/19/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/19/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/20/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/19/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 19, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 20, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/20/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/22/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/21/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/22/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 22, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 21, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/21/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/23/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/22/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/23/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 23, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 22, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/22/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/24/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/23/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/24/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 24, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 23, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/23/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/25/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/26/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/25/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 25, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 26, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/26/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/26/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/27/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/26/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 26, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 27, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/27/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/29/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/28/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/29/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 29, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 28, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/28/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/30/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/29/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/30/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 30, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 29, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/29/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/31/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>08/30/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/31/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 31, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>August 30, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>8/30/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/01/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/03/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/1/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 1, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 3, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/3/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/02/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/04/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/2/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 2, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 4, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/4/2013</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="13%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=BOTTOM>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=BOTTOM>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=BOTTOM>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="15%" VALIGN=BOTTOM>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="15%" VALIGN=BOTTOM>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=BOTTOM>
<P ALIGN=CENTER> </P>
</TD>
</TR>
<TR>
<TD ROWSPAN="24" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/06/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/05/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/6/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 6, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 5, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/5/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/07/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/06/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/7/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 7, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 6, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/6/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/08/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/09/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/8/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 8, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 9, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/9/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/09/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/10/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/9/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 9, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 10, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/10/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/12/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/11/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/12/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 12, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 11, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/11/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/13/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/12/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/13/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 13, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 12, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/12/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/14/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/13/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/14/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 14, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 13, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/13/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/15/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/16/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/15/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 15, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 16, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/16/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/16/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/17/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/16/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 16, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 17, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/17/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/19/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/18/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/19/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 19, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 18, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/18/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/20/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/19/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/20/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 20, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 19, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/19/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/21/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/20/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/21/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 21, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 20, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/20/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/22/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/23/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/22/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 22, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 23, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/23/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/23/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/24/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/23/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 23, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 24, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/24/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/26/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/25/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/26/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 26, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 25, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/25/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/27/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/26/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/27/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 27, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 26, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/26/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/28/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/27/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/28/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 28, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 27, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/27/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/29/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/30/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/29/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM nowrap>
<P ALIGN=CENTER><FONT SIZE=2>September 29, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM nowrap>
<P ALIGN=CENTER><FONT SIZE=2>September 30, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/30/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>09/30/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/01/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>9/30/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>September 30, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 1, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/1/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/03/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/02/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/3/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 3, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 2, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/2/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/04/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/03/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/4/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 4, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 3, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/3/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/05/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/04/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/5/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 5, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 4, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/4/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/06/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/07/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/6/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 6, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 7, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/7/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/07/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/08/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/7/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 7, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 8, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/8/2013</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="13%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=BOTTOM>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=BOTTOM>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=BOTTOM>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="15%" VALIGN=BOTTOM>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="15%" VALIGN=BOTTOM>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=BOTTOM>
<P ALIGN=CENTER> </P>
</TD>
</TR>
<TR>
<TD ROWSPAN="31" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/10/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/09/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/10/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 10, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 9, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/9/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/11/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/10/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/11/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 11, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 10, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/10/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/12/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/11/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/12/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 12, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 11, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/11/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/13/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/14/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/13/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 13, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 14, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/14/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/14/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/15/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/14/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 14, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 15, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/15/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/17/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/16/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/17/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 17, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 16, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/16/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/18/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/17/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/18/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 18, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 17, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/17/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/19/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/18/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/19/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 19, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 18, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/18/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/20/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/21/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/20/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 20, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 21, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/21/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/21/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/22/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/21/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 21, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 22, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/22/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/24/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/23/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/24/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 24, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 23, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/23/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/25/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/24/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/25/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 25, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 24, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/24/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/26/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/25/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/26/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 26, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 25, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/25/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/27/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/28/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/27/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 27, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 28, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/28/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/28/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/29/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/28/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 28, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 29, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/29/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/31/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/30/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/31/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 31, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>October 30, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/30/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/01/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/31/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/1/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM nowrap>
<P ALIGN=CENTER><FONT SIZE=2>November 1, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM nowrap>
<P ALIGN=CENTER><FONT SIZE=2>October 31, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>10/31/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/02/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/01/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/2/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 2, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 1, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/1/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/03/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/04/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/3/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 3, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 4, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/4/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/04/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/05/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/4/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 4, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 5, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/5/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/07/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/06/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/7/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 7, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 6, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/6/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/08/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/07/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/8/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 8, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 7, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/7/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/09/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/08/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/9/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 9, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 8, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/8/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/10/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/11/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/10/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 10, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 11, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/11/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/11/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/12/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/11/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 11, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 12, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/12/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/14/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/13/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/14/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 14, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 13, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/13/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/15/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/14/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/15/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 15, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 14, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/14/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/16/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/15/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/16/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 16, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 15, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/15/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/17/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/18/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/17/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 17, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 18, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/18/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/18/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/19/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/18/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 18, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 19, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/19/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/21/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/20/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/21/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM nowrap>
<P ALIGN=CENTER><FONT SIZE=2>November 21, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM nowrap>
<P ALIGN=CENTER><FONT SIZE=2>November 20, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/20/2013</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="13%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=BOTTOM>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=BOTTOM>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=BOTTOM>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="15%" VALIGN=BOTTOM>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="15%" VALIGN=BOTTOM>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=BOTTOM>
<P ALIGN=CENTER> </P>
</TD>
</TR>
<TR>
<TD ROWSPAN="5" VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/22/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/21/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/22/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 22, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 21, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/21/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/23/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/22/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/23/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 23, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 22, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/22/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/28/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/25/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/25/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 25, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 25, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/25/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/29/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/26/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/28/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 28, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>November 26, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/26/2013</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/30/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/27/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/29/2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM nowrap>
<P ALIGN=CENTER><FONT SIZE=2>November 29, 2011</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM nowrap>
<P ALIGN=CENTER><FONT SIZE=2>November 27, 2013</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P ALIGN=CENTER><FONT SIZE=2>11/27/2013</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=4>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>20
<FILENAME>medtronic062430s1_ex10-29.htm
<DESCRIPTION>FORM OF AMENDMENT TO FORM OF WARRANTS
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 10.29 to Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="10%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="72%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="3%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="15%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD ROWSPAN="2" STYLE='BORDER:SOLID BLACK 1PX'>
<P ALIGN=CENTER><FONT SIZE=2>Confidential Materials omitted and filed separately with the<BR>
Securities and Exchange Commission. Asterisks denote omissions.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD HEIGHT=30 VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD HEIGHT=30>
<P ALIGN=CENTER><FONT SIZE="3"><B>Exhibit 10.29</B> </FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2><B>AMENDMENT TO<BR>CONFIRMATION</B></FONT></P>
<P><FONT SIZE=2> THIS
AMENDMENT (this <B>“Amendment”</B>) is
made as of this 13th day of April, 2006, between __________________. (<B>“Dealer”</B>) and Medtronic, Inc.
(<B>“Issuer”</B>).</FONT></P>
<P><FONT SIZE=2> WHEREAS,
Dealer and Issuer are parties to a Confirmation dated as of April 12, 2006
(Transaction Reference Number: _______________) (the <B>“Confirmation”</B>);</FONT></P>
<P><FONT SIZE=2> WHEREAS,
the parties wish to amend the Confirmation on the terms and conditions set
forth in this Amendment;</FONT></P>
<P><FONT SIZE=2> NOW,
THEREFORE, in consideration of their mutual covenants herein contained, the
parties hereto agree as follows:</FONT></P>
<P><FONT SIZE=2> Section
1. Terms Used but Not Defined Herein. Terms used but not defined herein shall
have the respective meanings given to them in the Confirmation.</FONT></P>
<P><FONT SIZE=2> Section
2. Amendment to the Confirmation. </FONT></P>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="90%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(a)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The
“Premium” under the Confirmation shall be USD [___________]. For the
avoidance of doubt, the Premium per Warrant set forth in the Confirmation
shall remain unchanged.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(a)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>The “Capped
Number” under the Confirmation shall be [___________].</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>(b)</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Annex A to
the Confirmation shall be replaced in its entirety with Annex A to this
Amendment. </FONT></P>
</TD>
</TR>
</TABLE>
<P><FONT SIZE=2> Section
3. Effectiveness. This Amendment shall become effective upon execution by the
parties hereto.</FONT></P>
<P><FONT SIZE=2> Section
4. Counterparts. This Amendment may be signed in any number of counterparts,
each of which shall be an original, with the same effect as if all of the
signatures thereto and hereto were upon the same instrument.</FONT></P>
<P><FONT SIZE=2> Section
5. Governing Law. This Amendment shall be governed by and construed in
accordance with the laws of the State of New York. </FONT></P>
<P><FONT SIZE=2> Section
6. Effectiveness of Confirmation. Except as amended hereby, all the terms of
the Confirmation shall remain and continue in full force and effect and are
hereby confirmed in all respects.</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<P><FONT SIZE=2>IN WITNESS
WHEREOF, the parties have signed this Amendment as of the date and year first
above written.</FONT></P>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="47%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="4%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="50%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>DEALER:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P> </P>
</TD>
<TD VALIGN=TOP>
<P> </P>
</TD>
<TD VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<HR SIZE=1 WIDTH="50%" NOSHADE ALIGN=LEFT>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P> </P>
</TD>
<TD VALIGN=TOP>
<P> </P>
</TD>
<TD VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>By:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="50%" NOSHADE ALIGN=LEFT>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Name:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Title:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>ISSUER:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD COLSPAN="2" VALIGN=TOP>
<P><FONT SIZE=2>MEDTRONIC,
INC.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>By:</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="50%" NOSHADE ALIGN=LEFT>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Name:</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Title:</FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>2</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<P ALIGN=RIGHT><FONT SIZE=2>Annex A</FONT></P>
<P><FONT SIZE=2>For each
Component of the Transaction, the Number of Warrants and Expiration Date is set
forth below.</FONT></P>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="30%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="30%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="30%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE="1"><B>Component Number</B> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE="1"><B>Number of Warrants</B> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE="1"><B>Expiration Date</B> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="42%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="45%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<HR SIZE=1 WIDTH="35%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>1.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>2.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>3.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>4.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>5.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>6.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>7.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>8.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>9.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>12.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>13.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>14.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>15.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>16.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>17.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>18.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>19.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>20.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>21.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>22.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>23.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>24.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>25.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>26.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>27.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>28.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>29.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>30.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>31.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>32.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>33.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>34.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>35.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>36.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>37.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>38.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>39.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>A-1</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="30%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="30%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="30%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>40.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>41.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>42.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>43.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>44.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>45.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>46.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>47.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>48.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>49.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>50.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>51.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>52.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>53.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>54.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>55.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>56.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>57.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>58.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>59.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>60.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>61.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>62.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>63.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>64.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>65.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>66.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>67.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>68.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>69.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>70.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>71.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>72.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>73.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>74.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>75.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>76.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>77.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>78.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>79.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>80.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>81.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>82.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>83.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>A-1</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="30%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="30%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="5%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="30%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>84.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>85.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>86.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>87.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>88.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>89.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>90.</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>[____________]</FONT></P>
</TD>
</TR>
</TABLE>
<P ALIGN=CENTER><FONT SIZE=2>A-1</FONT></P>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<P ALIGN=CENTER><FONT SIZE=2><U>Schedule to
Exhibit 10.29</U></FONT></P>
<P><FONT SIZE=2> On
April 12, 2006, the Company entered into six warrant transactions. On
April 13, 2006, the Company entered into six amendments to those warrant
transactions. A confirmation was
produced for each transaction. Each confirmation is substantially identical to
the form of warrant amendment confirmation appearing herein as Exhibit 10.29
(the “Form of Warrant Amendment Confirmation”). However, the six actual
confirmations differ from the Form of Warrant Amendment Confirmation as
follows: </FONT></P>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="12%" VALIGN=BOTTOM>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=BOTTOM>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=BOTTOM>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=BOTTOM>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=BOTTOM>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=BOTTOM>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=BOTTOM>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=BOTTOM>
<P> </P>
</TD>
<TD WIDTH="15%" VALIGN=BOTTOM>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=BOTTOM>
<P> </P>
</TD>
<TD WIDTH="15%" VALIGN=BOTTOM>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=BOTTOM>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=BOTTOM>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1><B>Issuer:</B></FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1><B>Deutsche Bank</B></FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1><B>Deutsche Bank</B></FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1><B>UBS AG</B></FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1><B>Merrill Lynch</B></FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1><B>Merrill Lynch</B></FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1><B>Goldman Sachs</B></FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=BOTTOM>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<HR SIZE=1 WIDTH="100%" NOSHADE COLOR=BLACK ALIGN=CENTER>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 1, in the first paragraph, the following
names replace the blank before the phrase “Dealer.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Deutsche Bank AG acting
through its London Branch (“<B>Dealer</B>”), with Deutsche Bank AG, New York
Branch acting as its agent,</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Deutsche Bank AG acting
through its London Branch (“<B>Dealer</B>”), with Deutsche Bank AG, New York
Branch acting as its agent,</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>UBS AG acting through its
London Branch (“<B>Dealer</B>”), represented by UBS Securities LLC as its agent,</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Merrill Lynch
International (“<B>Dealer</B>”), with Merrill Lynch, Pierce,
Fenner & Smith Incorporated acting as its agent</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>Merrill Lynch
International (“<B>Dealer</B>”), with Merrill Lynch, Pierce,
Fenner & Smith Incorporated acting as its agent</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP NOWRAP>
<P><FONT SIZE=2>Goldman, Sachs<BR>& Co. (“<B>Dealer</B>”)</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 1, the following numbers replace the blank
space following the phrase “Internal or Transaction Reference Number”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>104926</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>104928</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>1805700</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>0683241</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>0683243</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>FDB1620971448</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 1, in the first Section 2 (a), the following
amounts replace the blank that appears opposite the heading “Premium.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>USD[**]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On Page 1, in the second Section 2 (a), the
following</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<BR>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="15%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="15%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>amounts replace the blank that appears opposite the
heading “Capped Amount.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>On page 2 the following information replaces the
blank space following the word “Dealer:”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>DEUTSCHE BANK AG LONDON
<BR>
<BR>
and <BR>
<BR>
DEUTSCHE BANK AG NEW YORK as agent</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>DEUTSCHE BANK AG LONDON<BR>
<BR>
and <BR>
<BR>DEUTSCHE BANK AG NEW YORK as agent</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>UBS AG, LONDON BRANCH
<BR>
<BR>
and <BR>
<BR>UBS SECURITIES LLC, as agent</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>MERRILL LYNCH
INTERNATIONAL<BR><BR>
and<BR>
<BR>MERRILL LYNCH, PIERCE, FENNER &
SMITH INCORPORATED as agent</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>MERRILL LYNCH
INTERNATIONAL<BR>
<BR>
and <BR>
<BR>MERRILL LYNCH, PIERCE, FENNER &
SMITH INCORPORATED as agent</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>GOLDMAN, SACHS & CO.</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=2>In the table on Annex A the following amounts
replace each and every blank in the column entitled “Number of Warrants.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=2>[**]</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
</TR>
<TR>
<TD ROWSPAN=12 VALIGN=TOP>
<P><FONT SIZE=2>In the table on Annex A the following dates replace
the blanks in the column entitled “Expiration Date.”</FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P align=center><FONT SIZE=2>Expiration<BR>Date</FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=2> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P align=center><FONT SIZE=2>Expiration<BR>Date</FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=2> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P align=center><FONT SIZE=2>Expiration<BR>Date</FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=2> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P align=center><FONT SIZE=2>Expiration<BR>Date</FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=2> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P align=center><FONT SIZE=2>Expiration<BR>Date</FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P><FONT SIZE=2> </FONT></P>
</TD>
<TD VALIGN=BOTTOM>
<P align=center><FONT SIZE=2>Expiration<BR>Date</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/25/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/24/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/25/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/25/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/24/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/24/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/26/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/25/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/26/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/26/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/25/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/25/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/27/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/26/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/27/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/27/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/26/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/26/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/28/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/29/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/28/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/28/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/29/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/29/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/29/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/30/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/29/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/29/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/30/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/30/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/01/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/31/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/01/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/01/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/31/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>07/31/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/02/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/01/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/02/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/02/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/01/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/01/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/03/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/02/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/03/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/03/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/02/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/02/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/04/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/05/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/04/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/04/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/05/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/05/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/05/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/06/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/05/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/05/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/06/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/06/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/08/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/07/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/08/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/08/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/07/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/07/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/09/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/08/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/09/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/09/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/08/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/08/13</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="15%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="15%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/10/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/09/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/10/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/10/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/09/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/09/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/11/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/12/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/11/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/11/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/12/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/12/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/12/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/13/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/12/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/12/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/13/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/13/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/15/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/14/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/15/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/15/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/14/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/14/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/16/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/15/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/16/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/16/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/15/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/15/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/17/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/16/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/17/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/17/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/16/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/16/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/18/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/19/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/18/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/18/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/19/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/19/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/19/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/20/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/19/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/19/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/20/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/20/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/22/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/21/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/22/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/22/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/21/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/21/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/23/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/22/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/23/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/23/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/22/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/22/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/24/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/23/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/24/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/24/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/23/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/23/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/25/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/26/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/25/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/25/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/26/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/26/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/26/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/27/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/26/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/26/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/27/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/27/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/29/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/28/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/29/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/29/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/28/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/28/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/30/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/29/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/30/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/30/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/29/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/29/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/31/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/30/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/31/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/31/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/30/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>08/30/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/01/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/03/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/01/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/01/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/03/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/03/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/02/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/04/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/02/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/02/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/04/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/04/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/06/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/05/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/06/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/06/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/05/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/05/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/07/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/06/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/07/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/07/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/06/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/06/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/08/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/09/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/08/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/08/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/09/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/09/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/09/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/10/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/09/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/09/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/10/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/10/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/12/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/11/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/12/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/12/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/11/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/11/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/13/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/12/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/13/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/13/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/12/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/12/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/14/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/13/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/14/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/14/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/13/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/13/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/15/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/16/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/15/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/15/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/16/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/16/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/16/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/17/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/16/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/16/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/17/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/17/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/19/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/18/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/19/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/19/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/18/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/18/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/20/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/19/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/20/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/20/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/19/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/19/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/21/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/20/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/21/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/21/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/20/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/20/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/22/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/23/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/22/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/22/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/23/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/23/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/23/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/24/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/23/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/23/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/24/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/24/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/26/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/25/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/26/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/26/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/25/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/25/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/27/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/26/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/27/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/27/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/26/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/26/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/28/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/27/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/28/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/28/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/27/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/27/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/29/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/30/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/29/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/29/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/30/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/30/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/30/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/01/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/30/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>09/30/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/01/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/01/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/03/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/02/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/03/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/03/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/02/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/02/13</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=3><P STYLE='PAGE-BREAK-BEFORE: ALWAYS'></P><PAGE>
<TABLE ALIGN=CENTER BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">
<TR style="font-size:1px">
<TD WIDTH="12%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="2%" VALIGN=TOP>
<P> </P>
</TD>
<TD WIDTH="11%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="12%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="15%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="15%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="1%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
<TD WIDTH="10%" VALIGN=TOP>
<P ALIGN=CENTER> </P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/04/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/03/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/04/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/04/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/03/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/03/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/05/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/04/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/05/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/05/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/04/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/04/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/06/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/07/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/06/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/06/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/07/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/07/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/07/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/08/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/07/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/07/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/08/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/08/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/10/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/09/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/10/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/10/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/09/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/09/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/11/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/10/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/11/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/11/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/10/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/10/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/12/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/11/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/12/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/12/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/11/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/11/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/13/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/14/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/13/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/13/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/14/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/14/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/14/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/15/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/14/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/14/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/15/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/15/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/17/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/16/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/17/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/17/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/16/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/16/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/18/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/17/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/18/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/18/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/17/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/17/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/19/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/18/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/19/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/19/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/18/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/18/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/20/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/21/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/20/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/20/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/21/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/21/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/21/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/22/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/21/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/21/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/22/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/22/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/24/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/23/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/24/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/24/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/23/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/23/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/25/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/24/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/25/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/25/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/24/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/24/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/26/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/25/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/26/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/26/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/25/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/25/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/27/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/28/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/27/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/27/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/28/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/28/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/28/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/29/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/28/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/28/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/29/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/29/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/31/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/30/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/31/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/31/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/30/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/30/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/01/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/31/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/01/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/01/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/31/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>10/31/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/02/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/01/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/02/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/02/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/01/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/01/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/03/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/04/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/03/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/03/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/04/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/04/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/04/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/05/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/04/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/04/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/05/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/05/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/07/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/06/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/07/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/07/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/06/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/06/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/08/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/07/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/08/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/08/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/07/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/07/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/09/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/08/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/09/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/09/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/08/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/08/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/10/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/11/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/10/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/10/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/11/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/11/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/11/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/12/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/11/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/11/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/12/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/12/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/14/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/13/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/14/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/14/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/13/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/13/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/15/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/14/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/15/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/15/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/14/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/14/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/16/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/15/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/16/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/16/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/15/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/15/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/17/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/18/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/17/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/17/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/18/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/18/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/18/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/19/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/18/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/18/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/19/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/19/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/21/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/20/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/21/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/21/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/20/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/20/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/22/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/21/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/22/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/22/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/21/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/21/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/23/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/22/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/23/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/23/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/22/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/22/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/28/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/25/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/28/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/25/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/25/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/25/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/29/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/26/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/29/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/28/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/26/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/26/13</FONT></P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/30/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/27/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/30/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/29/11</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/27/13</FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=1> </FONT></P>
</TD>
<TD VALIGN=TOP>
<P ALIGN=CENTER><FONT SIZE=2>11/27/13</FONT></P>
</TD>
</TR>
</TABLE>
<BR>
<HR NOSHADE ALIGN=CENTER WIDTH="100%" SIZE=4>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>21
<FILENAME>medtronic062430s1_ex10-30.htm
<DESCRIPTION>NAMED EXECUTIVE OFFICER COMPENSATION
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 10.30 to Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR>
<P style="font-size:10pt;font-weight:bold;text-align:right">Exhibit 10.30</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">Summary of Compensation Arrangements for<BR>Named Executive Officers
and Directors</P>
<P style="font-size:10pt;font-weight:bold">Compensation Arrangements for Named Executive Officers</P>
<P style="font-size:10pt"> Following is a description of the compensation arrangements
that have been approved by the Compensation Committee of the Board of Directors of Medtronic, Inc. (the “Compensation
Committee”) on April 12, 2006 for the Company’s Chief Executive Officer and the other four most highly compensated
executive officers in fiscal 2006 (the “Named Executive Officers”).</P>
<P style="font-size:10pt;font-weight:bold">Annual Base Salary:</P>
<P style="font-size:10pt"> The Compensation Committee approved the following
base salaries, effective April 29, 2006, for the Named Executive Officers:</P>
<DIV align="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%">
<TR VALIGN="top" style="font-size:10pt" bgcolor="#D6F3E8">
<TD width="86%">Arthur D. Collins, Jr</TD>
<TD width="1%"> </TD>
<TD width="1%"> </TD>
<TD width="2%"> </TD>
<TD width="1%">$</TD>
<TD align="right" width="8%">1,275,000</TD>
<TD width="1%"> </TD>
</TR>
<TR VALIGN="top" style="font-size:10pt">
<TD>Chairman and Chief Executive Officer</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
</TR>
<TR VALIGN="top" style="font-size:10pt;padding-top:4pt" bgcolor="#D6F3E8">
<TD>William A. Hawkins</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">775,000</TD>
<TD> </TD>
</TR>
<TR VALIGN="top" style="font-size:10pt">
<TD>President & Chief Operating Officer</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
</TR>
<TR VALIGN="top" style="font-size:10pt;padding-top:4pt" bgcolor="#D6F3E8">
<TD>Stephen H. Mahle</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">595,000</TD>
<TD> </TD>
</TR>
<TR VALIGN="top" style="font-size:10pt">
<TD >Executive Vice President & President, Cardiac Rhythm Disease Management</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
</TR>
<TR VALIGN="top" style="font-size:10pt;padding-top:4pt" bgcolor="#D6F3E8">
<TD>Terrance L. Carlson</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">515,000</TD>
<TD> </TD>
</TR>
<TR VALIGN="top" style="font-size:10pt">
<TD >Senior Vice President, General Counsel and Corporate Secretary</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
</TR>
<TR VALIGN="top" style="font-size:10pt;padding-top:4pt" bgcolor="#D6F3E8">
<TD>Michael F. DeMane</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">530,000</TD>
<TD> </TD>
</TR>
<TR VALIGN="top" style="font-size:10pt">
<TD >Senior Vice President & President, Europe, Canada, Latin America & Emerging
Markets</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
</TR>
</TABLE>
</DIV>
<P style="font-size:10pt;font-weight:bold">Bonus:</P>
<P style="font-size:10pt"> The Compensation Committee has approved the following
bonus payments for performance in fiscal 2006:</P>
<DIV align="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%">
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD width="86%">Arthur D. Collins, Jr</TD>
<TD width="1%"> </TD>
<TD width="1%"> </TD>
<TD width="2%"> </TD>
<TD width="1%">$</TD>
<TD align="right" width="8%">1,827,125</TD>
<TD width="1%"> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD>William A. Hawkins</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">802,400</TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD>Stephen H. Mahle</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">534,191</TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD>Terrance L. Carlson</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">413,276</TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD>Michael F. DeMane</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">471,692</TD>
<TD> </TD>
</TR>
</TABLE>
</DIV>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> A description of the
performance goals for fiscal year 2006, which were previously approved by the Compensation Committee, is included
in a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 29, 2005 and is
incorporated herein by reference. </FONT></P>
<P style="font-size:10pt;font-weight:bold">Stock Option and Restricted Share Unit Grants:</P>
<P style="font-size:10pt"> The Compensation Committee approved the following
stock options and restricted stock units (“RSU”) grants under the Company’s 2003 Long-Term Incentive Plan. The
stock options were granted at an exercise price of $56.74, which was the fair market value of the Company’s Common Stock
on the date of grant and vest annually in 25% increments. The RSUs were granted at the fair market value of the Company’s
Common Stock on the date of grant. The RSUs will cliff vest in October 2010 except in the event of death, disability or retirement,
in which case they vest in full.</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" ALIGN="CENTER">
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt" bgcolor="#D6F3E8">
<TD WIDTH="53%">Arthur D. Collins, Jr</TD>
<TD WIDTH="2%"> </TD>
<TD WIDTH="26%">35,249 RSUs</TD>
<TD WIDTH="2%"> </TD>
<TD WIDTH="17%" nowrap>229,116 stock options</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>William A. Hawkins</TD>
<TD> </TD>
<TD></TD>
<TD> </TD>
<TD nowrap>75,785 stock options</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt" bgcolor="#D6F3E8">
<TD>Stephen H. Mahle</TD>
<TD> </TD>
<TD></TD>
<TD> </TD>
<TD nowrap>52,873 stock options</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Terrance L. Carlson</TD>
<TD> </TD>
<TD></TD>
<TD> </TD>
<TD nowrap>47,586 stock options</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt" bgcolor="#D6F3E8">
<TD>Michael F. DeMane</TD>
<TD> </TD>
<TD></TD>
<TD> </TD>
<TD nowrap>47,586 stock options</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<P style="font-size:10pt;font-weight:bold">Long Term Incentive Plan Awards:</P>
<P style="font-size:10pt"> The Compensation Committee approved the following
long-term incentive plan awards established for the three-year cycle ending in fiscal 2006. The amounts listed below include
the value of both cash and stock. Half of the award is paid in Company common stock, with the other half paid in cash. The
value of an award is determined at the end of the performance period based on Medtronic’s financial performance and the
average fair market value per share for the last 20 trading days of the performance cycle.</P>
<DIV align="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%">
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD width="86%">Arthur D. Collins, Jr.</TD>
<TD width="1%"> </TD>
<TD width="1%"> </TD>
<TD width="2%"> </TD>
<TD width="1%">$</TD>
<TD align="right" width="8%">1,130,011</TD>
<TD width="1%"> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD>William A. Hawkins</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">259,868</TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD>Stephen H. Mahle</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">323,190</TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD>Terrance L. Carlson</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">—</TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD>Michael F. DeMane</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">259,868</TD>
<TD> </TD>
</TR>
</TABLE>
</DIV>
<P style="font-size:10pt;font-weight:bold">Compensation Arrangements for Non-Employee Directors</P>
<P style="font-size:10pt"> Non-employee director compensation consists of an
annual retainer, an annual cash stipend for committee chairs and special committee members, an annual stock option grant and
an annual grant of deferred stock units. In addition, all new non-employee directors receive an initial stock option grant.</P>
<P style="font-size:10pt"> The annual retainer for all non-employee directors
for the 2006-2007 plan year (September 1, 2006 through August 31, 2007) is $70,000. The Chairs of the Corporate Governance,
Audit, Compensation and Technology and Quality Committees receive a cash stipend of $10,000. Members of a Special Committee
receive an additional annual fee of $10,000 for each Special Committee upon which they serve, paid quarterly ($2,500 per quarter),
so long as the committee is convened. The annual retainer and annual cash stipend are reduced by 25% if a non-employee director
does not attend at least 75% of the total meetings of the Board and Board committees on which such director served during the
relevant plan year.</P>
<P style="font-size:10pt"> Each non-employee director also receives on the first
day of each plan year an annual stock option grant for a number of shares of Medtronic common stock equal to the amount of
the annual retainer ($70,000) divided by the fair market value of a share of Medtronic common stock on the date of grant (which
will also be the exercise price of the option).</P>
<P style="font-size:10pt"> On the last day of each plan year, each non-employee
director is granted a number of deferred stock units (each representing the right to receive one share of Medtronic common
stock) equal to the amount of the annual retainer ($70,000) earned divided by the average closing price of a share of Medtronic
common stock for the last 20 trading days during the plan year. On the date he or she first becomes a director, each new non-employee
director receives a one-time initial stock option grant for a number of shares of Medtronic common stock equal to two times
the amount of the annual retainer ($140,000) divided by the fair market value of a share of Medtronic common stock on the date
of grant (which will also be the exercise price of such option).</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>22
<FILENAME>medtronic062430s1_ex12-1.htm
<DESCRIPTION>COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 12.1 to Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR>
<P style="font-size:10pt;font-weight:bold;text-align:right">Exhibit 12.1</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">MEDTRONIC, INC. COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES</P>
<P style="font-size:10pt"> The ratio of earnings to fixed charges for the fiscal
years ended April 28, 2006, April 29, 2005, April 30, 2004, April 25, 2003, April 26, 2002 was computed based on Medtronic’s
historical consolidated financial information included in Medtronic’s most recent Annual Report incorporated by reference
on Form 10-K.</P>
<DIV align="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM" style="font-size:8pt">
<TH colspan="2" align="left"></TH>
<TH> </TH>
<TH> </TH>
<TH colspan="2">Year ended<BR>April 28, 2006</TH>
<TH> </TH>
<TH> </TH>
<TH colspan="2">Year ended<BR>April 29, 2005</TH>
<TH> </TH>
<TH> </TH>
<TH colspan="2">Year ended<BR>April 30, 2004</TH>
<TH> </TH>
<TH> </TH>
<TH colspan="2">Year ended<BR>April 25, 2003</TH>
<TH> </TH>
<TH> </TH>
<TH colspan="2">Year ended<BR>April 26, 2002</TH>
<TH> </TH>
</TR>
<TR>
<TD colspan="2"></TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD width="38%">Earnings:</TD>
<TD width="1%"> </TD>
<TD width="1%"> </TD>
<TD width="3%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="7%"></TD>
<TD width="1%"> </TD>
<TD width="3%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="7%"></TD>
<TD width="1%"> </TD>
<TD width="3%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="7%"></TD>
<TD width="1%"> </TD>
<TD width="3%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="7%"></TD>
<TD width="1%"> </TD>
<TD width="3%"> </TD>
<TD width="1%"> </TD>
<TD align="right" width="7%"></TD>
<TD width="1%"> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD style="padding-left:10">Net earnings</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">2,546.7</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">1,803.9</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">1,959.3</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">1,599.8</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">984.0</TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD style="padding-left:10">Income taxes</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">614.6</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">739.6</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">837.6</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">741.5</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">540.2</TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD style="padding-left:10">Minority interest (loss)/income</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">—</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">(0.5</TD>
<TD>)</TD>
<TD> </TD>
<TD> </TD>
<TD align="right">2.5</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">(0.7</TD>
<TD>)</TD>
<TD> </TD>
<TD> </TD>
<TD align="right">3.0</TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD style="padding-left:10">Amortization of capitalized interest</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">0.1</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">0.1</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">0.1</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">0.1</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">0.1</TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD style="padding-left:10">Capitalized interest<SUP>(1)</SUP></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">(2.8</TD>
<TD>)</TD>
<TD> </TD>
<TD> </TD>
<TD align="right">(1.1</TD>
<TD>)</TD>
<TD> </TD>
<TD> </TD>
<TD align="right">—</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">(0.9</TD>
<TD>)</TD>
<TD> </TD>
<TD> </TD>
<TD align="right">(0.3</TD>
<TD>)</TD>
</TR>
<TR>
<TD colspan="2"></TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD style="padding-left:10"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">3,158.6</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">2,542.0</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">2,799.5</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">2,339.8</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">1,527.0</TD>
<TD> </TD>
</TR>
<TR>
<TD colspan="2"></TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt;padding-top:6pt">
<TD>Fixed Charges:</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right"></TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD style="padding-left:10">Interest expense<SUP>(2)</SUP></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">116.1</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">55.1</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">56.5</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">47.2</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">45.2</TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD style="padding-left:10">Capitalized interest<SUP>(1)</SUP></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">2.8</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">1.1</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">—</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">0.9</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">0.3</TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD style="padding-left:10">Amortization of debt issuance costs<SUP>(3)</SUP></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">3.8</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">0.8</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">—</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">—</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">32.0</TD>
<TD> </TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD style="padding-left:10">Rent interest factor<SUP>(4)</SUP></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">26.6</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">23.8</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">21.0</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">18.0</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">16.3</TD>
<TD> </TD>
</TR>
<TR>
<TD colspan="2"></TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD style="padding-left:10"></TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">149.3</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">80.8</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">77.5</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">66.1</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">93.8</TD>
<TD> </TD>
</TR>
<TR>
<TD colspan="2"></TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD>Earnings before income taxes and fixed charges</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">3,307.9</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">2,622.8</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">2,877.0</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">2,405.9</TD>
<TD> </TD>
<TD> </TD>
<TD>$</TD>
<TD align="right">1,620.8</TD>
<TD> </TD>
</TR>
<TR>
<TD colspan="2"></TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:3;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:3;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:3;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:3;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD></TD>
<TD colspan="2">
<HR style="height:3;color:black;background-color:black" noshade>
</TD>
<TD></TD>
</TR>
<TR VALIGN="BOTTOM" style="font-size:10pt" bgcolor="#D6F3E8">
<TD>Ratio of earnings to fixed charges</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">22.2</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">32.5</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">37.1</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">36.4</TD>
<TD> </TD>
<TD> </TD>
<TD> </TD>
<TD align="right">17.3</TD>
<TD> </TD>
</TR>
</TABLE>
</DIV>
<BR>
<HR noshade color="black" align="left" size="1" width="20%">
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%">(1)</TD>
<TD WIDTH="96%">Capitalized interest relates to construction projects in process.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(2)</TD>
<TD>Interest expense consists of interest on indebtedness.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(3)</TD>
<TD>Represents the amortization of debt issuance costs incurred in connection with the Company’s registered debt securities.
See Note 5 to the consolidated financial statements for further information regarding the debt securities.</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD>(4)</TD>
<TD>Approximately one-third of rental expense is deemed representative of the interest factor.</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13
<SEQUENCE>23
<FILENAME>medtronic062430s1_ex13.htm
<DESCRIPTION>EXCERPTS OF ANNUAL REPORT
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 13 to Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR>
<h1 ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=3>Exhibit 13 </FONT></h1>
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3>Table of Contents </FONT></H1>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TD WIDTH=93% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><A HREF="#managements">Management’s Discussion and Analysis of Financial Condition and Results of Operations</A></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=2% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><A HREF="#reports_of_management">Reports of Management</A></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>32</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><A HREF="#report_of_independent">Report of Independent Registered Public Accounting Firm</A></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>33</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><A HREF="#statements_of_earnings">Consolidated Statements of Earnings</A></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>34</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><A HREF="#balance_sheets">Consolidated Balance Sheets</A></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>35</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><A HREF="#shareholders_equity">Consolidated Statements of Shareholders’ Equity</A></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>36</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><A HREF="#cash_flows">Consolidated Statements of Cash Flows</A></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>37</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><A HREF="#notes">Notes to Consolidated Financial Statements</A></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>38</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><A HREF="#financial_data">Selected Financial Data</A></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>74</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><A HREF="#price_range">Price Range of Medtronic Stock</A></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>75</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
</TABLE>
<BR>
<BR><BR><BR><BR><BR><BR><BR><BR><BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Head Minor Center Bold" FSL="Default" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><A NAME="managements">Management’s</A> Discussion and Analysis of Financial Condition and Results of Operations </FONT></H1>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Understanding Our Financial Information </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The following discussion and
analysis provides information management believes to be relevant to understanding the financial condition and results of
operations of Medtronic, Inc. You should read this discussion along with our consolidated financial statements and related Notes
thereto as of April 28, 2006 and April 29, 2005 and for each of the three fiscal years ended April 28, 2006,
April 29, 2005 and April 30, 2004. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B><I>Organization of
Financial Information </I></B>Management’s discussion and analysis, presented on pages 2 to 31 of this report,
provides material historical and prospective disclosures designed to enable investors and other users to assess our financial
condition and results of operations. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The consolidated financial
statements are presented on pages 34 to 73 of this report, and include the consolidated statements of earnings, consolidated
balance sheets, consolidated statements of shareholders’ equity, consolidated statements of cash flows and the related Notes,
which are an integral part of the consolidated financial statements. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B><I>Financial
Trends</I></B><I></I> Throughout this financial information, you will read about transactions or events that
materially contribute to or reduce earnings and materially affect financial trends. We refer to these transactions and events as
either special (such as certain tax adjustments and restructuring charges), certain litigation or purchased in-process
research and development (IPR&D) charges. These charges result from facts and circumstances that vary in frequency and/or
impact to operations. While understanding these charges is important in understanding and evaluating financial trends, other
transactions or events may also have a material impact on financial trends. A complete understanding of the special,
certain litigation and IPR&D charges is necessary in order to estimate the likelihood that financial trends will continue.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Our fiscal year-end is the
last Friday in April, and therefore, the total weeks in a fiscal year can fluctuate between fifty-two and fifty-three weeks.
Fiscal year 2006 and 2005 consisted of fifty-two weeks; however, fiscal year 2004 fourth quarter and full year included fourteen
and fifty-three weeks, respectively, as opposed to thirteen and fifty-two weeks, respectively, in both fiscal years 2006 and 2005.
This extra week had a favorable impact on our fiscal year 2004 results; however, it is not possible to quantify the exact impact
because our growth throughout the fiscal year is not linear. </FONT></P>
<BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Executive Level Overview </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> We are the global leader in
medical technology, alleviating pain, restoring health and extending life for millions of people around the world. During the
fourth quarter of fiscal year 2006, we revised our operating segment reporting related to our Neurological and Diabetes operating
segment and our Spinal, Ear, Nose and Throat (ENT) and Navigation operating segment. As a result, we now function in seven
operating segments, consisting of Cardiac Rhythm Disease Management (CRDM); Spinal and Navigation; Neurological; Vascular;
Diabetes; Cardiac Surgery; and ENT. The applicable information for fiscal years 2005 and 2004 has been reclassified to conform to
the current presentation. Through these seven operating segments, we develop, manufacture, and market our medical devices in more
than 120 countries worldwide while expanding patient access to our products. Our primary products include those for heart and
vascular disease, neurological disorders, chronic pain, spinal disorders, diabetes, urologic and digestive system disorders, and
ear, nose and throat disorders. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Net earnings for the fiscal
year ended April 28, 2006 were $2.547 billion, a $742.8 million, or 41%, increase from net earnings of $1.804 billion for the
fiscal year ended April 29, 2005. Diluted earnings per share were $2.09 and $1.48 for the fiscal years ended April 28, 2006 and
April 29, 2005, respectively. Fiscal year 2006 net earnings include after-tax special and IPR&D charges of $135.9 million, or
$0.11 per diluted share. The net earnings for fiscal year 2005 include after-tax special and certain litigation charges of $466.6
million, or $0.38 per diluted share. The increase in net earnings was driven primarily by net sales growth. Net sales in fiscal
year 2006 were $11.292 billion, an increase of 12% from the prior fiscal year. We achieved solid worldwide sales growth
throughout our diversified and balanced portfolio. As illustrated in the table below, six of our seven operating segments had
growth rates ranging from 9% to 19%. </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Net Sales </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>FY06 vs. FY05<BR>% Change </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>(dollars in millions) </FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH="27%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CRDM</FONT></TD>
<TD WIDTH="13%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="8%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH="10%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 5,205.5</FONT></TD>
<TD WIDTH="8%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH="10%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 4,615.5</FONT></TD>
<TD WIDTH="8%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 13%</FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="3%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Spinal and Navigation</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,244.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,884.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>19</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Neurological</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,016.0</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>927.3</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Vascular</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>939.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>851.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Diabetes</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>722.3</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>649.4</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cardiac Surgery</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>663.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>668.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (1)</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ENT(1)</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>501.4</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>458.2</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 9</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Total Net Sales</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 11,292.0</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 10,054.6</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"> <B>12%</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1) </FONT></TD>
<TD WIDTH=97%><P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>During the third quarter of fiscal year 2006, we
sold our Tonometry product line. Excluding the Tonometry product line, ENT revenues increased 10% from $445.5 million for fiscal
year 2005 to $490.8 million for fiscal year 2006. </FONT></P></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> CRDM net sales increased 13%
over the prior fiscal year to $5.206 billion. CRDM growth was driven by continued acceptance of the Maximo, Intrinsic and
Entrust families of implantable cardioverter defibrillators (ICDs) and the InSync Sentry, a cardiac resynchronization device with
defibrillator back-up (CRT-D). Implantable defibrillator fiscal year 2006 net sales grew 23%. Spinal and Navigation net sales
increased 19% over the prior fiscal year to $2.244 billion. The increase reflects strong growth across our portfolio of
spinal surgery products including the INFUSE Bone Graft, the CD HORIZON LEGACY Spinal System family of products for thoracolumbar
stabilization, our Minimal Access Spinal Technologies (MAST) family of products, our cervical stabilization family of products
including the VERTEX Max Reconstruction System and MYSTIQUE Resorbable Graft Containment Plating System and the increasing
acceptance of the CAPSTONE Vertebral Body Spacer. Neurological sales increased 10% over the prior fiscal year to
$1.016 billion. The increase in Neurological net sales reflects solid growth in several product lines including the Restore
Rechargeable Neurostimulation System for pain management, continued strength of Activa Therapy for the treatment of movement
disorders associated with advanced Parkinson’s disease and essential tremor and InterStim Therapy for the treatment of
overactive bladder and urinary retention. Vascular net sales increased 10% over the prior fiscal year to $939.4 million.
Vascular growth was led by Coronary Vascular net sales which grew by 12% over fiscal year 2005. The growth in Coronary Vascular
was primarily a result of the release of our Endeavor Drug-Eluting Coronary Stent (DES) in various markets outside the U.S. and
the strong performance worldwide of our other coronary products, including balloons </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>and guidewires. Diabetes net sales increased 11% over the prior fiscal year
to $722.3 million. The sales increase reflects solid global growth of the MiniMed Paradigm family of insulin pumps and
disposable infusion sets used with our line of MiniMed Paradigm pumps. ENT net sales increased 9% over the prior fiscal year to
$501.4 million. The primary drivers of the increase in ENT net sales were continued physician acceptance of the NIM-Response 2.0
Nerve Integrity Monitor and XPS Powered ENT System. See our discussion of
net sales by operating segment within this management’s discussion and analysis for more information. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> While we continue to make
substantial investments for the expansion of our existing product lines and for the search of new innovative products, we have
also focused heavily on carefully planned clinical trials, which lead to market expansion and enable further penetration of our
life changing devices. Fiscal year 2006 research and development spending of $1.113 billion increased 17% in comparison to
the prior fiscal year. Our research and development efforts are focused on maintaining leadership in each of the markets we serve
to ensure that patients receive the most advanced and effective treatments possible. Research and development expenditures have
supported improvements in existing products and enhanced methods to deliver and/or monitor those products. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Increased investment in our
future is fortified by our continued strong cash flow generated from operations of over $2.2 billion during fiscal year 2006
and our $6.9 billion in cash, short-term debt securities and long-term debt securities as of April 28, 2006. We will use
our cash flow from operations to invest in research and development, certain strategic acquisitions and to participate in expanded
clinical trials, which support regulatory approval of our products. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In September 2005, we issued
two tranches of Senior Notes with the aggregate face value of $1.000 billion. The first tranche consisted of $400.0 million of
4.375 percent Senior Notes due 2010 and the second tranche consisted of $600.0 million of 4.750 percent Senior Notes due 2015.
Each tranche was issued at a discount which resulted in an effective interest rate of 4.433 percent and 4.760 percent for the five
and ten year Senior Notes, respectively. In April 2006, we issued $2.200 billion of 1.500 percent Senior Convertible Notes due
2011 and $2.200 billion of 1.625 percent Senior Convertible Notes due 2013, collectively the Senior Convertible Notes. The Senior
Convertible Notes have an initial conversion price of $56.14 per share. Concurrent with the issuance of the Senior Convertible
Notes, we purchased call options that allow us to receive shares of our common stock and/or cash from counterparties equal to the
amounts of common stock and/or cash related to the excess conversion value that we would pay to the holders of the Senior
Convertible Notes upon conversion. The call options, which cost an aggregate $1.075 billion ($698.5 million net of tax
benefit), were recorded as a reduction of shareholders’ equity. In separate transactions, we sold warrants to issue 82.2
million shares of our common stock at an exercise price of $76.56 per share. Proceeds received from the issuance of the warrants
totaled approximately $516.8 million and were recorded as an addition to shareholders’ equity. A portion of the proceeds from
the Senior Convertible Notes were used to repurchase approximately 49 million shares of our common stock. For more detail
regarding these transactions, see the “Debt and Capital” section within this management’s discussion and analysis.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> We remain committed to our
Mission of developing lifesaving and life enhancing therapies to alleviate pain, restore health and extend life. The diversity and
depth of our current product offerings enable us to provide medical therapies to patients worldwide. We will rigorously work to
improve patient access through well planned studies, which show the cost-effectiveness of our therapies and our alliance with
patients, clinicians, regulators and reimbursement agencies. Our investments in research and development, strategic acquisitions,
expanded clinical trials and infrastructure provide the foundation for our growth. We are confident in our ability to drive
long-term shareholder value using the principles of our Mission, our strong product pipelines and continued commitment to research
and development. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The delivery of our devices
is subject to regulation by United States Department of Health and Human Services (HHS) and comparable state and foreign agencies
responsible for reimbursement and regulation of healthcare items and services. United States (U.S.) laws and regulations are
imposed primarily in connection with the Medicare and Medicaid programs, as well as the government’s interest in regulating
the quality and cost of healthcare. In conjunction with those interests, the Centers for Medicare and Medicaid Services (CMS), a
division of HHS, annually issues rules governing the reimbursement of Inpatient and Outpatient hospital services provided to
Medicare recipients. In April 2006, CMS issued its proposed Hospital Inpatient Prospective Payment System rule governing inpatient
hospital reimbursement rates. The proposed rule attempts to incorporate a significant number of changes in the calculation of
in-patient reimbursement rates, including: 1) an attempt to move from the current charge-based methodology to a new cost-based
methodology; 2) an attempt to eliminate differences between hospitals’ cost structures when calculating reimbursement rates;
and 3) further segmenting of reimbursement rates based on disease severity. </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Medtronic and a number of
other interested parties have raised significant concerns with CMS’ proposed rule and the Medicare Payment Advisory Committee
(MedPAC) is in the process of a thorough review of the CMS proposed methodologies. The 60-day public comment period ended June
12, 2006. The final rule is expected to be published by August 1, 2006, with the new rates going into effect October 1, 2006. It
remains unclear if and how much the proposed in-patient reimbursement rates included in the draft rule will be modified by CMS or
to what extent, if any, any changes in hospital reimbursement will impact our net sales. </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Critical Accounting Estimates </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> We have adopted various
accounting policies to prepare the consolidated financial statements in accordance with accounting principles generally accepted
(GAAP) in the U.S. Our most significant accounting policies are disclosed in Note 1 to the consolidated financial statements.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The preparation of the
consolidated financial statements, in conformity with U.S. GAAP, requires us to make estimates and assumptions that affect the
amounts reported in the consolidated financial statements and accompanying Notes. Our estimates and assumptions, including those
related to bad debts, inventories, intangible assets, property, plant and equipment, asset impairment, legal proceedings,
IPR&D, warranty obligations, product liability, self-insurance, pension and post-retirement obligations, sales returns and
discounts, and income tax reserves are updated as appropriate, which in most cases is at least quarterly. We base our estimates on
historical experience, actuarial valuations or various assumptions that are believed to be reasonable under the circumstances.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Estimates are considered to
be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that
are uncertain at the time the accounting estimates are made and (2) material changes in the estimates are reasonably likely to
occur from period to period. Our critical accounting estimates include the following: </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Legal
Proceedings</B> We are involved in a number of legal actions. The outcomes of these legal actions are not within
our complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as
other relief, including injunctions barring the sale of products that are the subject of the lawsuit, which, if granted, could
require significant expenditures or result in lost revenues. In accordance with Statement of Financial Accounting Standards (SFAS)
No. 5, “Accounting for Contingencies,” we record a liability in our consolidated financial statements for these actions
when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or
probable loss is a range, and no amount within the range is a better estimate, the minimum amount of the range is accrued. If a
loss is reasonably likely but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is
disclosed in Note 13. If a loss is not probable or cannot be reasonably estimated, a liability is not recorded in the consolidated
financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded.
Our significant legal proceedings are discussed in Note 13 to the consolidated financial statements. While it is not possible to
predict the outcome for most actions discussed and we believe that we have meritorious defenses against the matters detailed in
Note 13, it is possible that costs associated with them could have a material adverse impact on our consolidated earnings,
financial condition or cash flows.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Tax
Strategies</B> Our effective tax rate is based on expected income, statutory tax rates and tax planning
opportunities available to us in the various jurisdictions in which we operate. Significant judgment is required in determining
our effective tax rate and evaluating our tax positions. We establish reserves when, despite our belief that our tax return
positions are fully supportable, we believe that certain positions are likely to be challenged and that we may or may not prevail.
We adjust these reserves in light of changing facts and circumstances, such as the progress of a tax audit. Our effective tax rate
includes the impact of reserve provisions and changes to reserves that we consider appropriate. This rate is then applied to our
quarterly operating results. In the event there is a special, certain litigation and/or IPR&D charge recognized in our
operating results, the tax attributable to that item would be separately calculated and recorded in the same period. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Tax regulations require
certain items be included in the tax return at different times than when those items are required to be recorded in the
consolidated financial statements. As a result, our effective tax rate reflected in our consolidated financial statements is
different than that reported in our tax return. Some of these differences are permanent, such as expenses that are not deductible
on our tax return, and some are timing differences, such as depreciation expense. Timing differences create deferred tax assets
and liabilities. Deferred tax assets generally represent items that can be used as a tax deduction or credit in our tax return in
future years for which we have already recorded the tax benefit in our consolidated statements of earnings. We establish valuation
allowances for our deferred tax assets when the amount of expected future taxable income is not likely to support the use of the
deduction or credit. Deferred tax liabilities generally represent tax expense recognized in our consolidated financial statements
for which payment has been deferred or expense has already been taken as a deduction on our tax return, but has not yet been
recognized as an expense in our consolidated statements of earnings. </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Excluding the impact of
special and IPR&D charges, our operational and tax strategies have resulted in a nominal tax rate of 26.0% versus the U.S.
statutory rate of 35%. An increase in our nominal tax rate of 1% would result in an additional income tax provision for the fiscal
year ended April 28, 2006 of approximately $36.3 million. See discussion of the tax rate in the “Income Taxes”
section of this management’s discussion and analysis. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Valuation of IPR&D,
Goodwill and Other Intangible Assets</B> When we acquire a company, the purchase price is allocated, as
applicable, between IPR&D, other identifiable intangible assets, net tangible assets and goodwill as required by U.S. GAAP.
IPR&D is defined as the value assigned to those projects for which the related products have not received regulatory approval
and have no alternative future use. Determining the portion of the purchase price allocated to IPR&D and other intangible
assets requires us to make significant estimates. The amount of the purchase price allocated to IPR&D and other intangible
assets is determined by estimating the future cash flows of each project or technology and discounting the net cash flows back to
their present values. The discount rate used is determined at the time of acquisition in accordance with accepted valuation
methods. For IPR&D, these methodologies include consideration of the risk of the project not achieving commercial feasibility.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Goodwill represents the
excess of the aggregate purchase price over the fair value of net assets, including IPR&D, of the acquired businesses.
Goodwill is tested for impairment annually, or more frequently if changes in circumstance or the occurrence of events suggest
impairment exists. The test for impairment requires us to make several estimates about fair value, most of which are based on
projected future cash flows. Our estimates associated with the goodwill impairment tests are considered critical due to the amount
of goodwill recorded on our consolidated balance sheets and the judgment required in determining fair value amounts, including
projected future cash flows. Goodwill was $4.346 billion and $4.281 billion as of April 28, 2006 and April 29, 2005,
respectively. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Other intangible assets
consist primarily of purchased technology, patents and trademarks and are amortized using the straight-line method over their
estimated useful lives, ranging from 3 to 20 years. We review these intangible assets for impairment annually or as changes
in circumstance or the occurrence of events suggest the remaining value may not be recoverable. Other intangible assets, net of
accumulated amortization, were $1.592 billion and $1.018 billion as of April 28, 2006 and April 29, 2005, respectively.
</FONT></P>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><A NAME="net_sales">Net Sales </A></FONT></H1>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><I>Net sales by operating segment for fiscal years 2006, 2005,
and 2004 are presented below:</I> </FONT></P>
<DIV align="center">
<img src="a62430sales_pi.jpg"></DIV>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The primary exchange rate
movements that impact our consolidated net sales growth are the U.S. dollar as compared to the Euro and the Japanese Yen. The
impact of foreign currency fluctuations on net sales is not indicative of the impact on net earnings due to the offsetting foreign
currency impact on operating costs and expenses and our hedging activities. See the “Market Risk” section of this
management’s discussion and analysis and Note 3 to the consolidated financial statements for further details on foreign
currency instruments and our related risk management strategies. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Forward-looking statements
are subject to risk factors (see “Risk Factors” set forth in our Form 10-K). </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Cardiac Rhythm Disease
Management</B> In order to more clearly reflect the scope of our products and the focus of our strategy, in fiscal
year 2006 we changed the name of Cardiac Rhythm Management to Cardiac Rhythm Disease Management. CRDM products consist
primarily of pacemakers, implantable and external defibrillators, leads, ablation products, electrophysiology catheters,
navigation systems and information systems for the management of patients with our devices. CRDM fiscal year 2006 net sales grew
by 13% from the prior fiscal year to $5.206 billion. Foreign currency translation had an unfavorable impact on net sales of
approximately $55.5 million when compared to the prior fiscal year. While the increase in CRDM net sales was solid across
most product lines, fiscal year 2006 highlights include the following: </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Implantable defibrillator net sales for fiscal year 2006 increased
23% over the prior fiscal year to $2.932 billion. This increase was driven by strong demand for the Maximo and EnTrust families of
ICDs, and continued market acceptance of the InSync Maximo and InSync Sentry CRT-Ds. EnTrust ICDs were released in the U.S. in
June 2005, and offer anti-tachycardia pacing during charging, a feature designed to stop fast, dangerous heartbeats as it prepares
to deliver a shock if needed. InSync Sentry is the world’s first implantable medical device offering automatic fluid status
monitoring in the chest area encompassing the heart and lungs. Both the InSync Maximo and InSync Sentry provide sequential
biventricular pacing, which optimizes the beating of the heart and bloodflow throughout the body. In addition, growth was aided by
continued strong performance of our Sprint Fidelis leads, which were first released in fiscal year 2005. The strong market
acceptance of these products reflects CRDM’s continued product innovation as well as an overall expansion of the
tachyarrhythmia and heart failure markets due to increasing clinical data that supports the uses of these devices for certain
patient populations. Net sales of implantable defibrillators for fiscal year 2006 also benefited from one key competitor being out
of the ICD market for a portion of the fiscal year due to quality concerns with its product. The negative publicity associated
with these quality concerns softened the ICD market growth in the latter half of fiscal year 2006. Market share gains in
defibrillator sales worldwide partially offset the impact of the slower market growth. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pacing system net sales for fiscal year 2006 increased by 2% over
the prior fiscal year to $1.795 billion. Current year increases are attributable primarily to increased market share in an
otherwise flat growth pacing market, as physicians continue to focus more on the ICD and CRT-D marketplace. Instrumental in the
year over year increase in sales was the introduction of the EnRhythm pacemaker, which was released in the U.S. in May 2005, and
the Adapta pacemaker family, introduced in certain markets outside of the U.S. in the third quarter of fiscal year 2006. Both sets
of products offer Managed Ventricular Pacing (MVP), an atrial based pacing mode that significantly reduces unnecessary pacing
in the right ventricle while providing the safety of a dual chamber backup if necessary. Clinical studies have suggested that
reducing this pacing stimulation decreases the risk of developing heart failure and atrial fibrillation, a potentially
life-threatening irregular heartbeat. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Fiscal year 2006 implantable defibrillator and pacing system sales
also benefited from the continued acceptance of the Medtronic CareLink Service. The Medtronic CareLink Service enables clinicians
to review data about implanted cardiac devices in real time and access stored patient and device diagnostics through a secure
Internet website. The data, which is comparable to information provided during an in-clinic device follow-up, provides the
physician with a comprehensive view of how the device and patient’s heart are operating. Today, over 70,000 implant patients
are being monitored through Medtronic’s CareLink Service in the U.S. and Canada up from 35,000 implant patients being
monitored a year ago. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>In addition to the growth noted in the core implantable products,
Emergency Response Systems net sales for the fiscal year were essentially flat as compared to the prior fiscal year at $411.8
million. Supplier issues impacted sales negatively in the second and third quarters, but growth accelerated in the fourth quarter
as supplier issues were corrected. We also experienced continued acceptance of the LIFEPAK CR Plus defibrillator, an automated
external defibrillator designed for both the commercial and consumer market and the LIFEPAK 20 defibrillator, an external
defibrillator for use by both first responders and professionals in a hospital or clinical setting. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> CRDM fiscal year 2005 net
sales grew by 9% from the prior fiscal year to $4.616 billion. Foreign currency translation had a favorable impact on net
sales of approximately $82.4 million when compared to the prior fiscal year. While the increase in CRDM net sales was solid
across most product lines, fiscal year 2005 highlights include the following: </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Implantable defibrillator net sales for fiscal year 2005 increased
21% over fiscal year 2004 to $2.379 billion. This increase was driven by strong demand for the Maximo and Intrinsic families
of ICDs, and enthusiastic market acceptance of the InSync Maximo and InSync Sentry CRT-Ds. Maximo and Intrinsic ICDs were released
in the U.S. in October 2003 and August 2004, respectively, and the InSync Maximo and InSync Sentry were released in the U.S. in
June and November of 2004, respectively. Fiscal year 2005 net sales also benefited from strong growth in sales of Sprint Fidelis
leads, which were released in September 2004. </FONT></TD>
</TR>
</TABLE>
<BR>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pacing system net sales for fiscal year 2005 decreased by 4% over
fiscal year 2004 to $1.756 billion. These decreases were attributable to several factors including the slight loss of market
share and the year over year decrease in the overall pacing market due to physicians focusing more on the CRT-D marketplace.
</FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Fiscal year 2005 implantable defibrillator and pacing system sales
also benefited from the continued acceptance of the Medtronic CareLink Service. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Emergency Response Systems net sales for fiscal year 2005
increased by 12% over fiscal year 2004 to $412.4 million. Growth in sales was led by the continued acceptance of the LIFEPAK CR
Plus defibrillator and the LIFEPAK 20 defibrillator.
</FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Looking ahead, we expect our
CRDM operating segment should benefit from the following: </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Improvement in ICD market growth, especially in the U.S. We
believe the market is significantly under-penetrated, and investments to expand the referral network, enhance clinical evidence
and develop technologies that promote both ease of use and care will drive increased usage of defibrillator therapies.
</FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Continued acceptance of the InSync Sentry CRT-D. InSync Sentry
provides what we believe to be an advantage in managing heart failure since thoracic fluid accumulation is a primary indicator of
worsening heart failure and often results in patient hospitalization. The results of the Medtronic Impedance Diagnostics in Heart
Failure Clinical Trial (MIDHeFT) were published in the first quarter of fiscal year 2006, and these results indicated that our
OptiVol Fluid Status Monitoring capability in the InSync Sentry was successful in warning of fluid accumulation an average of 15
days before heart failure symptoms appeared and 18 days before hospitalization. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Continued acceptance of the Intrinsic and EnTrust ICDs and
EnRhythm pacemaker. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Continued acceptance of the Medtronic CareLink Service and
CardioSight. CardioSight is a unique monitoring system designed to facilitate a heart failure clinic’s evaluation of patients
with InSync Sentry and its OptiVol Fluid Status Monitoring capability. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Acceptance of the Adapta, Versa and Sensia lines of pacemakers,
which were introduced to the European market during the third quarter of fiscal year 2006. In addition to offering MVP, these
products incorporate automatic features designed to help physicians improve pacing therapy and streamline the patient follow-up
process potentially minimizing the amount of time spent in a physician’s office. The U.S. introduction of these products is
expected in the summer of calendar year 2006. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Future acceptance of the Concerto CRT-D and Virtuoso ICD, which
were launched in the European market during the first quarter of fiscal year 2007. These product lines are the first to offer
Conexus Wireless Telemetry, which upon implant allows for automatic wireless data transmission during in-office follow-up visits
and to the patient’s home monitor. Device data is then transmitted to the clinician using the Medtronic CareLink Service. The
Concerto/Virtuoso line was launched in the U.S. in first quarter of fiscal year 2007. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Future acceptance of the Chronicle Implantable Hemodynamic Monitor
(IHM) that is designed to continuously track intracardiac pressure, body temperature, physical activity and heart rate in patients
with heart failure. Patients transmit the information from home using a remote monitor via a standard phone line, and clinicians
can view the data on a secure web site in order to make changes in treatment as appropriate. The Chronicle IHM is expected to be
commercially available in the U.S. by the end of fiscal year 2007. </FONT></TD>
</TR>
</TABLE>
<BR>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Spinal and
Navigation</B> Spinal and Navigation products include thoracolumbar, cervical and interbody spinal devices, bone
growth substitutes and surgical navigation tools. Spinal and Navigation net sales for fiscal year 2006 increased by 19% from the
prior fiscal year to $2.244 billion. Foreign currency translation had an unfavorable impact on net sales of
$11.3 million when compared to the prior fiscal year. Spinal net sales for fiscal year 2006 increased 20% from the prior
fiscal year to $2.136 billion. While this increase reflects solid growth across our portfolio of product offerings, biologics
net sales were $570.2 million, a 38% increase over the prior year, based on continued strong acceptance of INFUSE Bone Graft.
INFUSE Bone Graft contains a recombinant human bone morphogenetic protein, or rhBMP-2, that induces the body to grow its own bone,
eliminating the need for a painful second surgery to harvest bone from elsewhere in the body. In early fiscal year 2005, we
announced that the U.S. Food and Drug Administration (FDA) approved the use of INFUSE Bone Graft in the treatment of certain types
of acute, open fractures of the tibial shaft, a long bone in the lower leg. The approval broadened the indications of the use of
our INFUSE Bone Graft technology. Since late fiscal year 2005, we have had the right to market Wyeth’s InductOs Bone Graft,
the European equivalent of the INFUSE Bone Graft, for use in spinal fusion in European markets. Other products showing steady
growth include our CD HORIZON LEGACY Spinal System family of products for thoracolumbar stabilization, our MAST family of
products, our cervical stabilization family of products including the VERTEX Max Reconstruction System and MYSTIQUE Resorbable
Graft Containment Plating System and the CAPSTONE Vertebral Body Spacer. Released in fiscal year 2005, the CAPSTONE is designed to
replace and restore the height of all or part of a vertebral body (the weight bearing portion of the vertebra) that has been
removed for the treatment of a tumor or fracture. Navigation net sales for fiscal year 2006 increased by 9% from the prior fiscal
year. Navigation net sales growth was primarily the result of continued strong sales of the StealthStation TRIA and the PoleStar
N20 surgical navigation equipment. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Spinal and Navigation net
sales for fiscal year 2005 increased by 22% from the prior fiscal year to $1.884 billion. Foreign currency translation had a
favorable impact on net sales of $14.2 million when compared to the prior fiscal year. Spinal net sales for fiscal year 2005
increased 22% from fiscal year 2004 to $1.785 billion. This increase reflected solid growth across our portfolio of product
offerings including robust acceptance of INFUSE Bone Graft, steady growth in net sales of our CD HORIZON LEGACY Spinal System
family of products and the introduction of the CAPSTONE vertebral body spacer. Navigation net sales for fiscal year 2005 increased
by 17% from fiscal year 2004. Navigation net sales growth was primarily the result of strong sales of the StealthStation TRIA and
the PoleStar N20 surgical navigation equipment. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Looking ahead, we expect our
Spinal and Navigation operating segment should benefit from the following: </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Continued acceptance of the INFUSE Bone Graft for spinal fusion
and certain types of acute, open tibia fractures. We anticipate obtaining FDA approval in fiscal year 2007 for expanded indication
for use in Oral/Maxillofacial surgery. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Continued acceptance of the MYSTIQUE Resorbable Graft Containment
Plating System for cervical spine fusions, released in August 2005. This new plating system uses a high-tech biologic material
that is resorbed by the body over time and alleviates the need for a permanent implant in the patient’s neck. The
plate’s transparent nature allows doctors to visualize the spine during surgery and can improve the reading of postoperative
X-rays. Before insertion, the plate can also be contoured to better match the patient’s unique anatomy. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Continued acceptance outside the U.S. of our dynamic stabilization
products, including the DIAM System, BRYAN Cervical Disc System, MAVERICK Lumbar Artificial Disc, and PRESTIGE LP Cervical Disc
Systems. Enrollment began in May 2005 on the PRESTIGE LP U.S. clinical trial and was completed in the third quarter of fiscal year
2006. For the three other artificial disc clinical trials in the U.S., namely the PRESTIGE ST, BRYAN Cervical Disc System, and
MAVERICK Lumbar Artificial Disc, enrollment was completed in the second quarter of fiscal year 2005. We expect FDA approval of
these artificial disc systems in calendar year 2007. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Continued acceptance of our expanding suite of MAST products and
minimally invasive surgical techniques. During the first quarter of fiscal year 2006, we introduced the CD HORIZON SPIRE Spinal
System, the METRx II Instrument Set, and CD HORIZON SEXTANT II System for use in various types of minimally invasive spinal
surgery. The CD HORIZON SPIRE may be used as supplemental fixation with our existing CD HORIZON products when surgeons perform a
MAST Transforaminal Lumbar Interbody Fusion (TLIF). The METRx II Set is a spinal instrument set that may be used to simplify disc
removal in anticipation of spinal fusion and the CD HORIZON SEXTANT II System is a surgical instrumentation system that offers a
minimally invasive method of placing implants that provide stabilization during spinal fusion surgery. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Continued demand for core stabilization products used in spinal
fusion, including the CD HORIZON LEGACY family of products and the CAPSTONE Vertebral Body Spacer products. </FONT></TD>
</TR>
</TABLE>
<BR>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Neurological</B> Neurological
products consist of therapeutic and diagnostic devices, including implantable neurostimulation systems, external and implantable
drug administration devices, urology products, gastroenterology products and functional diagnostic and sensing equipment.
Neurological net sales for fiscal year 2006 increased 10% from the prior fiscal year to $1.016 billion. Foreign currency had
an unfavorable impact on net sales of $10.8 million when compared to the prior fiscal year. The increase in Neurological net
sales reflects solid growth in several product lines including the Restore Rechargeable Neurostimulation System for pain
management, which benefited from the introduction of our Single Stretch-Coil Extension that enabled physicians to convert patients
with existing neurostimulators to the new rechargeable technology. The Restore system, our first fully rechargeable
neurostimulation system, was launched in late fiscal year 2005. The Restore System is indicated to manage chronic,
difficult-to-treat pain in the trunk and/or multiple limbs that is associated with failed back syndrome, post laminectomy pain,
unsuccessful disc surgery or degenerative disc disease. Sales growth was also driven by continued strength of Activa Therapy for
the treatment of movement disorders associated with advanced Parkinson’s disease and essential tremor, as well as InterStim
Therapy for the treatment of overactive bladder and urinary retention. The increase in Neurological net sales was partially offset
by a decrease in sales of our Gastroenterology/Urology diagnostics product line as a result of supplier issues. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Neurological net sales for
fiscal year 2005 increased 8% from fiscal year 2004 to $927.3 million. Foreign currency had a favorable impact on net sales
of $14.6 million when compared to fiscal year 2004. This increase reflected solid net sales growth in all businesses within
the Neurological operating segment. Key product lines which drove growth during fiscal year 2005 include Activa Therapy for the
treatment of movement disorders associated with advanced Parkinson’s disease and essential tremor, full year sales of the
SynchroMed II implantable drug infusion pump, InterStim Therapy for the treatment of overactive bladder and urinary retention and
the BravopH Monitoring System for diagnosis of acid reflux. Fiscal year 2005 Neurological growth also benefited from the launch of
the Restore Rechargeable Neurostimulation System. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Looking ahead, we expect our
Neurological operating segment should benefit from the following: </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Continued acceptance of the Restore Rechargeable Neurostimulation
System for pain management that provides increased power without compromising device longevity. We expect to release the dual
stretch-coil extension and the RestorePRIME Neurostimulation System, a 16-electrode, non-rechargeable neurostimulator, during our
first quarter of fiscal year 2007. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Continued acceptance of our Activa Therapy for the treatment of
Parkinson’s disease and essential tremor. Strong interest in frameless deep brain stimulation lead placement continues since
our acquisition of Image-Guided Neurologics, Inc. (IGN) in the second quarter of fiscal year 2006. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Acceptance of the PROSTIVA RF Therapy System for the treatment of
symptomatic benign prostatic hyperplasia. This therapy, previously known as Transurethral Needle Ablation, or TUNA, delivers
low-level radio frequency energy through the urethra to destroy a precisely targeted area of an enlarged prostate. FDA approval of
PROSTIVA RF was received in May 2006. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Acceptance of our next generation InterStim (InterStim II)
which is expected to be launched in the U.S. in the first half of fiscal year 2007 pending FDA approval. The
InterStim II device is expected to meet the needs of patients who seek smaller generator for the treatment of urinary
control. Conformité Européenne approval, or CE Mark approval of InterStim II was received in April 2006. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Vascular</B> Vascular
products consist of coronary, endovascular, and peripheral stents and related delivery systems, stent graft systems, distal
embolic protection systems and a broad line of balloon angioplasty catheters, guide catheters, guidewires, diagnostic catheters
and accessories. Vascular net sales for fiscal year 2006 increased 10% from the prior fiscal year to $939.4 million. Foreign
currency translation had an unfavorable impact on net sales of $23.7 million when compared to the prior fiscal year. Coronary
Vascular net sales increased 12% in comparison to the prior fiscal year. The growth in Coronary Vascular net sales was primarily a
result of the second quarter fiscal year 2006 release of our Endeavor DES in approximately 85 markets outside the U.S., and the
worldwide strong performance in our other coronary products, including balloons and guidewires. Endeavor DES sales grew to
$138.0 million during fiscal year 2006, while stent sales in the U.S. were only $24.0 million of the total worldwide
stent sales of $365.5 million. Endovascular net sales increased 9% in comparison to the prior fiscal year. Endovascular
results were primarily a result of solid performance of the Talent Stent Graft System outside the U.S., which is used to treat
abdominal aortic aneurysms (AAA), and the recently released Valiant Thoracic Stent Graft outside the U.S. The Valiant stent graft
is a next-generation stent graft used for the minimally invasive repair of the thoracic aorta, the body’s largest artery, for
several disease states including aneurysms, penetrating ulcers, acute or chronic dissections, and contained or traumatic ruptures.
The Valiant stent graft was approved in Europe in March 2005. </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Vascular net sales for fiscal
year 2005 increased 1% from fiscal year 2004 to $851.3 million. Foreign currency translation had a favorable impact on net
sales of $26.5 million when compared to fiscal year 2004. Coronary Vascular net sales were flat in comparison to fiscal year
2004 as a result of declining U.S. coronary stent sales offset by the positive effects of a weaker U.S. dollar in comparison to
fiscal year 2004 and continued strong acceptance of the Driver Coronary Stent in markets outside the U.S., where drug-eluting
stent use had not yet dominated the market. The Driver is our cobalt-alloy coronary stent, introduced in fiscal year 2004. The
cobalt-alloy allows for engineering of thinner struts and provides greater maneuverability in placing the stent. Also contributing
to the fiscal year 2005 results was a net sales increase of 5% in Endovascular. Endovascular increases were primarily a result of
strong growth in sales of the Talent Stent Graft System outside the U.S. Peripheral Vascular fiscal year 2005 net sales were flat
in comparison to fiscal year 2004. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Looking ahead, we expect our
Vascular operating segment should benefit from the following: </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We anticipate continued growth in fiscal year 2007 from our
launches of Endeavor DES in France, China and Australia in calendar year 2006. The Endeavor stent was the first cobalt alloy
platform in the DES market, and we believe it offers physicians excellent deliverability and a strong safety profile. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our anticipated entry into the U.S. DES market. The clinical
trials for our Endeavor DES began in fiscal year 2003 and clinical results presented at the European Society of Cardiology, the
Transcatheter Cardiovascular Therapeutics and the Paris Course on Revascularization conferences further expanded the medical
evidence supporting the clinical performance of the Endeavor DES. In addition, we filed our first Pre-market Approval (PMA) module
for Endeavor DES with the FDA in early October 2005 and enrollment of the ENDEAVOR IV clinical trial is progressing as planned. As
of the end of fiscal year 2006, we had enrolled over 1,300 patients. Assuming continued positive results from these trials and our
current schedule, we anticipate U.S. approval of the Endeavor DES in calendar year 2007. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Continued market penetration of the Talent AAA Stent Graft and
Valiant Thoracic Stent Graft in the European markets. The Valiant device contains the Xcelerant Delivery System, which is designed
to provide physicians with a smooth, controlled and trackable delivery platform. The Xcelerant system was launched in fiscal year
2005 in markets outside of the U.S., excluding Japan. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Acceptance of the Exponent RX Self-Expanding Carotid Stent and
Interceptor PLUS Carotid Filter System in markets outside of the U.S. Together, these products provide patients afflicted by
carotid artery disease with a new, minimally-invasive treatment option to surgical procedures for the prevention of stroke. The
stent and filter system received regulatory approval in the fourth quarter of fiscal year 2006, and will be launched commercially
in fiscal year 2007. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Diabetes</B> Diabetes
products consist of external insulin pumps and related disposables, continuous glucose monitoring systems, a subcutaneous glucose
sensor and an implantable insulin pump. Diabetes net sales in fiscal year 2006 increased 11% over the prior fiscal year to $722.3
million. Foreign currency translation had an unfavorable impact on net sales of $6.3 million when compared to the prior
fiscal year. The sales increase reflects continued global growth of the MiniMed Paradigm family of insulin pumps and related
disposables. The MiniMed Paradigm family of insulin pumps offer increased customization of the insulin dosage based on patient
specific information and enhanced information management capabilities. During the fourth quarter of fiscal year 2006, insulin pump
sales increased at a higher rate than overall sales as our customers use their excess disposable supply. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Diabetes net sales in fiscal
year 2005 increased 16% over fiscal year 2004 to $649.4 million. Foreign currency translation had a favorable impact on net sales
of $9.0 million when compared to fiscal year 2004. This increase reflected positive U.S. growth of the MiniMed Paradigm 515
and 715 wireless insulin pumps and strong increases in net sales of disposable infusion sets used with our line of MiniMed
Paradigm insulin infusion pumps. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Looking ahead, we expect our
Diabetes operating segment should benefit from the following: </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Acceptance of the MiniMed Paradigm REAL-Time Insulin Pump and
Continuous Glucose Monitoring System (approved by the FDA in April 2006), a progressive new therapy available for patients who use
insulin to treat diabetes. This insulin pump integrates with REAL-Time continuous glucose monitoring. This new technology
will help patients take immediate corrective or preventive action to maintain healthy glucose levels and delay or prevent
diabetes-related complications, including coma, blindness, kidney failure, amputation, impotence, and heart disease. We expect
strong market acceptance of the MiniMed Paradigm REAL-Time System to contribute positively to our leadership position in insulin
pump sales, and the improvement of disposables sales growth in the latter half of fiscal year 2007. </FONT></TD>
</TR>
</TABLE>
<BR>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Continued acceptance of the Guardian RT Continuous Glucose
Monitoring System for diabetes management. The Guardian RT System is a real-time glucose monitoring system which measures glucose
values as many as 864 times in a three day period and every 5 minutes transmits this information to a monitor using radio
frequency. The monitor can then be programmed to alert the patient when glucose levels become too high or low. The Guardian RT
System was approved in the U.S. in August 2005 and released to the market on a controlled basis during the second quarter of
fiscal year 2006. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Cardiac
Surgery</B> Cardiac Surgery products include perfusion systems, products for the repair and replacement of heart
valves, minimally invasive cardiac surgery products, positioning and stabilization systems for beating heart surgery, surgical
accessories and surgical ablation products. Cardiac Surgery net sales for fiscal year 2006 decreased 1% as compared to the prior
fiscal year to $663.3 million. Foreign currency translation had an unfavorable impact on net sales of $7.3 million when
compared to the prior fiscal year. Excluding the negative impact of currency, the performance of Cardiac Surgery was flat with the
prior year, indicative of a market showing little to no growth. Cardiac Surgery Technologies enjoyed modest growth during the
year, led by the market leading Cardioblate BP2 (Bipolar) Surgical Ablation System, which offers surgeons the unique ability to
perform an irrigated surgical ablation procedure. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Cardiac Surgery net sales for
fiscal year 2005 increased 6% over fiscal year 2004 to $668.8 million. Foreign currency translation had a favorable impact on net
sales of $13.3 million when compared to the prior fiscal year. The primary drivers for fiscal year 2005 revenue were the Heart
Valve and Perfusion businesses, which grew net sales by 10% and 4%, respectively, as compared to fiscal year 2004. Tissue Valve
sales led the growth in the Heart Valve business with growth of 13%. Key components to the Tissue Valve growth were sales of the
Mosaic and Freestyle tissue valves, which benefited from full year sales in the Japanese market where they were reintroduced in
the fourth quarter of fiscal year 2004. The growth in Perfusion Systems net sales in fiscal year 2005 was primarily due to
continued market share gains in a market that continues to experience contraction. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Looking ahead, we expect our
Cardiac Surgery operating segment should benefit from the following: </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The full U.S. launch of our newest tissue valve repair products in
calendar year 2006. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The introduction of the Melody heart valve to European markets in
fiscal year 2007. Melody is expected to be the first commercially available pulmonic transcatheter heart valve. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>ENT</B> ENT
operating segment consists of ear, nose and throat related products and neurologic technology related products including powered
tissue-removal systems and other microendoscopy instruments, implantable devices, nerve monitoring systems, disposable
fluid-control products, image-guided surgery systems, a Ménière’s treatment device, hydrocephalus shunt
devices, external drainage systems, cranial fixation devices, neuroendoscopes and dura repair products. ENT net sales for fiscal
year 2006 increased by 9% over the prior fiscal year to $501.4 million. Foreign currency translation had an unfavorable impact on
net sales of $3.4 million when compared to the prior fiscal year. Ear, nose and throat related product net sales grew 11% to
$266.2 million in fiscal year 2006. The primary drivers of the increase in ear, nose and throat related product net sales were
continued physician acceptance of the Straightshot M4 Microdebrider, the NIM-Response 2.0 Nerve Integrity Monitor and image guided
surgery systems. Neurologic Technology related net sales grew 8% to $235.2 million in fiscal year 2006. The primary drivers of
growth in Neurologic Technology were continued acceptance of the high-speed powered surgical drill system, including the most
recently launched EHS Stylus system and the Strata valve, an adjustable flow control valve in which the resistance properties of
the valve can be changed non-invasively by the caregiver. The valve is designed to minimize overdrainage of cerebrospinal fluid
and maintain intraventricular pressure within a normal physiologic range, regardless of patient position. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> ENT net sales for fiscal year
2005 increased by 11% over fiscal year 2004 to $458.2 million. Foreign currency translation had a favorable impact on net
sales of $6.2 million when compared to the prior fiscal year. The primary drivers of the increase in ear, nose and throat
related product net sales were the physician preferences for the NIM-Response nerve monitor and XPS Microdebrider. Primary drivers
of growth in Neurologic Technology net sales in fiscal year 2005 were the Strata valve, the Durepair dura substitute and the
Legend high-speed drill systems. </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>12 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Looking ahead, we expect our
ENT operating segment should benefit from the following: </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Continued adoption of Nerve monitoring in ENT and Thyroid
procedures. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Continued development of the normal pressure hydrocephalus market,
resulting in increased sales of our shunt products, including the Strata valve. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Continued acceptance of our Legend high-speed drill systems and
our Durepair dura substitute. </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Continued net sales growth in
all operating segments is contingent on our ability to gain further market share, penetrate existing markets, develop new products
and improve existing products. </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Costs and Expenses </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The following is a summary of
major costs and expenses as a percent of net sales: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006</FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005</FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH="59%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cost of products sold</FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="2%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="4%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>24.9</FONT></TD>
<TD WIDTH="10%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="4%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>24.3</FONT></TD>
<TD WIDTH="10%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="4%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>24.8</FONT></TD>
<TD WIDTH="2%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Research and development expense</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Selling, general and administrative expense</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>32.4</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>32.0</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>30.8</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Special charges</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Certain litigation charges</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.5</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>IPR&D</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Other expense, net</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.5</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.9</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3.9</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Interest income, net</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Cost of Products Sold </B>Fiscal
year 2006 cost of products sold as a percent of net sales increased 0.6 percentage point from fiscal year 2005 to 24.9%. The
increase in cost of goods sold as a percentage of net sales was driven by two main components. Unfavorable foreign currency
translation reduced gross margin by 0.2 percentage point and product mix reduced gross margin by 0.4 percentage point. The product
mix impact was the result of increased sales of INFUSE Bone Graft and certain tissue products in our Spinal business, which have
margins that are below our average margins and strong ICD growth outside the U.S. We expect cost of products sold, as a percentage
of revenue, to continue in the 24.0%-25.0% range. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Fiscal year 2005 cost of
products sold as a percent of net sales decreased 0.5 percentage point from fiscal year 2004 to 24.3%. The decrease in cost
of goods as a percentage of net sales was due to favorable foreign currency translation and hedging impact, partially offset by
the impact of the Marquis battery field action and increased sales of INFUSE Bone Graft and certain tissue products in our Spinal
business, which have margins that are below our average margins. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Research and
Development</B> Consistent with prior periods, we have continued to invest heavily in the future by spending
aggressively on research and development efforts. Research and development spending was $1.113 billion in fiscal year 2006.
This level of spending represented 9.9% of net sales, an increase of $161.6 million, or 17.0%, over fiscal year 2005. We are
committed to developing technological enhancements and new indications for existing products and new, less invasive, technologies
to address unmet medical needs. Furthermore, we expect our development activities to help reduce patient care costs and the length
of hospital stays in the future. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Fiscal year 2005 research and
development expense increased $99.8 million from fiscal year 2004 to $951.3 million, or 9.5% of net sales. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In addition to our investment
in research and development, we continue to access new technologies in areas served by our existing businesses, as well as in new
areas, through acquisitions, licensing agreements, alliances and certain strategic equity investments. </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>13 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Presented below are
significant products that received FDA approval or clearance in the U.S. during fiscal year 2006: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=80%>
<TR VALIGN=Bottom>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Product </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH><TH></TH>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Operating Segment </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH><TH></TH>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Applicable for </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="TOP" BGCOLOR="#d6f3e8">
<TD WIDTH="35%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CardioSight Service</FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="5%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="16%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CRDM</FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="5%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="35%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Patient data transmission</FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Top style="padding-top:6pt; padding-bottom:6pt;">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>EnRhythm Pacemaker Family</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CRDM</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Abnormally slow heartbeats</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="TOP" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>EnTrust ICD Family</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CRDM</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Abnormally rapid heartbeats</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Top style="padding-top:6pt; padding-bottom:6pt;">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CD HORIZON ENGAGE Spinal System</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD nowrap ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Spinal and Navigation</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Spinal fusion</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="TOP" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CD HORIZON SEXTANT II</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Spinal and Navigation</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Spinal surgery</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Top style="padding-top:6pt; padding-bottom:6pt;">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>MYSTIQUE Resorbable Graft Containment Plating System</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Spinal and Navigation</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Spinal fusion</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="TOP" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>TSRH Silo</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Spinal and Navigation</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Spinal fusion</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Top style="padding-top:6pt; padding-bottom:6pt;">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>VERTEX Max Reconstruction System</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Spinal and Navigation</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Spinal fusion</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="TOP" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>RestorePrime Neurostimulator System</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Neurological</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pain management</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Top style="padding-top:6pt; padding-bottom:6pt;">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>AneuRx AAAdvantage</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Vascular</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Abdominal aorta aneurysms</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="TOP" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Micro-Driver Coronary Stent System</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Vascular</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Coronary stent</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Top style="padding-top:6pt; padding-bottom:6pt;">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Guardian RT Continuous Glucose Monitoring System</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Diabetes</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Diabetes management – continuous glucose management</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="TOP" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>MiniMed Paradigm REAL-Time Insulin Pump and Continuous Glucose Monitoring System</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Diabetes</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Diabetes management – sensor augmented insulin pump therapy</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Top style="padding-top:6pt; padding-bottom:6pt;">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Mosaic Ultra Heart Valve</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cardiac Surgery</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Heart valve replacement</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="TOP" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Performer Cardiopulmonary Bypass System</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cardiac Surgery</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Heart/lung bypass machine</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
</TABLE>
<BR>
<BR><BR><BR><BR><BR><BR><BR><BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>14 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Presented below are our
significant products that received regulatory approval or clearance outside of the U.S. during fiscal year 2006: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=80%>
<TR VALIGN=Bottom>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Product </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH><TH></TH>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Operating Segment </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH><TH></TH>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Applicable for </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="TOP" BGCOLOR="#d6f3e8">
<TD WIDTH="35%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Adapta Family of Pacemakers</FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="5%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="16%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CRDM</FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="5%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="35%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Abnormally slow heartbeats</FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Top style="padding-top:6pt; padding-bottom:6pt;">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Enpulse 2 Pacemaker</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CRDM</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Abnormally slow heartbeats</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="TOP" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Sensia Family of Pacemakers</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CRDM</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Abnormally slow heartbeats</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Top style="padding-top:6pt; padding-bottom:6pt;">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Sprint Fidelis Family of Leads</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CRDM</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Abnormally rapid heartbeats</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="TOP" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Versa Family of Pacemakers</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CRDM</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Abnormally slow heartbeats</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Top style="padding-top:6pt; padding-bottom:6pt;">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>SynchroMed EL Infusion System</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Neurological</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Spasticity</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="TOP" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Synergy Neurostimulation System</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Neurological</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pain stimulation</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Top style="padding-top:6pt; padding-bottom:6pt;">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Endeavor Drug-Eluting Stent</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Vascular</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Coronary restenosis</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="TOP" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Guardian RT Continuous Glucose Monitoring System</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Diabetes</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Diabetes management – continuous glucose management</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Top style="padding-top:6pt; padding-bottom:6pt;">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>MiniMed Paradigm REAL-Time Insulin Pump and Continuous Glucose Monitoring System</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Diabetes</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Diabetes management – sensor augmented insulin pump therapy</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="TOP" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Mosaic Ultra Heart Valve</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cardiac Surgery</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Heart valve replacement</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Top style="padding-top:6pt; padding-bottom:6pt;">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Performer Cardiopulmonary Bypass System</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cardiac Surgery</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Heart/lung bypass machine</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Selling, General and
Administrative</B> Fiscal year 2006 selling, general and administrative expense as a percentage of net sales
increased by 0.4 percentage point from fiscal year 2005 to 32.4%. The increase in selling, general and administrative expense
as a percentage of net sales primarily relates to our continued investment in expanding our sales organization, increased spending
on our global enterprise resource planning (ERP) infrastructure and the compensation expenses associated with our record revenues
and strong earnings. These increases were partially offset by continued cost control measures across all of our businesses.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Fiscal year 2005 selling,
general and administrative expense as a percentage of net sales increased by 1.2 percentage point from fiscal year 2004 to
32.0%. The increase in selling, general and administrative expense as a percentage of net sales primarily relates to our continued
investment in expanding our sales organization during the year and increased legal spending. This increase was partially offset by
continued cost control measures across all of our businesses. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Special, Certain
Litigation and IPR&D Charges</B> We believe that in order to properly understand our short-term and long-term
financial trends, investors may find it useful to consider the impact of special, certain litigation and IPR&D charges.
Special charges (such as restructuring charges and certain tax adjustments), certain litigation charges in connection with either
settlements or judgments from material litigation and IPR&D charges recorded during the previous three fiscal years are as
follows: </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>15 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH align=left><FONT FACE="Times New Roman, Times, Serif" SIZE=1>(dollars in millions, except per share data) </FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH="58%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Special charges:</FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="6%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="6%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH="6%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="6%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH="6%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="6%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH="2%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Medtronic foundation donation (net of $34.4 tax)</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 65.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Changes in restructuring obligation estimates (net of $1.8 tax)</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(3.0</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total special charges</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>65.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(3.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Certain litigation charges (net of $236.3 tax)</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>418.1</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>IPR&D charges (net of $68.5 and $– tax, respectively)</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>295.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>41.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Tax impact for the repatriation of foreign earnings</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>48.5</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Tax benefit from the reversal of tax reserves</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(225.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total special, certain litigation and IPR&D charges, after-tax</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 135.9</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 466.6</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 38.1</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Per Diluted Share Data:</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Special charges</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.05</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Certain litigation charges</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.34</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>IPR&D</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.24</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.03</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Tax impact for the repatriation of foreign earnings</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.04</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Tax benefit from the reversal of tax reserves</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.18</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total Per Diluted Share</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.11</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.38</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.03</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Special
Charges</B> In fiscal year 2006, we recorded a $65.6 million after-tax ($100.0 million pre-tax) charitable
donation to The Medtronic Foundation, which is a related party non-profit organization. The donation to The Medtronic Foundation
was paid in the second quarter of fiscal year 2006. We also recorded a $225.0 million tax benefit associated with favorable
agreements reached with the U.S. Internal Revenue Service (IRS) involving the review of our fiscal years 1997 through 2002
domestic income tax returns.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On October 22, 2004, the
<I>American Jobs Creation Act of 2004</I> (Jobs Creation Act) became law. The Jobs Creation Act allows U.S. corporations a
one-time deduction of 85 percent of certain “cash dividends” received from controlled foreign corporations. The
deduction is available to corporations during the tax year that included October 22, 2004 or the immediately subsequent tax
year. According to the Jobs Creation Act, the amount of eligible dividends is limited to $500.0 million or the amount described as
permanently reinvested earnings outside the U.S. in a company’s most recent audited financial statements filed with the
Securities and Exchange Commission (SEC) on or before June 30, 2003. During the fourth quarter of fiscal year 2006, we
repatriated the entire amount eligible under the Jobs Creation Act, or $933.7 million. The amounts repatriated were used for
“qualified expenditures” as defined under the Jobs Creation Act such as qualified research and development activities,
construction of a new U.S. facility and qualified selling and marketing activities. As of April 29, 2005, we had recorded a
deferred tax liability of $48.5 million associated with our planned repatriation of these funds, and we included that amount in
the table above and in the consolidated statements of earnings in <I>provision for income taxes</I>. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In fiscal year 2004, we
recorded a $3.0 million after-tax ($4.8 million pre-tax) reversal of a previously established reserve related to the
Vascular facility consolidation initiatives, which started in the first quarter of fiscal year 2003. The $4.8 million change
in estimate was a result of the following favorable outcomes in the execution of these initiatives: a decrease of
$2.4 million as a result of selling or utilizing existing assets which were previously identified for impairment; a decrease
of $1.8 million related to subleasing a facility earlier than anticipated; and a decrease of $0.6 million in severance
payments related to employees identified for elimination who found positions elsewhere in the Company. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Certain Litigation
Charges</B> There were no certain litigation charges recorded in fiscal years 2006 and 2004. At April 28,
2006, unpaid certain litigation charges from fiscal year 2005 related to the DePuy/AcroMed, Inc. (DePuy/AcroMed) litigation are
recorded in <I>other accrued expenses</I> in the consolidated balance sheets. </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>16 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In fiscal year 2005, we
recorded after-tax certain litigation charges of $418.1 million ($654.4 million pre-tax). The largest of the charges, in the
amount of $550.0 million pre-tax, occurred in the fourth quarter and relates to costs for the settlement of all outstanding
litigation and disputes with Gary Michelson, M.D. and Karlin Technology, Inc. (Michelson). The agreement reached with Michelson
required a total cash payment of $1.350 billion for the settlement of all ongoing litigation and the purchase of a portfolio of
more than 100 issued U.S. patents, over 110 pending U.S. patent applications and numerous foreign counterparts to these patents
and patent applications. The $550.0 million was assigned to past damages between the parties and was recorded as an expense in
fiscal year 2005. The remaining consideration, including $2.6 million of direct acquisition costs, was allocated between $627.5
million of acquired technology based intangible assets and $175.1 million of IPR&D that was expensed on the date of
acquisition (May 18, 2005). Also, in the fourth quarter of fiscal year 2005, we recorded a pre-tax charge of $80.1 million
resulting from a final arbitration award for breach of contract damages related to a March 2002 agreement between us and ETEX
Corporation (ETEX). The $80.1 million includes $63.6 million in damages, interest, and partial legal fees and the forgiveness of
an existing $16.5 million note owed to us by ETEX. In the third quarter of fiscal year 2005, we recorded a pre-tax charge of $24.3
million related to the DePuy/AcroMed litigation. The jury found that the thoracolumbar multiaxial screw design of Medtronic
Sofamor Danek, Inc. (MSD), which MSD no longer sells in the U.S., infringes patents held by DePuy/AcroMed under the doctrine of
equivalents. In February 2005, the Court entered judgment against MSD in the amount of $24.3 million, which included prejudgment
interest. Given the judgment entered by the Court and our conclusion that the incurrence of such an expense was both probable and
could be reasonably estimated under SFAS No. 5 at that point and time, we recorded a $24.3 million charge related to this
judgment. MSD has appealed the jury’s verdict and intends to continue to contest the charges vigorously. At April 29, 2005,
unpaid certain litigation charges related to Michelson, ETEX, and Depuy/AcroMed, were recorded in
<I>other accrued expenses</I> in the consolidated balance sheets. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>IPR&D</B> During
the first quarter of fiscal year 2006, we acquired Transneuronix, Inc. (TNI). At the date of the acquisition, $168.7 million of
the purchase price was expensed as IPR&D related to a product being developed for the treatment of obesity by stimulation of
the stomach, that had not yet reached technological feasibility and had no future alternative use. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> During the first quarter of
fiscal year 2006, we acquired substantially all of the spine-related intellectual property and related contracts, rights, and
tangible materials owned by Michelson. At the date of acquisition, $175.1 million of the purchase price was expensed as IPR&D
related to spinal technology based devices that had not yet reached technological feasibility and which had no future alternative
use. The patents pertain to novel spinal technology and techniques that have the potential for future patentable commercial
products in the area of spinal surgery. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> During the first quarter of
fiscal year 2006, we also entered into a royalty bearing, non-exclusive patent cross-licensing agreement with NeuroPace, Inc. On
the date of the agreement, $20.0 million was expensed as IPR&D related to the licensed technology since technological
feasibility of the project had not yet been reached and it had no future alternative use. This licensed technology is expected to
enhance our ability to further develop and expand our therapies for neurological disorders. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> There were no IPR&D
charges recorded in fiscal year 2005. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In the fourth quarter of
fiscal year 2004, we entered into an agreement which provided us an option to purchase substantially all the assets of a certain
third-party entity. We held a cost method equity investment in this entity and as a result of this new agreement, we applied the
equity method of accounting to this investment. At the date of the agreement, $17.2 million of the amount paid for the
investment was expensed for IPR&D related to cardiac surgery devices under development that had not yet reached technological
feasibility. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> During the third quarter of
fiscal year 2004, we acquired Vertelink Corporation (Vertelink). At the date of the acquisition, $22.0 million of the
purchase price was expensed for IPR&D related to spinal fixation devices that had not yet reached technological feasibility
and had no future alternative use. At the time of the acquisition, the KOBRA Fixation System was being reviewed by the FDA for
510(k) approval, which was subsequently obtained during the third quarter of fiscal year 2004. The technology will be adapted for
use in manufacturing spinal fixation devices that can achieve multi-level stabilization of the cervical, thoracic and lumbar
spine. Prior to the acquisition, we did not have a comparable product under development. The acquisition of Vertelink enhanced the
strategic position of our Spinal business that focuses on MAST. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> During the second quarter of
fiscal year 2004, we acquired TransVascular, Inc. (TVI). At the date of acquisition, $1.9 million of the purchase price was
expensed for IPR&D related to a cell and agent delivery device that had not yet reached technological feasibility and had no
future alternative use. This device will be used to deliver cells, genes and drugs to precise locations within the vascular
system. Prior to the acquisition, we did not have a comparable product under development. The acquisition of TVI complemented our
commitment to advance therapies and treatments by combining biologic and device therapies. </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>17 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> We are responsible for the
valuation of IPR&D charges. The values assigned to IPR&D are based on valuations that have been prepared using
methodologies and valuation techniques consistent with those used by independent appraisers. All values were determined by
identifying research projects in areas for which technological feasibility had not been established. Additionally, the values were
determined by estimating the revenue and expenses associated with a project’s sales cycle and the amount of after-tax cash
flows attributable to these projects. The future cash flows were discounted to present value utilizing an appropriate
risk-adjusted rate of return. The rate of return included a factor that takes into account the uncertainty surrounding the
successful development of the IPR&D. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> At the time of acquisition,
we expect all acquired IPR&D will reach technological feasibility, but there can be no assurance that the commercial viability
of these products will actually be achieved. The nature of the efforts to develop the acquired technologies into commercially
viable products consists principally of planning, designing and conducting clinical trials necessary to obtain regulatory
approvals. The risks associated with achieving commercialization include, but are not limited to, delay or failure to obtain
regulatory approvals to conduct clinical trials, delay or failure to obtain required market clearances, and patent litigation. If
commercial viability were not achieved, we would likely look to other alternatives to provide these therapies. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Other Expense,
Net</B> Other expense, net includes intellectual property amortization expense, royalty income and expense,
realized equity security gains and losses, realized foreign currency transaction and derivative gains and losses and impairment
charges. Net other expense decreased from $290.5 million in fiscal year 2005 to $166.7 million in fiscal year 2006, a
$123.8 million decrease. This decrease is primarily driven by a shift from a loss in fiscal year 2005 to a gain in fiscal
year 2006 on foreign exchange contracts used to hedge results of operations. In fiscal year 2006, our gain on foreign exchange
contracts was $91.9 million compared to a loss of $134.9 million in fiscal year 2005. During fiscal year 2006, the gains
on the foreign exchange contracts were partially offset by $41.7 million of expense associated with impairments on equity
securities and $86.2 million in increased royalty expense, primarily in our Vascular and Spinal business.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Net other expense decreased
from $351.0 million in fiscal year 2004 to $290.5 million in fiscal year 2005, a $60.5 million decrease. This
change primarily reflects a $52.3 million decrease in the amount of loss recorded associated with foreign exchange contracts
used to hedge results of operations in fiscal year 2005. Additionally, we experienced a decrease in net royalty expenses of
approximately $16.0 million primarily due to the end of certain incoming and outgoing royalty streams in our CRDM business
and the Michelson agreement pursuant to which we are no longer required to pay royalties and therefore reversed certain previous
accruals of approximately $20.0 million. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Interest
Income/Expense</B> In fiscal year 2006, net interest income was $87.4 million, an increase of
$42.3 million from net interest income of $45.1 million in fiscal year 2005. The increase in net interest income in
fiscal year 2006 as compared to fiscal year 2005 is primarily a result of increased levels of interest-bearing investments and
higher interest rates. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In fiscal year 2005,
net interest income was $45.1 million, an increase of $42.3 million from net interest income of $2.8 million in
fiscal year 2004. The increase in net interest income in fiscal year 2005 as compared to fiscal year 2004 is a result of increased
levels of interest-bearing investments, higher interest rates and relatively fixed levels of debt in comparison to the prior
fiscal year. </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Income Taxes </FONT></H1>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=4><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Percentage Point<BR>Increase/(Decrease) </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>FY06/05 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH><TH></TH>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>FY05/04 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>(dollars in millions) </FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH="37%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Provision for income taxes</FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="5%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH="6%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 614.6</FONT></TD>
<TD WIDTH="5%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH="6%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 739.6</FONT></TD>
<TD WIDTH="5%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH="6%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 837.6</FONT></TD>
<TD WIDTH="5%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="6%" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="5%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="6%" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="2%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Effective tax rate</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>19.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>29.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>29.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(9.7)</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.8)</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD nowrap ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Impact of repatriation, special, certain litigation and IPR&D charges</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(6.6</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.1</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.4</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(6.7)</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.3)</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Nominal tax rate (1)</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>26.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>29.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>29.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(3.0)</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.5)</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
</TABLE>
<BR>
<HR noshade color="black" align="left" size="1" width="20%">
<TABLE WIDTH=100% CELLPADDING=2 CELLSPACING=2>
<TR VALIGN=TOP>
<TD ALIGN=LEFT WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1) </FONT></TD>
<TD WIDTH=97%><P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Nominal tax rate is defined as the company’s
effective tax rate from normal operations excluding the impact of repatriation, special, certain litigation and IPR&D charges.
</FONT></P></TD>
</TR>
</TABLE>
<BR>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>18 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The effective tax rate
decreased by 9.7 percentage points from fiscal year 2005 to fiscal year 2006. This decrease reflects the 3.0 percentage
points decrease in the nominal tax rate and 6.7 percentage points decrease from the favorable IRS settlements, special,
certain litigation and IPR&D charges. The nominal tax rate decreased from 29.0% in fiscal year 2005 to 26.0% in fiscal year
2006 as result of increased benefits from our international operations subject to tax rates lower than our U.S. statutory tax
rates. The remaining 6.7 percentage points decrease is primarily due to a $225.0 million tax benefit associated with
favorable agreements reached with the IRS involving the review of our fiscal year 1997 through 2002 domestic tax returns, taxes
provided for amounts repatriated under the Jobs Creation Act, special, certain litigation and IPR&D charges. As a result of
the agreements reached with the IRS, we made approximately $326.0 million in incremental tax payments during the third
quarter of fiscal year 2006. These payments reduced <I>accrued income taxes</I> in the fiscal year 2006 consolidated balance
sheet. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The effective tax rate
decreased by 0.8 percentage point from fiscal year 2004 to fiscal year 2005. This decrease primarily reflects a 0.5 percentage
point decrease in the nominal tax rate and a 0.3 percentage point decrease from the tax impact of the fiscal year 2005
repatriation, special, certain litigation and IPR&D charges. The nominal tax rate decreased from 29.5% in fiscal year 2004 to
29.0% in fiscal year 2005 as a result of increased benefits from our international operations subject to tax rates lower than our
U.S. rate. The remaining 0.3 percent decrease is primarily due to the non-deductible IPR&D charges in fiscal year 2004 as
compared to deductible certain litigation charges in fiscal year 2005 neutralized by the tax liability associated with the Jobs
Creation Act. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Pursuant to the Jobs Creation
Act, in fiscal year 2006, we have repatriated the entire amount of eligible earnings, or $933.7 million. We concluded we would
repatriate this amount during the fourth quarter of fiscal year 2005 and accordingly had established a $48.5 million deferred tax
liability at April 29, 2005. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Tax audits associated with
the allocation of income, and other complex issues, may require an extended period of time to resolve and may result in income tax
adjustments if changes to our allocation are required between jurisdictions with different tax rates. Tax authorities periodically
review our tax returns and propose adjustments to our tax filings. The IRS has settled its audits with us for all years through
fiscal year 1996. Tax years settled with the IRS, however, remain open for foreign tax audits and competent authority proceedings.
Competent authority proceedings are a means to resolve intercompany pricing disagreements between countries. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In August 2003, the IRS
proposed adjustments related to the audits of the fiscal years 1997, 1998 and 1999 tax returns. We initiated defense of these
filings at the IRS appellate level in November 2004. In the second quarter of fiscal year 2006, the parties reached agreement in
principle on most, but not all matters. Also, during the second quarter of fiscal year 2006, the IRS issued their audit report for
fiscal years 2000, 2001 and 2002. We have also reached agreement with the IRS on substantially all of the fiscal years 2000, 2001
and 2002 proposed adjustments. The only items of significance, from the fiscal years 2000, 2001 and 2002 IRS audit report which
remain open, relate to unresolved issues that carry forward from the 1997 through 1999 tax audits. The unresolved issues from the
1997 through 1999 tax audits and tax positions taken by the IRS or foreign tax authorities, with respect to potential issues on
future tax audits could have a material unfavorable impact on our effective tax rate in future periods. We continue to believe
that we have meritorious defenses for our tax filings and will vigorously defend them through litigation in the courts, if
necessary. We believe we have provided for probable liabilities resulting from tax assessments by taxing authorities. </FONT></P>
<BR><BR><BR><BR><BR><BR><BR><BR><BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>19 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Liquidity and Capital Resources </FONT></H1>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>(dollars in millions) </FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH="62%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Working capital</FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="6%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH="9%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 5,970.8</FONT></TD>
<TD WIDTH="9%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH="9%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 4,041.5</FONT></TD>
<TD WIDTH="2%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Current ratio*</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.4:1.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.2:1.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cash, cash equivalents, and short-term investments</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 6,101.4</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3,391.6</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Long-term investments in public and private debt securities**</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>766.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,324.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cash, cash equivalents, short-term investments, and long-term debt securities</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6,868.0</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,715.7</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Short-term borrowings and long-term debt</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7,923.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,451.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net cash position***</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (1,055.1</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,263.9</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<HR noshade color="black" align="left" size="1" width="20%">
<TABLE WIDTH=100% CELLPADDING=2 CELLSPACING=2>
<TR VALIGN=TOP>
<TD ALIGN=LEFT WIDTH=4%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>* </FONT></TD>
<TD WIDTH=96%><P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Current ratio is the ratio of current assets to
current liabilities. </FONT></P></TD>
</TR>
</TABLE>
<TABLE WIDTH=100% CELLPADDING=2 CELLSPACING=2>
<TR VALIGN=TOP>
<TD ALIGN=LEFT WIDTH=4%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>** </FONT></TD>
<TD WIDTH=96%><P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Long-term investments include public and
private debt securities with a maturity date greater than one year from the end of the period. </FONT></P></TD>
</TR>
</TABLE>
<TABLE WIDTH=100% CELLPADDING=2 CELLSPACING=2>
<TR VALIGN=TOP>
<TD ALIGN=LEFT WIDTH=4%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>*** </FONT></TD>
<TD WIDTH=96%><P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net cash position is the sum of cash, cash
equivalents, short-term investments and long-term investments in debt securities less short-term borrowings and long-term debt.
</FONT></P></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The increase in our working
capital and current ratio since fiscal year 2005 is a result of the issuance of $4.400 billion of Senior Convertible Notes in
April 2006 and $1.000 billion of Senior Notes in September 2005 partially offset by the reclassification of $1.971 billion of
contingent convertible debentures from <I>long-term debt</I> to <I>short-term borrowings</I> in the second quarter of fiscal year
2006, as a result of the September 2006 put option date being within one year. See further discussion regarding the terms of these
transactions in the “Debt and Capital” section of this management’s discussion and analysis and the
“Summary of Cash Flows” section of this management’s discussion and analysis for further discussion of our cash
uses and proceeds. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> At April 28, 2006 and
April 29, 2005, $4.168 billion and $3.627 billion, respectively, of cash, cash equivalents and short- and long-term debt
securities were held by our non-U.S. subsidiaries. These funds are available for use by worldwide operations; however, if these
funds are repatriated to the U.S. or used for U.S. operations, the amounts would be subject to U.S. tax. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> We believe that our existing
cash and investments, as well as our available unused lines of credit and commercial paper capacity of $2.483 billion, if needed,
will satisfy our foreseeable working capital requirements for at least the next twelve months. However, we periodically consider
various financing alternatives and may, from time to time, seek to take advantage of favorable interest rate environments or other
market conditions. </FONT></P>
<BR><BR><BR><BR><BR><BR><BR><BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>20 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Summary of Cash Flows </FONT></H1>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>(dollars in millions) </FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cash provided by (used in):</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=6% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Operating activities</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,207.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,819.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,845.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Investing activities</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2,866.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,602.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,650.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Financing activities</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,316.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(488.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,010.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Effect of exchange rate changes on cash and cash equivalents</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>104.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(89.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(61.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net increase in cash and cash equivalents</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 762.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 638.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 123.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Operating Activities </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our net cash provided by operating activities was $2.207 billion in fiscal
year 2006 compared to $2.819 billion in fiscal year 2005. The $612.0 million decrease in net cash provided by operating activities
was primarily attributable to: </FONT></P>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$612.0 million payment for previously settled and accrued
litigation </FONT></TD>
</TR>
</TABLE>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$326.0 million payment of previously accrued income taxes in
conjunction with the settlement reached with the IRS </FONT></TD>
</TR>
</TABLE>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$49.0 million payment of income taxes associated with our
repatriation of foreign subsidiary income </FONT></TD>
</TR>
</TABLE>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$948.3 million related to the timing of payments on inventory and
other operating costs </FONT></TD>
</TR>
</TABLE>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>partially offset by: </FONT>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$1.292 billion increase in sales and the receipts and timing of
receipts on accounts receivable </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our net cash provided by operating activities was $2.819 billion in fiscal
year 2005 compared to $2.846 billion in fiscal year 2004. The $26.4 million decrease in net cash provided by operating activities
was primarily attributable to the timing of other receipts and payments in the ordinary course of business. </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Investing Activities </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our net cash used in investing activities was $2.867 billion in fiscal year
2006 compared to $1.603 billion in fiscal year 2005. The $1.264 billion increase in net cash used in investing activities was
primarily attributable to: </FONT></P>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>a $1.004 billion increase in cash used for acquisitions and
purchases of intellectual property </FONT></TD>
</TR>
</TABLE>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>a $439.9 million increase in cash used to purchase marketable
securities </FONT></TD>
</TR>
</TABLE>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>partially offset by: </FONT>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>a $44.9 million decrease in capital expenditures and an increase
of $135.7 million from other investing activities </FONT></TD>
</TR>
</TABLE>
<BR>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our net cash used in investing activities was $1.603 billion in fiscal year
2005 compared to $1.651 billion in fiscal year 2004. The $47.9 million decrease in net cash used in investing activities was
primarily attributable to: </FONT></P>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>a decrease in net purchases of marketable securities </FONT></TD>
</TR>
</TABLE>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>partially offset by: </FONT>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>an increase in cash used for acquisitions, purchases of
intellectual property and capital expenditures </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Financing Activities </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our net cash provided by financing activities was $1.316 billion in fiscal
year 2006 compared to net cash used in financing activities of $488.8 million in fiscal year 2005. The $1.805 billion increase in
net cash provided by financing activities was primarily attributable to: </FONT></P>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>proceeds of $5.428 billion from the issuance of long-term debt and
$518.1 million from the issuance of stock in fiscal year 2006, increases of $5.428 billion and $179.2 million over fiscal year
2005, respectively </FONT></TD>
</TR>
</TABLE>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>proceeds of $516.8 from the sale of warrants in fiscal year 2006
</FONT></TD>
</TR>
</TABLE>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>partially offset by: </FONT>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>stock repurchases of $3.589 billion, an increase of $3.078 billion
from fiscal year 2005 (see “Debt and Capital” section of this management’s discussion and analysis) </FONT></TD>
</TR>
</TABLE>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>cash of $1,074.6 million used to purchase call options in fiscal
year 2006 </FONT></TD>
</TR>
</TABLE>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>total dividend payments of $464.8 million, an increase of $59.9
million over fiscal year 2005 as a result of the increased quarterly cash dividend per share, as approved by the Board of
Directors </FONT></TD>
</TR>
</TABLE>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>21 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our net cash used in financing activities was $488.8 million in fiscal
year 2005 compared to $1.010 billion in fiscal year 2004. The $521.3 million decrease in net cash used in financing activities was
primarily attributable to: </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>a decrease of $369.5 million in repurchases of the Company’s
common stock </FONT></TD>
</TR>
</TABLE>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>an increase of $97.5 million in the proceeds from the exercise of
employee stock options </FONT></TD>
</TR>
</TABLE>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>an increase of $109.5 million in proceeds from short-term
borrowings </FONT></TD>
</TR>
</TABLE>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>partially offset by: </FONT>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>• </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>an increase of $53.4 million in cash dividends paid compared to
fiscal year 2004 due to an increase in the dividend rate </FONT></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Off-Balance Sheet Arrangements and Long-Term Contractual
Obligations </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> We acquire assets still in
development, enter into research and development arrangements and sponsor certain clinical trials that often require milestone
and/or royalty payments to a third-party, contingent upon the occurrence of certain future events. Milestone payments may be
required contingent upon the successful achievement of an important point in the development life cycle of a product or upon
certain pre-designated levels of achievement in clinical trials. In addition, if required by the arrangement, we may have to make
royalty payments based on a percentage of sales related to the product under development or in the event that regulatory approval
for marketing is obtained. In situations where we have no ability to influence the achievement of the milestone or otherwise avoid
the payment, we have included those milestone or minimum royalty payments in the following table. However, the majority of these
arrangements give us the discretion to unilaterally make the decision to stop development of a product or cease progress of a
clinical trial, which would allow us to avoid making the contingent payments. Although we are unlikely to cease development if a
device successfully achieves clinical testing objectives, these payments are not included in the table of contractual obligations
because of the contingent nature of these payments and our ability to avoid them if we decided to pursue a different path of
development or testing. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In the normal course of
business, we periodically enter into agreements that require us to indemnify customers or suppliers for specific risks, such as
claims for injury or property damage arising out of our products or the negligence of our personnel or claims alleging that our
products infringe third-party patents or other intellectual property. Our maximum exposure under these indemnification provisions
cannot be estimated, and we have not accrued any liabilities within our consolidated financial statements or included any
indemnification provisions in our commitments table. Historically, we have not experienced significant losses on these types of
indemnification obligations. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> We believe our off-balance
sheet arrangements do not have a material current or anticipated future effect on our consolidated earnings, financial position or
cash flows. Presented below is a summary of contractual obligations and other minimum commercial commitments. See Notes 3, 5, and
12 to the consolidated financial statements for additional information regarding foreign currency contracts, long-term debt and
lease obligations, respectively. </FONT></P>
<BR><BR><BR><BR><BR><BR><BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>22 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=20><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Maturity by Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Total </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2007 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2008 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2009 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2010 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2011 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Thereafter </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=20><FONT FACE="Times New Roman, Times, Serif" SIZE=1>(dollars in millions) </FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=34% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><I>Contractual obligations related to<BR> off-balance sheet arrangements:</I> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Foreign currency contracts<SUP>(1)</SUP></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,560.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,560.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Operating leases</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>247.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>72.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>56.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>41.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>24.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>41.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Inventory purchases<SUP>(2)</SUP></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>664.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>257.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>165.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>70.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>69.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>61.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>40.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Commitments to fund minority investments/contingent<BR> acquisition consideration<SUP>(3)</SUP></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>141.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>48.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>32.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>30.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>15.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>15.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Interest payments<SUP>(4)</SUP></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,124.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>139.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>139.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>139.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>139.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>126.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>440.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Other<SUP>(5)</SUP></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>424.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>184.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>123.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>30.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>26.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>17.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>43.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 4,163.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,262.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 516.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 311.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 275.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 216.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 580.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD colspan=24 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><I>Contractual obligations reflected in<BR> the balance sheet:</I> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Long-term debt, excluding capital leases<SUP>(6)</SUP></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 7,368.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,971.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,596.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,800.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Capital leases<SUP>(7)</SUP></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>95.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>13.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>16.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>37.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Other<SUP>(8)</SUP></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>38.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>17.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>14.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 7,501.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,994.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 26.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 13.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 15.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,614.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,837.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<HR noshade color="black" align="left" size="1" width="20%">
<TABLE WIDTH=100% CELLPADDING=2 CELLSPACING=2>
<TR VALIGN=TOP>
<TD ALIGN=LEFT WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1) </FONT></TD>
<TD WIDTH=97%><P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>As these obligations were entered into as hedges,
the majority of these obligations will be offset by losses/gains on the related assets, liabilities and transactions being hedged.
</FONT></P></TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2) </FONT></TD>
<TD WIDTH=97%><P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We have included inventory purchase commitments
which are legally binding and specify minimum purchase quantities. These purchase commitments do not exceed our projected
requirements and are in the normal course of business. These commitments do not include open purchase orders. </FONT></P></TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(3) </FONT></TD>
<TD WIDTH=97%><P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Certain commitments related to the funding of
minority investments and/or previous acquisitions are contingent upon the achievement of certain product-related milestones and
various other favorable operational conditions. While it is not certain if and/or when these payments will be made, the maturity
dates included in this table reflect our best estimates. </FONT></P></TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(4) </FONT></TD>
<TD WIDTH=97%><P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Interest payments in the table above reflect the
interest on our outstanding debt, including the $4.400 billion of Senior Convertible Notes, $1.000 billion of Senior Notes and
$1.971 billion of contingent convertible debentures. The interest rate on each outstanding obligation varies and interest is
payable semi-annually. The interest rate is 1.500% on the $2.200 billion Senior Convertible Notes due 2011 and 1.625% on the
$2.200 billion Senior Convertible Notes due 2013, 4.375% on the $400.0 million of Senior Notes due 2010, 4.750% on the $600.0
million of Senior Notes due 2015 and 1.25% on the contingent convertible debentures due 2021. </FONT></P></TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(5) </FONT></TD>
<TD WIDTH=97%><P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>These obligations include commitments to replace our
existing legacy enterprise resource systems, construction of our new CRDM campus and certain research and development
arrangements. </FONT></P></TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(6) </FONT></TD>
<TD WIDTH=97%><P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Long-term debt in the table above includes $4.400
billion Senior Convertible Notes issued in April 2006, $1.000 billion Senior Notes issued in September 2005 and the current
portion of long-term debt of $1.971 billion related to our contingent convertible debentures. These debentures were classified in
<I>short-term borrowings</I> in the consolidated balance sheet as of April 28, 2006 as the holders have the option to require us
to repurchase the outstanding securities (referred to as a put option) in September 2006. The table above also includes the impact
of the five year interest rate swap entered into in November 2005. </FONT></P></TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(7) </FONT></TD>
<TD WIDTH=97%><P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Capital lease obligations include a sale-leaseback
agreement entered into in the fourth quarter of fiscal year 2006 whereby certain manufacturing equipment was sold and is being
leased by us over a seven year period. </FONT></P></TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(8) </FONT></TD>
<TD WIDTH=97%><P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>These obligations include royalty payments and a
financing arrangement associated with our fiscal year 2002 acquisition of Kobayashi Pharmaceutical Co.’s interest in a joint
venture it had formed with us in 1996 to distribute spinal products in Japan. </FONT></P></TD>
</TR>
</TABLE>
<BR>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>23 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Debt and Capital </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Our capital structure
consists of equity and interest-bearing debt. Interest-bearing debt as a percent of total capital was 45.8% at April 28, 2006 and
19.0% at April 29, 2005. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In October 2003, our
Board of Directors authorized the repurchase of up to 30 million shares of our common stock and in October 2005 authorized
the repurchase of an additional 40 million shares. Shares are repurchased from time to time to support our stock-based
compensation programs and to take advantage of favorable market conditions. In April 2006, the Board of Directors made a special
authorization for the Company to repurchase up to 50 million shares of the Company’s common stock in conjunction with the
$4.400 billion convertible debenture offering (see below for further discussion). We repurchased approximately 68.9 million and
10.5 million shares at an average price of $52.12 and $48.77, respectively, during fiscal years 2006 and 2005, and
approximately 36.8 million shares remain under current buyback authorizations. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In April 2006, we issued
$2.200 billion of 1.500 percent Senior Convertible Notes due 2011 and $2.200 billion of 1.625 percent Senior Convertible Notes due
2013, collectively the Senior Convertible Notes. The Senior Convertible Notes were issued at par and pay interest in cash
semi-annually in arrears on April 15 and October 15 of each year, beginning on October 15, 2006. The Senior Convertible Notes are
unsecured unsubordinated obligations and rank equally with all other unsecured and unsubordinated indebtedness. The Senior
Convertible Notes have an initial conversion price of $56.14 per share. The Senior Convertible Notes may only be converted:
(i) during any calendar quarter beginning after June 30, 2006 if the closing price of our common stock reaches 140% of
the conversion price for 20 trading days during a specified period, or (ii) if specified distributions to holders of our
common stock are made or specified corporate transactions occur, or (iii) during the last month prior to maturity of the
applicable notes. Upon conversion, a holder would receive: (i) cash equal to the lesser of the principal amount of the note
or the conversion value and (ii) to the extent the conversion value exceeds the principal amount of the note, shares of our
common stock, cash, or a combination of common stock and cash, at our option. In addition, upon a change in control, as defined,
the holders may require us to purchase for cash all or a portion of their notes for 100% of the principal amount of the notes plus
accrued and unpaid interest, if any. The indentures under which the Senior Convertible Notes were issued contain customary covenants, all of which we remain in compliance as of April 28, 2006. A total of $2.500 billion of the net proceeds from
these note issuances were used to repurchase common stock under our stock repurchase program. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Concurrent with the issuance
of the Senior Convertible Notes, we purchased call options in private transactions. The call options allow us to receive shares of
our common stock and/or cash from counterparties equal to the amounts of common stock and/or cash related to the excess conversion
value that we would pay to the holders of the Senior Convertible Notes upon conversion. These call options will terminate the
earlier of the maturity dates of the related Senior Convertible Notes or the first day all of the related Senior Convertible Notes
are no longer outstanding due to conversion or otherwise. The call options, which cost an aggregate $1.075 billion
($698.5 million net of tax benefit), were recorded as a reduction of shareholders’ equity. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In separate transactions, we
sold warrants to issue shares of our common stock at an exercise price of $76.56 per share in private transactions. Pursuant to
these transactions, warrants for 41.1 million shares of our common stock may be settled over a specified period beginning in July
2011 and warrants for 41.1 million shares of our common stock may be settled over a specified period beginning in July 2013 (the
“settlement dates”). If the average price of our common stock during a defined period ending on or about the respective
settlement dates exceeds the exercise price of the warrants, the warrants will be settled in shares of our common stock. Proceeds
received from the issuance of the warrants totaled approximately $516.8 million and were recorded as an addition to
shareholders’ equity. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In September 2005, we issued
two tranches of Senior Notes with the aggregate face value of $1.000 billion. The first tranche consisted of $400.0 million of
4.375 percent Senior Notes due 2010 and the second tranche consisted of $600.0 million of 4.750 percent Senior Notes due 2015.
Each tranche was issued at a discount which resulted in an effective interest rate of 4.433 percent and 4.760 percent for the five
and ten year Senior Notes, respectively. Interest on each series of Senior Notes is payable semi-annually, on March 15 and
September 15 of each year. The Senior Notes are unsecured unsubordinated obligations and rank equally with all other unsecured and
unsubordinated indebtedness. The indentures under which the Senior Notes were issued contain customary covenants, all of which we
remain in compliance as of April 28, 2006. We used the net proceeds from the sale of the Senior Notes for repayment of a portion
of our outstanding commercial paper. </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>24 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In November 2005, we entered
into a five year interest rate swap agreement with a notional amount of $200.0 million. This interest rate swap agreement was
designated as a fair value hedge of the changes in fair value of a portion of our fixed-rate $400.0 million Senior Notes due 2010.
We pay variable interest equal to the three-month London Interbank Offered Rate (LIBOR) minus 55 basis points and we receive a
fixed interest rate of 4.375 percent. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In September 2001, we
completed a $2.013 billion private placement of 1.25 percent Contingent Convertible Debentures due September 2021 (Old
Debentures). Interest is payable semi-annually. Each Old Debenture is convertible into shares of common stock at an initial
conversion price of $61.81 per share; however, the Old Debentures are not convertible before their final maturity unless the
closing price of our common stock reaches 110% of the conversion price for 20 trading days during a consecutive 30 trading day
period. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In September 2002 and
2004, as a result of certain holders of the Old Debentures exercising their put options, we repurchased $38.7 million, or 1.9%,
and $0.6 million, or 0.03%, respectively, of the Old Debentures for cash. We may be required to repurchase the remaining
securities at the option of the holders in September 2006, 2008, 2011 or 2016. For put options exercised by the holders, the
purchase price is equal to the principal amount of the Old Debentures plus any accrued and unpaid interest on the Old Debentures
to the repurchase date. If the repurchase option is exercised, we may elect to repurchase the Old Debentures with cash, our common
stock, or some combination thereof. We may elect to redeem the Old Debentures for cash at any time after September 2006.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On January 24, 2005, we
completed an exchange offer whereby holders of approximately 97.7% of the total principal amount of the Old Debentures exchanged
their existing securities for an equal principal amount of 1.25 percent Contingent Convertible Debentures, Series B due 2021 (New
Debentures), and an exchange fee of $2.50 per $1,000 principal amount. The terms of the New Debentures are consistent with the
terms of the Old Debentures noted above, except that: (i) upon conversion, we will pay holders cash equal to the lesser of the
principal amount of the New Debentures or their conversion value, and shares of our common stock to the extent the conversion
value exceeds the principal amount; and (ii) the New Debentures require us to pay only cash (in lieu of shares of our common stock
or a combination of cash and shares of our common stock) when we repurchase the New Debentures at the option of the holder or in
connection with a change of control. The exchange fee paid to the holders of the New Debentures was capitalized and will be
amortized over the twenty month period ending in September 2006. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Following the completion of
the exchange offer, we repurchased approximately $1.8 million of the Old Debentures for cash. As of April 28, 2006,
approximately $43.2 million aggregate principal amount of Old Debentures and $1.928 billion aggregate principal amount of New
Debentures remain outstanding. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Twelve months prior to the
put options becoming exercisable, the remaining balance of the Old and New Debentures will be classified as<I> short-term
borrowings</I> in the consolidated balance sheets. At each balance sheet date without a put option within the subsequent four
quarters, the remaining balance will be classified as <I>long-term debt</I> in the consolidated balance sheets. During the second
quarter of fiscal year 2006, we reclassified $1.971 billion of these debentures to <I>short-term borrowings</I> due to the put
option becoming exercisable in September 2006. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> We maintain a commercial
paper program that allows us to have a maximum of $2.250 billion in commercial paper outstanding, with maturities up to
364 days from the date of issuance. At April 28, 2006 and April 29, 2005, outstanding commercial paper totaled $189.8
million and $249.9 million, respectively. During fiscal years 2006 and 2005, the weighted average original maturity of the
commercial paper outstanding was approximately 31 and 26 days, respectively, and the weighted average interest rate was 3.9% and
1.9%, respectively. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In connection with the
issuance of the contingent convertible debentures, Senior Notes, Senior Convertible Notes and commercial paper, Standard and
Poor’s Rating Group and Moody’s Investors Service issued us strong long-term debt ratings of AA- and A1, respectively,
and strong short-term debt ratings of A-1+ and P-1, respectively. These ratings remain unchanged from the same periods in the
prior year. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> We have existing lines of
credit of approximately $2.428 billion with various banks at April 28, 2006. The existing lines of credit include two
syndicated credit facilities totaling $1.750 billion with various banks. The two credit facilities consist of a five-year $1.000
billion facility, signed on January 20, 2005, which will expire on January 20, 2010, and a five-year $750.0 million
facility, signed on January 24, 2002, which will expire on January 24, 2007. The $1.000 billion facility provides us
with the ability to increase the capacity of the facility by an additional $250.0 million at any time during the life of the
five-year term of the agreement. The credit facilities provide backup funding for the commercial paper program and may also be
used for general corporate purposes. </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>25 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Interest rates on these
borrowings are determined by a pricing matrix, based on our long-term debt ratings, assigned by Standard and Poor’s Ratings
Group and Moody’s Investors Service. Facility fees are payable on the credit facilities and are determined in the same manner
as the interest rates. Under terms of the agreements, our consolidated tangible net worth must at all times be greater than or
equal to $1.040 billion, increased by an amount equal to 100% of the net cash proceeds from any equity offering occurring after
January 24, 2002. Our consolidated tangible net worth, defined as consolidated assets less goodwill, intangible assets (other
than patents, trademarks, licenses, copyrights and other intellectual property, and prepaid assets), and consolidated liabilities
at April 28, 2006 and April 29, 2005 was $4.931 billion and $6.029 billion, respectively. The agreements also contain other
customary covenants, all of which we remain in compliance with as of April 28, 2006. </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Acquisitions </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> During the second quarter of
fiscal year 2006, we acquired all the outstanding stock of IGN, a privately held company. Prior to the acquisition, we had an
equity investment in IGN, which was accounted for under the cost method of accounting. IGN specialized in precision navigation and
delivery technologies for brain surgery. The IGN product line includes the NexFrame disposable, “frameless” sterotactic
head frame, which is used in conjunction with image-guided surgery systems during deep brain stimulation. This acquisition
complements our position in deep brain stimulation by offering instruments that simplify the procedure for surgeons and improve
patient comfort during surgery. The total consideration for IGN was approximately $65.1 million, which included
$57.9 million in net cash paid. The $57.9 million in net cash paid results from the $65.1 million in consideration
less the value of our prior investment in IGN and IGN’s existing cash balance. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> During the first quarter of
fiscal year 2006, we acquired all of the outstanding stock of TNI, a privately held company. Prior to the acquisition, we had an
equity investment in TNI, which was accounted for under the cost method of accounting. TNI focused on the treatment of obesity by
stimulation of the stomach with an implantable gastric stimulator, known as the Transcend device. This acquisition is expected to
complement our formation of a new business unit, Emerging Therapies, and our strategy to deliver therapeutic solutions for the
worldwide challenges of obesity. Emerging Therapies is part of the Neurological operating segment. The consideration for TNI was
approximately $268.7 million, which includes $227.3 million in net cash paid. The $227.3 million in net cash paid
resulted from the $268.7 million in consideration less the value of our prior investment in TNI and TNI’s existing cash
balance. The purchase price is subject to increases which would be triggered by the achievement of certain milestones. During the
third quarter of fiscal year 2006, we announced that we missed the primary clinical endpoint in the Screen Health Assessment and
Pacer Evaluation (SHAPE) trial, a trial designed to study the efficacy and safety of gastric stimulation to treat obesity.
Medtronic will continue following patients enrolled in the SHAPE trial through 24-months of follow-up. The SHAPE trial evaluated
implantable gastric stimulation for the management of obesity. The announcement has no impact on our obesity feasibility study,
Appetite Suppression Induced by Stimulation Trial (ASSIST), which evaluates implantable gastric stimulation therapy in obese
patients with type 2 diabetes. We continue to refine and evaluate the technology, although no definitive determination has
been made about its commercialization. Our fiscal year 2006 operating results include the results of TNI and IGN since their
respective acquisition dates. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> During the first quarter of
fiscal year 2006, we acquired substantially all of the spine-related intellectual property and related contracts, rights, and
tangible materials owned by Michelson and settled all outstanding litigation and disputes between Michelson and the Company. The
acquired patents pertain to novel spinal technology and techniques that have both current application and the potential for future
patentable commercial products. The agreement requires total consideration of $1.350 billion for the purchase of a portfolio of
more than 100 issued U.S. patents, over 110 pending U.S. patent applications and numerous foreign counterparts to these patents
and patent applications, and the settlement of all ongoing litigation. A value of $550.0 million was assigned to the settlement of
past damages between the parties and was recorded as an expense in the fourth quarter of fiscal year 2005. The remaining
consideration, including $2.6 million of direct acquisition costs, was allocated between $627.5 million of acquired technology
based intangible assets that have a useful life of 17 years and $175.1 million of IPR&D that was expensed on the date of
acquisition. During the first quarter of fiscal year 2006, we paid $1.320 billion and committed to three future installments of
$10.0 million to be paid in May 2006, 2007, and 2008. The first installment of $10.0 million was paid in May 2006. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> During the third quarter of
fiscal year 2005, we acquired all of the outstanding stock of Angiolink Corporation (Angiolink) for approximately $42.3 million in
cash, subject to purchase price increases, which would be triggered by the achievement of certain milestones. Angiolink was a
privately held company that developed wound closure devices for vascular procedures. Angiolink’s EVS (Expanding Vascular
Stapling) Vascular Closure System, which has received FDA approval, is engineered to close the femoral artery access site after
vascular procedures, such as diagnostic angiography, balloon angioplasty and stenting. The EVS system provides safe and effective
mechanical closure of arterial puncture sites without disturbing the lumen, or interior, of the targeted vessel. This acquisition
provided us with an additional vascular closure offering to our current closure product — the non-invasive Clo-Sur P.A.D.
</FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>26 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> During the second quarter of
fiscal year 2005, we acquired substantially all of the assets of Coalescent Surgical, Inc. (Coalescent) for approximately
$65.1 million in cash, including a $5.0 million milestone payment made in March 2005 for the successful transition of product
and technology to us following the acquisition and a $6.0 million payment made in December 2005 related to the release of an
indemnification escrow established at the date of acquisition. Coalescent developed the U-Clip Anastomotic Device and the SPYDER
Proximal Anastomotic Device. The U-Clip device creates high-quality anastomoses (a seamless connection) without sutures and is
primarily used in coronary artery bypass surgery. The SPYDER device automatically deploys a series of U-Clip devices when
attaching the bypass graft to the aorta. This acquisition complemented our surgical product line and strategy to develop
technologies to promote surgical procedures that produce better patient outcomes, and reduce trauma and hospitalization. Our
fiscal year 2005 operating results include the results of Angiolink and Coalescent since their respective acquisition dates.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>New Accounting Pronouncement </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In December 2004, the
Financial Accounting Standards Board (FASB) issued SFAS No. 123(R), “Share-Based Payment” (SFAS No. 123(R)).
This Statement is a revision to SFAS No. 123, “Accounting for Stock-Based Compensation,” and supersedes Accounting
Principles Board Opinion (APB) No. 25, “Accounting for Stock Issued to Employees.” SFAS No. 123(R) requires
the recognition of the cost of employee services received in exchange for an award of equity instruments based on the grant date
fair value of the award. The cost will be recognized over the period during which an employee is required to provide service in
exchange for the award. No compensation cost is recognized for equity instruments for which employees do not render the required
service period. We intend to adopt SFAS No. 123(R) using the “modified prospective” method of application. Under
the “modified prospective” method, compensation cost is recognized prospectively for both new grants issued subsequent
to the date of adoption, and all unvested awards outstanding at the date of adoption. The Statement is effective for us beginning
in the first quarter of fiscal year 2007. The adoption of SFAS No. 123(R) will have a material impact on our consolidated
earnings but will not have a material impact our financial position or cash flows. Based on unvested stock-based awards currently
outstanding, the expense associated with the employee stock purchase plan and anticipated fiscal year 2007 grants, the effect of
adopting SFAS No. 123(R) is expected to reduce our after-tax net earnings by $140.0 - $150.0 million in fiscal year
2007. The total expense recorded in future periods will depend on several variables, including the number of stock-based awards
granted, the vesting period, the number of grants that ultimately vest, the number of awards granted to retirement eligible
individuals and the fair value assigned to those awards. </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1" FSL="Default" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><A NAME="operations_outside_the_us">Operations Outside the U.S. </A></FONT></H1>
<!-- MARKER FORMAT-SHEET="Head Minor Center" FSL="Default" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><I>The following charts illustrate U.S. net sales versus net sales outside the U.S. by fiscal year:</I> </FONT></P>
<DIV align="center"><img src="a62430us.jpg"></DIV>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>27 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Market Risk </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> From fiscal year 2005 to
fiscal year 2006, consolidated net sales in the U.S. grew at 13.5%, or 3.6% faster than consolidated net sales outside the U.S.
primarily as a result of the strong performance in both CRDM and Neurological operating segments and the negative impact of
foreign currency translation. CRDM and Neurological sales increased approximately 15.3% and 12.1%, respectively, in the U.S. while
sales of those products outside the U.S. grew 8.0% and 3.7%, respectively. The growth in CRDM during fiscal year 2006 was driven
by the strong demand for implantable defibrillation systems in the U.S. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Net sales outside the U.S.
are accompanied by certain financial risks, such as collection of receivables, which typically have longer payment terms.
Outstanding receivables from customers outside the U.S. totaled $1.179 billion at April 28, 2006, or 45.1% of total
outstanding accounts receivable, and $1.090 billion at April 29, 2005, or 44.2% of total outstanding accounts
receivable. The increase in the percentage of accounts receivable from customers outside the U.S. is primarily driven by increased
sales volume outside the U.S. and the impact of foreign currency exchange rates. Operations outside the U.S. could be negatively
impacted by changes in political, labor or economic conditions, changes in regulatory requirements or potentially adverse foreign
tax consequences, among other factors. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Additionally, markets outside
the U.S. are commonly funded directly by government-sponsored healthcare systems. These governments frequently impose
reimbursement limits to control government spending and to ensure local healthcare consumers can obtain medical products and
services at a low cost. Decisions made by these government agencies to further limit or eliminate reimbursement for our products
could have a material adverse affect on net earnings. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Due to the global nature of
our operations, we are subject to the exposures that arise from foreign currency exchange rate fluctuations. We manage these
exposures using operational and economic hedges as well as derivative financial instruments. The primary currencies hedged are the
Euro and the Japanese Yen. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Our objective in managing
exposure to foreign currency fluctuations is to minimize earnings and cash flow volatility associated with foreign exchange rate
changes. We enter into various contracts, principally forward contracts that change in value as foreign exchange rates change, to
protect the value of existing foreign currency assets, liabilities, net investments, and probable commitments. The gains and
losses on these contracts offset changes in the value of the related exposures. It is our policy to enter into foreign currency
hedging transactions only to the extent true exposures exist; we do not enter into foreign currency transactions for speculative
purposes. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> We had foreign exchange
derivative contracts outstanding in notional amounts of $1.561 billion and $2.894 billion at April 28, 2006 and
April 29, 2005, respectively. The fair value of these contracts at April 28, 2006 was $18.4 million more than the
original contract value. A sensitivity analysis of changes in the fair value of all foreign exchange derivative contracts at
April 28, 2006 indicates that, if the U.S. dollar uniformly strengthened/weakened by 10% against all currencies, the fair
value of these contracts would increase/decrease by $139.2 million, respectively. Any gains and losses on the fair value of
derivative contracts would be largely offset by gains and losses on the underlying transactions. These offsetting gains and losses
are not reflected in the above analysis. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> We are also exposed to
interest rate changes affecting principally our investments in interest rate sensitive instruments. A sensitivity analysis of the
impact on our interest rate sensitive financial instruments of a hypothetical 10% change in short-term interest rates compared to
interest rates at April 28, 2006 indicates that the fair value of these instruments would change by $12.5 million.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> We have periodically sold
specific pools of trade receivables in Japan. During fiscal year 2006 no trade receivables were sold, and in fiscal year 2005, we sold
approximately $145.5 million of our trade receivables to financial institutions in Japan. Additionally, we entered into
agreements to sell specific pools of receivables in Italy in the amount of $52.9 million and $4.1 million in fiscal
years 2006 and 2005, respectively. The discount cost related to the Japan and Italy sales was insignificant and recorded in
<I>interest (income)/expense</I> in the consolidated statements of earnings. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In the third quarter of
fiscal year 2004, we began lending certain fixed income securities to enhance our investment income. These lending activities are
collateralized at an average rate of 102%, with the collateral determined based on the underlying securities and creditworthiness
of the borrowers. The value of the securities on loan at April 28, 2006 and April 29, 2005 was $361.8 million and $361.3
million, respectively. </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>28 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Government Regulation and Other Considerations </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Our medical devices are
subject to regulation by numerous government agencies, including the FDA and comparable foreign agencies. To varying degrees, each
of these agencies requires us to comply with laws and regulations governing the development, testing, manufacturing, labeling,
marketing and distribution of our medical devices. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Authorization to commercially
distribute a new medical device in the U.S. is generally received in one of two ways. The first, known as the 510(k) process,
requires us to demonstrate that our new medical device is substantially equivalent to a legally marketed medical device. In this
process, we must submit data that supports our equivalence claim. If human clinical data is required, it must be gathered in
compliance with FDA investigational device exemption regulations. We must receive an order from the FDA finding substantial
equivalence to another legally marketed medical device before we can commercially distribute the new medical device. Modifications
to cleared medical devices can be made without using the 510(k) process if the changes do not significantly affect safety or
effectiveness. A very small number of our devices are exempt from 510(k) clearance requirements. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The second, more rigorous
process, known as pre-market approval (PMA), requires us to independently demonstrate that the new medical device is safe and
effective. We do this by collecting data, including human clinical data for the medical device. The FDA will authorize commercial
release if it determines there is reasonable assurance that the medical device is safe and effective. This process is generally
much more time-consuming and expensive than the 510(k) process. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Both before and after a
product is commercially released, we have ongoing responsibilities under FDA regulations. The FDA reviews design and manufacturing
practices, labeling and record keeping, and manufacturers’ required reports of adverse experience and other information to
identify potential problems with marketed medical devices. We may be subject to periodic inspection by the FDA for compliance with
the FDA’s good manufacturing practice regulations among other FDA requirements, such as restrictions on advertising and
promotion. These regulations, also known as the Quality System Regulations, govern the methods used in, and the facilities and
controls used for, the design, manufacture, packaging and servicing of all finished medical devices intended for human use. If the
FDA were to conclude that we are not in compliance with applicable laws or regulations, or that any of our medical devices are
ineffective or pose an unreasonable health risk, the FDA could ban such medical devices, detain or seize adulterated or misbranded
medical devices, order a recall, repair, replacement, or refund of such devices, and require us to notify health professionals and
others that the devices present unreasonable risks of substantial harm to the public health. The FDA may also impose operating
restrictions, enjoin and restrain certain violations of applicable law pertaining to medical devices, and assess civil or criminal
penalties against our officers, employees, or us. The FDA may also recommend prosecution to the Department of Justice. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The FDA, in cooperation with
U.S. Customs and Border Protection (CBP), administers controls over the import of medical devices into the U.S. The CBP imposes
its own regulatory requirements on the import of our products, including inspection and possible sanctions for noncompliance. The
FDA also administers certain controls over the export of medical devices from the U.S. International sales of our medical devices
that have not received FDA approval are subject to FDA export requirements. Each foreign country to which we export medical
devices also subjects such medical devices to their own regulatory requirements. Frequently, we obtain regulatory approval for
medical devices in foreign countries first because their regulatory approval is faster or simpler than that of the FDA. However,
as a general matter, foreign regulatory requirements are becoming increasingly stringent. In the European Union, a single
regulatory approval process has been created, and approval is represented by the CE Mark. To obtain a CE Mark in the European
Union, defined products must meet minimum standards of safety and quality (i.e., the essential requirements) and then comply with
one or more of a selection of conformity routes. A Notified Body assesses the quality management systems of the manufacturer and
the product conformity to the essential and other requirements within the Medical Device Directive. Medtronic is subject to
inspection by Notified Bodies for compliance. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> To be sold in Japan, medical
devices must undergo thorough safety examinations and demonstrate medical efficacy before they are granted approval, or
“shonin.” The Japanese government, through the Ministry of Health, Labour, and Welfare (MHLW), regulates medical devices
under recently enacted revisions to the Pharmaceutical Affairs Law (PAL). Implementation of PAL and enforcement practices
thereunder are evolving, and compliance guidance from MHLW is still in development. Consequently, companies continue to work on
establishing improved systems for compliance with PAL. Penalties for a company’s noncompliance with PAL could be severe,
including revocation or suspension of a company’s business license and criminal sanctions. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The process of obtaining
approval to distribute medical products is costly and time-consuming in virtually all of the major markets where we sell medical
devices. We cannot assure that any new medical devices we develop will be approved in a timely or cost-effective manner.
</FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>29 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Federal and state laws
protect the confidentiality of certain patient health information, including patient medical records, and restrict the use and
disclosure of patient health information by healthcare providers. In particular, in April 2003, the HHS published patient privacy
rules under the Health Insurance Portability and Accountability Act of 1996 (HIPAA privacy rule). The HIPAA privacy rule governs
the use and disclosure of protected health information by “Covered Entities,” which are healthcare providers that submit
electronic claims, health plans and healthcare clearinghouses. Other than our Diabetes operating segment and our health insurance plans,
each of which is a Covered Entity, and the role representatives play in patient care, the HIPAA privacy rule affects us only
indirectly. The patient data that we receive and analyze may include protected health information. We are committed to maintaining
patients’ privacy and working with our customers and business partners in their HIPAA compliance efforts. The ongoing costs
and impacts of assuring compliance with the HIPAA privacy rules are not material to our business.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Government and private sector
initiatives to limit the growth of healthcare costs, including price regulation, competitive pricing, coverage and payment
policies, and managed-care arrangements, are continuing in many countries where we do business, including the U.S. These changes
are causing the marketplace to put increased emphasis on the delivery of more cost-effective medical devices. Government programs,
including Medicare and Medicaid, private healthcare insurance and managed-care plans have attempted to control costs by limiting
the amount of reimbursement they will pay for particular procedures or treatments, and other mechanisms designed to constrain
utilization and contain cost, including, for example, gain sharing, where a supplier of medical goods or services is required to
share any realized cost savings with either the medical provider or payor as a condition of doing business with an entity. This
has created an increasing level of price sensitivity among customers for our products. Some third-party payors must also approve
coverage for new or innovative devices or therapies before they will reimburse healthcare providers who use the medical devices or
therapies. Even though a new medical device may have been cleared for commercial distribution, we may find limited demand for the
device until reimbursement approval has been obtained from governmental and private third-party payors. As a result of our
manufacturing efficiencies and cost controls, we believe we are well-positioned to respond to changes resulting from the worldwide
trend toward cost-containment; however, uncertainty remains as to the nature of any future legislation, making it difficult for us
to predict the potential impact of cost-containment trends on future operating results. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The delivery of our devices
is subject to regulation by HHS and comparable state and foreign agencies responsible for reimbursement and regulation of
healthcare items and services. U.S. laws and regulations are imposed primarily in connection with the Medicare and Medicaid
programs, as well as the government’s interest in regulating the quality and cost of healthcare. Foreign governments also
impose regulations in connection with their healthcare reimbursement programs and the delivery of healthcare items and services.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Federal healthcare laws apply
when we submit a claim on behalf of a Federal healthcare program beneficiary, or when a customer submits a claim for an item or
service that is reimbursed under Medicare, Medicaid or other federally-funded healthcare programs. The principal federal laws
include: (1) the False Claims Act which prohibits the submission of false or otherwise improper claims for payment to a
federally-funded healthcare program; (2) the Anti-Kickback Statute which prohibits offers to pay or receive remuneration of any
kind for the purpose of inducing or rewarding referrals of items or services reimbursable by a Federal health care program; and
(3) the Stark law which prohibits physicians from referring Medicare or Medicaid patients to an entity for the provision of
certain designated health services if the physician (or a member of the physician’s immediate family) has a financial
relationship with that entity. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The laws applicable to us are
subject to evolving interpretations. If a governmental authority were to conclude that we are not in compliance with applicable
laws and regulations, Medtronic, its officers and employees, could be subject to severe criminal and civil penalties including,
for example, exclusion from participation as a supplier of product to beneficiaries covered by Medicare or Medicaid. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> We operate in an industry
characterized by extensive patent litigation. Patent litigation can result in significant damage awards and injunctions that could
prevent the manufacture and sale of affected products or result in significant royalty payments in order to continue selling the
products. At any given time, we are generally involved as both a plaintiff and a defendant in a number of patent infringement
actions. While it is not possible to predict the outcome of patent litigation incident to our business, we believe the costs
associated with this litigation could generally have a material adverse impact on our consolidated results of operations,
financial position or cash flows. See Note 13 to the consolidated financial statements for additional information. </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>30 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> We operate in an industry
susceptible to significant product liability claims. These claims may be brought by individuals seeking relief or by groups
seeking to represent a class. In addition, product liability claims may be asserted against us in the future based on events we
are not aware of at the present time. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> We are also subject to
various environmental laws and regulations both within and outside the U.S. Like other medical device companies, our operations
involve the use of substances regulated under environmental laws, primarily manufacturing and sterilization processes. We do not
expect that compliance with environmental protection laws will have a material impact on our consolidated results of operations,
financial position or cash flows. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> At the beginning of fiscal
year 2003, we elected to transition most of our insurable risks to a program of self-insurance, with the exception of director and
officer liability insurance, which was transitioned in fiscal year 2004. This decision was made based on current conditions in the
insurance marketplace that have led to increasingly higher levels of self-insurance retentions, increasing number of coverage
limitations and dramatically higher insurance premium rates. We will continue to monitor the insurance marketplace to evaluate the
value to us of obtaining insurance coverage in the future. Based on historical loss trends, we believe that our self-insurance
program accruals will be adequate to cover future losses. Historical trends, however, may not be indicative of future losses.
These losses could have a material adverse impact on our consolidated results of operations, financial position or cash flows.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cautionary Factors That May Affect Future Results </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> This Annual Report may
include “forward-looking” statements. Forward-looking statements broadly involve our current expectations or forecasts
of future results. Our forward-looking statements generally relate to our growth strategies, financial results, product
development, regulatory approvals, competitive strengths, intellectual property rights, litigation, mergers and acquisitions,
market acceptance of our products, accounting estimates, financing activities, ongoing contractual obligations, and sales efforts.
Such statements can be identified by the use of terminology such as “anticipate,” “believe,”
“could,” “estimate,” “expect,” “forecast,” “intend,” “may,”
“plan,” “possible,” “project,” “should,” “will” and similar words or
expressions. One must carefully consider forward-looking statements and understand that such statements may be affected by
inaccurate assumptions and may involve a variety of risks and uncertainties, known and unknown, including, among others, those
discussed in the previous section, in the section entitled “Risk Factors” in our Form 10-K, as well as those related to
competition in the medical device industry, reduction or interruption in our supply, quality problems and price decrease for our
products and services, and international operations. Consequently, no forward-looking statement can be guaranteed and actual
results may vary materially. We intend to take advantage of the Safe Harbor provisions of the Private Securities Litigation Reform
Act of 1995 regarding our forward-looking statements, and are including this sentence for the express purpose of enabling us to
use the protections of the safe harbor with respect to all forward-looking statements. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> We undertake no obligation to
update any statement we make, but investors are advised to consult any further disclosures by us in our filings with the
Securities and Exchange Commission, especially on Forms 10-K, 10-Q, and 8-K, in which we discuss in more detail various important
factors that could cause actual results to differ from expected or historical results. In addition, actual results may differ
materially from those anticipated due to a number of factors, including, among others, those discussed in the section entitled
“Risk Factors” in our Form 10-K. It is not possible to foresee or identify all such factors. As such, investors should
not consider any list of such factors to be an exhaustive statement of all risks, uncertainties or potentially inaccurate
assumptions. </FONT></P>
<BR><BR><BR><BR><BR><BR><BR><BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>31 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1" FSL="Default" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><A NAME="reports_of_management">Reports of Management </A></FONT></H1>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Management’s Report on the Financial Statements </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The management of
Medtronic, Inc. is responsible for the integrity of the financial information presented in this Annual Report. The
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America. Where necessary, and as discussed under <I>Critical Accounting Estimates</I> on pages 5-6, the consolidated
financial statements reflect estimates based on management’s judgment. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The consolidated financial
statements have been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, who conducted their
audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). The independent
registered public accounting firm’s responsibility is to express an opinion that such financial statements present fairly, in
all material respects, our financial position, results of operations and cash flows in accordance with accounting principles
generally accepted in the United States. </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Management’s Report on Internal Control over Financial
Reporting </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Management is responsible for
establishing and maintaining adequate internal control over financial reporting for the Company. Management conducted an
evaluation of the effectiveness of internal control over financial reporting based on the framework in <I>Internal Control</I>
– <I>Integrated Framework</I> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on
this evaluation, management concluded that the Company’s internal control over financial reporting was effective as of
April 28, 2006. Management’s assessment of the effectiveness of the Company’s internal control over financial
reporting as of April 28, 2006 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting
firm, as stated in their report which is included herein. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2">/s/ Arthur D. Collins, Jr.
<BR>Arthur D. Collins, Jr.
<BR><I>Chairman of the Board and Chief Executive Officer</I> </FONT> </P>
<!-- MARKER FORMAT-SHEET="Head Left" FSL="Default" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2">/s/ Gary L. Ellis
<BR>Gary L. Ellis
<BR><I>Senior Vice President and Chief Financial Officer</I> </FONT> </P>
<BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>32 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1" FSL="Default" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><A NAME="report_of_independent">Report of Independent </A>Registered Public Accounting Firm
</FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> To the Shareholders and Board
of Directors of Medtronic, Inc.: </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> We have completed integrated
audits of Medtronic, Inc.’s April 28, 2006 and April 29, 2005 consolidated financial statements and of its internal
control over financial reporting as of April 28, 2006, and an audit of its April 30, 2004 consolidated financial
statements in accordance with the standards of the Public Company Accounting Oversight Board (United States). Our opinions, based
on our audits, are presented below. </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Left" FSL="Default" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U>Consolidated financial statements</U> </FONT> </P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In our opinion, the
accompanying consolidated balance sheets and the related consolidated statements of earnings, shareholders’ equity and cash
flows present fairly, in all material respects, the financial position of Medtronic, Inc. and its subsidiaries (the Company) at
April 28, 2006 and April 29, 2005, and the results of their operations and their cash flows for each of the three fiscal
years in the period ended April 28, 2006 in conformity with accounting principles generally accepted in the United States of
America. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an
opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance with the
standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit of
financial statements includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall
financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Left" FSL="Default" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U>Internal control over financial reporting</U> </FONT> </P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Also, in our opinion,
management’s assessment, included in the accompanying Management’s Report on Internal Control over Financial Reporting,
that the Company maintained effective internal control over financial reporting as of April 28, 2006 based on criteria
established in <I>Internal Control – Integrated Framework</I> issued by the Committee of Sponsoring Organizations of the
Treadway Commission (COSO), is fairly stated, in all material respects, based on those criteria. Furthermore, in our opinion, the
Company maintained, in all material respects, effective internal control over financial reporting as of April 28, 2006, based
on criteria established in <I>Internal Control – Integrated Framework</I> issued by the COSO. The Company’s management
is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of
internal control over financial reporting. Our responsibility is to express opinions on management’s assessment and on
the effectiveness of the Company’s internal control over financial reporting based on our audit. We conducted our audit of
internal control over financial reporting in accordance with the standards of the Public Company Accounting Oversight Board
(United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective
internal control over financial reporting was maintained in all material respects. An audit of internal control over financial
reporting includes obtaining an understanding of internal control over financial reporting, evaluating management’s
assessment, testing and evaluating the design and operating effectiveness of internal control, and performing such other
procedures as we consider necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinions.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> A company’s internal
control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles. A company’s internal control over financial reporting includes those policies and procedures that
(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to
permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition
of the company’s assets that could have a material effect on the financial statements. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Because of its inherent
limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any
evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in
conditions, or that the degree of compliance with the policies or procedures may deteriorate. </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Left" FSL="Default" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>/s/ PricewaterhouseCoopers LLP </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Left" FSL="Default" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>PricewaterhouseCoopers LLP
<BR>Minneapolis, Minnesota
<BR>June 21, 2006 </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>33 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold;text-align:left"><B>Consolidated </B>
<FONT STYLE="font-size:16pt"><I><A NAME="statements_of_earnings">Statements of Earnings</A></I> </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>(in millions, except per share data)<BR> </FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=55% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Net sales</B> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 11,292.0</FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 10,054.6</FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 9,087.2</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Costs and expenses:</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Cost of products sold</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,815.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,446.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,252.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Research and development expense</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,112.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>951.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>851.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Selling, general and administrative expense</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,659.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,213.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,801.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Special charges</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>100.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(4.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Certain litigation charges</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>654.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Purchased in-process research and development (IPR&D) charges</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>363.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>41.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Other expense, net</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>166.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>290.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>351.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Interest income, net</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(87.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(45.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> Total costs and expenses</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8,130.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7,511.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6,290.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Earnings before income taxes</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,161.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,543.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,796.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Provision for income taxes</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>614.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>739.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>837.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Net earnings</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,546.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,803.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,959.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD colspan=12 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Earnings per share:</B> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> Basic</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.11</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.49</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.61</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> Diluted</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.09</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.48</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.60</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM">
<TD colspan=12 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Weighted average shares outstanding:</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Basic</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,204.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,209.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,213.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Diluted</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,217.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,220.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,225.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
</TABLE>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><I>See accompanying notes to the consolidated financial statements.</I> </FONT> </P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>34 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold;text-align:left"><B>Consolidated </B>
<FONT STYLE="font-size:16pt"><I><A NAME="balance_sheets">Balance Sheets</A></I> </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>April 28,<BR>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>April 29,<BR>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>(dollars in millions,<BR>except per share data) </FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH="72%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Assets</B> </FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="8%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH="6%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="8%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH="2%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Current assets:</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Cash and cash equivalents</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,994.3</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,232.2</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Short-term investments</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,107.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,159.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Accounts receivable, less allowances of $183.6 and $174.9, respectively</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,429.0</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,292.7</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Inventories</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,176.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>981.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Deferred tax assets, net</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>196.8</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>385.6</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Prepaid expenses and other current assets</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>472.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>370.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> Total current assets</B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10,376.6</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7,421.5</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Property, plant and equipment, net</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,881.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,859.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Goodwill</B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,345.6</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,281.2</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Other intangible assets, net</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,592.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,018.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Long-term investments</B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>957.0</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,565.7</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Other assets</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>512.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>471.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> Total assets</B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 19,664.8</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 16,617.4</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Liabilities and Shareholders’ Equity</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD colspan=9 ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Current liabilities:</B> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Short-term borrowings</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,436.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 478.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Accounts payable</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>318.6</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>371.8</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Accrued compensation</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>722.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>542.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Accrued income taxes</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>461.1</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>923.3</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Other accrued expenses</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>466.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,064.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> Total current liabilities</B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,405.8</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,380.0</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Long-term debt</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5,486.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,973.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Deferred tax liabilities, net</B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>22.1</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>478.1</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Long-term accrued compensation</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>188.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>157.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Other long-term liabilities</B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>179.2</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>178.7</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> Total liabilities</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10,282.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6,167.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Commitments and contingencies (Notes 5, 12 and 13)</B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Shareholders’ equity:</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD colspan=9 ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Preferred stock-par value $1.00; 2.5 million shares authorized, none</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> outstanding</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Common stock-par value $0.10; 1.6 billion shares authorized, 1,155,237,090</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> and 1,210,186,635 shares issued and outstanding, respectively</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>115.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>121.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Retained earnings</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9,112.2</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10,178.5</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Accumulated other comprehensive income</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>154.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>150.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> Total shareholders’ equity</B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9,382.5</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10,449.5</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> Total liabilities and shareholders’ equity</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 19,664.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 16,617.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><I>See accompanying notes to the consolidated financial statements.</I> </FONT> </P>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>35 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold;text-align:left"><B>Consolidated </B>
<FONT STYLE="font-size:16pt"><I><A NAME="shareholders_equity">Statements of Shareholders’ Equity</A></I> </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Common<BR>Shares</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Common<BR>Stock</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Retained<BR>Earnings</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Accumulated<BR>Other<BR>Comprehensive Income/(Loss)</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Receivable<BR>from Employee<BR>Stock<BR>Ownership Plan</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Total<BR>Shareholders’<BR>Equity</FONT></TH></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=17><FONT FACE="Times New Roman, Times, Serif" SIZE=1>(in millions, except per share data)</FONT></TH></TR>
<TR><td> </td></tr>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=38% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Balance April 25, 2003</B> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,218.1</FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 121.8</FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 7,808.4</FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (12.1</FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (11.7</FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 7,906.4</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net earnings</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,959.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,959.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><I>Other comprehensive income</I> </FONT></TD><TD COLSPAN=19 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Unrealized gain on investments</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Translation adjustment</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>80.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>80.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Minimum pension liability</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(6.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(6.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Unrealized gain on foreign exchange derivatives</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=3></TD>
<TD COLSPAN=3></TD>
<TD COLSPAN=3></TD>
<TD COLSPAN=3></TD>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Total comprehensive income</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,043.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Dividends paid - $0.29 per share</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(351.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(351.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD style="padding-left:5pt;text-indent:-5pt">
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>Issuance of common stock under employee benefits and incentive plans</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>240.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>241.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD style="padding-left:5pt;text-indent:-5pt">
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>Issuance of common stock in connection with acquisition</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>57.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>57.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Repurchases of common stock</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(17.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(878.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(880.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD style="padding-left:5pt;text-indent:-5pt">
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>Income tax benefit from restricted stock and nonstatutory stock options</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>55.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>55.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Repayments from employee stock ownership plan</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Balance April 30, 2004</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,209.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 120.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 8,890.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 72.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (6.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 9,077.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net earnings</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,803.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,803.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><I>Other comprehensive income</I> </FONT></TD><TD colspan=19 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Unrealized loss on investments</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(15.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(15.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Translation adjustment</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>62.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>62.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Minimum pension liability</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(5.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(5.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Unrealized gain on foreign exchange derivatives</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>36.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>36.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=3></TD>
<TD COLSPAN=3></TD>
<TD COLSPAN=3></TD>
<TD COLSPAN=3></TD>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Total comprehensive income</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,881.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Dividends paid - $0.34 per share</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(404.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(404.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD style="padding-left:5pt;text-indent:-5pt">
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>Issuance of common stock under employee benefits and incentive plans</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>337.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>338.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Repurchases of common stock</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(10.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(510.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(511.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD style="padding-left:5pt;text-indent:-5pt">
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>Income tax benefit from restricted stock and nonstatutory stock options</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>60.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>60.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Repayments from employee stock ownership plan</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Balance April 29, 2005</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,210.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 121.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 10,178.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 150.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10,449.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net earnings</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,546.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,546.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><I>Other comprehensive income</I> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Unrealized gain on investments</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Translation adjustment</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(13.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(13.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Minimum pension liability</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(8.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(8.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Unrealized gain on foreign exchange derivatives</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>26.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>26.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=3></TD>
<TD COLSPAN=3></TD>
<TD COLSPAN=3></TD>
<TD COLSPAN=3></TD>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Total comprehensive income</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,551.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Dividends paid - $0.39 per share</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(464.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(464.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD style="padding-left:5pt;text-indent:-5pt">
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>Issuance of common stock under employee benefits and incentive plans</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>13.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>516.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>518.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Repurchases of common stock</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(68.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(6.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(3,582.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(3,589.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD style="padding-left:5pt;text-indent:-5pt">
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>Income tax benefit from restricted stock and nonstatutory stock options</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>98.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>98.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Purchased call options, net of tax benefit</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(698.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(698.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Sale of warrants</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>516.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>516.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Balance April 28, 2006</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,155.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 115.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 9,112.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 154.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 9,382.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><I>See accompanying notes to the consolidated financial statements.</I> </FONT> </P>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>36 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold;text-align:left"><B>Consolidated </B>
<FONT STYLE="font-size:16pt"><I><A NAME="cash_flows">Statements of Cash Flows</A></I> </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year</FONT>
<HR WIDTH=100% SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006</FONT><HR WIDTH=100% SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005</FONT><HR WIDTH=100% SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT><HR WIDTH=100% SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>(dollars in millions)</FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=63% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Operating Activities:</B> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Net earnings</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,546.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,803.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,959.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Adjustments to reconcile net earnings to net cash provided by operating activities:</FONT></TD><TD COLSPAN=10 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Depreciation and amortization</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>543.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>463.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>442.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> IPR&D charges</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>363.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>41.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Special charges</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(4.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Certain litigation charges</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>654.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Provision for doubtful accounts</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>39.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>43.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>70.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Tax benefit from exercise of stock-based awards</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>98.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>60.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>55.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Deferred income taxes</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>104.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(142.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>110.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Change in operating assets and liabilities:</FONT></TD><TD COLSPAN=10 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Accounts receivable</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(216.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(270.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(241.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Inventories</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(257.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(51.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>127.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Prepaid expenses and other assets</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(85.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(107.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(97.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Accounts payable and accrued liabilities</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(968.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>423.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>326.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Other long-term liabilities</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>38.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(57.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>56.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Net cash provided by operating activities</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,207.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,819.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,845.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Investing Activities:</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Acquisitions, net of cash acquired</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(285.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(107.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(30.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Purchase of intellectual property</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(837.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(10.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Additions to property, plant and equipment</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(407.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(452.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(424.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Sales and maturities of marketable securities</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6,626.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>807.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,473.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Purchases of marketable securities</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(8,064.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,805.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2,684.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Other investing activities, net</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>100.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(35.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>15.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Net cash used in investing activities</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2,866.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,602.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,650.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Financing Activities:</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Change in short-term borrowings, net</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(18.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>90.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(19.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Payments on long-term debt</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Issuance of long-term debt</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5,428.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Purchase of call options</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,074.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Sale of warrants</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>516.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Dividends to shareholders</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(464.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(404.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(351.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Repurchase of common stock</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(3,589.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(511.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(880.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Issuance of common stock</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>518.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>338.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>241.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Net cash provided by (used in) financing activities</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,316.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(488.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,010.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Effect of exchange rate changes on cash and cash equivalents</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>104.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(89.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(61.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Net change in cash and cash equivalents</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>762.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>638.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>123.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cash and cash equivalents at beginning of period</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,232.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,593.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,470.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Cash and cash equivalents at end of period</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,994.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,232.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,593.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Supplemental Cash Flow Information:</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Cash paid during the year for:</FONT></TD><TD COLSPAN=10 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Income taxes</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 860.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 551.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 490.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Interest</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>108.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>55.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>56.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Supplemental Noncash Investing and Financing Activities:</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Issuance of common stock in connection with an acquisition</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 57.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Reclassification of debentures from short-term to long-term debt</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,973.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Reclassification of debentures from long-term to short-term debt</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,971.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,973.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
</TABLE>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><I>See accompanying notes to the consolidated financial statements.</I> </FONT></P>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>37 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt"><A NAME="notes">Notes </A></FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I> </I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1. Summary of Significant Accounting Policies </FONT></H1>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Nature of Operations</B> Medtronic, Inc.
(Medtronic or the Company) is the global leader in medical technology, alleviating pain, restoring health and extending life for
millions of people around the world. The Company provides innovative products and therapies for use by medical professionals to
meet the healthcare needs of their patients. Primary products include those for heart and vascular disease, neurological
disorders, chronic pain, spinal disorders, diabetes, urologic and digestive system disorders and ear, nose and throat disorders.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The Company is headquartered
in Minneapolis, Minnesota, and markets its products primarily through a direct sales force in the United States (U.S.) and a
combination of direct sales representatives and independent distributors in international markets. The primary markets for
products are the U.S., Western Europe, and Japan. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Principles of
Consolidation</B> The consolidated financial statements include the accounts of Medtronic, Inc., and all of
its subsidiaries. All significant intercompany transactions and accounts have been eliminated. The principles of Financial
Accounting Standards Board (FASB) Interpretation (FIN) No. 46, “Consolidation of Variable Interest Entities” and
Accounting Research Bulletin (ARB) No. 51, “Consolidated Financial Statements” are considered when determining
whether an entity is subject to consolidation. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Fiscal
Year-End</B> The Company utilizes a 52/53-week fiscal year, ending the last Friday in April. Fiscal year 2004 was
a 53-week year. As a result of the additional week, the Company’s 2004 fiscal year and fourth quarter included 53 and 14
weeks, respectively, as opposed to 52 and 13 weeks, respectively, in both fiscal years 2006 and 2005. The Company’s fiscal
years 2006, 2005 and 2004 ended on April 28, 2006, April 29, 2005 and April 30, 2004, respectively. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Use of
Estimates</B> The preparation of the financial statements in conformity with accounting principles generally
accepted (GAAP) in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the
financial statements and accompanying notes. Actual results could differ materially from those estimates. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Cash
Equivalents</B> The Company considers highly liquid investments with maturities of three months or less from the
date of purchase to be cash equivalents. These investments are carried at cost, which approximates fair value. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Investments</B> Investments
in marketable equity securities and debt securities are classified and accounted for as available-for-sale (AFS) at April 28, 2006
and April 29, 2005. AFS debt securities are recorded at fair value in both <I>short-term</I> and <I>long-term investments</I>
and AFS equity securities are recorded at fair value in <I>long-term investments</I> in the consolidated balance sheets<I>.</I>
The change in fair value for AFS securities is recorded, net of taxes, as a component of <I>accumulated other comprehensive
income</I> in the consolidated balance sheets. Management determines the appropriate classification of its investments in debt and
equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Certain of the Company’s
investments in equity securities are long-term, strategic investments in companies that are in varied stages of development. The
Company accounts for these investments under the cost or the equity method of accounting, as appropriate. The valuation of equity
securities accounted for under the cost method considers all available financial information related to the investee, including
valuations based on recent third-party equity investments in the investee. If an unrealized loss for any investment is considered
to be other-than-temporary, the loss will be recognized in the consolidated statements of earnings in the period the determination
is made. Equity securities accounted for under the equity method are recorded at the amount of the Company’s investment and
adjusted each period for the Company’s share of the investee’s income or loss and dividends paid. Equity securities
accounted for under both the cost and equity methods are reviewed quarterly for changes in circumstance or the occurrence of
events that suggest the Company’s investment may not be recoverable. In fiscal year 2006 the Company recognized $41.7 of
expense associated with impairments on equity securities. As of April 28, 2006 and April 29, 2005, the Company has
$190.4 and $241.6, respectively, of equity securities, which are recorded as <I>long-term investments</I> in the consolidated
balance sheets. Of these investments, $176.1 and $230.7, respectively, represent investments in companies that do not have quoted
market prices. </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>38 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Accounts
Receivable</B> The Company grants credit to customers in the normal course of business, but generally does not
require collateral or any other security to support its receivables. The Company maintains an allowance for doubtful accounts for
potential credit losses. Uncollectible accounts are written-off against the allowance when it is deemed that a customer account is
uncollectible. The allowance for doubtful accounts was $183.6 at April 28, 2006 and $174.9 at April 29, 2005. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Inventories</B>
Inventories are stated at the lower of cost or market, with cost
determined on a first-in, first-out basis. Inventory balances are as follows: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>April 28,<BR>2006 </FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>April 29,<BR>2005 </FONT></TH></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=58% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Finished goods</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=7% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=12% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 736.1</FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=12% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 606.9</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Work in process</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>196.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>148.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Raw materials</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>244.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>226.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Total</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,176.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 981.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Property, Plant and
Equipment </B>Property, plant and equipment is stated at cost. Additions and improvements that extend the lives
of the assets are capitalized while expenditures for repairs and maintenance are expensed as incurred. Depreciation is provided
using the straight-line method over the estimated useful lives of the various assets. Property, plant and equipment balances and
corresponding lives are as follows: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>April 28,<BR>2006 </FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>April 29,<BR>2005 </FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Lives<BR>(in years) </FONT></TH></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=51% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Land and land improvements</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 91.8</FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 85.3</FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="10%" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Up to 20</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Buildings and leasehold improvements</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>954.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>891.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="CENTER" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Up to 40</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Equipment</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,513.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,363.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="CENTER" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3-7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Construction in progress</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>234.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>289.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="CENTER" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Subtotal</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,794.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,628.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="CENTER" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Less: Accumulated depreciation</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,913.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,769.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="CENTER" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Property, plant and equipment, net</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,881.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,859.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="CENTER" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Depreciation expense of
$369.2, $335.5 and $326.5 was recognized in fiscal years 2006, 2005 and 2004, respectively. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Goodwill</B> Goodwill
is the excess of purchase price of an acquired entity over the amounts assigned to assets acquired and liabilities assumed in a
business combination. In accordance with Statement of Financial Accounting Standards (SFAS) No. 142, “Goodwill and Other
Intangible Assets,” goodwill is not amortized. Goodwill is tested for impairment annually and when an event occurs or
circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is done at a
reporting unit level. An impairment loss is recognized when the carrying amount of the reporting unit’s net assets exceeds
the estimated fair value of the reporting unit. The estimated fair value is determined using discounted future cash flows
analysis. The Company completed its annual goodwill impairment test in the third quarter of fiscal years 2006, 2005 and 2004 and
determined that no goodwill was impaired. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Intangible
Assets</B> Intangible assets include patents, trademarks and purchased technology. Intangible assets with a
definite life are amortized on a straight-line or accelerated basis, as appropriate, with estimated useful lives ranging from 3 to
20 years. Intangible assets with a definite life are tested for impairment whenever events or circumstances indicate that a
carrying amount of an asset (asset group) may not be recoverable. Impairment is calculated as the excess of the asset’s
carrying value over its fair value. Fair value is generally determined using a discounted future cash flows analysis. </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>39 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Warranty
Obligation</B> The Company offers a warranty on various products. The Company estimates the costs that may be
incurred under its warranties and records a liability in the amount of such costs at the time the product is sold. Factors that
affect the Company’s warranty liability include the number of units sold, historical and anticipated rates of warranty claims
and cost per claim. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as
necessary. The amount of the reserve recorded is equal to the costs to repair or otherwise satisfy the claim. The Company includes
the covered costs associated with field actions, if any, in warranty expense. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Changes in the Company’s
product warranty obligations during the years ended April 28, 2006 and April 29, 2005 consisted of the following: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=79% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Balance April 30, 2004</B> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=6% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=11% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 35.5</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Warranty claims provision</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>50.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Settlements made</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(42.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Balance April 29, 2005</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>42.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Warranty claims provision</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>47.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Settlements made</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(48.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Balance April 28, 2006</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 41.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Self-Insurance</B> It
is the Company’s policy to self-insure the vast majority of its insurable risks including medical and dental costs,
disability coverage, physical loss to property, business interruptions, workers’ compensation, comprehensive general,
director and officer and product liability. Insurance coverage is obtained for those risks required to be insured by law or
contract. A provision for losses under the self-insured program is recorded and revised quarterly. Additionally, the Company uses
claims data and historical experience to estimate current medical and dental liabilities. Based on historical loss trends, the
Company believes that its self-insurance program accruals are adequate to cover future losses. Historical trends, however, may not
be indicative of future losses. These losses could have a material adverse impact on the Company’s consolidated financial
statements. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Retirement Benefit Plan
Assumptions</B> The Company sponsors various retirement benefit plans, including defined benefit pension plans,
defined contribution savings plans, post-retirement medical plans, and termination indemnity plans, covering substantially all
U.S. employees and many employees outside the U.S. Pension benefit and post-retirement medical plan costs include assumptions for
the discount rate, retirement age, compensation rate increases, and the expected return on plan assets. Post-retirement medical
plan costs also incorporate healthcare cost trend rate assumptions. Refer to Note 11 for additional information regarding the
Company’s retirement benefit plans. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Annually, the Company
evaluates the discount rate, retirement age, compensation rate increases, expected return on plan assets and healthcare cost trend
rates of its pension benefit and post-retirement medical plans. In evaluating these assumptions, many factors are considered,
including an evaluation of assumptions made by other companies, historical assumptions compared to actual results, current market
conditions, asset allocations and the views of leading financial advisors and economists. In evaluating the expected retirement
age assumption, the Company considers the retirement ages of past employees eligible for pension and medical benefits together
with expectations of future retirement ages. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> It is reasonably possible
that changes in these assumptions will occur in the near term and, due to the uncertainties inherent in setting assumptions, the
effect of such changes could be material to the Company’s consolidated financial statements. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Revenue Recognition</B> The
Company sells its products primarily through a direct sales force and a combination of direct sales representatives and
independent distributors in international markets. Accordingly, a significant portion of the Company’s revenue is generated
from inventory maintained at hospitals or with field representatives. For these products, revenue is recognized at the time the
Company is notified that the product has been used or implanted. Estimated revenue is accrued as of a period end for products that
have been implanted, but for which the Company has not yet been notified. For all other transactions, the Company recognizes
revenue when title to the goods and risk of loss transfer to customers providing there are no remaining performance obligations
required of the Company or any matters requiring customer acceptance. In cases where the Company utilizes distributors or ships
product directly to the end user, it recognizes revenue upon shipment provided all revenue recognition criteria have been met. The
Company records estimated sales returns, discounts and rebates as a reduction of net sales in the same period revenue is
recognized. </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>40 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Research and
Development</B> Research and development costs are expensed when incurred. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>IPR&D</B> When
the Company acquires another entity, the purchase price is allocated, as applicable, between IPR&D, other identifiable
intangible assets, net tangible assets, and goodwill. The Company’s policy defines IPR&D as the value assigned to those
projects for which the related products have not received regulatory approval and have no alternative future use. Determining the
portion of the purchase price allocated to IPR&D requires the Company to make significant estimates. The amount of the
purchase price allocated to IPR&D is determined by estimating the future cash flows of each project or technology and
discounting the net cash flows back to their present values. The discount rate used is determined at the time of acquisition in
accordance with accepted valuation methods. These methodologies include consideration of the risk of the project not achieving
commercial feasibility. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Other Expense,
Net</B> Other expense, net includes intellectual property amortization expense, royalty income and expense,
realized equity security gains and losses, realized foreign currency transaction and derivative gains and losses and impairment
charges on equity securities. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Stock-Based
Compensation</B> The Company accounts for stock-based employee compensation using the intrinsic value method as
prescribed under Accounting Principles Board Opinion (APB) No. 25, “Accounting for Stock Issued to Employees” and
related Interpretations. Accordingly, the Company would record compensation expense if the quoted market price on the date of
grant exceeds the exercise price. Compensation expense for stock options and other equity based awards is calculated as the number
of options or shares granted multiplied by the amount the market price exceeds the exercise price. The Company’s practice is
to grant options with an exercise price equal to the market value on the effective date of the award, as established by the
Compensation Committee of the Board of Directors for executive management and the effective date of the award as established by
the Internal Stock Committee for awards to all other employees. The majority of these grants are made each year at the end of the
second fiscal quarter. For options or shares with a vesting period, the expense is recognized over the vesting period.
Compensation expense is recognized immediately for options or shares that are fully vested on the date of grant. The Company has
not recognized any stock option related employee compensation expense during each of the last three fiscal years. Stock-based
compensation expense included in reported net earnings relates primarily to restricted stock awards. Performance shares are
expensed over the performance period based on the probability of achieving the performance objectives. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The table below illustrates
the effect on net earnings and earnings per share as if the Company had applied the fair value recognition provisions of SFAS No.
123, “Accounting for Stock-Based Compensation” (SFAS No. 123), to all stock-based compensation for each of the last
three fiscal years: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year</FONT>
<HR WIDTH=100% SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT></TH></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=69% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net earnings as reported</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,546.7</FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,803.9</FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,959.3</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Add: Stock-based compensation expense included in reported net earnings (1)</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>16.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>12.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD nowrap ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Deduct: Stock-based compensation expense determined under fair value method for all awards(1)</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(142.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(223.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(180.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pro forma</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,420.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,592.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,787.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Basic Earnings Per Share:</B> </FONT></TD><TD COLSPAN=10 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> As reported</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.11</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.49</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.61</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Pro forma</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.01</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.32</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.47</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Diluted Earnings Per Share:</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> As reported</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.09</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.48</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.60</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Pro forma</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.98</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.31</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.46</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
</TABLE>
<BR>
<HR noshade color="black" align="left" size="1" width="20%">
<TABLE WIDTH=100% CELLPADDING=2 CELLSPACING=2>
<TR VALIGN=TOP>
<TD ALIGN=LEFT WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1) </FONT></TD>
<TD WIDTH=97%><P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Compensation expense is net of related tax effects.
</FONT></P></TD>
</TR>
</TABLE>
<BR>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>41 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In fiscal year 2005, in
response to numerous external factors, including rising medical benefit costs and evolving workforce demographics, the Company
completed an extensive study to realign its portfolio of employee benefits. As a result of this study and the planned changes to
employee benefits, including the cessation of the Employee Stock Ownership Plan contribution at the end of fiscal year 2005 and
changes to both the U.S. defined benefit pension and post-retirement medical plans, the Company awarded fully vested, nonqualified
stock options to eligible employees as part of its annual broad employee-based stock option award, which took place during the
second quarter of fiscal year 2005. Due to the immediate vesting provisions, this award, with an aggregate fair value, net of tax,
of $64.2, resulted in increased pro forma compensation expense for the fiscal year ended April 29, 2005 as compared to the typical
grant that is expensed over a four-year vesting period. Executive officers who received stock options in connection with the
fiscal year 2005 annual grant did not receive fully vested awards, but instead received awards subject to the Company’s
standard policy on option vesting, which is generally over a four-year period. The broad employee-based stock option award granted
in fiscal year 2006 carried the standard four-year vesting provisions. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> For purposes of the pro forma
disclosures above, the weighted average fair value per stock option granted in fiscal years 2006, 2005 and 2004 was $15.53, $8.50
and $11.94, respectively. The lower fair value per stock option granted for fiscal year 2005 resulted from the fully vested stock
option award mentioned previously. To determine the expected option term of the fully vested options, the Company performed an
analysis on the average holding period of options from the vesting date to the exercise date. The fair value was estimated using
the Black-Scholes option-pricing model with the following weighted average assumptions: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year</FONT>
<HR WIDTH=100% SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT></TH></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=55% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Assumptions</B> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=7% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=7% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Risk-free interest rate</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.28%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3.34%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3.14%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Expected dividend yield</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.69%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.67%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.62%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Annual volatility factor</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>25.0%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>22.5%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>22.8%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Expected life of options</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5 years</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3 years</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5 years</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Most of the Company’s
stock option awards provide for immediate vesting upon retirement, death or disability of the participant. The Company has
traditionally accounted for the pro forma compensation expense related to stock-based awards made to retirement eligible
individuals using the nominal vesting period of the grant. The nominal vesting approach requires recognition of the compensation
expense over the vesting period except in the instance of the participants’ actual retirement. The FASB clarified the
accounting for stock-based awards made to retirement eligible individuals with the issuance of SFAS No. 123(R), “Share Based
Payment” (SFAS No. 123(R)). SFAS No. 123(R) explicitly provides that the vesting period for a grant made to a retirement
eligible employee is considered non-substantive and should be ignored when determining the period over which the award should be
expensed. Upon adoption of SFAS No. 123(R) in the first quarter of fiscal year 2007, the Company will be required to expense
stock-based awards over the period between grant date and retirement eligibility or immediately if the employee is retirement
eligible at the date of grant. If the Company had historically accounted for stock-based awards made to retirement eligible
individuals under the requirements of SFAS No. 123(R), the pro forma expense disclosed above would have been increased by $2.3 in
fiscal year 2006 and decreased by $16.2 and $6.8 in fiscal years 2005 and 2004, respectively. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Foreign Currency
Translation</B> Assets and liabilities are translated to U.S. dollars at period-end exchange rates, and the
resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as a cumulative
translation adjustment, a component of <I>accumulated other comprehensive income</I> in the consolidated balance sheets. Elements
of the consolidated statements of earnings are translated at average exchange rates in effect during the period and foreign
currency transaction gains and losses are included in <I>other expense, net</I> in the consolidated statements of earnings.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Comprehensive Income and
Accumulated Other Comprehensive Income</B> In addition to net earnings, comprehensive income includes changes in
foreign currency translation adjustments (including the change in current exchange rates, or spot rates, of net investment
hedges), unrealized gains and losses on foreign exchange derivative contracts qualifying and designated as cash flow hedges,
minimum pension liabilities, and unrealized gains and losses on available-for-sale marketable securities. Comprehensive income in
fiscal years 2006, 2005 and 2004 was $2,551.5, $1,881.9 and $2,043.4, respectively. </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>42 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Presented below is a summary
of activity for each component of <I>accumulated other comprehensive income</I> for fiscal years 2006, 2005 and 2004: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Unrealized<BR>Gain<BR>(Loss) on<BR>Investments</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Cumulative<BR>Translation<BR>Adjustment</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Minimum<BR>Pension<BR>Liability</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Unrealized<BR>Gain<BR>(Loss) on<BR>Foreign<BR>Exchange<BR>Derivatives</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Accumulated<BR>Other<BR>Comprehensive<BR>Income/(Loss)</FONT></TH></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=37% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Balance April 25, 2003</B> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (1.0</FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 47.4</FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (4.2</FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (54.3</FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (12.1</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Period Change</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>80.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(6.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>84.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Balance April 30, 2004</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>128.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(10.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(47.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>72.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Period Change</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(15.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>62.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(5.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>36.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>78.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Balance April 29, 2005</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(14.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>190.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(15.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(10.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>150.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Period Change</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(13.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(8.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>26.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Balance April 28, 2006</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (13.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 177.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (24.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 15.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 154.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Translation adjustments are
not adjusted for income taxes as substantially all translation adjustments relate to permanent investments in non-U.S.
subsidiaries. The tax expense on the unrealized gain on derivatives in fiscal years 2006, 2005 and 2004 was $14.3, $21.3 and $2.9,
respectively. The tax benefit on the minimum pension liability was $4.7, $2.7 and $3.3 in fiscal years 2006, 2005 and 2004,
respectively. The tax benefit/(expense) on the unrealized gain/(loss) on investments in fiscal years 2006, 2005 and 2004 was $(0.8),
$8.9 and $(1.2), respectively. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Derivatives</B> SFAS
No. 133, “Accounting for Derivative Instruments and Hedging Activities,” as amended, requires companies to
recognize all derivatives as assets and liabilities on the balance sheet and to measure the instruments at fair value through
earnings unless the derivative qualifies as a hedge. If the derivative is a hedge, depending on the nature of the hedge and hedge
effectiveness, changes in the fair value of the derivative will either be recorded currently through earnings or recognized in
<I>accumulated other comprehensive income</I> in the consolidated balance sheets until the hedged item is recognized in earnings.
The changes in the fair value of the derivative will offset the change in fair value of the hedged asset, liability, net
investment or probable commitment. The Company evaluates hedge effectiveness at inception and on an ongoing basis. If a derivative
is no longer expected to be highly effective, hedge accounting is discontinued. Hedge ineffectiveness, if any, is recorded in
earnings. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The Company uses derivative
instruments, primarily forward exchange contracts, to manage its exposure related to foreign exchange rate changes. The Company
enters into contracts with major financial institutions that change in value as foreign exchange rates change. These contracts are
designated either as cash flow hedges, net investment hedges or freestanding derivatives. It is the Company’s policy to enter
into forward exchange derivative contracts only to the extent true exposures exist; the Company does not enter into forward
exchange derivative contracts for speculative purposes. Principal currencies hedged are the Euro and the Japanese Yen. All
derivative instruments are recorded at fair value in the consolidated balance sheets, as a component of <I>prepaid expenses and
other current assets, other assets, other accrued expenses</I>, or <I>other long-term liabilities</I> depending upon the gain or
loss position of the contract and contract maturity date. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Forward contracts designated
as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a
foreign currency that will take place in the future. Changes in value of derivatives designated as cash flow hedges are recorded
in <I>accumulated other comprehensive income</I> in the consolidated balance sheets until earnings are affected by the variability
of the underlying cash flows. At that time, the applicable amount of gain or loss from the derivative instrument, that is deferred
in shareholders’ equity, is reclassified to earnings and is included in <I>other expense, net</I> or <I>cost of products sold
</I>in the consolidated statements of earnings, depending on the underlying transaction that is being hedged. </FONT></P>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>43 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The purpose of net investment
hedges is to hedge the long-term investment (equity) in foreign operations. The gains and losses related to the change in the
forward exchange rates of the net investment hedges are recorded currently in earnings as <I>other expense, net.</I> The gains and
losses based on changes in the current exchange rates, or spot rates, are recorded as a cumulative translation adjustment, a
component of <I>accumulated other comprehensive income</I>. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In addition, the Company uses
forward exchange contracts to offset its exposure to the change in value of certain foreign currency intercompany assets and
liabilities. These forward exchange contracts are not designated as hedges, and therefore, changes in the value of these
freestanding derivatives are recognized currently in earnings, thereby offsetting the current earnings effect of the related
foreign currency assets and liabilities. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Earnings Per
Share</B> Basic earnings per share is computed based on the weighted average number of common shares outstanding.
Diluted earnings per share is computed based on the weighted average number of common shares outstanding adjusted by the number of
additional shares that would have been outstanding had the potentially dilutive common shares been issued and reduced by the
number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares.
Potentially dilutive shares of common stock include stock options and other stock-based awards granted under stock-based
compensation plans and shares committed to be purchased under the employee stock purchase plan. As a result of the adoption of
Emerging Issues Task Force (EITF) No. 04-8, “The Effect of Contingently Convertible Instruments on Diluted Earnings Per
Share,” the computation of diluted earnings per share for fiscal years 2006 and 2005 includes approximately 700,000 shares
related to the 1.25 percent Contingent Convertible Debentures (Old Debentures) (see Note 5). As required, diluted shares
outstanding for fiscal year 2004 were also restated to include these shares. However, the inclusion of the shares issuable upon
conversion of the Old Debentures did not impact diluted earnings per share as previously reported (see Note 5). </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The table below sets forth
the computation of basic and diluted earnings per share (shares in millions): </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year</FONT>
<HR WIDTH=100% SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT></TH></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=59% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Numerator:</B> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net earnings</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,546.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,803.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,959.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Denominator:</B> </FONT></TD><TD COLSPAN=10 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Basic-weighted average shares outstanding</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,204.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,209.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,213.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Effect of dilutive securities:</FONT></TD><TD COLSPAN=10 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Employee stock options</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Shares issuable upon conversion of Old Debentures</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Other</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Diluted-weighted average shares outstanding</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,217.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,220.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,225.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Basic earnings per share</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.11</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.49</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.61</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Diluted earnings per share</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.09</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.48</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.60</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The calculation of weighted
average diluted shares outstanding excludes options for approximately 12 million, 11 million and 14 million common shares in
fiscal years 2006, 2005 and 2004, respectively, as the exercise price of those options was greater than the average market price,
resulting in an anti-dilutive effect on diluted earnings per share. </FONT></P>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>44 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>New Accounting Standards </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In November 2005, the FASB
issued FASB Staff Position (FSP) FAS 115-1 and FAS 124-1, “The Meaning of Other-Than-Temporary Impairment and Its
Application to Certain Investments,” (FSP FAS 115-1) which replaces the measurement and recognition guidance set forth
in EITF Issue No. 03-1, “The Meaning of Other-Than-Temporary Impairment and Its Application to Certain
Investments,” and codifies certain existing guidance on investment impairment. FSP FAS 115-1 clarifies that an investor
should recognize an impairment loss no later than when the impairment is deemed other-than-temporary, even if a decision to sell
the security has not been made, and also provides guidance on the subsequent accounting for an impaired debt security. FSP
FAS 115-1 was effective for the Company beginning in the fourth quarter of fiscal year 2006. Adoption of FSP FAS 115-1
did not have a material impact on the Company’s consolidated earnings, financial condition or cash flows. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In November 2004, the
FASB issued SFAS No. 151, “Inventory Costs, an amendment of Accounting Research Bulletin No. 43, Chapter 4,”
which adopts wording from the International Accounting Standards Board’s (IASB) IAS 2 “Inventories” in an
effort to improve the comparability of cross-border financial reporting. The FASB and IASB both believe the standards have the
same intent; however, an amendment to the wording was adopted to avoid inconsistent application. The new standard indicates that
abnormal freight, handling costs, and wasted materials (spoilage) are required to be treated as current period charges rather than
as a portion of inventory cost. Additionally, the standard clarifies that fixed production overhead should be allocated based on
the normal capacity of a production facility. The Statement is effective for the Company beginning in fiscal year 2007. Adoption
is not expected to have a material impact on the Company’s consolidated earnings, financial condition or cash flows.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In December 2004, the FASB
issued SFAS No. 123(R), “Share Based Payment.” This Statement is a revision of SFAS No. 123, and supersedes
APB Opinion No. 25. SFAS No. 123(R) requires the recognition of the cost of employee services received in exchange for
an award of equity instruments based on the grant date fair value of the award. The cost will be recognized over the period during
which an employee is required to provide service in exchange for the award. No compensation cost is recognized for equity
instruments that are forfeited because employees do not render the required service period. As permitted by SFAS No. 123, the
Company currently accounts for stock-based payments to employees using the intrinsic value method under APB Opinion No. 25
and, as such, generally recognizes no compensation expense for employee stock options. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In April 2005, the Securities
and Exchange Commission (SEC) issued release No. 33-8568 which delayed the implementation of SFAS No. 123(R). The Statement
is effective for the Company beginning in the first quarter of fiscal year 2007. The Company intends to adopt SFAS No. 123(R)
using the “modified prospective” method of application. Under the “modified prospective” method, compensation
cost is recognized prospectively for both new grants issued subsequent to the date of adoption, and all unvested awards
outstanding at the date of adoption. Accordingly, the adoption of the fair value method under SFAS No. 123(R) will have a
significant impact on the Company’s consolidated earnings, although it will not have a material impact on the Company’s
financial condition or cash flows. Based on unvested stock-based awards currently outstanding, the expense associated with the
employee stock purchase plan and anticipated fiscal year 2007 grants, the effect of adopting SFAS No. 123(R) is expected to
reduce the Company’s after-tax net earnings by $140.0 – $150.0 in fiscal year 2007. The total expense recorded in future
periods will depend on several variables, including the number of stock-based awards granted, the vesting period, the number of
grants that ultimately vest, the number of awards granted to retirement eligible individuals and the fair value assigned to those
awards. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In March 2005, the FASB
issued FIN No. 47, “Accounting for Conditional Asset Retirement Obligations” (FIN No. 47). This Interpretation clarifies
the term “conditional asset retirement obligation” as used in SFAS No. 143, “Accounting for Asset Retirement
Obligations,” and requires a liability to be recorded for a conditional obligation if the fair value of the obligation can be
reasonably estimated. FIN No. 47 maintains the notion of a liability being recognized when a legal obligation exists, but
clarifies the timing of accrual recognition. This Interpretation was effective for the Company beginning in the fourth quarter of
fiscal year 2006. Adoption did not have a material impact on the Company’s consolidated earnings, financial condition or cash
flows. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In June 2005, the FASB issued
SFAS No. 154, “Accounting Changes and Error Corrections” (SFAS No. 154), a replacement of APB Opinion No. 20,
“Accounting Changes,” and SFAS No. 3, “Reporting Accounting Changes.” SFAS No. 154 changes the requirements
related to accounting for and reporting of a change in accounting principle. This Statement applies to all voluntary changes in
accounting principle and changes required by a new accounting pronouncement, in the unusual instance that the pronouncement does
not include specific transition provisions. SFAS No. 154 requires retrospective application to prior periods’ financial
statements of changes in accounting principle versus the previous guidance which allowed the recording of the impact of an
accounting change in the current period’s net income as a cumulative effect adjustment. The Statement is effective for the
Company beginning in fiscal year 2007. Adoption is not expected to have a material impact on the Company’s consolidated
earnings, financial condition or cash flows. </FONT></P>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>45 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2. Acquisitions and IPR&D Charges </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The Company is responsible
for the valuation of IPR&D charges. The values assigned to IPR&D are based on valuations that have been prepared using
methodologies and valuation techniques consistent with those used by independent appraisers. All values were determined by
identifying research projects in areas for which technological feasibility had not been established. Additionally, the values were
determined by estimating the revenue and expenses associated with a project’s sales cycle and the amount of after-tax cash
flows attributable to these projects. The future cash flows were discounted to present value utilizing an appropriate
risk-adjusted rate of return. The rate of return included a factor that takes into account the uncertainty surrounding the
successful development of the IPR&D. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> At the time of acquisition,
the Company expects all acquired IPR&D will reach technological feasibility, but there can be no assurance that the commercial
viability of these products will actually be achieved. The nature of the efforts to develop the acquired technologies into
commercially viable products consists principally of planning, designing and conducting clinical trials necessary to obtain
regulatory approvals. The risks associated with achieving commercialization include, but are not limited to, delay or failure to
obtain regulatory approvals to conduct clinical trials, delay or failure to obtain required market clearances, and patent
litigation. If commercial viability were not achieved, the Company would likely look to other alternatives to provide these
therapies. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <I>Fiscal Year 2006</I> </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On August 26, 2005, the
Company acquired all the outstanding stock of Image-Guided Neurologics, Inc. (IGN), a privately held company. Prior to the
acquisition, the Company had an equity investment in IGN, which was accounted for under the cost method of accounting. IGN
specialized in precision navigation and delivery technologies for brain surgery. The IGN product line includes the NexFrame
disposable, “frameless” sterotactic head frame, which is used in conjunction with image-guided surgery systems during
deep brain stimulation. This acquisition complements the Company’s position in deep brain stimulation by offering instruments
that simplify the procedure for surgeons and improve patient comfort during surgery. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The total consideration for
IGN was approximately $65.1, which includes $57.9 in net cash paid. The $57.9 in net cash paid results from the $65.1 in
consideration less the value of the Company’s prior investment in IGN and IGN’s existing cash balance. As a result of
the acquisition of IGN, the Company acquired $22.3 of intangible assets of which $22.2 are technology-based intangible assets that
have an estimated useful life of 12 years. Goodwill of $41.5 related to the acquisition was assigned entirely to the
Neurological operating segment. This goodwill is not deductible for tax purposes. </FONT></P>
<BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>46 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The
following table summarizes the allocation of the purchase price to the estimated fair
values of the assets acquired and liabilities assumed: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=70% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Current assets</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=6% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=12% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3.1</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Property, plant and equipment</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Other intangible assets</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>22.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Goodwill</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>41.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Total assets acquired</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>67.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Current liabilities</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Deferred tax liability – long term</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Total liabilities assumed</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net assets acquired</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 65.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On July 1, 2005, the Company
acquired all of the outstanding stock of Transneuronix, Inc. (TNI), a privately held company. Prior to the acquisition, the
Company had an equity investment in TNI, which was accounted for under the cost method of accounting. TNI focused on the treatment
of obesity by stimulation of the stomach with an implantable gastric stimulator, known as the Transcend device. This acquisition
is expected to complement the Company’s formation of a new business unit, Emerging Therapies, and the Company’s strategy
to deliver therapeutic solutions for the worldwide challenges of obesity. Emerging Therapies is part of the Neurological operating
segment. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The consideration for TNI was
approximately $268.7, which included $227.3 in net cash paid. The $227.3 in net cash paid resulted from the $268.7 in
consideration less the value of the Company’s prior investment in TNI and TNI’s existing cash balance. The purchase
price is subject to increases which would be triggered by the achievement of certain milestones. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> As a result of the
acquisition of TNI, the Company acquired $54.6 of intangible assets of which $54.4 are technology-based intangible assets that
have an estimated useful life of 15 years and $168.7 of IPR&D that was expensed on the date of acquisition related to a
product being developed for the treatment of obesity by stimulation of the stomach, that had not yet reached technological
feasibility and had no future alternative use. Goodwill of $50.5 related to the acquisition was assigned entirely to the
Neurological operating segment. This goodwill is not deductible for tax purposes. </FONT></P>
<BR><BR><BR><BR><BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>47 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The following table
summarizes the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed:
</FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=70% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Current assets</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=12% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 13.6</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Other intangible assets</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>54.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>IPR&D</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>168.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Goodwill</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>50.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Total assets acquired</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>287.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Current liabilities</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>14.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Deferred tax liability – long-term</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Total liabilities assumed</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>18.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net assets acquired</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 268.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The pro forma impact of the
IGN and TNI acquisitions was not significant, individually or in the aggregate, to the results of the Company for fiscal year
ended April 28, 2006. The results of operations related to each company have been included in the Company’s consolidated
statements of earnings since the date each company was acquired. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On May 18, 2005, the Company
acquired substantially all of the spine-related intellectual property and related contracts, rights, and tangible materials owned
by Gary Michelson, M.D. and Karlin Technology, Inc. (Michelson) and settled all outstanding litigation and disputes between
Michelson and the Company. The acquired patents pertain to novel spinal technology and techniques that have both current
application and the potential for future patentable commercial products. The agreement requires total consideration of $1,350.0
for the purchase of a portfolio of more than 100 issued U.S. patents, over 110 pending U.S. patent applications and numerous
foreign counterparts to these patents and patent applications, and the settlement of all ongoing litigation. A value of $550.0 was
assigned to the settlement of past damages between the parties and was recorded as an expense in the fourth quarter of fiscal year
2005. The remaining consideration, including $2.6 of direct acquisition costs, was allocated between $627.5 of acquired technology
based intangible assets that have a useful life of 17 years and $175.1 of IPR&D that was expensed on the date of acquisition
related to spinal technology based devices that had not yet reached technological feasibility and had no future alternative use.
The patents pertain to novel spinal technology and techniques that have the potential for future patentable commercial products in
the area of spinal surgery. During the first quarter of fiscal year 2006, the Company paid $1,320.0 and committed to three future
installments of $10.0 to be paid in May 2006, 2007, and 2008. The first installment of $10.0 was paid in May 2006. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> During the first quarter of
fiscal year 2006, the Company also entered into a royalty bearing, non-exclusive patent cross-licensing agreement with NeuroPace,
Inc. Under the terms of the agreement, the two companies cross-licensed patents and patent applications of neurological technology
related to direct electrical stimulation or monitoring of the brain. On the date of the agreement, $20.0 was expensed as IPR&D
related to the licensed technology since technological feasibility of the project had not yet been reached and had no future
alternative use. This licensed technology is expected to enhance the Company’s ability to further develop and expand its
therapies for neurological disorders. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <I>Fiscal Year 2005</I> </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On November 1, 2004, the
Company acquired all of the outstanding stock of Angiolink Corporation (Angiolink), a privately held company that developed wound
closure devices for vascular procedures. Angiolink’s EVS (Expanding Vascular Stapling) Vascular Closure System,
which has received U.S. Food and Drug Administration (FDA) approval, is engineered to close the femoral artery access site after
vascular procedures, such as diagnostic angiography, balloon angioplasty and stenting. The EVS system provides safe and effective
mechanical closure of arterial puncture sites without disturbing the lumen, or interior, of the targeted vessel. This acquisition
provided the Company an additional vascular closure offering to the current closure product — the non-invasive Clo-Sur P.A.D.
The net consideration paid for Angiolink was approximately $42.3 in cash, subject to purchase price increases, which would be
triggered by the achievement of certain milestones. The net cash purchase price of $42.3 is the net difference of the $45.2
purchase price, including direct acquisition costs, less $2.9 of acquired cash. </FONT></P>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>48 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In connection with the
acquisition of Angiolink, the Company acquired $62.5 of technology-based intangible assets that have an estimated useful life of
12 years and $11.2 in goodwill. The goodwill was assigned entirely to the Vascular operating segment and is not deductible for tax
purposes. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The following table
summarizes the allocation of the Angiolink purchase price to the estimated fair values of the assets acquired and liabilities
assumed: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=70% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Current assets</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=6% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=12% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3.1</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Property, plant and equipment</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Other intangible assets</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>62.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Goodwill</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Deferred tax asset – long-term</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Total assets acquired</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>82.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Current liabilities</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Deferred tax liability – long-term</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>34.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Total liabilities assumed</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>37.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net assets acquired</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 45.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On August 25, 2004, the
Company acquired substantially all of the assets of Coalescent Surgical, Inc. (Coalescent). Coalescent developed the U-Clip
Anastomotic Device and the SPYDER Proximal Anastomotic Device. The U-Clip device creates high-quality anastomoses (a seamless
connection) without sutures and is primarily used in coronary artery bypass surgery. The SPYDER device automatically deploys a
series of U-Clip devices when attaching the bypass graft to the aorta. This acquisition complemented the Company’s surgical
product line and strategy to develop technologies to promote surgical procedures that produce better patient outcomes, and reduce
trauma and hospitalization. The consideration paid for Coalescent was approximately $65.1 in cash, including a $5.0 milestone
payment made in March 2005 for the successful transition of product and technology to the Company following the acquisition and a
$6.0 payment made in December 2005 related to the release of an indemnification escrow established at the date of acquisition.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In connection with the
acquisition of Coalescent, the Company acquired $42.2 of technology-based intangible assets that have an estimated useful life of
12 years, $1.5 of other intangible assets with an estimated useful life of 5 years, and $18.0 of goodwill, including the $5.0
milestone payment and $6.0 payment related to the release of the indemnification escrow. The goodwill was assigned entirely to the
Cardiac Surgery operating segment and is deductible for tax purposes. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The following table
summarizes the allocation of the Coalescent purchase price to the estimated fair values of the assets acquired and liabilities
assumed: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=70% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Current assets</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=6% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=12% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.6</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Property, plant and equipment</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Other intangible assets</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>43.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Goodwill</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>18.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Total assets acquired</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>65.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Current liabilities</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Total liabilities assumed</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net assets acquired</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 65.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The pro forma impact of the
Angiolink and Coalescent acquisitions was not significant, individually or in the aggregate, to the results of operations of the
Company for the fiscal year ended April 29, 2005. The results of operations related to each company acquired have been
included in the Company’s consolidated statements of earnings since the date each company was acquired. </FONT></P>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>49 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <I>Fiscal Year 2004</I> </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In the fourth quarter of
fiscal year 2004, the Company entered into an agreement which provided the Company an option to purchase substantially all the
assets of a certain third-party entity. The Company held a cost method equity investment in this entity and as a result of this
new agreement, applied the equity method of accounting to this investment. At the date of the agreement, $17.2 of the amount paid
for the investment was expensed for IPR&D related to cardiac surgery devices under development that had not yet reached
technological feasibility. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On January 8, 2004, the
Company acquired certain assets of Radius Medical Inc. (Radius), which was accounted for as a purchase of assets. Radius was
a privately held corporation that specialized in the research, development and manufacture of interventional guidewires and
related products for the cardiovascular marketplace. The assets acquired from Radius broadened and enhanced the Company’s
existing guidewire product and technology portfolio. The consideration paid was $5.6 in cash, including a $0.5 milestone payment
made in fiscal year 2005 for the successful transfer of assets. The purchase price remains subject to purchase price increases,
which would be triggered by the achievement of certain milestones. The aggregate $5.6 consideration was allocated to intangible
assets. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On January 5, 2004, the
Company acquired substantially all of the assets of Premier Tool, Inc. (Premier Tool). Premier Tool was a privately held
corporation engaged in the engineering and manufacturing of metal instruments used to implant spinal devices. The assets acquired
enhanced the Company’s current line of spinal instrumentation. The consideration paid was approximately $4.0 in cash. The
purchase price was allocated primarily to other intangible assets and property and equipment, with the remainder allocated to
goodwill. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On November 19, 2003,
the Company acquired all of the outstanding stock of Vertelink Corporation (Vertelink). Vertelink was a privately held development
stage company that developed materials and techniques for over-the-wire spinal fixation devices that can achieve multi-level
stabilization of the cervical, thoracic and lumbar spine. Key Vertelink products include the KOBRA Fixation System and the SST
Spinal Fixation System. Both systems permit surgeons to place spinal instrumentation utilizing tissue-sparing, minimally invasive
methods. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The consideration paid for
Vertelink was approximately $28.1 in cash, including two $3.0 milestone payments made in fiscal year 2005. The purchase price
remains subject to purchase price increases, which would be triggered by the achievement of certain milestones. In connection with
the acquisition the Company has allocated $22.0 of the costs to IPR&D, which was expensed on the date of the acquisition
related to spinal fixation devices that had not yet reached technological feasibility and had no future alternative use, and the
remaining amount to fixed assets and other intangible assets. At the time of the acquisition, the KOBRA Fixation System was being
reviewed by the FDA for 510(k) approval, which was subsequently obtained during the third quarter of fiscal year 2004. The
technology will be adapted for use in manufacturing spinal fixation devices that can achieve multi-level stabilization of the
cervical, thoracic and lumbar spine. Prior to the acquisition, the Company did not have a comparable product under development.
The acquisition of Vertelink enhanced the strategic initiative of the Company’s Spinal business that focuses on Minimal
Access Spinal Technologies (MAST). In the third and fourth quarters of fiscal year 2005, Vertelink obtained FDA approval for the
KOBRA II System and CE Mark approval for the SST Spinal Fixation System, respectively. As a result of attaining these approvals
two existing milestone payments in the purchase agreement were triggered requiring the Company to pay the additional consideration
of $6.0 in cash during fiscal year 2005. The $6.0 was allocated between technology-based intangible assets of $10.0 and an
offsetting long-term deferred tax liability of $4.0. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On September 10, 2003,
the Company acquired substantially all of the assets of TransVascular, Inc. (TVI). Prior to the acquisition, the Company had
an equity investment in TVI, which was accounted for under the cost method of accounting. TVI developed and marketed the Pioneer
Catheter (formerly the CrossPoint TransAccess Catheter System), a proprietary delivery technology for several current and
potential intravascular procedures, such as the potential ability to deliver therapeutic agents, including cells, genes and drugs
to precise locations within the vascular system. The Pioneer Catheter received FDA 510(k) clearance in 2002 and is indicated to
facilitate the positioning and placement of catheters within the peripheral vasculature. This strategic acquisition complemented
the Company’s commitment to advance therapies and treatments by combining biologic and device therapies. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The consideration paid was
approximately $58.7 subject to purchase price increases, which would be triggered by the achievement of certain milestones. The
initial consideration included approximately 1.2 million shares of Medtronic common stock valued at $57.5, the Company’s
prior investment in TVI and acquisition-related costs. The Medtronic common shares were valued based on the average of
Medtronic’s trading share prices several days before and after the date when the trading share prices to be issued became
known. In connection with the acquisition of TVI, the Company acquired $27.3 of technology-based intangible assets that have an
estimated useful life of 15 years and $1.9 of IPR&D that was expensed on the date of acquisition related to a cell and
agent delivery device that had not yet reached technological feasibility and had no future alternative use. Prior to the
acquisition, the Company did not have a comparable product under development. Goodwill of $31.9 related to the acquisition was
assigned entirely to the Vascular operating segment. </FONT></P>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>50 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The following table
summarizes the allocation of the TVI purchase price to the estimated fair values of the assets acquired and liabilities assumed:
</FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=70% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Current assets</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=6% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=12% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.6</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Property, plant and equipment</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Other intangible assets</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>27.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>IPR&D</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Goodwill</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>31.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Deferred tax asset – long-term</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Total assets acquired</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>70.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </td></tr>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Current liabilities</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Deferred tax liability – long-term</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Total liabilities assumed</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net assets acquired</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 58.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The pro forma impact of the
results of Radius, Premier Tool, Vertelink and TVI was not significant, individually or in the aggregate, to the results of the
Company for the fiscal year ended April 30, 2004. The goodwill recorded as a result of these acquisitions is not deductible
for tax purposes. The results of operations related to each entity, or portion of the company, acquired have been included in the
Company’s consolidated statements of earnings since the date of acquisition. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Contingent
Consideration</B> Certain of the Company’s business combinations involve the potential for the payment of
future contingent consideration upon the achievement of certain product development milestones and/or various other favorable
operating conditions. While it is not certain if and/or when these payments will be made, the Company has developed an estimate,
based upon its evaluation of the latest available information (e.g. trial results, product launch, dates and nature of milestone
targets, etc.), of the potential contingent consideration for each of its acquisitions with an outstanding potential obligation.
At April 28, 2006, the estimated potential amount of future contingent consideration that the Company is expected to make
associated with all business combinations is approximately $81.0. This estimated potential payment amount reflects results
announced in the third quarter of fiscal year 2006 of the Screened Health Assessment and Pacer Evaluation clinical trial for the
evaluation of implantable gastric stimulation for the management of obesity, including the resulting delay in the Company’s
anticipated receipt of U.S. FDA regulatory approval for such treatment. The milestones associated with the contingent
consideration must be reached in future periods ranging from fiscal years 2007 to 2012 in order for the consideration to be paid.
</FONT></P>
<BR><BR><BR><BR><BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>51 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3. Financial Instruments and Investments </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Investments</B> The
carrying amounts of cash and cash equivalents approximate fair value due to their short maturities. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Information regarding the Company’s <I>short-term</I> and <I>long-term
investments</I> is as follows: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=17><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year</FONT>
<HR WIDTH=100% SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006</FONT><HR WIDTH=100% SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005</FONT><HR WIDTH=100% SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT><HR WIDTH=100% SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Debt</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Equity</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Debt</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Equity</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Debt</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Equity</FONT></TH></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=27% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cost</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3,900.9</FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 184.5</FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,506.3</FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 240.9</FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,563.7</FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 224.6</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Gross unrealized gains</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>15.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Gross unrealized losses</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(27.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(24.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(12.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Fair value</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3,873.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 190.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,483.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 241.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,551.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 238.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Proceeds from sales</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 6,625.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 790.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 17.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,445.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 28.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net gains/(losses) realized</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (1.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (0.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 11.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 14.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Impairment losses recognized</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 41.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 6.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 28.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> As of April 28, 2006,
the Company has $1,132.4 in debt securities that have been in an unrealized loss position for more than twelve months. The
aggregate amount of unrealized losses for these investments is $20.7. These investments are in high quality, investment grade
securities but are currently in a loss position due to recent increases in interest rates. The Company considers these unrealized
losses temporary as it has the intent and ability to hold these investments long enough to avoid realizing any significant losses.
The total fair value of all investments currently in an unrealized loss position as of April 28, 2006 is $2,086.5.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> As of April 28, 2006,
the aggregate carrying amount of equity securities accounted for using the cost or equity method was $176.1. The total carrying
value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the
Company’s investment may not be recoverable. The fair value of cost or equity method investments is not estimated if there
are no identified events or changes in circumstances that may have material adverse effect on the fair value of the investment.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Gains and losses recognized
on AFS debt instruments are recorded as <I>interest (income)/expense</I> in the consolidated statements of earnings. Gains and
losses recognized on equity instruments are recorded in <I>other expense, net</I> in the consolidated statements of earnings.
Gains and losses from the sale of investments are calculated based on the specific identification method. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In the third quarter of
fiscal year 2004, the Company began lending certain fixed income securities to enhance its investment income. These lending
activities are collateralized at an average rate of 102%, with the collateral determined based on the underlying securities and
creditworthiness of the borrowers. The value of the securities on loan at April 28, 2006 and April 29, 2005 was $361.8 and
$361.3, respectively. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Derivatives and Foreign
Exchange Risk Management</B> The Company uses operational and economic hedges, as well as forward exchange
derivative contracts to manage the impact of foreign exchange rate changes on earnings and cash flows. In order to reduce the
uncertainty of foreign exchange rate movements, the Company enters into derivative instruments, primarily forward exchange
contracts, to manage its exposure related to foreign exchange rate changes. These contracts are designed to hedge anticipated
foreign currency transactions and changes in the value of specific assets, liabilities, net investments, and probable commitments.
At inception of the forward contract, the derivative is designated as either a freestanding derivative, net investment hedge, or
cash flow hedge. Principal currencies hedged are the Euro and the Japanese Yen. The Company does not enter into forward exchange
derivative contracts for speculative purposes. </FONT></P>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>52 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Notional amounts of these
contracts outstanding at April 28, 2006 and April 29, 2005 were $1,560.6 and $2,894.0, respectively. All derivative
instruments are recorded at fair value in the consolidated balance sheets, as a component of <I>prepaid expenses and other current
assets, other assets, other accrued expenses</I>, or <I>other long-term liabilities</I> depending upon the gain or loss position
of the contract and contract maturity date. Aggregate foreign currency gains/(losses) were $52.3, $(98.3) and $(177.8), in fiscal
years 2006, 2005 and 2004, respectively. These gains/(losses), which were offset by gains/(losses) on the related assets,
liabilities, and transactions being hedged, were recorded in either <I>other expense, net</I> or <I>cost of products sold</I> in
the consolidated statements of earnings. As a result of hedging inventory-related forecasted transactions, the Company recognized
gains/(losses) of $(39.6) and $36.6 in <I>cost of products sold</I> in the consolidated statements of earnings in fiscal year 2006
and 2005, respectively; the remaining $91.9 and $(134.9) gain/(loss) was recognized in <I>other expense, net</I> in the
consolidated statements of earnings for fiscal year 2006 and 2005, respectively. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Freestanding derivative
forward contracts are used to offset the Company’s exposure to the change in value of certain foreign currency intercompany
assets and liabilities. These derivatives are not designated as hedges, and, therefore, changes in the value of these forward
contracts are recognized currently in earnings, thereby offsetting the current earnings effect of the related foreign currency
assets and liabilities. The aggregate foreign currency transaction gains/(losses) were $(3.0), $5.7 and $11.1 in fiscal years
2006, 2005 and 2004, respectively, and are recognized in <I>other expense, net</I> in the consolidated statements of earnings.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Net investment hedges are
used to hedge the long-term investment (equity) in foreign operations. Net gains/(losses) related to changes in the current rates,
or spot rates, were $56.7, $(83.0) and $(60.1) during fiscal years 2006, 2005 and 2004, respectively, and recorded as a cumulative
translation adjustment, a component of <I>accumulated other comprehensive income</I> in the consolidated balance sheets<I>.</I>
Net gains associated with changes in forward rates of the contracts totaled $14.9, $8.4 and $8.4 in fiscal years 2006, 2005 and
2004, respectively, and are reflected in <I>other expense, net</I> in the consolidated statements of earnings. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Forward contracts designated
as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions, denominated in a
foreign currency, that will take place in the future. Net unrealized gains/(losses) related to the Company’s outstanding cash
flow hedges totaled $15.5 and $(10.8) in fiscal years 2006 and 2005, respectively, and were recorded in <I>accumulated other
comprehensive income</I> in the consolidated balance sheets. During fiscal years 2006, 2005 and 2004, the Company’s net
gains/(losses) related to the settlement of cash flow hedges were $40.4, $(112.4) and $(197.3), respectively. In fiscal year 2006,
2005 and 2004, gains/(losses) of $80.0, $(149.0) and $(206.7) were recorded as <I>other expense, net</I> and offsetting
gains/(losses) of $(39.6), $36.6 and $9.4 were recorded in <I>cost of products sold</I> in the consolidated statements of
earnings. No gains or losses relating to ineffectiveness of cash flow hedges were recognized in earnings during fiscal years 2006,
2005 or 2004. No components of the hedge contracts were excluded in the measurement of hedge ineffectiveness and no hedges were
derecognized or discontinued during fiscal years 2006, 2005 or 2004. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The following table
summarizes activity in <I>accumulated other comprehensive income</I> related to all derivatives classified as cash flow hedges in
fiscal years 2006, 2005, and 2004 (amounts are net of tax): </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=83% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Accumulated derivative losses, April 25, 2003</B> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (54.3</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net losses reclassified to earnings</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>103.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Change in fair value of hedges</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(95.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=3></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Accumulated derivative losses, April 30, 2004</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(47.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net losses reclassified to earnings</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>66.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Change in fair value of hedges</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(30.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=3></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Accumulated derivative losses, April 29, 2005</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(10.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net gains reclassified to earnings</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(14.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Change in fair value of hedges</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>40.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Accumulated derivative gains, April 28, 2006</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 15.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The Company expects that the
$15.5, net of tax, in accumulated derivative gains at April 28, 2006 will be reflected in the consolidated statements of
earnings over the next twelve months. </FONT></P>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>53 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Concentrations of Credit
Risk</B> Financial instruments, which potentially subject the Company to significant concentrations of credit
risk, consist principally of interest-bearing investments, forward exchange derivative contracts and trade accounts receivable.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The Company maintains cash
and cash equivalents, investments, and certain other financial instruments (including forward exchange contracts) with various
major financial institutions. The Company performs periodic evaluations of the relative credit standings of these financial
institutions and limits the amount of credit exposure with any one institution. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Concentrations of credit risk
with respect to trade accounts receivable are limited due to the large number of customers and their dispersion across many
geographic areas. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course
of business. However, a significant amount of trade receivables are with national healthcare systems in many countries. Although
the Company does not currently foresee a credit risk associated with these receivables, repayment is dependent upon the financial
stability of the economies of those countries. As of April 28, 2006 and April 29, 2005, no customer represented more
than 10% of the outstanding accounts receivable. </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4. Goodwill and Other Intangible Assets </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The changes in the carrying
amount of goodwill for fiscal years 2006 and 2005 are as follows: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year</FONT>
<HR WIDTH=100% SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005</FONT></TH></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=64% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Beginning balance</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=11% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 4,281.2</FONT></TD>
<TD WIDTH=6% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=11% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 4,236.9</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Goodwill as a result of acquisitions</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>104.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>24.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Purchase accounting adjustments, net (1)</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(32.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Currency adjustment, net</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(7.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>19.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Ending balance</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 4,345.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 4,281.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1) Fiscal year 2006 includes $32.1 related to the
reversal of tax valuation allowances on deferred tax assets previously established with certain prior year acquisitions. The
reversal is a result of favorable agreements reached with the U.S. Internal Revenue Service (IRS) involving the review of the
Company’s fiscal years 1997 through 2002 domestic income tax returns. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The Company completed its
fiscal years 2006, 2005 and 2004 impairment tests of all goodwill and concluded there were no impairments. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Balances of acquired
intangible assets, excluding goodwill, are as follows: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Purchased<BR>Technology<BR>and Patents</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Trademarks<BR>and<BR>Tradenames</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Other</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Total</FONT></TH></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=42% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Amortizable intangible assets as of April 28, 2006:</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Original cost</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,761.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 264.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 230.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,256.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Accumulated amortization</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(423.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(123.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(117.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(664.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Carrying value</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,338.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 141.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 112.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,592.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Weighted average original life (in years)</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>14.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Amortizable intangible assets as of April 29, 2005:</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Original cost</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,030.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 264.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 247.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,542.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Accumulated amortization</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(319.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(97.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(108.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(524.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Carrying value</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 711.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 167.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 139.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,018.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Weighted average original life (in years)</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>13.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Amortization expense for
fiscal years 2006, 2005 and 2004 was $174.4, $127.8 and $116.0, respectively. </FONT></P>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>54 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Estimated aggregate
amortization expense based on the current carrying value of amortizable intangible assets is as follows: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN="2" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Amortization<BR>Expense</FONT></TH></TR>
<TR>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=55% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2007</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 172.2</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2008</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>167.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2009</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>160.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2010</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>153.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2011</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>143.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Thereafter</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>795.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,592.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5. Financing Arrangements </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Debt consisted of the following: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN="2" WIDTH="10%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>April 28, 2006</FONT>
<HR WIDTH=100% SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>April 29, 2005</FONT>
<HR WIDTH=100% SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN="2" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Maturity by<BR>Fiscal Year</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Payable</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Average<BR>Interest<BR>Rate</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Payable</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Average<BR>Interest<BR>Rate</FONT></TH></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN="2" ALIGN="RIGHT" WIDTH="10%"><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=34% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Short-Term Borrowings:</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Contingent convertible debentures</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2007-2022</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,971.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.25%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Bank borrowings</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2007</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>269.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.31%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>228.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.09%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Commercial paper</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2007</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>189.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.67%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>249.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.84%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Current portion of capital lease obligations</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2007</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5.20%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.15%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN="2" ALIGN="RIGHT" WIDTH="10%"></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"> <B>Total Short-Term Borrowings</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,436.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 478.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN="2" ALIGN="RIGHT" WIDTH="10%"></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Long-Term Debt:</FONT></TD><TD COLSPAN=16 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Contingent convertible debentures</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2007-2022</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.25%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,971.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.25%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2011 senior convertible notes</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2011</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,200.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.50%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2010 senior notes</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2011</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>400.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.38%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2013 senior convertible notes</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2013</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,200.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.63%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2015 senior notes</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2016</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>600.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.75%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Other</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2008-2013</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>86.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5.38%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5.49%</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN="2" ALIGN="RIGHT" WIDTH="10%"></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"> <B>Total Long-Term Debt</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT" WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 5,486.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,973.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN="2" ALIGN="RIGHT" WIDTH="10%"></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Senior Convertible
Notes</B> In April 2006, the Company issued $2,200.0 of 1.500 percent Senior Convertible Notes due 2011 and
$2,200.0 of 1.625 percent Senior Convertible Notes due 2013, collectively the Senior Convertible Notes. The Senior Convertible
Notes were issued at par and pay interest in cash semi-annually in arrears on April 15 and October 15 of each year,
beginning on October 15, 2006. The Senior Convertible Notes are unsecured unsubordinated obligations and rank equally with all
other unsecured and unsubordinated indebtedness. The Senior Convertible Notes have an initial conversion price of $56.14 per
share. The Senior Convertible Notes may only be converted: (i) during any calendar quarter beginning after June 30, 2006
if the closing price of the Company’s common stock reaches 140% of the conversion price for 20 trading days during a
specified period, or (ii) if specified distributions to holders of the Company’s common stock are made or specified
corporate transactions occur, or (iii) during the last month prior to maturity of the applicable notes. Upon conversion, a
holder would receive: (i) cash equal to the lesser of the principal amount of the note or the conversion value and
(ii) to the extent the conversion value exceeds the principal amount of the note, shares of the Company’s common stock,
cash, or a combination of common stock and cash, at the Company’s option. In addition, upon a change in control, as defined,
the holders may require the Company to purchase for cash all or a portion of their notes for 100% of the principal amount of the
notes plus accrued and unpaid interest, if any. The indentures under which the Senior Convertible Notes were issued contain
customary covenants. A total of $2,500.0 of the net proceeds from these note issuances were used to repurchase common stock under
the Company’s stock repurchase program. </FONT></P>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>55 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Concurrent with the issuance
of the Senior Convertible Notes, the Company purchased call options in private transactions. The call options allow the Company to
receive shares of the Company’s common stock and/or cash from counterparties equal to the amounts of common stock and/or cash
related to the excess conversion value that it would pay to the holders of the Senior Convertible Notes upon conversion. These
call options will terminate the earlier of the maturity dates of the related Senior Convertible Notes or the first day all of the
related Senior Convertible Notes are no longer outstanding due to conversion or otherwise. The call options, which cost an
aggregate $1,074.6 ($698.5 net of tax benefit), were recorded as a reduction of shareholders’ equity. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In separate transactions, the
Company sold warrants to issue shares of the Company’s common stock at an exercise price of $76.56 per share in private
transactions. Pursuant to these transactions, warrants for 41.1 million shares of the Company’s common stock may be settled
over a specified period beginning in July 2011 and warrants for 41.1 million shares of the Company’s common stock may be
settled over a specified period beginning in July 2013 (the “settlement dates”). If the average price of the
Company’s common stock during a defined period ending on or about the respective settlement dates exceeds the exercise price
of the warrants, the warrants will be settled in shares of the Company’s common stock. Proceeds received from the issuance of
the warrants totaled approximately $516.8 and were recorded as an addition to shareholders’ equity. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Senior
Notes</B> In September 2005, the Company issued two tranches of Senior Notes with the aggregate face value of
$1,000.0. The first tranche consisted of $400.0 of 4.375 percent Senior Notes due 2010 and the second tranche consisted of $600.0
of 4.750 percent Senior Notes due 2015. Each tranche was issued at a discount which resulted in an effective interest rate of
4.433 percent and 4.760 percent for the five and ten year Senior Notes, respectively. Interest on each series of Senior Notes is
payable semi-annually, on March 15 and September 15 of each year. The Senior Notes are unsecured unsubordinated obligations of the
Company and rank equally with all other unsecured and unsubordinated indebtedness of the Company. The indentures under which
Senior Notes were issued contain customary covenants. The Company used the net proceeds from the sale of the Senior Notes for
repayment of a portion of its outstanding commercial paper. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In November 2005, the Company
entered into a five year interest rate swap agreement with a notional amount of $200.0. This interest rate swap agreement was
designated as a fair value hedge of the changes in fair value of a portion of the Company’s fixed-rate $400.0 Senior Notes
due 2010. The Company pays variable interest equal to the three-month London Interbank Offered Rate (LIBOR) minus 55 basis points
and it receives a fixed interest rate of 4.375 percent. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Contingent Convertible
Debentures</B> In September 2001, the Company completed a $2,012.5 private placement of 1.25 percent
Contingent Convertible Debentures due September 2021 (Old Debentures). Interest is payable semi-annually. Each Old Debenture
is convertible into shares of common stock at an initial conversion price of $61.81 per share; however, the Old Debentures are not
convertible before their final maturity unless the closing price of the Company’s common stock reaches 110% of the conversion
price for 20 trading days during a consecutive 30 trading day period. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In September 2002 and
2004, as a result of certain holders of the Old Debentures exercising their put options, the Company repurchased $38.7, or 1.9%,
and $0.6, or 0.03%, respectively, of the Old Debentures for cash. The Company may be required to repurchase the remaining
securities at the option of the holders in September 2006, 2008, 2011 or 2016. For put options exercised by the holders, the
purchase price is equal to the principal amount of the Old Debentures plus any accrued and unpaid interest on the Old Debentures
to the repurchase date. If the repurchase option is exercised, the Company may elect to repurchase the Old Debentures with cash,
common stock, or some combination thereof. The Company may elect to redeem the Old Debentures for cash at any time after
September 2006. </FONT></P>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>56 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On January 24, 2005, the
Company completed an exchange offer on its contingent convertible debentures, whereby holders of approximately 97.7% of the total
principal amount of the Old Debentures exchanged their existing securities for an equal principal amount of 1.25 percent
Contingent Convertible Debentures, Series B due 2021 (New Debentures), and an exchange fee of two dollars and fifty cents per one
thousand dollars principal amount. The terms of the New Debentures are consistent with the terms of the Old Debentures noted above,
except that: (i) upon conversion, the Company will pay holders cash equal to the lesser of the principal amount of the New
Debentures or their conversion value, and shares of its common stock to the extent the conversion value exceeds the principal
amount; and (ii) the New Debentures will require the Company to pay only cash (in lieu of shares of its common stock or a
combination of cash and shares of its common stock) when the Company repurchases the New Debentures at the option of the holder or
in connection with a change of control. The exchange fee paid to the holders of the New Debentures was capitalized and will be
amortized over the twenty month period ending in September 2006. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Following the completion of
the exchange offer, the Company repurchased approximately $1.8 of the Old Debentures for cash. As of April 29, 2005,
approximately $43.2 aggregate principal amount of Old Debentures and $1,928.2 aggregate principal amount of New Debentures remain
outstanding. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Twelve months prior to the
put options becoming exercisable, the remaining balance of the Old Debentures will be classified as <I>short-term borrowings</I>
in the consolidated balance sheets. At each balance sheet date without a put option within the subsequent four quarters, the
remaining balance will be classified as <I>long-term debt</I> in the consolidated balance sheets. During the second quarter of
fiscal year 2006, the Company reclassified $1,971.4 of contingent convertible debentures from <I>long-term debt </I>to
<I>short-term borrowings</I> due to the put option becoming exercisable in September 2006. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Commercial
Paper</B> The Company maintains a commercial paper program that allows the Company to have a maximum of
$2,250.0 in commercial paper outstanding with maturities up to 364 days from the date of issuance. At April 28, 2006 and
April 29, 2005, outstanding commercial paper totaled $189.8 and $249.9, respectively. During fiscal years 2006 and 2005, the
weighted average original maturity of the commercial paper outstanding was approximately 31 and 26 days, respectively, and the
weighted average interest rate was 3.9% and 1.9%, respectively. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Bank
Borrowings</B> Bank borrowings consist primarily of borrowings from non-U.S. banks at interest rates considered
favorable by management and where natural hedges can be gained for foreign exchange purposes. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Credit
Arrangements</B> The Company has existing lines of credit of approximately $2,428.0 with various banks, at
April 28, 2006. The existing lines of credit include two syndicated credit facilities totaling $1,750.0 with various banks.
The two credit facilities consist of a five-year $1,000.0 facility, signed on January 20, 2005, which will expire on
January 20, 2010, and a five-year $750.0 facility, signed on January 24, 2002, which will expire on January 24,
2007. The $1,000.0 facility provides the Company with the ability to increase the capacity of the facility by an additional $250.0
at any time during the life of the five-year term of the agreement. The credit facilities provide backup funding for the
commercial paper program and may also be used for general corporate purposes. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Interest rates on these
borrowings are determined by a pricing matrix, based on the Company’s long-term debt ratings, assigned by Standard and
Poor’s Ratings Group and Moody’s Investors Service. Facility fees are payable on the credit facilities and are
determined in the same manner as the interest rates. Under terms of the agreements, the consolidated tangible net worth of the
Company must at all times be greater than or equal to $1,040.4, increased by an amount equal to 100% of the net cash proceeds from
any equity offering occurring after January 24, 2002. The Company’s consolidated tangible net worth, defined as
consolidated assets less goodwill, intangible assets (other than patents, trademarks, licenses, copyrights and other intellectual
property, and prepaid assets), and consolidated liabilities at April 28, 2006 and April 29, 2005 was $4,931.0 and $6,029.3,
respectively. The agreements also contain other customary covenants. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Maturities of long-term debt,
including capital leases, for the next five fiscal years are as follows: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN="2" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year</FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Obligation</FONT></TH></TR>
<TR>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=80% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2007</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,977.1</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2008</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2009</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2010</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>13.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2011</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,612.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Thereafter</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,837.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total long-term debt</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7,463.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Less: Current portion of long-term debt</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,977.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Long-term portion of long-term debt</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 5,486.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>57 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The Company has periodically
sold specific pools of trade receivables in Japan. During fiscal year 2006 no trade receivables were sold, and in fiscal year 2005, the
Company sold approximately $145.5 of its trade receivables to financial institutions in Japan. Additionally, the Company entered
into agreements to sell specific pools of receivables in Italy in the amount of $52.9 and $4.1 in fiscal years 2006 and 2005,
respectively. The discount cost related to the Japan and Italy sales was insignificant and recorded in <I>interest
(income)/expense</I> in the consolidated statements of earnings. </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6. Interest (Income)/Expense
</FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Interest income and interest
expense for fiscal years 2006, 2005 and 2004 are as follows: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year</FONT>
<HR WIDTH=100% SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT></TH></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=46% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Interest income</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (203.4</FONT></TD>
<TD WIDTH=7% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (100.2</FONT></TD>
<TD WIDTH=7% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (59.3</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Interest expense</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>116.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>55.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>56.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Interest (income)/expense</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (87.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (45.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (2.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7. Shareholders’ Equity
</FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Repurchase of Common
Stock</B> In October 2003, the Company’s Board of Directors authorized the repurchase of up to
30 million shares of the Company’s common stock and in October 2005 authorized the repurchase of an additional 40
million shares. Shares are repurchased from time to time to support the Company’s stock-based compensation programs and to
take advantage of favorable market conditions. In April 2006, the Board of Directors made a special authorization for the Company
to repurchase up to 50 million shares of the Company’s common stock in conjunction with the $4,400.0 convertible debenture
offering (see Note 5 for further discussion). The Company repurchased approximately 68.9 million and 10.5 million shares at
an average price of $52.12 and $48.77, respectively, during fiscal years 2006 and 2005, and approximately 36.8 million shares
remain under the buyback authorizations. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Shareholder Rights
Plan</B> On October 26, 2000, the Company’s Board of Directors adopted a Shareholder Rights Plan and
declared a dividend of one preferred share purchase right (a “right”) for each outstanding share of common stock with a
par value $.10 per share. Each right will allow the holder to purchase 1/5000 of a share of Series A Junior Participating
Preferred Stock at an exercise price of $400 per share, once the rights become exercisable. The rights are not exercisable or
transferable apart from the common stock until 15 days after the public announcement that a person or group (the Acquiring
Person) has acquired 15% or more of the Company’s common stock or 15 business days after the announcement of a tender offer
which would increase the Acquiring Person’s beneficial ownership to 15% or more of the Company’s common stock. After any
person or group has become an Acquiring Person, each right entitles the holder (other than the Acquiring Person) to purchase, at
the exercise price, common stock of the Company having a market price of two times the exercise price. If the Company is acquired
in a merger or other business combination transaction, each exercisable right entitles the holder to purchase, at the exercise
price, common stock of the acquiring company or an affiliate having a market price of two times the exercise price of the right.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The Board of Directors may
redeem the rights for $0.005 per right at any time before any person or group becomes an Acquiring Person. The Board may also
reduce the threshold at which a person or group becomes an Acquiring Person from 15% to no less than 10% of the outstanding common
stock. The rights expire on October 26, 2010. </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8. Employee Stock Ownership Plan </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The Company has an Employee
Stock Ownership Plan (ESOP) for eligible U.S. employees. In December 1989, the ESOP borrowed $40.0 from the Company and used
the proceeds to purchase 18,932,928 shares of the Company’s common stock. Shares of common stock acquired by the plan were
allocated to each employee in amounts based on Company performance and the employee’s annual compensation. An allocation of
2.50% of qualified compensation was made to plan participants’ accounts in each of the fiscal years 2005 and 2004,
respectively. Up to and including fiscal year 2005, the Company match on the supplemental retirement plan (SRP) was made in the
form of an annual allocation of Medtronic stock to the participants’ ESOP account. The expense to the Company related to this
match has been included in the table below. </FONT></P>
<BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>58 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Fiscal year 2005 was the
final year of the ESOP allocation, as all shares were either allocated or committed to be allocated at April 29, 2005. The
ESOP made the final principal and interest payment to the Company upon commitment of the final shares to the participants, as
required under the original terms of the loan. Prior to the fiscal year 2005 repayment of the remaining principal balance of the
note, the receivable from the ESOP was recorded as a reduction of the Company’s shareholders’ equity. The allocated and
unallocated shares of the ESOP are treated as outstanding common stock in the computation of basic earnings per share. As a
result of the final ESOP share allocation, the Company’s fiscal year 2006 and succeeding years’ contributions to the SRP
for U.S. employees will be made in cash. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Up to and including fiscal
year 2005, the Company made contributions to the plan which were used, in part, by the ESOP to make principal and interest
payments. ESOP expense was determined by debt service requirements, offset by dividends received by the ESOP. Components of ESOP
related expense are as follows: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=Center WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year</FONT>
<HR WIDTH=100% SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT></TH></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=45% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Interest expense</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD WIDTH=7% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.2</FONT></TD>
<TD WIDTH=7% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.6</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Dividends paid</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(4.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(4.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Compensation expense</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>39.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total expense</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 35.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In addition to the fiscal
year 2005 allocation of shares to the ESOP, the Company made a $33.0 cash contribution to the ESOP to supplement the portion of
the Company’s ESOP and SRP requirements that were not covered by the remaining unallocated shares in the ESOP as of
April 29, 2005. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> At April 28, 2006
cumulative allocated shares remaining in the trust were 13.6 million and unallocated shares were zero. </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9. Stock Purchase and Award Plans </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>2003 Long-Term Incentive
Plan</B> In August 2003, the 2003 long-term incentive plan was approved by the Company’s shareholders.
The 2003 plan provides for the grant of nonqualified and incentive stock options, stock appreciation rights, restricted stock,
performance shares, and other stock and cash-based awards. The total number of shares available for future grants at
April 28, 2006 under the Plan was 35.1 million. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>1994 Stock Award
Plan</B> The 1994 stock award plan provides for the grant of nonqualified and incentive stock options, stock
appreciation rights, restricted stock, performance shares, and other stock-based awards. There were 2.2 million shares
available under this plan for future grants at April 28, 2006. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Nonqualified stock options
and other stock awards are granted to officers and key employees at prices not less than fair market value at the date of grant.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Outside Directors
Plan</B> In fiscal year 1998, the Company adopted a stock compensation plan for outside directors which replaced
the provisions in the 1994 stock award plan relating to awards granted to outside directors. At April 28, 2006 the 1998 Plan
had 2.3 million shares available for future grants. </FONT></P>
<BR><BR><BR><BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>59 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> A summary of nonqualified
stock option transactions is as follows: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=17><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Options<BR>(in thousands) </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Wtd. Avg.<BR>Exercise<BR>Price </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Options<BR>(in thousands) </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Wtd. Avg.<BR>Exercise<BR>Price </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Options<BR>(in thousands) </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Wtd. Avg.<BR>Exercise<BR>Price </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH="25%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Beginning balance</FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="2%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>85,114</FONT></TD>
<TD WIDTH="4%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 44.29</FONT></TD>
<TD WIDTH="5%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>78,879</FONT></TD>
<TD WIDTH="4%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 42.22</FONT></TD>
<TD WIDTH="5%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>69,243</FONT></TD>
<TD WIDTH="4%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 40.24</FONT></TD>
<TD WIDTH="2%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Granted</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>13,740</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>56.16</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>15,884</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>50.02</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>18,034</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>46.74</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Exercised</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(9,866</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>38.92</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(7,344</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>33.54</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(5,152</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>29.28</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Canceled</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,938</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>47.58</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2,305</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>46.84</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(3,246</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>45.81</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Outstanding at year-end</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>87,050</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 46.70</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>85,114</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 44.29</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>78,879</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 42.22</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Exercisable at year-end</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>61,335</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 44.73</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>60,407</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 43.48</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>44,213</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 39.40</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> A portion of the stock
options assumed as a result of certain acquisitions in fiscal years 1996 through 2002 remain outstanding. A summary of stock
options assumed as a result of these acquisitions is as follows: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=17><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Options<BR>(in thousands) </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Wtd. Avg.<BR>Exercise<BR>Price </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Options<BR>(in thousands) </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Wtd. Avg.<BR>Exercise<BR>Price </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Options<BR>(in thousands) </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Wtd. Avg.<BR>Exercise<BR>Price </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH="25%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Beginning balance</FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="2%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,541</FONT></TD>
<TD WIDTH="4%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 22.34</FONT></TD>
<TD WIDTH="5%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,361</FONT></TD>
<TD WIDTH="4%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 22.40</FONT></TD>
<TD WIDTH="5%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6,239</FONT></TD>
<TD WIDTH="4%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 22.16</FONT></TD>
<TD WIDTH="2%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Granted</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Exercised</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(751</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>19.22</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,763</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>21.38</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,818</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>19.51</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Canceled</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>57.72</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(57</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>56.87</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(60</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>84.81</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Outstanding at year-end</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,788</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 23.38</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,541</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 22.34</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,361</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 22.40</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Exercisable at year-end</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,788</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 23.38</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,541</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 22.34</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,361</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 22.40</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> A summary of stock options as
of April 28, 2006, including options assumed as a result of acquisitions, is as follows: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN="3" WIDTH="12%"><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Options Outstanding </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Options Exercisable </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN="1" ALIGN="center" WIDTH="12%"><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Range of<BR>Exercise Prices </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Options<BR>(in thousands) </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Wtd. Avg.<BR>Exercise Price </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Wtd. Avg.<BR>Remaining<BR>Contractual Life<BR>(in years) </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Options<BR>(in thousands) </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Wtd. Avg.<BR>Exercise Price </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH="12%" ALIGN="LEFT" STYLE="text-indent:16;"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$ 0.01 – $ 2.50</FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="7%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="9%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1</FONT></TD>
<TD WIDTH="7%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH="9%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.60</FONT></TD>
<TD WIDTH="7%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="9%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5.35</FONT></TD>
<TD WIDTH="7%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="9%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1</FONT></TD>
<TD WIDTH="7%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH="9%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.60</FONT></TD>
<TD WIDTH="2%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN="LEFT" WIDTH="12%" STYLE="text-indent:16;"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.51 – 5.00</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>43</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.23</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.86</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>43</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.23</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT" WIDTH="12%" STYLE="text-indent:16;"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 5.01 – 7.50</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>61</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.28</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.48</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>61</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.28</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN="LEFT" WIDTH="12%" STYLE="text-indent:16;"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 7.51 – 10.00</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>14</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8.89</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.34</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>14</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8.89</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT" WIDTH="12%" STYLE="text-indent:16;"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 10.01 – 20.00</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,252</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>16.48</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.19</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,252</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>16.48</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN="LEFT" WIDTH="12%" STYLE="text-indent:16;"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 20.01 – 30.00</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,140</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>24.61</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.84</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,140</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>24.61</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT" WIDTH="12%" STYLE="text-indent:16;"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 30.01 – 40.00</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8,456</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>34.55</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3.42</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7,875</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>34.19</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN="LEFT" WIDTH="12%" STYLE="text-indent:16;"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 40.01 – 50.00</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>50,995</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>46.32</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.75</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>40,111</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>46.30</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT" WIDTH="12%" STYLE="text-indent:16;"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 50.01 – 69.82</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>24,876</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>54.45</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7.47</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10,626</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>52.72</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN="3" WIDTH="12%" STYLE="text-indent:16;"></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN="LEFT" WIDTH="12%" STYLE="text-indent:16;"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$ 0.01 – $69.82</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>88,838</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 46.23</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.38</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>63,123</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 44.12</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN="3" WIDTH="12%" STYLE="text-indent:16;"></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Nonqualified options are
normally exercisable beginning one year from the date of grant in cumulative yearly amounts of 25% of the shares under option;
however, certain nonqualified options granted are exercisable immediately. Nonqualified options generally have a contractual
option term of 10 years, provided the optionee’s employment with the Company continues. </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>60 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Restricted stock, performance
shares and other stock awards are dependent upon continued employment and, in the case of performance shares, achievement of
certain performance objectives. Restricted stock awards are expensed over their vesting period, ranging from three to five years
and performance shares are expensed over the performance period based on the probability of achieving the performance objectives.
The Company awarded 1.1 million, 0.2 million and 0.5 million shares of restricted stock and restricted stock units in fiscal 2006,
2005 and 2004, respectively. The weighted average fair value per share for restricted stock and restricted stock units awarded in
fiscal 2006, 2005 and 2004 was $54.68, $50.14 and $47.71, respectively. Total net expense recognized for restricted stock,
performance share and other stock awards was $16.4, $12.3 and $8.4 in fiscal years 2006, 2005 and 2004, respectively. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Stock Purchase
Plan</B> The stock purchase plan enables employees to contribute up to the lesser of 10% of their wages or the
statutory limit under the U.S. Internal Revenue Code toward the purchase of the Company’s common stock at 85% of the market
value. Employees purchased 2.5 million shares at an average of $43.11 per share in fiscal year 2006. As of April 28, 2006,
plan participants have had approximately $6.3 withheld to purchase Company common stock at 85% of the market value on June 30,
2006, the last day of the calendar quarter purchase period. </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10. Income Taxes </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The provision for income
taxes is based on earnings before income taxes reported for financial statement purposes. The components of earnings before income
taxes are: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH>
</TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>U.S.</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,581.0</FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 932.1</FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,262.5</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>International</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,580.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,611.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,534.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Earnings before income taxes</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3,161.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,543.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,796.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The provision for income
taxes consists of: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH>
</TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Current tax expense:</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> U.S.</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 470.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 516.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 344.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> International</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>390.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>395.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total current tax expense</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>482.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>907.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>739.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD colspan=12 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Deferred tax expense (benefit):</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> U.S.</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>159.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(192.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>116.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> International</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(26.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>25.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(19.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net deferred tax expense (benefit)</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>132.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(167.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>97.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Total provision for income taxes</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 614.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 739.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 837.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Deferred taxes arise because
of the different treatment of transactions for financial statement accounting and income tax accounting, known as
“temporary differences.” The Company records the tax effect of these temporary differences as “deferred tax
assets” and “deferred tax liabilities.” Deferred tax assets generally represent items that can be used as a tax
deduction or credit in a tax return in future years for which the Company has already recorded the tax benefit in the consolidated
statements of earnings. The Company establishes valuation allowances for deferred tax assets when the amount of expected future
taxable income is not likely to support the use of the deduction or credit. The Company has established valuation allowances
related to certain acquisitions that, if not ultimately required, will result in a reduction to goodwill; these allowances were
approximately $31.1 and $54.9 at April 28, 2006 and April 29, 2005, respectively. The Company has established valuation
allowances for capital loss carryforwards in the amount of $1.1 and $35.1 at April 28, 2006 and April 29, 2005,
respectively. In addition, at April 28, 2006 and April 29, 2005, approximately $3.6 and $6.5, respectively, of non-U.S. tax
losses were available for carryforward. These carryforwards are offset by valuation allowances and generally expire within one to
five years. The capital loss carryforwards expire within one to five years. Deferred tax liabilities generally represent tax
expense recognized in the consolidated financial statements for which payment has been deferred or expense has </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>61 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>already been taken as a deduction on the Company’s tax return, but has
not yet been recognized as an expense in the consolidated statements of earnings. Deferred tax assets/(liabilities) are comprised
of the following: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH="73%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Deferred tax assets:</FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH="7%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH="2%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Inventory (intercompany profit in inventory and excess of tax over book valuation)</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 206.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 170.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Accrued losses on legal settlements</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8.5</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>229.0</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Accrued liabilities</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>81.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>62.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Allowance for doubtful accounts</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>62.4</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>54.0</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Warranty reserves</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>20.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Unrealized loss on minority investments</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>38.9</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>25.3</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Unrealized loss on investments</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>16.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Convertible debt interest</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>197.0</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Other</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>154.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>144.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Total deferred tax assets</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>769.5</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>712.2</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Deferred tax liabilities:</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Intangible assets</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(394.0</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(365.8</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Convertible debt interest</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(124.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Pension and post-retirement benefits</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(87.5</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(97.7</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Accumulated depreciation</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(42.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(77.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Unremitted earnings of foreign subsidiaries</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(48.5</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Unrealized gain on investments</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(4.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Other</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(66.6</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(91.0</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Total deferred tax liabilities</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(594.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(804.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Deferred tax liabilities, net</B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 174.7</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (92.5</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The Company’s effective
income tax rate varied from the U.S. Federal statutory tax rate as follows: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH="62%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>U.S. Federal statutory tax rate</FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="2%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="6%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>35.0</FONT></TD>
<TD WIDTH="6%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="6%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>35.0</FONT></TD>
<TD WIDTH="6%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="6%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>35.0</FONT></TD>
<TD WIDTH="2%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Increase (decrease) in tax rate resulting from:</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>U.S. state taxes, net of Federal tax benefit</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.9</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.9</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.9</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Research & development credit</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>International</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(10.9</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(7.7</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(5.8</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Impact of repatriation, special, certain litigation and IPR&D charges</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Reversal of tax reserves</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(7.1</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Other, net</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Effective tax rate</B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>19.4</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>29.1</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>29.9</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On October 22, 2004, the
<I>American Jobs Creation Act of 2004</I> (Jobs Creation Act) became law. The Jobs Creation Act allows U.S. corporations a
one-time deduction of 85 percent of certain “cash dividends” received from controlled foreign corporations. The
deduction is available to corporations during the tax year that included October 22, 2004 or the immediately subsequent tax
year. According to the Jobs Creation Act, the amount of eligible dividends is limited to $500.0 or the amount described as
permanently reinvested earnings outside the U.S. in a company’s most recent audited financial statements filed with the SEC
on or before June 30, 2003. Based on these requirements, $933.7 of cash held outside the U.S. was eligible for the special
deduction upon repatriation. This amount was repatriated in the fourth quarter of fiscal year 2006 and used for “qualified
expenditures” as defined under the Jobs Creation Act such as qualified research and development activities, construction of a
new U.S. facility and qualified selling and marketing activities. As of April 29, 2005, the Company had recorded a deferred tax
liability of $48.5 associated with its planned repatriation of these funds and included that amount in the table above and in the
consolidated statements of earnings in <I>provision for income taxes</I>. </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>62 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Except for taxes provided for
amounts to be repatriated under the Jobs Creation Act, the Company has not provided U.S. income taxes on certain of its non-U.S.
subsidiaries’ undistributed earnings as such amounts are permanently reinvested outside the U.S. At April 28, 2006 and
April 29, 2005, such earnings were approximately $6,110.0 and $4,170.0, respectively. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Currently, the Company’s
operations in Puerto Rico, Switzerland, and Ireland have various tax incentive grants. Unless these grants are extended, they will
expire between fiscal years 2007 and 2020. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Tax audits associated with
the allocation of income, and other complex issues, may require an extended period of time to resolve and may result in income tax
adjustments if changes to the Company’s allocation are required between jurisdictions with different tax rates. Tax
authorities periodically review the Company’s tax returns and propose adjustments to its tax filings. The IRS has settled its
audits with the Company for all years through fiscal year 1996. Tax years settled with the IRS, however, remain open for foreign
tax audits and competent authority proceedings. Competent authority proceedings are a means to resolve intercompany pricing
disagreements between countries. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In August 2003, the IRS
proposed adjustments related to the audits of the fiscal years 1997, 1998 and 1999 tax returns. The Company initiated defense of
these filings at the IRS appellate level in November 2004. In the second quarter of fiscal year 2006, the parties reached
agreement in principle on most, but not all matters. Also, during the second quarter of fiscal year 2006, the IRS issued their
audit report for fiscal years 2000, 2001 and 2002. The Company has also reached agreement with the IRS on substantially all of the
fiscal years 2000, 2001 and 2002 proposed adjustments. The only items of significance, from the fiscal years 2000, 2001 and 2002
IRS audit report which remain open, relate to unresolved issues that carry forward from the 1997 through 1999 tax audits.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> During the second quarter of
fiscal year 2006, the Company recorded a $225.0 tax benefit associated with the favorable agreements reached with the IRS
involving the review of the Company’s fiscal years 1997 through 2002 domestic income tax returns. The $225.0 tax benefit is
recorded in <I>provision for income taxes </I>on the consolidated statements of earnings for fiscal year 2006. As a result of the
agreements reached with the IRS, the Company made approximately $326.0 of incremental tax payments during the third quarter of
fiscal year 2006. These payments reduced <I>accrued income taxes</I> in the fiscal year 2006 consolidated balance sheet.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11. Retirement Benefit Plans </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The Company sponsors various
retirement benefit plans, including defined benefit pension plans (pension benefits), post-retirement medical plans
(post-retirement benefits), defined contribution savings plans and termination indemnity plans, covering substantially all U.S.
employees and many employees outside the U.S. The cost of these plans was $187.8 in fiscal year 2006, $112.8 in fiscal year 2005
and $72.6 in fiscal year 2004. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In the U.S., the Company
maintains a qualified pension plan designed to provide guaranteed minimum retirement benefits to all eligible U.S. employees.
Pension coverage for non-U.S. employees of the Company is provided, to the extent deemed appropriate, through separate plans. In
addition, U.S. and Puerto Rico employees of the Company are also eligible to receive specified Company paid healthcare and life
insurance benefits through the Company’s post-retirement medical plans. In addition to the benefits provided under the
qualified pension plan, retirement benefits associated with wages in excess of the IRS allowable wages are provided to certain
employees under a non-qualified plan. </FONT></P>
<BR><BR><BR><BR><BR><BR><BR><BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>63 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The Company uses a
January 31<SUP>st</SUP> measurement date for its U.S. plans and an April 30<SUP>th</SUP> measurement date for the
majority of its plans outside the U.S. </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>U.S.<BR>Pension Benefits </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Non-U.S.<BR>Pension Benefits </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Post-Retirement<BR>Benefits </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=40% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Accumulated benefit obligation at end of year:</B> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 628.6</FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 547.8</FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 224.3</FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 205.0</FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 172.4</FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>169.0</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Change in projected benefit obligation:</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Projected benefit obligation at beginning of year</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 678.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 547.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 257.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 179.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 169.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 166.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Service cost</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>51.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>47.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>23.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>15.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>12.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Interest cost</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>38.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>34.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Plan amendments</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(14.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Medicare Part D impact</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(23.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Actuarial loss/(gain)</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>24.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>60.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>12.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>36.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(7.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Curtailments/Settlement Recognition</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(13.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Benefits paid</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(14.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(11.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(3.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(5.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(4.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(4.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Foreign currency exchange rate changes</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(12.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>17.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Projected benefit obligation at end of year</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>750.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>678.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>285.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>257.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>172.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>169.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD colspan=21 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Change in plan assets:</B> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Fair value of plan assets at beginning of year</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>711.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>600.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>162.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>126.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>81.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>67.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Actual return on plan assets</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>87.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>38.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>20.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Employer contributions</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>66.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>83.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>44.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>22.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>14.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>14.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Benefits paid</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(14.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(11.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(3.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(5.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(4.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(4.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Foreign currency exchange rate changes</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(7.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Fair value of plan assets at end of year</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>851.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>711.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>216.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>162.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>102.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>81.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Funded status</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>100.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>33.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(68.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(95.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(70.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(87.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Unrecognized net actuarial loss</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>254.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>281.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>41.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>54.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>46.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>61.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Unrecognized prior service cost</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(14.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>12.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Net prepaid (accrued) benefit cost</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 340.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 315.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (18.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (28.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (21.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (18.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD nowrap ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Amounts recognized in the consolidated balance sheets consist of:</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Prepaid benefit cost</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 375.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 350.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 9.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 11.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Other intangible assets, net</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Accrued benefit liability</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(56.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(40.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(41.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(58.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(21.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(18.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Accumulated other comprehensive income</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>21.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Net prepaid (accrued) benefit cost</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 340.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 315.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (18.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (28.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (21.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (18.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>64 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> A minimum pension liability
adjustment is required when the actuarial present value of the accumulated benefit obligation exceeds the fair value of plan
assets and accrued benefit liabilities. The minimum pension liabilities relate to plans outside the U.S and the U.S. non-qualified
plan. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The net periodic benefit
costs of the plans include the following components: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>U.S. Pension Benefits </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Non-U.S. Pension Benefits </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=40% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Service cost</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 51.4</FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 47.7</FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 38.2</FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 23.3</FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 15.6</FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 8.1</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Interest cost</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>38.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>34.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>27.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Expected return on plan assets</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(64.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(53.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(43.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(9.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(8.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(3.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Amortization of prior service cost</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>13.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net periodic benefit cost</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>39.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>39.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>25.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>28.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>18.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>13.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Curtailment/Settlement Recognition</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total Cost for Fiscal Year</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 41.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 39.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 25.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 28.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 18.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 13.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Post-Retirement Benefits </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Service cost</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 10.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 12.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 9.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Interest cost</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Expected return on plan assets</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(7.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(5.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(4.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Amortization of prior service cost</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net periodic benefit cost</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>16.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>21.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>17.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Curtailment/Settlement Recognition</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total Cost for Fiscal Year</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 16.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 21.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 17.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In April 2004, the FASB
issued FSP FAS 106-2, “Accounting and Disclosure Requirements Related to the Medicare Prescription Drug, Improvement and
Modernization Act of 2003” (MMA). The FSP required companies to assess the effect of MMA on their retirement-related benefit
costs and obligations and reflect the effects in the financial statements, pursuant to SFAS No. 106, “Employer’s
Accounting for Post-retirement Benefits Other Than Pensions.” On January 21, 2005, the Centers for Medicare and Medicaid
Services (CMS) released the final regulations (the Regulations) for the implementation of the MMA. As a result of these
Regulations, the Company determined that the benefits provided under its plan are actuarially equivalent to the benefits provided
under Part D of the MMA. The Company recognized the effect of the MMA in its January 31, 2005 measurement date; however,
given the timing of the Regulations, the MMA did not have an impact on the fiscal year 2005 net periodic benefit cost. The
application of the MMA as of the fiscal year 2005 measurement date reduced the accumulated post-retirement benefit obligation by
$23.0, all of which was related to benefits attributed to past service and was accounted for as an actuarial gain as required by
the FSP. The net periodic benefit cost for fiscal year 2006 was reduced by approximately $4.5, as a result of the MMA. </FONT></P>
<BR><BR><BR><BR><BR><BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>65 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The actuarial assumptions
were as follows: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>U.S. Pension Benefits </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Non-U.S. Pension<BR>Benefits </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Post-Retirement Benefits </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR WIDTH=95% SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR WIDTH=95% SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR WIDTH=95% SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD nowrap WIDTH=36% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Weighted average assumptions – projected benefit obligation:</B> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=3% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=3% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=3% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=3% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=3% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=3% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=3% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=3% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=3% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Discount rate</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.00</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.00</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.25</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.34</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.39</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.90</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.00</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.00</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.30</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Rate of compensation increase</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.24</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.00</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.00</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3.07</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.99</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.97</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Healthcare cost trend rate</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.00</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.00</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD nowrap colspan=30 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Weighted average assumptions – net periodic benefit cost:</B> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Discount rate</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.00</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.25</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.75</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.39</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.90</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5.12</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.00</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.25</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.75</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Expected return on plan assets</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8.75</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8.75</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8.75</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5.46</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5.86</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5.92</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8.75</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8.75</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8.75</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Rate of compensation increase</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.00</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.00</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.00</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.99</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.97</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3.49</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Healthcare cost trend rate</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD></TR>
</TABLE>
<BR>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The Company’s discount
rates are determined by considering current yield curves representing high quality, long-term fixed income instruments, The
resulting discount rates are consistent with the duration of plan liabilities. </FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The expected long-term rate
of return on plan assets assumptions is determined using a building block approach, considering historical averages and real
returns of each asset class. In certain countries, where historical returns are not meaningful, consideration is given to local
market expectations of long-term returns. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Retirement Benefit Plan
Investment Strategy</B> The Company has a master trust that holds the assets for both the U.S. pension plan and
other post-retirement benefits, primarily retiree medical. For investment purposes the plans are managed in an identical way, as
their objectives are similar. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The Company has a Qualified
Plan Committee (the Committee) that sets investment guidelines with the assistance of an external consultant. These guidelines are
established based on market conditions, risk tolerance, funding requirements, and expected benefit payments. The Committee also
oversees the investment allocation process, selects the investment managers, and monitors asset performance. As pension
liabilities are long-term in nature, the Company employs a long-term total return approach to maximize the long-term rate of
return on plan assets for a prudent level of risk. An annual analysis on the risk versus the return of the investment portfolio is
conducted to justify the expected long-term rate of return assumption. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The investment portfolio
contains a diversified portfolio of investment categories, including equities, fixed income securities, hedge funds and private
equity. Securities are also diversified in terms of domestic and international securities, short- and long-term securities, growth
and value styles, large cap and small cap stocks, active and passive management and derivative-based styles. The Committee
believes with prudent risk tolerance and asset diversification, the plan should be able to meet its pension and other
post-retirement obligations in the future. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Plan assets also include
investments in the Company’s common stock of $63.7 and $67.3 at April 28, 2006 and April 29, 2005, respectively.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The Company’s pension
plan weighted-average asset allocations and the target allocations at April 28, 2006 and April 29, 2005, by asset
category, are as follows: </FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B><I> U.S. Plans</I></B> </FONT> </P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=4><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Pension Benefits Allocation </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH><TH></TH>
<TH COLSPAN=4><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Target Allocation </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH><TH></TH>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH><TH></TH>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH><TH></TH>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=36% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Asset Category</B> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=8% ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=7% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=8% ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=7% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=8% ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=7% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=8% ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Equity securities</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 65.1%</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 63.8%</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 60.0%</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 60.0%</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Debt securities</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11.5</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>14.2</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>15.0</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>15.0</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cash</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.1</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.2</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Other</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>23.3</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>21.8</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>25.0</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>25.0</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 100%</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 100%</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 100%</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 100%</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<BR><BR><BR><BR><BR><BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>66 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B><I> Non-U.S. Plans</I></B> </FONT> </P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=4><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Pension Benefits Allocation </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH><TH></TH>
<TH COLSPAN=4><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Target Allocation </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH><TH></TH>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH><TH></TH>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH><TH></TH>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=36% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Asset Category</B> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=8% ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=7% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=8% ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=7% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=8% ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=7% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=8% ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Equity securities</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 40.3%</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 38.9%</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 37.0%</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 37.0%</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Debt securities</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 9.6</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>40.1</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>16.0</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>16.0</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cash</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.7</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> —</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Other</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>47.4</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>21.0</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>47.0</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>47.0</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 100%</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 100%</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 100%</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 100%</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In certain countries outside
the U.S., fully funding pension plans is not a common practice, as funding provides no income tax benefit. Consequently, certain
pension plans were partially funded as of April 28, 2006 and April 29, 2005. Plans with accumulated benefit obligations
and projected benefit obligations in excess of plan assets consist of the following: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH><TH></TH>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=62% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Accumulated benefit obligation</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=8% ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$164.5 </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=8% ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$198.9 </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Projected benefit obligation</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>204.3</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>239.6</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Plan assets at fair value</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 78.6</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>107.1</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> It is the Company’s
policy to fund retirement costs within the limits of allowable tax deductions. During fiscal year 2006, the Company made
discretionary contributions of approximately $66.8 to the qualified U.S. pension plan and approximately $14.6 to post-retirement
benefits. Internationally, the Company contributed approximately $44.1 for pension benefits during fiscal year 2006. During fiscal
year 2007, the Company anticipates that its contribution for pension benefits and post-retirement benefits will be in the range of
$75.0 and $95.0. Based on the guidelines under the U.S. Employee Retirement Income Security Act (ERISA) and the various guidelines
which govern the plans outside the U.S., the majority of anticipated fiscal year 2007 contributions will be discretionary.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Retiree benefit payments,
which reflect expected future service, are anticipated to be paid as follows: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>U.S.<BR>Pension Benefits </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Non-U.S.<BR>Pension Benefits </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Post-Retirement Benefits </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Gross Payments </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Gross Payments </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Gross<BR>Payments </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Gross Medicare<BR>Part D Receipts </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=29% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2007</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 11.1</FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 19.7</FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3.8</FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.2</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2008</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>15.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2009</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>18.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2010</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>22.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2011</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>26.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2012 – 2016</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>197.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>53.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>50.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 292.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 100.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 75.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 5.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>67 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The healthcare cost trend
rate for other retirement benefit plans was 10.0% at April 28, 2006. The trend rate is expected to decline to 5% over a
five-year period. Assumed healthcare cost trend rates have a significant effect on the amounts reported for the healthcare plans.
A one-percentage-point change in assumed healthcare cost trend rates would have the following effects: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>One-Percentage-<BR>Point Increase </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>One-Percentage-<BR>Point Decrease </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=61% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Effect on post-retirement benefit cost</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.3</FONT></TD>
<TD WIDTH=10% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.9</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Effect on post-retirement benefit obligation</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>15.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>13.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <B>Defined Contribution
Savings Plans</B> The Company has defined contribution savings plans that cover substantially all U.S. employees
and certain non-U.S. employees. The general purpose of these plans is to provide additional financial security during retirement
by providing employees with an incentive to make regular savings. Up to and including fiscal year 2005, the Company match on the
SRP for U.S. employees was made in the form of an annual allocation of Medtronic stock to the participants’ ESOP account (see
Note 8). Company contributions to the plans are based on employee contributions and Company performance and starting in
fiscal year 2006, the entire match is made in cash. Expense under these plans was $83.3 in fiscal year 2006, $32.8 in fiscal year
2005, and $16.9 in fiscal year 2004. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Effective May 1, 2005, the
Company froze participation in the existing defined benefit pension plan in the U.S. and implemented two new plans including an
additional defined benefit pension plan and a new defined contribution pension plan, respectively: the Personal Pension Account
(PPA) and the Personal Investment Account (PIA). Employees in the U.S. hired on or after May 1, 2005 have the option to
participate in either the PPA or the PIA. Participants in the PPA receive an annual allocation of their salary and bonus on which
they will receive an annual guaranteed rate of return which is based on the 10-year Treasury bond rate. Participants in the PIA
also receive an annual allocation of their salary and bonus, however, they are allowed to determine how to invest their funds
among identified fund alternatives. The cost associated with the PPA is included in the U.S. Pension Benefits in the tables
presented earlier. The defined contribution cost associated with the PIA was approximately $17.8 in fiscal year 2006. </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>12. Leases </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The Company leases office,
manufacturing and research facilities, and warehouses, as well as transportation, data processing and other equipment under
capital and operating leases. A substantial number of these leases contain options that allow the Company to renew at the fair
rental value on the date of renewal. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Future minimum payments under
capitalized leases and non-cancelable operating leases at April 28, 2006 are: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=1><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year</FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Capitalized<BR>Leases </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Operating<BR>Leases </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=52% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2007</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=13% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 10.6</FONT></TD>
<TD WIDTH=10% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 72.3</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2008</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>16.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>56.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2009</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>15.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>41.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2010</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>16.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>24.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2011</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>18.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2012 and thereafter</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>39.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>41.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total minimum lease payments</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>116.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 247.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Less amounts representing interest</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>21.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Present value of net minimum lease payments</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 95.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>N/A</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Rent expense for all
operating leases was $88.7, $79.5, and $70.0 in fiscal years 2006, 2005, and 2004, respectively. </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>68 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In April 2006, the Company
entered into a sale-leaseback agreement with a financial institution whereby certain manufacturing equipment was sold to the
financial institution and is being leased by the Company over a seven year period. The transaction has been recorded as a capital
lease and included in the table above. Payments for the remaining balance of the sale-leaseback agreement are due semi-annually.
The lease provides for an early buyout option whereby the Company at its option could repurchase the equipment at a predetermined
fair market value in calendar year 2009. </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>13. Commitments
and Contingencies </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The Company is involved in a
number of legal actions. The outcomes of these legal actions are not within the Company’s complete control and may not be
known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief, including injunctions
barring the sale of products that are the subject of the lawsuit, which, if granted, could require significant expenditures or
result in lost revenues. In accordance with SFAS No. 5, “Accounting for Contingencies” (SFAS No. 5), the Company records
a liability in the consolidated financial statements for these actions when a loss is known or considered probable and the amount
can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is
a better estimate, the minimum amount of the range is accrued. If a loss is reasonably likely but not known or probable, and can
be reasonably estimated, the estimated loss or range of loss is disclosed. If a loss is not probable or cannot be reasonably
estimated, a liability is not recorded in the consolidated financial statements. In most cases, significant judgment is required
to estimate the amount and timing of a loss to be recorded. While it is not possible to predict the outcome for most of the
actions discussed below and the Company believes that it has meritorious defenses against these matters, it is possible that costs
associated with them could have a material adverse impact on the Company’s consolidated earnings, financial condition or cash
flows.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On October 6, 1997, Cordis
Corporation (Cordis), a subsidiary of Johnson & Johnson (J&J), filed suit in U.S. District Court for the District of
Delaware against Arterial Vascular Engineering, Inc., which Medtronic acquired in January 1999 and which is now known as Medtronic
Vascular, Inc. (Medtronic Vascular). The suit alleged that Medtronic Vascular’s modular stents infringe certain patents owned
by Cordis. Boston Scientific Corporation is also a defendant in this suit. On December 22, 2000, a jury rendered a verdict that
Medtronic Vascular’s previously marketed MicroStent and GFX stents infringed valid claims of two Cordis patents and awarded
damages to Cordis totaling approximately $270.0. On March 28, 2002, the District Court entered an order in favor of Medtronic
Vascular, deciding as a matter of law that Medtronic Vascular’s MicroStent and GFX stents did not infringe the patents.
Cordis appealed, and on August 12, 2003, the U.S. Court of Appeals for the Federal Circuit reversed the District Court’s
decision and remanded the case to the District Court for further proceedings. The District Court thereafter issued a new patent
claim construction and a new trial was held in March 2005. On March 14, 2005, the jury found that the previously marketed
MicroStent and GFX stent products infringed valid claims of Cordis’ patents. On March 27, 2006, the District Court denied
post-trial motions filed by the parties, including Cordis’ motion to reinstate the previous damages award. On April 26, 2006,
Medtronic filed its Notice of Appeal of the judgment of infringement. The District Court has deferred any hearing on damages
issues until after the U.S. Court of Appeals for the Federal Circuit resolves the appeal on the finding of liability. Medtronic
has not recorded an expense related to damages in this matter because any potential loss is not currently probable or reasonably
estimable under SFAS No. 5. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On December 24, 1997,
Advanced Cardiovascular Systems, Inc. (ACS), a subsidiary of Guidant Corporation (Guidant), sued Medtronic Vascular in U.S.
District Court for the Northern District of California alleging that certain models of Medtronic Vascular’s stents infringe
the Lau stent patents held by ACS, and seeking injunctive relief and monetary damages. Medtronic Vascular denied infringement and
in February 1998, Medtronic Vascular sued ACS in U.S. District Court for the District of Delaware alleging infringement of
Medtronic Vascular’s Boneau stent patents. On January 5, 2005, the District Court found as a matter of law that the ACS
products in question did not infringe any of Medtronic Vascular’s Boneau stent patents. Medtronic Vascular appealed this
finding by the District Court, and on May 25, 2006 the U.S. Court of Appeals for the Federal Circuit affirmed the trial
court’s ruling that the ACS products do not infringe Medtronic’s Boneau patents. In February 2005, following trial, a
jury determined that the ACS Lau stent patents were valid and that Medtronic’s Driver, GFX, MicroStent, S540, S660, S670,
Bestent2 and S7 stents infringe those patents. Medtronic Vascular has made numerous post-trial motions challenging the
jury’s verdict of infringement and validity and the District Court has not yet ruled on those motions. On June 7
and 8, 2005, the District Court held an evidentiary hearing on Medtronic Vascular’s claim that the ACS Lau stent patents
are unenforceable due to inequitable conduct of ACS in obtaining the Lau patents. The District Court has not yet issued a decision
on Medtronic Vascular’s claim of inequitable conduct. Issues of damages have been bifurcated from the liability phase of the
proceedings. On August 9, 2005, the Court issued an order continuing a stay of any further proceedings on the questions of damages
or willfulness. These issues likely will not be addressed by a jury or the Court until the U.S. Court of Appeals for the Federal
Circuit has reviewed the underlying liability issues concerning alleged infringement. In January 2006, Medtronic filed a Request
for Reexamination at </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>69 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>the United States Patent and Trademark Office (USPTO) related to each of the
four Lau patents asserted by ACS in the above matter. On February 14, 2006, the USPTO granted Medtronic’s Request for
Reexamination for each of the four Lau patents, finding that “substantial questions exist” regarding the validity of the
Lau patent claims in view of prior art submitted by Medtronic with the Request for Reexamination. The USPTO will now reconsider
whether the Lau patents should have been granted in the first instance, though the timing of such reexamination is not known.
Until this reexamination is concluded, its potential impact upon the claims relating to the Lau patents in the above proceeding
remains unknown. The Company has not recorded an expense related to damages in this matter because any potential loss is not
currently probable or reasonably estimable under SFAS No. 5. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On September 12, 2000, Cordis
filed an additional suit against Medtronic Vascular in U.S. District Court for the District of Delaware alleging that Medtronic
Vascular’s S670, S660 and S540 stents infringe the patents asserted in the October 1997 Cordis case above. Cordis
subsequently added claims that Medtronic Vascular’s S7 and Driver stents infringe the asserted patents. The court thereafter
granted Medtronic Vascular’s motion to stay the trial proceedings pending arbitration of Medtronic Vascular’s defense
that its products are licensed under a 1997 Agreement between Medtronic Vascular and Cordis. The arbitration commenced
November 14, 2005 before a panel of three neutral arbitrators. The scope of the arbitration was limited to the question of
whether the products that are the subject of the lawsuit are covered by the 1997 Agreement, and also whether a separate covenant
by J&J not to sue Medtronic and its affiliates contained within a 1998 amendment to the 1997 Agreement precludes the lawsuit.
On February 20, 2006, the Arbitration Panel issued its award concluding that the accused Medtronic products are licensed and
that the covenant not to sue contained within the 1998 amendment bars J&J’s and Cordis’ claims that Medtronic
Vascular has infringed the Cordis patents asserted in the 2000 lawsuit. On April 24 and 26, 2006, J&J served the
Company demands for arbitration for royalty payments on the products that have been determined to be licensed and covered by the
covenant not to sue. The parties have not yet selected arbitrators, and no dates have been set for the arbitration proceedings.
The Company has not recorded an expense related to damages in this matter because any potential loss is not currently probable or
reasonably estimable under SFAS No. 5. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On January 26, 2001,
DePuy/AcroMed, a subsidiary of J&J, filed suit in U.S. District Court for the District of Massachusetts alleging that MSD was
infringing a patent relating to a design for a thoracolumbar multiaxial screw (MAS). In March 2002, DePuy/AcroMed supplemented its
allegations to claim that MSD’s M10, M8 and Vertex screws infringe the patent. On April 17, 2003 and February 26,
2004, the District Court ruled that those screws do not infringe. On October 1, 2004, a jury found that the MAS screw, which
MSD no longer sells in the U.S., infringes under the doctrine of equivalents. The jury awarded damages of $21.0 and on
February 9, 2005, the Court entered judgment against MSD, including prejudgment interest, in the aggregate amount of $24.3.
In the third quarter of fiscal year 2005, the Company recorded an expense equal to the $24.3 judgment in the matter. DePuy/AcroMed
has appealed the Court’s decisions that the M10, M8 and Vertex screws do not infringe, and MSD has appealed the jury’s
verdict that the MAS screw infringes valid claims of the patent. On June 5, 2006, the U.S. Court of Appeals for the Federal
Circuit heard oral argument on the parties’ respective appeals, and has taken the appeals under advisement. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On May 2, 2003, Cross Medical
Products, Inc. (Cross) sued MSD in the U.S. District Court for the Central District of California. The suit alleges that
MSD’s CD HORIZON, Vertex and Crosslink products infringe certain patents owned by Cross. MSD has countered that Cross’
cervical plate products infringe certain patents of MSD, and Cross has filed a reply alleging that certain MSD cervical plate
products infringe certain patents of Cross. On May 19, 2004, the Court found that the MAS, Vertex, M8, M10, CD HORIZON SEXTANT and
CD HORIZON LEGACY screw products infringe one Cross patent. A hearing on the validity of that patent was held on July 12, 2004,
after which the District Court ruled that the patents were valid. Cross made a motion for permanent injunction on the multiaxial
screw products, which the District Court granted on September 20, 2004, but stayed the effect of the injunction until January 3,
2005. MSD requested an expedited appeal of the ruling and the U.S. Court of Appeals for the Federal Circuit granted the request.
The Federal Circuit heard the appeal on March 11, 2005. On September 30, 2005, the Federal Circuit vacated the injunction,
modified the trial court’s claim construction rulings, and remanded the matter for trial in the District Court. The Federal
Circuit awarded costs to Medtronic on the appeal. In April 2005, the District Court ruled invalid certain claims in the patents
Cross asserted against MSD’s Crosslink and cervical plate products. The Court also ruled that Cross cervical plate products
infringe MSD’s valid patents and that MSD’s redesigned pedicle screw products infringe one claim of one of the patents
owned by Cross. Cross thereafter moved for an injunction against the redesigned screw products, which the District Court granted
on May 24, 2005. The District Court then stayed the effectiveness of the injunction until August 22, 2005. On July 27, 2005, the
U.S. Court of Appeals for the Federal Circuit granted MSD’s motion to stay the District Court’s injunction pending a
full hearing on the appeal. In granting the further stay, the Federal Circuit stated MSD had shown a “…likelihood of </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>70 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>success…” on the merits of its appeal. The Federal Circuit heard
oral argument on this appeal on March 10, 2006, but has not issued its ruling as of the date of filing this report. The trial
court held a status hearing on December 19, 2005, to determine further proceedings in light of the appellate rulings, and it held
a second status conference in May 2006. No trial date has been set. The Company has not recorded an expense related to damages in
this matter because any potential loss is not currently probable or reasonably estimable under SFAS No. 5. Separately, on February
1, 2006, MSD filed a lawsuit against Biomet Inc., the corporate parent of Cross (Biomet) and its subsidiary EBI Spine, L.P., for
patent infringement. The suit, which involves seven Medtronic patents and seeks injunctive relief and monetary damages, was filed
in the U.S. District Court for the District of New Jersey. Three of the patents were purchased by Medtronic from Michelson and
involve single-lock anterior cervical plating systems used in cervical spinal fusions. Medtronic claims that a cervical plate
marketed by Biomet under the trade name VueLock Anterior Cervical Plate System, and openly promoted as a plate that has a
“Secure One Step Locking” mechanism feature, infringes these patents. The other patents involve rod reducer instruments
and surgical implantation methods commonly used in spinal surgeries to implant pedicle screws. The lawsuit alleges that
Biomet’s pedicle screw systems utilize a rod reducer instrument in a variety of lumbar and thoracic spinal fusion surgeries.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On September 4, 2003,
Medtronic was informed by the Department of Justice that the government is investigating allegations that certain payments and
other services provided to physicians by MSD constituted improper inducements under the federal Anti-Kickback Statute. The
allegations were made as part of a civil qui tam complaint brought pursuant to the federal False Claims Act. On November 21, 2003,
Medtronic was served with a government subpoena seeking documents in connection with these allegations. On September 2, 2004,
Medtronic received a copy of a second civil qui tam complaint brought by a second relator asserting similar allegations under the
False Claims Act. The Company views the second complaint as having arisen out of essentially similar facts and circumstances as
the first qui tam complaint, and believes that the second complaint does not materially expand the nature of the existing inquiry
in which the Company is cooperating. The cases remain under seal in the U.S. District Court for the Western District of Tennessee.
The Company is cooperating fully with the investigations and is independently evaluating these matters, the internal processes
associated therewith, and certain employment matters related thereto, in each case under the supervision of a special committee of
the Board of Directors. The Company has not recorded an expense related to damages in this matter because any potential loss is
not currently probable or reasonably estimable under SFAS No. 5. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On October 2, 2003, Cordis
sued Medtronic Vascular in the U.S. District Court for the Northern District of California, alleging that Medtronics calendar. On
June 9, 2006, the parties advised the Court that they had been unable to finalize their tentative settlement, and the Court
sdcheduled a status hearing for July 13, 2006 where the Court may seek to enforce a settlement if the parties are still
unable to finalize a resolution. At the time of this filing, the parties remain unable to resolve their dispute, and there can be
no assurance that a satisfactory resolution can or will be reached or whether a settlement may be imposed by the Court.
Vascular’s S7 stent delivery system infringes certain catheter patents owned by Cordis. Pursuant to stipulation of the
parties, the Court has stayed the suit and referred the matter to arbitration. The arbitrators have not yet been selected. The
Company has not recorded an expense related to damages in this matter because any potential loss is not currently probable or
reasonably estimable under SFAS No. 5. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On October 15, 2004, Dr.
Eckhard Alt filed suit in U.S. District Court for the Eastern District of Texas against Medtronic, Inc. Dr. Alt alleges that
certain Medtronic pacemakers and defibrillators infringe four patents Dr. Alt claims he now owns. Dr. Alt is also seeking
injunctive relief and monetary damages. On February 15, 2006, Dr. Alt filed a second lawsuit in U.S.
District Court for the Eastern District of Texas against Medtronic, Inc. alleging that certain Medtronic defibrillators infringe
one other patent in which Dr. Alt claims to have certain rights. Medtronic was served with a complaint for this second lawsuit on
March 3, 2006, but no trial date or other deadlines have been set for this second lawsuit. On May 8,
2006, the parties informed the Court that they had tentatively settled their disputes, and they jointly requested the Court to
remove the previously scheduled May 15, 2006 trial date from the Court’s calendar. On June 9, 2006, the parties advised
the Court that they had been unable to finalize their tentative settlement, and the Court scheduled a status hearing for July 13,
2006 at which the Court may seek to enforce a settlement if the parties are still unable to finalize a resolution. At the time of this
filing, the parties remain unable to resolve their dispute, and there can be no assurance that a satisfactory resolution can or
will be reached or whether a settlement may be imposed by the Court. The Company has not recorded an
expense in either matter because any potential loss is not currently probable or reasonably estimable under SFAS No. 5.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On February 11, 2005,
Medtronic voluntarily began advising physicians about a potential battery shorting mechanism that may occur in a subset of
implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds), including certain of
the Marquis VR/DR and Maximo VR/DR ICDs and certain of the InSync I/II/III Marquis and InSync III CRT-D devices. The Company
provided physicians with a list of potentially affected patients and recommended that physicians communicate with those patients
so they could manage the potential issue in a manner they felt was appropriate for their individual patients. Subsequent to this
voluntary field action, later classified by the FDA as a Class II Recall, a number of lawsuits were filed against Medtronic in
various state and federal jurisdictions. The cases were brought either by individuals claiming personal injury or by third party
payors seeking reimbursement of costs associated with the field action. The personal injury complaints generally alleged strict
liability, negligence, warranty and other common law and/or statutory claims; </FONT></P>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>71 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>and seek compensatory as well as punitive damages. Cases filed in federal
court (either personal injury or third party payor) have been consolidated before one federal judge under a process known as a
Multidistrict Litigation case (MDL). There are 209 federal cases, most of which have been consolidated in the MDL. We expect all
federal cases will be transferred to the MDL. There are 28 state court cases that are not part of the MDL. Separate master
complaints were filed in the MDL for the personal injury and third party payor claims. The third party payor master complaint
contains class allegations and lawyers for the plaintiffs have indicated that they will request the court’s permission to
amend the personal injury master complaint to add class allegations which were omitted from it. The Company intends to challenge
any attempt at class certification because it believes individual issues far outweigh any common issues in the various cases.
Cases claiming personal injury will be subject to dismissal in connection with Medtronic’s summary judgment motion based, in
part, upon the legal theory of federal preemption. The motion is scheduled to be heard on July 10, 2006. Discovery limited to
issues associated with federal preemption has been completed. Medtronic also filed a motion to dismiss the third party payor cases
in March 2006. Additionally, five putative class actions have been filed in Canada. The Company is unaware of any confirmed injury
or death resulting from a device failure due to the shorting mechanism that was the subject matter of the field action though
certain of the lawsuits make such allegations. The Company has not recorded an expense related to damages in connection with the
various Marquis related lawsuits because potential losses are not currently probable or reasonably estimable under SFAS No. 5.
</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> On October 24, 2005,
Medtronic received a subpoena from the Office of the United States Attorney for the District of Massachusetts issued under the
Health Insurance Portability & Accountability Act of 1996 requesting documents the Company may have, if any, relating to
pacemakers and defibrillators and related components; monitoring equipment and services; a provision of benefits, if any, to
persons in a position to recommend purchases of such devices; and the Company’s training and compliance materials relating to
the fraud and abuse and federal Anti-Kickback statutes. The Company intends to fully cooperate with the Office of the United
States Attorney for the District of Massachusetts with respect to this subpoena. </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> In the normal course of
business, the Company periodically enters into agreements that require it to indemnify customers or suppliers for specific risks,
such as claims for injury or property damage arising out of the Company’s products or the negligence of its personnel or
claims alleging that its products infringe third-party patents or other intellectual property. The Company’s maximum exposure
under these indemnification provisions cannot be estimated, and the Company has not accrued any liabilities within the
consolidated financial statements. Historically, the Company has not experienced significant losses on these types of
indemnifications. </FONT></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>14. Quarterly Financial Data </FONT></H1>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>First<BR>Quarter </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Second<BR>Quarter </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Third<BR>Quarter </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fourth<BR>Quarter </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal<BR>Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=14><FONT FACE="Times New Roman, Times, Serif" SIZE=1>(unaudited) </FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH="22%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Net Sales</B> </FONT></TD>
<TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="7%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH="7%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH="7%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH="7%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH="7%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH="7%" ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH="2%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 2006</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 2,690.4</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 2,765.4</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 2,769.5</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 3,066.7</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 11,292.0</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2005</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,346.1</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,399.8</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,530.7</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,778.0</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10,054.6</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Gross Profit</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 2006</B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 2,036.6</B> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 2,070.6</B> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 2,070.8</B> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 2,298.7</B> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 8,476.7</B> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2005</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,795.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,815.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,925.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,072.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7,608.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD colspan=18 ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Net Earnings</B> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 2006</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 320.6</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 816.5</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 669.6</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 740.0</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 2,546.7</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2005</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>529.7</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>535.7</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>544.1</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>194.4</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,803.9</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Basic Earnings per Share</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 2006</B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 0.26</B> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 0.68</B> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 0.55</B> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 0.62</B> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 2.11</B> </FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2005</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.44</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.44</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.45</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.16</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.49</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Diluted Earnings per Share</B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 2006</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 0.26</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 0.67</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 0.55</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 0.61</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 2.09</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2005</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.43</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.44</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.45</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.16</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.48</FONT></TD>
<TD ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
</TABLE>
<BR>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>72 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;font-weight:bold"><FONT STYLE="font-size:14pt">Notes </FONT> <FONT STYLE="font-size:10pt">to Consolidated Financial Statements <B><I>(continued)</I></B></font></p>
<P style="font-size:10pt;font-style:italic;margin-top:-14pt"><I>(dollars in millions, except per share data)</I></P>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>15. Segment and Geographic Information </FONT></H1>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> During the fourth quarter of
fiscal year 2006, the Company revised its operating segment reporting related to the Neurological and Diabetes operating segment
and the Spinal, Ear, Nose and Throat (ENT) and Navigation operating segment. As a result, the Company now maintains seven
operating segments, which are aggregated into one reportable segment—the manufacture and sale of device-based medical
therapies. The information for fiscal years 2005 and 2004 below has been reclassified to conform to the current presentation. Each
of the Company’s operating segments has similar economic characteristics, technology, manufacturing processes, customers,
distribution and marketing strategies, regulatory environments, and shared infrastructures. Net sales by operating segment are as
follows: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=46% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cardiac Rhythm Disease Management</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 5,205.5</FONT></TD>
<TD WIDTH=9% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 4,615.5</FONT></TD>
<TD WIDTH=9% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 4,238.3</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Spinal and Navigation</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,244.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,884.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,548.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Neurological</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,016.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>927.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>856.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Vascular</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>939.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>851.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>842.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Diabetes</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>722.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>649.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>558.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cardiac Surgery</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>663.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>668.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>630.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ENT</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>501.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>458.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>412.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 11,292.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 10,054.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 9,087.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
</TABLE>
<BR>
<H1><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Geographic Information </FONT></H1>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>United<BR>States </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Europe </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Asia<BR>Pacific </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Other<BR>Foreign </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Consolidated </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=30% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Fiscal year 2006</B> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net sales to external customers</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 7,626.2</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 2,313.9</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 1,022.6</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 329.3</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 11,292.0</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Long-lived assets*</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 7,100.3</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 1,038.7</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 156.0</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 36.2</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>$</B> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> 8,331.2</B> </FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Fiscal year 2005</B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B> </B> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net sales to external customers</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 6,710.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,098.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 985.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 259.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 10,054.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Long-lived assets*</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 6,434.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 989.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 169.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 37.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 7,630.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD colspan=18 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Fiscal year 2004</B> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net sales to external customers</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 6,159.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,846.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 859.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 221.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 9,087.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Long-lived assets*</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 6,202.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 932.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 175.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 31.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 7,341.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
</TABLE>
<BR>
<HR noshade color="black" align="left" size="1" width="20%">
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD ALIGN=LEFT WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>* </FONT></TD>
<TD WIDTH=97%><P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Excludes other long-term financial instruments. </FONT></P></TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> No single customer represents
over 10% of the Company’s consolidated net sales in fiscal years 2006, 2005 or 2004. </FONT></P>
<BR><BR><BR><BR><BR><BR><BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>73 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<P style="font-size:10pt;text-align:left">Selected
<FONT STYLE="font-size:16pt"><I><A NAME="financial_data"><B>Financial Data</B></A></I> </FONT> </P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=14><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Year </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2006 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004<SUP>(2)</SUP> </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2003 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2002 </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN=Bottom>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
<TH COLSPAN=14><FONT FACE="Times New Roman, Times, Serif" SIZE=1>(dollars in millions, except per share data) </FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD WIDTH=36% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Operating Results for the Fiscal Year:</B> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Net sales</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 11,292.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 10,054.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 9,087.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 7,665.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 6,410.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Cost of products sold</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,815.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,446.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,252.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,890.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,652.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Gross margin percentage</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>75.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>75.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>75.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>75.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>74.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Research and development expense</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,112.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 951.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 851.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 749.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 646.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Selling, general and administrative expense</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,659.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,213.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,801.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,371.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,962.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Special charges</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>100.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(4.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>45.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Certain litigation charges</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>654.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(8.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>244.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Purchased in-process research and development<BR> charges</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>363.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>—</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>41.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>114.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>293.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Other expense, net</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>166.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>290.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>351.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>188.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>34.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Interest (income)/expense</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(87.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(45.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Earnings before income taxes</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,163.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,543.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,796.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,341.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,524.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Provision for income taxes</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>614.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>739.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>837.6</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>741.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>540.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD><TD></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Net earnings</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,546.7</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,803.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,959.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,599.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 984.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR>
<TD COLSPAN=3></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD>
<TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=3></TD><TD></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD colspan=18 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Per Share of Common Stock:</B> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Basic earnings</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.11</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.49</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.61</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.31</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.81</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Diluted earnings</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.09</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.48</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.60</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.30</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.80</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Cash dividends declared</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.39</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.34</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.29</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.25</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.23</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD colspan=18 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Financial Position at Fiscal Year-end:</B> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Working capital<SUP>(1)</SUP></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 5,970.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 4,041.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,072.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,792.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (496.9</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Current ratio<SUP>(1)</SUP></FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.4:1.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.2:1.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.3:1.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.5:1.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0.9:1.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Total assets</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 19,664.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 16,617.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 14,110.8</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 12,405.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 10,904.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Long-term debt</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5,486.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,973.2</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,980.3</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Shareholders’ equity</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9,382.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10,449.5</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9,077.0</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7,906.4</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6,431.1</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD colspan=18 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Additional Information:</B> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Full-time employees at year-end</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>32,280</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>29,835</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>27,868</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>26,732</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>25,137</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Full-time equivalent employees at year-end</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>35,733</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>33,067</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>30,900</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>29,581</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>27,731</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
</TABLE>
<BR>
<HR noshade color="black" align="left" size="1" width="20%">
<TABLE WIDTH=100% CELLPADDING=2 CELLSPACING=2>
<TR VALIGN=TOP>
<TD ALIGN=LEFT WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1) </FONT></TD>
<TD WIDTH=97%><P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Working capital and the current ratio in fiscal
years 2002 and 2004 were substantially lower than other years. In fiscal year 2002 approximately $4.1 billion in cash was
paid for acquisitions. Approximately $2.0 billion of the cash paid was funded by issuing contingent convertible debentures
that were classified as short-term borrowings as of April 26, 2002. The debentures were classified as short-term borrowings
as holders had the option to require the Company to repurchase the debentures (referred to as a put feature) in
September 2002. As the next put feature was due in September 2004, the debentures were again classified as short-term
borrowings as of April 30, 2004, which reduced the working capital and current ratio in comparison to fiscal years 2005 and
2003 when the debentures were classified as long-term debt. The working capital and current ratios have remained strong in fiscal
year 2006, even though the contingent convertible debentures are classified in short-term borrowings similar to fiscal years 2002
and 2004, as a result of our increased cash balances resulting from the proceeds of the $4.4 billion of Senior Convertible Notes
issued in April 2006. </FONT></P></TD>
</TR>
<TR VALIGN=TOP>
<TD ALIGN=LEFT WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2) </FONT></TD>
<TD WIDTH=97%><P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Fiscal year 2004 consisted of 53 weeks, as compared
to 52 weeks in all other fiscal years disclosed above. See Note 1 to the consolidated financial statements. </FONT></P></TD>
</TR>
</TABLE>
<BR>
<BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>74 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<BR><BR>
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><A NAME="price_range">Price Range </A>of Medtronic Stock </FONT></H1>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal Qtr. </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>1st Qtr. </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2nd Qtr. </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>3rd Qtr. </FONT><HR SIZE=1 COLOR=BLACK NOSHADE></TH><TH></TH>
<TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1>4th Qtr.</FONT><HR WIDTH=95% SIZE=1 COLOR=BLACK NOSHADE></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2006 High</FONT></TD>
<TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 53.94</FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 57.85</FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 59.54</FONT></TD>
<TD WIDTH=8% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 57.14</FONT></TD>
<TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2006 Low</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>51.56</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>52.87</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>55.41</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>49.05</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#d6f3e8">
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2005 High</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>51.25</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>53.19</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>53.28</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>54.92</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
<TR VALIGN=Bottom>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2005 Low</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>46.40</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>48.55</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>47.01</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
<TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>50.30</FONT></TD>
<TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD></TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Prices are closing
quotations. On June 26, 2006, there were approximately 53,700 shareholders of record of the Company’s common stock. The
regular quarterly cash dividend was 9.625 cents per share for fiscal year 2006 and 8.375 cents per share for fiscal year 2005.
</FONT></P>
<BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR>
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>75 </FONT></P>
<HR SIZE=3 COLOR=GRAY NOSHADE>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>a62430sales_pi.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a62430sales_pi.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````4```_^X`#D%D
M;V)E`&3``````?_;`(0``@("`@("`@("`@,"`@(#!`,"`@,$!00$!`0$!08%
M!04%!04&!@<'"`<'!@D)"@H)"0P,#`P,#`P,#`P,#`P,#`$#`P,%!`4)!@8)
M#0L)"PT/#@X.#@\/#`P,#`P/#PP,#`P,#`\,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,_\``$0@`R`)H`P$1``(1`0,1`?_$`,,``0`#``,!`0$!````
M```````&!P@$!0D#`@H!`0$``@,!`0$`````````````!`4"`P8'`0@0``$$
M`0,#`@(&"`,%!04(`P(!`P0%!@`1!Q(3""$4,2)!T1655QA1,B.%M18W"6%Q
M0H$S)#5UD5)B0Q>A<E.#-/"Q@I)SD[-T)28V$0`"`0(#!`<&!0,#`P0#````
M`0(1`R$Q!$%1$@5A<8&1L<$&\*'1(C(3X4)2<A3Q8C22LC."XB.BPM)#)!46
M_]H`#`,!``(1`Q$`/P#T:X!\>^$<QXFQC)LJXOQ_(,AN7;-^UN9T0'I$AS[2
ME#UN.%NI+LB)ZZ`N/\JOCC^"^*?=[?U:`?E5\<?P7Q3[O;^K0#\JOCC^"^*?
M=[?U:`?E5\<?P7Q3[O;^K0#\JOCC^"^*?=[?U:`?E5\<?P7Q3[O;^K0#\JOC
MC^"^*?=[?U:`?E5\<?P7Q3[O;^K0%2YW@WA1QME.*83EW%U)%RS.FI;V&T$#
M%;*UDV8P![DM(@5T.3W28#8W`'Y@!4,D0515`^_'>`^$'+$RXK^/\$P[(;#'
MX=?/NH(U#L9Z-'M4>6&;C<EEHD[G8<]-MQ4=B1%VT!:?Y5?''\%\4^[V_JT!
M")_#GA]5Y[0<8S^,<4BYQE-;+M\?I#J'/^+AP2093C;Z-*QNTI#U"I]2=0KM
ML2;@5G7M^`%M%RN968'1SVL&OX6+9:VQB%P;T&ZL)/LXL!UA*_N=YR0J-(*"
MJ]9`*[$8(H&@_P`JOCC^"^*?=[?U:`?E5\<?P7Q3[O;^K0%"G&_MXM9/GV&O
M5?'3&2<7UDRYSNN=A=O[/@UYHU,>)TFT;<[#B]MQ&R(A/Y%1"3;0'ZF0O[?-
M=45MW94&"5L"TG6-<TDRK=CR&)%.X+5D,R*ZR+\089F"/G(`!:Z@4R%"'<"Q
M!X8\/W,R7CV-QIA]AF348)L^B@UBRW(,=T"<9=GDPV80Q>$%[2R"!'%]`ZE]
M-`33\JOCC^"^*?=[?U:`?E5\<?P7Q3[O;^K0#\JOCC^"^*?=[?U:`?E5\<?P
M7Q3[O;^K0#\JOCC^"^*?=[?U:`?E5\<?P7Q3[O;^K0#\JOCC^"^*?=[?U:`?
ME5\<?P7Q3[O;^K0#\JOCC^"^*?=[?U:`?E5\<?P7Q3[O;^K0#\JOCC^"^*?=
M[?U:`?E5\<?P7Q3[O;^K0#\JOCC^"^*?=[?U:`?E5\<?P7Q3[O;^K0#\JOCC
M^"^*?=[?U:`AV1\,^&6'38-;EV(\:8M8V8$[6P+<X$%Z0`KL1--R'`(T1?15
M%%T!^\:X5\-<S>E1\/PWC;*Y$*.Q+FL4Q09QLQY1.#'><&.X:B#JLN(!+Z$H
MEMOTKH"7?E5\<?P7Q3[O;^K0'3/>/'BC'O(>,2.-<$8R2QC.3*_'G&8HSGX[
M2[./-1E)'#`%]")!V3Z=`18.,/!QR/<2VZ3BDXN/2`B7\D95:K<&0X:M@S))
M'=FC(Q44$]E545/CH"PORJ^./X+XI]WM_5H!^57QQ_!?%/N]OZM`0H.'O"QR
M]R+%V\5XQ/)<0B?:&6XZ+M>LZKB=".>XG1D<[D=OI5"ZW!$=O7?0'&3BOPA6
MFI\C2@XK7'LBF?9V/WR2:WV4Z9N2>WBR.[VW7-P+Y`)2]%]/30'8EPIX;AE3
M>"'AG&X9P\/6UAI%!2U(4961N,)7.^J=H5<]`_53J^'KH"6_E5\<?P7Q3[O;
M^K0#\JOCC^"^*?=[?U:`?E5\<?P7Q3[O;^K0#\JOCC^"^*?=[?U:`?E5\<?P
M7Q3[O;^K0#\JOCC^"^*?=[?U:`?E5\<?P7Q3[O;^K0#\JOCC^"^*?=[?U:`?
ME5\<?P7Q3[O;^K0#\JOCC^"^*?=[?U:`?E5\<?P7Q3[O;^K0#\JOCC^"^*?=
M[?U:`?E5\<?P7Q3[O;^K0#\JOCC^"^*?=[?U:`?E5\<?P7Q3[O;^K0#\JOCC
M^"^*?=[?U:`@>4<4>$>$6#-3FF/<6XA:2(XRX];=R*ZOD'',S;%X6I+K9*"D
MV0H2)MN*I]"Z`[?'N"/$'+>__*F!\>9/[5F/(D_9*0YO;9EH11W#[!GTBZ@$
MH*OH6R[;[+H"2_E5\<?P7Q3[O;^K0'2%X]^)P9"WB1\;X$&5O0?M-K&":BI8
M%!1Q6O=#%ZNZK76*CU]/3U)MOOH"'L\>^"$B-.FL5_$;\.LE,0;*6W.JR:CR
MI7<]NPZ:/*@..]ESH$E12Z"V1>E=`67^57QQ_!?%/N]OZM`/RJ^./X+XI]WM
M_5H",!P7X?N6%_4MX+QV=KBC'NLHK!]DLBM84>ONS&D/J8#I3?J<1$V]=`?`
MN%?#8(%':'AO&PUF424A8U8J4%&+&21*",1'>YTO&I(HH(*J[^FV@.\=\;O%
MIBUB43W%F$,W<^.]+@4QQHXRWX\<@%YYMA5ZS!LG`0B1-D4AW^*:`[+\JOCC
M^"^*?=[?U:`?E5\<?P7Q3[O;^K0#\JOCC^"^*?=[?U:`?E5\<?P7Q3[O;^K0
M#\JOCC^"^*?=[?U:`?E5\<?P7Q3[O;^K0%.<_>/?".'<39/DV*\7X_C^0TSM
M8_57,&(#,B.Y]I11ZVW!V45V54]-`7'XN?T*P;]Y_P`3EZ`O_0#0#0#0#0#0
M#0#0'G9YD<#<G\U<T^-<W#*V^K\3Q"HY$J\VY#H)]3$ETQ9=2M5<)UEJ=,8>
M=0'`4GD:;4NUOT+UJB(!4'D'PWY26O)G.C_&E#DL+#<ENL,N^.Y-?:UQU#[U
M+2W06\655+;1'FF)TZ:RIF*-FCPA)3J5K?0$6LN(/+AC$.8H]QA&>9!RN4]3
MX_O\8S>'#QQ[%[`:1&Z<VY<\)#QUGV>\/:5IH74<D+WD.1UD!-?&WAWR4J.9
M^&\FY0P.\B8_Q\[RA6.WMI:T\D8=;?2HLFC9989MITA&4!DFA`.M&OE'?M['
MH"5\E>._*TGRRY<Y`XRP^?1XKG?$<G[+S(+.K8KO_5>%%FQ*.WD0?>>[48L6
M3VP<6.O3(7N[?*CJ`9@ROA+S(=XMPJGQ#!^4(]T]2W99%6V&74QLUF1C0UL1
MN7"::MVG.EZ?%<D,RCE$X+IR7/:[R!W`VQXT<.\K-\M<A<I<U0,TI9HNU,GC
MJ%8Y0U,K%"901XETVY55]G+C":30<-5)M$ZNDP)?H`SGY+\"^0GD5>\TU5=X
M\+@T!S$I&*\2YG*R/'VHQP(MG'O)`+`@R'WTDW,V*((;Q"VRRJH:`X;AJ!5&
M<^%_D/<Y-R]RG4X5(GGSK.Y.A5^`2K"O:?HF<K"OC5-A-ZI*L"KB1G''NT9F
MV(LHH]74@`7[XT>./DEPSY&.39+]@W@-KF&<6W*N2NVK<FKR.BEUE<UAS<:"
M;QNM28<D9`GNT)`V'2KI-FV.@/6C0#0#0#0#0#0#0#0#0#0#0#0#0#0#0'F;
MYV8QR'EO+WBJQQPSE51:4,C,3E\BT6-VMS#QYRWI_85\F5(A0Y+375(]%W7K
M`?VFR(B%H"AN3Z/G7BSEKF"#P;BF65D"0&&RW9E9BU^_77KS$"]LKZ"S>UL!
MV2V+LM]HFS:5QL)#@M*(-N/=`'<OYAY;P<,Y;M,C'FR#R;BX-L8/@]!CZVE?
M;X[90:-F(Z5FU7N1O?PY`RSE'&_XO=UPA94&D;`#L/'^=S=EODIPE>\H87GS
M7\I'RS3#D5[C5W'B1*N?*BR:%IVTFP&!,'([1BTX^2&72@%^T414#N.3N-\W
MQCR^Y33B7%LI=QCD[`ESFQA_8%@YB,SE3'69)8X$BQ]F4,!-SLRW4[J"4AL.
MZ2E^S4"EL@SSS>B<3X?+J5YAN<GO:BYDV,`,.MX;U+?0,8A"D>6ZL9V;*5RT
M!QZ/LRW!<-YP!)6V09`#7WC:]S9G//?)629UEO*=!@V,1L9G8=AM]12:>AMW
MK7&VPO@5;.K9=7VEJ1&#;3PH!"G2*M;[@9*\G<"M.9,^YRK>)O'+D/'<K@XA
MD.,XYER8M*HZF^.3+2WO;&5<R0;6<<QQE8<&.FZ&CKKW6HF`"!3^2>/WD,_*
MY7S![`\NM\*Y%>Y;J^.\2"GG.38EAD%95Q84U^`3/?AM6#D4VQ=>``'M=9D(
MN@1@;2\<^+>0J/R4AY9(7+;.3$C3:3FAS/L*C0@&765,>NAVV+Y3V.J7&DNL
M(V#;;Y&3*D3H#Z:`]6-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`>8GG#AG*V9
M>0/BHYQ''OJ>\H:#E.*[R3!H;&RK*&;D&/-P*DIDR*PXTPKT@";0R+=K='2'
MI1.H"C.5(O-_#O*/DBQP%B%]BN*A9X3-QUJLQ&=&;R")!HKIZTKH%_#IY1&;
M4UR.D='NXRA],;<6G%:,#MK3E3RF@8QS/:V]KR[4<A8G>_95!Q[6X4=C!G8L
M[.I1K+-JR:@O--O%%]X$HV"=D(;SCB,[1@!`.^\6K3FC-_(;B7,>4\5SCWN.
MX1R'BUME%_C=I!98_P#]E9>J(TB<_6P67#*"T.SA")&HJAIW>H=`?C/>,>2,
M!\HO(B/P[B>36&%YIQ\[R[3U14,QW&)?+U0CZ5L3WKD8HAD2D-BH=T4<E@R!
M$BMH&@*BS?F'S(I^,,0GXE>\IY#?VU1=7'0Y@EG&=K;6)64QE`EO%7..RR8E
MI,44<C-Q#[S@H\J1@!`-S^.\OFO.N:^6,IS7,.0J7C[&+*,.!8/>8\M/46L.
MWJ(SL@P<GUD>4?LYPN(""]N/ZJ_*J]0'G_Y/\>V7)U]Y+KPCXU\C8ADB86_C
M53?!B$^[email protected]&0P[[(K618OM`[/E359*/$C]!..AW'2-5,&P`K_+^$N?[&RY
MXR<,.R>ZPOF2YY?9X,J&:R<KT:5D&24\BN?=CFR+D`9XQ7'FG'Q;!`!7"(4+
M0&QN(<&\F8/GSCF:<O\`'LM^$O&5Q0SN2(=B_8TBQF9X_9_;-(;3,5]P604X
MJN*9D;LGJV7MH!ZVZ`:`:`:`:`:`H#RC_H5G/[L_B<30#Q<_H5@W[S_B<O0%
M_P"@&@&@&@&@&@&@&@,[<B<]0<`SV?C<U@%J,3QFJR')^AM79\U_)[=R@Q^N
MKA)YAD')$YEQ#<>/I3Y!V%#)QL"ML(\M8UA53XF7XW9-9/3Y3/H\LE5,.,Y!
MQV/-SF[PW''+1K[4<=,WW*G9](A/H*H3BJ#)`6@(?C/F);T6.3LQY6J6+*E9
MXVP;,0BXG""-(;G9$>4I8-DMG:(T32)0!V![B'U&C7[4R%5`L&/YH8!)M?9!
M@^9-4TC,&<'J<S?;I6*B=;/L!*$&'G;87$3LNMF(NM@XZIHVR#CJ$`@3?,>>
M6,'Y#R#$)>.WF2R(T7#&:+'*>'7A(D2\JE7S#3X3IMO'9-LRJ2;)MUMA62;4
M^MX'D[0'"RGRCQ#&N-N,N4F,/RK)L>Y5QYW)Z"+5-5@S(\!FB<R)Q983K&(V
M!)"9<+I`S^8>A/51Z@*EY`\NY?\`*G)-KQ_4R\<R/CS#\\M9-%EE3&F-.6F*
M5%3>,@Y(K;Q.V!Q;-DD$1<Z^ZG431LDV8'+@>5-I19;G,#D`&CJ,6RG+J.HB
M4=0B.6+=26/-5K*295PG9DD]<(T76TK+JN"2N1A;)"`F:>8&#_S:SAQ8-F0V
M+%_"QK)Y:LU"QZ.PL+V/CT8)RC:*X:'+F1E0HP/)VW@/Z'$`#[8AY04V=V'&
M%M05C\7".1<HL,")JT".W:PLBC4KU\UWABS9([email protected]%>8=`'VI"(AH*(J:`
MU;H!H!H!H!H!H!H!H!H!H!H!H!H!H!H"G\SYAH\,RU,<LA1F#44"Y-F-R:.F
MD.'(D_9]:Q'89;=<DR9LOJ!IH$W5&S1-S)L2`K'"_+/![JNENY:Q(Q&WC9+/
MH7Z]8=F^S`:&_DX]52+5]8+?L$GRXQ-A[@`3K0T15$"+0'1X7Y=5LN#>VO)6
M.AAU92XM09$LJG.=?$9W$_)H3[*M,0&W!&.F-N.=Q1V(2]>@MA4"P0\J>%7K
M-VI8O+E]]NT"F;DMXW>K%?G'"^T59CRO8=EX@B*CY=LBV;(2^!)N!V&:\^XI
MQWFMGC.5K)&+'K\><KVZJJN[6R>GY!.GPH[7MX5<ZRK3AQ0!LP?(NXI-N`VJ
MM*Z!],B\D>(\8Q#`<YL;RQDXYR=$>FX3(K:2UL'I;$>M>MWB*-$B.O,JW#8<
M=(70$A0"W3<2V`JG/O,;#Z7&,DR'!&6LHEXSCF7W4C';IBYH9;[N+TD+(.VT
MK]4XV@/09S+R$Z0*0.M$VAHIJ`$F;\F*>JRW-*+.&Z_%:[#+;(8;\L"LYS\J
M%31*64U(CBQ7*T;KGVN#9QT<[O6K8LB_U*H@=PUY7\(.WU7BW\QV3>165C'J
M'Z@Z&X1ROGR;5BD:CV)>S[<0EGR66?VQ"G[5H]^VZV9`=G1>0.'Y5)XZLL8,
M[C!^2[63CU)E'9DQE&V;K7;B*BM/L@A1Y,..[LZA?(Z@,D/<(A;`OK0#0#0#
M0#0#0#0#0#0#0#0#0#0#0#0#0%293S#CN)9;.QJT%6HF/44&^RZY7NG[-NZG
MNU=)&CQ6&7GI<BPEQGVFFFTZE5O9.HS`"`K;C[RJP;+:2`Y?F.*978Y#:8\U
M0&S:/18[[&36F,U/OYQUK"0"LY%82,A+;9<4U5I`(TV4"/8#Y>T-OC\O)>2:
M(./JJ/C&.9(T_!>G7Y$EW`M;"2R;42N!P$AMU#Y*YTJ)`G6O;7Y$`LEGR<X6
MD7[N,LY-8E;M6HTJ-KC]XC#LY55":8E+`1AY&T'J<-LR%L5$W"$"%5`Y&5<_
M83@F79+C>7RSA-TC..^T;K*Z\M[)^3D16B1@*%!JG1[;GV8X+1L//=1BX#@L
MD((Z!R,J\BN'\-Q?"\SO,I?7&>0JIV\P^SK:FUM4F5K$!+-V7VZ^)(<;:"&O
M>(G!%$!%5?@NP%8YSY;XC2U5E:80W%RQ^IH<BMY-!;#<X_/<=QTZDI#302J=
MP.E(]H+I$X8*O5'[8N-O$ZT!W-;Y,4C62Y+2YHS78A$QF3E#4ASOV,V1):H;
M&FK8[L(&JP69!R'K<`-@74?!PV&VFY".J8`=_'\IN"Y5_68PUF;XWMI)&&,!
MVEN&5BR"L':I&;`W(0A!/WC),=,HFUZ^E/\`6'4!VU#SOAN467'BX\;UGBO*
M!R8.(Y4K$J*+UG'KCN0BE&EQV'$%^N:=D-.HJB2-F/HO3U`79H!H!H!H!H!H
M"@/*/^A6<_NS^)Q-`/%S^A6#?O/^)R]`7_H!H!H!H!H!H!H!H"J\WX=PKD"U
M=LLEKTG,V=1]@Y)6DI"U80&9*3X7439`XT]"ECWH[S9(;9$?3\Q"0`1^#XU\
M+5SD5Z+AQ]^+).84AZTM'W)#Y6CEV+DPWI9E*)NR><F-*^I]J09O-]+A$2@=
M1(\3N`Y<*-7R\)D2H<.'#KHC+UW=.=J'`;L68T<%*<JHT#5O-:Z$7I5N0\VJ
M*#A"H':UGC3PM3UHT]?B3[-7[Y;%V"5Q;.MO/J,42[XN3"[P$D&/U-N=0%VP
M515130$CR+A;CK*LH+-+NHFOY,2U1?:<>WM(BI]AN2G:W9N++:;1(YS9!"B#
M\735=U)=`==.X`XGLL3P[!Y>-R3Q3`*V53XE3A;6C01($R"=8]&ZVY8FX'LW
M"8%'"+H;51#I30$>?\5^#)(7#;^)376\AC3X=ZV5_>=,QBT@1:N<V^GO]G$D
M1(,=ESJWZA:#?]5-`<MWQDX2DO6$B;B#]D[:NV;]E[ZXMY8OO7`1@FO."_,,
M2<<]E')#5.H#:;,%$P$D`YLCQTX?E3XMH]C$DK&+)CS?>)<6PN/RHEJ-VQ(E
M*,Q/<N-SVP?0WNLNH`]=@!!`^N-\"\>XC<8[8X]7/0(6+37KBKJCDR):%<O5
M+=`ED_(ENOONNLU3?LV44^D6B-%0E4%`"Z-`-`-`-`-`-`-`-`-`-`-`-`-`
M-`-`4AR-P?1<CWK]M8V$R"Q=4(8[DC4-XV'S:@SAMJB9%?!45F3`FBKC:JA"
M2.&AB6P[`0V%XD\91)TBQ>L\DLY5Q+;F9B4V<TX-\;%T>111L`2.(]#%D\Z^
M`L(TB]PVSZFB[>@(]?\`B'P^5*U7W.6Y+60/;U5<DH[6+'5QJHD7$N(T9%&0
M7%0[N:7S(J[FA)L;31`!SORV\,%@AXG99=86^*OWT2XE2Y]A7N$Y80X42*QL
M^D84:<!B$RH.-=#P*/<;<`E4E`L'(N(L%Y(RYO.UR:P=M(2T(]-5+B'&%<<L
M'K6N0@5AU=QDOF9;E\WHB_*B)H#AR_&_`)>(\:86<RZ;JN)XT^)B3XRFUDBW
M8U,ND>5]PF2[A>SG/`*JGQ+K]31%0")V'A]Q;:M6[,^RR)]J]K+6IM`]W&'N
MQ;G':[%I@[C%114ZVJC-(H[**@II\Y$J@=I?>*O'&4R[F9D5GD-J[?OVTJR4
MIC+'5(N(U='=>`HT=H@-K[)B.-**IT.-(7KN6X'Q?\3^.9=X[E,VXR29E$V1
M#G7.0'+C#(G3H%W7W\:4\+<4&A-N551$06@!M&VA;0.E2Z@/MAWC)B6#6^-N
MTEG-.CH,D?S63"E*V4B?D1T_V$S*D.,`PVHA$-TW-VE=D2220\Z3@DK@&E]`
M-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`4+R+P55\A9-9W4FYFU,;)J>CJ\B.O<
M5B>U(Q*Y/(,;L($A4<!MV%.?>)1-HA<0QWV1OI,")U'B1QY4.SG5R')[/[<L
MXMUE;,Z1!-JWL(&1S<M@R9;800%"CV]@](%&4;$T5&G1<9%&]`16;X.<966/
M-8O/S/-I=.S`JZM(SDJKZ3B5$.S@Q6W02L0'%%NU?)#,5,7$;=;('&Q)`)</
MB=@+U)745SD>29'%K<G_`)N8DV!UGN$LT*(:.MNQZYE6"18@[.,=MT1-T$<0
M'"%0)7E_`-#F.?'R+)R_):BZ+^7NF+7G6I%!,7=LI%;TC(KWW/E=MY1EN?S*
M:(ORB*(!T%UXM8)=8-QAQ^YD.20:3B;%Y^'XR_&?@^Y<K+&F^P7$DF["<$S&
M$J@)"(^J]2]2[;`1FU\-,"N9%M*L,XS-V3<P;JOF/(]4"J,Y!&J(EATH-4B(
MKC5'$%%V^7I)1V4R50.QM_$7`\@L;&SO,NRVRD6+MQ*V)^M91B5<V%3;.265
M8KFB%QB;107V5550293="$C$@/E*\/\`C^5DDK+OYNS"-D5A+BV%I:,RX`N2
M9D.[*_9D%O`5`(9)(*(V@`C8B""FV^@.XP3QHQOCRYQ+[`L7RQC$+VSS.-`D
MBTDA_)[2K.C<E],5J-%8:&"\_P!3;3"=U]\WS5'.M70-,:`:`:`:`:`:`H#R
MC_H5G/[L_B<30#Q<_H5@W[S_`(G+T!?^@&@&@&@&@&@&@&@&@&@,_P#D3R1=
M<98WA5I23XM<=]FE50V+LD8BJ42:+ZO"R4Z3#C@XB-H0DXZ@ILN^@,U8UY`<
MUY';56+Q[S&I47,;2NI<:Y(J*T;*-67GV"U9V%5<18TYQM!-7E=BR&GNAQ&7
MFU+<F#<`TGXX9EF7(.#RLMRS*:7)@E7-S65RTT'V8L?8UQ/K2ZR25)0^ZW':
M<^CI52^**FP&@M`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`=+D=]`Q;'[O)K1'
MUK,>@2+*Q]LT3[R,16R==5MH$4C)!%5013=?HT!5^.>0?%63.+&C9"=3-:C-
M39L"\BR*EZ-#D0G;%B8ZDT&4]N['8=,'A56UZ'!ZNILQ$#N*?FSBJ\EYI#A9
MU4-.\?OQV<I*7*;B@PW+A0K"/*$WR!#C.LV#"@^.[1*72)*J:`[N'R9QS8-N
MNPL]QZ2##EBT\06<5>DZAU6;!%_:>GMG$Z7?^XOZVV@)C'D1Y<=B7$?;E193
M8NQI+1(;;C9HA"8$*JA(2+NBI\=`?;0%%\^<;Y)R70X97XP=:U.QK,JK(I#E
MD\+")'@(]U]@G*^S;5U5<1!1QA1VWW_0H&=,:\1+J#?U5O91<7BT<RPKH7(V
M!BX=K5WU'64C4"'(<:=KH+35C'D`ZBN-LB#S#[HFB*C(M`:+\?N*/_27"7Z:
M?18_4Y#-M[F78R<>W-E^++N)\^`#CIQ8AD3#,Q`V4-A7=!51VT!>F@&@&@&@
M&@&@&@&@&@&@&@&@&@&@&@&@&@/D^^S&9<D27@CL,BIO/N$@``IZJI$NR(B?
MXZ`^3$Z%*;8>C2V)#,K?VSK3@F+G3OOT**JA;;+OMH#[`ZTX3H-N@X<<T;?`
M215`U$3021/@O22+LOT*BZ`^F@&@&@,_^1-GG-7C>%/8&%TY,?S2J8OFJ1B6
M\X548O\`NTD'"@V+S+.R)U."PJBO3MZJF@,TXY)\D;2VJJ67D><.8/E=K6T]
MCDQ52UESC5@Q1,O29S96-9']W639#CPH1L=3,AIH2'9XP:`TIXX,YJ[@\JWS
MO(<JM[F?<W,8:_*H0P'XT:!<3X\)QIE8<-SI?AHP6Y(J%LAC^LNX&@M`-`-`
M-`-`-`-`-`-`-`-`4!Y1_P!"LY_=G\3B:`>+G]"L&_>?\3EZ`O\`T`T`T`T!
M">2ZVSN>.L\J:6-)F7-GCUE%IXL.0,20Y+=BN`P+,@G6!:-7%3I-7!Z5]>I/
MCH#!D?%?*_#78MIA&+Y)]A1J6MCOXC<Y#66DUJ[9H;)JTLXARK*6TVQ(E.P1
M;9ZG4[K3SRL"A_M`.CQHO/.K'*;5VGM($K,)U?-R**^S17#E8J46,P'9E''>
MMV6E<.;&LC=B&\+`M_M6Q!PP!T"<A:><<.7*A-P)LAJ.Q<O-3I=;C;\>6^_9
MVBL(CS-NV]$:C0RK5C#[>29+[H'1<Z6S$#<N$RLBFX9B4W+ZTJ?+)=+`>RBH
M-UE\HMBY';*6PKL=$9-6W5(>IM.A=MQ]-M`2?0&1<R\D<TQKE3D?C"GXA7*;
M/%L>K[W!H3-RD:;DX/JTD[V@%$<8#V2&:NM&][A1;ZV6'D=3H`BF.^8,K**F
M3=U>%UEA5R\:L<BQJ4W:OMC)"B+&PL2,'X#;PB19$)1OV6Y(S^V[).H@`7CE
MW/&*XMS#QQPRLJ!(R3-WG$LFWI[,=ZO8<@6,J"8QS_:2"DNUSC2('H'HIJ*N
M,BX!>F@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@.BRBACY5C608Q+ER8$7(ZV5
M62IL-6TD--RV29,V5>;=;0Q0U4>H"3?XHOPT!B'*.!_'R;;W%;?<_P!G$SWC
MZ@@-6]E(NJ%BRIZ*!7RJ^`U(9&"T###*6SKW5T`XKD@3-Q4)E$`ATWQ+\;L.
MK0:R#F>3"/'VZJYC2,@+'75BA,@5]7'=F19E:K3T:3#Q411M]M6T[4E[]<$-
MD"P[#PXX=2]K8TW/)Z2\@B3XN+44J/CAO(R,JSM22J=^RAEL`P5U-ZRBN@2M
MNB!&@@":`V1B6/-8CBF,8HS93KEG&*F%4LV]FZCTZ4,)@&$?E.B((;KB!U&2
M"FY*J[)H"0Z`P!R)A_DR[SSRQ/XO:LW\3RS%:R+'MLAR2165E6XVT+<C^76X
M2S0[[X`X*)(A=;$C>0CHMN"V^!6>;X1Y&3*AUFMNLPI\ER3'J&O>J+"];=:A
MVU4Q#66W01V+"(4Z+)99>=EJ3;4@7$1Q''`ZV=`:-5C.K3D[@J9+P7D:D>QN
M!T9G>C>1Y5(71#EPRA2X[=DVU)1YY])+DHHQ.+V(Z"VA'U,@:^T`T`T`T`T`
MT`T`T`T`T`T`T`T`T`T`T`T!#>1,?E99@&<8M!9AR)V24%C5PV;`B"(3LN,X
MR"/D+;Q(WU&G4J-DNW^E?AH#"2>,7/&/R0O^/Y^&X3-&EK*F;BM1:V+$&5)K
M:&RK7KA9#=8P839CLUD#5L&B%J*TO>(U_9@1W'?&_P`NJ-K))P<BQJ^US"7`
MFYX-+DTB(=PK%)C50;C$AZE?&'.0Z>6^<H62)T70:/JW)QH";!PCY9PY4F-!
MY/>8KP9NC@S0RV4\KLFRL[.43LR+)HR5Q2CS8C;(1Y$88Y1"5LP%\@T!N3"8
MN1P<,Q*%F+T63ET.E@,93(@N//17+)N.V,LV')&SIMJZA*).?,J;*7KOH"3Z
M`P3R+Y29S@'.'*''0U$+)ZZJQN#.X\JL?I[*[G!->9:*4Y?E7.NOPVXRO(^7
M3$('(ZAT.@_LVZ!_EMY,Y8WB.>W2Y5B.'.T>#X+DF/3+^NDM$=CDT6P(X+T6
M1.AD1R)<9EMKJ-E&P<4B4NGJ4"\8O(^5WV6\01\6R?"[W',QB2)&85]:P_92
M&FJZ";L^9#LVK!ID6@F28$9`.,9?MNI2]4%`-#:`:`:`:`:`:`:`:`:`:`:`
MH#RC_H5G/[L_B<30#Q<_H5@W[S_B<O0%_P"@&@&@&@&@,!YAF?.+7-O.5!4Y
M+FB8I384W?X*Q14,`6(MBPC3+-43UG42Q?<GR>LFGFW'$(">`A;6.AM@17/.
M1>3,<D<I8_&YDY#D7&/U55555I&P8'F'LG(7161"=CT+["0`5U@YBKWC/M/B
MP#:(@N`:&+,\PNN8>)EQ2UO)^&38UA"Y%I953)JV6$;AV"L6!,3JD#1"FPQ9
M(AFHHJ3(BT0.DXH&H-`-`5M<\.<59#>VN3W?'U%9Y%>-1&;6\D0FCE/!!,3C
M]3JCU(HJV"=2+N2`V)*HM@@@4YS'AV%X6_@][%P7'6L/RK*Z?$N7&!K8[:OU
M%JV-55?M0$2;%FT"L$D'9%:!$+Y6PZ0-&,8GC48X;L>CA-.U]F_=0G!:%":L
M93+T=^6*[;HZXU(=`B^*B9)].@)!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH##W(?B-:YUR[D?(XYE7UM);E0S7\+:@R6X]M84LYB0R];&W+%5-EECMM/1T
M;-55HC1?;"CH$=;\&[`*VT"=SADN3Y3<4M%"=SJ[;CG8,6M=`MZB7:HY$;C/
M2"<KK=Z*RW)?<0`,NZ3_`$M]`%D6_&F.\?<B<3<CYCS$N,QJ"4N&XEC4T8#%
M2]$.'.CUD!EZ4RY(;DNM$A2#20B2'0%!`=F@$#7>@&@&@,W^4#C>.8'2\O#U
M#*X)R6NS9UT-NI*EI3K[\=_IZJB;+V3Z20?T:`L8^9N'VU07.5\.;)414$KV
MO1=E^"^K_P!.A\<DC\#S7PT?ZG+>%GNJCZ7U<OJB[*G^_P#T^FLN%TK051-:
M;(:#(F%E8_>5][%']:37R6I3:;J0^I-$2?$53_8OZ-8GT[C0#0#0#0#0$>R;
M*\=PVL2WR:U9J8#DEB%'<=ZB-^5*<1J/'8:!"<===,D$&VQ(B7T%%T!7<'R"
MX?L;(J>-F;268H7_``;T2:P9.`$IQ6`[S`(3VT"2B-#NXJLO"@]31H('TJ^?
M^'+DJ(*_/:]QS)9E?`I671>8<>?MVG'JT>AYL"!)H-&4<C1!>Z5[:ELN@)WC
M>8XSEZWR8U;M7"8Q;RJ&]<80^B/90E09,53(4$C:)>DT%5Z2^5?5%30$FT`T
M`T`T`T`T`T!YW<D8-SG9\Q\U+22N3:_",OQFL2AR6AN&&RJ[2)*BJS'JHAV3
M#11I21C60J"Q(9ZG_P!L@2!(@(;R%QGY/V=-D[N-3,TC65O7TK$N&MR2QZBQ
MA5LB)+CT;8VH*_`D.-LFCQHW(;>-J4Z<A6WV4`T$=3S-=<XX=DHTV04&,0G:
MIB:$FU9*O:@0H>31KAIZ/'D=+Y2I3M<\T9M*3@]D]FU8,6P-@Z`:`XR0X:27
MYJ164F2F6X\J6@#W7&62<)MLSVW(05TU%%79%(MOBN@,^<]D&),<<\@M!'8Q
M_&\TJ(G(L(VF^Q,H[I'*)"D(H^HP9,^/+15_4%DOHWT!H1J)%84%9C-,JVA"
MVH`(]*&J*2)LGINHIO\`Y)H#D:`:`:`:`:`:`:`:`:`:`:`H#RC_`*%9S^[/
MXG$T`\7/Z%8-^\_XG+T!?^@&@&@&@&@&@&@()R%C&3Y131F,.SR;Q[D57,"?
M6V\:-'G17S;;<;]M8PY`_MXSB.?.#;C3FZ"0.@0HN@*FJ.=;/#[*#B?D1CT;
MC6ZFNC%I>0H;QR,*NGB+H;!BR=$2KY#J_"+.0"55Z&79&W5H"ZLIS?$L*CL2
M<IR"'3)+)0KXKQ[R9;@INK46,'4](<_0#0$2_0FL)W(VUQ2:2WO`RA"4W2*;
M?04EEGD1*KZ>ZM,+XQN\I&IAO38SMFX%(S.%AM35J.T82)Z.ET](B[##==O7
M;UU37/46CA-14JU=,%@NUTPZJEI#DFJE!RX:45:-XOVZ:&,N9.><]Y4XQR['
M["PP_$</RBF?[EF#$EYV$A@CD66W9O3&6D5AQ!=%Q8R>J"J(FWK:?>>XXQ\X
MDY4C#XD)XN\NN3.7,7AW=#S+/]]&8C!DL2%549-1)[K(N.QD==J3`^VJKZ@2
M^FRJOJFD[DDS#5:_46I4:2W8;.\DM!SSSU+CR)$KF"U?)FRLHHMK4XZ(JW&F
MOQV]^FI%=T`$^GXZZ[EG*K.ITT;DZ\3KD^EHD0UMQQ3=,B;UWD;S=5D))E59
M?CNG="]J&7$V]=^C[-.M5%]?IW_RU)GZ>LOZ927<_)&U:V6U(LJA\P<DB$+>
M8<>Q+6,'J]9X[.5F2?\`@W73A1M%1?I*<G_L]8%WT]=C]$D_=\3='6Q>:H:#
MPWR+XGS.3&K6<B_ER]E$C3%!D+:UK[KQ;;,QW'?^'DGZIZ1W7-5%_1WK'UQ:
M\._(DPNQGDR\=1C8-`-`4ESK-R^#C^)NXT-[]C.996M\CO8Q'.5<-8\0O>X*
M(TP+DA=WT8%U8P$\+*N$UL2(2`9%F3.;:SEQLL:<Y2L>('H[`RKFRBVSLP5F
M1,@$(R5S\<#1KN_9Z'*!?<L=ME3;W?DN@!$I=WY8UT+CFSPAC/+B/04V*W&:
MU&0P)R2+'((=1;3LCIV?<M-N*Q/5B+'1Q[]BU*=;]L8BCHB!LKQND\FS,>SN
M7RT-FQE<C-K5QJ#.:?:C1(+@LN1HE<KJ(#L6.AJT#K>Z.=*FJJ2KH#16@&@&
M@&@&@&@&@&@.KNJ2FR2IL*'(JF'>T=LP4:TI[!AN3%DLFFQ-O,NH0&*_2BIM
MH#+=SB69>.-9)R/C'*HMWQ35BBV'#^<VO8;@-D2"(X]D,LC.+ZJ@MQ)BN,*O
M2VTY&'7QM)5>1]2;=$1`O.##;]MV%C5>N&74=^MA6L/D<DI)L&5<$VS#!*<#
M<E255YT6]^IEDUW5N00HI:I]9SF%E?\`CB[E4W\OTX9_-EAT5+/3<KG=?SR4
M*-+'ZL<OE_H?G.BY7RK'KUMOE"T@WC\1QRE@4B-TE<U-;%581'(R%8(T1(B.
M"4T]T5=MEVVY=^JM1*XG1*%<4LZ;<7^!?R].6?M22;<VG1[GL=/C4PY<0Z[*
M,:E7ZXRWFMS.K7'(\2\?[DZ2X;:HL9^?+[[H.*N[9*9+TK\?AKLU/BHZX'CM
MVY>C=<+DFFG1]%.@JSQ@RS.<IP&3&SBC3'Y>%SAQ:)">%U)II6QF1-Z61JB$
M9*:)N(BFXJOTIK*XDG@?=?;A"Y\CK7'HQW%KXO\`\NG?];N_XI*UZ5RG_$M_
MM)L/ICU+P.=)HJ29)"9+IH,J8VJJW*>CM&X*JFR[&0JJ>G^.ID[,)_5%/K1F
MI-9,FU%FO(&+&)XSR'DE0@+L$8YYV40`^EMN%:),C-BO_@:%4^A474"]R?37
M/RTZL/P]QNCJKD=M2_L3\M\WJ":CYUBT+,(**B':X^J5U@`)NB;PY;IQGS7T
M4B21'%/7I#X)JGU/IZ<<;4J]#P?P\"5#6I_4J&O^/N6<!Y0C/NX??MS)L(`.
MTH9(.1+*&AJJ"LB%($'@$E14$^GH/9>@B1-]4-VS.U+AFFGTDR,U)53+'UJ,
MAH"I>5<1CYLN$5\',(F)YKC&0,Y5A1RF6YP/R*]EZ/(!Z`3T=R0R4>6X!]IU
ML@4A-#%430%"9#XZG;9TO-]WS%5QK:N:8BR'@JD:Q\?;MVT"7W8CMH;2.[VK
M@-/=:/LD"CW31U\7`(=DWAO0Y#6XPF6\O10L,&HZ3#,9NHM<W"]@F/UEE'K'
MVQ<L'?\`CVIEDDY#,B'J9:$&@'N*8&F.$^,*CA>KOL&@9*Q<_:MU-R.##-H(
M\UJ/*1ALUD(CSBOFK@]3C_2'69^HHJ^H%W:`:`:`:`:`:`:`:`:`@G(6`5_(
ME-&JY=U>8U.JY@65!D>/6#M?/@3FVW&@?`@56G4072$FGVW&3150VR30%+AR
M7R;PTJ0^=JQ,QP9A-F.=\5@N($<$785R.C95UV&J)ZG*B]V-\3<&*.PZ`L&P
MYYXR9997'L@;Y`F2V6GX<#$E"WZVWQ$V2<DL'[2.+@%U@4AYL3'U%5U$U6OL
M:55NS2\>[,DZ?1WM0Z6XM^'?D51FG-?+@X[>6V%X31U$NMAO3:JON7WK:;,5
MH.M(KD2$<-EATME%%"8\/4J>NWKJAEZKL.XHQBZ-T;>%.FF/D6__`/.7U;E)
MR7$DZ+.KW5P\S$_*'*F;<@\;Y;&S;E&P=P'(J*3]LQ*VN@M1O92&"ZG&DC0R
MFD(@?4B=XE]$7]9$75_]V39YV^:7Y3X4DG7+^I4G!?/=_P`TX7'O(V?\@K-I
M1CUF0S_YEO(T9ZS&.VY)]L@ST(A130MR`?0D_P`=OLY2B\SYK;^HLSHYYXKJ
M)WCF49P_$DOO\F9X\ZS;VK39'EU\2(VQ8R&FQV6=LJ"`(GK]":[OEW+]/=TT
M)2@FVL25'47.%.NQ>!/:_DSE2G("I^4<EB*BHKB2Y3=NAHBJJHJ6[4U$WWV^
M79?\=;Y\DTLLHM=3?G4V+5W%M+.H?*/EZE0&[5JAS>*TOZLMARKG.HOQ0YD1
M7(X[?1TP]0+WIV/_`-<WV_A\#='7/:B_<2\MN/+8FXF9PYW'4Y?E.;8H,FH(
MDW4B&QC]2--BB?KRVXZ?HU3:GE6HL8N-5O6/XDJ&IA/::?A3H5E$C6%=,8L(
M$QL7HDV,X+K+K9)N)MN`JB2*GP5%U7&\Y6@&@*2YUQS*\DQ_$V\:JY&2U]3E
ME;99OAL2<W`?NJ5@7A>A@Z^XPR>SQM/$R\ZVV\+9-&72:HH&19G!_*L?EQO,
M,2XZFX_QP<=AN9B2V]>-J9R8F0,.@KPV+L<HK13XO?B%Z$@,]IY1B`VZ!$I?
M`7DDW"XYG8-63L*FX%38K(?I)-S"=:LLKQZHMG)LMWMS'P9B6<MR'#DJVJN2
M!5QYUI%:`C`V5XW85GN$X]G<?DKNR<JOLVM;J1<F^R^W.;FBRXCL;M.&34<3
MZP9:<0";;$14?I4#E^4?]"LY_=G\3B:`>+G]"L&_>?\`$Y>@+_T`T`T`T`T`
MT`T!U=W>4V-5%C?Y#:Q*.CJ&#DVEO/>"/&[email protected]*(B*?I5=`E4\ZK3S,
MPKG#,;'AS$'1H\4MX[D8<JOJUB1_,:$A([#KX<\7&6$440MYK!DZ/4(L"J=:
M0>?2U?+],KT+=4\W^GK73_4Z'1<BE)IWZQ3R6U]#W&7N7.)N>^(DQ[\H%;+O
MJZ=(A?S107%A7NK"B5#D=R/%AV-M(;F(Q)%M6G&%=<;$-T:%OJVUQ&FYA8UC
M?\Z6*5$\=M=D53#9@NTM[^BO:6G\..#>*PV=+QQVXLW]6294VMKYDZN=IYLN
M,T],J7S:==BNN`A&P;C!N-D39*HJH$0JJ?*JIZZYR22;2=5OWE[%MI-JAB/,
M(=+@C^>T&1HRUBF/1WK<$E`CC"8_,!UX1)O8A[3"MOQD!=UZ&D54^9-_1N3Z
MO^3IXO\`,L'UKXJC/%O5'+'I->^!83^:/6\UWE"\66O#G',!G&L'&R@0\XM4
MNJ^I.))=[;MH81F00A;+M@0L(8HX7RMIU&J#MJVE5YE-J(WKKXITP5.XMO&/
M^7S?^M77\4E:]$Y%_A6^W_<R5;^A=2)%JW,QH#XR(\>6P[&E,-R8SXJ#\=T4
M,#%?11(2145%_0NOC2:HSZ6#@7+')'%[@CC-V=[CX(*%@N0/O2("`&R($*2O
M<?@>B((HWUL`GK[<EU2:SD=J[5V_EE[N[9V=Q*M:N4<)8H]">*^;<,Y89?C5
M+KM1E-:TCUUAUCTMSH[:J@]YOI4@D,*JHB.M$0[KT'T.(0#RFITMS3RX9JG@
M^HLK=R,U5%PZCF9C3G?G/+>,N8L*QB'DN*T^)Y!B-Q.="X(`6-:Q^KVTNW=<
M=:-BK1!^=^.CAM*#A.M$U\X`0.\\G+2EX2Q2\O\`E[!,&Y;?NEAV-79OPY%?
M.<.VL(4/MN*_&[=9,:K9#S,Q1%QUEOJ;'NEV]`1VK\F^7;.XQRJ8M,65^TL<
M:DY1CS[K,?((A6UC-@7&/4T$D5)LFF0(;TE'>AP&WD4E4B$-`:8P_EBUROGF
M]Q2JR3%<LXV_E9;;'IN+6+%E(BR6UJU,+OM[K&<?&=W8:`1`\QU&O2H)U@:1
MT`T`T`T`T`T`T`T!E3R4\K\(\>ZY*X@'*^2+*.C]'@\=Y&R!HU(1EV#J(?MH
MZD*H*]*FXJ*C8ETF02=-I9ZB5(]KW$[0\ONZR?#!8;7L1Y3XOY?Y=:<HCF/-
M9LY10245J($2*?3C'5Z=^IAB3GR**JC_`*'(,=MG#Z$:./ZF]+7=3ID]/-\4
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MRQ[`X\QU@O?,M`WLC;<=TU4"0Q<525>@;[@3.=6EMRXDLU\,-G>:"Q)SNU,E
MWH)ON7%T7;--B'>SE+L2?0J?3KTGE/\`B6_VDB/TKJ7@2?5B?1H!H#X&Q_Q4
M*PCOR*ZUK#5VJN8+SD6;$<)-E)B0R0N-J2>A;+L2?*6XJJ:TW]/;OQX9JJ,X
M3<'5,V'Q+Y3OPWX6+\R26&V7B1BLY-00CQR)=A!JW:!!;CF2_"0""R2^A`S\
MO<Y#F/)Y:>LX8P]ZZ_B65C5*>#P9N<S!L"<<)``$4C,EV1$3U555?AMJE)9B
M+,,$L>>N3L!YIX7RFHK:"LI+K%['DO9^2\^#<PV]H$"5$6.^++R&Y&FQWVUZ
MNM4=<:7H<`@;_C/SB/'V*<8T]GC])_Z7SKS(,#RZ':SX\7[5O7[\J^04-R-,
M=-VD)^&^(/J;;_><#K0F4<<`M+(?'_*\CN0>=J,?K&X/*C^?8[DL'(+%I^O:
MZJ]%)VH"L").=FMLR1>:?=Z&U-"!PS)2`"P\/XSR>)S9>\NW%34XN>0XY]D9
M#75>06%X%G,%*U8TGLS:Z"W!]H,5]C_A_20)@X\*&`B(&AM`-`-`-`-`-`-`
M-`-`5_R9RC@W$&*RLQY`OF:*FCDC+'7N<B7((2((T2."*X^Z:"2H`(J[(1+L
M(DJ90A*;X8JK9LM6I79*,%5O8>9$;SBB<S<@/XCD:SN*>.)R@UBRLSTCOV4A
M7"1&;N:QTE&[J=';:CN]LB4VG774)L2@^I=%S#2Z;[EBC7YJ8RCU=&][#JM)
MR&-EJ6HQ\$_[O:FS=6&<[^,_)<M:)SQ5R*FX@;6S8M<RH7)LVOIIDB`^Q)A.
M,UT.))8;-'6MW2;%ONILCG7KS_0<SLJO\M.>%$Z)R5:IXMI]6=-A8:SE]UT_
MC-0QJU5I898)-=>\V]6%9'6UYW+,:/<%&:6U8A.&]&"2H)WA8<<!HS!#W02(
M!54V511?35'*E7PY;"WC6BKF8MRQ@./+;-ZA(,F;!H63OZ"LKV3D2G:R8CKS
M<>.P"*I$V^T_':;#_0#?Z=>B<EU7\G31;S7ROL_"AXQZKY9_%U[X<(W/F6['
M/WF:L5Y8XQPMJ!`I\57$8>:3DM9X)(AL0XTN?(*.Z;I.R&Q#MC'4GD;38%3M
MHBGU"ERXME+<T]RYBW6F&W9[8%TXH8N5DLP)#`[JZ(#%=T5%M)2HJ*FO2>4_
MXEO]I+C]*ZEX$EU8GT:`:`[G#<IRWC:<Y8\>WI8Z4AU7["D-OW%/--54C65`
M4@'J-5^9UDFGEV1.[T^FJS6<JLZG&E);UY[R1:U,H=*/07B#R(QODM]C&[>,
MF(<@*V1ICK[R.QYZ-BIN.5DI1;]P(BBD8*(N@B*I!T;&7(:S07=+*DUAL>QE
MG:O1N+`T/J$;3'G,^2<R4'/''`\>0[[+:&9C%J,W"(L9R'4C8BZGMYLNV*.]
M&,5W1MUAYQDFQZ7&7.L^VX!4,KD[DI.'*7&LBL>6*KG"GR%U^TETF'SYSXQ)
MU]<-5EC8QJR!8M'!]M7.HC#1=)JC(F0M.`ZH''R[(?)2!F4=S#%S6\PE[DB+
M(9<DU=D+KM,25K$UA1>KH;K#@NA(=:1UO[-)MPT[HDVTJ@:;Q>[RV[Y[G3ZQ
M[)WN+IV&NE-BW=;95,:#=@]6.Q&V(]E60^ONQ9+Q*33ID#@/-O[$+8-`<_RC
M_H5G/[L_B<30#Q<_H5@W[S_B<O0%FX=R%AO(#$R5AUZS>1H!-H^^R#@"HO"I
M,NMJX`=QIP450<#<#V7I)=M`22ML8MO7P[."3A0Y[0OQB=:<8<4#3=.IIX0<
M!?TH0HJ?2F@(\]GV(QZG([U^Z;9J\2FO5N027&W16/+84!)GH4.LR)7`0$!"
MZU(>CJZDT!(*JTK[NLKKJIE!.J[>*S-K9K7J#T>0".-."J[>A"2*F@.?H!H"
M/97E6/8/C=SEV5VC-+CN/Q3F6MF^JH#;0?H1-R(B781$44B)4$44E1-?4FW1
M'V,7)I+%L_GT\EO)_+/(?(#;ZI6/\95CPN8O@Y$**1-JO1.L>A5%R26^Z#NH
M,I\H;EUNN=1H.7*RE.>,O#\3O>4<ECIDKES&?^W\>GN,ONM`\!-N#U`6WTJB
MHJ+NBHJ>J*B^J*GPU93A&<7&2JGFB]G!33C)53/13QS\I5GN5_'O*UD`6;QM
M0\2S-[J1)I%L#<2P-=T&0J^C;R["[Z`6SW2KWC?JOT=+1MZC2JMK-QVP_P"W
MPZB*V[3I+Z=C\GY/;D\<^\M\O\C+&WY%CTS;U6M7=3$IF&XR@3-;'DRJ^NBQ
MDD54IAU^P-(DU77'#!&3=!2C(B.#S4+.DC&#EC5*O71-M_,G2/S1IOI]6172
MNZEN5,*/#JQ263Q>$J[JY'QG+F&7<185R+D#%ICN6U`C5Y+:S&6VYQP[@(Y.
MRBB.Q&FFBBSC;0FR`@9`'T$W$^<K'E=^&FUDK46G">5,DU6F-76JV[:K!'/>
MI=%+6<O5YQ^>WCCM7YMW=LH5)<\!X1>P:B#-62'V.<AYJ6RW"!UUZ5**6X3J
M+&)LAZW'$%OH1L1,D$4]-NP4VCR^.LG%MK;U]6\F6)M`Q5266AZ6V;>Y!L=U
M781LY*(FZ^OPUZ+R+_"M]O\`N9/M_2NI$FU;F0T`T`T!\]I#,ROM*Z?)IKNF
M?]U27T$T:EPG^E1[C)JA)\PDH&)(H&"D#@D!$*Z-1IH:B'!-57MD9PN.#JC6
MV)^6629^K/$&%4$&T\BTC=VW<=7IQVJJ]P!<BF[.H[V]W!08(%WS=7H0D8_X
MI.#UVC>EN.#=?;;N9<6;JN1J:[P##Y6&XW6U=QE%GG>0L^X>M\QN30I4J3-=
M[\E6FQ^2,PI[(U':1&VP$`%%Z=UAFTEP083<V19-PV`L9;#,:5/%L4>=9CDZ
M;+1N(G40MD\XHBJ["IDJ?K+N!RM`-`-`82Q?S-)B-9KR!@=BMA7ND_9P\8",
M^W55XLQY'O'GYD]IJ?%=9E-O1Y5>3R/AU;--N#VU`Y-;YU<?!41W[?%<ID3?
ML>%8+)AQ*QAB=)F!3FD.&R];D[WMKR.J`:[+\X@9F@H0$NR+R:&@XASCDUNJ
M2WDP+HJS`:.%&>=E6C;T!BS81(HN$3CS<1QQTP$P0D:+8@WW0"[.(>0@Y3X\
MQO.0KBK4NXR&3:.,O,/$'RE)ANLNNHY%?5.Y'<545QH@<Z40DT!96@&@,L^5
MODA7^/>"H_`!BRY$RD7HN#4CVY-"X`HCL^4(JA*Q&ZQ4A145PE%M"'J4PDZ7
M32U$^%=KW$[E^AGK+JA'+:]R/Y\KV]N\IN[7)LFM9%[D5[(*7<W,LD)^2^2(
MBD2HB(B(B((B*(("B`""(HB=A9LQM148K`](TVFAIX*$%1(ZK6TWE^<&<^W_
M``U9+"D!)R#`;)Y"M,<1S<X1F>[LRO0_E$EW4G&MQ%Q?7<352+B?5/I*',HN
M]9I&\NZ?0^G<R+<MN#XH8[UYKI\>O$V'0\"8QG,;(LMI<\^V\=S>RLKZ@M(#
M\]LFI5O+F+)D.`$P&O<18DZ1`;$FD3HV&0V?1V]>47M=<T\E;G#AE!*+32_*
MEAE6C:4GTY/:5T=#&?%)2P;;VYMNNW-)N/BCN+3B:TP;AFGCS[T\NMN->U..
M80.`+E4Q$;AV,=EDW'E%LHX')&."]'=$``4$01-_+^9Q6MXJ<,9X/M=4WVX5
MSIF5G/.4/4<NE;K6</FC_P!*R76JX$>!&U03!!5%%$`QV_5^*;*GT:[D\5(3
MB_\`RZ=_UN[_`(I*UZ;RG_$M_M+J'TQZEX$CU8GT:`:`:`X5C+KX,"9,M9#$
M2LC,FY/DRB$&`91%ZR<(]A043X[^FL9-)-O(^I5R)%P=R)<\QV&,<2<D7-G2
M>-]I(.-A\"0V4>;DKB(U[2FM9#B]YBH?V<]NTHB<CY([ABR;4=[BN9:'AK>M
MQI;;]G39%[/Z%K8NU^63Q/8:#!A5D*'6UL-BOKJ]AN-`@1FQ:989:%`;::;!
M$$!`41!%$V1/1-4Y*.5H!H!H!H!H"@\3\F>&LJ@0K,LQ@8K"N9:P\8>R27$K
M/M=Q#1I4@(\_NZ8.*C;C7HZV:H+C8$J(H'?U_/?#4Z",Q_D_$ZEX*R/;V%9.
MOJL),.'*5A&GI(MRG!`"*4R*'U*"JX'22]8[@?:RYGPBHPW-\\LY;L+',!G.
MU]U-<[2";@=A6S9<[O:5MY)+:@X9B*(6YJ"(JH!,,.S''<]QVMRG%K)FTJ+-
MI#;=:,")IS9.Y'?$2+MO-%N#C9?,!(HDB*F@)/H!H"L>7^6<3X4P.WS[,'S2
MOKD%J#6Q^A9=A-=1>Q#B@9"A..*B_%4010C)1`2),[=N5R2C%5;-MFS.]-0@
MJMG\[W-',^:<[9K(S/,Y"-HTAQ\;QR.9%"J(1$B^WCH2#U$72BNNJB$Z2;J@
M@(-AUVCT4=/'?+:_;8>B\LY7#10PQF\WY+H*C<;;=;-IT!<:<%0<;-$42%4V
M5%1?145-3&JEDTFJ,V_XZ^4;V-%"P/E.S<E8\9MQL:S&1\QUR;(`1[!SXDQZ
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MB<6VGGU'UQ0!;K)8`*``75T(`*;(B):2D1$1->F<I_Q+?[2TC]*ZEX$EU8GT
M:`:`:`X\F,W*%I#)QIR.\W)B2F'#9?8?9-'&GF7FU$VW&S%"$Q5"%4W1=:[M
MJ-V+C-53,HR<75&A^.O)_D+F2P#@+$;*#5\A0D>9RKFYX65B,0(XMJ\-=#4%
M:DWB`Y\S"#[=I$]R?I_PFN#U^C_CW&HNL=_3N?2BXLW>...9O+C_``+'^-<6
M@8GC@R3AQ#>D3+*>^<N?/FRG"?ESILESYWGY#IDXX:_$E]$0=D2`;B::`:`:
M`H#RC_H5G/[L_B<30'Y\7S!O@?"''"0`!+0C,EV1$2SEJJJJ_#;0&2R\3:NR
MR+#Z)C.,=RRHR!;.^.;7P8;#=&#D>""V5!7%9N^U=FRXQND]"'V[3Q=01@W5
M=`<N9X!PFF&8!<M5D:=<5T/'W'9.--&[8Q8#%(7M#0K(3<'IH%<Z0)"#N.&"
MBHH6@+HN/%FUR+A>WXAON2QF#D-NU/R*V9JGXT>PB-US,#VDB,%GWEW5D'^L
M)0_M1%=NE%$@+EX-X^'C'CBFQ-O(H&6M,./S&\E@0&ZX9WO'%?.2ZTR^^T3C
MIF1F32@WNNS;;;:"`@6[H!H#Q`\_^?I.=YXYP]CLPAPKCN2G\QDT7R65^*;F
M)[*O4W`1>VB+M^W5WJ'=ILM7_*-)_P#;+L^)U_ISER_R)K]OF_)=IY[:OSKA
MH#\F`.`;;@(XVXBB8$FZ$B^BHJ+\477QI-49\:35&;J\<_*-ZF.OX_Y3LW)-
M2X79Q_/9KW4<527]G%LG#]5;]>D'R55'T1WT_::\E]6>C/M5U.D7RYR@MG3'
MHZ"(T[.>,=_Z>OHZ=FW>>B5I60+VJL:>R8&95W,1Z'81E7Y78\AM6W`54^@A
M)4]->:0FX24E@TZF<X*<7%XIJABVO;FPEGT5JZ3]SC,QVJM7S%`-XV-E:DJ"
M>@I)8)N0*)\!<1->HZ34+46HW%M7OVKL9X%S?0/0ZJ=EY)X=3R]Q&,8_Y?-_
MZU=?Q25KT_D7^%;[?]S-UOZ%U(D6K<S&@&@&@*GO<LN<CMIN%<<O-A.@.(QE
MF;&`O1*553=6&@+Y9$Q4^#>_2UNA._Z0.'<O2G)PM9K.6R/QET;-NXVQBDJR
M[M_X$RP['0XX;J9>!R7*G)*&>MQ7Y'*(I4J19$*B\_.=)>M])(*33Z*2=31$
M`]"=/3A>Y?;N67:[:[>+?[=1]C>E&7$>QW&.?UO)N$4695K?MOM-H@LZQ31P
MX,]@E9F0W"'T4F7@(-T]"VZA^5477!W;<K<W"6:="YC)2543W6L^C0#0'Y-3
M0"5L4(T1>@27I15^A%5$7;_LT!YT4')7C;93L<S&ZX_K.*H'&\:WNLKQ]:^,
MB5\YX:QJ/+F5T6M=)YJ1$D1I<.<V8_L^I"Z5`P$"TK?+/$*-)AUSV&X1)@')
ML85U*?QD`C0@IH%I-?ZB*N5LE!O&WU$.I-VV4<#J%&^H#X.\R^'U?0U^&1<?
MJG*.YLXKD'!8^$S&F7YK]Y%QI'AKW:UH"=9GR6FC1!5U/H%?30$AP[R+\<,>
MQBI&CEU^'Q;8Z]T<<H:2:316MXM>K,)D($!!D3'5M(A*RV*O*#S;A`@$A:`T
MEC61TF8XYC^78U8!;8YE-;$MZ"U:0A"3"G,C(CO"AH)(CC9B2(J(OKZIH#L9
MTV)6PIEC826X<"O8<DS9;Q(+;3+0J;CADOHB"**JKH#^9WG;ERQYQY2R;D28
M3K==/<2'B-<[U(L.EBD20F>@E7H,T(GG1^'=<<V]-M=?R_2_8M*N;Q?P[#T?
MDV@6EL*J^:6+^'9\2H]3RV&@&@+BX8YIR7AF]617=5GB5H^CF58GN*)(^5`]
MS%(E1&I(BB>JJ@N(B`Y\`-OD_4WI:US6''&D;R6#W]$OCL(]RTT^*&>U;_QZ
M>Q[&O7O"\TQCD;&8&48M/"UI+1M412%0<;-/1QA]HT0FW`7T,"3=->&:O27=
M)==J[%QE'-'R$U-51E`:8L3M+K"3]&\8D(W3^BIUU+Z=VO5-_54;:7VY%_J<
M:-=>A\LU?\K3QGMR?6OCGVGAWJ7EW\'6S@E\LOFCU/X/`B.+_P#+IW_6[O\`
MBDK7KG*?\2W^TUP^F/4O`D>K$^C0#0'27V1TF,54Z[O;)FNK*Y$]U(<7?8EV
MZ&Q$=R(S4D00%%(E5$%%54UKN78VXN4G1(RC%R=$5K"Q^XY)F1K_`#N`Y4XE
M$=&1C/'4A$ZWB!=VYET'J).(J(;<?U%I=B/J<V[<:-N5]\5Q4CLCYR\ELVXY
M;')0PCGO^!;DN*W-C/172<`'AV1UDR:=;)/43;<!4(#!40A(5115$5%14U*N
M0C<BXRQ3-2;3JCT[\>>29?)?',.9=O@]E^-2'*+,2!!'NS(H@;<KH!$$/=QW
M&I'2*;`KBA_IUYYK-,]/=E;>SPV%W:GQQ3+SU&-@T`T`T!^3)``C5%5`125!
M1279/T(B*J_Y)H#SSQ_@KB3,\CQV1A7(UCF6.\A1+JRSZSD&TLRZCPVH-,X*
MR(]4#!.@]%%J:;I!-4U17'5)-M`2Z=X4\0Q6J>E/-,VA%8(U6UHLR8)*XD.+
M6JK;B_9A@H$Q0,]:.IT'\XJB]SIT!/K7QAXZ>XN7C'),KOIV.2+N-/<L[-ZK
M5Y^0<1NG8B.@4`8;S;C:BV(.,$2N*)(O<0%0"UN(,.HL%X^H,?QC(+;)<=;:
M6336ET;;DPV)*]U.XX$>.3A$I*9..BKID1&Z9F1$H%F:`:`_GK\R>=Y'-?+$
M^'635=X^X]?D5&(1VRW9E2`/MS;-=E435YP.AHD54[(B0[*XYOTW*=)]N'W'
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M:\B+8O\`\NG?];N_XI*UZMRG_$M_M-T/ICU+P)'JQ/HT`T!_BJB(JJNR)ZJJ
MZ`IF7=W'*$J12X7/?IL'BNDQD'($9>A^<39*+D2E/945$(5%V5\!]19ZCW-N
M"[DM0^&#I';+?T1\Y=W1N24,7GN^)9M)21,2A4<;"VFL6?Q1]J9BDF(W_P#1
M2V54@>0445/J521U"+]J)&+BDAEOLO:.W<LNU2D?#I,8W91EQ;3UYXGY!C<G
MX%19<TP$*=+;.-?50%UI#LHIJS+8151"41=%5;)43K;4#VV)->?WK,K,W"6:
M9=0DI)-%C:U&0T`T!0'E'_0K.?W9_$XF@/\`/%[?_P!",'Z412VL]D5=DW^T
MY?T^N@,V6/BKS7C.+RJOB#D"MQ>1.H#8C5#EI8Q&J6]GO17;>95V<:(;XQYS
ML-N44<V>@7U>]%%]>V!W'(?$/DA6XUD658_R%-R'*JI^ZL<6H8MI/,VFK'%+
MJ*W&;1P4;><8OK@7FS[8J,2)'!L5<3MZ`KFMX&\L<JB8?;R\T.NI65JYMSB%
MWF^3MRI#]=EL*[<0G%A/.,@]$A''CFO3(::>$'D,VR4@)U6^.7DQ$KZ&I?YG
M7V-<_CB620LANX7N*JL=H/M&H;%A@>Q[E(%@XDULA?7W?8).T"$@%\TG*-%P
MSAW'6`<TYG+G<A4V*U$7*<J&KN)L*RL&(HLR97VB$)6E.0ZRXYTF2.>NZCH"
M'<J^9O#F$\;YKE-'E86=_3U,AW':UVOL6VY%B8]N$TX9QP%!-\@$EW^&^WKZ
M:RA'BDEO,[<..2CO9_-Y><GXU7-%:65X5O*F2][*1U=V6X\^2D](>$MB(B-5
M(U^*JJK\==:]98L023P5$>B2YEI=):BE+!45%GW>),JF9#NV(4NMELOP[#I6
M-,ZNEM4)=MR(MNE$7X[_``^G4R%R,X\4<465N[&Y!3BZIFA@\><EF,P'Z7)*
M*\9O(C\K&78QS&DL4A1)$V<+22HK!-K'9C$2J\((2$"@JH7I'_F16::IGEAL
M1#__`&4%7BBU3/+"K263>;>SI(OR1P_DW:_=2([email protected]+,Y&&U`1(
M$-R7%C(A.?/L'ZR=!=2)Z;YV=1&[6GE\3;I=;#45X<*;Z>395"HA(HDB$))L
MJ+ZHJ+J02S8'COY-R./O98/R%+.5@`"W&H;M15QZD^;I%IY4W(X:(J(B_%A$
MV]6?]UYCZL]&?<XM3I%\V<H+;TQZ=ZVD.479Q7T;OT_]OAU9:LY8JV8&4T.8
MUY`]49K&&LGOLF)-%-C-G)@OCTKLO>C]X"<]=^VR._PURGIK5-<5B6S%>#7A
M[S@/7?+N.$-5'9\LNI_2_;>4KC'_`"^;_P!:NOXI*U[GR+_"M]O^YG%6_H74
MB1:MS,:`:`R>[R+R#GO*N5<55]-:XO@<27[8N3(4"43A#&9$9D-J2H*PP;KW
M6(/[[@@KTIUD)!4/4W;U^5E)J'ZDGVJN2QVDK[<8P4LWN-,T5%48S4PJ.A@-
M5E57AT18;6^PHJJ1$JJJD1$2J1$2J1*JJJJJJNK2W;C;BHQ5$B-*3;JSM]9G
MPU%XBY6Y69MEV`OO*L'**],FJ&%7T:F5Y,09Z[K]+S3T51%%].TX6WS*NN2]
M0:?AN1N+\V#ZU^'@66BG5..X]`]<Z3AH!H#_`!40D5%WV5-EV79?^U-`82K0
M\0^>*#CT`Q2UM*G/G7N/<(N'F[VO?FQ::)8W`12LVWFG58;9@RE;1Q[J!>XS
MTB2N!H"+\PSO$E*/EK`K-96,VU-+6/DM]#)TI+=I88XN-&\X[(DCU.%3R#C(
ML@@5U'#*.1OFKF@);A/C[XS6-G/QLX]WE^;\55%&_=9`%ID41YAEZ:Y;5#4<
M&)R&IQ':]M6D'K=;1ID"<)P?0"QL"X,\<,TP_!,\Q'"E7',BKL?RO#W2FV;"
M@C;5;-J9R,E*3MRFVZ^&/=5.[T-`T1*`].@)A+Q/E/"H.-8KPHN"U7'F*T\.
MFIL9R"/;.2HS$)I66@;G,RS16VVP;`0)I2V1=S^":`R)YIYOY$X=P)D<+('^
M/&(6?/LXHJU/VM[HVYPN.RFA[RH'2Y%8>`M_H5=M2M':=R[&*]J8D[EFG=_4
M0BJ9UQRPQQ/!?*I7);$"+]AP*YV>4QH4**Z9[A\REW`>;`1!4395Z_3Z%UTF
MHEJ5%<"5:[/Q67:=QK9ZZ,%]N,>*JR;]]52G:6!6E8G!BE;-,,V2MI[QJ*9&
MRA_3T$:"NW^:?]OQU-M\7"N*E>@L[3FX+C24MM,C9CF+\*0F\F?R""Q6186,
MXY/%84IUTG)\O'(3DF'6.++<0I*6IN=\'1-`;ZO5M`74'[EYTIO?=Q/%X9<.
M15?=U+X>%U^:2RV*3HY89<.5*8[R(\U8UQA!Q[%[[email protected]$^T:&.\Z_)$
MI#2D0O*[83%[email protected](KO^\/TULTT[CDU.O7[)9^1NT-V\YRC<J^G9X+/R
MR,WZFEF63Q9ROE?#^1%?XR:3(DQ!#(,8D.D$.Q:'X=6R%VW@3_=O(*J/P5"!
M5!><]0^G+/-K6/RW%],O)[T1[MEM\</J]SZ_)[.K`W_D^98KR/38GRYA<U9$
M)I\,:S6N/I&3"*:0%#":TBDJ.L2C%L$15%1D$X*D"B6O+.5VKW+=7/27U1O%
M;FUM70UX'$>M-"M5I5?BOFMO%;://NP?5B5OB_\`RZ=_UN[_`(I*U[MRG_$M
M_M.`A],>I>!(]6)].7#@39Y/C"C.22BL.RI/;%5[;+(]3CA+]`BB?%=8RFHY
MO/`^I-G=Q\,RF6^<6+12GY3:,]V*`;N`K^ZM"0?K"1"*D@JF_2BEMTHJZU2U
M5J*JY*GP]O(R5N3V&1:C@W(V^;+WE?(LRBVM;-F*]6X44-Q^.QV&4C0Y(.F^
M(-R&6A]#%I=NHT1?FWU"AH)_R'>E*J>4:=B>>:ZMYM=Y<'"EVFE-6A'&@-&^
M*&0'5<IW>-D9)$S+'2E;%OT#+I)`(V((GHA.LSW5)?I1H?T:Y;U%9QA<[/->
M98:&6<3T8US)8#0#0#0'^+OLO2J(6WHJINF_^7IH#S]R3P\Q_)\;LJG#.78F
M-N936!CM\$2`$VJDW,(66Y5E&@A8-%'GO,5S22>V_NIQP=5!(7>X!\N1?%L@
MQW,W<4Y)AER,VW>7=<U,1J(D5NTQ:WI9;8.+)5UEC[0R&7:J3AK^T)IHC$0%
MW0%>T'A+.M6Z.WM^2<2H;3#VX)9)AS6.M383+T#)HF4C]H"S<-B(R2@M]UC=
M6VD<>!@T:Z-@+"K?!ZKE0*44Y3:R*J@R\?EF;U0$D)[>/OT*K5R"2>H.UK_V
M$I%$5%07Y$AWK7J4-`7U27L_@?#N.N*W<&S[DV-A6*U%&O(%'6193$LZ^*,1
M#>:6>LD731CK/]FH(I)\_KH"FO)3RKE8;PKG,^LXSY%QN]M(*TV/W-E2>U9C
MR[)?;"\+ON%V-D#)T$V]5#6VQ;^Y-1WLD:2S]Z[&%&ZO9G3;[C^=[(N0X6+U
M<:4-#9=H'VHOM78KL<4!=TV!PAZ%)$3T3?U_3KJK^NC9BGPO.F5#OM5S2.FM
MI\$LTJ4:[GD3ZMG-V<&+/:9?CMRVT<%B4T3+P[_08%LJ+_\`9/34RW/CBI*N
M.\L[5Q7(*235=ZH^XT.?$>--V%S6OYQ+A.5N,T&3,S9%4V,-&+ZOJY+(S'O?
M[L(+]H#.X`[Z(IKLGIJ/_(E1/AVM9[F\L.@A_P`R=$^'.4HYX_*Y+##'"-=A
MQN5N&_\`TXJZ&ZK[T\FI[Q4)NU[,5AKH>#KBJV+$V6I]Q&WEZD^384Z2+?T^
MV-3]UM-4:]MR/NDUOWY.+5&MF/;L71TE'ZE$\TKP#Y%6G$4IO'\B*7=\;2W$
M18+:=V13&9[G(AA^L;2J2DZPG_OM)U]0.\!ZK]'QUJ>HTR2N[5LG_P!WCM(D
M[;MOBCBMJ\UYKM6.>SN3&JQ^XQ3D;'IL:RQW.8854NQB&+K+KS0.2JV2!@O3
MTFWWVC)=U)>P"?#7"^G=1*W*>FFFFL4GL>4EX>\X'USR]7;4-5#\N#ZGD^Q^
M)3F+_P#+IW_6[O\`BDK7O/*?\2W^TXJ'TQZEX$CU8GT:`:`R@['YDSWE;*L9
MR:AL*W@5R7VV9+#L6*_*2(R+1,N$KHR2B2W!,C1L-R3I3J0"-"J&M1>ORA)-
M6NQ5I[^%DKY(P33^8U/%B18$6/"@QFH<.(V+,2(P`MM--@G2(``HB"(HFR(B
M>FK9))461&;J<C7T^&H/$3)'*S.LRP@S%(.55@9+!83=.F=6FS`G.$JKZJ\P
M_$%$3X(RJZY+U#I^&<;BVJC[/P\"RT4ZIQW'H+KG2<-`-`4!Y1_T*SG]V?Q.
M)H!XN?T*P;]Y_P`3EZ`QS@'%O-6-0,'@W_&W(UVM#R0_<P,L#+*\[*OJ(DN-
M)5;>.]D#,::4Y4<COO1XY$Y&1Y4C=UT3=`[KD?$?(/DR!S1-XGXXS+BN3R7A
M"QF+#*\G@Q'ICTB$](!(S,:RMR@SFGWVHHM'&CMBPV\/N@-UHHX&A<"JN<JK
MDODF\Y)QEJSI,XJJF+5.8MD:S(M<4$[YU666;!FI>CIV"BLF;74IR'`>3I;)
M[VH%F<"4^6X[P;PWCN>QY,7.<>PF@J\Q9F26ILA+2%7L,3%<DLNO@\1/`2]:
M.%U;[[^N@+:T!@'^Y#=NUGC_`%56#BBQE>9U=;,;VW1P(\>99@*_Y.P0+_--
M6'*X\6HCT5\"XY#;X]9#HJ_<>$EE45EPTRQ:PFI[##PR&F'AZ@[@(J"2BOHN
MVZ^B^FNJN6HW%22J>@7K$+R2FDTG7'>=FR2,&T0-@HLJ*BT0HH*@_`5'X*G^
M&LZ&RF%"UK+FG.;-FQ8)RK@MV;#L9U(-7#C*V$B,Y"?[1-M(H*[%=*.6R_[K
MI;381%$T1TT%3/O?7XX]9%CH;4:9X;V]]?''KQ.@R+D?+<IHZK'+F>V_3TG:
M&LB-L--=IM@#;8;0@%%Z6Q<-!3?_`%+OOZ;9PLQ@W)9LV6]-;MR<HK%D&UM-
MXT!=_'/,MEC.-6/&N1O.6&!VJ@[3RW5<>=QR>P8R(DN.V*$;D9N2VV;D<?5$
M0E:1556W.%Y_Z7X[JUND5+L<917YUM_ZFJ]94\QT"O6)VJ5A).JW=,>IXT[L
M<'>W&=_`RK#[email protected];F?;2F%`Q<1.NRDJH=8*HJHKN*JB[;IKM.1?X5OM_
MW,\9=IVODEFL"?:MSX3C"XV*/E;KDLYN*XL&2W6`Z#B@+BQGB1Y"#T4Q,00!
M+T52_2B;Q-5*ZJ<"VJO>L/B;;:CC4M=N-Q/'R!^,80"K70$H?<D-2666V93\
M=L3>:=9(R?3M/GNO6([B1""+U5[EJG;KC7JIL3RH\L8[MN9NI;K[>W29]LF6
M(\^8Q%?25':=(6GTZ=B1%^*=*J*I_BGHOT:N(-N*;P(KS.%K,^#0%A\,S#@<
MV<424]&7+>;$EJB+U*W*J)[0"GS)Z=Y6E7??T3?;=$VI>?0XM-7<U\/,EZ-T
MN=AZQ:XHM1H!H!H#+^+>+.,XD_36-=G&3N7=-G5CR%]KO)5*<VXL:B;1D4T!
MKT%Q$B3W=U'H,S7J(]A`1`BMIX4X!E*WMCG&7Y'E&39C$A-9S=N-U#;5M)B,
M,-$_(A%7.L.BILJXRR^CK<4B7VHL[#T@6KAGC]B7'=[/O\)R/+*23;PH\&WB
M/W#MM&DA'.UD=:MVXS>V9R[9R4:M*&[H#LB`Y(!\"P>.,'K.,>/L(XXI9LVQ
MI<!HJ_'::;9$R<MR)61PBQU?)AIALC[;8HJBV._QVT!--`>87]SRP(<&XGIE
M54;E9++L=E+85<AP'&!^7Z2Z9A;+]";_`*=6O)E6_P!C\CH/32KJGT1?BCQT
MUU)WHT`T`T`T!_A$(BI$J"(IN1+Z(B)]*Z!NA-L++D")%NKO":BULL?LH!P,
MMD18SYU$N"XA!V9<P`5EDT4U5EU3$VS7J!?4A+GN=Z/1ZV"^Y)*<,8R6+B_A
MO3*+F>NT7"XSN1JU2B^:J>QI5?P-0\/W<K(^/J:\GL%$L[-^PD6L(P5LF)3D
MZ03[1`2(J*!JJ?#_`-FNAY2T]);IN/)+UK[4N#=3NIA[BS=6)J)9B^6R,7^T
M!9KHD]NQ8=9>]P)=2=;#S";$))\J=Y2(5]"V3Z414C:C3*]2K:I\4_(V0N<)
M/7.9IYW+EJM4CP2`/W<64^,A73=E.ODI.&QNHBV^;+8[?*.VZETHFHBY9'@X
M:]RIL2W[U5FS^0ZUH5%8RQGSI<P61CC)=(Q8';845?1/1!15_2NR;K]&K&$>
M&*1H;JSAZS/@T!:7!1$/-W&""2BAS[-#1%5$5/L.R79?TINB+JC]0+_\=?N7
M@R7HOK[#U3UQA:C0#0#0#0'GQQ-XP\B\;-\8FU58>S&X\Y.NLMB4T>QD&[%H
MYF,W%&S7Q9YU:/R?V]D+@I+-2!IL0)XMA!H#X\B>,?*W,%#R_-!ZBX9N^;L5
M:@YKC7VU998Q/GI7.QF@>E*Q5G6I')6`+V:O,.HR/<8<#J!T"Q^+>!,ZPO.N
M5KS,$Q?/,=Y5E]5I629$GV\9D+"\M!]G728,I&6W'Y[*N1CE.CW7)$@7DZ6X
MY@:`XCP5.-N-\2PQQ(BV%5"[E^]`!6XK]K,<.792&`41Z0>EO.N"FR;(6VV@
M+&T!YK_W-[5QCBKC>F;=%M++,TE/AU?.XW$K)P]/3](]3XDJ_0J#^G5IRB-;
M_4F7WIR"EJT]R;\O,\6G&67NVKS0.JR:.,J8H70:;HA#O\%3=?5-=2TGF=\X
MIYH^NOI])!995D=PLE;.YE3%F1X<27W'%V<CUX"W$:)$VW%D`$03X"B(B?!-
M81MQCDO9FN-F$<EO]^?>+3*\ENX46MM[V=8U\(^N)"D/F;39;=*=(*NR;(JH
MB?1NNVVZZ1MQBZI"%F$'5))D?UF;!H"QL*Y;LN/J6ZQ6=,%S`LC)7YU>Z2==
M=8"8O1[.O0R$4=:D`VZ;1?(]T[+TDO5KD?4'IV&IFM59I&]'L4U^E]:PJ57,
M]'"[9G!TX9)IKS7]U<>GWFG>+KZ-E.$UF30Q5N+D,FQLH[9;]0A*GR'4$D5$
M5%3JV7=-=?RI4TMOJ/&96W;?"]E%W(L#5@8DUP^SQRL&Z6[8=.7+KY4:N?1E
MM]MLG(KPI\I^J&3BMHA)\$ZD7T7=(NIMW)\/#DFF]FU>539;<56I8M'R'0I9
MM_S&#%@PU`@@MLL4.X;Z*;CPJTL<P46G9)+ZCLO9!=B7HVA7=%/A^3#%X5V;
M,:[4O_4^DW1NJN/M[>125E[/W\SV!$</NE[<S554AW^.Y(*[+]&Z;_I]=6D*
M\*KF1G2N!PM9GP:`L[@R6<3G+BP&^I%LIUK">(5VW:^P[&2HE^E%.."[?I1/
MT:H^?QKIT]TEYDO1.D^P]5]<86HT`T!0'E'_`$*SG]V?Q.)H!XN?T*P;]Y_Q
M.7H"_P#0#0#0#0#0'FQ_=`D"QPSQ<!;)[KDZ(RBK^G^7KXT_[>G;5ERJ5-0N
MFO@77I^?#K(]*:]QXO:ZP]#&@&@&@))BF&9CGCW8P?$[?+C1Q6G':F&[)8:<
M1=NEZ2(]EGU]/VABFHUS5VK><O,K=7SC2:7_`)+B3W9ON1K/"O`_F'(5;?RV
MQIN.X1]/4T\Y]KV`_26\>(8Q]OH14E_[/TP;G-/T1[_;S.8U?K:U'"S!RZ7@
MN[%^!?\`0>%O%D*_9PV.Y=9[E`1VY>39-9N]FIH6'?02;B1$9!^0^@KV(\@W
MQ%-WGD4$`'>?YMSZ>GA]7S/)+#MWT*>/.]?KWC/@A_;AV5S]YEGAB12UIYGA
M^/-%#QRLN9=KAL!QPG"CU%G)?<9C]3BD9DV0D1DI*JJ:*J[KZ]5Z?NR>G4)N
MLDD_]6+]]>\A^H.7/2SMSV7(*7;M\B\]7QSXT`T`T`T`T!)..K$(7,G"<8U1
M"N,N2(UO\>H:R?)]/\=F%U3<]E33-;VB5HU6X>P.N)+8:`:`:`:`:`:`:`:`
M\GO[ITA8]-P/NO2V_D%NRZ2_#YX(="?[3Z4U9<JGPWUTIHO/3T^'5KI37MVG
MDQKK#T$_)&("1F2``IN1DNR(B?2JKKY6@;H2_%,`SO.^V6%85>94P]MT6%;!
M?>A;K\$.:@I'!5^CK<34:>LM0SEW8^!5ZGG>BT_UW8UW+%^ZII;%_!GG>_1I
MZZ8H<&CDJ(^U:3_=S`W^D&:X)+![?2BR!U$GS2*^F->O#XG/ZGUMIX86H2EU
M_*O-FEL3_M[85![3V;Y_=9,^&W7%JF&*B(XGTH8G[U__`"4'@U$GS&[+*BZO
MQJ<_J?66LN8048+H57[_`(&A*W@CQXXGKCO&..J=I*Y6^Q9V,=V[L>Z9H#34
M4YBRY).NN$(@VU\QFHB(J2HFH5Z\Z.4Y8+>RAO:_5:N5)SE*NROED<W/3M:7
MCS,N7\UC!"=Q2E?L^../9`-.!76;;9)7/SE$G&WIQR";04%>W'54%M3-%>+C
M]7S&6MO1L6\(-I=?X%UR[EO#)+.<FEU5/*S@ZP"LEW&'*X1,E&9M:E7"4C+M
M"W#EINOP0>E@O\2,EUZGR>Y1.WVKP?EWECZVY<M/?A<BOEE&G;'#PH:,U=G$
MC0#0#0#0#0$JX<N59\F."L?`ND[%_([!U$WW5N'0S&NE?7X*4E%]4^C_``U0
M^H*NPDM]?;O)NB7S-]!Z]ZXXLQH!H!H!H!H!H!H!H!H#R?\`[ITQJ'1\&$\8
M--/7ER!NFJ"(HD`#W555$3]75ERF:C?QVIEYZ>N*&JQVI_'R/*RGH<AR-`7&
M<<N,H5Q$5L*2OE61$BHBHJ#$;=5?1=_A\-=)+56HYR7>=E=YII+7UW8KM1;-
M+XU<_9`H_9G$]X(?%QRQ]M4H";[*JI9/Q27;]`HJ_H36F7,;*R;?9\2LN^JN
M7V_SUZD_P+8IO!3GFTZ7)R8QCC/IUM6-HZY(3??]4(464VNRIZ[NI\?\]M$N
M:1V1?;A\2MN^MM-'Z+<GUT7Q+9IO[=MN:"[D/+,..1?KP*ZE<>Z?\I+TUOJ_
M_936B7-)O))>_P"!67?7%U_1:BNMM^%"V:?^W]Q#!4#MLGRZ_+=%>8=E0HS!
M(B[](I&A-NBBIZ+^UW_0J:TRU]Y[:=B*R[ZNU\\I*/4EYU)^[XR^+W'T$+"R
MP")(9-UN/&8M9-C=.2Y+FZ-L,1)3\E7W7%W06FVU(E]!'TU%NZN2BY3FTNO`
MKY<WU^H?#]V;KL3IX'SRO!L6P3CK,>2K7CFAX_Q;&JJ1+IN,J>##@2[:2HHW
M$CW,N"([#)?5MI(K!]"HNS[KH&K(<KJ>;2U5U6;&'$Z<6WLW%CI.73G)?<;E
M-M))NN+,`\&25:QZUQUQQ"<I)ZNL(@B'4S.%'R=Z1V1.N2KZ[)KU'D[2L\"_
M+X>U3[ZJY>M'K.&/TN,6N[A?O1=VK8YH:`:`:`:`:`DW%%JD3R,\>*P%W>ML
MBO>XVB[?L(^)7AF?P7=$<5M/]NJ/G[?\>BWKN_K0F:)?/V'K_KC"T&@&@*`\
MH_Z%9S^[/XG$T`\7/Z%8-^\_XG+T!?\`H!H!H!H!H#R]_NQN&QP#QO):%3=A
M\HULAIM/B:LTMV?0G_O(/3_MUOTUS[=Q2W$_ELW;OJ2V8]QXX),B+%;F^X;&
M(Z`N-R2)!!1-$45W7;X[Z[7C5.*N!Z7]R/#Q5PWEO89P9S#R#VW,3XYNIT%W
MU"WELC6P2#T_:-R9Y1VW1]?_`"E-?\-1+FOM0VUZO:A2ZOU+H=-@Y\3W1Q]^
M7O-=87_;VRB8K<CD3D"!1LJB=VIQQ@YT@D7UW2;,%AMLA^&WMG$7]/Z8-SF<
MW]*2]YS&K];S>%BVETRQ]R^+-<X7X@<"88C+JX6WE]BTB=5CE#BVG62)LA^T
M<1(8$GQ108'9=0;E^Y<^J3?MN.8U?.]9JL+EQTW+!=R-*1HT>''9BQ&&XL6.
M"-QXS(H#;8"FPB(BB(B(GP1-:BJ(9D5S<6$X\*P=Z.F7OLM/V%F^WWXM'">(
MA2;*;0AZS/H-([.Z*Z8KOTM`Z85_,.80TD*O&3R7ML)FCT;OR_M6;.;EQ0.'
MN&\^N:8B5[%<<M[L["6?7)FSV(CCRR)+J(BN.O.`FZHGQV$41$$4X=2GJKZX
MG5R:][.IM6DDH170CPHP&8WB^58H3:J$$]J"2GHO[&8@-L;)^GW+;";_`$(I
M:]?Y?<^W>CN>'?E[Z'6>LN7JYH%**QM-?Z<GY/L-B:Z@\A&@&@&@&@&@(7@-
M_P#:GF7X^8O#)7@QZ?-F6+0?-_Q,JLE$"*B?`F8[1&O_`(7-]57.+?%I+D]D
M>%=K:?N2]Y.T:HZGNSKA2R&@&@&@&@&@&@&@&@/);^[C">;XHXMR)HE'[*RJ
M1%:+;<4?>KWI;2JN_P`46"JHFWKZZVV9N$E)9HFZ";A<XEFE7NH_(B'"WA1Q
MEF.'8SG&09U>9,W=PP?>JZX(]5%:>15"5%?'_BY".,/";1]$@=B$D^.KB?,;
ML\G3J_$UZKUAK;CI#A@NA5?O^!LC$?'/@[!R9>Q[C*D";&5%C6M@RMI.;V_[
MDRP*0^/^P]1)W)3^IMG/ZCF&HU'_`"7)2ZWAW9%AVN;8?16T*ANLGK*FYL6B
M>A5LN4TRZXV(.N*2"9)Z*##I)O\`%&S5-^@ML*D11;53\8MG6&9PU+?PW*JK
M*F(!`$Y^JEM2P9,^I1!PF2)!+857I7UV]=O5-$ZAQ<<T<O),FJL5KVY]H;I+
M*D-0JROC-D_+FS'UV9C1F0W)QP]E79/010C)1`2),+MV-N+E)T2,K=N5R7#%
M59\<6PNRF6D7-<_;CO9'#)W^6*".9.PZ-EX5!5$E7I?F.-JHNR.E.D55IE!!
M7">XCF?-9:I\,<(;M_6=-H]%&PJYRWF=//7*OLKB6EQ-ES]OF^0Q6Y;`KL?L
MJM"L#<1?T#):C"O_`+^WTZW>G;'W-4I?I3?EYG2\BL?=U<=T:R[LO>T>4-':
M?8.38Y?*YVV(,T6+%=^D5AS$]N\KA?0#76+R_P#Z::](TEW[=V,ME:/J?M4O
M_5NA_E:"36</F79G[JFS]=8>*C0#0#0#0#0%?^*N0.YUYPXO:UZK)IL<AW,.
M$X"_)[6-62V7)/Q5%1R5(Z4)/0@[:ZJN>0X=!QO.<U3]L5+'M=7U4+'2QHZ=
M![RZX4GC0#0#0#0#0#0#0#0#0'FI_<6EV&/EXRYM6`4B;BW(ROQZ_I%1E$W!
M=F^W(B5$3O)"5O\`R)514VUG;S-=Z25J==WFC65)<UF1TU3D%-*&=47D-B?5
MS0W078\EM'6C1%V5.H21?74PH&J'9Z^@R_R-Y-5O'N<3L&>Q*7;63+2)7,LR
M$"5*=.$LY)`1>T1>Q`45MV4A$C9B2$WL.^L'*C-T+/$JU)KPAS73<UT-G;UT
M1NKEU4I(\VH22LAUH2%1$W=V65#J=;=$15-^D$)=NKI3[&53&Y;<&32URY]R
MT>Q;#*U,IRUE!6?'1SLP*L'$0A=M)B":,[HJ*#0";[B+U`WVT-P(>MYA:TL:
MR>.Q;6;]-HYWWA@MY)L5P!FGG)D>0V!97FKC1M%?R&T;:AM.[*Y&K(VYC%9)
M13JV4G'.D>\XXH"J<5KN8W=5+YL%L6PZ/3Z6%A4CGO,<?W`,X2'BN%<;1G4[
MV4V)W5TUZDBP:CH5ELT3X*<MYIT%7XJR6WP]+3TUIN.^[CRBO>_PJ=+Z>TWW
M=2I/*"KVY+X]AY\\4V'L,V*(1=#.0UKC)*O^N1"/O,"G_P`MR0O^S7IO*KG#
M=<=Z\/9F/K[2UMVKRV-Q?;BO!FG]=">8C0#0#0#0#0$+X/OOYE\[N&H$$D>@
MX(.01Y#B$FR29>/6*R=OH+I_8!_@2>+JJYS"NBG<?ZE%>,O)=:9/TBHSW9
MUPI8C0#0%`>4?]"LY_=G\3B:`>+G]"L&_>?\3EZ`O_0#0#0#0#0&%O[C.(2,
MJ\6\KFQ&5D2L*LZS(1:3?_=-/^TDGZ)\&X\IPUW^@=91>)(TLN&[%F+_`.WF
M[QQ'I(F.V^*4C?('5,L\/S&1$:.QE0U><]Q";E."1@<5?F$`(>IDDZ07LN%J
M9&3:2;ZBGYEJ+ER[*+DVHMJE<$ME$>J>LBL,J<RR^?QY'QVIXEL(X0KBL$(J
M2HY'75LEMFV]W,N2]J:&RX90$8%M\'4-MSI`P,]L)5K@;K?!P_-[>V)QO'#*
M^9+6ZSBDY1J+U^%$E$_C.46K21V2KU",[#;81NIK6W^Z$DU)U51X2;)M^/'4
M0ZT6]HNQBDN$O_(\ALV[*OQ'[email protected]`=Y7'14X=1!ZE`[*PZ2!>A%1199$D
M-]Q%`5$!>=:B:_70TD.)Y[%O-FDTLK\J;-K)[B.(5.&US\*M[DF78R3GWUW)
M42F64YU!%V5*,1%",D$1%!1``!%ML0;``'@M1J)WYN<W5LZFW;C;BHQR10/F
M=>?8WCYES+9JDN_EU55&;3_S!>L&#D@OZ4]LVZJI^C_#4[DMO[FK@MSKW(LN
M66_N:JW'^Y/NQ\CQ0EL+*BOQQ=5@W05&I`IN39_Z'!W^D5V5/\4UZ0>D:BQ&
M_:E;EE)-/M-BXI>#DN-TMYT"T[8Q0<EQQWV9D(G2^SZ^N[;B$"_Y:Z^Q=^[!
M2WH_/FHL2L796Y9Q;3["0ZVF@:`:`:`B>;9?68-CD_(;/=P(R(W#A`J([*DN
M+TLL-[_ZC+Z?@*;DORBJZQ;>"2JW@EO?MW9F48\3H0S^WSC]IG/E/$S.U,I$
MW%JNYR:UGHBHVLJ8PE2#(_'9$">2-BJ^@-[;_+J)ZIII=%;L5^:4JOIHL?>U
M3HP+'3+YNH_H$UYZ31H!H!H!H!H!H!H!H#%/]PKCF5R-XI<ELUD<Y5SAL=O*
MZQD$4B)*O<IB(*(JD2PC?043U4MM?4Z&RU/@E4QQXZ\OM<:9'(QG)9G8P/,)
M0&$YXT1JHMB1&T>,B7Y(\I!$7%WZ6W$$]MG'3&;D<O!\2IM-K\Q<]<4\`T]5
MD'+62NXK2W<LH%=9#665@T4D05SM&M?%D]LE`54>OIZMEZ=]EV2DHYFRW:E<
M=(E>9+Q!@/D;,PWDM^1(=P7(J.*=M5$W.A/9'6HS/6L9F-.N,]EAH;5]X45E
M'E5S;J;3="^.*EB9JX[=5M\#A\>\8.\!7&1VCN;VF;S^0I;[^/\`'+*OH]*M
MI+44Y2,^\GO`]T'',TD/(+C3+A>ZD.@V!AJNW8:>+G-T1LC&6H:C%8FEL.PJ
M;#GGF.82`L<UG1^P,9APW:ZFCDJ$4*M0P;54543O2"`7'R%%)`;%IEKA^8\R
MGJY;HK)>;Z3HM+I(V(X9[665JM)9Y%^>65?;/+6.XLTYW(N$8\CA]*^@3;E[
MN/MDGTJC$6,2?H0_\==KZ8L4MSN;W3N_J==Z7L?\ESJBO%^1B"0PU*8>C/CU
MLR&R:>#](FBB2?[4773G63@IQ<7D\#6''UX[D.'TEC*<5ZP!E8EHZNR*<N(9
M1WSV3X(9MJ2?X*FNLTEW[MJ,MM,>M8,_/W,=(])J)V7^6379L]Q,]22$-`-`
M-`9YYSY,2@@.890RMLEN6/\`_)26BV*N@N[BKFZ>HNO(BBW]*>KG^D4+.Q8>
MHN?;67YGN6[K?NSW5W6X;6:&_M:<?D_EW)7)11>S7XY41\3IW1']F3\]UN;+
M;';T$F&XL9=MOU74U2^M-3'CMZ>.455KKP2[E[RPTT<&SVEUPY*&@&@&@&@&
M@&@&@&@&@,=^<>'CD_"35QVT=>X\R6JR5H=MU0=W*Q]S?_2C;$]PR7_NBNLX
M.DD1]5%RM22W&2_';GS&N.:JSP;DB]AXYBT`)%GA^0SG.TPVA$3\NL,E^)]:
MD['%-U-"-H1_9@A2JT*6%;BPS.=8V'EYR9SOQ[D?'US<\;^+]T\"Y%67=;3-
M7#C%>"O.OC&DPCL(;-EL++2.NH^"];A-LIT#K'YF\,B2E;C!IXR-K7&/XDU+
ML,OO1;CR(U5(ARKV9+=:"#7N(A2NR9NH$031L2=-OH4N@5(EZ!VV$9-Y(KW"
M,"AS@GAQUCR\5X#;$*V%\PP46UMFP5PT;K(SJ+[&,IO&2/&"&2FZ3+(*X,I>
M=YASN-JL+.+W[%\?`NM+RZ4Z2N]WQ-`T%3CF,UB4]`Q%KJ^$^K;K#1HJ^Y?)
M")7C)5,WG2<0B(U4S(NHE52WURER<KDN*3JV748J*HLCO6W&W0%QHQ<;--P<
M!4453_!4UK/IX:>4>=)G_.F;3H[Z2*K&'&\5IB$]Q[=21C*W%/1%]\[)3?Z1
M0?T(B>A<@TWV=*F\Y8_#W'>>F]-]O3N;SF_<L%Y]Y0\"P^Q[F@N^KH2HLH[S
M[OT!'<+L2B7_`"CNN:Z'37/MW8RW/\'[C+U-I?Y'+[L=J7$O^G'PJ;6UUQX<
M-`-`-`-`5KRER!'X_P`<.6WVY%_9J4;'*\]U1Q_;U=<1%1>TRB]1KNGT"B]1
M#HHRG)0A]3]V]OH7X9LSA'B?0=C_`&SL-F7_`#GDF:2N[,BX3CLEV98G^N5M
M>2$;:<<5-D4G6FYA%Z?'UU7>L)QL6+.FCO<N["KZVWVEEIE5MGN]K@26-`-`
M4!Y1_P!"LY_=G\3B:`>+G]"L&_>?\3EZ`O\`T`T`T`T`T!T64XW3YEC.0XCD
M,5)U#E-;+J;J$7P=B3628>#Z?U@-4T!_/1(Q:RX+.SQ7([I<=ON)[62*921!
M&*.;+Y/PK%LG.H$%]AUMT4+<2`^@Q5%(=2XM.)1ZOC_D2=,6Z]=2VLES_FGS
M0Q6GQ#BS-)7`6<8DR%G_`#$W<6]&_ERD1,/)7PHI,J,1&Q202ODXZV:@V+?;
M/OG\=998&RVX6W5X]&#H>J.'XZ&(XKCV+A:3[O[`KX\$[JTD.2ITPV6T$Y,E
M]TB-QUTD4S)5]55=;4J$63JZG#R/(I4:7&Q?&FF+'-[EAQZJKWU56(K`*@'/
MG="B0QVB)$5$5"<+9L/F7<8FMUL-+;XI=BWDC2Z:5^5%EM95&2\K4GCSE&$\
M>3J>QS7(N1X]A;VN5(8)8VDV$WU.`U':94#=4!06&"-D>@19C=TQ1O7%W/N:
MURNR>7<OP]F=-;A&RE"*P)5P?Y#5_,=CD-(]2-XO?X^AI(I%E/RGE)AWM2NI
M7(441%I7&4WW524U39$#<H^HTSM).M4_;>;8SJ4%_<(O.UB7&>+B:`Y9W\JY
M/])-5D(XI!_^>Q`O]G_;=>F;?%?E+='Q9T'IRWQZNOZ8M^7F>:Y8SD@+)$L?
MLA*'_P#5BL1Y%:_9=_Y_D^7]E\_K_I^;X:[?B1W7W[?ZECTKJ\<"RN%+=13)
M,7=<W2"^W:U@*J[#'G=2/`*+\>F0T;A;?_%35_RF[6+ANQ['^/B>2>M=#]C6
M_<65Q5[5@_)]I?&K<X\:`:`Z/(\DI<3J)5Y?S@KZZ(GSN%NI&:_JM-`FY..&
MOH("BD2^B)K&4J>V?491BVZ(\_\`/,\M^1;H+6Q;*!5P%,<=H=T+VP'Z$Z\H
MJJ&^XB?,J*H@GR!NG49W?+]`[?\`Y+GU[%^E?_)[7V+:W(2451'MA_;BX<?P
M3B2PY'N8GM[[EMYB9``T5#;HH:&-?N*^B*^3KTA%']9MQK?U'T\W]2\Q6LU;
MX7\D/E7F^U^ZA868<,3T1USYN&@&@&@&@&@&@&@&@/FZTU(:=8?:!YAX";>9
M<%"`P)-B$A7=%1479470'\\7-U?&XGY0R[A?&FV,ZLJPR=HXC#[:QHE1*^>,
MU;R$[B1W(X$C+@$*NN=(NBUTNCJ3"=53:4FITW!/BK2+]L#N,%:P_*&!QCRV
M*5RMC3T=B'C-LZ[*2%B8MN(?;8A@X2J!;"!3"ZY`@G0X2L$7;RX=YC'4?HP?
MC[=QZUV.85D&!1Q\3BMY99Y$P!8A25+K2M2(VP(DLGPZFV83(F)./[**"HB`
MN.FVV>O5:JWIX<<WAX]1]L:>=Z7"NWH)7AV$E0NR;V^L!R+-+0%;L;Y649;8
MCJ?<&#!:W)68S:[;"I$9JB&Z1GZZX37:^YJYUE@MBW'3Z;31L1I'O,^\W#S+
M9<Q\;UW&-U.@4#$!]K+UBF;K<-Z>XK,2<Y';)&22/LKKC<WY'FA((Q`^*EKY
M8^VK<G-8[/;X9;<#;*M<#\>-T/G"BR?,:'DJ/:V..-B\5%D]O,F27'6F7P]B
MH#*DO"*O@]((T1$<'M@+J`/:0FJ=IQ3AGN$*[3S&Y2R2)R!S/R#DTVQ]I676
M22FF+1&R>'[/@*D"&\VT'JO7&C-DB;INJ[JJ;JNN^Y59^SI81VTKWXGH_);3
MLZ*+2JW\W77+W4)M'\?Y<^+?RJS)FK%:)'^[!9B&LKN,0V'R:=:[G[,T??1@
MO4A#H-PR$$12F?=Z#Z^;*+BI1I7IPS:\%7IJDL2*\.6)PK?)<8D(K12D"WB,
MFBH?<;Z(DP5W_50$%CT7Z2+70<HN_5#M7@_(X'UUHN#40OQRFJ/KC^%.XT!J
MZ.%&@&@*`Y1YM@8O[O'<4-JVRQ$)J5(39R)5ELJ;R%1?G=1?5&47?Z3444>K
M.Q9GJ)<,,MLMB^+Z.^FW;"W7%Y&/Z^NNLBN8U?71YF2Y3D\]MF,R/[698V$L
MQ;;'?T13<)4%/@(ILGRBGI>SE9Y=IW)X1BJO>WYM_@;TG)T1_3GXY<.0^">(
M<3X^:,)5M$9*;E=DW\)5O,7NS'!7855L37MM=7JC0`*JJIOKQK6ZN>KO2NSS
MDZ_!=BP+*,>%4+QU%,AH!H!H!H!H!H!H!H!H#.'*W*55;/Y%PEA&)+S!GUQ7
MN5N4XHR^L6GIX=BP0*YD=J@F$)MQDU46@$Y+HKNTR2?,@'B?;<.7_'V<6U'R
M9<O9#R)@\X!@7+)%'C0OE!^%85+8(':<<:('$>3=T3Z@ZTZ%%)4/F564.IK9
MEPQP7CU_`]`^(/*1N9`J\,Y$9D3^19+P5V*R8#(`&3/$B]IL>I6H\:6HBJNB
M9`TJ(KK9"/6VU\NWXV8.4\D+-IWY4AG[>XU94\?3KJ;#R'DIZ/:3(;K<FEPN
M*1.4U8\"H8.EUB"SI`$B$+SP(+:B),M-%U&?&\PYQ<U/RQ^6'O?7\#H])H(6
M<7C+?\"V]4Q///"_\,;R^?Y&E+E!1QNKEH\'A/'$?%IAZQO)4^PM4.O4'W>G
M(90QP1.Z``VBR4)P^BSCKE'APV8]RP6/]JKX&EVR\X$[)O'KQBD3,SEULW(>
M/\=*/50X2-C`!\!2+55[)-QHB*"NJTT*JTA(BH)$XJ*X>F-M:G4*,/S/^K-]
MFU*<HP6;:2[<#Q4J:R=8/PZR*KEC8R51M'7C3N/.+ZFXZX:HFY+N1$2HGQ55
MUZ;&*A%)9(]4A&&GM*/Y8I+N)E.XESIV#:A+QMY(+$9Y9[_=9[?8&$$UTP<1
MSI,1C/`XI"JHB$/TDB*XXLT2UFGN+@<OJPICM;CXU1?F$7#M]B./6L@^N9)@
MM)9*GT2VD[<D?_PNB2:[#37/N6XRWKW[3P75V'8O3MO.,FNYDIUO(XT`T!!<
M[Y"Q_C^L29;/*_/DH25%&PJ+*EN"GJ@"OZH"JIU&6PCNFZ[JB+\59248JLGD
MO;)=)G&#D8#R;)KC++B7DN2R0*8Z'2TPVJI&A1A52%AGJV^4=]R)?4U^9=O0
M1O\`1Z2.E@YS:XFL7L26Q="]^;Z)"6Q']"?@WPG,X:X0K5R&O*NS;/GUR+*8
MCPJ+\5'@$(4)Q"]1)B.(=8?Z72=_3KR;G/,'KM5*[^7*/[5EWY]I8VX<,:&R
M-59L&@&@*`\H_P"A6<_NS^)Q-`/%S^A6#?O/^)R]`7_H!H!H!H!H"J^3.1K7
M"TJ:?%<"NN1,WR='QQRB@-%'KP]OT=V1:6[H+%@L-]P>I34G2WV9:=+Y=`85
MY^\0,ZSZ&O.&6WD?D#F2@:!QW!:B$C-$U51T<<&'4,$*R9$R,3AFU(DD1O*I
M-@VSU@C><)4>)'U-EW(/AP?M@87:<;DC$FQ)+C3K#@2JVRB.FP^P\'J#S#S2
MBXTX"_`A5"1=2\SGTW!])J3%?,')L3I1J<^IUS">Z;<+'\MC"C!*^\8MMK;Q
MX[9%VV]R-QZ(T1J*;#&4O4M=V[]N+D\:$FQ%7I**P9O/CAK%TQ>RS+#[ROY$
MMLD!95QE\-]E!LY48"%N.C@$X,=EC=6VV55>TBKU]3A.&?`:W47;]VMS#HW+
MV[SK+%F%J'#'(R7XJ<C9=Y0Y9R)GG,7$D/#8V&2:7_TB[22'6)5>3TN0,T+%
M>VS:-I(C`XR\`=H53K:0552+=K+4=/&,82K6M?Z;#[!N6+1MG'N.<'Q2WL;[
M'<9A5-Q;(:65BR*]UXG2`WC-55=S>)L%=/\`6<Z`ZU+H#:!*[*2HW@;4DCSS
M\P,]CT/D7Q,[*96?$X[J8MXL4.V:H5C8N=Y$%T3;Z^FM:(4)-OAOZ;:Z[TS9
MK:N2WNG<OQ.FY!I7>M7DL*I17;6OD4S5<[XQ":O*F;C;TNCM(S;2=EAF,XY)
M>@-,6<MQEIY`$IK\<")L"Z.DC$^Z.P:Z1VF75SE5R3C)2I)/I>%6XK+\J>>>
M5*9F>L4MVZ7.*"U$4C0YLDZF6WU*J"Q9$(-"/5OOM)%CU7UZ=]66@N_;O1Z<
M._\`&A6^L]#]_0_<6,K;KV/!^3[#7FNI/'AH"D\UYTQ+&/<P*=P<LOV%5LH$
M)Q$C,N)Z*DF6B&`*BILH@AN)](;>NLK-N=]TMJO3^5=ODJOH-L;;>>!CS*,I
MR#-;0+?)IR3'X_4E=!:%6X<,338DCLJ1;*2?K&2D9?!2Z=A2\TG+X6'Q2^:>
M_=^U;/'I-JHE1&GO$'QBL_(3.69UU"=8XGQ*4V[F=F2$`6#@[.#41W$VW-U-
ME?45W;:7?<3-I5H?4_/%I8.Q:?\`Y)+%_I7Q>S=GN)%BUQ.KR/Z,(\>/$CL1
M(C#<6+%;%J-&:%`;;;!$$0`11$%!1-D1/AKS`G'VT`T`T!P+6P;J:RQM'679
M#5;%>E.1V>GNN"R"FHAUD`]2HFR=1(F_Q5-`9VPSRXX/S2M:N6<I#&ZDX-9)
M>G9$<>M1B59OV$<*U]IY[NMRV3K'U=`@Z4!$<0B`D+0$T+R&X,!R*TYRQC#+
MTU"6&P[8L-N.],=B4O0!$BE^QDM'Z)\#']*:`X\+R&XFEV%C#<RV!7PH91!@
M7\J7$>Z[H$L5P'S+:.ZR;+_=!OMN)L7Q15`^J^0?#Q7OV#&S^BFR&6I+E
MB\Q:0"]H;#L)EIIUA9"22*24]I&5:9,#W1.I%-M#`Y</G'C>YOL6Q_%LABYE
M(RF>U7A+HY,67'A%)J;"YBO2B1Y"1J0Q6/HV38GN:=*[)U*('(Y,PG,L]2IH
MJ;D25Q_B#R/_`,ZG21^B_G-KT(S&@VA.*,$"^?NN`R3VW3VG&B^?0%<\@^+/
M&V2<7Q>/L/I(.#2<;<>L,*MXC2D4:Q>1.\Y+-55V4,O9$E*X:N.?[SK[H@X/
MV,N%U-=VTKL>%GD;>4608G>V>*9=4.4.3TAB%K5N*IBG7OT/1W>D4>8=1%5M
MT4V)$5/0A(1F1DI(YZ]9E:E1G)X>Y#R_B;)\NN<'EQ&&Y=A&C7%!.CH]!F1V
MHS4D07H4'6"1R4^8FT:)UN$3@._JZH.;68W9I2W%[RRXXVNTWLWYL\4?R=?S
M^0F[CCB?7U<EZ2TV#DUI\A;7Y*VPBM[*Z1*(,H^VP9N*B`!:Y]\ON*2X:/VV
MK^I;*]%K$ZCP<\><EX:I\ZSC*<_<SNSYP2GR&5[J65I+KGFFY2G#>M>ZX,]6
MQ?`/<"@(:B2H"#MNU^IC=:BE3AJMWNV=1]M0X<=YJCF#,3X_XMS_`#)@Q"=0
M44V14(2;H<]6B"&ULOQ5Q\@!/\5U&TUG[UV,-[2-]N#N245FVDNW`_GTB-#"
M9C,M*I#$``:5S8U5&T1$ZNK="^'KO\=>JI45#U>$%"*BLDJ'YR#R%L>+K!^?
M97]A7OYI*>F6-BS%"0W)DCW.M7DZ2^9/<D0IT_%>H?F'=-5R4(TXBHYCJ-)I
M5"-Z+I2D<&TJ4PP[.L[3'KO[(R#&\D(C:9:EMC8J]NV21)R=AY7M_5$:[B/$
MB_2WZZG:.[]N[&6S+L?M4A>JM%_*Y?)I8PI)=F?NJ;0UUAXL5GE7+N!XD3\:
M9<C96S"J)4=8B2Y2&FR]#B`O0RJHOIWC!%_3KY"MQT@G)]'F\EVM&<;;9E_-
M^;<LRT'J^K4L2HW=Q-J(ZJSWP7TV<E#T]I%3XBTB*B_^82:M+'*G+&Z\/TKS
MEY*G6S;&"CTE----L@VPPT@`BHVRPV/Q4EV$1$4]555V1$^*ZMV[=B&R,8KJ
M21GBV>XO@UX=R.-!B\Q\I5J-<A3HQ)B&-/CN=#%D-J#CSZ+Z),?;)05/BRVJ
MAOU&X*>5^H>>O7SX+>%J.7]SWOR)]FUP*KS/3'7-&X:`:`:`:`^;J(33HDUW
MQ4"0F?1>M-OU=B5$]?AZKMH#RWQ_@/R<X_'%KK!'/:-P<?L8;%?,^Q9V28ZY
M;W%>Y8P*YV8\Y7OQT",<J(#KW2TCLAG<$5H-`6=*JO..5:S*YK))M9%;?=^S
M;Z..(NPC-DLKDLH^CT)9*175D4$8^AA'^AB42=LR1UT#BCC/EL&5V61Q8]C%
M.RC)&=O"/$RNUJ66;-8E>YTBE><EFQDL.JY[=&UAB8]?N%Z5`KZHO?,G.<GN
MO9A:R['C[)[5B"%C2T-71HV-5ED!B=6S)T9)O=*1)K6Q$@+9H#>-3:E$R`%I
MV5/Y1765T\2_QJXOL"BW&/VT%9LS$CFPWJ_(*&R*0Z["&M(7!@M649QME'`5
M>CI-T75[0&\@::;)TVV@;.0:./F(HBF:"((1*GQ7I%$W7Z$1-`9+\JN`G^4Z
M.-E^(1FRY&Q&.3<6*JHVEO6J7<=KS-=D1P54G(Q'\J.*0*H`\9CG"?"R-J=.
MKT:;=AXY6B1;.5C;+\=3;^UY#$R#*:)MQIYB'-!QEYEU!-MQIP5$@)$("145
M$)-8:]_^*JWD#ET7&\T\Z>:-F\4^4^:8$$6CS9J7R)B;6S<>Q5T5OX3:)L*=
MU\A"<">B?MC!U$W)775V#7+7]#&>,<'[OP.BA>:S+3\@_,.7B_%<+)_'*CK>
M8,XO+-JFB8DX^ZU:PI$AEUYLSH4`+"272R9=H4!>@2<ZN@574?3:'BN4NOA2
MQKL[\C9*YA6.)K;B^YNLCXTX[R')`5O(KW&:BQOFU:["C-E0VG9"=K9.C9PB
M^7;T^&H5V*C.262;-D<48K_N`9PL3','XVBO*CN1SW+R\;%45%AU:"##3H_1
MW)+X.@OZ6%UT'IK3<=YW'E%>]_A4O_3NF^[J>-Y05>UX+S?8>8(**$*FBD"*
MG6(KTJJ?2B*J+M_V:[D[XNVI\BGL<FY,Q80H$J%EDQV7&H94D`"(R?5TLQA<
M`MT`A9Z25%44;3HZ"52UIE;6&)3W^7VGP)SX9)=LNG/K[\:G)X8MDEU>052]
M`+6VARHC#:(@I&L123U"B>B"4A7T3_+73<IN5M..Y^./C4\P]7Z7[',)-932
MEY/WHN;5H<N<&QLZVHAO6%M81JN!'3JD3I;H,,@GZ2<<413_`&KK&4E%5;H?
M4F\C.&;>1$)@7J_`8B6DI445R*:!MPVE^&[+*]#KZ_'U7H#X*A&GIJ58T=V]
MDN&.]^4<^^BZS;&UO,K3ID^VL)%O<SW[>XF(B2[.2J$Z:#OT@G2@B`#NO2`(
M@I]")J]TNCMZ=?+F\V\WU_#);$;3T9\#/%.7R+D5;S/GM8ZQQYBTP9.'5T@.
MD;VSC'\C_22;E$BN"A;ILCKHH.Z@#@GQ'JGGRE72V7^]_P#M7_N[MY*L6OS,
M]TM<$2QH!H!H"@/*/^A6<_NS^)Q-`=!P/$>G^,55`CPELGYM7?L,UZ*VBOFY
M-G"+6[I`W\ZKT_.2#^E430&;L.\?/)[CDH+.)9@KE&[58?5Q?<3XB7]7#@,W
MKT^L>GRXEDU)C1K";'5L^E7%B[-;.*P@N@2F%AGFH<Z<,S,9L6'"B32INS8T
MIMS)##%0RR$PG*]QUL9/8L3!6T56W'F2/84,1`_%?QOY60+_`"2VK[)*Z;?H
MXA7_`+BI&5(>:>F%CSMFH-."^%;#<8BSA!M"?(5)KK$150()@R>7&<RVLS6-
MD:3(,F<P<+):NMQMZ-72YU$^_#K'Y\!)X.2HD&6AET=@'G&1!=FNXV!;N+81
MY)%RYB%SR-##)\.Q>^@6%)8'9U<J76BF/7U/8N];,*K5[W+EC$</H8;_`-TY
MLWOTJX!N?0#0&#/(OQ*_F638<@\118L#*)!.2\EPGY(T2Y>)5-R1&<7I"/,<
M554E+9MXO5Q6S(GEV0N</40]5I%=Q6$CRZR%N1$L(=780Y-7;U5U'CVM/.9.
M-+BO(A+VWV'4$P545"3=/450AW%45?FK:=ET(&CMRMWTI*CQ\#HLHLK<;5G$
M<-N;#&;S,XQAF%U3RGH3X4#:*U(1\V"#N*]U]AE'-T%2)P4W;75)&*:K)5IE
MUE_5K(VK@GE9R1A-954$R@Q[+:"EBLP:V(#:T4IN.R`MMCW8C;\7I;$=A!N&
MVFVR;I\=5]S0PFZIM/O]N\VQO-9F@:;S5P.4@-WV'9-0O"B>XDM-PYT1%7;_
M`'9,R4D&GK],<5_PU%ER^:R:9M5^)Y<>2/.&$YUSAGE[6VDMRI%ROA5#DBNG
M,.]F/714<%6W&!(4203NR*GT[_3KLN205C3*,LVVSM/3^NT]G3M2E1N3>3Z%
MNZ#(/)H4>:)1.567RL=GUT@T?GQV)NY1C#<AZ6@'J)#$>G<DV12U8W7&=*.A
MMYO.QJ^!PO<#3S2EEV=-*=IV<3E2H*O^PK.)-A6O:*-%>B`7:?Z!1!?BN35:
M/=/0NESYT5/]2)U+DM0EUGU\ZT]RR[-U/%..&35*57%1]^/7F:(/R=MI]17O
M4V)1XTN7$9=<FV$DC`'#!"+:*P*=0[KZ?MT77H>DT5[46HW,(J23VMXJN6'^
MX\@E849--Y,J3).0,VRX'6;_`")]Z"]^O3Q$2)#V7;<";:V)T?3X/&>K2URJ
MU'&=9=>7<O.I]22R(>(@V"``H``FPBB;(B)^A-6:22HL@;.\8O#/.>?ID'([
MQN9A7$F_<>RLVT"7:"G_`)52TZ*H:%],@A5H?]/=)"%..YWZJA83MZ9J4]LO
MRQ^+]W@2;5AO&61[_P"&89B_'N+TV&893,4&-4#"1ZRLCHO2`[J1$1$JD9F2
MJ9F:J1DJD2J2JNO-KER5R3E)U;S9-2H2?6`&@&@&@.OMJ\+>JLZIQ]V*W9Q'
MHCDICH[K:/`K:FWW!,.H>K=.H53?XHJ>F@,[EXE\/?:D:_CP;2NR-MBBC6&0
MUU@[!ESPQZ%-K8BRRB]H3,HD]QDW$%#5$;42$VFR$"@X>+^(=789>ZWGV2`/
MO++&LA?)VR.(VZB0"><:E#$46VJ\J>)_Q+;B-,JR/=<^=>X!R&\7\3BM[-W^
M:<LF3KFQDT5\T%?;*+Q9&^#]B,DF:P>B+>2;@'ED*0LO&Z*Q71$400/\XX\9
M>.X-_.XZR?D^WR+.\;)S(894M3(Q=MLG9=7,.='EG[KW;K,N#!4NU+,&>AMD
MF@`B`P-!4?C'@&.9\QR14W.4ADC<Z)8279=LY/&4["B3H+/NBF`^Z]TL6<H.
MHW%/9Q=B3I#I`T7H!H"F^8^#<(YJIV(>21W(%[5BY_+>7P.D+"O-W;K0")%%
MQISI3N,N(0%LA;(8@8_5)K(UW+4;BI)'D5R'P5R/P98WLC-H+4_&+.P!ZLSZ
MJ%PZLP]NQ&$9:%N<%TB:WZ'E4%4D%MYTM]H6MC*<N)+8?--:^U'AKM,[R43-
MLS""G[7&,`D-R+%?BW+O.E'&&?T*,,"1TD_^(3?TMJFHB^6/2_`D%JTTRRQJ
M6Y/QBXLL6F/DIRI%).DUI/JOK_Q'M7&D>3=-]G$)-:914OJ2?6?5)K(ZSGCG
MGF29QA)QJVSM[(*BVLX`2HUC!@[]$1Y)K0]V(Q%>7]K'#=2-55-T7X[ZW<OT
M]N%]2BJ-=9/T&HG"_&2HVG7'H[C%;?(N2(G[5JM-?T@P\/\`]\@M=/\`?D=A
M'GU_;&/O^)U-WDSV1,Q6+FFI[)J%(25&9DQW7&T=0"!"4%>1"^4U]%]-?)7>
M+-(TZCFKOI*Y;BZ.JJF\<M_218\CS"G@OU\26DW'GD<`JUIKKD16#3;MQRD$
M\3@(F_RDJDG^A=D0=8?=DE380WS+4VX.":<'LI5I;E6M5T/LW%D!G>29O30I
M-OE]AD$>2P'N65DJ$8SZ=C%R,QVV55%W14(-TUZQR_2::]9C<7SU2S=57;AE
M[CSIQX7E0X;;;;+8-,MBTTVFP-@B"*(GT(B>B:N(Q451*B/A/^.>,,_Y;R$,
M7XYQ:;E-LB@LWVPH,:$V:^CLR4XHLQP]%V5PDZMM@0B]-5O,><:;01K=ECLB
ML9/L\W@9PMN>1[>^+O@OBG"DB!G&=RHV<<H,`APG1;5:JE<5%ZE@`X*&X\F_
M3[AQ$+;_`'8-;GU>9<XY_?YB^%_+;V17GO?N)MNTH=9OK5$;1H!H!H!H!H!H
M!H#RUY;F^3Z<@<^5N!'F]C5SSJ7L3MW6;6+5U`-]YLX01ZY''Y`/*".-RJQ5
M-.H1FL]*$2@=KF=GY/C-RRPQ=S+;;';&=%F2VI5/<0I\8H5==F>,,,19+?4S
M(FQ*]LK:O!M.E_?J).LQ`TBQD'-5[Y`X/*'&+.GX6:HKZ!:"J@T!V[91]I4U
MMY&WU$767&8NP()@2OBK@.)V@-2:`:`:`QMY%^)E-RM*;SK"G(N,\F0'/<.]
MQ%;K;LA8-@1L$:`B!Y&S4`D@)$B=(N"Z(`(878<<>$Q45Q<5,<CS%NZ>\Q>[
MEXQE=),QG)8`H<NDL`0'>VJJ*/-&*DV^RI(J"ZR9MDJ*B$JHNJJ=N4'B;2H,
M<0\ORM_/.\ZQ68ZK]9Q]+C.N,/"?5T3K-AYHA,"<($::,"14`"(5V=U]E\L>
M'?G\`C6^+^1?-N)J#<?-`R:`VB`U69/$&P%L/IZ9+)Q9AE_XG9#G^6H,]':E
MLIU>U#:KLD8PY]\A,GSSE[([?*:*+W:R)6U$%NOD&+;45F*$KI!MUM5^9Z6\
MXO4XJIU=.ZH*+KH^3PCI[-%C5MG5\BYG'36Y5A6KSKNV4IU[=I5@<GU1)N=-
M:-E]**,5?^Q4D:MOY$>DZ!<_LO\`++W?$KOD1S$.16*AFTK[F*M1)-X7XX1.
MZ;1@HFT*G(44ZB0"W5%_5UJNRA<I6I6<TU.DUZBIJ:X77!*M-V?5W$VXZY\F
M\>V[[5KC[<MJQKQ@L3C?"O8?]H[_`,(KH--RACDB/."J(J@O4G2J+L&KGDE^
MMUP;2JLW@L'ADG3/;ATUHCD_4MUZM6VU1QJJT6*V?*G@UC@FUNID6E<<_P#(
M=F)-UY5N-M'ZB<2.LF2'I\$=E*;1)_\`(37=PY3)_7/_`$KS=?!')J$45!93
M[*[E!-O;29>3&E569,]\Y"M*OQ[*&JBTB[_!M!3_``U/L:"S9=8QQWO%][R[
M#.IQA0C-ML`)QUXQ;9:!%(S,U00`!3=2(E5$1$3=5]$U(NW86HN<VDEFWD$J
MY'I_XN?V^KS*I%=G?/E=(QW%`47ZSC5U38L[%?B)6:)TG$8^"]E%1X_@YVD1
M1<\]YYZK=U.UI6U';+:_V[NO/J)=JQ3&1[40H4*LA1*VMB,U]=7LMQH$",V+
M3+#+0H#;338(@@("B((HFR)Z)KAR4<K0#0#0#0%`>4?]"LY_=G\3B:`>+G]"
ML&_>?\3EZ`^GD[&RZ9P;GT7!IUY5Y.Y$9.MLL=9=D3FE8D-O$B-1WF)!-NBV
MK3O8+NHV9$VBDB)H"I(>2<MU6-944J@RJHS*_P"+\/J,7JI+DFXC0,WDM6[#
MY>]='LGVS=@+)>1-O];GZCBB!"(K7D36T-R>+GF3MXY49L'&;%\4R8C;PTU8
M58MC[XB$G5LFYJQ_>N(BITBA"V8Z`^68M^0TGBFKHL:;RY,JI8V7I5Y##6VA
MOV5B_%M8V'S)@S9<F0`+(8:=E,/N*RVKC1.`#)(``>B6@&@&@&@,Y>1O%W"F
M687=9KRS#2H;P>N>L`S^O46+>O9C"3FS#O0:/?,OR,.@XV9JB=LB5-?))25'
MD?**M3S.J_#;G?&Z(^0I&/M97<9NW&L;>AC2&F;RGC=&\:N?BO\`:8/VC1+W
M>P\1$\3O0VNZ*L.[IG3Y<D9IE5V(/TUG]AWD.7C]XJ$J4=O&>KYJB"[*:1I0
M-.J/JFQ(.RIZHNVH<K<HYH^G^:P!A;D/_P#[S+?_`.^G_P#"UJ]TG_$B[T7_
M`!(A^I!*.++AQ9[!QIC(OL'\0+Z%3X*BIZHJ?0J>J:-&,HJ2HS]U,ZQQZJIU
ML2*SI)$>,#$X!WDQB<$4%MT$]71]=D(4ZO\`O(OZVO4=!JKFBTEJ5U\5IPC\
MVV%4L)+;'<UBMJ>9QEV*E.26=6;*X?\`%+G3F^)77.&8:4'$K5L7H6;W[BUM
M6ZT:(H.LJ8G)D-F*[B<=AP%_[R:QUOJO1Z?"#<Y?VY?ZOA4QC8D^@]8>#_[=
M_%/'1PK[D9Y.6<L8Z70C3V$9H8SB>J*U7*3G?4?AU23,55$,6VRUPO,_4>JU
MU8M\,/TKS>;\.@E0LQCUGH,``V`MMB@`"((`*;(B)Z(B(GPVU0FT_6@&@&@&
M@&@&@&@,43_"['L@O^1;+)\MDSJKD?(8UO;U%?'*KZ8S<9V/[email protected]#
MRM63BM$DIH`Z@%X4>0"VJ;A.<U*D2<IS=S*4GYK%S6S9^SFHJ2GX`.K`CNEW
M724(KHQ#:V5$%(K2(/4KAD!(,?XN?@<AAR;?7S%OD[6-%C)R8%>E8DR.ZY$D
M..V`@^\,@VGHJE&78>P+SX)U(YZ`6[H!H!H#\`XVZ*DT8N"A$"D*HJ=0$HDG
MI]**BHO^.@*<YSSZ9A.'-U^.0HUUR)R#-#%>-<=E#ULRK:>!_M9((B[Q8;(N
M2Y*__!:-/UE%%`SNO@%Q978G44V)7MQBV15T5M+/(&R&5%MIZ[%)FS*Y]5!M
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M6"?V[/*'+6ZVQK\.B<9RC89&78Y5-9C192-@B$,F%$65+0DVV$E9$O\`Q=.N
MTO\`J+2V(QGI^+[E%7#Y)47YDZ=DDJ]-,#DU9D\\C6WCCX5<4VN02L1Y^N;V
M/R[3-G*L>'C(::%*A"2#[^NG1GG7[2)U;(C\9]E0ZD"0RTXJ!JKUWJW6:C"%
M+:Z,_P#5\*&<=/%9XGKMA^-X)@=:QA.#5%-B]=6CUMXY5-LQD#K1-W39;V52
M/T4C)%(E]555US,IN;K)U;-Y+'7V8XH;[P,@I""&X2"BD2["FZ[>JKZ)K$'[
M`P<`7&R0P-$(#%=T5%]45%3X[Z`^"S(8RA@E*92:8=T8:F/=4/5.I`WZMOE7
MUV^C0')T`T`T`T`T`T`T`T`T`T`T`T`T!DGRDH:CE=K#O']BNC3<LY#DN39&
M0*T)RL7QRO-I;>XCO(G7'?=$PA1B%4ZGGT5>IMMQ-?&D\P9[S#P.O,;BLM\/
MY+#M:.`R#,'$<A3V<EAEOT0&+"(T33B""(+;;D=OX?.\N^Z1;FE4L4S[4RCE
MF`<@8";Z9O@E[C$>-U*_;2(BOU@"GJA%9Q%?A)U)ZHBO=7QW1%142++3SCL,
MJGG;R/)C3.0<ME0Y#4J,\_#)F0R:&!I]G1/42%51?]FK71JEI=OB7.A_X^TA
MNI),&@/I`::?M@8?:!YEV!*!UEP4(2%7&$5"1?14775>D8*>KG&2JG;>'_5$
MIN=?\<>OR)1BN#Y[;RO:<9XI>\D5[9]$C'Z.%(LY<)/I5HHX.?(*?$'%39/U
M2V^7737]?:Y8\+BE;_15.<?V;6O[7EL>PH5!SV8FY?'CP=Y`YYIH68O93285
MA3[ILOR%="VMP?9+9Z*[7QG1&,\WMT.-R7FW63]#9W11U5Z[UI;BJ:>#D]\L
M%W9OW&<=,]IZ^\(>(G"_!!1[/'*)S(,R9!1+.[\@EV0]:=)>WZ0;9BHJ+TKV
M&P4D]#4OCKBM=S34ZUUO3;W+)+LR\R3&"CD:>U7F8T`T`T`T`T!0'E'_`$*S
MG]V?Q.)H!XN?T*P;]Y_Q.7H"_P#0#0#0#0$7S8LO#$,F<X_^S"SAJLDGB;=R
MTX]7N6`-D4=N4#+\8^V9H@DHNBJ(N^_IMH#"M=YY0V7*U^^PXVFLXAA88#C*
MJ5?>``Q)K3S$Z'()TS);.HG,`30H1"C79:?4E70$B_/C@IXBSG3-77?RY*!U
M(Q/Y##8F=YBILK96GHA-]UE9+5820U<1/<=UI1Z>HN@#KFO..FJ;A<*L(55F
M&7G;6E?#>J[.+71I!AF,C'(#8C(<>%M"8$'S(GE5!0BZ>C8M`7SF^+Y/RER/
M@>-7M,]5\68.S"S7+%-P'&+S(&GR^R*D>E45QFO>86:^JHB$X,1$0D5S8#1&
[email protected]"BR6O=J<CI8&053ZHKU991FI<<U3X*33PD*[;_2F@*$NO$?Q^NB,QP(
M:$U+J:"AGSZEAI?7_=Q(4AJ,B>OZO:Z?\/1-:W:@\T*E!WO]LWQWOK*3:OVF
M:1)4P^Y*]O9Q5$RV045>]"=7T1$3T7_/U]=;(?(J+(D6]5<@J)X'5M_VM_'(
M'&S*\SEX0)")D[."@FB+NHETUXELOP7947_'67&S/^==W^XGE%_;E\4*<D=F
M8-99)(!=VW[.\LT1/UD5.S$D1F2]%_U`OP1?CZZ<3,):JZ_S&DL%X/X>XR1@
ML`XRQK%),<>ANQKZZ.W,4=NG8Y?0KY^GI\QKZ>FOL[DITXFW3!5(YUV*\,4N
M`9M/R;`+:7B.,Y"DE_+.,(@-%0R[)\D-+.-'(=X,A2ZE>]NH@_OU.@3B(>L`
M9RL/*F7BN-Y5R%E&78BIX]DE[CTGA0E6ON8RQ+T*:L-^6;LAT%,.F0Z;D5&R
M1]KMJ(H).@=!;^<?VA6U$_&Z6CI*^WMZ]*J\MKQET+"M*ZJZN8,9MII`*0B6
M(FH(ZO;;V=+J11$@/UC?]P##K2508^]7U;MW:UU%(2R?NF*Z$KUC2NVTIM\G
MVR&.XA,]A@$-P777&P[@*I=($KY2\H[?BOF>VQVV2LLL#K(+1)%KR9*<W):A
M),G-V).2!=B*VU)8?;<[!1S:[email protected]@.@D>>53]G5UU7X)$ETUM>0<<@V#
MF1QFT*PG0Y$UL"!N,ZHB3<4T`U^4EVZE!-U0#MJ7S5>R19;M!Q8EG'@U&09+
M*98R6NE3@I<>;K2D]<&$,EUN>A60B4%Q!=!0+=?F;ZP-CX=D7\W8KC^4C`=K
M&<B@LV4."_OW0CR11UCN"0@HF39"I"J;BJJ*^J:`DN@&@&@&@&@(OFV'8_R%
MB&38+E<$++&\NK)-3=0C05ZX\ILFCZ>I"1"1"W%=O1414]4T!@:/P/Y;8X=4
MY2Y[3RK>^A"/*.70Y[]>]/FL0YU6Q(;K_;$V1##8JU(N^!JZ#W:..A=1`2/_
M`--?,8\0%I_**QW/10F)MFSE]BQ6/@]3V34=V/&2H(F2@3I$12ZB+W:,*;G0
MIFA@=./$/E?#MBAXY.K,-X_=M;!]RBH\D=C268MKF,F]?6,'V8L<'$KW5C(O
MQ12]"4$Z4`V8WQG7ER16\CV5K-N9N.XVF.XE63%$V:U9#RN64YLMNHY,T6X[
M9F7J(-=(;(XYU`65H!H!H!H!H!H!H#B/0(,B5#G/PF'IU>CB0)CC8DZPCR(+
MG:-44@ZT1$+9?7Z=`8>L>"N88&*Y718=385"SF5DMW;4O-975C773\#(;Y+&
M2TZ42M<D,O)#08YKWW`5&64%.E>ED"-V/`'DS?5U*639A69!/<M(%Q:UDK++
M@8,"97W-7/;>BBW5H#J>UCR&4:5H!;<47!4E+]F`Q[AKS&J9])$F9KCCF)U]
M?10K&FKLJN82NG5TSL`W8Y_8[B1]IAMRB;;`6WT:1MT40CZ@)AREP3S%=\Q7
M')O&=E1XU*EP@CA/F6+JG)2'!;;B$C?V:^[!?5YV0RX;+Y,N1^GN,$Z@D@%2
M9_@WEKBU3CDI_)[[*;^SR",W/AXG>W,J*-6Q`D]QA>W7QE8?<E*SVWG>E@ND
MO<.`GRF!+Y/%'DO14=[?Y+R5DEG/KJ>_>K8>.Y!-M7YF42_LQBFE,UC556`$
M'J:DFY"<?)MGNJ7=(?F8`W+A===U.)X[7Y+8K;Y)'@,?S#9;DHO3B!"DDWUJ
M2BWW5+H'=>D=A^C0$GT`T`T`T`T`T!F?GSD_DSC&VPE<4K*BVHL]2=BE4DJO
MF2I$7,YC7<QTI3D>6T(USYMNM2"4$)LNVJ.?-L@%,4G]P#CVPCTB/4SSIV<I
MNL.Z;E16JWWDJ)&F0C-[O/`PR\U([ADXXJ`(/&R4EMAQU`)7:^8>/J^%55MU
M<"[K+.C3(V9%C!LHX5TV?BS$PVGH<P`3>/E#91WU4FR)EW<>E$50)9P5Y24_
M/EG*@XMB,N/&IZD++([(YT-T83K\V?$CQ.P)I()QQ(!.+^S$10A]?45("4\(
M8ED"NY5S!R%7.UG(O*SK+I4,DA-W'L=A*XE-1[BJBAL@Z;\GI]%DO/;*0B"Z
M`O\`T`T!565<%<*YR\]*S'B7#\EFR"ZW;&PI83\I2WWZDD&TKB+_`(H6A]4F
MLF5#-\%_%">[WGN'*YHD39`BS;**&VZK_NV);8_3^C7WB9M6HN+\S[SBCX%^
M)8D))Q!&515%3>UN%3T_2BSMETXF/Y%S]3+$H/%OQQQAQJ13\'X4U+8V[-A(
MIHDN4&R[[C(DMNNHN_JNQ>OI^A-.)[S7*<I9NI>,6)%@QVHD*,U#B,)TL1F`
M%ML$^.P@*(B?[-?#$@3'%F'P>1)'*%1$D4>56<-863%72'(\.Y!$1&'+.("]
MF0]'1%1IXA[@"J@A]"].@,FS^4>5\8H,OR<V<\R#E6HR.ZKTXO3$IT['TK9%
M\,*GDLG`AMDZRU7BV\+C4LS<4WE<0NVHL@=%;<]^15[64DR/@%MB<*XMJZ76
MI!Q#(9,]R&U=5<>5!E"XVJL=4.4Z^3ILB)-@0M[&!D`'ZQSR=YW<FT./6/#6
M21&WZZA]]E%GAV2'[:4]3.2IP26XC&[JNS@;C(X`-HPKBFXV0A\X$IY3Y-YL
MPKFRV?Q>BR+.,)AUP(SC4.GG>WC.Q80R)3A&S`=&:R\DL.VXQ)1X)#9,*PX'
MS"!",D\M.;L=J:R]MN.8>+0;.W8K4B7=!D#$IB,D"1-E6;H/%&VBLJR(.FG^
MY[@]>Z["0$CB^1/D1(K[F\F<;4N/5=#2Y'D=HW:U61P49&D;KE:HG9UDS7PT
MFO'*D(,@'#C.(SNVJ_M.T!M;"[6WO<3QV\OJU*:WN8#$^;3[*A0UD@CHQW$4
MC_:-"2`>R[=2+MZ;:`J?RC_H5G/[L_B<30#Q<_H5@W[S_B<O0%_Z`:`:`:`:
M`\^N0?+X<,NN5J?)N':]Y.,K*P8:*98NBIU46EFV;%@^05,EIIJ<<=([*@9H
MCCR-/]ISI%T#L\T\LRP*VRFLR'A9N(S0/Q)$F8[*F,!(A28^]=T*_2-@<R0@
MFPPT)DP3C3K0R^IM14"Z8?+/&5ESI+X#K:RCEW5912[B[D"]"0X\V&Y`<"![
M%$5XC5BS20KBH@HFZ#UEW>T!HG0#0#0#0#0#0#0#0#0'Q2/'1UQ]&&T?>0!=
M>Z4ZR1M54$(MMU05)53]&^@([F%E,QW$,DOJ7'@R6VQRGFSZ3&D?:A>]D1(Y
MNLQ!DO(K;'>,!#N$G2&_4OHF@,(PO/G'TH*F_N,','BQZ/,O68'O7B/(YY6H
MUV.1_<08RM27/L=TW7)*@TVO2VV;_4+F@+UP/G.?F&<851S,4@1ZS,*G)6W,
MB82T0HUYC5@%?8U!++K([2D#S4D.DG1<7VQ.=I`(=`?7&5H?(@,RI^5\!8@V
M_%&5O4:U34VT%E]J550IA&7>C5;C\=X9A,$)M$P_VNX/4!"B`7YD6+4.645E
MC-_7I-H[E.FUKQ<<8&0'6CA`X3)`2B:CL8[[&.XDBBJHH'?``-@+;8H``B"`
M"FR(B>B(B)\-M`?K0#0#0#0#0#0'E9R1@_E7-R#FUKCU,^BP+#-G['&[I[('
M83I1EHK-M(,1EJP5CVCCYQABOM`VL<S9*8W(2*\R(%^TN-<N5M_D5B\_G-K4
M7')./7%4[:6#@3(<)R;,^V*]8T6Q<B+5Q6"!6D!H.X)[&#KC0'H"S*J!G,[R
M`BY=&8R:LP!W$;.OR&CN)+HP!M#DU9P)$6,%D_&4NTP^*=$0#%2>)QXD<;#0
M&BM`-`-`-`-`-`-`-`-`-`1#D&NL;C`LWJ*A^VBVUI064.LDT,EF%;-R'XKC
M;1P)4@A:9D"9(K3CA((GTD2HB+H#S&J\-\WX6(8RS60[./:0L/"DJDD6'>=A
MM.#?'86RC.MGD:N'4^S6X[;RO--(XK8)&`7D9`N#BG&_(G'N7*[)\PH<@E8+
M75-C3PL?B6#9@Y'^T7FJNT>27:/$3ST-&7),9Y2,'B-Y'B]64`MSQ*QKE[%\
M.RV'S$MFY>3+]J96.VLX9KPQRJ:]IYE"!U\2[4EIT3?0A22YUR4::1U`0#5F
M@&@&@&@&@&@&@&@*OYHSJ?QEQ?E_(%9B+V<S\3B#/8QF.:@X_P!+H"9H0MO%
MLR!*Z70!&J"J`*DJ)H#(P^9G'$&9FS<C!<?-C'L32[KI]3:L2`NWY<*H>:@Q
M3=@Q@4'2LR;=(BZV`9[LMAAMYA3`OG&.0).7Y)DU7'XII9357B%;E&'VL2TC
M2UGC.5\(<24OLP;A$][5#8(77D5G8S1HD[>@)OPY>KF&(LY7,P:MPFUD3;*M
M=CU;XSH<EBNG/1&ID&>L2"<B+*%D7F#)AOJ`A)!Z50E`MG0#0#0#0#0#0#0#
M0#0#0$0Y!N+3'L"S>_HWZF+=4=!96%/*OG'&JEN5&BN.LG/<9_:#'$Q175#Y
MD#J5/70'GWQ]YE9OEB8+77/V7CQW-$S'L<D?@1@:=R24F0%\K#MT#108K="X
M)/-/JCKYAU+%;0Q$"7\/>4V=Y1EF+5/('\OT,29(^Q;^`3*PWA(*IV:MZU(]
MY)86&Y.;2O;4#-EPR$FGSZA#0%I\"Y;=<[4E^]S%@5'*L<#O(#$%UR!'?BQ;
MI*F)(M8\,R?G-N%73GWHPR&7/5!Z%_:`XI`:BLZJLNH3M=<5T6VKWB;-Z!,9
M!]DR:,76U)MQ"%5`Q$AW3T5$5/5-`<_0%`>4?]"LY_=G\3B:`>+G]"L&_>?\
M3EZ`O_0#0#0#0#0%8#PKQ.$Z^L4P"F67E-NU>Y$11A()M@P?=;>?;7<#Z7OV
M_2J=/?W?V[RJ>@.S'B_CT9?OOY0K2DK9-W#CALH:.3V#)V/)=$MQ<-APR-E2
M1>T2J3?22JN@._@XSC]:_6R8-/%BR:>++A5<@&T0X\:>ZR_*:;+XH+KD=LB3
MZ5`5^C0'>Z`:`:`:`:`:`:`:`:`:`X=C75]O7SJFV@Q[.KLX[L2RK9;0/QY$
M=\%;=9>:<0A,#$E$A)%1479=`5JSP7PTQ"KZX.+\96#5P'*R%&.MCN",5X)+
M;H+U@O4IC-DH1%N2]Y[=?VKG4!SXG#_%L!QUZ'Q_1,//IL\Z,)KJ)2>"29JJ
MCNI./-`XX7ZQF(D:DJ(N@)+C.)8QAE>=5BE#"Q^N<=[[L6"R+0F[T`TAGTIN
M2HVV`(J_`!$4^441`)%H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H
M!H!H!H!H!H!H!H!H!H!H!H!H".Y9B>.YSCUEBN6535UC]N`!/KGE(1/MN"ZV
M2$"B8&#@"8$*H0DB$*HJ(N@(K5<-<6T;]A(IL&JJLK6M>J)S<5KM-'#D,1HS
M[:-"J`*O,PH[;A"*$8LM(:JC8;`=0OC_`,/%9Y#=+A$9;;*FG&+ZP[\KNOM.
ML!&,.KO;@BLM@&P;?*`)_H'8";85@N)<=4+&,X52,T%'',G&H#).&B$2(BJI
M.D9KZ"@INOHB(B>B(F@);H!H!H!H!H!H!H!H!H!H!H#K4IZ@8[$0:J&,6+&]
ME%C(PVC;<;81[`#T["&PHG2GIZ)Z:`^ZP(*F+BPF%<%H61-6QW1L20A!%V_5
M0D143X;Z`^S##,9EN/&9".PR*`RPV*``"GHB"*;(B)_AH#ZZ`:`H#RC_`*%9
MS^[/XG$T`\7/Z%8-^\_XG+T!?^@&@&@&@&@,UY)SY<IR%R7QIQEQP[R-DO$6
M-U^09K'<LQJD5VW%YVNK("E&D(])?:CN'^T5IM/E3K557I`Y5GY9>/=0_*C2
M^1F')$6R9J4:B0+&83\M^=)K&QB)&BN^Y'WL1V,KC/6"/(C1$AD(J!^*[RW\
M=+ACW-3R?`M&?:5TL7(D::]U?:Q0A@1QZ(ZJ4F0MA'Z(R?MUZ_\`=^A;`5*?
MG7QZO($C&X\2"]@HRL7]ERF=KV:]R!D=3=69R76W8@]AR(M(\V;)GU*G4:J"
MMF"`=MAGG/POD`9M/R2W;PO'\<R%RHQV^E!8&W;P`K8-I]J]IR`P[$8%BP:5
MPG@[8[]2.$"B:@3*B\P>";B5;PIV3R,4D5.46>*DW?0)<'KD5-A$J),DR-KI
M8C>_FLQD=?4![IBV72:][email protected].?IN!407U5PO55]O27)RI,2-D,>R
MK7K)DVO<0`<8%1944-`=`T5#`B%470$9X\\Y..LR1AW(*\^/4A1G*[,:&V>>
M>OZ?+6;)FN/'W*F-$-QXC[PNM.M&JF&ZJT/2?2!.8OEGQU?83SOG&$5UYF57
MP/7)869Q8#S+5R+E0%RRM6\Z""\#C#@_.GP11<V5HVS,#I>/O,[B'+*ANWOL
MFHJ&):VY0,3LZNP?NJ^RAHM/']^<D(4<H0).NF(1C,;9('OE7]9-`<3`?-[A
M?(,(KLGSW(('&=T^[;-6V-R9#T]N$5987,$!.<U%;;ZY844MYAHA%UP`+H`N
MG0')Y^\O<5X5Q#CC+X=*[DM9R5=A4U5E.=.CKX_0^VV^,R7.9%(KJ@KBMC(1
ML%[9]1@@^H'^Y1Y:1L8K_)*?(XOO7_RX557:W$1)M:CEBQ:0'[`7FE&0;;;0
M-M)Z]1.+U?[I%3IT!,>=>>K3AGC:LY-@\9V.>U!I"D9%'@SXL1R#%F/1HP(T
MDCYI4AQV6`LL-BBN;%\PKTH0&?(7G_!OIG*M5B7$=G>W'&]':Y.W">MX=>#M
M117%G463]B[)`1@&V58K@-_M5)'6D51W-0`G?*7FMB?%F+<2Y1;87</)R7B)
MYY94[IA&F4M%%;KW9Q/@0FCLEE+$=F$4>KH<3K%4%"`VKH!H!H!H!H!H!H!H
M!H#,M;Y"V.4Y+R'"P;C]<AQ#B?-H.#9YEDJU"O<9F$L8K:3%BN1S!V/5,RP=
M?(WVR)$/H$NE%(#XSO,[QHK8$>SE\GLC"E"ZXPXW66KI*PU6A<+(4&X9&C!P
M#]RV\J=MQI#,"(0-1`[>3Y9>/,9BVE%R9"?CTLQV!-?BQ9TH2D1VIK\D(ZL1
MS]Q[=NND&^K/6C0MJKBBFVX%05?G;Q[_`#?DM)ED2%B.*8W>915EGSEHLN'+
MC8_%HYD:7$!J(BOK-"]91&FR(@+H$5=[H:`E/&GF?Q5FE%32\IDK@>37UW94
ME;B;C5A.>=<A7,FCCDA#`9-M9DJ,0,M/--N$:HT@*Y\N@.=BOFUXYY+B=-F$
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M4\5()4UYB9:PJN8M8R['C*,N3'2XB(XVRBN"CH$8"A:`^/*_EE0\:\G<(<;L
M8\=PO-),O5>02Y85418LCK`!B.RP%MZ2A]M5CF;9J+@("&9H*`5YE7GIC^+5
M5M*E<97(W-3EV<8X[C;\Z&#_`+/CRC._O)Q.LJ^PAI';4&61,D,U%%=`54A`
MGG(OF-@O'W(&!X4[33+6!EU'09+;9*+@QVZRJRBY:HJJ0K#@*3W5*=W='<%;
M;123K7Y=`5)1_P!Q/$[7B3,>63P;KC4=XU2XYBU9=L6%I-W>::D29\=([1U;
M<9)#*N*^*_,[email protected])@:5S3R/P?$.9\,X).5#7.,LC1[%\[&<W708D25*6+&
M:1XQ<)^;+,'/:Q6PZG.V2F;0])$!H70#0#0#0#0#0#0#0#0#0%#<G<VK@_)'
M$?$5!CC63Y[R^=P_41YE@M97PJ^AC#)G294EN--=ZE1P0:`&"ZR5=R`14M`0
MY_RYXQPR/,K.;+%CB[/J)B;*RW$6$GWS%>U&:L)S*_:4*`+3AR:ZN<FML](O
M*UM^SW5-P.55^9OC9<>U2'R,39RY,V*C,RENH;C)5P0'99R6Y,%HH[33=I%<
M)UU!;Z'.OJZ!-1`IODS^X3QIB'V=-PR''SN@DX]D%S9VLEZUIWZY^EC4\QAB
M37G329:-3(]VPX#XMJ(CN72HH2B!-W_-KBZ/S#:\=$1O8A24$Z;8\CL,6KH?
M;<#)*_&'*B-"&K5)>\NP`>_%?=`2%1(4]20#[Q/._P`<94V\5<KGLXS44V-6
M\7,EI;8X,]<I*7[*+&1N&3I/=$534%!"5.YTHOMY';`[''?+WC_.^:<#XJXX
M[6;TF8UE]+FY]%.:Q%A2Z.-7S%B-(_`&/,5QFR:(B8E*K2_*X`JH[@5;CWGK
M52,_O.-<ZP>%QMDF+Y3D,&Z=M;UTH<C$\;BW+\W**IY*L"F,MN4<EIUE0;5L
ME#=SU)!`O#CWRRX>Y7Y%K>.>.[*SR:;/Q^??OW`5-C&B10@30A+'DE)C-$RX
M1]:IW$%/04W576T("I,%\]N.;^7EJYM&A\?0,/F2:NZK')=A89)`LFI[L9B)
M84+52T^TK[#7?1Q@GVA^<%<W#<@.ZJ?.WA;^8LRKLPO(6)XY5SJ)K`<K`YT\
M,A@7V/0LC:GK':@`Y";:C3FT<5W<`W12,=T30$QS/RNP2#P5R-SAQHQ-Y/JN
M/^AF3&@P+".!NF^RPZ]U/11-R/%1Y7I#C(.=+;;FVY#TZ`IK%/[@&-9#GW&V
M#O8G`[7($K':UF^J\@9LA<E9*%ZL6171V8V\J&T5*C<ATG&C8<?!MQI"`TT!
MU/)']QC&N/,@Y`J7>-YEK78=<6]'77+5@2^YD8W84U?=O2V&(4@XS,9;8G`)
MOOF8L'NVV1"F@)WQGY:<A\E9-PK'B<%U]?@/-#$N33YPF8LR7@C5T`IDR8U6
M-UB..1P<[<="=<9<[C@"XTTNZ:`NC$^9,GN^=LWX8ON,W,;AXWCS.3468MVS
M-@,V$_8OUS*2XK+(I"<D%&<>8!7G%-I%4NV8FV(%_P"@&@&@*`\H_P"A6<_N
MS^)Q-`4YP#Y"<(X=Q-C&,Y5RAC^/Y#3.V;%K33I8,R([GVE*+H<;+917947U
MT!<?YJO''\:,4^\&_KT`_-5XX_C1BGW@W]>@'YJO''\:,4^\&_KT`_-5XX_C
M1BGW@W]>@'YJO''\:,4^\&_KT!1]WF'B79<AW_)]-Y%1\'RK,:6)C^;R,=NH
MD8+B#!,BB^X[T=\VGF1<-L'XQM/"!;(XBH*B!4)\?^!P6E7;UO/J4TS';J)=
M8HL:]@NC5'#OY64#&CI+B/\`6R=K+60:/]PUZ0!#1OJ`@(QCO"7]O7&9N.VL
M+G?O76'-5[>'WCUW6C+KCJ95;,@.`XS!:[_MW:QM0"2CK:=;R]'4Z2Z`^J\+
M?V\SBG6.\Y]ZBDC5C84!Y!#6/)^RJZVK15PDB(]N^W>SC=Z7!W-U5#H00$0.
MOON"_`/**5ZBR+R5M+>')DG+EE(R6OZGGBJ8=*#C@C`$"-N)!:$'%'K1>M>K
M]H?4!,BX]\!GLMD9G+YS:G6T^ZR"XM&I%]$./)')YH6-G")OVW[-ER2'6A-*
M#P]2HCW3LB`2[C-GPTXIQ_/L<QOR.]U%Y"QVKQ:SEV=W7R7XE92U[E77-0U]
MF("K$1SMBK@GN@BI=2INH'69]C'@1R/?R,QR#EZG;SF:QC_VGF4.T@M2YD[&
MG^_`LI3"QBB/2-E)MQ385LVU[:M](AT@2C'K'P\Q.NY(K<=\B_LEODTZ=ZU?
M8R".CL*320HL!B1!)6%Z'#:A,]Q7$-"4?1!1510*CR7B/^W_`)58K;V'/0Q;
M-^\>R2Q?@759$9DVC[U:\LI834$8C#B?94<>J.RT1#U]Q34R50/]JN)/`&E]
MR4#GP4=LH$F!>O/W%5(^T0E6$^S(I0/5YMEL[9/BH"(M.-KVWFW`]%`F^45'
MA/DG"6,<`!S]#JN.\;5IERM9N(CGOX0V3-F]$E@ZR3?23C*(!-B"L_\`E](_
M*H')M(7AE9U_,U1^8](-1SG45=!E];&MZM`8K:>*D&)&@FY`<<;08N[*D9F1
M(JDI=SY]`=!EU;XW9[93G,G\WLD9HV)E1-Q>AI<GBU[<"155;5<D@=H[@`XX
M0F\J1P9;1PNYT=SY]`=KE=)X1Y8QFSC_`)")2Y#R++K7<QS*HOH<6SF0JA2*
M#5]7M29;B-FJ.$+;0FZ8B3QN+U;@=9?8;X,9;'J8^9>1,W,EJ@&*DF\RU)SS
M]:Y%KXTZL<-UM5&-/*M;?D"WT$3I.D!@CIBH&P_S5>./XT8I]X-_7H!^:KQQ
M_&C%/O!OZ]`/S5>./XT8I]X-_7H!^:KQQ_&C%/O!OZ]`/S5>./XT8I]X-_7H
M!^:KQQ_&C%/O!OZ]`/S5>./XT8I]X-_7H!^:KQQ_&C%/O!OZ]`/S5>./XT8I
M]X-_7H#/Z7?AY'R+D"YJ?(*/05'*UFU<\CX367L:/56T]MD6''W%1A9C*R``
M$D#'DMB]T[."2$:$!2LGB+P%D0HT,?(9^.4:I?Q\9C=]6D\50[C)8@U`)78)
MCVX]4ZZRV2"CG4X3AF9H!`!^(_#G]ON--M+EKGKHR:U8?BOY2U=UK,Q(\N':
[email protected]_$N'F"<>:-P0%H6S!&QT`G\-_V^;`93#G/+C%><^RLJRL8R*&
MVW72;%NF;0XCB1.\GMDQ^`K/6X>RM?/U]1]0'*9XK\#PR3#<KD>1TRPN,%O5
MR6C<DY#7DTEF5\62.2%9&"("KDTE4^V@=0;`NZ`'2!UT'A#^W;!IY%"O-R3:
MJ=BJ8A9QY60Q7"D0&4E)#)7/;(;3D1)1=M62`2Z1[PN_-U`7EB>0>*.&8=EF
M(T_DZ1.9GER9Q=95*MZM^T6Y]Q%E&\!E!["(;L-LE%653X[;;Z`@>381_;XR
M/+['.6>4:/&<CM<B>R>=(IK:*TR<Z97E6SU2.\P\T*3&E0G2$4/NHCS9MN[D
MH$\IKWQ&QS%;+$:#R0&JK['-+#.1?"[@O.,3;20]*EQ`"1%=8.(XY(<4FG6C
MZD)4(E]-@*,D<)?V]SL*2R@\]N4TC'D>*K:@W]>+#+TEVS?D.LL.0G&X_=<M
MY!$TP+;._1LTG0.P'UB\+_V]85#98O$YR9#'[B!6P+.J=MZJ4R_]F0(U:V\X
MDFO=ZC-F(TI(NX"Z*/-@VZ(F(%K\@_DOY(C<2T^0\\U[N*<22JF178FMRR[$
MG+1QI#%>4DW`)X76U?ZE=:<`C1.D]_11`B=QA?@OD4&ZAW_D"-L]>Y1D>52[
M0[NN8E`_E]:[4Y!$:<C0F4&-/B.JVX&W4.PDT39)OH#C#A_A79Y*N69?Y$Q\
M@M(MO(D4K`W_`&H\6E9M&[>DI!ZU==2+4RFD>C`VX`B:D/2K72V@'WRK`?[?
M^?XW.IN0^9(>>7U@;9/\C7-^PYD'2TD0!#W+++3*HK<)H"4F5(D3<B4_FT!W
M9TO@Y)SFBY"M.>AO;^ALHMFR5IDC<L'RK+>3=U##I.M$ZC-;)DDD8&W`V;$&
MC[C8(.@-6?FJ\<?QHQ3[P;^O0#\U7CC^-&*?>#?UZ`?FJ\<?QHQ3[P;^O0#\
MU7CC^-&*?>#?UZ`?FJ\<?QHQ3[P;^O0#\U7CC^-&*?>#?UZ`?FJ\<?QHQ3[P
M;^O0#\U7CC^-&*?>#?UZ`?FJ\<?QHQ3[P;^O0#\U7CC^-&*?>#?UZ`K+/>4/
M$?D*YP?*+/FNCJ<PXWF2IN$9;4V[4>=`*>Q[:8T*F+C3C4AK87&G6S`MA7;<
M15`*4R_$/`#.9=K.R7EZ%9S+Z"L6^E2<E*2Y-D%6SJCW[QR>Z7N$AV4AH5%4
M`.H2`!-ML@`ZE.-_[>CY-A<<LUN101N?M]ZNL;R.8.6"PX<`GD<:9;?:ZV(+
M(&C+@(:(HGU"1(H'46?#_P#;NM89Q)/,C`K(KY=583&\B9%^5"F0:ZM-AYQ6
M551&+4Q6AZ=E3H4M^MQPC`[:QXY_M_6DRZFR>;NER\28,AEK*E;8;"QO&,DF
M@TR(HV@R+&.#QBHJG^A$0-A0#C5G%G]O&FKZ^OJ^9$A!4LT85CS>7/=3+V-R
MY4JJD]*JK9NQO>O,BI@0]HU#I]550+"PEGP9X_Y!KN2,;YGAMW50]<2JV#+R
M=V9":DW\:'&M)';D$9FY)&`R1J9E\P]2;:`Y5X7@EE<.GBY?RCCV4OTDG,'H
M5M.MF@F(UGD:?&R"*KT46%[$H;)XNA-NDNA15.@=@/KQ_.\*>-LIQK-,>YS8
M>R+&,><Q:+,GY0[("16$8FVQ)94D;<1I1103I1.KYR0G/GT!!LFPOP(S2(Q'
MRSFYF^D0X%;3PK9_(VVYC=75/N28T$WV6FRD-(XXB[R.X?R-HAH@)H#K*3C7
M^WY03:FR@\W*EG1+7C4V2Y6K;[$>NIFL>;C`XR+:]LZYAEDO]2=L#`@<124"
M?5B>$5'Q]R/QW1<UUU+`Y0F,V62W$&];B3EFQ6HS3$@#C"RWUI[5M75("60O
M7[A7>L]P.KBU7@S3X[!I<?YAHZV7C=-?U^"61W;BI26.2#(6RN8H1GHII,=<
MDF2/"X+C0KVXYL!Z(!TD'!_`6,Y!L9W-$.ZR:O*#.C97.R)'9H7,1^IEOW**
M:$"RYDJEBOR",2`S$_D1'7$,"=T$CP<Q3'8F,XQS!68]!K,.M<(I95=D1QI=
M?`O)OVA9OPY#9(;$F5)0'#=!47<`1$1!1-`<KCN\\/\`C?D#(^2Z[R-DY%DN
M4-.MV(9'F$BTA"3WMA)YF(\7:!U&HC32.(/6C8]&_2JIH"__`,U7CC^-&*?>
M#?UZ`?FJ\<?QHQ3[P;^O0#\U7CC^-&*?>#?UZ`ISG[R$X1S'B;)\9Q7E#'\@
<R&Y=K&*JF@RP>D2'/M**70VV.ZDNR*OIH#__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>25
<FILENAME>medtronic062430s1_ex21.htm
<DESCRIPTION>LIST OF SUBSIDIARIES
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 21 to Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR>
<P style="font-size:10pt;font-weight:bold;text-align:right">Exhibit 21</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">MEDTRONIC, INC. AND SUBSIDIARIES</P>
<DIV align="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM" style="font-size:8pt;padding-top:0pt">
<TH align="left">Company</TH>
<TH> </TH>
<TH>Jurisdiction of Incorporation</TH>
</TR>
<TR>
<TD>
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD>
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD width="66%">Arterial Vascular Engineering Canada, Company</TD>
<TD width="4%"> </TD>
<TD width="30%">Canada</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Arterial Vascular Engineering Netherlands Holding</TD>
<TD> </TD>
<TD>Netherlands</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Arterial Vascular Engineering UK Limited</TD>
<TD> </TD>
<TD>United Kingdom</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>AVE Ireland Limited</TD>
<TD> </TD>
<TD>Ireland</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>AVECOR Cardiovascular Limited</TD>
<TD> </TD>
<TD>United Kingdom</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>B.V. Medtronic FSC</TD>
<TD> </TD>
<TD>Netherlands</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Cardiotron G.m.b.H.</TD>
<TD> </TD>
<TD>Germany</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>IGN AB</TD>
<TD> </TD>
<TD>Sweden</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>IGN GmbH</TD>
<TD> </TD>
<TD>Germany</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>India Medtronic Private Limited</TD>
<TD> </TD>
<TD>India</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Magnolia Medical LLC</TD>
<TD> </TD>
<TD>Delaware</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medical Education K.K.</TD>
<TD> </TD>
<TD>Japan</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic (Africa) (Proprietary) Limited</TD>
<TD> </TD>
<TD>South Africa</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic (Schweiz) A.G. / Medtronic (Suisse) S.A.</TD>
<TD> </TD>
<TD>Switzerland</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic (Shanghai) Ltd.</TD>
<TD> </TD>
<TD>China</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic (Thailand) Limited</TD>
<TD> </TD>
<TD>Thailand</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic A/S</TD>
<TD> </TD>
<TD>Denmark</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Aktiebolag</TD>
<TD> </TD>
<TD>Sweden</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Angiolink, Inc.</TD>
<TD> </TD>
<TD>Delaware</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Asia, Ltd.</TD>
<TD> </TD>
<TD>Minnesota</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Australasia Pty. Limited</TD>
<TD> </TD>
<TD>Australia</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic B.V.</TD>
<TD> </TD>
<TD>Netherlands</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Bakken Research Center B.V.</TD>
<TD> </TD>
<TD>Netherlands</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Belgium S.A./N.V.</TD>
<TD> </TD>
<TD>Belgium</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Bio-Medicus, Inc.</TD>
<TD> </TD>
<TD>Minnesota</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic China, Ltd.</TD>
<TD> </TD>
<TD>Minnesota</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Comercial Ltda.</TD>
<TD> </TD>
<TD>Brazil</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Czechia s.r.o.</TD>
<TD> </TD>
<TD>Czech Republic</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Danmark A/S</TD>
<TD> </TD>
<TD>Denmark</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic do Brasil Ltda.</TD>
<TD> </TD>
<TD>Brazil</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Emergency Response Systems International, Inc.</TD>
<TD> </TD>
<TD>Washington</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Emergency Response Systems Manufacturing, Inc.</TD>
<TD> </TD>
<TD>Washington</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Emergency Response Systems, Inc.</TD>
<TD> </TD>
<TD>Washington</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Endonetics, Inc.</TD>
<TD> </TD>
<TD>California</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Europe BVBA</TD>
<TD> </TD>
<TD>Belgium</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Europe Capital Corp.</TD>
<TD> </TD>
<TD>Cayman Islands</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Europe Sàrl</TD>
<TD> </TD>
<TD>Switzerland</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Fabrication SAS</TD>
<TD> </TD>
<TD>France</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Finland OY</TD>
<TD> </TD>
<TD>Finland</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic France S.A.S.</TD>
<TD> </TD>
<TD>France</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Functional Diagnostics Zinetics, Inc.</TD>
<TD> </TD>
<TD>Utah</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Functional Diagnostics, Inc.</TD>
<TD> </TD>
<TD>New Jersey</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic G.m.b.H.</TD>
<TD> </TD>
<TD>Germany</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Hellas Medical Device Commercial S.A.</TD>
<TD> </TD>
<TD>Greece</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Holding Switzerland G.m.b.H.</TD>
<TD> </TD>
<TD>Switzerland</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Hungary Limited</TD>
<TD> </TD>
<TD>Hungary</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Ibérica S.A.</TD>
<TD> </TD>
<TD>Spain</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Image-Guided Neurologics, Inc.</TD>
<TD> </TD>
<TD>Delaware</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic InStent (Israel) Ltd.</TD>
<TD> </TD>
<TD>Israel</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic International Technology, Inc.</TD>
<TD> </TD>
<TD>Minnesota</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM" style="font-size:8pt;padding-top:0pt">
<TH width=66% align="left">Company</TH>
<TH width=4%> </TH>
<TH width=30%>Jurisdiction of Incorporation</TH>
</TR>
<TR>
<TD>
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD>
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD >Medtronic International Trading Sàrl</TD>
<TD> </TD>
<TD>Switzerland</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic International Trading, Inc.</TD>
<TD> </TD>
<TD>Minnesota</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic International, Ltd.</TD>
<TD> </TD>
<TD>Delaware</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Interventional Vascular, Inc.</TD>
<TD> </TD>
<TD>Massachusetts</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Ireland Holdings Company</TD>
<TD> </TD>
<TD>Ireland</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Ireland Limited</TD>
<TD> </TD>
<TD>Ireland</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Ireland Manufacturing Limited</TD>
<TD> </TD>
<TD>Ireland</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Italia S.p.A.</TD>
<TD> </TD>
<TD>Italy</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Japan Capital Corp.</TD>
<TD> </TD>
<TD>Cayman Islands</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Japan Co., Ltd.</TD>
<TD> </TD>
<TD>Japan</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Korea Co., Ltd.</TD>
<TD> </TD>
<TD>Korea</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Latin America, Inc.</TD>
<TD> </TD>
<TD>Minnesota</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Lifelink MD, Inc.</TD>
<TD> </TD>
<TD>Delaware</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Limited</TD>
<TD> </TD>
<TD>United Kingdom</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD >Medtronic Medical Appliance Technology and Service (Shanghai) Ltd.</TD>
<TD> </TD>
<TD>China</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Medical Technology Ticaret Limited Sirketi</TD>
<TD> </TD>
<TD>Turkey</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Mediterranean SAL</TD>
<TD> </TD>
<TD>Lebanon</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Mexico S. de R.L. de C.V.</TD>
<TD> </TD>
<TD>Mexico</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Micro Motion Sciences, Inc.</TD>
<TD> </TD>
<TD>Delaware</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic MiniMed, Inc.</TD>
<TD> </TD>
<TD>Delaware</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Navigation, Inc.</TD>
<TD> </TD>
<TD>Delaware</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Oesterreich G.m.b.H.</TD>
<TD> </TD>
<TD>Austria</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic of Canada Ltd.</TD>
<TD> </TD>
<TD>Canada</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Pacific Trading, Inc.</TD>
<TD> </TD>
<TD>Minnesota</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Physio-Control Limited</TD>
<TD> </TD>
<TD>United Kingdom</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Poland Sp. Z O.O.</TD>
<TD> </TD>
<TD>Poland</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD >Medtronic Portugal—Comercio e Distribuiacao de Aparelhos Medicos Lda</TD>
<TD> </TD>
<TD>Portugal</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic PS Medical, Inc.</TD>
<TD> </TD>
<TD>California</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Puerto Rico Operations Co.</TD>
<TD> </TD>
<TD>Cayman Islands</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic S. de R.L. de C.V.</TD>
<TD> </TD>
<TD>Mexico</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic S.A.I.C.</TD>
<TD> </TD>
<TD>Argentina</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Servicios S. de R.L. de C.V.</TD>
<TD> </TD>
<TD>Mexico</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Sofamor Danek (NZ) Limited</TD>
<TD> </TD>
<TD>New Zealand</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Sofamor Danek (UK) Ltd.</TD>
<TD> </TD>
<TD>United Kingdom</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Sofamor Danek Australia Pty. Ltd.</TD>
<TD> </TD>
<TD>Australia</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Sofamor Danek Co., Ltd.</TD>
<TD> </TD>
<TD>Japan</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Sofamor Danek Deggendorf GmbH</TD>
<TD> </TD>
<TD>Germany</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Sofamor Danek South Africa (Proprietary) Limited</TD>
<TD> </TD>
<TD>South Africa</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Sofamor Danek USA, Inc.</TD>
<TD> </TD>
<TD>Tennessee</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Sofamor Danek, Inc.</TD>
<TD> </TD>
<TD>Indiana</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Synectics Aktiebolag</TD>
<TD> </TD>
<TD>Sweden</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Trading NL BV</TD>
<TD> </TD>
<TD>Netherlands</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Transneuronix, Inc.</TD>
<TD> </TD>
<TD>Delaware</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Treasury International, Inc.</TD>
<TD> </TD>
<TD>Minnesota</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Treasury Management, Inc.</TD>
<TD> </TD>
<TD>Minnesota</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic U.K. Capital Corp.</TD>
<TD> </TD>
<TD>Cayman Islands</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic USA, Inc.</TD>
<TD> </TD>
<TD>Minnesota</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Vascular Connaught</TD>
<TD> </TD>
<TD>Ireland</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Vascular Galway Limited</TD>
<TD> </TD>
<TD>Ireland</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Vascular, Inc.</TD>
<TD> </TD>
<TD>Delaware</TD>
</TR>
</TABLE>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 0; page: 0" -->
<BR>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM" style="font-size:8pt;padding-top:0pt">
<TH width=66% align="left">Company</TH>
<TH width=4%> </TH>
<TH width=30%>Jurisdiction of Incorporation</TH>
</TR>
<TR>
<TD>
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
<TD></TD>
<TD>
<HR style="height:1;color:black;background-color:black" noshade>
</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Vertelink, Inc.</TD>
<TD> </TD>
<TD>California</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic VidaMed, Inc.</TD>
<TD> </TD>
<TD>Delaware</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Vingmed AS</TD>
<TD> </TD>
<TD>Norway</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic World Trade Corporation</TD>
<TD> </TD>
<TD>Minnesota</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Xomed France S.A.S.</TD>
<TD> </TD>
<TD>France</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Xomed Instrumentation SAS</TD>
<TD> </TD>
<TD>France</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Xomed U.K. Limited</TD>
<TD> </TD>
<TD>United Kingdom</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic Xomed, Inc.</TD>
<TD> </TD>
<TD>Delaware</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Medtronic-Mediland (Taiwan) Ltd.</TD>
<TD> </TD>
<TD>Taiwan</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>MG Biotherapeutics LLC</TD>
<TD> </TD>
<TD>Delaware</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>MiniMed Distribution Corp.</TD>
<TD> </TD>
<TD>Delaware</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>MiniMed Medical Supply, Inc.</TD>
<TD> </TD>
<TD>Florida</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>MiniMed Pty Ltd.</TD>
<TD> </TD>
<TD>Australia</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Physior SNC</TD>
<TD> </TD>
<TD>France</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Restoragen, Inc.</TD>
<TD> </TD>
<TD>Delaware</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Sofamor S.N.C.</TD>
<TD> </TD>
<TD>France</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Spike SNC</TD>
<TD> </TD>
<TD>France</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>SpinalGraft Technologies, LLC</TD>
<TD> </TD>
<TD>Tennessee</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD >Synectics Medical - Equipamento Electronico de Medicina, Limitada</TD>
<TD> </TD>
<TD>Portugal</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Synectics Medical Limited</TD>
<TD> </TD>
<TD>United Kingdom</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Transneuronix International GmbH</TD>
<TD> </TD>
<TD>Germany</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vidamed International Limited</TD>
<TD> </TD>
<TD>United Kingdom</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vitatron (Israel) Limited</TD>
<TD> </TD>
<TD>Israel</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vitatron A.G.</TD>
<TD> </TD>
<TD>Switzerland</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vitatron B.V.</TD>
<TD> </TD>
<TD>Netherlands</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vitatron Belgium S.A. / N.V.</TD>
<TD> </TD>
<TD>Belgium</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vitatron Czechia s.r.o.</TD>
<TD> </TD>
<TD>Czech Republic</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vitatron Denmark A/S</TD>
<TD> </TD>
<TD>Denmark</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vitatron Finland Oy</TD>
<TD> </TD>
<TD>Finland</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vitatron G.m.b.H.</TD>
<TD> </TD>
<TD>Austria</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vitatron G.m.b.H.</TD>
<TD> </TD>
<TD>Germany</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vitatron Holding B.V.</TD>
<TD> </TD>
<TD>Netherlands</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vitatron Japan Co., Ltd.</TD>
<TD> </TD>
<TD>Japan</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vitatron Medical Espana S.A.</TD>
<TD> </TD>
<TD>Spain</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vitatron Medical Italia S.r.l.</TD>
<TD> </TD>
<TD>Italy</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vitatron Nederland B.V.</TD>
<TD> </TD>
<TD>Netherlands</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vitatron Poland Sp. z o.o.</TD>
<TD> </TD>
<TD>Poland</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD >Vitatron Portugal - Comércio e Distribuição de Dispositivos Médicos,
Lda</TD>
<TD> </TD>
<TD>Portugal</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vitatron S.A.R.L.</TD>
<TD> </TD>
<TD>France</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vitatron Sweden Aktiebolag</TD>
<TD> </TD>
<TD>Sweden</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Vitatron U.K. Limited</TD>
<TD> </TD>
<TD>United Kingdom</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Warsaw Orthopedic, Inc.</TD>
<TD> </TD>
<TD>Indiana</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Xomed Australia PTY Limited</TD>
<TD> </TD>
<TD>Australia</TD>
</TR>
<TR VALIGN="TOP" style="font-size:10pt;padding-top:0pt">
<TD>Xomed France Holdings, SNC</TD>
<TD> </TD>
<TD>France</TD>
</TR>
</TABLE>
</DIV>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>26
<FILENAME>medtronic062430s1_ex23.htm
<DESCRIPTION>CONSENT OF PRICEWATERHOUSECOOPERS LLP
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 23 to Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR>
<P style="font-size:10pt;font-weight:bold;text-align:right">Exhibit 23</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</P>
<P style="font-size:10pt"> We hereby consent to the incorporation by reference
in the Registration Statements on Form S-8 (Nos. 33-37529, 33-44230, 33-55329, 33-63805, 333-04099, 333-07385, 333-65227, 333-71259,
333-71355, 333-74229, 333-75819, 333-90381, 333-52840, 333-44766, 333-66978, 333-68594, 333-100624, 333-106566, 333-112267,
333-128531 and 333-129872) of Medtronic, Inc. of our report dated June 21, 2006 relating to the consolidated financial statements,
management’s assessment of the effectiveness of internal control over financial reporting and the effectiveness of internal
control over financial reporting, which appears in Exhibit 13 to this Annual Report on Form 10-K. We also consent to the incorporation
by reference in the above Registration Statements of our report dated June 21, 2006 relating to the financial statement schedule,
which appears in this Annual Report on Form 10-K.</P>
<P style="font-size:10pt">/s/ PricewaterhouseCoopers LLP<BR>
<BR>PricewaterhouseCoopers LLP<BR>Minneapolis, Minnesota<BR>June 28, 2006</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">Report of Independent Registered Public Accounting Firm on<BR>Financial
Statement Schedule</P>
<P style="font-size:10pt"> <B>To the Board of Directors of Medtronic, Inc.:</B>
</P>
<P style="font-size:10pt"> Our audits of the consolidated financial statements,
of management’s assessment of the effectiveness of internal control over financial reporting and of the effectiveness
of internal control over financial reporting referred to in our report dated June 21, 2006 appearing in Exhibit 13 to this
Annual Report on Form 10-K of Medtronic, Inc. (which consolidated financial statements and assessment are included in Exhibit
13 to this Annual Report on Form 10-K) also included an audit of the financial statement schedule listed in Item 15(a)(2) of
this Form 10-K. In our opinion, this financial statement schedule presents fairly, in all material respects, the information
set forth therein when read in conjunction with the related consolidated financial statements.</P>
<P style="font-size:10pt">/s/ PricewaterhouseCoopers LLP<BR>
<BR>PricewaterhouseCoopers LLP<BR>Minneapolis, Minnesota<BR>June 21, 2006</P>
<BR>
<BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>27
<FILENAME>medtronic062430s1_ex24.htm
<DESCRIPTION>POWERS OF ATTORNEY
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 24 to Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR>
<P style="font-size:10pt;font-weight:bold;text-align:right">Exhibit 24</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">POWER OF ATTORNEY</P>
<P style="font-size:10pt"> Each of the undersigned directors of Medtronic, Inc.,
a Minnesota corporation, hereby constitutes and appoints each of ARTHUR D. COLLINS, JR. and TERRANCE L. CARLSON, acting individually
or jointly, their true and lawful attorneys-in-fact and agents, with full power to act for them and in their name, place and
stead, in any and all capacities, to do any and all acts and execute any and all documents which either such attorney and agent
may deem necessary or desirable to enable Medtronic, Inc. to comply with the Securities Exchange Act of 1934, as amended, and
any rules, regulations and requirements of the Securities and Exchange Commission in respect thereof, in connection with the
filing with the Commission of Medtronic’s Annual Report on Form 10-K for the fiscal year ended April 28, 2006, including
specifically, but without limiting the generality of the foregoing, power and authority to sign the names of the undersigned
directors to the Form 10-K and to any instruments and documents filed as part of or in connection with the Form 10-K or any
amendments thereto; and the undersigned hereby ratify and confirm all actions taken and documents signed by each said attorney
and agent as provided herein.</P>
<P style="font-size:10pt"> The undersigned have set their hands this 22nd day
of June 2006.</P>
<DIV align="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%">
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD width="45%">/s/ Richard H. Anderson<BR>
<HR style="width:100%;height:1;color:black;background-color:black" noshade>
Richard H. Anderson</TD>
<TD width="10%"> </TD>
<TD width="45%">/s/ Denise M. O’Leary<BR>
<HR style="width:100%;height:1;color:black;background-color:black" noshade>
Denise M. O’Leary</TD>
</TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD>/s/ Michael R. Bonsignore<BR>
<HR style="width:100%;height:1;color:black;background-color:black" noshade>
Michael R. Bonsignore</TD>
<TD> </TD>
<TD>/s/ Robert C. Pozen<BR>
<HR style="width:100%;height:1;color:black;background-color:black" noshade>
Robert C. Pozen</TD>
</TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD> <BR>
<HR style="width:100%;height:1;color:black;background-color:black" noshade>
William R. Brody, M.D., Ph.D.</TD>
<TD> </TD>
<TD>/s/ Jean-Pierre Rosso<BR>
<HR style="width:100%;height:1;color:black;background-color:black" noshade>
Jean-Pierre Rosso</TD>
</TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD>/s/ Arthur D. Collins, Jr.<BR>
<HR style="width:100%;height:1;color:black;background-color:black" noshade>
Arthur D. Collins, Jr.</TD>
<TD> </TD>
<TD>/s/ Jack W. Schuler<BR>
<HR style="width:100%;height:1;color:black;background-color:black" noshade>
Jack W. Schuler</TD>
</TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD> <BR>
<HR style="width:100%;height:1;color:black;background-color:black" noshade>
Antonio M. Gotto, Jr., M.D., D. Phil.</TD>
<TD> </TD>
<TD>/s/ Gordon M. Sprenger<BR>
<HR style="width:100%;height:1;color:black;background-color:black" noshade>
Gordon M. Sprenger</TD>
</TR>
<TR><TD> </TD></TR>
<TR VALIGN="BOTTOM" style="font-size:10pt">
<TD> <BR>
<HR style="width:100%;height:1;color:black;background-color:black" noshade>
Shirley Ann Jackson, Ph.D.</TD>
<TD> </TD>
<TD></TD>
</TR>
</TABLE>
</DIV>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>28
<FILENAME>medtronic062430s1_ex31-1.htm
<DESCRIPTION>CERTIFICATION OF CEO PURSUANT TO SECTION 302
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 31.1 to Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR>
<P style="font-size:10pt;font-weight:bold;text-align:right">Exhibit 31.1</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">Certification of Chief Executive Officer<BR>Pursuant to Section
302 of the<BR>Sarbanes-Oxley Act of 2002</P>
<P style="font-size:10pt"> I, Arthur D. Collins, Jr., certify that:</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">1.</TD>
<TD WIDTH="92%">I have reviewed this annual report on Form 10-K of Medtronic, Inc.;</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>2.</TD>
<TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this report;</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>3.</TD>
<TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present
in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the
periods presented in this report;</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>4.</TD>
<TD>The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">(a)</TD>
<TD WIDTH="88%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed
under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD> </TD>
<TD>(b)</TD>
<TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally accepted accounting principles;</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD> </TD>
<TD>(c)</TD>
<TD>Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this
report based on such evaluation; and</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD> </TD>
<TD>(d)</TD>
<TD>Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during
the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial
reporting; and</TD>
</TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">5.</TD>
<TD WIDTH="92%">The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation
of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s
board of directors (or persons performing the equivalent functions): </TD>
</TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">(a)</TD>
<TD WIDTH="88%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report
financial information; and</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD> </TD>
<TD>(b)</TD>
<TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting.</TD>
</TR>
</TABLE>
<DIV style="font-size:10pt;margin-left:50%">
<P>/s/ Arthur D. Collins, Jr.</P>
<HR align="left" color="black" width="1" noshade style="width:70%;margin-top:-12pt;position:relative">
<P style="margin-top:-10pt">Arthur D. Collins, Jr.<BR>Chairman of the Board and Chief Executive Officer</P>
</DIV>
<P style="font-size:10pt">Date: June 28, 2006</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>29
<FILENAME>medtronic062430s1_ex31-2.htm
<DESCRIPTION>CERTIFICATION OF CFO PURSUANT TO SECTION 302
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 31.2 to Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR>
<P style="font-size:10pt;font-weight:bold;text-align:right">Exhibit 31.2</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">Certification of Chief Financial Officer<BR>Pursuant to Section 302
of the<BR>Sarbanes-Oxley Act of 2002</P>
<P style="font-size:10pt"> I, Gary L. Ellis, certify that:</P>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">1.</TD>
<TD WIDTH="92%">I have reviewed this annual report on Form 10-K of Medtronic, Inc.;</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>2.</TD>
<TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this report;</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>3.</TD>
<TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present
in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the
periods presented in this report;</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD>4.</TD>
<TD>The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">(a)</TD>
<TD WIDTH="88%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed
under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD> </TD>
<TD>(b)</TD>
<TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally accepted accounting principles;</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD> </TD>
<TD>(c)</TD>
<TD>Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this
report based on such evaluation; and</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD> </TD>
<TD>(d)</TD>
<TD>Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during
the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial
reporting; and</TD>
</TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">5.</TD>
<TD WIDTH="92%">The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation
of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s
board of directors (or persons performing the equivalent functions): </TD>
</TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING="2" CELLSPACING="2">
<TR style="font-size:10pt" VALIGN="TOP">
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%"> </TD>
<TD WIDTH="4%">(a)</TD>
<TD WIDTH="88%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report
financial information; and</TD>
</TR>
<TR style="font-size:10pt" VALIGN="TOP">
<TD> </TD>
<TD> </TD>
<TD>(b)</TD>
<TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting.</TD>
</TR>
</TABLE>
<DIV style="font-size:10pt;margin-left:50%">
<P>/s/ Gary L. Ellis</P>
<HR align="left" color="black" width="1" noshade style="width:70%;margin-top:-12pt;position:relative">
<P style="margin-top:-10pt">Gary L. Ellis<BR>Senior Vice President and Chief Financial Officer</P>
</DIV>
<P style="font-size:10pt">Date: June 28, 2006</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>30
<FILENAME>medtronic062430s1_ex32-1.htm
<DESCRIPTION>CERTIFICATION OF CEO PURSUANT TO SECTION 906
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 32.1 to Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR>
<P style="font-size:10pt;font-weight:bold;text-align:right">Exhibit 32.1</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">Certification of Chief Executive Officer<BR>Pursuant to Section 906
of the<BR>Sarbanes-Oxley Act of 2002</P>
<P style="font-size:10pt"> In connection with this annual report on Form 10-K
of Medtronic, Inc. for the fiscal year ended April 28, 2006, the undersigned hereby certifies, in his capacity as
Chief Executive Officer of Medtronic, Inc., for purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that:</P>
<P style="font-size:10pt;padding-left:30"> (1) The report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</P>
<P style="font-size:10pt;padding-left:30"> (2) The information contained
in this report fairly presents, in all material respects, the financial condition and results of operations of Medtronic, Inc.</P>
<DIV style="font-size:10pt;margin-left:50%">
<P>/s/ Arthur D. Collins, Jr.</P>
<HR align="left" color="black" width="1" noshade style="width:70%;margin-top:-12pt;position:relative">
<P style="margin-top:-10pt">Arthur D. Collins, Jr.<BR>Chairman of the Board and Chief Executive Officer</P>
</DIV>
<P style="font-size:10pt">Date: June 28, 2006</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>31
<FILENAME>medtronic062430s1_ex32-2.htm
<DESCRIPTION>CERTIFICATION OF CFO PURSUANT TO SECTION 906
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 32.2 to Medtronic, Inc. Form 10-K for fiscal year ended April 28, 2006 </TITLE>
</HEAD>
<BODY>
<BR>
<P style="font-size:10pt;font-weight:bold;text-align:right">Exhibit 32.2</P>
<P style="font-size:12pt;font-weight:bold;text-align:center">Certification of Chief Financial Officer<BR>Pursuant to Section 906
of the<BR>Sarbanes-Oxley Act of 2002</P>
<P style="font-size:10pt"> In connection with this annual report on Form 10-K
of Medtronic, Inc. for the fiscal year ended April 28, 2006, the undersigned hereby certifies, in his capacity as
Chief Financial Officer of Medtronic, Inc., for purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that:</P>
<P style="font-size:10pt;padding-left:30"> (1) The report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</P>
<P style="font-size:10pt;padding-left:30"> (2) The information contained
in this report fairly presents, in all material respects, the financial condition and results of operations of Medtronic, Inc.</P>
<DIV style="font-size:10pt;margin-left:50%">
<P>/s/ Gary L. Ellis</P>
<HR align="left" color="black" width="1" noshade style="width:70%;margin-top:-12pt;position:relative">
<P style="margin-top:-10pt">Gary L. Ellis<BR>Senior Vice President and Chief Financial Officer</P>
</DIV>
<P style="font-size:10pt">Date: June 28, 2006</P>
<BR>
<BR>
<P style="font-size:10pt;text-align:center"> </P>
<HR color="gray" size="3" noshade>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
